0001493152-24-014918.txt : 20240417 0001493152-24-014918.hdr.sgml : 20240417 20240417122445 ACCESSION NUMBER: 0001493152-24-014918 CONFORMED SUBMISSION TYPE: S-1/A PUBLIC DOCUMENT COUNT: 90 FILED AS OF DATE: 20240417 DATE AS OF CHANGE: 20240417 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OneMedNet Corp CENTRAL INDEX KEY: 0001849380 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 862076743 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-1/A SEC ACT: 1933 Act SEC FILE NUMBER: 333-276130 FILM NUMBER: 24849990 BUSINESS ADDRESS: STREET 1: TRIDENT COURT, 1 OAKCROFT ROAD STREET 2: CHESSINGTON CITY: SURREY STATE: X0 ZIP: KT9 1BD BUSINESS PHONE: 011-44-208-090-2009 MAIL ADDRESS: STREET 1: TRIDENT COURT, 1 OAKCROFT ROAD STREET 2: CHESSINGTON CITY: SURREY STATE: X0 ZIP: KT9 1BD FORMER COMPANY: FORMER CONFORMED NAME: Data Knights Acquisition Corp. DATE OF NAME CHANGE: 20210304 S-1/A 1 forms-1a.htm
true 0001849380 S-1/A 0001849380 2023-01-01 2023-12-31 0001849380 dei:BusinessContactMember 2023-01-01 2023-12-31 0001849380 2023-12-31 0001849380 2022-12-31 0001849380 us-gaap:RelatedPartyMember 2023-12-31 0001849380 us-gaap:RelatedPartyMember 2022-12-31 0001849380 ONMD:SeriesATwoPreferredStockMember 2023-12-31 0001849380 ONMD:SeriesATwoPreferredStockMember 2022-12-31 0001849380 ONMD:SeriesAOnePreferredStockMember 2023-12-31 0001849380 ONMD:SeriesAOnePreferredStockMember 2022-12-31 0001849380 us-gaap:CommonClassAMember 2023-12-31 0001849380 us-gaap:CommonClassAMember 2022-12-31 0001849380 ONMD:CommonClassAOneMember 2023-12-31 0001849380 ONMD:CommonClassAOneMember 2022-12-31 0001849380 2022-01-01 2022-12-31 0001849380 us-gaap:PreferredStockMember ONMD:SeriesATwoPreferredStockMember 2021-12-31 0001849380 us-gaap:PreferredStockMember ONMD:SeriesAOnePreferredStockMember 2021-12-31 0001849380 us-gaap:CommonStockMember us-gaap:CommonClassAMember ONMD:DataKnightsAcquisitionCorpMember 2021-12-31 0001849380 us-gaap:CommonStockMember us-gaap:CommonClassBMember ONMD:DataKnightsAcquisitionCorpMember 2021-12-31 0001849380 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2021-12-31 0001849380 ONMD:CommitmentMember 2021-12-31 0001849380 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001849380 us-gaap:RetainedEarningsMember 2021-12-31 0001849380 2021-12-31 0001849380 us-gaap:PreferredStockMember ONMD:SeriesATwoPreferredStockMember 2022-12-31 0001849380 us-gaap:PreferredStockMember ONMD:SeriesAOnePreferredStockMember 2022-12-31 0001849380 us-gaap:CommonStockMember us-gaap:CommonClassAMember ONMD:DataKnightsAcquisitionCorpMember 2022-12-31 0001849380 us-gaap:CommonStockMember us-gaap:CommonClassBMember ONMD:DataKnightsAcquisitionCorpMember 2022-12-31 0001849380 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-12-31 0001849380 ONMD:CommitmentMember 2022-12-31 0001849380 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001849380 us-gaap:RetainedEarningsMember 2022-12-31 0001849380 us-gaap:PreferredStockMember ONMD:SeriesATwoPreferredStockMember 2022-01-01 2022-12-31 0001849380 us-gaap:PreferredStockMember ONMD:SeriesAOnePreferredStockMember 2022-01-01 2022-12-31 0001849380 us-gaap:CommonStockMember us-gaap:CommonClassAMember ONMD:DataKnightsAcquisitionCorpMember 2022-01-01 2022-12-31 0001849380 us-gaap:CommonStockMember us-gaap:CommonClassBMember ONMD:DataKnightsAcquisitionCorpMember 2022-01-01 2022-12-31 0001849380 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-01-01 2022-12-31 0001849380 ONMD:CommitmentMember 2022-01-01 2022-12-31 0001849380 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001849380 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001849380 us-gaap:PreferredStockMember ONMD:SeriesATwoPreferredStockMember 2023-01-01 2023-12-31 0001849380 us-gaap:PreferredStockMember ONMD:SeriesAOnePreferredStockMember 2023-01-01 2023-12-31 0001849380 us-gaap:CommonStockMember us-gaap:CommonClassAMember ONMD:DataKnightsAcquisitionCorpMember 2023-01-01 2023-12-31 0001849380 us-gaap:CommonStockMember us-gaap:CommonClassBMember ONMD:DataKnightsAcquisitionCorpMember 2023-01-01 2023-12-31 0001849380 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2023-01-01 2023-12-31 0001849380 ONMD:CommitmentMember 2023-01-01 2023-12-31 0001849380 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001849380 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001849380 us-gaap:PreferredStockMember ONMD:SeriesATwoPreferredStockMember 2023-12-31 0001849380 us-gaap:PreferredStockMember ONMD:SeriesAOnePreferredStockMember 2023-12-31 0001849380 us-gaap:CommonStockMember us-gaap:CommonClassAMember ONMD:DataKnightsAcquisitionCorpMember 2023-12-31 0001849380 us-gaap:CommonStockMember us-gaap:CommonClassBMember ONMD:DataKnightsAcquisitionCorpMember 2023-12-31 0001849380 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2023-12-31 0001849380 ONMD:CommitmentMember 2023-12-31 0001849380 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001849380 us-gaap:RetainedEarningsMember 2023-12-31 0001849380 ONMD:SecuritiesPurchaseAgreementMember ONMD:DataKnightsAcquisitionCorpMember 2023-06-28 2023-06-28 0001849380 ONMD:SecuritiesPurchaseAgreementMember ONMD:DataKnightsAcquisitionCorpMember 2023-06-28 0001849380 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember ONMD:OneCustomerMember 2023-01-01 2023-12-31 0001849380 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember ONMD:TwoCustomersMember 2022-01-01 2022-12-31 0001849380 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember ONMD:ThreeCustomersMember 2023-01-01 2023-12-31 0001849380 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember ONMD:TwoCustomersMember 2022-01-01 2022-12-31 0001849380 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember ONMD:CustomerOneMember 2023-01-01 2023-12-31 0001849380 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember ONMD:CustomerOneMember 2022-01-01 2022-12-31 0001849380 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember ONMD:CustomerTwoMember 2023-01-01 2023-12-31 0001849380 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember ONMD:CustomerTwoMember 2022-01-01 2022-12-31 0001849380 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember ONMD:CustomersMember 2023-01-01 2023-12-31 0001849380 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember ONMD:CustomersMember 2022-01-01 2022-12-31 0001849380 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember ONMD:CustomerOneMember 2023-01-01 2023-12-31 0001849380 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember ONMD:CustomerOneMember 2022-01-01 2022-12-31 0001849380 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember ONMD:CustomerTwoMember 2023-01-01 2023-12-31 0001849380 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember ONMD:CustomerTwoMember 2022-01-01 2022-12-31 0001849380 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember ONMD:CustomerThreeMember 2023-01-01 2023-12-31 0001849380 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember ONMD:CustomerThreeMember 2022-01-01 2022-12-31 0001849380 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember ONMD:CustomerFourMember 2023-01-01 2023-12-31 0001849380 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember ONMD:CustomerFourMember 2022-01-01 2022-12-31 0001849380 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember ONMD:CustomerFiveMember 2023-01-01 2023-12-31 0001849380 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember ONMD:CustomerFiveMember 2022-01-01 2022-12-31 0001849380 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember ONMD:CustomersMember 2023-01-01 2023-12-31 0001849380 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember ONMD:CustomersMember 2022-01-01 2022-12-31 0001849380 us-gaap:ComputerEquipmentMember 2023-12-31 0001849380 us-gaap:ComputerEquipmentMember 2022-12-31 0001849380 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001849380 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001849380 us-gaap:DomesticCountryMember 2023-12-31 0001849380 us-gaap:StateAndLocalJurisdictionMember 2023-12-31 0001849380 ONMD:DataKnightsAcquisitionCorpMember 2023-12-31 0001849380 ONMD:DataKnightsAcquisitionCorpMember 2023-01-01 2023-12-31 0001849380 us-gaap:NonrelatedPartyMember 2023-12-31 0001849380 us-gaap:NonrelatedPartyMember 2022-12-31 0001849380 us-gaap:RelatedPartyMember ONMD:ConvertiblePromissoryNotesMember 2022-11-11 0001849380 us-gaap:RelatedPartyMember ONMD:ConvertiblePromissoryNotesMember 2022-11-10 2022-11-11 0001849380 us-gaap:RelatedPartyMember ONMD:SeriesATwoPreferredStockMember ONMD:ConvertiblePromissoryNotesMember 2022-11-11 0001849380 us-gaap:RelatedPartyMember ONMD:ConvertiblePromissoryNotesMember 2019-11-30 0001849380 ONMD:ConvertiblePromissoryNotesMember 2022-12-31 0001849380 us-gaap:RelatedPartyMember ONMD:DataKnightsAcquisitionCorpMember 2023-11-30 0001849380 ONMD:CEBALoanMember 2020-12-01 2020-12-31 0001849380 ONMD:CEBALoanMember 2020-01-01 2020-12-31 0001849380 ONMD:CEBALoanMember 2020-12-31 0001849380 ONMD:SeriesATwoPreferredStockMember 2023-01-01 2023-12-31 0001849380 ONMD:SeriesAOnePreferredStockMember 2023-01-01 2023-12-31 0001849380 ONMD:BoardOfDirectorsMember 2023-01-01 2023-12-31 0001849380 ONMD:BoardOfDirectorsMember 2022-01-01 2022-12-31 0001849380 ONMD:BoardOfDirectorsMember 2023-12-31 0001849380 us-gaap:CommonStockMember srt:BoardOfDirectorsChairmanMember 2022-12-31 0001849380 us-gaap:CommonStockMember srt:BoardOfDirectorsChairmanMember 2023-01-01 2023-12-31 0001849380 us-gaap:CommonStockMember srt:BoardOfDirectorsChairmanMember 2023-12-31 0001849380 ONMD:EmployeesDirectorsAndConsultantsMember ONMD:NewEquityIncentivePlanMember 2020-01-01 2020-12-31 0001849380 ONMD:EmployeesDirectorsAndConsultantsMember ONMD:NewEquityIncentivePlanMember srt:MaximumMember 2020-01-01 2020-12-31 0001849380 ONMD:EmployeesDirectorsAndConsultantsMember ONMD:NewEquityIncentivePlanMember 2020-12-31 0001849380 2021-01-01 2021-12-31 0001849380 2023-11-07 0001849380 2023-10-17 2023-10-17 0001849380 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001849380 2020-12-31 0001849380 us-gaap:MeasurementInputExpectedTermMember 2022-01-01 2022-12-31 0001849380 us-gaap:MeasurementInputExpectedTermMember 2021-01-01 2021-12-31 0001849380 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001849380 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001849380 us-gaap:MeasurementInputExpectedDividendRateMember 2022-12-31 0001849380 us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001849380 us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001849380 us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001849380 ONMD:TwentyTwentyOneServiceMember 2022-12-31 0001849380 ONMD:TwentyTwentyTwoServiceMember 2022-12-31 0001849380 ONMD:ConvertiableNotesMember 2022-12-31 0001849380 ONMD:ConvertiableNotesMember 2023-12-31 0001849380 ONMD:WarrantOneMember 2023-12-31 0001849380 us-gaap:CommonStockMember 2023-12-31 0001849380 ONMD:PubliclyTradedWarrantsMember 2022-12-31 0001849380 ONMD:PubliclyTradedWarrantsMember 2023-12-31 0001849380 ONMD:PrivateWarrantsMember 2023-12-31 0001849380 ONMD:PrivateWarrantsMember 2022-12-31 0001849380 us-gaap:WarrantMember 2023-12-31 0001849380 us-gaap:WarrantMember 2022-12-31 0001849380 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member ONMD:InvestmentsHeldInTrustMember 2023-12-31 0001849380 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member ONMD:InvestmentsHeldInTrustMember 2023-12-31 0001849380 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member ONMD:InvestmentsHeldInTrustMember 2023-12-31 0001849380 us-gaap:FairValueMeasurementsRecurringMember ONMD:InvestmentsHeldInTrustMember 2023-12-31 0001849380 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member ONMD:InvestmentsHeldInTrustMember 2022-12-31 0001849380 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member ONMD:InvestmentsHeldInTrustMember 2022-12-31 0001849380 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member ONMD:InvestmentsHeldInTrustMember 2022-12-31 0001849380 us-gaap:FairValueMeasurementsRecurringMember ONMD:InvestmentsHeldInTrustMember 2022-12-31 0001849380 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001849380 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001849380 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001849380 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001849380 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001849380 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001849380 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001849380 ONMD:DataKnightsAcquisitionCorpMember us-gaap:RelatedPartyMember 2023-12-31 0001849380 us-gaap:RelatedPartyMember ONMD:ManagementAndDirectorsMember 2023-12-31 0001849380 ONMD:SecuritiesPurchaseAgreementMember 2023-11-01 2023-11-30 0001849380 ONMD:SeniorConvertibleNotesMember ONMD:SecuritiesPurchaseAgreementMember 2023-11-01 2023-11-30 0001849380 us-gaap:RelatedPartyMember ONMD:SecuritiesPurchaseAgreementMember 2023-11-30 0001849380 ONMD:SecuritiesPurchaseAgreementMember us-gaap:WarrantMember 2023-11-01 2023-11-30 0001849380 ONMD:SecuritiesPurchaseAgreementMember 2023-11-30 0001849380 srt:ScenarioForecastMember ONMD:EFHuttonMember 2024-01-01 2024-12-31 0001849380 srt:ScenarioForecastMember ONMD:KingwoodCapitalPartnersLLCMember 2024-01-01 2024-12-31 0001849380 srt:ScenarioForecastMember 2024-01-01 2024-12-31 0001849380 us-gaap:SubsequentEventMember us-gaap:MajorityShareholderMember 2024-01-01 2024-12-31 0001849380 us-gaap:SubsequentEventMember 2024-01-01 2024-12-31 0001849380 srt:ScenarioForecastMember srt:BoardOfDirectorsChairmanMember 2024-03-26 2024-03-27 0001849380 srt:ScenarioForecastMember srt:BoardOfDirectorsChairmanMember 2024-03-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure ONMD:Integer

 

As filed with the Securities and Exchange Commission on April 16, 2024

 

Registration No. 333-276130

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Amendment No. 1 to

FORM S-1

 

REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933

 

ONEMEDNET CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware   3721   86-2049355

(State or other jurisdiction

of incorporation or organization)

 

(Primary Standard Industrial

Classification Code Number)

 

(I.R.S. Employer

Identification Number)

 

OneMedNet Corporation

6385 Old Shady Oak Road, Suite 250
Eden Prairie, MN 55344

Telephone: 800-918-7189

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

The Corporation Trust Company

Corporation Trust Center

1209 Orange Street

Wilmington, DE 19801

Telephone: 302-658-7581

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

Copies to:

 

Debbie A. Klis, Esq.

Rimon P.C.

1990 K. Street, NW, Suite 420

Washington, DC 20006

Telephone: (202) 935-3390

 

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. ☒

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

Indicate by check mark whether the registrant is a large-accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large-accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large-accelerated filer ☐ Accelerated filer ☐
   
Non-accelerated filer Smaller reporting company
   
  Emerging growth company

 

If an emerging growth company, indicate by check market if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

 

The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission acting pursuant to said section 8(a), may determine.

 

 

 

 
 

 

The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

 

PRELIMINARY PROSPECTUS   SUBJECT TO COMPLETION   DATED APRIL __, 2024

 

A logo with blue and black letters

Description automatically generated

 

Primary Offering of

Up to 12,085,275 Shares of Common Stock

Upon the Exercise of Warrants

 

Secondary Offering of

Up to 19,683,367 Shares of Common Stock

Up to 681,019 Warrants

 

This prospectus relates to the primary issuance by us of up to an aggregate of 12,085,275 shares of common stock, par value $0.0001 per share (the “Common Stock”), of OneMedNet Corporation, a Delaware corporation (“we,” “us,” the “Company” and “OneMedNet”), which consists of (i) up to 11,500,000 shares of Common Stock issuable upon the exercise of 11,500,000 warrants (the “Public Warrants”) originally issued in the initial public offering of Data Knights Acquisition Corp” as a special purpose acquisition company (“DKAC”), and (ii) up to an aggregate of 585,275 shares of Common Stock issuable upon the exercise of 585,275 warrants (the “Placement Warrants,” together with the Public Warrants, the “Warrants”) that made up a part of the private units originally issued in a private placement in connection with DKAC’s initial public offering. We will receive the proceeds from any exercise of the Warrants for cash.

 

This prospectus also relates to the offer and resale from time to time, upon the expiration of lock-up agreements, if applicable, by: (a) the selling shareholders named in this prospectus (including their permitted transferees, donees, pledgees and other successors-in-interest) (collectively, the “Selling Securityholders”) of up to an aggregate of 19,683,367 shares of Common Stock consisting of (i) 797,872 shares of Common Stock upon conversion of up to $1,595,744.70 of OneMedNet Senior Secured Convertible Notes (the “Pre-Closing PIPE Notes”) issued at the closing of the Business Combination (as defined below) subject to a floor price of $2.00 per share pursuant to the terms of the Securities Purchase Agreement dated June 28, 2023, by and among Data Knights Acquisition Corp, a Delaware corporation (“Data Knights”) and the named investors (the “Pre-Closing PIPE”), (ii) 95,744 shares underlying 95,744 warrants related to the Pre-Closing PIPE and the Warrant Agreements executed at the closing of the Business Combination, (iii) 7,312,817 shares of Common Stock upon conversion (the “Conversion Shares) of up to $4,547,500 of funding to the Company pursuant to the Securities Purchase Agreement and convertible promissory notes dated March 28, 2024 (the “PIPE Notes Financing”) with Helena Global Investment Opportunities 1 Ltd. (the “Notes Investor”), (iv) 3,656,408 shares underlying 3,656,408 warrants related to the PIPE Notes Financing with the Notes Investor, (v) 277,778 shares of Common Stock issued pursuant to the terms of the Satisfaction and Discharge Agreement at $10.88 per share dated as of June 28, 2023, by and among the Company, Data Knights, and EF Hutton LLC (“EF Hutton”), (vi) 1,315,840 shares of Common Stock issuable pursuant to the outstanding loans converted to equity at $1 per share to Data Knights to fund its extension payments prior to the Business Combination by certain of the Selling Securityholders named in this prospectus, (vii) 1,439,563 shares of Common Stock issued upon the closing of the Business Combination to ARC Group Limited, as consideration for its financial advisory services, (viii) 1,327,070 shares of Common Stock at $0.7535 (95% of VWAP 10-day average $0.7932) for $1,000,000 investment by Dr. Thomas Kosasa, and (ix) 3,609,859 shares of Common Stock issued to Data Knights LLC (the “Sponsor”) and its affiliates, including 2,875,000 shares of Common Stock originally issued as share of Class B Stock in connection with the initial public offering of DKAC for aggregate consideration of $25,000, or approximately $0.009 per share, and 585,275 shares of Common Stock originally issued to Sponsor as part of the Placement Units issued to the Sponsor in connection with DKAC’s initial public offering at $10.00 per unit, and which are subject to six month lock-up restrictions set forth herein; and (b) the selling warrant holders named in this prospectus (including their permitted transferees, donees, pledgees and other successors-in-interest) (collectively, the “Selling Warrantholders” and, together with the Selling Shareholders and including their permitted transferees, the “Selling Securityholders”) of up to an aggregate of 585,275 Placement Warrants.

 

On April 25, 2022, the Company, Data Knights Merger Sub, Inc., a Delaware corporation (“Merger Sub”), and Data Knights, LLC, the Company’s sponsor (the “Sponsor”), entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) with OneMedNet Corporation, Inc., a Delaware corporation (the “Target,” which has since been renamed “OneMedNet Solutions Corporation”), and together with the Company and Merger Sub, the “Parties”) and Paul Casey, as seller representative (“Casey”). Pursuant to the Merger Agreement, upon the closing (the “Closing”) of the transactions contemplated in the Merger Agreement (collectively, the “Business Combination”), the Parties would consummate the merger of Merger Sub with and into the Target, with the Target continuing as the surviving entity (the “Merger”), which would result in all of the issued and outstanding capital stock of the Target being exchanged for shares of the Company’s Common Stock upon the terms set forth in the Merger Agreement. The Merger and Merger Agreement and the related transactions were approved unanimously by the boards of directors of each of the Company and the Target.

 

As described herein, the Selling Securityholders named in this prospectus or their permitted transferees, may resell from time to time up to 19,683,367 shares of our Common Stock and 681,019 Warrants. We are registering the offer and sale of these securities to satisfy certain registration rights we have granted. The Selling Securityholders may offer, sell or distribute all or a portion of the securities hereby registered publicly or through private transactions at prevailing market prices or at negotiated prices. We will not receive any of the proceeds from such sales of our shares of our Common Stock or Warrants, except with respect to amounts received by us upon the exercise of the Warrants. We will bear all costs, expenses and fees in connection with the registration of these securities, including with regard to compliance with state securities or “blue sky” laws. The Selling Securityholders will bear all commissions and discounts, if any, attributable to their sale of shares of our Common Stock or Warrants. See section entitled “Plan of Distribution” beginning on page 61 of this prospectus.

 

Our Common Stock and warrants are listed on The Nasdaq Stock Market LLC (“Nasdaq”) under the symbols, “ONMD” and “ONMDW.” As of April 15, 2024, we had approximately 23,850,010 shares of Common Stock and 12,181,019 warrants outstanding. On April 15, 2024, the last reported closing price of our of Common Stock and warrants as reported on Nasdaq was $0.68 per share and $0.180 per warrant.

 

We are an “emerging growth company” as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced public company reporting requirements. We may amend or supplement this prospectus from time to time by filing amendments or supplements as required. You should read this entire prospectus and any amendments or supplements carefully before you make your investment decision.

 

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 32 of this prospectus for a discussion of information that should be considered in connection with an investment in our securities.

 

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

 

Prospectus dated ______, 2024.

 

 
 

 

TABLE OF CONTENTS

 

Page
ABOUT THIS PROSPECTUS 1
   
MARKET AND INDUSTRY DATA 1
   
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 2
   
TRADEMARKS AND COPYRIGHTS 3
   
IMPLICATIONS OF BEING AN EMERGING GROWTH COMPANY AND A SMALLER REPORTING COMPANY 3
   
PROSPECTUS SUMMARY 4
   
THE OFFERING 31
   
RISK FACTORS 32
   
USE OF PROCEEDS 46
   
DILUTION 46
   
DESCRIPTION OF SECURITIES WE ARE OFFERING 47
   
SHARES ELIGIBLE FOR FUTURE SALE 49
   
LEGAL MATTERS 62
   
EXPERTS 62
   
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 62
   
LEGAL PROCEEDINGS 69
   
WHERE YOU CAN FIND MORE INFORMATION 70
   
INCORPORATION OF DOCUMENTS BY REFERENCE 70

 

 

 

You should rely only on the information contained in this prospectus or any supplement. Neither we nor the Selling Securityholders have authorized anyone else to provide you with different information. The securities offered by this prospectus are being offered only in jurisdictions where the offer is permitted. You should not assume that the information in this prospectus or any supplement is accurate as of any date other than the date on the front of each document. Our business, financial condition, results of operations and prospects may have changed since that date.

 

Except as otherwise set forth in this prospectus, neither we nor the Selling Securityholders have taken any action to permit a public offering of these securities outside the United States or to permit the possession or distribution of this prospectus outside the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about and observe any restrictions relating to the offering of these securities and the distribution of this prospectus outside the United States.

 

i
 

 

ABOUT THIS PROSPECTUS

 

This prospectus is part of a registration statement that we filed with the SEC using a “shelf” registration process. By using a shelf registration statement, the Selling Securityholders may sell up to 19,683,367 shares of Common Stock and up to 681,019 Warrants from time to time in one or more offerings as described in this prospectus. We will not receive any proceeds from the sale of Common Stock or Warrants by the Selling Securityholders. This prospectus also relates to the issuance by up to 12,085,275 Common Stock upon the exercise of Warrants. We will receive the proceeds from any exercise of the Warrants for cash.

 

We may also file a prospectus supplement or post-effective amendment to the registration statement of which this prospectus forms a part that may contain material information relating to these offerings. The prospectus supplement or post-effective amendment, as the case may be, may add, update or change information contained in this prospectus with respect to such offering. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement or post-effective amendment, you should rely on the prospectus supplement or post-effective amendment, as applicable. Before purchasing any of the Common Stock or Warrants, you should carefully read this prospectus and any prospectus supplement and/or post-effective amendment, as applicable, together with the additional information described under “Where You Can Find More Information.”

 

Neither we nor the Selling Securityholders have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus and any prospectus supplement and/or post-effective amendment, as applicable, prepared by or on behalf of us or to which we have referred you. We and the Selling Securityholders take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We and the Selling Securityholders will not make an offer to sell the Common Stock or Warrants in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus and any prospectus supplement and/or post-effective amendment, as applicable, is accurate only as of the date on the respective cover. Our business, prospects, financial condition or results of operations may have changed since those dates. This prospectus contains, and any prospectus supplement or post-effective amendment may contain, market data and industry statistics and forecasts that are based on independent industry publications and other publicly available information. Although we believe these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently verified this information. In addition, the market and industry data and forecasts that may be included in this prospectus and any prospectus supplement and/or post-effective amendment, as applicable, may involve estimates, assumptions and other risks and uncertainties and are subject to change based on various factors, including those discussed under “Risk Factors” in this prospectus and any prospectus supplement and/or post-effective amendment, as applicable. Accordingly, investors should not place undue reliance on this information.

 

MARKET AND INDUSTRY DATA

 

Unless otherwise indicated, information contained in this prospectus concerning our industry and the regions in which we operate, including our general expectations and market position, market opportunity, market share and other management estimates, is based on information obtained from various independent publicly available sources and other industry publications, surveys and forecasts. While we believe that the market data, industry forecasts and similar information included in this prospectus are generally reliable, such information is inherently imprecise. In addition, assumptions and estimates of our future performance and growth objectives and the future performance of our industry and the markets in which we operate are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those discussed under the headings “Risk Factors,” “Cautionary Note Regarding Forward-Looking Statements” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this prospectus.

 

Information contained in this prospectus concerning our industry, market and competitive position data in this prospectus from our own internal estimates and research as well as from publicly available information, industry and general publications and research, surveys and studies conducted by third parties.

 

1
 

 

Industry publications and forecasts generally state that the information they contain has been obtained from sources believed to be reliable, but such information is inherently imprecise. Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications and uncertainties as the other forward-looking statements in this prospectus. These forecasts and forward-looking information are subject to uncertainty and risk due to a variety of factors, including those described under “Risk Factors.” These and other factors could cause results to differ materially from those expressed in any forecasts or estimates.

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This prospectus contains forward-looking statements that involve risks and uncertainties. You should not place undue reliance on these forward-looking statements. All statements other than statements of historical facts contained in this prospectus are forward-looking statements. The forward-looking statements in this prospectus are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. In some cases, you can identify these forward-looking statements by terms such as “anticipate,” “believe,” “continue,” “could,” “depends,” “estimate,” “expects,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms or other similar expressions, although not all forward-looking statements contain those words. We have based these forward-looking statements on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, strategy, short- and long-term business operations and objectives, and financial needs. These forward-looking statements include, but are not limited to, statements concerning the following:

 

  our projected financial position and estimated cash burn rate;
     
  our estimates regarding expenses, future revenues and capital requirements;
     
  our ability to continue as a going concern;
     
  our need to raise substantial additional capital to fund our operations;
     
  our ability to compete in the global space industry;
     
  our ability to obtain and maintain intellectual property protection for our current products and services;
     
  our ability to protect our intellectual property rights and the potential for us to incur substantial costs from lawsuits to enforce or protect our intellectual property rights;
     
  the possibility that a third party may claim we have infringed, misappropriated or otherwise violated their intellectual property rights and that we may incur substantial costs and be required to devote substantial time defending against these claims;
     
  our reliance on third-party suppliers and manufacturers;
     
  the success of competing products or services that are or become available;
     
  our ability to expand our organization to accommodate potential growth and our ability to retain and attract key personnel; and
     
  the potential for us to incur substantial costs resulting from lawsuits against us and the potential for these lawsuits to cause us to limit our commercialization of our products and services.

 

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in “Risk Factors.” Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this prospectus may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

 

2
 

 

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this prospectus to conform these statements to actual results or to changes in our expectations.

 

You should read this prospectus and the documents that we reference in this prospectus and have filed with the SEC as exhibits to the registration statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements including those described in the “Risk Factors” section beginning on page 32 and elsewhere in this prospectus.

 

TRADEMARKS AND COPYRIGHTS

 

We own or have rights to trademarks or trade names that we use in connection with the operation of our business, including our corporate names, logos and website names. In addition, we own or have the rights to copyrights, trade secrets and other proprietary rights that protect the content of our products and the formulations for such products. This prospectus may also contain trademarks, service marks and trade names of other companies, which are the property of their respective owners. Our use or display of third parties’ trademarks, service marks, trade names or products in this prospectus is not intended to, and should not be read to, imply a relationship with or endorsement or sponsorship of us. Solely for convenience, some of the copyrights, trade names and trademarks referred to in this prospectus are listed without their ©, ® and ™ symbols, but we will assert, to the fullest extent under applicable law, our rights to our copyrights, trade names and trademarks. All other trademarks are the property of their respective owners.

 

IMPLICATIONS OF BEING AN EMERGING GROWTH COMPANY AND

A SMALLER REPORTING COMPANY

 

We qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). For so long as we remain an emerging growth company, we are permitted, and currently intend, to rely on the following provisions of the JOBS Act that contain exceptions from disclosure and other requirements that otherwise are applicable to public companies and file periodic reports with the SEC. These provisions include, but are not limited to:

 

  being permitted to present only two years of audited financial statements and selected financial data and only two years of related “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our periodic reports and registration statements, including this prospectus, subject to certain exceptions;
     
  not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (“SOX”);
     
  reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements, and registration statements, including in this prospectus;
     
  not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board (the “PCAOB”) regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements; and
     
  exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

 

We will remain an emerging growth company until the earliest to occur of:

 

  December 31, 2028 (the last day of the fiscal year that follows the fifth anniversary of the completion of our initial public offering);

 

  the last day of the fiscal year in which we have total annual gross revenue of at least $1.235 billion;
     
  the date on which we are deemed to be a “large-accelerated filer,” as defined in the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”); and
     
  the date on which we have issued more than $1 billion in non-convertible debt over a three-year period.

 

We have elected to take advantage of certain of the reduced disclosure obligations in this prospectus and may elect to take advantage of other reduced reporting requirements in our future filings with the SEC. As a result, the information that we provide to holders of our Common Stock may be different than what you might receive from other public reporting companies in which you hold equity interests. We have elected to avail ourselves of the provision of the JOBS Act that permits emerging growth companies to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. As a result, we will not be subject to new or revised accounting standards at the same time as other public companies that are not emerging growth companies.

 

We are also a “smaller reporting company” as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies until the fiscal year following the determination that our voting and non-voting common stock held by non-affiliates is $250 million or more measured on the last business day of our second fiscal quarter, or our annual revenues are less than $100 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is $700 million or more measured on the last business day of our second fiscal quarter.

 

3
 

 

PROSPECTUS SUMMARY

 

This summary of the prospectus highlights material information concerning our business and this offering. This summary does not contain all of the information that you should consider before making your investment decision. You should carefully read the entire prospectus, including the information presented under the section entitled “Risk Factors” and the financial data and related notes, before making an investment decision. It does not contain all the information that may be important to you and your investment decision. You should carefully read this entire prospectus, including the matters set forth under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and our financial statements and related notes included elsewhere in this prospectus. This summary contains forward-looking statements that involve risks and uncertainties. Our actual results may differ significantly from future results contemplated in the forward-looking statements as a result of factors such as those set forth in “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements.”

 

In this prospectus, unless the context indicates otherwise, “OneMedNet,” the “Company,” “we,” “our,” “ours” or “us” refer to OneMedNet Corporation a Delaware corporation, and its direct and indirect subsidiaries, including, but not limited to, OneMedNet Solutions Corporation, a Delaware corporation and its wholly-owned subsidiary, OneMedNet Technologies (Canada) Inc., incorporated on October 16, 2015 under the provisions of the Business Corporations Act of British Columbia whose functional currency is the Canadian dollar.

 

We have not authorized anyone to provide you with different information and you must not rely on any unauthorized information or representation. We are not making an offer to sell these securities in any jurisdiction where an offer or sale is not permitted. This document may only be used where it is legal to sell these securities. You should assume that the information appearing in this prospectus is accurate only as of the date on the front of this prospectus, regardless of the time of delivery of this prospectus, or any sale of our Common Stock. Our business, financial condition and results of operations may have changed since the date on the front of this prospectus. We urge you to carefully read this prospectus before deciding whether to invest in any of the Common Stock being offered.

 

The Company

 

OneMedNet Corporation a Delaware corporation (the “Company,” “we,” “us,” or “OneMedNet”) together with its wholly-owned subsidiary OneMedNet Solutions Corporation, a Delaware corporation, founded in 2009 and incorporated in November 20, 2015, and its wholly-owned subsidiary, OneMedNet Technologies (Canada) Inc., incorporated on October 16, 2015 under the provisions of the Business Corporations Act of British Columbia whose functional currency is the Canadian dollar. All refences in this prospectus to the “Company,” “we,” “us,” or “OneMedNet” include OneMedNet Solutions Corporation.

 

Corporate History

 

We were originally incorporated in Delaware on February 8, 2021 under the name “Data Knights Acquisition Corp” as a special purpose acquisition company, formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

 

On May 11, 2021, we consummated an initial public offering (the “Initial Public Offering”). The registration statement for the Company’s Initial Public Offering was declared effective on May 6, 2021. The Company’s Initial Public Offering of 10,000,000 units (the “Units” and, with respect to the Common Stock included in the Units being offered, the “Public Shares”), at $10.00 per Unit, generated gross proceeds of $100,000,000. The Company granted the underwriter a 45-day option to purchase up to an additional 1,500,000 Units at the Initial Public Offering price to cover over-allotments, which the underwriters exercised the over-allotment option in full, and the closing of the issuance and sale of the additional Units occurred (the “Over-allotment Option Units”). The total aggregate issuance by the Company of 1,500,000 units at a price of $10.00 per unit resulted in total gross proceeds of $15,000,000. Simultaneously with the consummation of the closing of the Offering, the Company consummated the private placement of an aggregate of 585,275 units (the “Placement Units”) to the Sponsor at a price of $10.00 per Placement Unit, generating total gross proceeds of $5,852,750 (the “Private Placement”).

 

4
 

 

The Placement Units were issued pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, as the transactions did not involve a public offering. A total of $117,300,000, comprised of the proceeds from the Offering and the proceeds of private placements that closed on May 11, 2021, net of the underwriting commissions, discounts, and offering expenses, was deposited in a trust account established for the benefit of the Company’s public stockholders. On June 22, 2021, the Common Stock and Public Warrant included in the Units began separate trading.

 

No payments for our expenses were made in the offering described above directly or indirectly to (i) any of our directors, officers or their associates, (ii) any person(s) owning 10% or more of any class of our equity securities or (iii) any of our affiliates, except in connection with the repayment of outstanding loans and pursuant to the administrative support agreement disclosed herein which we entered into with our sponsor.

 

On April 25, 2022, the Company, Data Knights Merger Sub, Inc., a Delaware corporation (“Merger Sub”), and Data Knights, LLC, the Company’s sponsor (the “Sponsor”), entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) with OneMedNet Corporation, Inc., a Delaware corporation (the “Target,” which has since been renamed “OneMedNet Solutions Corporation”), and together with the Company and Merger Sub, the “Parties”) and Paul Casey, as seller representative (“Casey”). Pursuant to the Merger Agreement, upon the closing (the “Closing”) of the transactions contemplated in the Merger Agreement (collectively, the “Business Combination”), the Parties would consummate the merger of Merger Sub with and into the Target, with the Target continuing as the surviving entity (the “Merger”), which would result in all of the issued and outstanding capital stock of the Target being exchanged for shares of the Company’s Common Stock upon the terms set forth in the Merger Agreement. The Merger and Merger Agreement and the related transactions were approved unanimously by the boards of directors of each of the Company and the Target.

 

On December 31, 2022, substantially all of the assets held in the Trust Account were held in mutual funds.

 

On June 28, 2023, the Company executed a Securities Purchase Agreement for PIPE financing in the aggregate original principal amount of $1,595,744.70 and a purchase price of $1.5 million (the “Pre-Closing PIPE”). Pursuant to the Securities Purchase Agreement, the Company agreed to issue and sell to each of Thomas Kosasa, Dr. Jeffrey Yu, Aaron Green and Steve Kester (the “PIPE Investors”), a new series of senior secured convertible notes (the “Pre-Closing PIPE Notes”), which Notes shall be convertible into shares of Common Stock at the PIPE Investors election at the conversion price (rounded to the nearest 1/100th of one cent) which shall be computed as the lesser of:

 

(a) with respect to a conversion pursuant to Section 4.1 of the Securities Purchase Agreement (discussed below), the lesser of: (i) a price per share equal to the product of (x) 100% less the Discount and (y) the lowest per share purchase price of the Equity Securities issued in the Next Equity Financing; and (ii) $2.50 per share; and

 

(b) with respect to a conversion pursuant to Section 4.2 (discussed below), (relating to payment at maturity) or Section 4.3, $2.50 per share. The Securities Purchase agreement provided that the PIPE Investors’ $1.5 million investment in the Pre-Closing PIPE Notes would close and fund contemporaneous to the Closing of the Business Combination.

 

Section 4.1 of the Securities Purchase Agreement provides that the principal balance and unpaid accrued interest on each Note will automatically convert into the PIPE Conversion Shares upon the closing of the Next Equity Financing (“Next Equity Financing” means the next sale or series of related sales by the Company of its Common Stock in one or more offerings relying on Section 4(a)(2) of the Securities Act or Regulation D thereunder for exemption from the registration requirements of Section 5 of the Securities Act, from which the Company receives gross proceeds of not less than US$5,000,000 (excluding, for the avoidance of doubt, the aggregate principal amount of the Notes).

 

Section 4.2 of the Securities Purchase Agreement provides that in the event of a Corporate Transaction or the repayment of such Note, at the closing of a corporate transaction, the holder of each Note may elect that either: (a) the Company will pay the holder of such Note an amount equal to the sum of (x) the outstanding principal balance of such Note, and (y) a premium equal to 20% of the outstanding principal balance of such Note (which premium, is in lieu of all accrued and unpaid interest due on such Note); or (b) such Note will convert into that number of Conversion Shares equal to the quotient (rounded down to the nearest whole share) obtained by dividing (x) the outstanding principal balance and unpaid accrued interest of such Note on a date that is no more than five days prior to the closing of such corporate transaction by (y) the applicable Conversion Price.

 

5
 

 

Notwithstanding the foregoing, any sale (or series of related sales) of the Company’s Equity Securities to a special purpose acquisition company will not be deemed a “Next Equity Financing. Notwithstanding the foregoing, the Company may, at its option, pay any unpaid accrued interest on each Note in cash at the time of conversion. The number of PIPE Conversion Shares the Company issues upon such conversion will equal the quotient (rounded down to the nearest whole share) obtained by dividing (x) the outstanding principal balance and unpaid accrued interest under each converting Note on a date that is no more than five days prior to the closing of the Next Equity Financing by (y) the applicable Conversion Price. At least five days prior to the closing of the Next Equity Financing, the Company will notify the holder of each Note in writing of the terms of the Equity Securities that are expected to be issued in such financing. The issuance of PIPE Conversion Shares pursuant to the conversion of each Note will be on, and subject to, the same terms and conditions applicable to the Equity Securities issued in the Next Equity Financing.

 

Also on June 28, 2023, EF Hutton LLC (“EF Hutton”) waived $3,025,000 of the $4,025,000 cash deferred underwriting commission do to it at the Closing of the Business Combination, pursuant to a Satisfaction and Discharge Agreement. In accordance with the Satisfaction and Discharge Agreement, EF Hutton accepted, in lieu of the cash deferred underwriting commission due at closing (i) a one-time cash payment of $500,000 at the time of the Closing; (ii) a $500,000 promissory note executed by the Company on June 30, 2023 in which it is obligated to make six monthly payments to EF Hutton in the cash amount of $83,333.33 commencing after the Closing; and (iii) 277,778 shares of common stock of the Company (the “Common Stock”) at $10.89 per share, for an aggregate value of $3,025,000.

 

On September 21, 2023, the Securities and Exchange Commission (the “SEC”) declared effective the Company’s registration statement and proxy statement/prospectus on Form S-4 (the “Definitive Proxy”).

 

As of the close of business on September 20, 2023 (the “Record Date”), 5,172,973 shares of common stock of the Company (the “Common Stock”) were issued and outstanding and entitled to vote at the Special Meeting. On October 17, 2023, the Company held a special meeting of its stockholders (the “Stockholders”) in lieu of its 2023 annual meeting of Stockholders (the “Special Meeting”) in connection with the transactions contemplated by the Merger Agreement. At the Special Meeting, the Stockholders were asked to consider and vote on the proposals identified in the Definitive Proxy; 4,690,565 shares of Common Stock were represented in person or by proxy at the Special Meeting, and, therefore, a quorum was present and all proposal were approved.

 

On November 7, 2023, we held the Closing of the previously announced Merger whereby Merger Sub merged with and into OneMedNet Solutions Corporation (formerly named OneMedNet Corporation), with OneMedNet Solutions Corporation continuing as the surviving entity, which resulted in all of the issued and outstanding capital stock of OneMedNet Solutions Corporation being exchanged for shares of the Company’s Common Stock upon the terms set forth in the Merger Agreement. The Merger and other transactions that closed on November 7, 2023, pursuant to the Merger Agreement, led to Data Knights changing its name to “OneMedNet Corporation” and the business of the Company became the business of OneMedNet Solutions Corporation.

 

Pursuant to the terms of the Merger Agreement, the total consideration for the Business Combination and related transactions (the “Merger Consideration”) was approximately $200 million. In connection with the Special Meeting, certain public holders (the “Redeeming Stockholders”) holding 1,600,741 shares of Common Stock exercised their right to redeem such shares for a pro rata portion of the funds held by Continental Stock Transfer & Trust Company, as trustee (“Continental”) in the trust account established in connection with Data Knights’ initial public offering (the “Trust Account”).

 

Effective November 7, 2023, Data Knights’ units ceased trading, and effective November 8, 2023, OneMedNet’s common stock began trading on the Nasdaq Capital Market under the symbol “ONMD” and the warrants began trading on the Nasdaq Capital Market under the symbol “ONMDW.”

 

As a result of the Merger and the Business Combination, holders of Data Knights common stock automatically received common stock of OneMedNet, and holders of Data Knights warrants automatically received warrants of OneMedNet with substantively identical terms. At the Closing of the Business Combination, all shares of Data Knights owned by the Sponsor (consisting of shares of Common Stock and shares of Class B common stock, which we refer to as the founder shares), automatically converted into an equal number of shares of OneMedNet’s Common Stock, and the Private Placement Warrants held by the Sponsor, automatically converted into warrants to purchase one share of OneMedNet Common Stock with substantively identical terms.

 

6
 

 

Effective as of the Closing on November 7, 2023, among other holders, public stockholders own 98,178 shares of OneMedNet Common Stock approximately representing 0.35% of the outstanding shares of OneMedNet Common Stock; the Sponsor and its affiliates own approximately 15.1% of the outstanding shares of OneMedNet common stock (inclusive of shares received upon conversion of the Sponsor’s loan); OneMedNet’s former security holders own approximately 61.992% of the outstanding shares of OneMedNet common stock from the conversion of their shares; PIPE investors own 0.46% of the outstanding shares of OneMedNet Common Stock and former convertible note holders own approximately 16.24% of the outstanding shares of OneMedNet Common Stock resulting from the issuance of 5,238,800 shares of Common Stock upon conversion of their notes.

 

On March 28, 2024, the Company entered into a definitive securities purchase agreement (the “Notes Securities Purchase Agreement”) with Helena Global Investment Opportunities 1 Ltd. (the “Notes Investor”), an affiliate of Helena Partners Inc., a Cayman-Islands based advisor and investor providing for up to USD$4.54 million in funding through a private placement (the “PIPE Notes Financing”) for the issuance of senior secured convertible notes (the “PIPE Notes”). In connection with the issuance of the Notes, the Company will issue to the Investor common stock purchase warrants (the “Warrants”) across multiple tranches (the “Tranches”) consisting of an initial tranche (the “Initial Tranche”) of (i) an aggregate principal amount $2,000,000.00 and including an original issue discount (“OID”) of up to an aggregate of $300,000.00 plus Warrants to purchase a number of shares of Common Stock equal to the applicable Warrant Share Amounts (defined below). The second tranche (the “Second Tranche”) consists of an aggregate principal amount of Notes of up to $350,000.00 and including an OID of up to $52,500.00 and Warrants to purchase a number of shares of Common Stock equal to the applicable Warrant Share Amounts with respect to such Tranche. The Notes Securities Purchase Agreement contemplates three subsequent Tranches each of which shall be in an aggregate principal amount of Notes of up to $1,000,000 each and each including an OID of 15.0% of the applicable principal amount, and Warrants to purchase a number of shares of Common Stock equal to the applicable Warrant Share Amounts with respect to such Tranches.

 

The purchase price of a PIPE Note and its accompanying Warrant shall be computed by subtracting the portion of the OID represented by that such PIPE Note from the portion of the principal amount represented by such Note (a “Purchase Price”).

 

The Notes Securities Purchase Agreement defines Warrant Share Amounts means in respect of any Warrant issued in a Closing the initial amount of shares of Common Stock (the “Warrant Shares”) for which such Warrant may be exercised and which shall be equal to the applicable principal amount of the Note issued to the Investor in such closing multiplied by 50% and divided by the 95% of lowest VWAP over the ten Trading Day period immediately preceding the applicable Closing Date.

 

In connection with the closings of each Tranche, a portion of the proceeds will be held in escrow (the “Escrow”) pursuant to an executed Escrow Agreement dated as of March 28, 2024 in accordance with the following: (i) $1,350,000.00 of the net proceeds of the Initial Tranche will be paid into the Escrow Account for distribution in accordance with the release of proceeds conditions (the “Release Conditions” discussed below), with the balance of the net proceeds paid to the Company less initial closing expenses relating to such Initial Tranche; (ii) 100% of the net proceeds of the Third Tranche shall be paid into the Escrow Account for distribution in accordance with the Release Conditions; and (iii) 75% of the net proceeds of the Third Tranche shall be paid into the Escrow Account for distribution in accordance with the Release Conditions with the balance of the net proceeds of the Third Tranche being paid to the Company less initial closing expenses relating to such Third Tranche.

 

7
 

 

The Securities Purchase Agreement provides that the amounts in Escrow (the “Escrowed Proceeds”) related to the Initial Tranche, Second Tranche and Third Tranche are governed by the following terms:

 

  a) The Escrowed Proceeds will be released to the Investor for payment amounts owing in respect of the Notes, if the closing price of the Common Stock shall have been less than the then Floor Price (as defined in the Notes) for a period of 10-consecutive trading days, or an event of default shall have occurred;
     
  b) The Escrowed Proceeds will be released to the Company if the aggregate outstanding amount is equal to zero;
     
  c) If on the date that is 20 trading days following the closing of the Initial Tranche, the aggregate outstanding amount is more than zero but less than $1,700,000.00, then the Escrowed Proceeds will be released to the Company in an amount equal to the difference between $1,700,000.00 and the aggregate outstanding amount; and
     
  d) If on the date that is 40 trading days following the Closing Date of the Initial Tranche and every 20 trading days thereafter, the aggregate outstanding amount is more than zero but less than $1,700,000.00 minus the amount of any prior disbursement from the Escrow Account pursuant to this provision (d) or provision (c) above (the “Adjusted Escrow Reference Amount”), then the Escrowed Proceeds will be released to the Company an amount equal to the difference between the Adjusted Escrow Reference Amount and such aggregate outstanding amount.

 

In connection with the Notes Securities Purchase Agreement, the Company and the Investor also entered into a Registration Rights Agreement, dated as of March 28, 2024 (the “RRA”), providing for the registration of the Note shares (the “Note Conversion Shares”) and the Warrant Shares (the “Registerable Securities”). The Company has agreed to prepare and file a registration statement (the “Registration Statement”) with the Securities and Exchange Commission (the “SEC”) promptly, and in any event within 30 days of the closing of the private placement. The Company has granted the Investor customary indemnification rights in connection with the Registration Rights Agreement. The Investors have also granted the Company customary indemnification rights in connection with the Registration Statement.

 

The securities to be issued pursuant to the Notes Securities Purchase Agreement was made in reliance on the exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933, as amended (the “Securities Act”), as promulgated by the Securities and Exchange Commission under the Securities Act.

 

Who We Are

 

We are OneMedNet, and our goal is to be a leader in the future of regulatory-grade Imaging Real Word Data (“RWD”) through our intelligent, thoughtful and inclusive iRWDTM solution. We strive to revolutionize access fast and secure access to curated medical images with our strategic thinking, successful market entry and execution to continue to open new possibilities for providing clinical imaging evidence.

 

We are bold, decisive and eager to advance a global platform for our OneMedNet iRWD™ solution.

 

We aim to constantly push boundaries in our approach to technology, service innovation, customer engagement and curation excellence, all for the sake of delivering an exceptional customer experience.

 

Our mission is affect a material positive impact on the lives of tens of millions of people while improving our customers’ business productivity. First and foremost, OneMedNet’s iRWDTM offering plays a significant role in enabling Life Science companies to bring safer and more effective patient care to market sooner. Using our highly curated de-identified clinical data in our iRWDTM offering in Life Science product development, validation, and regulatory approval processes, they contribute to patient care advancements in more meaningful ways, which Life Sciences industry can improve their product development and validation processes, which benefits all parties.

 

At OneMedNet, our motto is to “Unlock the Value in Imaging ArchivesTM”. By utilizing OneMedNet’s iRWDTM offering, providers can greatly improve their research efforts with streamlined data access. Health care providers such as hospitals, clinics, and imaging centers can also accelerate life science patient care innovations by sharing de-identified data in a well-defined and de-identified and secure manner. In return for doing so, income is generated and applied to critical and possibly unfunded provider projects. In that spirit, we are breaking boundaries by focusing on the future, constantly innovating from a technology and user experience perspective and are ready to push forward. With that said, we recognize that we cannot do this alone, and we urge those who share this desire to unite with us on our journey to a brighter and greener future.

 

Come join the charge with us.

 

Our Business

 

OneMedNet is a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real-World Data3 or iRWDTM. OneMedNet’s innovative solutions connect healthcare providers and patients satisfying a crucial need within the Life Sciences field offering direct access to clinical images and the associated contextual patient record. OneMedNet’s innovative technology proved the commercial and regulatory viability of imaging Real-World Data, an emerging market, and provides regulatory-grade image-centric iRWDTM that exactly matches OMN’s Life Science partners Case Selection Protocols and paves the way for Real World Evidence.

 

OneMedNet was founded to solve a deficiency in how clinical images were shared between healthcare providers. This resulted in OMN’s initial product BEAMTM image exchange that enabled the successful sharing of images for more than a decade with OMN’s largest customer being the Country of Ireland.

 

8
 

 

OneMedNet continued to innovate by responding to the demand for and utilization of Real-World Data and Real-World Evidence, specifically data that focused on clinical images with its associated contextual clinical record. We were able to leverage internal technological competencies along with OneMedNet’s formidable healthcare provider installed base from its first product with BEAMTM to become the first RWD solution for Life Science companies with its launch of iRWDTM in 2019.

 

OneMedNet provides innovative solutions that unlock the significant value contained within clinical image archives. With a growing federated network of 95+ healthcare facilities, OneMedNet has the immediate ability to quickly search and extensively curate multi-layer data from a Federated group of healthcare facilities. The term “healthcare facilities” refers specifically to the hospitals, integrated delivery networks (“IDNs”) and imaging centers that provide imaging to OneMedNet, which represent the core source of our data. At present, OneMedNet works with more than 95 facilities who provide regulatory grade imaging to us. OneMedNet has access to these more than 95 facilities because these 95+ contracted facilities have more than 200 locations among them including offices and clinics, which in total generates regulatory grade imaging from more than 200 customers. Among these customers, all are data providers and some are data purchasers.

 

OneMedNet is ahead of the curve when it comes to providing fast and secure access to curated medical images. Initially, it was all about solving the diverse access needs of patient care providers. This focus systematically evolved to addressing the rapidly growing needs of image analysis and researchers, clinicians, regulators, scientists and more.

 

 

Real-world data is any data that is collected in the context of the routine delivery of care, in contrast to data collected within a clinical trial where study design controls variability in ways that are not representative of real-world care and outcomes.

 

A key component driving its mission is that OneMedNet believes we have a unique opportunity to affect a material positive impact on the lives of tens of millions of people while improving our customers’ business productivity. First and foremost, OneMedNet’s iRWDTM offering plays a significant role in enabling Life Science companies to bring safer and more effective patient care to market sooner. Using our highly curated de-identified clinical data in our iRWDTM offering in Life Science product development, validation, and regulatory approval processes, they contribute to patient care advancements in more meaningful ways. Moreover, Life Sciences improve their product development and validation processes, which benefits all parties.

 

Significant documentation exists that shows that Real-World Data can provide expanded insights across broader and more representative patient populations.1 For this reason, the Food and Drug Administration (“FDA”) has instituted Real-World Data guidelines for regulatory approvals. Utilization of highly reliable and quality Real-World Data that strictly adheres to all of the very specific data stratification requirements can supplement or supplant clinical trials.

 

OneMedNet covers the complete value chain in imaging Real-World Data; it begins with our 10+ year federated network of providers and is supported by a multi-faceted data curation process managed by an expert in-house clinical team. Additionally, we work hand-in-hand with our Life Science partners regarding the Case Selection Protocol and when required producing Case Report Forms for regulatory clearance. We are focused on delivering value by supporting Life Science Advancements with OneMedNet’s iRWDTM which holds the key to unlocking boundless patient care advances. We unleash the power of research-grade image-centric iRWDTM that is highly curated to painstakingly meet every cohort requirement and stand up to all of the rigors of prospective clinical trials.

 

Today, life science companies, including pharmaceutical companies, artificial intelligence (AI) developers, medical device businesses, and clinical research organizations share the same widespread challenge in obtaining insight-rich, high-quality patient data that explicitly matches their precise cohort specifications. A substantial portion of patient diagnosis involves clinical imaging and approximately 90% of healthcare data, by size, is associated with imaging. Historically, much of imaging value has been derived from its initial review and further gains from the image archives have been very limited.

 

 

1 See https://www.fda.gov/media/120060/download

 

9
 

 

We help providers to “Unlock the Value in Imaging Archives”.TM By utilizing OneMedNet’s iRWDTM offering, providers can greatly improve their research efforts with streamlined data access. Health care providers such as hospitals, clinics, and imaging centers can also accelerate life science patient care innovations by sharing de-identified data in a well-defined and de-identified and secure manner. In return for doing so, income is generated and applied to critical and possibly unfunded provider projects.

 

The OneMedNet Difference

 

OneMedNet has been a leader in the business of extracting, securing, and transferring medical data for 12+ years. Doing so requires specialized expertise in:

 

  Compliancy (HIPAA, GDPR, 21 Part11)
     
  Advanced privacy & security measures
     
  Clinical patient condition(s) and hospital processes
     
  Radiology interpretation
     
  AI/ML technology

 

Attaining in-house expertise in all essential elements is quite a challenge and deters many organizations from even attempting such a venture. We take pride in this ambitious achievement – while continually working to maintain state-of-the-art expertise. OneMedNet strictly adheres to the highest level of professional and ethical standards and applicable regulations throughout all interactions and activities.

 

We believe there is a reason OneMedNet is the leader in an uncrowded field of regulatory-grade imaging RWD curators. Doing so requires specialized expertise in AI/ML technology, data privacy/security, as well as expertise in clinical patient condition(s) and healthcare record keeping. Having, or achieving, expertise in all essential disciplines is a challenging achievement. OneMedNet had a significant head start with our clinical image exchange solution which served to launch the company nearly a decade ago. All data remains “native” within the federated OneMedNet iRWDTM provider network – meaning all the data remains locally onsite until specific de-identified data is licensed for a particular Life Science research opportunity.

 

A close-up of a text

Description automatically generated

 

OneMedNet’s Competitive Advantages

 

We believe that OneMedNet iRWDTM offers the best of advanced technology, clinical expert curation, and service. Medical imaging and associated clinical data is indexed at each network site using state-of-the-art AI/ML technology. This typically includes electronic health records (“EHR”), radiology, cardiology, lab, path and more. Our in-house clinical team performs intensive curation of the data ensuring that results meet the exact specification and requirements of Life Science Data Collection Protocol (“DCP”) – regardless of the complexity.

 

10
 

 

We believe that OneMedNet unlocks the value in imaging and electronic health records data in the following three principal ways:

 

  Regulatory Grade — Our imaging results serve as proof of effectiveness for regulatory agencies, meeting requirements for quality & diversity;
     
  On Demand — Our powerful indexing platform access and harmonizes complete patient profiles across fragmented data silos, delivering images and records on-demand;
     
  Expertly Curated — We curate to the most stringent multi-level stratified requirements, providing unmatched data accuracy and completeness.

 

A diagram of a data security system

Description automatically generated

 

OneMedNet’s data is fully de-identified using a multi-step quality control process and goes beyond PHI to include PII (personally identifiable information), SII (Site Identifiable Information), and more. Importantly, Life Science users receive the data in the exact format that they require. No data sifting or manipulation is needed. The data is simply ready for use. Moreover, OneMedNet has the unique combination of knowledge, tools, and experience to:

 

  Access and harmonize complete patient profiles across fragmented data silos;
     
  Provide unmatched data accuracy and completeness;
     
  Ensure the security and privacy of patients’ Protected Health Information (PHI)Imaging RWD is our singular passion and focus and no one does it better.

 

Finally, OneMedNet has the most experienced and clinically trained data curators in the industry. This team appreciates the complexity and criticality of clinical data and can effectively communicate with both Provider and Life Science specialists.

 

11
 

 

A diagram of a company's company

Description automatically generated

 

OneMedNet has been a leader in the business of extracting, securing, and transferring medical data for 12+ years. Doing so requires specialized expertise in:

 

  Compliancy (HIPAA, GDPR, 21 Part11)
  Advanced privacy & security measures
  Clinical patient condition(s) and hospital processes
  Radiology interpretation
  AI/ML technology

 

Attaining in-house expertise in all essential elements is quite a challenge and deters many organizations from even attempting such a venture. We take pride in this ambitious achievement – while continually working to maintain state-of-the-art expertise. OneMedNet strictly adheres to the highest level of professional and ethical standards and applicable regulations throughout all interactions and activities.

 

Industry Background

 

A 2016 analysis published in the Journal of Health Economics and authored by the Tufts Center for the Study of Drug Development placed the cost of bringing a drug to market, including post-approval research and development, at a staggering $2.87 billion.2 Meanwhile, a 2018 study from the Tufts Center noted that the timeline for new drug development ranged from 12.8 years for the average drug to 17.2 years for ultra-orphan drugs that only affect several hundred patients.3 This places the onus on life science organizations to find ways to deliver treatments to patients faster — especially those who cannot wait 17 years for a potentially life-saving treatment. Knowing how a medicinal product is actually used by patients can help stakeholders across the healthcare ecosystem make important and potentially life-saving real-time decisions.

 

Real-World Data is observational data typically gathered when an approved medical product is on the market and used by “real” patients in real life, as opposed to clinical trials or real world images for real patients. The FDA cites several potential sources of Real-World Data, including electronic health records (“EHRs”), claims, disease and product registries, there are multiple types of data including structured and unstructured data, clinical and billing data, transactional and claims data, patient-generated data, and data gathered from additional sources that can shed light on a patient’s health status and more. As reliance on healthcare data grows exponentially, OneMedNet has observed that the reliance on information has increased coming from multiple additional sources including EHRs, claims, registries, clinical trials, patient and provider surveys, wearable devices and more. These additional sources include the internet of things (“IoT”), social media forums and blogs. Real-World Data has the potential to break down inefficiencies and fill gaps in information silos among stakeholders throughout the healthcare ecosystem of providers, payers, manufacturers, government entities and patients. This information sharing, in turn, enables all parties to derive new insights, support value-based care and deliver better health outcomes.

 

Commercializing a drug requires its developer to harness various sources of Real-World Data to identify patient populations and refine sales and marketing strategies for those populations among many other undertakings. Historically, this practice involved purchasing large amounts of data from data aggregators or data platforms, if not directly from the source itself, sometimes without much knowledge about the quality of the data. Preparing this data for analysis is both expensive and time-consuming thus many organizations would outsource the process to consultants or third-party vendors; moreover, the process of preparing this data for analysis by untrained consultants can yield a static analysis that is difficult to modify or rerun in response to follow-up questions or potential discrepancies.

 

 

2 https://www.outsourcing-pharma.com/Article/2016/03/14/Tufts-examines-2.87bn-drug-development-cost

3 https://www.hcplive.com/view/new-data-reinforces-difficulty-orphan-drug-development

 

12
 

 

Definitions of Real-World Data and Real-World Evidence

 

Real-World Data has become a powerful tool in the life sciences industry. After decades of relying on clinical data as the gold standard for decision making, industry leaders now recognize how data collected in the real world adds valuable context and insight to their efforts. From identifying unmet medical needs and defining the patient journey, to supporting regulatory submissions, proving value to payers, and shaping market strategies, Real-World Data adds value at every stage of the drug development lifecycle. Real-World Data also sets the foundation for Real World Evidence, and while the terms are often used interchangeably, they are distinct and they are changing health care. Here’s how it happens:

 

1. First, Real-World Data are data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources. Real-World Data is aggregated and transformed such as through OneMedNet’s robust analytics. Real-World Data are the data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources. There are many different types, sources and uses of Real-World Data, for example:

 

  Clinical Data For example, clinical data from EHRs and case report forms (“eCRF”) including biopsies and other pathology tests, diagnostic imaging, social determinants of health, cancer organoids, that provide patient demographics, family history, comorbidities, procedure and treatment history, and outcomes.
     
  Patient Generated Data — For example, patient-generated data from patient-reported outcome surveys, which data provide insights directly from the patient, and they help researchers understand what happens outside of clinic visits, procedures, and hospital stays.
     
  Cost and Utilization Data (Qualitative Studies) — For example, cost and utilization data from claims and public datasets, which data provides information regarding healthcare services utilization, population coverage, and prescribing patterns.
     
  Public Health Data For example, public health data from various government data sources. These add critical information to enable stakeholders to best serve the needs of the populations they serve.

 

The availability of medical imaging in Real-World Data such as that provided by OneMedNet is facilitated by the development of digital image analysis to increase the accuracy of diagnostics and conduct passive screening on large databases of medical images using artificial-intelligence (“AI”) algorithms such as those applied by OneMedNet. Algorithms can also help identify additional diagnostic tests of value from medical images with pathology.

 

Real-World Evidence is the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of Real-World Data, as defined by the Food and Drug Administration. Real-World Evidence can be generated by different study designs or analyses, including but not limited to, randomized trials, including large simple trials, pragmatic trials, and observational studies (prospective and/or retrospective). The difference in Real World Evidence and Real World Data focuses on the end use case. Real World Data can take the form of claims, electronic health records, labs, data etc. Often this insight is used to better understand a patient’s journey or a natural history of a disorder (how does a disease progress if left untreated.)

 

13
 

 

A diagram of data and information

Description automatically generated with medium confidence

 

Real World Evidence in contrast builds upon many of these data sets and prepares them for submission, as part of regulatory review such as to the Food and Drug Administration or the European Medicines Agency, for example, in support of a customer’s clinical trial application. When data and in particular imaging data is submitted to the FDA the agency requires the following:

 

  Guard against biased — evidence must align with the patient population being study — expectations focus on the similar patient demographics, comorbidities, disease severity, etc.;
     
  Traceability — confirm the chain of custody, the source of the data is known and can be validated if required; and
     
  Go forward basis — regulatory agencies seek evidence that aligns with the trials timeframe and when possible collect evidence that mirrors the clinical trials timeline.

 

One area where Real World Evidence has been relief on heavily relates to oncology approvals. Food and Drug Administration’s Oncology Center of Excellence actually presented an analysis of this at American Society of Clinical Oncology in 2021, looking at oncology applications containing Real-World Data and Real-World Evidence. That analysis looked at 94 applications that were submitted from 2011-2020, and showed that inclusion of Real-World Data to support regulatory decision-making has increased dramatically over that period. In 2020 alone, there were 28 submissions for oncology products that contained Real-World Data. Outside of the oncology context, probably the most notable recent example of an approval relying on Real World Evidence is the July 2021 approval of a new indication for Astellas’ drug Prograf (or tacrolimus) for the prevention of organ rejection in lung transplant patients. The approval there was based on a non-interventional study providing Real-World Evidence of effectiveness.4 FDA’s press release announcing the approval noted that the approval was “significant because it reflects how a well-designed, non-interventional study relying on fit-for-purpose real-world data, when compared to a suitable control, can be considered adequate and well-controlled under FDA regulations.”

 

 

4See https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-use-transplant-drug-based-real-world-evidence

 

14
 

 

An additional recent approval of note was the December 2021 approval of the supplemental BLA for Orencia to prevent graft versus host disease.5 The application included data from a randomized clinical trial, with additional evidence of effectiveness provided by a registry-based clinical study that was conducted using real-world data from the Center for International Blood and Marrow Transplant Research.6 And that registry study analyzed outcomes of 54 patients treated with Orencia for the prevention of graft versus host disease, in combination with standard immunosuppressive drugs, versus 162 patients treated with the standard immunosuppressive drugs alone, and showed efficacy in that indication.

 

AI is employed in Real-World Data to enhance data anomaly detection, standardization, and quality checking at the pre-processing stage. AI is expected to offer pharma and biotech companies the ability to increase meaningful Real World Evidence output, decrease time to insights, and make the most of the available vast data sources. A Real World Evidence technology platform that delivers smart data processing, analysis, and outcomes offers an unparalleled opportunity to capitalize on these computing advancements.

 

When used as part of an overall comprehensive Real World Evidence strategy, AI innovations can enhance drug development, improve patient treatment and access, and drive valuable new business opportunities.

 

In post-marketing studies, adverse events reporting is an area where AI is used, creating greater automation and efficiency in historical data sets. Techniques like natural language processing (“NLP”) enable AI to scan tens of thousands of records and quickly find adverse event details. AI integrated analytics and automation provide access to crucial insights from historical clinical trial Real-World Data and Real World Evidence, expanding end-to-end clinical trial capabilities:

 

  Data ingestion — publicly/historical available Real-World Data
     
  Text extraction — NLP used to extract key entities from clinical trial documents
     
  Data transformation & standardization — data standardization using pre-built models
     
  AI model deployment — predicting trial design impacts on costs, feasibility, cycle times, and quality risk

 

AI is driving ground-breaking leaps in protein structure identification, and advances in regulations are providing healthcare research organizations with access to real-world data to accelerate clinical trial processes. We believe that AI-enabled technologies have unparalleled potential to offer innovative trial design and collection, organizing, and analyzing the increasing amount of data generated by clinical trials. AI has many applications in clinical trials, both short and long-term. AI technologies make possible innovations crucial for transforming clinical trials, such as seamlessly combining Phases I and II, developing novel patient-centered endpoints, and collecting and analyzing Real-World Data.

 

OneMedNet believes that AI tools also have wider benefits for hospitals and health systems. Professor Alexander Wong, University of Waterloo Canada Research Chair in AI and Medical Imaging, points out that AI benefits include the potential to ease the burden on radiology departments in terms of assessing scans and predicting upcoming demand for general hospital and intensive care beds, and demand for equipment such as respirators and ventilators, medicines, masks, and ventilator mouthpieces, as well as aiding workforce planning.7

 

Across a diverse set of imaging modalities, digital images typically include metadata and/or annotations that may include protected health information (e.g., patient name, date of birth). Although diagnostic images generally do not warrant the same level of privacy concerns as genomic data, researchers must also remove facial characteristics or other features that could identify a patient.

 

Digital image analysis can be used to support research and development by analyzing large volumes of tissue specimens or other medical images to run molecular screens that model biomarkers and treatment responses by transplanting a portion of a patient’s tumor into humanized mice or 3D tissue cultures derived from stem cells that resemble miniature organs. These models allow researchers to conduct controlled laboratory experiments that can inform treatment approaches and link predicted treatment response to actual clinical outcomes by linking this data to EHR, claims, and other sources of Real-World Data. Similarly, preclinical studies can be informed by safety assessments conducted in animal models or studies of animal molecular biomarkers or anatomic abnormalities to minimize the burden on human study participants. Findings can also inform clinical trial optimization by stratifying participants according to predicted response and determining appropriate eligibility criteria.

 

 

5 See https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-prevent-graft-versus-host-disease

6 See https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-orencia-abatacept-prophylaxis-acute-graft-versus-host-disease

7 See https://www.eurekalert.org/news-releases/936861

 

15
 

 

2. Second, Real-World Evidence is the clinical evidence about the usage and potential benefits or risks of a medical product derived from analysis of Real-World Data. Real World Evidence provides clinically-rich insights into what actually happens in everyday practice and why. The FD&C Act defines Real-World Evidence as “data regarding the usage, or the potential benefits or risks, of a drug derived from sources other than traditional clinical trials.8 In developing its Real-World Evidence program, FDA believes it is helpful to distinguish between the sources of Real-World Data and the evidence derived from that data.

 

Evaluating Real-World Evidence in the context of regulatory decision-making depends not only on the evaluation of the methodologies used to generate the evidence but also on the reliability and relevance of the underlying Real-World Data; these constructs may raise different types of considerations. Real-World Evidence refers to evidence about the risks and benefits of a product derived from analysis of the Real-World Data. For example, the FDA has used Real-World Data and Real-World Evidence, derived from its Sentinel system for monitoring the safety of regulated products, in place of post-marketing studies. It has carried this out for nine potential safety issues involving five products.

 

Real-World Evidence is the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of Real-World Data. Real World Evidence can be generated by different study designs or analysis, including but not limited to, randomized trials, including large simple trials, pragmatic trials, and observational studies (prospective and/or retrospective).

 

Unlike traditional clinical trials, where necessary data elements can be curated and collection mandated, the creation of Real World Evidence requires assessing, validating and aggregating various, often disparate, sources of data available through routine clinical practice. Real-world evidence is used by different stakeholders in many different ways.

 

It gives life sciences companies insight into how their drugs are being used.
It helps providers improve the delivery of care.
It enables regulatory authorities to monitor post-market safety and adverse events.
It helps payers assess outcomes from treatments.

 

From Real-World Data to Real World Evidence

 

The creation of Real World Evidence requires a combination of high-powered analytics, a validated approach and a robust knowledge of available Real-World Data sources (e.g., what data is captured within existing quality registries, what data can be captured through electronic health records and case report forms or claims, which patient organizations capture data on relevant patient cohorts). This process includes several steps, which are summarized here:

 

  1. Defining a study protocol answering relevant clinical questions.
     
  2. Defining which data elements can be collected from which Real-World Data sources.
     
  3. Establishing data capture arrangements and protocols with existing Real-World Data sources.
     
  4. Blending disparate data sources through probabilistic record matching algorithms.
     
  5. Validating and supplementing blended data through editable eCRFs.
     
  6. Defining and calculating clinically relevant outcomes and measures.
     
  7. Appropriately assessing and controlling for variability in data quality, availability and confounding patient factors affecting measured outcomes.
     
  8. Real World Evidence can provide a holistic view of patients that in many cases cannot be studied through traditional clinical trials.

 

 

8 See 21 U.S.C. 355(g)(b).

 

16
 

 

Real World Evidence has been proven to fill a gap between research (what we learn) and everyday practice (what we do) in healthcare, and it creates a difference between what is expected to happen and what really happens. Driving measurable improvements in healthcare requires us all to be rooted in the reality of what actually happens before, during, and after clinical procedures, interventions, and office visits. Real World Evidence fill those gaps and documents the truth by establishing definitively what really happens when doctors treat a wide range of patients that do not look like the homogeneous patient groups in a clinical trial. Because of this, Real World Evidence serves many uses and provides many benefits across the healthcare ecosystem.

 

As more countries battle to contain healthcare costs, and as the population ages and the number of patients with chronic diseases increases, the need to remove inefficiencies and upgrade the delivery of coordinated care that improves outcomes is more pressing. At the same time, life sciences companies are facing tumultuous times. Industry globalization, the end of the blockbuster era, and an increasingly complex regulatory environment all add to the difficulty of bringing products to market. And across the board, companies are moving toward a patient-centric and outcome-focused model. In this environment, Real World Evidence can be transformative for the industry when Real-World Data is combined with the right technology framework and the regulatory intelligence to make sense of it. As data is consumed across life sciences in different ways and by different stakeholders, it can provide valuable insights and “evidence” across the product life cycle. In addition, stakeholders across the healthcare ecosystem use this new knowledge to support decision-making and improve safety and effectiveness, and ultimately, patient outcomes.

 

Uses of Real World Evidence in Life Sciences, Among Regulators, Clinicians, Researchers and Healthcare Systems

 

According to repeated studies by Deloitte,9 the importance of Real World Evidence continues to rise as it promises to accelerate regulatory decision-making and support the approval of new indications for drugs already on the market. Life Sciences, pharmaceutical and medical device companies are significant consumers of Real World Evidence because it can provide value across the entire product lifecycle from pre-trial design to clinical studies and trials to post-market surveillance. Medical product developers are using Real World Evidence to support clinical trial designs (e.g., large simple trials, pragmatic clinical trials) and observational studies to generate innovative, new treatment approaches.

 

Real World Evidence can be used to make clinical trials more effective and efficient, for example in patient recruitment or label extension, Real World Evidence gathered from other studies or from currently marketed products in a similar category, for example, can have a positive effect on the product portfolio by exposing positive side effects as new potential indications. The most famous example is Viagra, which was initially studied as a drug to lower blood pressure, but an unexpected side effect led to the drug ultimately being approved for erectile dysfunction.

 

The benefits of Real World Evidence derived from Real-World Data are increasingly being recognized by regulatory authorities. The FDA released a framework for using Real World Evidence to support the process of drug regulation and submission. This is a major step toward recognizing that clinical trials, while still relevant, are not the only way to assess the efficacy and safety of a product. Indeed, the FDA is soon expected to conduct its first full post-market safety approval using only Real World Evidence.

 

Real World Evidence is now accepted as a reliable source of information for regulatory decision making in certain circumstances. A primary rationale for the FDA to use Real World Evidence E is to help support the approval of a new or extended use for a drug approved under the FD&C Act and to help support or satisfy post-approval study requirements always with the condition that the data quality is up to the standard required. In a recent statement, the FDA even noted how new tools for capturing data in the post-market period, including more sophisticated use of Real-World Data and Real-World Evidence are providing new approaches to address important questions about the safety and benefits of new drugs in real world settings and that these approaches have the potential to do to so more rapidly and with greater efficiency than traditional methods.10

 

 

9 See https://www2.deloitte.com/content/dam/insights/us/articles/4354_Real-World-Evidence/DI_Real-World-Evidence.pdf

10 See https://www.fda.gov/science-research/science-and-research-special-topics/real-world- evidence

 

17
 

 

Why Do We Need Real-World Evidence?

 

There’s a gap between research (what we learn) and everyday practice (what we do) in healthcare, and it creates a difference between what is expected to happen and what really happens. But it’s what really happens that matters. Driving measurable improvements in healthcare requires us all to be rooted in the reality of what actually happens before, during, and after clinical procedures, interventions, and office visits. Real-World Evidence is here to fill those gaps and root us in truth. It tells us what really happens when doctors treat a wide range of patients that don’t look like the homogeneous patient groups in a clinical trial. Because of this, Real-World Evidence serves many uses and provides many benefits across the healthcare ecosystem.

 

Uses of Real-World Evidence in Pharmaceutical and Device Companies

 

Pharmaceutical and medical device companies are major consumers of Real-World Evidence, as it can provide value across the entire product lifecycle. Real-World Evidence plays an important role for research across the product lifecycle for both pharmaceutical and device companies. It can inform pre-trial study design by helping researchers identify potential patients and create proper inclusion criteria for clinical trials. Much of medical innovation is driven by traditional clinical trials, where new pharmaceuticals and devices are rigorously studied and tracked before they can be sold and widely distributed.

 

Although clinical trials are incredibly important to determine the safety and efficacy of new technologies, when compared to real-world evidence they do have some limitations. For example, traditional clinical trials can have strict inclusion criteria that makes it challenging for providers to accurately extrapolate the results of a clinical trial to a broader population. Clinical trial participation is often limited by who the study administrators are able to recruit, and various demographics are often not able to participate. This again challenges the generalizability of clinical trial results across patient populations. Real-world evidence can help overcome the limitations of clinical trials by providing information about a broader cross-section of society. This can help clinicians, researchers, and industry partners better understand their products and how they work.

 

Once a product is approved and marketed, Real-World Evidence assists pharmaceutical or medical device company understand their products’ relative safety, effectiveness, value, off-label use and more. This post-market surveillance, or post-marketing surveillance, is valuable to stakeholders across the healthcare industry.

 

18
 

 

A diagram of a patient's health

Description automatically generated

 

The AI-enabled patient enrichment and recruitment process can improve suitable cohorts and increase clinical trial effectiveness, data management, analysis, and interpretation of multiple Real-World Data sources, including EHRs and medical imaging data. This presents a unique opportunity for NLP to perform the sophisticated analysis necessary to combine genomic data with electronic medical records (“EMRs”) and other patient data, present in various locations, owners, and formats — from handwritten paper copies to digital medical images — to surface biomarkers that lead to endpoints that can be more efficiently measured, and thereby identify and characterize appropriate patient subpopulations. AI-enabled systems can help to improve patient cohort composition and aid with patient recruitment.

 

AI technologies can help biopharma companies identify target locations, qualified investigators, and priority candidates and collect and collate evidence to satisfy regulators that the trial process complies with good clinical practice (“GMP”) requirements. One of the most important elements of a clinical trial is a selection of high-functioning investigator sites. Site qualities such as resource availability, administrative procedures, and experienced clinicians with in-depth knowledge and understanding of the disease can shape study timelines and data quality, accuracy, completeness, and consistency.

 

AI integrated clinical trial programs can help monitor and manage patients by automating real-world data capture, sharing data across systems, and digitalizing standard clinical assessments. AI technologies and wearable technologies can help enable continuous patient monitoring and generate real-time insights into the safety and effectiveness of treatment while predicting the possible risk of dropouts, thereby enhancing patient engagement and retention. To comply with trial adherence criteria, patients must keep detailed records of their medication intake and other data points related to their bodily functions, response to medication, and daily protocols. This can be an overwhelming and tedious task, leading to 40% of patients becoming non-adherent after 150 days into a clinical trial. Wearable devices/sensors and video monitoring are used to collect patient data automatically and continuously, thereby relieving the patient of this task. In combination with wearable technology, AI techniques offer new approaches to developing real-time, power-efficient, mobile, and personalized patient monitoring systems.

 

Among regulators, clinicians, academic researchers and healthcare systems, the reliance on curated Real World Evidence has grown significantly because of the value it can provide, which is unique relative to each parties’ objectives and mandates. It also helps that the FDA has also sharpened its focus on Real-World Data and Real World Evidence. For example, late last year, the FDA published proposed guidance related to data standards for product submissions with Real-World Data and also weighed in on the use of Real-World Data and Real World Evidence to support regulatory decision-making for drugs and biological products with specific advice for data from electronic health records and medical claims.11 In addition, the FDA uses Real-World Data and Real World Evidence to monitor post-market safety and adverse events and to make regulatory decisions. The health care community is using these data to support coverage decisions and to develop guidelines and decision support tools for use in clinical practice.

 

 

11See https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-real-world-data-and-real-world-evidence-support-regulatory-decision-making-drug

 

19
 

 

AI with deep-learning capability is also helpful in organizing and translating a vast amount of structured and unstructured data to RWE.12 The human mind can possibly manage 4-5 variables, therefore, AI-enabled data mapping and integration and their normalization into a common data model according to disease pathway and workflow will likely be useful for both quality management in clinical trials and generating meaningful insight for human disease by providing a broader perspective based on real-world data.13

 

Market Size

 

The global real world evidence solutions market is projected to grow from $16.13 billion in 2023 to $36.24 billion by 2030, at a CAGR of 12.3%.14 The drug development and approvals segment accounted for the highest revenue share of around 28.9% in 2020. Real-world evidence solutions services allow pharmaceutical companies and healthcare providers as well as payers for efficient management of operations and accelerate the process of drug development and its approval, which fuels market growth. Support from regulatory bodies for using Real World Evidence solutions and an increase in research and development spending are anticipated to boost the market growth.

 

A graph of a bar chart

Description automatically generated

 

Based on end user, the global Real World Evidence solutions market is segmented into pharmaceutical, biotechnology, and medical device companies; healthcare payers; healthcare providers; and other end-users (academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies). In 2021, the pharmaceutical, biotechnology, and medical device companies segment is estimated to account for the largest share of 36.5% of the global real-world evidence solutions market. The large share of this segment is primarily attributed to the increasing importance of Real World Evidence studies in drug development and approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings.

 

With the growing need for evidence generated from Real-World Data, the increasing importance of epidemiological data in decision making, and a shift from volume to value-based care, there has been an increased focus on patient registries, a rise in the adoption of EMR in hospitals, and exponential growth in mobile health data and social media which have resulted in the generation of huge amounts of medical data. In 2021, the real-world datasets segment is estimated to account for the larger share of 51.2% of the global real-world evidence solutions market.15 According to Coherent Market Insights, the global real-World Data market is estimated to be valued at $1.59 billion in 2023 and is expected to exhibit a CAGR of 14.4% during the forecast period (2023-2030).16

 

 

12 Franklin JM, Schneeweiss S. When and how can real world data analyses substitute for randomized controlled trials? Clin Pharmacol Ther. 2017;102(6):924-33.

13 From real-world data to real-world evidence: An interregional perspective | RAPS, July 30, 2021

14 https://www.fortunebusinessinsights.com/real-world-evidence-solutions-market-107676

15 Meticulous Research® Analysis, which derived its analysis after a detailed assessment of various quantitative and qualitative factors, such as the historical revenue growth trends of leading players, major market growth drivers, restraints, and challenges, along with their impacts over the forecast period and relevant macroeconomic and microeconomic indicators.

16 Real-world Data (RWD) Market to reach $4.07 billion by (globenewswire.com)

 

20
 

 

Our Long-Term Growth Strategies

 

Our long-term growth strategy is anchored on the following key pillars:

 

Increase Global Reach to Meet Demand: Our strategy is to continue growing our global footprint into areas where we expect high demand growth in the global real world evidence solutions market, which is projected to grow from $16.13 billion in 2023 to $36.24 billion by 2030, at a CAGR of 12.3%. There is a rise in emphasis on evidence-based medicine that relies on Real-World Evidence, which comes from Real-World Data. Market players in healthcare industries, including regulators, healthcare providers, and payers are becoming more aware of the importance of using Real-World Data for making informed decisions regarding comparative effectiveness, treatment effectiveness, cost-effectiveness, and safety. As a result, the demand for real world data solutions is increasing rapidly, which is further driving growth of the market.
     
    Regulatory agencies such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) are making use of real-world evidence in regulatory decision making processes. These regulatory authorities have frameworks and guidelines for using Real-World Evidence and Real-World Data in regulatory submissions, post-market surveillance, and drug approvals. As a result, the demand for real-world data is rising, which in turn is expected to support growth of the market in the coming future.17
     
    The use of Real-World Evidence derived from Real-World Data demonstrates value and cost-effectiveness of medical devices and drugs for healthcare technology assessment agencies and payers. With this Real-World Evidence, market access becomes easier and it also enables reimbursement negotiations. This further facilities the inclusion of new therapies in the coverage of healthcare, which in turn creates major opportunities in the global market.18
     
Innovate Our Commercial Approach to Drive Incremental Market Share: We intend to rapidly expand our sales network across the globe, while simultaneously building out our sales infrastructure. We intend to focus on our target markets, which include (i) Imaging AI; (ii) medical device companies; and (iii) pharmaceutical companies, as summarized here:

 

A screenshot of a device

Description automatically generated

 

 

17 Id.

18 Id.

 

21
 

 

  Enhance and Refine Our Service Offering: Building on our customer-centric mindset throughout our development, curation and commercial processes, we plan to continue expanding and improving our service offering. As we continue to expand into additional geographies globally, we plan to build upon these three pillars:

 

A screenshot of a phone

Description automatically generated

 

 

Expand Our Product Offering: We plan to continually evaluate the benefits of expanding our portfolio into other high-growth, high-demand Real-World Data and Real-World Evidence solutions in the future.

 

Corporate Information

 

We were originally incorporated in Delaware on February 8, 2021 under the name “Data Knights Acquisition Corp” as a special purpose acquisition company, formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. On November 7, 2023, we held the Closing of the previously announced Merger whereby Merger Sub merged with and into OneMedNet Solutions Corporation (formerly named OneMedNet Corporation), with OneMedNet Solutions Corporation continuing as the surviving entity, which resulted in all of the issued and outstanding capital stock of OneMedNet Solutions Corporation being exchanged for shares of the Company’s Common Stock upon the terms set forth in the Merger Agreement.

 

22
 

 

The Merger and other transactions that closed on November 7, 2023, pursuant to the Merger Agreement, led to Data Knights changing its name to “OneMedNet Corporation” and the business of the Company became the business of OneMedNet Solutions Corporation. We are located at 6385 Old Shady Oak Road, Suite 250, Eden Prairie, MN 55344 and reachable by telephone on 800-918-7189.

 

The information contained on our website is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our website as part of this prospectus or in deciding whether to purchase our Common Stock.

 

OneMedNet Corporation a Delaware corporation (the “Company,” “we,” “us,” or “OneMedNet”) together with its wholly-owned subsidiary OneMedNet Solutions Corporation, a Delaware corporation, founded on October 13, 2009 in the State of Hawaii and later incorporated in the State of Delaware on November 20, 2015 and its wholly-owned subsidiary, OneMedNet Technologies (Canada) Inc., incorporated on October 16, 2015 under the provisions of the Business Corporations Act of British Columbia whose functional currency is the Canadian dollar. All refences in this prospectus to the “Company,” “we,” “us,” or “OneMedNet” include OneMedNet Solutions Corporation and its wholly-owned subsidiary, OneMedNet Technologies (Canada) Inc., incorporated on October 16, 2015 under the provisions of the Business Corporations Act of British Columbia whose functional currency is the Canadian dollar.

 

Recent Developments

 

Closing of Business Combination

 

OneMedNet Corporation, a Delaware corporation (the “Company,” “we,” “us” or “OneMedNet”) together with its wholly-owned subsidiary, OneMedNet Solutions Corporation, a Delaware corporation, and its wholly-owned subsidiary, OneMedNet Technologies (Canada) Inc., incorporated under the provisions of the Business Corporations Act of British Columbia whose functional currency is the Canadian dollar. All references in this prospectus to the “Company,” “we,” “us,” or “OneMedNet” include OneMedNet Corporation and both OneMedNet Solutions Corporation and OneMedNet Technologies (Canada) Inc., except that references to the “Company” “we,” “us,” or “Data Knights” in this Item 7 refer to OneMedNet Corporation f/k/a Data Knights Acquisition Corp.

 

We were originally incorporated in Delaware on February 8, 2021 under the name “Data Knights Acquisition Corp” as a special purpose acquisition company, formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. On May 11, 2021, we consummated an initial public offering.

 

On November 7, 2023, following the approval at the special meeting of the shareholders of Data Knights Acquisition Corp., a Delaware corporation held on October 17, 2023 (the “Special Meeting”), Data Knights Merger Sub, Inc., a Delaware corporation (“Merger Sub”) and a wholly-owned subsidiary of Data Knights Acquisition Corp., a Delaware corporation (“Data Knights”), consummated a merger (the “Merger”) with and into OneMedNet Solutions Corporation (formerly named OneMedNet Corporation), a Delaware corporation (“OneMedNet”) pursuant to an agreement and plan of merger, dated as of April 25, 2022 (the “Merger Agreement”), by and among Data Knights, Merger Sub, OneMedNet, Data Knights, LLC, a Delaware limited liability company (“Sponsor” or “Purchaser Representative”) in its capacity as the representative of the stockholders of Data Knights, and Paul Casey in his capacity as the representative of the stockholders of OneMedNet (“Seller Representative”). Accordingly, the Merger Agreement was adopted, and the Merger and other transactions contemplated thereby (collectively, the “Business Combination”) were approved and completed.

 

At the closing, on November 7, 2023, of the Business Combination pursuant to the Merger Agreement, Merger Sub merged with and into OneMedNet with OneMedNet surviving the Merger, as a wholly-owned subsidiary of Data Knights, and Data Knights changed its name to “OneMedNet Corporation.”

 

The Business Combination was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Data Knights was treated as the acquired company and OneMedNet Corporation was treated as the acquirer for financial statement reporting purposes.

 

23
 

 

At the closing of the Merger, holders of Data Knights common stock automatically received common stock of OneMedNet, and holders of Data Knights warrants automatically received warrants of OneMedNet with substantively identical terms. At the Closing of the Business Combination, all shares of Data Knights owned by the Sponsor (consisting of shares of Class A common stock and shares of Class B common stock), which we refer to as the founder shares, automatically converted into an equal number of shares of OneMedNet’s common stock, and Private Placement Warrants held by the Sponsor, automatically converted into warrants to purchase one share of OneMedNet common stock with substantively identical terms.

 

Closing of the Pre-Closing PIPE

 

On June 28, 2023, the Company and Data Knights entered into a Securities Purchase Agreement (the “PIPE SPA”) with certain investors (collectively referred to herein as the “Purchasers”) for PIPE financing (the “Pre-Closing PIPE”) in the aggregate original principal amount of $1,595,744.70 and the purchase price of $1.5 million. Pursuant to the Securities Purchase Agreement, Data Knights will issue and sell to each of the Purchasers, a new series of senior secured convertible notes (the “Pre-Closing PIPE Notes”), which are convertible into shares of Common Stock at the Purchasers election at a conversion price equal to the lower of (i) $10.00 per share, and (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) Trading Days immediately preceding the Conversion Date. The Purchasers’ $1.5 million investment in the Pre-Closing PIPE Notes closed and funded contemporaneous to the Closing of the Business Combination. Effective immediately prior to the Closing, Data Knights issued the Pre-Closing PIPE Notes to the Purchasers pursuant to the private offering rules under the Securities Act of 1933, as amended (the “Securities Act”).

 

As of the Closing, among other holders, public stockholders own 98,178 shares of OneMedNet common stock approximately representing 0.35% of the outstanding shares of OneMedNet common stock; the Sponsor and its affiliates own approximately 15.1% of the outstanding shares of OneMedNet common stock (inclusive of shares received upon conversion of the Sponsor’s loan); OneMedNet’s former security holders own approximately 61.992% of the outstanding shares of OneMedNet common stock from the conversion of their shares; PIPE investors own 0.46% of the outstanding shares of OneMedNet common stock and former convertible note holders own approximately 16.24% of the outstanding shares of OneMedNet common stock resulting from the issuance of 5,238,800 shares of Common Stock upon conversion of their notes.

 

In addition, at the closing of the Merger, the Company issued an aggregate of 277,778 shares of the Company’s Company Stock at $10.89 per share, for an aggregate value of $3,025,000 (the “Compensation Shares”) to EF Hutton LLC, (“EF Hutton”) win partial satisfaction of fees due to them in connection with the Merger.

 

Lock-up Agreements

 

Effective April 25, 2022, in connection with the execution of the Merger Agreement, certain stockholders of OneMedNet and certain of OneMedNet’s officers and directors (such stockholders, the “Company Holders”) entered into a lock-up agreement (the “Lock-up Agreement”) pursuant to which the Company Holders will be contractually restricted, during the Lock-up Period (as defined below), from selling or transferring any of (i) their shares of OneMedNet common stock held immediately following the Closing and (ii) any of their shares of OneMedNet common stock that result from converting securities held immediately following the Closing (the “Lock-up Shares”). Effective November 7, 2023, the newly appointed officers and directors of OneMedNet Corporation have entered into a Lock-Up Agreement.

 

The “Lock-up Period” means the period commencing at Closing and end the earliest of: (a) six months from the Closing, and (b) the date after the Closing on which the Purchaser consummates a liquidation, merger, capital stock exchange, reorganization, or other similar transaction with an unaffiliated third party that results in all of the Purchaser’s stockholders having the right to exchange their shares of the Purchaser Common Stock for cash, securities, or other property: (i) lend, offer, pledge, hypothecate, encumber, donate, assign, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Restricted Securities, (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Restricted Securities, or (iii) publicly disclose the intention to do any of the foregoing, whether any such transaction described in clauses (i), (ii), or (iii) above is to be settled by delivery of Restricted Securities or other securities, in cash or otherwise (any of the foregoing described in clauses (i), (ii), or (iii), a “Prohibited Transfer”).

 

24
 

 

In addition, the Sponsor is subject to a lock-up pursuant to a letter agreement (the “Sponsor Lock-up Agreement”), entered into on May 6, 2021, at the time of the IPO (as defined below), among Data Knights, the Sponsor and each of the individuals who were a member of Data Knights’ board of directors and/or management team (each, an “Insider” and collectively, the “Insiders”), who agreed that it, he or she shall not transfer any founder shares which means the 2,875,000 shares of Data Knights Class B common stock, par value $0.0001 per share, initially held by the Sponsor, or shares of OneMedNet’s Common Stock issuable upon conversion thereof) until the earlier of (A) six months after the date of Data Knights’ initial Business Combination or (B) subsequent to the initial Business Combination, (x) if the reported last sale price of the Common Stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, right issuances, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the Company’s initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of our stockholders having the right to exchange their shares of common stock for cash, securities or other property. Further, the Sponsor and each of the Insiders agreed further in the Sponsor Lock-Up Agreement that he, she or it shall not transfer any private placement units, the private placement shares, the private placement warrants or shares of Common Stock issued or issuable upon the exercise of the private placement warrants, until 30 days after the completion of the initial Business Combination.

 

Registration Rights Agreements

 

At the Closing of the Business Combination and funding of the PIPE, the PIPE Investors each executed a PIPE Note and a PIPE Warrant in the amount corresponding to each PIPE Investor’s investment amount and in accordance with the terms set forth in the PIPE SPA as well as a registration rights agreement (the “PIPE Registration Rights Agreement”). We are registering the offer and sale of these securities to satisfy the registration rights we have granted in the PIPE Registration Rights Agreement. At the Closing of the Business Combination, OneMedNet, Data Knights and the Sponsor entered into a registration rights agreement (the “Registration Rights Agreement”), pursuant to which, among other things, the Company is obligated to file a registration statement to register the resale of certain securities of the Company held by the holders, as defined in the Registration Rights Agreement and the Sponsor. The Registration Rights Agreement also provides the holders and the Sponsor with “piggy-back” registration rights, subject to certain requirements and customary conditions.

 

Voting Agreement and Sponsor Support Agreement

 

In connection with entry into the Merger Agreement, the Company entered into voting agreements (the “Voting Agreements”) with certain stockholders of OneMedNet representing approximately 55% of the outstanding voting power of OneMedNet’s equity securities (the “OneMedNet Stockholders”) pursuant to which OneMedNet Stockholders agreed to vote their securities in favor of the approval of the Merger Agreement and the Business Combination, be bound by certain covenants and agreements related to the Business Combination and to take other customary actions to cause the Business Combination to occur.

 

In connection with entry into the Merger Agreement, the Company, the Sponsor and OneMedNet entered into a sponsor support agreement (the “Sponsor Support Agreement”) pursuant to which the Sponsor agreed to vote its Data Knights securities in favor of the approval of the Merger Agreement and the Business Combination and to take other customary actions to cause the Business Combination to occur.

 

Executive Employment Agreements

 

In connection with the Closing of the Business Combination, the Company has entered into employment agreements (the “Employment Agreements”) with executive officers: Aaron Green (President), Lisa Embree (Chief Financial Officer), and Paul Casey (Chief Executive Officer). The Employment Agreements provide for at-will employment that may be terminated by the Company with or without cause, by the executive with or without good reason, or mutually terminated by the parties.

 

The Employment Agreement for Mr. Green provides for $350,000 annual salary, eligibility to receive an annual cash performance bonus of $175,000 upon his achievement of the performance goals set by the Company’s CEO and Board of Directors, and eligibility to receive 600,000 of the Company’s outstanding shares at closing, as part of the Company’s Restricted Stock Unit Plan, subject to the approval of the Company’s Board of Directors. In the event that his employment is terminated by the Company without Cause (as defined in the Employment Agreement), or is terminated by Mr. Green for Good Reason (as defined in the Employment Agreement), after six months of employment, and he signs and does not revoke a standard release of claims with the Company in a form reasonably satisfactory to the Company’s Board of Directors (a “Release”), which Release becomes irrevocable no later than sixty (60) days (the “Release Deadline”), after the date of his termination of employment (the “Termination Date”) he will be entitled to the following severance payment, as follows: (a) if the Termination Date is after six (6) months’ of employment, but before he has completed 12 months’ of employment, he will receive three (3) months’ salary; and (b) if the Termination Date is after 12 months’ employment he will receive six (6) months’ salary. If the Release does not become effective and irrevocable by the Release Deadline, he will forfeit any right to severance.

 

25
 

 

The Employment Agreement for Ms. Embree provides for $225,000 annual salary, eligibility to receive an annual cash performance bonus of twenty-five percent (25%) of her annual salary upon her achievement of the performance goals set by the Company’s CEO and Board of Directors, and eligibility to receive 260,000 of the Company’s outstanding shares, as part of the Company’s Restricted Stock Unit Plan, subject to the approval of the Company’s Board of Directors. In the event that her employment with the Company is terminated by the Company without Cause (as defined in the Employment Agreement) or is terminated by Ms. Embree for Good Reason (as defined in the Employment Agreement) she will receive six (6) months’ salary as a Severance Payment.

 

The Employment Agreement for Mr. Casey provides for $144,000 annual salary, eligible to receive 147,000 shares of stock upon the successful fundraising of an amount equal to or greater than $5,000,000 and, as part of the Company’s Restricted Stock Unit Plan, further equity will be rewarded to Mr. Casey subject to the approval of the Company’s Board of Directors. In the event that his employment with the Company is terminated by the Company without Cause (as defined in the Employment Agreement) or is terminated by Mr. Casey for Good Reason (as defined in the Employment Agreement) he will receive six (6) months’ salary as a Severance Payment.

 

Note Securities Purchase Agreement

 

On March 28, 2024, the Company entered into a definitive securities purchase agreement (the “Notes Securities Purchase Agreement”) with Helena Global Investment Opportunities 1 Ltd. (the “Investor”), an affiliate of Helena Partners Inc., a Cayman-Islands based advisor and investor providing for up to USD$4.54 million in funding through a private placement for the issuance of senior secured convertible notes (the “Notes”).

 

In connection with the issuance of the Notes, the Company will issue to the Investor common stock purchase warrants (the “Warrants”) across multiple tranches (the “Tranches”) consisting of an initial tranche (the “Initial Tranche”) of (i) an aggregate principal amount $2,000,000.00 and including an original issue discount (“OID”) of up to an aggregate of $300,000.00 plus Warrants to purchase a number of shares of Common Stock equal to the applicable Warrant Share Amounts (defined below). The second tranche (the “Second Tranche”) consists of an aggregate principal amount of Notes of up to $350,000.00 and including an OID of up to $52,500.00 and Warrants to purchase a number of shares of Common Stock equal to the applicable Warrant Share Amounts with respect to such Tranche. The Notes Securities Purchase Agreement contemplates three subsequent Tranches each of which shall be in an aggregate principal amount of Notes of up to $1,000,000 each and each including an OID of 15.0% of the applicable principal amount, and Warrants to purchase a number of shares of Common Stock equal to the applicable Warrant Share Amounts with respect to such Tranches.

 

The purchase price of a Note and its accompanying Warrant shall be computed by subtracting the portion of the OID represented by that such Note from the portion of the principal amount represented by such Note (a “Purchase Price”).

 

The Notes Securities Purchase Agreement defines Warrant Share Amounts means in respect of any Warrant issued in a Closing the initial amount of shares of Common Stock (the “Warrant Shares”) for which such Warrant may be exercised and which shall be equal to the applicable principal amount of the Note issued to the Investor in such closing multiplied by 50% and divided by the 95% of lowest VWAP over the ten Trading Day period immediately preceding the applicable Closing Date.

 

In connection with the closings of each Tranche, a portion of the proceeds will be held in escrow (the “Escrow”) pursuant to an executed Escrow Agreement dated as of March 28, 2024 in accordance with the following: (i) $1,350,000.00 of the net proceeds of the Initial Tranche will be paid into the Escrow Account for distribution in accordance with the release of proceeds conditions (the “Release Conditions” discussed below), with the balance of the net proceeds paid to the Company less initial closing expenses relating to such Initial Tranche; (ii) 100% of the net proceeds of the Third Tranche shall be paid into the Escrow Account for distribution in accordance with the Release Conditions; and (iii) 75% of the net proceeds of the Third Tranche shall be paid into the Escrow Account for distribution in accordance with the Release Conditions with the balance of the net proceeds of the Third Tranche being paid to the Company less initial closing expenses relating to such Third Tranche.

 

26
 

 

The Securities Purchase Agreement provides that the amounts in Escrow (the “Escrowed Proceeds”) related to the Initial Tranche, Second Tranche and Third Tranche are governed by the following terms:

 

  a) The Escrowed Proceeds will be released to the Investor for payment amounts owing in respect of the Notes, if the closing price of the Common Stock shall have been less than the then Floor Price (as defined in the Notes) for a period of 10-consecutive trading days, or an event of default shall have occurred;
     
  b) The Escrowed Proceeds will be released to the Company if the aggregate outstanding amount is equal to zero;
     
  c) If on the date that is 20 trading days following the closing of the Initial Tranche, the aggregate outstanding amount is more than zero but less than $1,700,000.00, then the Escrowed Proceeds will be released to the Company in an amount equal to the difference between $1,700,000.00 and the aggregate outstanding amount; and
     
  d) If on the date that is 40 trading days following the Closing Date of the Initial Tranche and every 20 trading days thereafter, the aggregate outstanding amount is more than zero but less than $1,700,000.00 minus the amount of any prior disbursement from the Escrow Account pursuant to this provision (d) or provision (c) above (the “Adjusted Escrow Reference Amount”), then the Escrowed Proceeds will be released to the Company an amount equal to the difference between the Adjusted Escrow Reference Amount and such aggregate outstanding amount.

 

In connection with the Notes Securities Purchase Agreement, the Company and the Investor also entered into a Registration Rights Agreement, dated as of March 28, 2024 (the “RRA”), providing for the registration of the Note shares (the “Note Conversion Shares”) and the Warrant Shares (the “Registerable Securities”). The Company has agreed to prepare and file a registration statement (the “Registration Statement”) with the Securities and Exchange Commission (the “SEC”) promptly, and in any event within 30 days of the closing of the private placement. The Company has granted the Investor customary indemnification rights in connection with the Registration Rights Agreement. The Investors have also granted the Company customary indemnification rights in connection with the Registration Statement.

 

The securities to be issued pursuant to the Notes Securities Purchase Agreement was made in reliance on the exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933, as amended (the “Securities Act”), as promulgated by the Securities and Exchange Commission under the Securities Act.

 

Government Regulation

 

Many aspects of our businesses are regulated by federal and state laws, rules and regulations. Accordingly, we maintain a robust compliance program aimed at ensuring we operate our business in compliance with all existing legal requirements material to the operation of our businesses. There are, however, occasionally uncertainties involving the application of various legal requirements, the violation of which could result in, among other things, fines or other sanctions. See “Risk Factors” for additional detail.

 

Regulation of Patient Information. Our information management services relate to the processing of information regarding patient diagnosis and treatment of disease and are, therefore, subject to substantial governmental regulation. In addition, the confidentiality of patient-specific information and the circumstances under which such patient-specific records may be released for inclusion in our databases or used in other aspects of our business is heavily regulated. Federal, state and foreign governments are contemplating or have proposed or adopted additional legislation governing the possession, use and dissemination of personal data, such as personal health information and personal financial data, as well as security breach notification rules for loss or theft of such data. Additional legislation or regulation of this type might, among other things, require us to implement additional security measures and processes or bring within the legislation or regulation deidentified health or other data, each of which may require substantial expenditures or limit our ability to offer some of our services.

 

27
 

 

In particular, personal health information is recognized as a special, sensitive category of personal information, subject to additional mandatory protections. Violations of data protection regulations are subject to administrative penalties, civil money penalties and criminal prosecution, including corporate fines and personal liability.

 

Data Privacy

 

Patient health information is among the most sensitive of personal information, and it is critically important that information about an individual’s healthcare is properly protected from inappropriate access, use and disclosure. Real world evidence — information that allows us to examine actual practices and outcomes — is essential to increase access to care, improve outcomes, and lower costs.

 

OneMedNet uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. We employ a wide variety of methods to manage privacy requirements, including:

 

  governance, frameworks, models and training to promote good decision making and accountability;
     
  a layered approach to privacy and security management to avoid a single point of failure;
     
  ongoing evaluation of privacy and security practices to promote continuous improvement;
     
  use of technical, administrative, physical and organizational safeguards and controls;
     
  collaboration with data suppliers and trusted third parties for our syndicated market research and analytics offerings to remove identifiable information or employ effective encryption or other techniques to render information non-identified before data is delivered to us; and
     
  work with leading researchers, policy makers, thought leaders and others in a variety of fields relevant to the application of effective privacy and security practices, including statistical, epidemiological and cryptographic sciences, legal, information security and compliance, and privacy.

 

We have relied on expertise in the industry with de-identifying data. Our capabilities allow us to render data non-identified while still maintaining data utility, thus protecting privacy while still advancing innovation. Not only do we make use of de-identification techniques with respect to the data we hold, but we also share our expertise in this area with policymakers, regulators and others to help them understand de-identification methodologies and practical considerations to avoid re-identification risk. We operate in more than 100 countries around the world, many of which have data protection and privacy laws and regulations based on similar core principles (e.g., openness, accountability, security safeguards, etc.). We apply those principles globally and augment our practices to address local laws, contractual obligations and other data privacy requirements.

 

Our Compliance team, led by our Chief Compliance Officer, is comprised of privacy professionals and privacy law experts who drive our strategy and develop and manage our policies and standards. The Compliance team provides subject matter expertise related to the proper management of all data types. In addition, our Compliance team liaises with our Legal, IT, Information Security and other teams so that privacy requirements are addressed in technology, contracting, offerings and other business activities.

 

The OneMedNet Privacy Policy (the “Privacy Policy”) is our foundational privacy policy. It explains how, when applicable, we collect, hold, use and disclose personal information, including that of our personnel, consumers, healthcare professionals, patients, medical research subjects, clinical investigators, customers, suppliers, vendors, business partners and investors.

 

Cybersecurity

 

We employ an array of data security technologies, processes, and methods across our infrastructure to protect systems and sensitive information from unauthorized access. OneMedNet maintains comprehensive identity and access management practices (e.g., roles and access privileges for each user; multi-factor authentication, privileged user accounts, single sign-on, user lifecycle management) and employs a variety of security information and event management tools. We developed, maintain and utilize a global integrated information security framework to guide our practices, based on relevant industry frameworks and laws, including, but not limited to NIST, GxP, HITRUST, the ISO 27000 family, COBIT, GDPR, and HIPAA.

 

28
 

 

The framework consists of policies, standards, procedures, work Instructions and documentation. Information is classified into four categories to help individuals apply the right level of controls and safeguards to information, applications and systems. Our cybersecurity program focuses on all areas of our business, including cloud-based environments, data centers, devices used by employees and contractors, facilities, networks, applications, vendors, disaster recovery / business continuity and controls and safeguards enabled through business processes and tools. We continuously monitor for threats and unauthorized access.

 

We draw on the knowledge and insight of external cybersecurity experts and vendors, and internally employ dedicated, certified, cybersecurity staff, such as but not limited to, CISSP, CISM, CISA, CSSP or other equivalent certifications, that leverage an array of third-party tools to secure OneMedNet information infrastructure and protect systems and information from unauthorized access. Non-technical safeguards also play an important role in our cybersecurity program. We provide various training programs and tools to employees so they can avoid risky practices and help us promptly identify potential or actual issues. We also have global incident response procedures, global service tools to log incidents and issues for investigation, and an ethics line to report concerns and follow-up on matters already reported. The Compliance team, led by our Chief Compliance Officer, develops and implements our strategy, as well as monitors systems and devices for risks and threats.

 

Regulatory Quality Compliance (FDA 21 CFR Part 11)

 

OneMedNet provides high-quality, de-identified, regulatory-grade imaging and clinical data; as such OneMedNet adheres to all applicable local and Federal regulatory quality requirements, including but not limited to FDA 21 CFR Part 11. OneMedNet maintains a rigorous and ongoing internal quality management system to enable the organization to produce the highest quality regulatory compliant clinical data for our clients and consumers. This program includes:

 

  Ongoing internal audits, policy reviews, and procedure testing to ensure validation, audit trails, legacy systems, and record handling and retention adhere to the latest regulatory guidelines and best practices.
     
  Regular third-party or client initiated external audits to assess the compliance of OneMedNet to ensure operations are in accordance with, but not limited to the applicable regulations, standards, policies, and standard operation procedures.

 

Organizational Structure

 

The following is a current organizational chart of our Company:

 

A diagram of a company

Description automatically generated

 

29
 

 

Employees

 

Our workforce is comprised of approximately 20 employees (as of December 31, 2023), including approximately 0 part-time employees (references herein to “employees” include to the employees of our subsidiaries). Our Board of Directors and its committees oversee human capital matters through regular reporting from management and advisors.

 

Facilities

 

Prior to the closing of the Business Combination, the Company’s executive offices were located at Unit G6, Frome Business Park, Manor Road, Frome, United Kingdom, BA11 4FN and its telephone number was +44 203 833 4000. The Company agreed to pay ARC Group Ltd., an affiliate of the Sponsor, up to an amount of $10,000 per month for office space, secretarial and administrative support. For the nine months ended September 30, 2023 and 2022, we had incurred $60,000 in fees under this agreement, respectively. Upon completion of our Business Combination, the Company ceased paying these monthly fees.

 

After the closing of the Business Combination, our headquarters is located at 6385 Old Shady Oak Road, Suite 250, Eden Prairie, MN 55344 and our telephone number is (800) 918-7189, where we lease and occupy our office space with an aggregate floor area of approximately 67 square feet from unrelated third parties under operating lease agreements. We consider our current office space adequate for our current operations and needs and that, should it be needed, suitable additional or alternative space will be available to accommodate our operations.

 

Implications of Being an Emerging Growth Company

 

As a company with less than $1.235 billion in revenues during our last fiscal year, we qualify as an emerging growth company as defined in the Jumpstart Our Business Startups Act (“JOBS Act”) enacted in 2012. As an emerging growth company, we expect to take advantage of reduced reporting requirements that are otherwise applicable to public companies. These provisions include, but are not limited to:

 

  being permitted to present only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced “Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosure in this prospectus;
     
  not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (“Sarbanes-Oxley Act”);
     
  reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and
     
  exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

 

30
 

 

THE OFFERING

 

Issuer   OneMedNet Corporation
     
Common Stock Offered by us   12,085,275 shares of Common Stock issuable upon the exercise of Warrants.
     
Common Stock Offered by the Selling Securityholders   Up to 19,683,367 shares of Common Stock.
     
Warrants Offered by the Selling Securityholders   Up to 681,019 Warrants.
     
Exercise Price of Warrants   $11.50 per share, subject to adjustment as defined herein.
     
Shares Outstanding Prior to Exercise of All Warrants   23,850,010 shares.
     
Shares Outstanding Assuming Exercise of All Warrants   35,935,285 shares.
     
Use of proceeds   We will not receive any proceeds from the sale of Common Stock or Warrants by the Selling Securityholders. We would receive up to an aggregate of approximately $138.9 million from the exercise of the warrants, assuming the exercise in full of all of such warrants for cash, however, it is not certain how many warrants would be exercised for cash or if at all. We expect to use the net proceeds from the exercise of any warrants for general corporate purposes. See “Use of Proceeds.”
     
Market for Common Stock and Public Warrants   Our Common Stock and our Public Warrants are listed on the Nasdaq Capital Market under the symbols “ONMD” and “ONMDW,” respectively.
     
Risk factors   Any investment in the securities offered hereby is speculative and involves a high degree of risk. You should carefully consider the information set forth under “Risk Factors” and elsewhere in this prospectus.

 

In this prospectus, unless otherwise indicated, the number of shares of Common Stock outstanding as of April 15, 2024 and the other information based thereon:

 

  Does not reflect 1,685,881 shares of Common Stock reserved for issuance under our 2023 Equity Incentive Plan; or

 

  Does not reflect the exercise of Warrants to purchase up to 12,085,275 shares of Common Stock.

 

31
 

 

RISK FACTORS

 

An investment in our securities involves a high degree of risk. This prospectus contains a discussion of the risks applicable to an investment in our securities. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations. The occurrence of any of these known or unknown risks might cause you to lose all or part of your investment in the offered securities. We may not be successful in preventing the material adverse effects that any of the following risks and uncertainties may cause. You could lose all or a significant portion of your investment due to any of these risks and uncertainties.

 

You should carefully consider the following risks, as well as the other information contained in this prospectus, including our historical financial statements and related notes included elsewhere in this prospectus before you decide to purchase our securities. Any one of these risks and uncertainties has the potential to cause material adverse effects on our business, prospects, financial condition and operating results which could cause actual results to differ materially from any forward-looking statements expressed by us and a significant decrease in the value of our Common Stock shares and warrants. Refer to “Cautionary Statement Regarding Forward-Looking Statements.”

 

Risks Related to this Offering and Our Common Stock

 

Our stock price may be volatile, and purchasers of our Common Stock could incur substantial losses.

 

The stock market in general has experienced significant price and volume fluctuations that have often been unrelated or disproportionate to operating performance of individual companies, particularly following a public offering of a company with a small public float. There is the potential for rapid and substantial price volatility of our Common Stock following this offering. These broad market factors may seriously harm the market price of our Common Stock, regardless of our actual or expected operating performance and financial condition or prospects, which may make it difficult for investors to assess the rapidly changing value of our Common Stock.

 

We are currently listed on The Nasdaq Capital Market. If we are unable to maintain listing of our securities on Nasdaq or any stock exchange, our stock price could be adversely affected and the liquidity of our stock and our ability to obtain financing could be impaired and it may be more difficult for our stockholders to sell their securities.

 

Although our Common Stock is currently listed on The Nasdaq Capital Market, we may not be able to continue to meet the exchange’s minimum listing requirements or those of any other national exchange. If we are unable to maintain listing on Nasdaq or if a liquid market for our Common Stock does not develop or is sustained, our Common Stock may remain thinly traded.

 

The listing rules of Nasdaq require listing issuers to comply with certain standards in order to remain listed on its exchange. If, for any reason, we should fail to maintain compliance with these listing standards and Nasdaq should delist our securities from trading on its exchange and we are unable to obtain listing on another national securities exchange, a reduction in some or all of the following may occur, each of which could have a material adverse effect on our stockholders:

 

  the liquidity of our Common Stock;
     
  the market price of our Common Stock;
     
  our ability to obtain financing for the continuation of our operations;
     
  the number of institutional and general investors that will consider investing in our Common Stock;
     
  the number of investors in general that will consider investing in our Common Stock;
     
  the number of market makers in our Common Stock;
     
  the availability of information concerning the trading prices and volume of our Common Stock; and
     
  the number of broker-dealers willing to execute trades in shares of our Common Stock.

 

32
 

 

Our principal stockholders will continue to have significant influence over the election of our board of directors and approval of any significant corporate actions, including any sale of the company.

 

Our founders, executive officers, directors, and other principal stockholders, in the aggregate, beneficially own a majority of our outstanding stock. These stockholders currently have, and likely will continue to have, significant influence with respect to the election of our board of directors and approval or disapproval of all significant corporate actions. The concentrated voting power of these stockholders could have the effect of delaying or preventing an acquisition of the company or another significant corporate transaction.

 

We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.

 

Our management will have broad discretion in the application of the net proceeds from this offering, including for any of the currently intended purposes described in the section entitled “Use of Proceeds.” Because of the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Our management may not apply our cash from this offering in ways that ultimately increase the value of any investment in our securities or enhance stockholder value. The failure by our management to apply these funds effectively could harm our business. Pending their use, we may invest the net proceeds from this offering in short-term, investment-grade, interest-bearing securities. These investments may not yield a favorable return to our stockholders. If we do not invest or apply our cash in ways that enhance stockholder value, we may fail to achieve expected financial results, which may result in a decline in the price of our shares of Common Stock, and, therefore, may negatively impact our ability to raise capital, invest in or expand our business, acquire additional products or licenses, commercialize our product, or continue our operations.

 

We could be subject to securities class action litigation.

 

In the past, securities class action litigation has often been brought against companies following a decline in the market price of their securities. In 2020, 22% of securities class action litigation filings were against defendants in the health technology and services sector, which accounted for 22% of new filings. If we face such litigation, it could result in substantial costs and a diversion of management’s attention and resources, which could harm our business.

 

If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, the market price for the shares and trading volume could decline.

 

The trading market for our Common Stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If research analysts do not establish and maintain adequate research coverage or if one or more of the analysts who covers us downgrades our Common Stock or publishes inaccurate or unfavorable research about our business, the market price for our Common Stock would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which, in turn, could cause the market price or trading volume for our common stock to decline.

 

We do not expect to pay dividends in the foreseeable future, and you must rely on price appreciation of your shares of Common Stock for return on your investment.

 

We have paid no cash dividends on any class of our stock to date, and we do not anticipate paying cash dividends in the near term. For the foreseeable future, we intend to retain any earnings to finance the development and expansion of our business, and we do not anticipate paying any cash dividends on our stock. Accordingly, investors must be prepared to rely on sales of their shares after price appreciation to earn an investment return, which may never occur. Investors seeking cash dividends should not purchase our shares. Any determination to pay dividends in the future will be made at the discretion of our board of directors and will depend on our results of operations, financial condition, contractual restrictions, restrictions imposed by applicable law and other factors our board deems relevant.

 

As the public offering price is substantially higher than our net tangible book value per share, you will experience immediate and substantial dilution.

 

If you purchase Common Stock in this offering, you will pay more for your shares of Common Stock than the amount paid by our existing stockholders for their shares on a per share basis. As a result, you will experience immediate and substantial dilution in net tangible book value per share in relation to the price that you paid for your shares. In addition, you will experience further dilution to the extent that our shares are issued upon the exercise of any warrants or exercise of stock options under any stock incentive plans. See “Dilution” for a more complete description of how the value of your investment in our shares will be diluted upon completion of this offering.

 

33
 

 

Future sales of substantial amounts of our Common Stock or securities convertible into or exchangeable or exercisable for shares of Common Stock, either by us or by our existing stockholders, or the possibility that such sales could occur, could adversely affect the market price of our Common Stock.

 

Future sales in the public market of shares of our Common Stock or securities convertible into or exchangeable or exercisable for shares of Common Stock, shares held by our existing stockholders or shares issued upon exercise of our outstanding stock options or warrants, or the perception by the market that these sales could occur, could lower the market price of our Common Stock or make it difficult for us to raise additional capital.

 

There is no public market for the warrants being offered in this offering.

 

There is no established public trading market for the warrants being offered in this offering, and we do not expect a market to develop. In addition, we do not intend to apply to list the warrants on any securities exchange or nationally recognized trading system, including The Nasdaq Capital Market. Without an active market, the liquidity of the warrants will be limited.

 

Holders of the warrants purchased in this offering will have no rights as common stockholders until such holders exercise such warrants and acquire our Common Stock.

 

Until holders of the warrants acquire shares of our Common Stock upon exercise of such warrants, holders of the warrants will have no rights with respect to the shares of our Common Stock underlying such warrants. Upon exercise of the warrants, the holders will be entitled to exercise the rights of a Common Stockholder only as to matters for which the record date occurs after the exercise date.

 

We will incur increased costs as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.

 

As a public company, and particularly after we no longer qualify as an emerging growth company, we will incur significant legal, accounting, and other expenses that we did not incur previously. The Sarbanes-Oxley Act of 2002 (“SOX”), the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq, and other applicable securities rules and regulations impose various requirements on U.S. reporting public companies, including the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified senior management personnel or members for our board of directors. In addition, these rules and regulations are often subject to varying interpretations, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. Pursuant to Section 404 of SOX (“Section 404”), we will be required to furnish a report by our senior management on our internal control over financial reporting.

 

While we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To prepare for eventual compliance with Section 404, once we no longer qualify as an emerging growth company, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404.

 

34
 

 

We are an “emerging growth company,” and the reduced reporting requirements applicable to emerging growth companies may make our common stock less attractive to investors.

 

We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act (“the JOBS Act”). For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including exemption from compliance with the auditor attestation requirements of Section 404, reduced disclosure obligations regarding executive compensation and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the closing of our initial public offering, (b) in which we have total annual gross revenue of at least $1.235 billion or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock held by non-affiliates exceeds $700 million as of the end of our prior second fiscal quarter, and (2) the date on which we have issued more than $1 billion in non-convertible debt during the prior three-year period.

 

In addition, under the JOBS Act, emerging growth companies may delay adopting new or revised accounting standards until such time as those standards apply to private companies. We may elect not to avail ourselves of this exemption from new or revised accounting standards and, therefore, may be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile.

 

Anti-takeover provisions contained in our certificate of incorporation and bylaws as well as provisions of Delaware law, could impair a takeover attempt.

 

Our certificate of incorporation, bylaws and Delaware law contain provisions which could have the effect of rendering more difficult, delaying or preventing an acquisition deemed undesirable by our board of directors. Our corporate governance documents include provisions:

 

  authorizing “blank check” preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend, and other rights superior to our common stock;
     
  limiting the liability of, and providing indemnification to, our directors and officers;
     
  limiting the ability of our stockholders to call and bring business before special meetings;
     
  requiring advance notice of stockholder proposals for business to be conducted at meetings of our stockholders and for nominations of candidates for election to our board of directors;
     
  controlling the procedures for the conduct and scheduling of board of directors and stockholder meetings; and
     
  providing our board of directors with the express power to postpone previously scheduled annual meetings and to cancel previously scheduled special meetings.

 

These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management. As a Delaware corporation, we are also subject to provisions of Delaware law, including Section 203 of the Delaware General Corporation law, which prevents some stockholders holding more than 15% of our outstanding common stock from engaging in certain business combinations without approval of the holders of substantially all of our outstanding common stock.

 

Any provision of our certificate of incorporation, bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our Common Stock and could also affect the price that some investors are willing to pay for our Common Stock.

 

35
 

 

Our amended and restated certificate of incorporation, as amended, designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or other employees.

 

Our certificate of incorporation requires that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will, to the fullest extent permitted by law, be the sole and exclusive forum for each of the following:

 

  any derivative action or proceeding brought on our behalf;
     
  any action asserting a claim for breach of any fiduciary duty owed by any director, officer, or other employee of ours to the Company or our stockholders, creditors or other constituents;
     
   ● any action asserting a claim against us or any director or officer of ours arising pursuant to, or a claim against us or any of our directors or officers, with respect to the interpretation or application of any provision of, the DGCL, our certificate of incorporation or bylaws; or
     
  any action asserting a claim governed by the internal affairs doctrine;

 

provided, that, if and only if the Court of Chancery of the State of Delaware dismisses any of the foregoing actions for lack of subject matter jurisdiction, any such action or actions may be brought in another state court sitting in the State of Delaware.

 

The exclusive forum provision is limited to the extent permitted by law, and it will not apply to claims arising under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Securities Act of 1933, as amended (the “Securities Act”), or for any other federal securities laws which provide for exclusive federal jurisdiction.

 

Our Amended and Restated Certificate of Incorporation, as amended, provides that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act or the Securities Exchange Act of 1934, as amended. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock are deemed to have notice of and consented to this provision.

 

Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our second amended and restated certificate of incorporation provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring such a claim arising under the Securities Act against us, our directors, officers, or other employees in a venue other than in the federal district courts of the United States of America. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our second amended and restated certificate of incorporation.

 

Although we believe this provision benefits us by providing increased consistency in the application of Delaware law in the types of lawsuits to which it applies, this provision may limit or discourage a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. Alternatively, if a court were to find the choice of forum provision contained in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.

 

We note that there is uncertainty as to whether a court would enforce the provision and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Although we believe this provision benefits us by providing increased consistency in the application of Delaware law in the types of lawsuits to which it applies, the provision may have the effect of discouraging lawsuits against our directors and officers.

 

36
 

 

Our Business Risks

 

We have a history of operating losses and may never achieve profitability in the future.

 

We have experienced significant recurring operating losses and negative cash flows from operating activities since inception. For example, for the years ended December 31, 2023 and 2022, we had net losses of approximately $8.2 million and $11.06 million, respectively. As of December 31, 2023, we had accumulated deficit of $55,082,677.

 

We expect to continue to incur significant losses in the development, marketing, sale and delivery of our services. If we do not grow our revenues or if we lose existing customers, we expect to continue to incur losses from operations for the foreseeable future. Because of the numerous risks and uncertainties associated with the development, marketing, sale and delivery of our imaging real world data (“iRWDTM”) services, we may experience larger than expected future losses and may never become profitable. Moreover, there is a substantial risk that we may not be able to successfully commercialize our iRWDTM services, which would make it unlikely that we would ever achieving profitability.

 

OneMedNet believes it has demonstrated its quality and responsiveness in clinical imaging and curation of RWD based upon success in compiling one of the largest networks of imaging centers (comprised of hospitals, imaging centers and clinics) throughout the United States covering more than 15 million patients to date. On the global front, OneMedNet works with hospitals and life science companies around the world including Ireland, United Kingdom, Ghana, Denmark and South Korea and growing. We base these claims on our understanding of our competition in the United States and globally. However, if we were to lose these relationships with our network of imaging centers or lose our customers or our competitors’ technology surpasses ours, our competitors could claim a greater market share domestically or abroad, which could reduce our growth and our profits, which could harm our business, financial position, results of operations and prospects.

 

Two significant customers represented 53% and 52% of our revenues for 2022 and 2023 respectively, and is expected to continue to represent a significant portion of our forecasted revenue for 2024.

 

Change Healthcare and Siemens Medical Solutions USA, collectively represented 53% and 52% of our revenues in 2023 and 2022, respectively. Change Healthcare is expected to continue to represent a significant portion of our forecasted revenue for 2024. If we fail to maintain and grow our relationships with Change Healthcare, we could lose a significant portion of our revenue for 2023, which would materially adversely affect our results of operations and our business. If OneMedNet were to lose one or more of its significant customers, its revenue may significantly decline. In addition, revenue from significant customers may vary from period to period depending on the timing of renewing existing agreements or entering into new agreements for additional OneMedNet products as well as other unforeseen risks and variables discussed in this proxy statement/prospectus. The loss of one or more of OneMedNet’s significant customers could adversely affect its business, results of operations and financial condition. You should not rely on our historical relationship with these companies as an indication of our future performance.

 

37
 

 

We may encounter difficulties in managing our attempted growth of our business, which could negatively impact our operations.

 

As we expand, market, sell and deliver our service offerings, we anticipate that we will need to increase our service development, sales and marketing and administrative headcount. Such an evolution may impact our strategic focus and our deployment and allocation of resources.

 

Our ability to manage our operations and growth effectively depends upon the continual improvement of our procedures, reporting systems and operational, financial and management controls. We may not be able to implement administrative and operational improvements in an efficient or timely manner and may discover deficiencies in existing systems and controls. If we do not meet these challenges, we may be unable to execute our business strategies and may be forced to expend more resources than anticipated addressing these issues.

 

We may acquire additional technology and complementary businesses in the future. Acquisitions involve many risks, any of which could materially harm our business, including the diversion of management’s attention from core business concerns, failure to effectively exploit acquired technologies, failure to successfully integrate the acquired business or realize expected synergies or the loss of key employees from either our business or the acquired businesses.

 

In addition, in order to continue to meet our obligations as a public listed company in both Australia and the United States and to support our anticipated long-term growth, we will need to increase our general and administrative capabilities. Our management, personnel and systems may not be adequate to support this future growth. If we are unable to successfully manage our growth and the increased complexity of our operations, our business, financial position, results of operations and prospects may be harmed.

 

Our recent growth rates may not be sustainable, or indicative of future growth.

 

Our historical revenue is extremely low in absolute dollars. While our revenues grew significantly on a percentage basis from 2020 to 2022, our revenue declined in 2023 over 2022 due to our attention to the Business Combination. Our future rate of growth may not be sustainable or indicative of our future rate of growth. We believe that our continued revenue growth, as well as our ability to reach profitability, will depend upon, among other factors, our ability to address the challenges, risks and difficulties described elsewhere in this proxy statement/prospectus. We cannot provide assurance that we will be able to successfully manage any such challenges or risks to our future growth. Any of these factors could cause our revenue growth to decline and may adversely affect our margins and reaching profitability. Failure to continue our revenue growth or improve margins would have a material adverse effect on our business, financial condition and results of operations. You should not rely on our historical rate of revenue growth as an indication of our future performance.

 

38
 

 

We may be unable to execute our business objectives and growth strategies successfully or sustain our growth and, as a result, this could have a material adverse effect on our operating results.

 

The highly complex nature of our industry requires that we effectively execute and manage our business objectives and growth strategies, such as expanding our marketing and commercialization of our services in the U.S. and internationally, adding new customers, and increasing our service delivery capacity. However, we may not be able to execute on these strategies as effectively as anticipated. Our ability to execute on these strategies depends on a number of factors, including, without limitation:

 

our ability to obtain adequate capital resources to complete execute our growth plans;
   
our ability to hire, train and retain skilled managers and personnel, including quality and production personnel, and marketing and commercial specialists;
   
our ability to protect our existing and new services by registering and defending our intellectual property rights; and
   
our ability to successfully add new customers.

 

To the extent we are unable to execute on our growth strategies in accordance with our expectations, this could have a material adverse effect on our business, financial condition, and future results of operations.

 

The real-world data and real-world evidence business market continues to evolve, is highly competitive, and we may not be successful in competing in this industry or establishing and maintaining confidence in our long-term business prospects among current and future partners and customers.

 

The real-world data and real-world evidence business market in which we compete continues to evolve and is highly competitive. To date, we have focused our efforts on its expertise in clinical imaging innovation solutions that connects healthcare providers and patients and satisfies a crucial need with the life sciences. We offer direct access to clinical images and associated contextual patient record. OneMedNet proved the commercial and regulatory viability of imaging Regulatory Grade Real-World Data (“iRWDTM”), a promising emerging market, that exactly matches OneMedNet’s life science partners’ case selection protocol. OneMedNet has the immediate ability to quickly search and extensively curate multi-layer data from a federated group of healthcare facilities and to provide fast access to curated medical images that has proved the commercial and regulatory viability of imaging RWD and covers the complete value chain in imaging RWD, validated by an increasing federated network of providers. However, real-world data and real-world evidence has been increasingly adopted and our current competitors have, and future competitors may have, greater resources than we do and may also be able to devote greater resources to the development of their current and future technologies. These competitors also may have greater access to customers and may be able to establish cooperative or strategic relationships amongst themselves or with third parties that may further enhance their resources and competitive positioning.

 

Developments in improvements in real-world data and real-world evidence curation by competitors may materially adversely affect the sales, pricing and gross margins of our business. If a competing technology or process is developed that has superior operational or price performance, our business will be harmed. Similarly, if we fail to accurately predict and ensure that our real-world data and real-world evidence offering can address customers’ changing needs or emerging technological trends, or if our customers fail to achieve the benefits expected from our real-world data and real-world evidence offering, our business will be harmed.

 

We must continue to commit resources to develop our real-world data and real-world evidence technology in order to establish a competitive position, and these commitments will be made without knowing whether such investments will result in products potential customers will accept. There is no assurance we will successfully identify new customer requirements, develop and bring our real-world data and real-world evidence to market on a timely basis, or that products and technologies developed by others will not render our real-world data and real-world evidence obsolete or noncompetitive, any of which would adversely affect our business and operating results.

 

If we are unable to attract and retain key employees and qualified personnel, our ability to compete could be harmed.

 

We depend on the talents and continued efforts of our senior management and key employees. The loss of members of our management or key employees may disrupt our business and harm our results of operations. Further, our ability to manage further expansion will require us to continue to attract, motivate and retain additional qualified personnel. Competition for this type of personnel is intense, and we may not be successful in attracting, integrating and retaining the personnel required to grow and operate our business effectively. There can be no assurance that our current management team or any new members of our management team will be able to successfully execute our business and operating strategies.

 

39
 

 

Our operating and financial results forecast relies in large part upon assumptions and analyses developed by us. If these assumptions or analyses prove to be incorrect, our actual operating results may be materially different from our forecasted results.

 

The projected financial and operating information appearing elsewhere in this prospectus reflect current estimates of future performance. Whether actual operating and financial results and business developments will be consistent with our expectations and assumptions as reflected in our forecasts depends on a number of factors, many of which are outside our control, including, but not limited to:

 

  success and timing of development activity;
  customer acceptance of our products;
  competition, including from established and future competitors;
  whether we can obtain sufficient capital to sustain and grow our business;
  our ability to manage our growth;
  whether we can manage relationships with key suppliers;
  our ability to retain existing key management, integrate recent hires and attract, retain and motivate qualified personnel; and
  the overall strength and stability of domestic and international economies.

 

Unfavorable changes in any of these or other factors, most of which are beyond our control, could materially and adversely affect our business, results of operations and financial results.

 

Our operations could be damaged or adversely affected as a result of natural disasters and other catastrophic events.

 

Our operations could be adversely affected by events outside of our control, such as natural disasters, wars, health epidemics, and other calamities. We cannot assure you that any backup systems will be adequate to protect us from the effects of fire, floods, typhoons, earthquakes, power loss, telecommunications failures, break-ins, war, riots, terrorist attacks or similar events. Any of the foregoing events may give rise to interruptions, breakdowns, system failures, technology platform failures or internet failures, which could cause the loss or corruption of data or malfunctions of software or hardware as well as adversely affect our ability to provide services.

 

Any financial or economic crisis, or perceived threat of such a crisis, including a significant decrease in consumer confidence, may materially and adversely affect our business, financial condition, and results of operations.

 

In recent years, the United States and global economies suffered dramatic downturns as the result of the COVID-19 pandemic, a deterioration in the credit markets and related financial crisis as well as a variety of other factors including, among other things, extreme volatility in security prices, severely diminished liquidity and credit availability, ratings downgrades of certain investments and declining valuations of others. The United States and certain foreign governments have taken unprecedented actions in an attempt to address and rectify these extreme market and economic conditions by providing liquidity and stability to the financial markets. If the actions taken by these governments are not successful, the return of adverse economic conditions may negatively impact the demand for iRWDTM offering and may negatively impact our ability to raise capital, if needed, on a timely basis and on acceptable terms or at all.

 

40
 

 

Our ability to utilize our net operating loss and tax credit carryforwards to offset future taxable income may be subject to certain limitations.

 

In general, under Section 382 of the Code, a corporation that undergoes an “ownership change” is subject to limitations on its ability to use its pre-change net operating loss carryforwards (“NOLs”), to offset future taxable income. The limitations apply if a corporation undergoes an “ownership change,” which is generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period. If we have experienced an ownership change at any time since our incorporation, we may already be subject to limitations on our ability to utilize our existing NOLs and other tax attributes to offset taxable income or tax liability. In addition, the Business Combination and future changes in our stock ownership, which may be outside of our control, may trigger an ownership change. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. As a result, even if we earn net taxable income in the future, our ability to use these or our pre-change NOL carryforwards and other tax attributes to offset such taxable income or tax liability may be subject to limitations, which could potentially result in increased future income tax liability to us.

 

There is also a risk that changes in law or regulatory changes made in response to the need for some jurisdictions to raise additional revenue to help counter the fiscal impact from unforeseen reasons, including suspensions on the use of net operating losses or tax credits, possibly with retroactive effect, may result in our existing net operating losses or tax credits expiring or otherwise being unavailable to offset future income tax liabilities.

 

We are subject to many hazards and operational risks that can disrupt our business, some of which may not be insured or fully covered by insurance.

 

Our operations are subject to many hazards and operational risks inherent to our business, including: (a) general business risks; (b) warranty liability; and (c) damage to third parties (e.g., our vendors), our infrastructure or properties caused by fires, floods and other natural disasters, power losses, telecommunications failures, terrorist attacks, riots, cyberattacks, public health crises such as the current COVID-19 pandemic (and other future pandemics or epidemics), human errors and similar events. As a result of the COVID-19 outbreak, or similar pandemics, we have and may in the future experience disruptions that could severely impact our business and the business of our customers.

 

Our insurance coverage may be inadequate to cover our liabilities related to such hazards or operational risks. For example, we do not currently maintain cybersecurity insurance and our insurance providers may take the position that our coverage, under present circumstances, does not extend to business interruptions as they relate to the COVID-19 pandemic. In addition, we may not be able to maintain adequate insurance in the future at rates we consider reasonable and commercially justifiable, and insurance may not continue to be available on terms as favorable as our current arrangements. The occurrence of a significant uninsured claim or a claim in excess of the insurance coverage limits maintained by us could have a material adverse effect on our business, financial condition and results of operations.

 

Our management has limited experience in operating a public company.

 

Our executive officers have limited experience in the management of a publicly traded company. Our management team may not successfully or effectively manage our transition to a public company that will be subject to significant regulatory oversight and reporting obligations under federal securities laws. For example, in connection with the closing of the Business Combination, the Company was required to restate and refile its Form 10-Q for quarter end September 30, 2023. The Company failed to file timely a disclosure under Item 4.02 Form 8-K to announce the restatement and refiling of the Form 10-Q, which it filed December 15, 2023 and its related failure to file a Form NT 10-Q for the quarter ended September 30, 2023 to disclose in SEC Form 12b-25 filings a request for seeking a delayed quarterly or annual reporting filing was caused by an anticipated restatement or correction of prior financial reporting, which filing failures reflect certain of the Company’s executive officers limited experience in the management of a publicly traded company. Their limited experience in dealing with the increasingly complex laws pertaining to public companies could be a significant disadvantage in that it is likely that an increasing amount of their time may be devoted to these activities which will result in less time being devoted to the management and growth of our Company. We may not have adequate personnel with the appropriate level of knowledge, experience, and training in the accounting policies, practices or internal controls over financial reporting required of public companies in the United States. The development and implementation of the standards and controls necessary for us to achieve the level of accounting standards required of a public company in the United States may require costs greater than expected. It is possible that we will be required to expand our employee base and hire additional employees to support our operations as a public company which will increase our operating costs in future periods.

 

41
 

 

The requirements of being a public company may strain our resources and divert management’s attention, and the increases in legal, accounting, insurance and compliance expenses may be greater than we anticipate.

 

We are a public company, and as such (and particularly after we are no longer an “emerging growth company”), will incur significant legal, accounting and other expenses that OneMedNet did not incur prior to the business combination. We are subject to the reporting requirements of the Exchange Act, and are required to comply with the applicable requirements of the Sarbanes-Oxley Act and the Dodd-Frank Wall Street Reform and Consumer Protection Act, as well as the rules and regulations subsequently implemented by the SEC and the listing standards of The Nasdaq Stock Market, including changes in corporate governance practices and the establishment and maintenance of effective disclosure and financial controls. Compliance with these rules and regulations can be burdensome. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our historical legal and financial compliance costs and will make some activities more time-consuming and costly.

 

For example, we expect that these rules and regulations may make it more difficult and more expensive for us to attract and retain qualified members of our Board as compared to OneMedNet prior to the business combination as well as significantly more expensive to provide the required insurance. In particular, we expect to incur significant expenses and devote substantial management effort toward ensuring compliance with the requirements of Section 404 of the Sarbanes-Oxley Act, which will increase when we are no longer an “emerging growth company.” We will need to hire additional accounting and financial staff, and engage outside consultants, all with appropriate public company experience and technical accounting knowledge and maintain an internal audit function, which will increase our operating expenses. Moreover, we could incur additional compensation costs in the event that we decide to pay cash compensation closer to that of other public companies, which would increase our general and administrative expenses and could materially and adversely affect our profitability. We are evaluating these rules and regulations, and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs.

 

If securities or industry analysts do not publish or cease publishing research or reports about us, our business, or the market in which we operate, or if they change their recommendations regarding our securities adversely, the price and trading volume of our securities could decline.

 

The trading market for our securities will be influenced by the research and reports that industry or securities analysts may publish about us, our business, market or competitors. Securities and industry analysts do not currently, and may never, publish research on us. If no securities or industry analysts commence coverage of us, our share price and trading volume would likely be negatively impacted. If any of the analysts who may cover us change their recommendation regarding our shares of Common Stock adversely, or provide more favorable relative recommendations about our competitors, the price of our shares of Common Stock would likely decline. If any analyst who may cover us were to cease our coverage of us or fail to regularly publish reports on it, we could lose visibility in the financial markets, which in turn could cause our share price or trading volume to decline.

 

Risks Related to Ownership of Our Common Stock, this Offering, and Our Certificate of Incorporation and Bylaws Provisions

 

Our Common Stock has been and may in the future continue to be subject to extreme volatility.

 

The trading price of our Common Stock may be subject to extreme volatility. We cannot predict the magnitude of future fluctuations in the trading price of our Common Stock. The trading price of our Common Stock may be affected by a number of factors, including events described in the risk factors set forth in this prospectus and in our periodic reports filed with the SEC from time to time, as well as our operating results, financial condition and other events or factors. Any of the factors listed below could have a material adverse effect on your investment in our securities. Factors affecting the trading price of our securities may include:

 

  announcements by us or our competitors regarding technical developments and levels of performance achieved by our or their real-world data and real-world evidence offering;
  announcements by us regarding developments in our relationship with existing and future key customers;
  our ability to bring our products and technologies to market on a timely basis, or at all;
  our operating results or development efforts failing to meet the expectation of securities analysts or investors in a particular period;
  actual or anticipated fluctuations in our quarterly financial results or the quarterly financial results of companies perceived to be similar to it;
  changes in the market’s expectations about our operating results or the real-world data and real-world evidence industry;

 

42
 

 

  success of competitors actual or perceived development efforts;
  changes in financial estimates and recommendations by securities analysts concerning the Company or the real-world data and real-world evidence industry in general;
  operating and share price performance of other companies that investors deem comparable to the Company;
  disputes or other developments related to proprietary rights, including patents, litigation matters and our ability to obtain intellectual property protection for our technologies;
  changes in laws and regulations affecting our business;
  our ability to meet compliance requirements;
  commencement of, or involvement in, litigation involving the Company;
  changes in our capital structure, such as future issuances of securities or the incurrence of additional debt;
  the volume of shares of Common Stock available for public sale;
  the level of demand for our Common Stock, including the amount of short interest in our stock;
  any major change in our Board or management;
  sales of substantial amounts of the shares of Common Stock by our directors, executive officers or significant stockholders or the perception that such sales could occur;
  the expiration of contractual lock-up agreements with our executive officers, directors and stockholders, which we have entered into and may enter into in the future from time to time; and
  general economic and political conditions such as recessions, interest rates, fuel prices, international currency fluctuations and acts of war or terrorism.

 

Broad market and industry factors may materially harm the market price of our securities irrespective of our operating performance. The stock market in general, and the Nasdaq in particular, have experienced price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of the particular companies affected. The trading prices and valuations of these stocks, and of our securities, may not be predictable. A loss of investor confidence in the market for retail stocks or the stocks of other companies which investors perceive to be similar to the Company could depress our share price regardless of our business, prospects, financial conditions or results of operations. A decline in the market price of our securities also could adversely affect our ability to issue additional securities and our ability to obtain additional financing in the future.

 

Following certain periods of volatility in the market price of our securities, we may become subject of securities litigation. We have experienced, and may in the future experience additional litigation following periods of volatility. This type of litigation may result in substantial costs and a diversion of management’s attention and resources.

 

Sales of substantial amounts of our Common Stock in the public markets, or the perception that such sales could occur, could reduce the price that our Common Stock might otherwise attain.

 

Sales of a substantial number of shares of our Common Stock in the public market after this offering, or the perception that such sales could occur, could adversely affect the market price of our Common Stock and may make it more difficult for you to sell your Common Stock at a time and price that you deem appropriate. Based on the total number of outstanding shares, approximately 23,850,010 shares of our Common Stock as of that date hereof, the issuance of up to 19,683,367 shares of Common Stock pursuant to this offering would represent a substantial amount of dilution to existing stockholders. A majority of the shares of Common Stock sold in this offering will be freely tradable without restrictions or further registration under the Securities Act, except for any shares held by existing officers and directors of the Company and former officers and directors of DKAC.

 

Future sales, or the perception of future sales, by us or our stockholders in the public market could cause the market price for our Common Stock to decline.

 

The sale of our Common Stock in the public market, or the perception that such sales could occur, could harm the prevailing market price of our Common Stock. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that it deems appropriate.

 

Significant additional capital will be needed in the future to continue our planned operations, including further development of our iRWDTM offering, growth of our sales and marketing team, development activities and costs associated with operating a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner as determined from time to time. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our Common Stock.

 

43
 

 

Pursuant to the Company’s 2023 Equity Incentive Plan, our board of directors or compensation committee is authorized to grant stock options to our employees, directors and consultants. Initially, the maximum aggregate number of shares of Common Stock that may be issued pursuant to stock awards under the 2023 Equity Incentive Plan is 1,685,881 shares of Common Stock. Additionally, the number of shares of Common Stock reserved for issuance under the 2023 Equity Incentive Plan will automatically increase on January 1 of each year, beginning on January 1, 2025 and continuing through and including January 1, 2032, by 5% of the total number of shares of Common Stock outstanding on December 31 of the preceding calendar year, subject to a maximum annual increase of 1,000,000 shares of Common Stock or a lesser number of shares determined by our board of directors. Unless our board of directors elects not to increase the number of shares available for future grant each year, our stockholders may experience additional dilution, which could cause our stock price to fall. Our issuance of additional shares of common stock or other equity securities of equal or senior rank would, all else being equal, have the following effects:

 

  the amount of cash available per share, including for payment of dividends in the future, may decrease;

 

  the relative voting strength of each previously outstanding share of common stock would be diminished; and

 

  the market price of shares of shares of Common Stock may decline.

 

In the future, we may also issue its securities in connection with investments or acquisitions. The amount of Common Stock issued in connection with an investment or acquisition could constitute a material portion of the then-outstanding Common Stock. Any issuance of additional securities in connection with investments or acquisitions may result in additional dilution to our stockholders.

 

The unaudited pro forma financial information included herein is not indicative of what our actual financial position or results of operations would have been.

 

The unaudited pro forma financial information included herein is presented for illustrative purposes only and is not necessarily indicative of what our actual financial position or results of operations would have been had the Business Combination been completed on the dates indicated.

 

There is no guarantee that the warrants will ever be in the money; they may expire worthless or the terms of warrants may be amended.

 

The exercise price for the warrants is $11.50 per share of Common Stock. There is no guarantee that the Public Warrants will ever be in the money prior to their expiration, and as such, the warrants may expire worthless.

 

In addition, our warrants were issued in registered form under a warrant agreement between Continental Stock Transfer & Trust Company, as warrant agent, and DKAC. The warrant agreement provides that the terms of the warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, but requires the approval by the holders of at least a majority of the then outstanding Public Warrants to make any other change. Accordingly, we may amend the terms of the warrants in a manner adverse to a holder if holders of at least a majority of the then outstanding Public Warrants approve of such amendment. Although our ability to amend the terms of the warrants with the consent of at least a majority of the then outstanding Public Warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the warrants, shorten the exercise period or decrease the number of shares and their respective affiliates and associates have of shares of Common Stock purchasable upon exercise of a warrant.

 

If certain holders of our Common Stock sell a significant portion of their securities, it may negatively impact the market price of the shares of our Common Stock and such holders still may receive significant proceeds.

 

As of the date of this prospectus, the market price of our common stock is below $10.00 per share, which was the price per share of Class A Common Stock sold in the initial public offering of our predecessor, Data Knights, the per share price of the PIPE shares sold to certain investors in connection with our Pre-Closing PIPE financing and also the per share value of the consideration issued to former Selling Securityholders of OneMedNet upon consummation of our Business Combination. However, certain of our stockholders who hold shares of our Common Stock that were originally purchased by our predecessor’s sponsor, Data Knights LLC, in a private placement prior to our predecessor’s initial public offering (the “Founder Shares”). In particular, 2,875,000 of the currently outstanding Founder Shares were purchased at an effective price of $0.009 per share, and the 1,439,563 of the currently outstanding shares of Common Stock held by ARC Group Limited and registered for resale in this prospectus were issued solely in consideration for services to Data Knights. Accordingly, holders of these shares of Common Stock could sell their securities at a per share price that is less than $10.00 and still realize a significant return from the sale of those securities that could not be realized by our other stockholders.

 

44
 

 

In connection with the transactions contemplated by the Merger Agreement (the “Transactions”), certain holders of the Company’s securities entered into a Lock-Up Agreement pursuant to which they agreed to certain restrictions on the transfer of their Common Stock.

 

The PIPE Investors under the Pre-Closing PIPE are entitled to require us to register shares underlying the Pre-Closing PIPE Notes and the PIPE Warrants owned by them for public sale in the United States, and the Investors under the Notes Securities Purchase Agreement are entitled to require us to register shares underlying the Notes and Warrants related thereto, thus we are filing this proxy statement/prospectus, to register those shares of Common Stock. Subject to the satisfaction of applicable exercise periods and expiration of the lock-up agreements referred to above, the shares issued upon exercise of the Pre-Closing PIPE Notes and the PIPE Warrants will be available for immediate resale in the United States in the open market. See the section titled “Shares Eligible for Future Sale” for additional information.

 

We may redeem the unexpired warrants prior to their exercise at a time that is disadvantageous to warrant holders, thereby making their warrants worthless.

 

We have the ability to redeem outstanding warrants at any time after they become exercisable and prior to their expiration, at a price of $0.01 per warrant, provided that the last reported sales price of the Common Stock equals or exceeds $18.00 per share for any 20 trading days within a 30 trading-day period ending on the third trading day prior to the date we send the notice of redemption to the warrant holders. If and when the warrants become redeemable by us, we may exercise its redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws. Additionally, ninety (90) days after the warrants become exercisable, we may redeem all (but not less than all) of the outstanding warrants at $0.01 per warrant upon a minimum of 30 days’ prior written notice of redemption if the following conditions are satisfied: (i) the last reported sale prices of the Common Stock equals or exceeds $18.00 per share (as may be adjusted for stock splits, stock dividends, reorganizations, recapitalizations or the like) on the trading day prior to the date of the notice; (ii) the private placement warrants are also concurrently exchanged at the same price as the outstanding Public Warrants; and (iii) there is an effective registration statement covering the issuance of Common Stock issuable upon exercise of the warrants and a current prospectus relating thereto available throughout the 30-day period after written notice of redemption is given. In either case, redemption of the outstanding warrants could force you (i) to exercise your warrants and pay the exercise price therefor at a time when it may be disadvantageous for you to do so, (ii) to sell your warrants at the then-current market price when you might otherwise wish to hold your warrants or (iii) to accept the nominal redemption price which, at the time the outstanding warrants are called for redemption, is likely to be substantially less than the market value of your warrants.

 

We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.

 

Our management has broad discretion in the application of the net proceeds from this offering, including to provide sufficient funding to grow our customer base and for working capital and general corporate purposes, and we may spend or invest these proceeds in a way with which our stockholders disagree. Because of the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. The failure by our management to apply these funds effectively could harm our business. Pending their use, we may invest such proceeds in a manner that does not produce income or that loses value, which may negatively impact the market price of our common stock.

 

Our business model is capital-intensive, and we may not be able to raise additional capital on attractive terms, if at all, which could be dilutive to stockholders. If we cannot raise additional capital when needed, our operations and prospects could be materially and adversely affected.

 

We can be expected to continue to sustain substantial operating expenses without generating sufficient revenues to cover expenditures. Over time, we expect that we will need to raise additional funds, including through the issuance of equity, equity-related or debt securities or through obtaining credit from financial institutions to fund, together with our principal sources of liquidity, ongoing costs, any significant unplanned or accelerated expenses, and new strategic investments. We cannot be certain that additional capital will be available on attractive terms, if at all, when needed, which could be dilutive to stockholders, and our financial condition, results of operations, business and prospects could be materially and adversely affected.

 

We do not expect to declare any dividends in the foreseeable future.

 

We do not anticipate declaring any cash dividends to holders of our Common Stock in the foreseeable future. Consequently, investors may need to rely on sales of their shares after price appreciation, which may never occur, as the only way to realize any future gains on their investment.

 

There can be no assurance that we will be able to comply with the continued listing standards of the Nasdaq.

 

Our Common Stock and public Warrants are listed on the Nasdaq under the symbols “ONMD” and “ONMDW”, respectively. If the Nasdaq delists our securities from trading on its exchange for failure to meet the listing standards and we are not able to list such securities on another national securities exchange, we expect such securities could be quoted on an over-the-counter market. If this were to occur, we and our stockholders could face significant material adverse consequences including:

 

  a limited availability of market quotations for our securities;
  reduced liquidity for our securities;
  a limited amount of news and analyst coverage; and
  a decreased ability to issue additional securities or obtain additional financing in the future.

 

Risks Related to Our Warrants

 

We may redeem unexpired Warrants prior to their exercise at a time that is disadvantageous to Warrantholders.

 

Our public Warrants are currently exercisable for one share of Common Stock at a price of $11.50 per share. We have the ability to redeem outstanding Warrants at any time prior to their expiration, at a price of $0.01 per Warrant, provided that the last reported sales price of Common Stock equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date we send the notice of redemption to Warrantholders and provided certain other conditions are met. If and when the Warrants become redeemable by us, we may exercise our redemption rights even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws. As a result, we may redeem the Warrants, as set forth above even if the holders are otherwise unable to exercise the Warrants.

 

Redemption of the outstanding Warrants could force Warrantholders (i) to exercise their Warrants and pay the exercise price therefor at a time when it may be disadvantageous for them to do so, (ii) to sell their Warrants at the then-current market price when they might otherwise wish to hold their Warrants or (iii) to accept the nominal redemption price which, at the time the outstanding Warrants are called for redemption, we expect would be substantially less than the market value of their Warrants. None of the private placement Warrants will be redeemable by us so long as they are held by the Sponsor or its permitted transferees.

 

45
 

 

USE OF PROCEEDS

 

All of the shares of Common Stock offered by the Selling Securityholders pursuant to this prospectus will be sold by the Selling Securityholders for their respective accounts. The Company will not receive any of the proceeds from these sales.

 

The Company will receive up to an aggregate of approximately $138.9 million from the exercise of the Warrants, assuming the exercise in full of all of the Warrants for cash. The Company expects to use the net proceeds from the exercise such warrants for other general corporate purposes. There is no assurance that the holders of the Warrants will elect to exercise any or all of such warrants. To the extent that warrants are exercised on a “cashless basis,” the amount of cash we would receive from the exercise of such warrants will decrease. See “Description of Securities we are Offering” for additional information regarding the warrants.

 

The Selling Securityholders will pay any underwriting fees, discounts and selling commissions incurred by such Selling Securityholders in disposing of their Common Stock. Pursuant to the Registration Rights Agreement, the Company will bear all other costs, fees and expenses incurred in effecting the registration of the Common Stock covered by this prospectus, including, without limitation, all registration and filing fees, Nasdaq listing fees and fees and expenses of counsel and independent registered public accountants.

 

DILUTION

 

If you invest in our securities, your ownership interest will be diluted to the extent of the difference between public offering price per share of our Common Stock and the as adjusted net tangible book value per share of our Common Stock immediately after this offering.

 

As of December 31, 2023 we had a historical net tangible book value of $(12,859,605), or $(0.55) per share of Common Stock, based on 23,572,232 shares of Common Stock outstanding at December 31, 2023.

 

To the extent that stock options or warrants are exercised, new stock options are issued under our equity incentive plan, or we issue additional common stock in the future, there will be further dilution to investors participating in this offering. In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders.

 

46
 

 

DESCRIPTION OF SECURITIES WE ARE OFFERING

 

Common Stock

 

The description of our Common Stock under the section “Description of Capital Stock” in this prospectus is incorporated herein by reference.

 

Warrants

 

General - The following is a brief summary of certain terms and conditions of the warrants being offered by us. The following description is subject in all respects to the provisions contained in the form of warrant, the form of which will be filed as an exhibit to the registration statement of which this prospectus forms a part.

 

Duration and Exercise Price - The warrants offered hereby will have an exercise price of $[*] per share. The warrants will be immediately exercisable and may be exercised at any time on or after the initial exercise date and on or before the five-year anniversary of the date of issuance. The exercise prices and numbers of shares of Common Stock issuable upon exercise are subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our Common Stock. Warrants will be issued in certificated form only.

 

Exercisability - The warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of our Common Stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of such holder’s warrants to the extent that the holder would own more than 4.99% (or 9.99%, at the holder’s election) of our outstanding Common Stock immediately after exercise, except that upon notice from the holder to us, the holder may decrease or increase the limitation of ownership of outstanding stock after exercising the holder’s warrants up to 9.99% of the number of shares of our Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the warrants, provided that any increase in such limitation shall not be effective until 61 days following notice to us.

 

Cashless Exercise - If, at the time a holder exercises its warrants, a registration statement registering the issuance of the shares of Common Stock underlying the warrants under the Securities Act, is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according to a formula set forth in the warrant.

 

Alternative Cashless Exercise - On or after the thirty (30) day anniversary of the date of the underwriting agreement, a holder of common warrants may also provide notice and elect an “alternative cashless exercise” pursuant to which they would receive an aggregate number of shares equal to the product of (x) the aggregate number of shares of common stock that would be issuable upon a cash exercise and (y) [*].

 

47
 

 

Transferability - A warrant may be transferred at the option of the holder upon surrender of the warrant to us together with the appropriate instruments of transfer.

 

Fractional Shares - No fractional shares of Common Stock will be issued upon the exercise of the warrants. Rather, the number of shares of Common Stock to be issued will, at our election, either be rounded up to the nearest whole number or we will pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price.

 

Trading Market - There is no established trading market for any of the warrants, and we do not expect a market to develop. We do not intend to apply for a listing for any of the warrants on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the warrants will be limited.

 

Rights as a Shareholder - Except as otherwise provided in the warrants or by virtue of the holders’ ownership of shares of our Common Stock, the holders of warrants do not have the rights or privileges of holders of our Common Stock, including any voting rights, until such warrant holders exercise their warrants.

 

Fundamental Transaction - In the event of a fundamental transaction, as described in the warrants and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding Common Stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, the holders of the warrants will be entitled to receive upon exercise of the warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the warrants immediately prior to such fundamental transaction. In the event of a Change of Control (as defined in each common warrant) approved by our Board of Directors, the holders of the common warrants have the right to require us or a successor entity to redeem the common warrants for cash in the amount of the Black-Scholes Value (as defined in each common warrant) of the unexercised portion of the common warrants on the date of the consummation of the Change of Control. In the event of a Change of Control which is not approved by our Board of Directors, the holders of the common warrants have the right to require us or a successor entity to redeem the common warrants for the consideration paid in the Change of Control in the amount of the Black-Scholes Value of the unexercised portion of the common warrants on the date of the consummation of the Change of Control.

 

Waivers and Amendments - No term of the warrants may be amended or waived without the written consent of the holder of such warrant.

 

48
 

 

SHARES ELIGIBLE FOR FUTURE SALE

 

Our Common Stock is listed on NASDAQ under the symbol “ONMD”. Future sales of substantial amounts of our Common Stock in the public market could adversely affect market prices prevailing from time to time and future distributions of the shares owned by the PIPE Investors could also adversely affect the market price of our common stock.

 

Sale of Restricted Shares

 

As of December 31, 2023, we had approximately 23,572,232 shares of Common Stock issued and outstanding. Of these shares, all of the shares of our Common Stock received in the distribution are, and all of the shares sold pursuant to this registration statement of which this prospectus forms a part will be freely transferable without restriction under the Securities Act, unless purchased by our “affiliates” as that term is defined in Rule 144 under the Securities Act.

 

Rule 144

 

In general, under Rule 144 as currently in effect, a person (or persons whose shares are aggregated) who is not deemed to be or have been one of our affiliates for purposes of the Securities Act at any time during 90 days preceding a sale and who has beneficially owned the shares proposed to be sold for at least six months, including the holding period of any prior owner other than an affiliate, is entitled to sell such shares without registration, subject to compliance with the public information requirements of Rule 144. If such a person has beneficially owned the shares proposed to be sold for at least one year, including the holding period of a prior owner other than an affiliate, then such person is entitled to sell such shares without complying with any of the requirements of Rule 144.

 

In general, under Rule 144, as currently in effect, our affiliates or persons selling shares on behalf of our affiliates, who have met the six-month holding period for beneficial ownership of “restricted shares” of our Common Stock, are entitled to sell within any three-month period, a number of shares that does not exceed the greater of:

 

  1.0% of our then-outstanding shares of Common Stock, which will equal approximately 2,357,223 shares immediately after this offering; and
     
  the average weekly trading volume of our Common Stock on NASDAQ during the four calendar weeks preceding the filing of a notice of the sale on Form 144.

 

Sales under Rule 144 by our affiliates or persons selling shares on behalf of our affiliates are also subject to certain manner of sale provisions and notice requirements and to the availability of current public information about us. The sale of these shares, or the perception that sales will be made, could adversely affect the price of our common stock after this offering because a greater supply of shares would be, or would be perceived to be, available for sale in the public market.

 

Registration Statement on Form S-8

 

In the near future, we intend to file with the SEC a Registration Statement on Form S-8 registering an aggregate of 360,000 shares of Common Stock underlying equity awards we have made and will make to our employees and certain other qualifying individuals, and the resale of those shares of common stock. The Form S-8 became effective upon filing and shares of common stock so registered will become freely tradable when issued.

 

Registration Rights

 

We have entered into the stockholder and registration rights agreement with the PIPE Investors. This prospectus is part of the registration statement filed pursuant to the stockholder and registration rights agreement. We do not have any other contractual obligations to register our Common Stock.

 

In connection with the Notes Securities Purchase Agreement, the Company and the Investor also entered into a Registration Rights Agreement, dated as of March 28, 2024 (the “RRA”), providing for the registration of the Note shares (the “Note Conversion Shares”) and the Warrant Shares (the “Registerable Securities”).

 


49
 

 

DESCRIPTION OF CAPITAL STOCK

 

The following summary is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference to the Articles, a copy of which is filed as an exhibit to the registration statement of which this prospectus forms a part. We urge you to read the Articles in their entirety for a complete description of the rights and preferences of our securities following the consummation of the Business Combination.

 

We exist under the laws of the State of Delaware and our affairs are governed by our Certificate of Incorporation and its Bylaws, each as amended and restated from time to time. Pursuant to the governing documents, our authorized share structure consists of 101,000,000 shares, consisting of (a) 100,000,000 shares of common stock (the “Common Stock”), (b) 1,000,000 shares of preferred stock. 

  

Common Stock

 

Holders of Common Stock are entitled to receive notice of and to attend any meetings of shareholders of the Company and at any meetings of shareholders to cast one vote for each such share of Common Stock held. Holders of Common Stock do not have cumulative voting rights. Save and except for certain conversion rights, as described below, the rights attaching to all Common Stock rank pari passu in all respects.

 

All of the DKAC Class B shares of Common Stock were converted into Common Stock shares of OneMedNet automatically on the closing of the Business Combination, on a one-to-one basis. In connection with and as consideration for the signing of the Business Combination Agreement DKAC and the Sponsor agreed to waive all anti-dilution adjustments with respect to the DKAC Class B Common Stock.

 

Our Board will be divided into three staggered classes, each of which will generally serve for a term of three years with only one class of directors being elected in each year. There is no cumulative voting with respect to the appointment of directors, with the result that the holders of more than 50% of the shares voted for the appointment of directors can appoint all of the directors. Holders of Common Stock are entitled to receive dividends as and when declared by the Board at its discretion from funds legally available therefor and to receive a pro rata share of the assets of OneMedNet available for distribution to the shareholders in the event of the liquidation, dissolution or winding-up of OneMedNet after payment of debts and other liabilities, in each case subject to the rights, privileges, restrictions and conditions attached to any other series or class of shares ranking senior in priority to or on a pro-rata basis with the holders of Common Stock with respect to dividends or liquidation. There are no pre-emptive, subscription, conversion or redemption rights attached to the Common Stock nor do they contain any sinking or purchase fund provisions.

 

50
 

 

Warrants

 

Each whole warrant entitles the registered holder to purchase one share of Common Stock at a price of $11.50 per share, subject to adjustment as discussed below, at any time commencing 30 days after the completion of the initial Business Combination. Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of shares of Common Stock. This means only a whole warrant may be exercised at a given time by a warrant holder. No fractional warrants will be issued upon separation of the units and only whole warrants will trade.

 

The warrants will at 5:00 p.m., New York City time, on November 7, 2028, or earlier upon redemption or liquidation.

 

OneMedNet will not be obligated to deliver any shares of Common Stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the shares of Common Stock underlying the warrants is then effective and a current prospectus relating thereto is current, subject to OneMedNet satisfying its obligations described below with respect to registration. No warrant will be exercisable, and OneMedNet will not be obligated to issue shares of Common Stock upon exercise of a warrant unless shares of Common Stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will DKAC be required to net cash settle any warrant. In the event that a registration statement is not effective for the exercised warrants, the purchaser of a unit containing such warrant, if not cash settled, will have paid the full purchase price for the unit solely for the shares of Common Stock and warrants underlying such unit.

 

We have agreed that as soon as practicable, but in no event later than 20 business days after the closing of the Business Combination, to use its best efforts to file with the SEC a registration statement registering the issuance of the shares of Common Stock issuable upon exercise of the warrants, to cause such registration statement to become effective and to maintain a current prospectus relating to those shares of Common Stock until the warrants expire or are redeemed, as specified in the Warrant Agreement. If a registration statement covering the shares of Common Stock issuable upon exercise of the warrants is not effective by the 60th business day after the closing of the Business Combination or within a specified period following the consummation of the Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when we shall have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” pursuant to the exemption provided by Section 3(a)(9) of the Securities Act; provided that such exemption is available. If that exemption, or another exemption, is not available, holders will not be able to exercise their warrants on a cashless basis. Once the warrants become exercisable, we may call the warrants for redemption:

 

  in whole and not in part;

 

  at a price of $0.01 per warrant;

 

  upon not less than 30 days’ prior written notice of redemption given after the warrants become exercisable (the “30-day redemption period”) to each warrant holder; and

 

  if, and only if, the reported last sale price of the shares of Common Stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period commencing once the warrants become exercisable and ending three business days before we send the notice of redemption to the warrant holders.

 

51
 

 

If and when the warrants become redeemable by us, we may not exercise our redemption right if the issuance of shares of Common Stock upon exercise of the warrants is not exempt from registration or qualification under applicable state blue sky laws or we are unable to effect such registration or qualification. We have established the last of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and we issue a notice of redemption of the warrants, each warrant holder will be entitled to exercise its warrant prior to the scheduled redemption date. However, the price of the shares of Common Stock may fall below the $18.00 redemption trigger price (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) as well as the $11.50 warrant exercise price after the redemption notice is issued.

 

If we call the warrants for redemption as described above, our management will have the option to require any holder that wishes to exercise its warrant to do so on a “cashless basis.” In determining whether to require all holders to exercise their warrants on a “cashless basis,” our management will consider, among other factors, its cash position, the number of warrants that are outstanding and the dilutive effect on shareholders of issuing the maximum number of shares of Common Stock issuable upon the exercise of the warrants. If our management takes advantage of this option, all holders of warrants would pay the exercise price by surrendering their warrants for that number of shares of Common Stock equal to the quotient obtained by dividing (x) the product of the number of shares of Common Stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the “fair market value” (defined below) by (y) the fair market value.

 

The “fair market value” for this purpose shall mean the average reported last sale price of the shares of Common Stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. If our management takes advantage of this option, the notice of redemption will contain the information necessary to calculate the number of shares of Common Stock to be received upon exercise of the warrants, including the “fair market value” in such case. Requiring a cashless exercise in this manner will reduce the number of shares to be issued and thereby lessen the dilutive effect of a warrant redemption. We believe this feature is an attractive option to us if we do not need the cash from the exercise of the warrants after the Business Combination. If we call the warrants for redemption and our management does not take advantage of this option, the Sponsor and its permitted transferees would still be entitled to exercise their placement warrants for cash or on a cashless basis using the same formula described above that other warrant holders would have been required to use had all warrant holders been required to exercise their warrants on a cashless basis, as described in more detail below.

 

A holder of a warrant may notify us in writing in the event it elects to be subject to a requirement that such holder will not have the right to exercise such warrant, to the extent that after giving effect to such exercise, such person (together with such person’s affiliates), to the warrant agent’s actual knowledge, would beneficially own in excess of 4.9% or 9.8% (or such other amount as a holder may specify) of the shares of Common Stock outstanding immediately after giving effect to such exercise.

 

If the number of outstanding shares of Common Stock is increased by a stock dividend payable in shares of Common Stock, or by a split-up of shares of Common Stock or other similar event, then, on the effective date of such stock dividend, split-up or similar event, the number of shares of Common Stock issuable on exercise of each whole warrant will be increased in proportion to such increase in the outstanding shares of Common Stock. A rights offering to holders of shares of Common Stock entitling holders to purchase shares of Common Stock at a price less than the fair market value will be deemed a stock dividend of a number of shares of Common Stock equal to the product of (i) the number of shares of Common Stock actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for shares of Common Stock) and (ii) one (1) minus the quotient of (x) the price per shares of Common Stock paid in such rights offering divided by (y) the fair market value. For these purposes (i) if the rights offering is for securities convertible into or exercisable for shares of Common Stock, in determining the price payable for shares of Common Stock, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii) fair market value means the volume weighted average price of shares of Common Stock as reported during the ten (10) trading day period ending on the trading day prior to the first date on which the shares of Common Stock trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights.

 

52
 

 

In addition, if we, at any time while the warrants are outstanding and unexpired, pay a dividend or make a distribution in cash, securities or other assets to the holders of shares of Common Stock on account of such shares of Common Stock (or other shares of our capital shares into which the warrants are convertible), other than as described above, or certain ordinary cash dividends, then the warrant exercise price will be decreased, effective immediately after the effective date of such event, by the amount of cash and/or the fair market value of any securities or other assets paid on each shares of Common Stock in respect of such event.

 

If the number of outstanding DKAC’s shares of Common Stock is decreased by a consolidation, combination, reverse stock split or reclassification of shares of Common Stock or other similar event, then, on the effective date of such consolidation, combination, reverse stock split, reclassification or similar event, the number of shares of Common Stock issuable on exercise of each warrant will be decreased in proportion to such decrease in outstanding shares of Common Stock.

 

Whenever the number of shares of Common Stock purchasable upon the exercise of the warrants is adjusted, as described above, the warrant exercise price will be adjusted by multiplying the warrant exercise price immediately prior to such adjustment by a fraction (x) the numerator of which will be the number of shares of Common Stock purchasable upon the exercise of the warrants immediately prior to such adjustment, and (y) the denominator of which will be the number of shares of Common Stock so purchasable immediately thereafter.

 

In case of any reclassification or reorganization of the outstanding shares of Common Stock (other than those described above or that solely affects the par value of such shares of Common Stock), or in the case of any merger or consolidation us with or into another corporation (other than a consolidation or merger in which we are the continuing corporation and that does not result in any reclassification or reorganization of our outstanding shares of Common Stock), or in the case of any sale or conveyance to another corporation or entity of the assets or other property of us as an entirety or substantially as an entirety in connection with which we are dissolved, the holders of the warrants will thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the warrants and in lieu of the shares of Common Stock immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, the kind and amount of shares of stock or other securities or property (including cash) receivable upon such reclassification, reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that the holder of the warrants would have received if such holder had exercised their warrants immediately prior to such event.

 

However, if less than 70% of the consideration receivable by the holders of shares of Common Stock in such a transaction is payable in the form of shares of Common Stock in the successor entity that is listed for trading on a national securities exchange or is quoted in an established over-the-counter market, or is to be so listed for trading or quoted immediately following such event, and if the registered holder of the warrant properly exercises the warrant within thirty days following public disclosure of such transaction, the warrant exercise price will be reduced as specified in the warrant agreement based on the Black-Scholes value (as defined in the warrant agreement) of the warrant. The purpose of such exercise price reduction is to provide additional value to holders of the warrants when an extraordinary transaction occurs during the exercise period of the warrants pursuant to which the holders of the warrants otherwise do not receive the full potential value of the warrants in order to determine and realize the option value component of the warrant. This formula is to compensate the warrant holder for the loss of the option value portion of the warrant due to the requirement that the warrant holder exercise the warrant within 30 days of the event. The Black-Scholes model is an accepted pricing model for estimating fair market value where no quoted market price for an instrument is available.

 

The warrants were issued in registered form under the Warrant Agreement between Continental Stock Transfer & Trust Company, as warrant agent, and DKAC. You should review a copy of the Warrant Agreement, which has been filed by DKAC with the SEC, for a complete description of the terms and conditions applicable to the warrants. The warrant agreement provides that the terms of the warrants may be amended without the consent of any holder to cure any ambiguity or correct any mistake, including to conform the provisions of the warrant agreement to the description of the terms of the warrants and the warrant agreement set forth in this prospectus, or defective provision, but requires the approval by the holders of at least a majority of the then outstanding public warrants to make any change that adversely affects the interests of the registered holders of public warrants.

 

53
 

 

The warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by certified or official bank check payable to OneMedNet, for the number of warrants being exercised. The warrant holders do not have the rights or privileges of holders of shares of Common Stock and any voting rights until they exercise their warrants and receive shares of Common Stock. After the issuance of shares of Common Stock upon exercise of the warrants, each holder will be entitled to one (1) vote for each share held of record on all matters to be voted on by shareholders.

 

No fractional shares will be issued upon exercise of the warrants. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, round down to the nearest whole number of shares of Common Stock to be issued to the warrant holder.

 

We have agreed that, subject to applicable law, any action, proceeding or claim against us arising out of or relating in any way to the Warrant Agreement will be brought and enforced in the courts of the State of New York or the United States District Court for the Southern District of New York, and we irrevocably submits to such jurisdiction, which jurisdiction will be the exclusive forum for any such action, proceeding or claim. See “Risk Factors — Our warrant agreement will designate the courts of the State of New York or the United States District Court for the Southern District of New York as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by holders of our warrants, which could limit the ability of warrant holders to obtain a favorable judicial forum for disputes with our company.” This provision applies to claims under the Securities Act but does not apply to claims under the Exchange Act or any claim for which the federal district courts of the United States of America are the sole and exclusive forum.

 

Transfer Agent

 

The transfer agent for our shares of Common Stock is Continental Stock Transfer & Trust Company. We have agreed to indemnify Continental Stock Transfer & Trust Company in its role as transfer agent, its agents and each of its shareholders, directors, officers and employees against all claims and losses that may arise out of acts performed or omitted for its activities in that capacity, except for any claims and losses due to any gross negligence or intentional misconduct of the indemnified person or entity.

 

Listing of Securities

 

Our shares of Common Stock and warrants are listed on Nasdaq under the symbols “ONMD” and “ONMDW.”

 

54
 

 

CERTAIN U.S. FEDERAL INCOME AND ESTATE TAX CONSEQUENCES

TO NON-U.S. HOLDERS

 

The following is a summary of certain U.S. federal income and estate tax consequences of the purchase, ownership and disposition of our common stock as of the date hereof. Except where noted, this summary deals only with common stock that is held as a capital asset by a non-U.S. holder (as defined below).

 

A “non-U.S. holder” means a beneficial owner of our common stock (other than an entity treated as a partnership for U.S. federal income tax purposes) that is not, for U.S. federal income tax purposes, any of the following:

 

  an individual citizen or resident of the United States;
  a corporation (or any other entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state thereof or the District of Columbia;
  an estate the income of which is subject to U.S. federal income taxation regardless of its source; or
  a trust if it (1) is subject to the primary supervision of a court within the United States and one or more United States persons have the authority to control all substantial decisions of the trust or (2) has a valid election in effect under applicable United States Treasury regulations to be treated as a United States person.

 

This summary is based upon provisions of the Code, and regulations, rulings and judicial decisions as of the date hereof. Those authorities may be changed, perhaps retroactively, so as to result in U.S. federal income and estate tax consequences different from those summarized below. This summary does not address all aspects of U.S. federal income and estate taxes and does not deal with foreign, state, local or other tax considerations that may be relevant to non-U.S. holders in light of their particular circumstances. In addition, it does not represent a detailed description of the U.S. federal income and estate tax consequences applicable to you if you are subject to special treatment under the U.S. federal income tax laws (including if you are a United States expatriate, foreign pension fund, “controlled foreign corporation,” “passive foreign investment company” or a partnership or other pass-through entity for U.S. federal income tax purposes). We cannot assure you that a change in law will not alter significantly the tax considerations that we describe in this summary.

 

If a partnership (or other entity treated as a partnership for U.S. federal income tax purposes) holds our common stock, the tax treatment of a partner will generally depend upon the status of the partner and the activities of the partnership. If you are a partner of a partnership holding our common stock, you should consult your tax advisors.

 

If you are considering the purchase of our Common Stock, you should consult your own tax advisors concerning the particular U.S. federal income and estate tax consequences to you of the purchase, ownership and disposition of our Common Stock, as well as the consequences to you arising under other U.S. federal tax laws and the laws of any other taxing jurisdiction.

 

Dividends

 

In the event that we make a distribution of cash or other property (other than certain pro rata distributions of our stock) in respect of our common stock, the distribution generally will be treated as a dividend for U.S. federal income tax purposes to the extent it is paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Any portion of a distribution that exceeds our current and accumulated earnings and profits generally will be treated first as a tax-free return of capital, causing a reduction in the adjusted tax basis of a non-U.S. holder’s common stock, and to the extent the amount of the distribution exceeds a non-U.S. holder’s adjusted tax basis in our common stock, the excess will be treated as gain from the disposition of our common stock (the tax treatment of which is discussed below under “—Gain on Disposition of Common Stock”).

 

Dividends paid to a non-U.S. holder generally will be subject to withholding of U.S. federal income tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty. However, dividends that are effectively connected with the conduct of a trade or business by the non-U.S. holder within the United States (and, if required by an applicable income tax treaty, are attributable to a United States permanent establishment) are not subject to the withholding tax, provided certain certification and disclosure requirements are satisfied. Instead, such dividends are subject to U.S. federal income tax on a net income basis in the same manner as if the non-U.S. holder were a United States person as defined under the Code. Any such effectively connected dividends received by a foreign corporation may be subject to an additional “branch profits tax” at a 30% rate or such lower rate as may be specified by an applicable income tax treaty.

 

55
 

 

A non-U.S. holder who wishes to claim the benefit of an applicable treaty rate and avoid backup withholding, as discussed below, for dividends will be required (a) to provide the applicable withholding agent with a properly executed IRS Form W-BEN or Form W-8BEN-E (or other applicable form) certifying under penalty of perjury that such holder is not a United States person as defined under the Code and is eligible for treaty benefits or (b) if our common stock is held through certain foreign intermediaries, to satisfy the relevant certification requirements of applicable United States Treasury regulations. Special certification and other requirements apply to certain non-U.S. holders that are pass-through entities rather than corporations or individuals.

 

A non-U.S. holder eligible for a reduced rate of U.S. federal withholding tax pursuant to an income tax treaty may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS.

 

Gain on Disposition of Common Stock

 

Subject to the discussion of backup withholding below, any gain realized by a non-U.S. holder on the sale or other disposition of our common stock generally will not be subject to U.S. federal income tax unless:

 

  the gain is effectively connected with a trade or business of the non-U.S. holder in the United States (and, if required by an applicable income tax treaty, is attributable to a United States permanent establishment of the non-U.S. holder);
  the non-U.S. holder is an individual who is present in the United States for 183 days or more in the taxable year of that disposition, and certain other conditions are met; or
  we are or have been a “United States real property holding corporation” for U.S. federal income tax purposes and certain other conditions are met.

 

A non-U.S. holder described in the first bullet point immediately above will be subject to tax on the gain derived from the sale or other disposition in the same manner as if the non-U.S. holder were a United States person as defined under the Code. In addition, if any non-U.S. holder described in the first bullet point immediately above is a foreign corporation, the gain realized by such non-U.S. holder may be subject to an additional “branch profits tax” at a 30% rate or such lower rate as may be specified by an applicable income tax treaty. An individual non-U.S. holder described in the second bullet point immediately above will be subject to a 30% (or such lower rate as may be specified by an applicable income tax treaty) tax on the gain derived from the sale or other disposition, which gain may be offset by United States source capital losses even though the individual is not considered a resident of the United States.

 

Generally, a corporation is a “United States real property holding corporation” if the fair market value of its United States real property interests equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests and its other assets used or held for use in a trade or business (all as determined for U.S. federal income tax purposes). We believe we are not and do not anticipate becoming a “United States real property holding corporation” for U.S. federal income tax purposes.

 

Federal Estate Tax

 

Common Stock held by an individual non-U.S. holder at the time of death will be included in such holder’s gross estate for U.S. federal estate tax purposes, unless an applicable estate tax treaty provides otherwise.

 

Information Reporting and Backup Withholding

 

Distributions paid to a non-U.S. holder and the amount of any tax withheld with respect to such distributions generally will be reported to the IRS. Copies of the information returns reporting such distributions and any withholding may also be made available to the tax authorities in the country in which the non-U.S. holder resides under the provisions of an applicable income tax treaty.

 

56
 

 

A non-U.S. holder will not be subject to backup withholding on dividends received if such holder certifies under penalty of perjury that it is a non-U.S. holder (and the payor does not have actual knowledge or reason to know that such holder is a United States person as defined under the Code), or such holder otherwise establishes an exemption.

 

Information reporting and, depending on the circumstances, backup withholding will apply to the proceeds of a sale or other disposition of our common stock made within the United States or conducted through certain United States-related financial intermediaries, unless the beneficial owner certifies under penalty of perjury that it is a non-U.S. holder (and the payor does not have actual knowledge or reason to know that the beneficial owner is a United States person as defined under the Code), or such owner otherwise establishes an exemption.

 

Backup withholding is not an additional tax and any amounts withheld under the backup withholding rules will be allowed as a refund or a credit against a non-U.S. holder’s U.S. federal income tax liability provided the required information is timely furnished to the IRS.

 

Additional Withholding Requirements

 

Under Sections 1471 through 1474 of the Code (such Sections commonly referred to as “FATCA”), a 30% U.S. federal withholding tax may apply to any dividends paid on our common stock to (i) a “foreign financial institution” (as specifically defined in the Code) which does not provide sufficient documentation, typically on IRS Form W-8BEN-E, evidencing either (x) an exemption from FATCA, or (y) its compliance (or deemed compliance) with FATCA (which may alternatively be in the form of compliance with an intergovernmental agreement with the United States) in a manner which avoids withholding, or (ii) a “non-financial foreign entity” (as specifically defined in the Code) which does not provide sufficient documentation, typically on IRS Form W-8BEN-E, evidencing either (x) an exemption from FATCA, or (y) adequate information regarding certain substantial United States beneficial owners of such entity (if any). If a dividend payment is both subject to withholding under FATCA and subject to the withholding tax discussed above under “—Dividends,” the withholding under FATCA may be credited against, and therefore reduce, such other withholding tax. You should consult your own tax advisors regarding these requirements and whether they may be relevant to your ownership and disposition of our Common Stock.

 

57
 

 

SELLING SECURITYHOLDERS

 

The Selling Securityholders may offer and sell, from time to time, any or all of the Common Stock or Warrants being offered for resale by this prospectus, which consist of:

 

797,872 shares of Common Stock upon conversion of up to $1,595,744.70 of OneMedNet Senior Secured Convertible Notes (the “Pre-Copsing PIPE Notes”) issued at the closing of the Business Combination (as defined below) subject to a floor price of $2.00 per share pursuant to the terms of the Securities Purchase Agreement dated June 28, 2023, by and among Data Knights Acquisition Corp, a Delaware corporation (“Data Knights”) and the named investors (the “Pre-Closing PIPE”),
95,744 shares underlying 95,744 warrants related to the Pre-Closing PIPE and the Warrant Agreements executed at the closing of the Business Combination,
7,312,817 shares of Common Stock upon conversion (the “Conversion Shares) of up to $4,547,500 of funding to the Company pursuant to the Securities Purchase Agreement and convertible promissory notes dated March 28, 2024 (the “PIPE Notes Financing”) with Helena Global Investment Opportunities 1 Ltd. (the “Notes Investor”),
3,656,408 shares underlying 3,656,408 warrants related to the PIPE Notes Financing with the Notes Investor,
277,778 shares of Common Stock issued pursuant to the terms of the Satisfaction and Discharge Agreement at $10.88 per share dated as of June 28, 2023, by and among the Company, Data Knights, and EF Hutton LLC (“EF Hutton”),
1,315,840 shares of Common Stock issuable pursuant to the outstanding loans converted to equity at $1 per share to Data Knights to fund its extension payments prior to the Business Combination by certain of the Selling Securityholders named in this prospectus,
1,439,563 shares of Common Stock issued upon the closing of the Business Combination to ARC Group Limited, as consideration for its financial advisory services,
1,327,070 shares of Common Stock at $0.7535 (95% of VWAP 10-day average $0.7932) for $1,000,000 investment by Dr. Thomas Kosasa on January 2, 2024, and
3,609,859 shares of Common Stock issued to Data Knights LLC (the “Sponsor”) and its affiliates, including 2,875,000 shares of Common Stock originally issued as share of Class B Stock in connection with the initial public offering of DKAC for aggregate consideration of $25,000, or approximately $0.009 per share, and 585,275 shares of Common Stock originally issued to the Sponsor as part of the Placement Units issued to Sponsor in connection with DKAC’s initial public offering at $10.00 per unit, and which are subject to six month lock-up restrictions set forth herein

The Selling Securityholders may from time to time offer and sell any or all of the Common Stock and Warrants set forth in the table below pursuant to this prospectus. When we refer to the “Selling Securityholders” in this prospectus, we refer to the persons listed in the table below, and the pledgees, donees, transferees, assignees, successors and other permitted transferees that hold any of the Selling Securityholders’ interest in the shares of Common Stock or warrants after the date of this prospectus.

 

The following tables provide, as of the date of this prospectus, information regarding the beneficial ownership of our Common Stock and Warrants of each Selling Securityholder, the number of shares of Common Stock or Warrants that may be sold by each Selling Securityholder under this prospectus and that each Selling Securityholder will beneficially own after this offering. The immediately following table also sets forth the percentage of shares of Common Stock or Warrants beneficially owned by a Selling Securityholder after giving effect to the sale by the Selling Securityholder of all securities being offered hereby, based on 23,850,010 shares of Common Stock outstanding including approximately 20,000,000 shares issued as Transaction consideration, 200,000 shares of Common Stock issued in connection with the PIPE financing, and reflects the valid redemption of 11,388,043 shares of Class A Common Stock by public shareholders of DKAC. The Common Stock issuable upon exercise of the Warrants are not included in the table below as the table assumes the Warrants are sold in the offering prior to their exercise by the applicable Selling Securityholder. The following table does not include Public Warrants or the primary issuance of Common Stock underlying the Public Warrants, but includes the 681,019 warrants outstanding as of the date hereof.

 

58
 

 

We cannot advise you as to whether the Selling Securityholders will in fact sell any or all of such Common Stock or Warrants. In particular, the Selling Securityholders identified below may have sold, transferred or otherwise disposed of all or a portion of their securities after the date on which they provided us with information regarding their securities in transactions exempt from registration under the Securities Act.

 

The following table sets forth certain information provided by or on behalf of the Selling Securityholders concerning the Common Stock and Warrants that may be offered from time to time by each Selling Securityholder with this prospectus. For the purposes of this following table, we have assumed that the Selling Securityholders will have sold all of the securities covered by this prospectus upon the completion of the offering. Please see the section entitled “Plan of Distribution” for further information regarding the Selling Securityholders’ method of distributing the Common Stock and Warrants.

 

Unless otherwise indicated below, the address of each beneficial owner listed in the tables below is c/o OneMedNet Corporation, 6385 Old Shady Oak Road, Suite 250, Eden Prairie, MN 55344.

 

Name of Selling
Securityholder
  Number of
Shares of Common Stock
Owned Prior
to the Offering
   Number of
Warrants
Owned
Prior to
the
Offering(11)
   Maximum
Number
of Shares of Common Stock
To Be
Sold Pursuant
to this
Prospectus
   Maximum Number
of Warrants
To Be
Sold
Pursuant
to this
Prospectus(11)
   Number of
Shares of Common Stock
Owned After
the Offering
   %(1)  Number of
Warrants
Owned
After the
Offering
 
Data Knights, LLC (2)(10)   3,609,859    585,275    3,609,859    585,275    --    --   -- 
EF Hutton LLC(3)   --    --    277,778    --    277,778    1%  -- 
ARC Group Limited(4)   --    --    1,439,563    --    1,439,563    6%  -- 
Thomas Kosasa(5)   8,333,824    31,914    2,477,070    31,914    10,842,808    45%  31,914 
Jeffrey Yu (6)   2,435,617    31,914    516,256    31,914    2,983,787    13%  31,914 
Helena Global Investment Opportunities 1 Ltd.(7)   --    --    7,312,817    3,656,408    10,969,225    46%  3,656,408 
Aaron Green(8)   --    15,958    148,936    15,958    164,894    1%  15,958 
Steven Kester(9)   444,942    15,958    148,936    15,958    164,894    1%  15,958 

 

59
 

 

(1) The percentage of beneficial ownership after this offering is calculated based on 23,850,010 shares of Common Stock outstanding as of the date of this prospectus. Unless otherwise indicated, we believe that all persons named in the table have sole voting and investment power with respect to all shares beneficially owned by them.

 

(2) Data Knights LLC is Sponsor of DKAC, our predecessor company, and certain former officers and directors of DKAC may have a pecuniary interest in Data Knights LLC that consisted of the Founders Shares and 585,275 shares of Common Stock from the conversion of the Placement Units. Data Knights LLC disclaims any such beneficial ownership except to the extent of its pecuniary interest.

 

(3) EF Hutton LLC was the underwriter in DKAC’s initial public offering. Consists of 277,778 shares of Common Stock issued pursuant to the terms of the Satisfaction and Discharge Agreement at $10.88 per share dated as of June 28, 2023, by and among the Company, Data Knights, and EF Hutton LLC. EF Hutton’s address is 590 Madison Ave, 39th Floor, New York, NY, 10022.

 

(4) Consists of 1,439,563 shares of Common Stock issued upon the closing of the Business Combination to ARC Group Limited, as consideration for its financial advisory services. ARC Group Limited’s address is 1118 Yan’an Xi Road, Suite 2605, Shanghai 200050, China.

 

(5) Consists of 8,333,824 existing shares of Common Stock plus 2,227,070 shares of Common Stock and 250,000 upon conversion of the Pre-Closing PIPE Notes and 31,914 shares underlying 31,914 warrants related to the Pre-Closing PIPE and the Warrant Agreements executed at the closing of the Business Combination to Thomas Kosasa, a member of our Board of Directors.

 

(6) Consists of 2,435,617 existing shares of Common Stock plus 266,256 share of Common Stock and 250,000 upon conversion of the Pre-Closing PIPE Notes and 31,914 shares underlying 31,914 warrants related to the Pre-Closing PIPE and the Warrant Agreements executed at the closing of the Business Combination to Jeffrey Yu, our founder and Chairman of the Board, and to the Revocable Trust of Jeffrey N.C. Yu. Mr. Yi disclaims any such beneficial ownership except to the extent of his pecuniary interest.

 

(7) Consists of 10,969,225 shares of Common Stock potentially to be issued to Helena Global Investment Opportunities 1 Ltd. representing up to (a) 7,312,817 shares of Common Stock upon conversion of up to $4,547,500 of funding to the Company pursuant to the Securities Purchase Agreement and convertible promissory notes dated March 28, 2024 and (b) 3,656,408 shares underlying 3,656,408 warrants related to the financing and the percentage ownership assumes conversion of the notes and exercise of the warrants.  

 

(8) Consists of up to 148,936 shares of Common Stock issuable to Aaron Green, our chief executive officer, president and a member of the Board of Directors, upon conversion of the Pre-Closing PIPE Notes and 15,958 shares underlying 15,958 warrants related to the Pre-Closing PIPE and the Warrant Agreements executed at the closing of the Business Combination.

 

(9)

Consists of existing 444,942 shares of Common Stock and up to 148,936 shares of Common Stock issuable to Iron Family Holdings LLC owned by Steve Kester upon conversion of the Pre-Closing PIPE Notes and 15,958 shares underlying 15,958 warrants related to the Pre-Closing PIPE and the Warrant Agreements executed at the closing of the Business Combination.

   
(10) Includes 1,777,926 shares of Common Stock issuable pursuant to the outstanding loans converted to equity for Data Knights to fund its extension payments prior to the Business Combination that are not otherwise allocated to Selling Securityholders referenced herein.
   
(11) Excludes 11,500,000 public warrants sold in DKAC’s initial public offering which converted to OneMedNet warrants at the closing of the Business Combination.

 

60
 

 

PLAN OF DISTRIBUTION

 

Each Selling Securityholder of the securities and any of their pledgees, assignees and successors-in- interest may, from time to time, sell any or all of their securities covered hereby on the principal trading market for such securities or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A Selling Securityholder may use any one or more of the following methods when selling securities:

 

  ordinary brokerage transactions and transactions in which the broker-dealer solicits Subscribers;

 

  block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;

 

  purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

 

  an exchange distribution in accordance with the rules of the applicable exchange;

 

  privately negotiated transactions;

 

  settlement of short sales;

 

  in transactions through broker-dealers that agree with the Selling Securityholders to sell a specified number of such securities at a stipulated price per security;

 

  through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;

 

  a combination of any such methods of sale; or

 

  any other method permitted pursuant to applicable law.

 

The Selling Securityholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under this prospectus.

 

Broker-dealers engaged by the Selling Securityholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the Selling Securityholders (or, if any broker-dealer acts as agent for the Subscriber of securities, from the Subscriber) in amounts to be negotiated, but except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or markdown in compliance with FINRA IM-2440.

 

In connection with the sale of the securities or interests therein, the Selling Securityholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Securityholders may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Securityholders may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).

  

The Selling Securityholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be “underwriters” within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each Selling Securityholder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities. 

 

The Company is required to pay certain fees and expenses incurred incident to the registration of the securities. The Company has agreed to indemnify the Selling Securityholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.

 

We agreed to keep this prospectus effective until the earlier of (i) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect, (ii) they may be sold pursuant to Rule 144 without volume or manner-of-sale restrictions; or (iii) it has been two years from the Closing Date. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.

 

Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities with respect to the shares of Common Stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the Selling Securityholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the shares of Common Stock by the Selling Securityholders or any other person. We will make copies of this prospectus available to the Selling Securityholders and have informed them of the need to deliver a copy of this prospectus to each Subscriber at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).

 

61
 

 

LEGAL MATTERS

 

The validity of the issuance of the shares of Common Stock and accompanying warrants offered by us in this offering will be passed upon for us by Rimon P.C., Washington DC.

 

Nelson Mullins Riley & Scarborough LLP (Washington, DC) has acted as counsel for the underwriters in connection with certain legal matters related to this offering.

 

EXPERTS

 

The financial statements of OneMedNet Corporation (fka Date Knights Acquisition Corp), as of December 31, 2023 and 2022 and for each of the years then ended incorporated by reference in this Registration Statement, of which this prospectus forms a part, have been so included in reliance on the report of BF Borgers CPA PC, an independent registered public accounting firm, appearing elsewhere herein, given on the authority of said firm as experts in auditing and accounting.

 

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Company Overview

 

Founded in 2009, we provide innovative solutions that unlock the significant value contained within the clinical image archives of healthcare providers. Employing our proven OneMedNet iRWD™ solution, we securely de-identifies, searches, and curates a data archive locally, bringing a wealth of internal and third-party research opportunities to providers. By leveraging this extensive federated provider network, together with industry leading technology and in-house clinical expertise, OneMedNet successfully meets the most rigorous RWD Life Science requirements.

 

Business Combination

 

On November 7, 2023, we held the closing of the previously announced merger (the “Merger”) whereby Data Knights Merger Sub, Inc., merged with and into OneMedNet Solutions Corporation (formerly named OneMedNet Corporation), with OneMedNet Solutions Corporation continuing as the surviving entity, which resulted in all of the issued and outstanding capital stock of OneMedNet Solutions Corporation being exchanged for shares of the Company’s Common Stock upon the terms set forth in the Merger Agreement (collectively, the “the Business Combination”). The Merger and other transactions that closed on November 7, 2023, pursuant to the Merger Agreement, led to Data Knights changing its name to “OneMedNet Corporation” and the business of the Company became the business of OneMedNet Solutions Corporation.

 

Pursuant to the terms of the Merger Agreement, the total consideration for the Business Combination and related transactions (the “Merger Consideration”) was approximately $200 million. In connection with the Special Meeting, certain public holders (the “Redeeming Stockholders”) holding 1,600,741 shares of Common Stock exercised their right to redeem such shares for a pro rata portion of the funds held by Continental Stock Transfer & Trust Company, as trustee (“Continental”) in the trust account established in connection with Data Knights’ initial public offering (the “Trust Account”). Effective November 7, 2023, Data Knights’ units ceased trading, and effective November 8, 2023, OneMedNet’s common stock began trading on the Nasdaq Global Market under the symbol “ONMD” and the warrants began trading on the Nasdaq Global Market under the symbol “ONMDW.”

 

As a result of the Merger and the Business Combination, holders of Data Knights common stock automatically received common stock of OneMedNet, and holders of Data Knights warrants automatically received warrants of OneMedNet with substantively identical terms. At the Closing of the Business Combination, all shares of Data Knights owned by the Sponsor (consisting of shares of Common Stock and shares of Class B common stock, which we refer to as the founder shares), automatically converted into an equal number of shares of OneMedNet’s Common Stock, and the Private Placement Warrants held by the Sponsor, automatically converted into warrants to purchase one share of OneMedNet Common Stock with substantively identical terms.

 

Key Components of Consolidated Statements of Operations

 

Revenue

 

The Company generates revenue from two streams: (1) iRWD (imaging Real World Data) which provides regulatory grade imaging and clinical data in the Pharmaceutical, Device Manufacturing, CRO’s and AI markets and (2) BEAM which is a Medical Imaging Exchange platform between Hospital/Healthcare Systems, Imaging Centers, Physicians and Patients. iRWD is sold on a fixed fee basis based on the number of data units and the cost per data unit committed to in the customer contract. Revenue is recognized when the data is delivered to the customer. Beam revenue is subscription-based revenue which is recognized ratably over the subscription period committed to by the customer. The Company invoices its Beam customers quarterly or annually in advance with the customer contracts automatically renewing unless the customer issues a cancellation notice.

 

The Company excludes from revenue taxes collected from a customer that are assessed by a governmental authority and imposed on and concurrent with a specific revenue-producing transaction. The transaction price for the products is the invoiced amount. Advanced billings from contracts are deferred and recognized as revenue when earned. Deferred revenue consists of payments received in advance of performance under the contract. Such amounts are generally recognized as revenue over the contractual period. The Company receives payments from customers based upon contractual billing schedules. Accounts receivable is recorded when the right to consideration becomes unconditional. Payment terms on invoiced amounts typically range from zero to 90 days, with typical terms of 30 days.

 

Cost of Revenue

 

Our cost of revenue is composed of our distinct performance obligations of hosting, labor, and data cost.

 

62

 

 

General, and Administrative

 

General and administrative functions, includes finance, legal, human resources, and information technology support. These functions include costs for items such as salaries and benefits and other personnel-related costs, maintenance and supplies, professional fees for external legal, accounting, and other consulting services, and depreciation expense.

 

Operation services

 

Operations consists primarily of labor cost for our operations team who provides services to our customers.

 

Research and Development

 

Costs incurred in the research and development of our products are expensed as incurred. Research and development costs include personnel, contracted services, materials, and indirect costs involved in the design and development of new products and services, as well as hosting expense.

 

Sales & Marketing

 

Our sales and marketing costs consist of labor and tradeshow costs.

 

Interest Expense

 

Interest incurred on convertible notes and shareholder loans.

 

Other Expense

 

Foreign exchange and tax expenses related to the Company’s operations and revenue outside of the United States.

 

Results of Operations

 

The following tables set forth our Consolidated Statements of Operations data for the periods presented:

 

   Year Ended December 31, 
   2023   2022 
Revenue  $1,021,651   $1,152,738 
Cost of Revenue   1,149,551    1,513,428 
Gross Margin   (127,900)   (360,690)
Operating Expenses          
General and administrative   5,273,503    8,755,620 
Operations   226,257    398,760 
Sales & Marketing   1,114,977    957,690 
Research and Development   1,631,613    952,701 
Total Operating Expenses   8,246,350    11,064,771 
Operating loss   (8,374,250)   (11,425,461)
Other Expense (income)          
Impairment   10,504,327    - 
Income tax provision   -    214,850 
Interest expense   749,213    403,307 
Other expense   52,256    46,820 
Change in FV of Warrants   (46,822)   (4,489,110)
Stock Expense   3,572,232      
Unrealized gain or loss   -    (1,371,689)
    14,831,206   $(5,195,822)
           
Net loss  $(23,205,456)  $(6,229,639)

 

63

 

 

Year Ended December 31, 2023 Compared to the Year Ended December 31, 2022

 

Revenue

 

   Year Ended
December 31,
2023
   Year Ended
December 31,
2022
  

%

Percentage

Change

 
Data Exchange (Beam)  $878,416   $678,138    30%
Data Broker (RWD)  $143,235   $474,600    -70%
Master Reseller Agreement  $1,021,651   $1,152,738    -11%

 

Our revenue comprises of sales made from our data exchange (BEAM) and from data broker (RWD). For the year ended 2023, overall revenue was down by 11%. The primary driver for exchange revenue increase was delivery of revenue to a significant customer. The primary drive for the decrease in broker revenue was revenue deliveries pushed to Q1 of Fiscal 2024.

 

Cost of Revenue

 

   Year Ended
December 31, 2023
   Year Ended
December 31, 2022
 
Cost of Revenue   1,149,551    1,513,428 
As a percentage of Revenue   113%   131%

 

In 2023 we were able to reduce our cost of revenue as a percentage of revenue by 24%. In the year ended 2023 our Software cost, iRWD consultants and iRWD Data cost each decreased by $0.2 million. The decrease was partially offset by a $0.2 million increase in payroll expenses.

 

General and Administrative

 

Our general and administrative expense increased year over year by $1.8 million from the year ended 2022 compared to the year ended 2023. The increase is primarily due to the additional cost incurred in connection with our Business Combination. We incurred an additional $1.0 million legal cost, $0.7 million on warrants issued to convertible note holders that were converted into share of commons stock, $0.4 million additional employees’ salaries, $0.3 million for investor relations cost, and $0.3 million in additional audit fees. The increase in general and administrative expenses were partially offset by $0.2 million decrease in both recruitment fees and bad debt expense.

 

Operation

 

Our operations expense includes payroll and consultant costs. Operations expense decreased year over year by $0.2 million from the year ended 2022 compared with the year ended 2023. This decrease was primarily due to a decrease in headcount.

 

Sales & Marketing

 

Our sales & marketing expense increased by $0.15 million year over year from the year ended 2022 compared to the year ended 2023. The increase is due to the addition of an employee and consultant in 2023.

 

Research and development

 

Our research and development expense increased by $0.7 million year over year from the year ended 2022 compared to the year ended 2023. The increase is primarily due to the additional cost in salaries for curators, consultants and increased hosting costs, which increased by $0.4 million, $0.2 million and $0.1 million, respectively.

 

64

 

 

Impairment

 

The Company recorded goodwill of $10.5 million in connection with the Business Combination. In December 2023, the Company concluded that the entire goodwill was impaired, as such the $10.5 million of goodwill was written-off.

 

Income tax provision

 

For the year ended 2023, the Company is in a significant loss, as such we did not record any income tax provision.

 

Interest Expense

 

The Company incurred interest expense on Loan extensions associated with the Business Combination, convertible promissory notes, the Pipe Senior Secured Convertible Notes and Loans made from related parties (Management and Directors). Interest expense in the year ended 2023 increased by $0.3 million. The increase was mainly from the Pipe Senior Secured Convertible Notes issued in 2023.

 

Change in Fair Value of Warrants

 

The change in Warrant Fair Value was due to the closing of the Business Combination Agreement and the resulting fluctuations of the share market price.

 

Stock Expense

 

The Company incurred approximately $3.5 million in common stock issuance expense for the Data Knight shares converted to OneMedNet Corporation shares.

 

Non-GAAP Financial Measure

 

In addition to providing financial measurements based on generally accepted accounting principles in the United States of America, or GAAP, we provide an additional financial metric that is not prepared in accordance with GAAP, or non-GAAP financial measure. We use this non-GAAP financial measure, in addition to GAAP financial measures, to understand and compare operating results across accounting periods, for financial and operational decision making, for planning and forecasting purposes, to measure executive compensation, and to evaluate our financial performance. This non-GAAP financial measure is Adjusted EBITDA, as discussed below.

 

We believe that this non-GAAP financial measure reflects our ongoing business in a manner that allows for meaningful comparisons and analysis of trends in the business, as it facilitates comparing financial results across accounting periods and to those of peer companies. We also believe that this non-GAAP financial measure enables investors to evaluate our operating results and future prospects in the same manner as we do. This non-GAAP financial measure may exclude expenses and gains that may be unusual in nature, infrequent, or not reflective of our ongoing operating results.

 

The non-GAAP financial measure does not replace the presentation of our GAAP financial measures and should only be used as a supplement to, not as a substitute for, our financial results presented in accordance with GAAP.

 

We consider Adjusted EBITDA to be an important indicator of the operational strength and performance of our business and a good measure of our historical operating trends. Adjusted EBITDA eliminates items that we do not consider to be part of our core operations. We define Adjusted EBITDA as GAAP net loss excluding the following items: interest income; income taxes; depreciation and amortization of tangible and intangible assets; unit and stock-based compensation; Business Combination transaction expenses; and other non-recurring items that may arise from time to time.

 

65

 

 

The non-GAAP adjustments, and our basis for excluding them from our non-GAAP financial measure, are outlined below:

 

  Unit and Stock-based compensation – Although unit and stock-based compensation is an important aspect of the compensation paid to our employees, the grant date fair value varies based on the derived stock price at the time of grant, varying valuation methodologies, subjective assumptions, and the variety of award types. This makes the comparison of our current financial results to previous and future periods difficult to interpret; therefore, we believe it is useful to exclude unit and stock-based compensation from our non-GAAP financial measures in order to highlight the performance of our business and to be consistent with the way many investors evaluate our performance and compare our operating results to peer companies.
     
  Business Combination transaction expenses – Business Combination transaction expenses represent the expenses incurred solely related to the Business Combination, which we completed on June 7, 2022. It primarily includes investment banker fees, legal fees, professional fees for accountants, transaction fees, advisory fees, due diligence costs, certain other professional fees, and other direct costs associated with strategic activities. These amounts are impacted by the timing of the Business Combination. We exclude Business Combination transaction expenses from our non-GAAP financial measures to provide a useful comparison of our operating results to prior periods and to our peer companies because such amounts vary significantly based on the magnitude of the Business Combination transaction and do not reflect our core operations.

 

The following table reconciles GAAP net loss to Adjusted EBITDA during the periods presented (in thousands):

 

   Year Ended
December 31, 2023
   Year Ended
December 31, 2022
 
Net loss  $(23,205,456)  $(6,229,639)
Interest Expense   749,213    403,307 
Impairment   10,504,327    - 
Depreciation and amortization   27,983    24,807 
Unit and Stock-based compensation   3,572,232    45,584 
Business combination transaction expenses   1,427,73    900,152 
Adjusted EBITDA  $(6,932,966)  $(4,855,789)

 

Liquidity and Capital Resources

 

As of December 31, 2023, our principal sources of liquidity were net proceeds received related to the Business Combination and cash received from customers.

 

The following table shows net cash and cash equivalents provided by (used in) operating activities, net cash and cash equivalents used in investing activities, and net cash and cash equivalents provided by financing activities during the periods presented:

 

   Year Ended 
   December 31, 2023   December 31, 2022 
Net cash provided by (used in)          
Operating activities  $8,220,910   $87,239,622 
Investing activities   (43,757)   (58,137)
Financing Activities   (8,431,875)   (88,032,226)

 

Operating Activities

 

Our net cash and cash equivalents provided by (used in) operating activities consists of net loss adjusted for certain non-cash items, including depreciation and amortization, business combination cost, stock-based compensation expense, cash held in trust account, and as well as changes in operating assets and liabilities. The primary changes in working capital items, such as the changes in accounts receivable and deferred revenue, result from the difference in timing of payments from our customers related to contract performance obligation. This may result in an operating cash flow source or use for the period, depending on the timing of payments received as compared to the fulfillment of the performance obligation.

 

66

 

 

Net cash used in operating activities was $8.2 million during the year ended December 31, 2023. Net cash used in operating activities was due to our net loss of $23.2 million adjusted for non-cash items of $31.4 million, primarily consisting of the redemption of public shares in connection with the Business Combination causing the withdrawal of $29.0 million of cash held in the trust account, $0.9 million business combination cost, $0.4 million extension loan, and use of cash for operating assets and liabilities of $1.1million due to the timing of cash payments to vendors and cash receipts from customers.

 

By comparison, the Company’s net cash provided by operating activities was $87.2 million during the year ended December 31, 2022. Net cash provided by operating activities was due to our net loss of $6.2 million adjusted for non-cash items of $93.5 million, primarily consisting of the redemption of public shares in connection with the Business Combination causing the withdrawal of $88.3 million of cash held in trust account $1.6 million of stock-based compensation expense, $2.5 million extension loan, less $0.5 million and use of cash for operating assets and liabilities of $.5 million due to the timing of cash payments to vendors and cash receipts from customers.

 

Investing Activities

 

Our investing activities have consisted primarily of property and equipment purchases.

 

Net cash and cash equivalents used in investing activities during the year ended December 31, 2023 consisted of $44 thousand of purchased property and equipment.

 

By comparison, the Company’s net cash and cash equivalents used in investing activities during the year ended December 31, 2022 consisted primarily of $58 thousand of purchased property and equipment.

 

Financing Activities

 

Net cash flows from financing activities was ($8.4 million) for the year ended December 31, 2023, which primarily consisted of $10.7 million repayment on convertible promissory note payable, $1.5 million proceeds from issuance of PIPE Convertible Notes and Warrants, $0.5 proceeds from related loan, $28.8 million from Common Stock subject to redemption in connection with the Business Combination, $0.5 million underwriting fee related to the Business Combination, $0.3 million decrease in warrant liability, $18.2 million additional paid in capital and $11.6 million retained earning adjustment.

 

By comparison, the Company’s net cash flows from financing activities was ($88.0 million) for the year ended December 31, 2023, which primarily consisted of $5.5 million proceeds from convertible promissory notes payable, $88.5 million from common stock subject to redemption in connection with the Business Combination, $4.5 million decrease in warrant liability, $2.8 million additional paid in capital and $3.4 million retained earning adjustment.

 

Contractual Obligations and Commitments and Liquidity Outlook

 

Currently, management does not believe the cash and cash equivalents is sufficient to meet our foreseeable cash needs for at least the next 12 months. Our foreseeable cash needs, in addition to our recurring operating expenses, include our expected capital expenditures to support the expansion of our infrastructure and workforce, interest expense and minimum contractual obligations. Management hopes to raise cash either through a public offering or private debt and equity offering. Our inability to raise cash would cause to operate as a going concern.

 

Our future capital requirements will depend on many factors, including our growth rate, the timing and extent of spending to support research and development efforts, the expansion of sales and marketing activities, the introduction of new and enhanced product and service offerings, and the cost of any future acquisitions of technology or businesses. In the event that additional financing is required from outside sources, we may be unable to raise the funds on acceptable terms, if at all.

 

The following table summarizes our current and long-term material cash requirements as of December 31, 2023:

 

       Payments due in: 
   Total   Less than 1 year   1-3 years 
Accounts payable and accrued expenses  $4,184,398   $4,184,398   $- 
Excise tax   113,353    113,353    - 
Income tax payable   120,017    120,017    - 
PIPE Notes, net of discount including interest   1,549,820    1,549,820    - 
Loan, related party of OMN including interest   465,023    -    465,023 
   $6,432,610   $5,967.587   $465,023 

 

67

 

 

Critical Accounting Policies and Estimates

 

Our management’s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements which have been prepared in accordance with accounting principles generally accepted in the United States of America. In preparing our financial statements, we make estimates, assumptions, and judgments that can have a significant impact on our reported revenue, results of operations, and net income or loss, as well as on the value of certain assets and liabilities on our balance sheet during and as of the reporting periods. These estimates, assumptions, and judgments are necessary because future events and their effects on our results and the value of our assets cannot be determined with certainty and are made based on our historical experience and on other assumptions that we believe to be reasonable under the circumstances. These estimates may change as new events occur or additional information is obtained, and we may periodically be faced with uncertainties, the outcomes of which are not within our control and may not be known for a prolonged period of time. Because the use of estimates is inherent in the financial reporting process, actual results could differ from those estimates.

 

We believe that the assumptions and estimates associated with the following critical accounting policies involve significant judgment and thus have the most significant potential impact on our Consolidated Financial Statements.

 

Revenue Recognition

 

We generate revenue from the sale of products and services. A description of our revenue recognition policies is included in Note 2, Summary of Significant Accounting Policies in the Notes to the Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K.

 

Although most of our sales agreements contain standard terms and conditions, certain agreements contain multiple performance obligations or non-standard terms and conditions. For customer contracts that contain more than one performance obligation, we allocate the total transaction consideration to each performance obligation based on the relative stand-alone selling price of each performance obligation within the contract. We rely on either observable standalone sales or an expected cost plus a margin approach to determine the standalone selling price of offerings, depending on the nature of the performance obligation.

 

As we further discuss in Note 2, Summary of Significant Accounting Policies in the Notes to the Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K, for contracts with customers entered into during fiscal years 2023 and 2022, revenue from the sales of our iRWD and BEAM are recognized over time as the asset created by our performance does not have alternative use to us and an enforceable right to payment for performance completed to date is present. We recognize revenue as work progresses, using costs incurred to date relative to total estimated costs at completion. Incurred costs represent work performed, which correspond with and best depict transfer of control to the customer. Contract costs are incurred over a period of time, which can span periods, and the estimation of these costs requires management’s judgment. Due to the nature of the work required to be performed on the iRWD and BEAM and our reliance on the availability the estimation of total revenue and cost at completion is complex, subject to many variables, and requires significant judgment on a contract-by-contract basis. As part of this process, we review information including, but not limited to, any outstanding key contract matters, progress towards completion and the related program schedule, identified risks and opportunities and the related changes in estimates of revenue and costs. The risks and opportunities relate to our judgment about the delays that may or may not be within our control. Risks and opportunities may also relate to supply chain trends and commodity pricing, as well as changes in foreign currencies. Changes in estimates of net sales, cost of sales, and the related impact to operating profit are recognized on a cumulative catch-up basis, which recognizes the cumulative effect of the profit changes on current and prior periods based on a performance obligation’s percentage of completion in the current period. A significant change in one or more of these estimates could affect the profitability of one of more of our performance obligations and could have a material impact on our financial condition and results of operations.

 

68

 

 

Stock-based Compensation

 

Prior to the Business Combination, OneMedNet Corporation (now OneMedNet Solutions Corporation) had five authorized classes of membership interests, consisting of a class of common units known as the Class A Common Units (the “Class A Units”), a class of preferred units known as the Series A-2 Preferred Units (the “A-2 Preferred Units”), a class of preferred units known as the Series A-1 Preferred Units (the “A-1 Preferred Units”), Convertible Notes, Stock Options units, known as the Options and Warrants units granted to employees, officers, and directors pursuant to an incentive plan.

 

Following the Business Combination, the Company has authorized 101,000,000 shares of common stock, including 100,000,000 shares of Common Stock and 1,000,000 shares of Preferred Stock. In addition, the Company has three classes of warrants (i.e., Public Warrants, Private Warrants and PIPE Warrants) issued and outstanding.

 

As the Business Combination is accounted for as a reverse recapitalization, all periods prior to the Business Combination have been retroactively adjusted using the Exchange Ratio as stipulated by the Merger Agreement for the equivalent number of shares outstanding immediately after the Merger to effect the reverse recapitalization. The Class A Units, A-2 Preferred Units, A-1 Preferred Units, Options and Warrants were converted into Common Stock using an exchange ratio of 1:1, the Convertible Notes were converted into Common Stock using an exchange ratio of 2.5 per share. This is presented within the consolidated statements of changes in redeemable preferred and common units and equity (deficit).

 

We typically issue restricted stock units (“RSUs”) as stock-based compensation. For RSUs, the fair value is the closing market price of the stock on the date immediately preceding the grant. We recognize compensation expense over the requisite service period for awards expected to vest. We account for forfeitures as they occur, rather than applying an estimated forfeiture rate. The graded-vesting method of expense recognition is applied to all awards with service-only conditions.

 

Certain RSUs involve stock to be issued upon the achievement of certain performance conditions. Such RSUs become available, subject to time-based vesting conditions if, and to the extent that, financial performance criteria for the applicable period are achieved. Accordingly, the number of RSUs earned will vary based on the level of achievement of financial performance objectives for the applicable period. Until such time that our financial performance can ultimately be determined, each quarter we estimate the number of RSUs to be earned based on an evaluation of the probability of achieving the financial performance objectives. Such estimates are revised, if necessary, in subsequent periods when the underlying factors change our evaluation of the probability of achieving the financial performance objectives. Accordingly, stock-based compensation expense associated with performance-based RSUs may differ significantly from the amount recorded in the current period.

 

The assumptions used in calculating the fair value of stock-based compensation awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and we use different assumptions, our stock-based compensation expense could be materially different in the future.

 

Warrant transactions

 

PIPE Warrants to purchase our shares of Common Stock may be accounted for as either liability or equity instruments depending on the terms of the warrant agreements. The warrants issued by us are accounted for as equity instruments due to our ability to settle the warrants through the issuance of units and the absence of terms which would require liability classification, including the rights of the grantee to require cash settlement. We classify these equity instruments within additional paid-in capital on the consolidated balance sheets.

 

Private Warrants to purchase units accounted for as liability instruments represent the warrants issued to significant shareholders and related parties.

 

In order to calculate warrant charges, we used the Black-Scholes pricing model, which required key inputs including volatility and risk-free interest rate and certain unobservable inputs for which there is little or no market data, requiring us to develop our own assumptions. We estimated the fair value of unvested warrants, considered to be probable of vesting, at the time. Based on that estimated fair value, we determined warrant charges, which were recorded as a reduction of the transaction price.

 

LEGAL PROCEEDINGS

 

From time to time and in the course of business, we may become involved in various legal proceedings seeking monetary damages and other relief. The amount of the ultimate liability, if any, from such claims cannot be determined. As of the date hereof, there are no legal claims currently pending or, to our knowledge, threatened against us or any of our officers or directors in their capacity as such or against any of our properties that, in the opinion of our management, would be likely to have a material adverse effect on our financial position, results of operations or cash flows.

 

69

 

 

WHERE YOU CAN FIND MORE INFORMATION

 

This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. You should rely only on the information contained in this prospectus or incorporated by reference into this prospectus. We have not authorized anyone else to provide you with different information. We are not making an offer of these securities in any jurisdiction where the offer is not permitted. You should assume that the information contained in this prospectus, or any document incorporated by reference in this prospectus, is accurate only as of the date of those respective documents, regardless of the time of delivery of this prospectus or any sale of our securities.

 

We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public from commercial document retrieval services and over the Internet at the SEC’s website at http://www.sec.gov. We maintain a website at www.sonnetbio.com. You may access our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not incorporated by reference into, and is not part of, this prospectus.

 

INCORPORATION OF DOCUMENTS BY REFERENCE

 

This prospectus is part of the registration statement but the registration statement includes and incorporates by reference additional information and exhibits. The SEC permits us to “incorporate by reference” the information contained in documents we file with the SEC, which means that we can disclose important information to you by referring you to those documents rather than by including them in this prospectus. Information that is incorporated by reference is considered to be part of this prospectus and you should read it with the same care that you read this prospectus. Information that we file later with the SEC will automatically update and supersede the information that is either contained, or incorporated by reference, in this prospectus, and will be considered to be a part of this prospectus from the date those documents are filed. We have filed with the SEC, and incorporate by reference in this prospectus:

 

  Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on April 9, 2024 and for December 31, 2022 filed with the SEC on March 31, 2023;
  Current Reports on Form 8-K, filed with the SEC on November 13, 2023, January 3, 2025, February 9, 2024, and April 2, 2024; and
  The description of our Common Stock contained in our Registration Statement on Form 8-A12b filed with the SEC on May 5, 2021, and any amendments or reports filed updating such description.

 

Notwithstanding the statements in the preceding paragraphs, no document, report or exhibit (or portion of any of the foregoing) or any other information that we have “furnished” to the SEC pursuant to the Securities Exchange Act of 1934, as amended shall be incorporated by reference into this prospectus. We will furnish without charge to you, on written or oral request, a copy of any or all of the documents incorporated by reference in this prospectus, including exhibits to these documents. You should direct any requests for documents to:

 

OneMedNet Corporation

6385 Old Shady Oak Road, Suite 250
Eden Prairie, MN 55344

Telephone: 800-918-7189

 

You also may access these filings on our website at http://www.sidusspace.com. We do not incorporate the information on our website into this prospectus or any supplement to this prospectus and you should not consider any information on, or that can be accessed through, our website as part of this prospectus or any supplement to this prospectus (other than those filings with the SEC that we specifically incorporate by reference into this prospectus or any supplement to this prospectus).

 

Any statement contained in a document incorporated or deemed to be incorporated by reference in this prospectus will be deemed modified, superseded or replaced for purposes of this prospectus to the extent that a statement contained in this prospectus modifies, supersedes or replaces such statement. Any statement contained herein or in any document incorporated or deemed to be incorporated by reference shall be deemed to be modified or superseded for purposes of the registration statement of which this prospectus forms a part to the extent that a statement contained in any other subsequently filed document which also is or is deemed to be incorporated by reference modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed to constitute a part of the registration statement of which this prospectus forms a part, except as so modified or superseded.

 

70

 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

  Page
Report of Independent Registered Public Accounting Firm (PCAOB ID No. 5041) F-1 
Consolidated Balance Sheets F-2
Consolidated Statements of Operations F-3
Consolidated Statements of Changes in Redeemable Preferred and Common Units and Equity (Deficit) F-4
Consolidated Statements of Cash Flows F-5
Notes to the Consolidated Financial Statements F-6

 

 

 

 

Report of Independent Registered Public Accounting Firm

 

To the shareholders and the board of directors of OneMedNet Corporation

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of OneMedNet Corporation as of December 31, 2023 and 2022, the related statements of operations, stockholders’ equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States.

 

Substantial Doubt about the Company’s Ability to Continue as a Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses from operations and has a significant accumulated deficit. In addition, the Company continues to experience negative cash flows from operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

 

/s/ BF Borgers CPA PC

 

BF Borgers CPA PC (PCAOB ID 5041)

 

We have served as the Company’s auditor since 2022

Lakewood, CO

April 9, 2024

 

F-1
 

 

ONEMEDNET CORPORATION

 

CONSOLIDATED BALANCE SHEETS

 

   December 31, 2023   December 31, 2022 
Current Assets          
Cash and cash equivalents  $47,008    301,730 
Investments held in Trust   -    29,029,415 
Accounts receivable, net of allowance   151,640    18,975 
Prepaid expenses and other assets   165,538    100,945 
Receivable from SPAC        

900,152

 
           
Total current assets   364,186    30,351,217 
           
Property and Equipment, Net   98,871    83,097 
           
Total assets  $463,057   $30,434,314 
           
Current Liabilities          
Accounts payable & accrued expenses   4,184,398    2,814,570 
Loan Amount due to related parties   11,200    11,500 
Excise tax   113,353    - 
Loan Extensions   2,991,679    - 
Deferred revenues   253,997    183,683 
Loan Payable   38,921    - 
Convertible promissory notes   -    8,490,000 
Canada Emergency Business Loan Act   44,673    - 
Income tax payable   120,017    214,850 
Franchise tax payable   -    69,966 
Pipe Notes, net of discount including interest   1,549,820    - 
Deferred underwriter fee payable   3,525,000    - 
Total current liabilities   12,833,058    11,784,569 
           
Long Term Liabilities          
Convertible promissory note        

1,500,000

 
Canada Emergency Business Loan Act        

44,144

 
Accrued interest        

690,772

 
Loan, related party of OMN   465,023    - 
Warrant liabilities   24,582    362,558 
Deferred underwriter fee payable   -    4,025,000 
Working capital Loan   -    207,081 
Extension loans   -    2,545,839 
Total liabilities   13,322,663    21,159,963 
           
Stockholders’ Equity (Deficit)          
           
Preferred Series A-2, par value $0.0001, 4,200,000 shares authorized and, 0 and 3,853,797 shares issued and outstanding as of December 31, 2023 and December 31, 2022   -    385 
           
Preferred Shares A-1, par value $0.0001, 4,400,000 shares authorized and, 0 and 3,204,000 shares issued and outstanding as of December 31, 2023 and December 31, 2022   -    320 
           
Common Stock, par value $0.0001, 30,000,000 shares authorized and 23,572,232 and 4,550,166 shares issued and outstanding as of December 31, 2023 and December 31, 2022   2,357    455 
           
Data Knights Acquisition Corp. Class A Common Stock, par value $0.0001, 4,200,000 shares authorized and, 0 and 3,853,797 shares issued and outstanding as of December 31, 2023 and December 31, 2022   -    59 
           
Data Knights Acquisition Corp. Class A Common Stock, par value $0.0001, 4,200,000 shares authorized and, 0 and 3,853,797 shares issued and outstanding as of December 31, 2023 and December 31, 2022   -    425 
           
Commitments and contingencies   -    28,750,110 
           
Additional paid in capital   42,220,714    24,032,561 
Accumulated deficit   (55,082,677)   (43,509,964)
           
Total stockholders’ equity (deficit)   (12,859,606)   9,274,351 
           
Total liabilities and stockholders’ equity (deficit)  $463,057   $30,434,314 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-2
 

 

ONEMEDNET CORPORATION

 

CONSOLIDATED STATEMENTS OF OPERATIONS

 

       
   Year Ended 
   2023   2022 
Revenue  $1,021,651   $1,152,738 
Cost of Revenue   1,149,551    1,513,428 
Gross Margin   (127,900)   (360,690)
           
Operating Expenses          
General and administrative   5,273,503    8,755,620 
Operations   226,257    398,760 
Sales & Marketing   1,114,977    957,690 
Research and development   1,631,613    952,701 
Total Operating Expenses   8,246,350    11,064,771 
           
Operating loss   (8,374,250)   (11,425,461)
           
Other Expense (income)          
Impairment   10,504,327      
Income tax provision   -    214,850 
Interest expense   749,213    403,307 
Other expense   52,256    46,820 
Change in FV of Warrants   (46,822)   (4,489,110)
Stock Expense   3,572,232      
Unrealized gain or loss   -    (1,371,689)
Other Expense (income)   14,831,206    (5,195,822)
           
Net loss  $(23,205,456)  $(6,229,639)
Loss per share of Common Stock:(1)          
Basic and Diluted  $(0.98)   N/M  
Weighted-average shares of Common Stock outstanding:          
Basic and Diluted   23,572,232    N/M  

 

(1) Loss per share information has not been presented for periods prior to the Business Combination (as defined in Note 3, Business Combination), as it resulted in values that would not be meaningful to the users of these consolidated financial statements. Refer to Note 3, Business Combination for further information. This has been indicated on these statements of operations as “N/M”.

 

The accompanying notes are an integral part of these consolidated financial statements

 

F-3
 

 

ONEMEDNET CORPORATION

 

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

 

                                                                       
              Data Knights Acquisition Corp.   Data Knights Acquisition Corp.                       
   Series A-2 Preferred Stock   Series A-1 Preferred Stock   Class A-Common Stock    Class B-Common Stock    Class A-Common Stock       Additional Paid-in   Accumulated   Stockholders’ 
   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Commitments   Capital   Deficit   Equity 
Balances, December 31, 2021   3,853,797   $385    3,204,000   $320    585,275   $59    2,875,000   $288    4,342,666   $434   $28,750,110   $19,607,173   $(33,920,734)  $14,438,035 
Issuance of common shares in exchange for services   -                                       200,000    20    -     199,980         200,000 
Issuance of common shares in exchange for cash at $1.00 per share                                           7,500    1    -     7,499         7,500 
Issuance of Data Knights Acquisition Corp. Class B Common Stock                                 1,378,517    137              -     2,825,823         2,825,960 
Re-Measurement of Data Knights Acquisition Corp. Class A Common Stock Subject to Possible Redemption                                                     -          (3,359,591)   (3,359,591)
Stock-based compensation expense                                                     -     1,392,086         1,392,086 
2022 net loss        -          -          -          -               -          (6,229,639)   (6,229,639)
Balances, December 31, 2022   3,853,797   $385    3,204,000   $320    585,275   $59    4,253,517   $425    4,550,166   $455   $28,750,110   $24,032,561   $(43,509,964)  $9,274,351 
Stock-based compensation expense                                                          1,892,741         1,892,741 
Preferred Stock to Common Stock   (3,853,797)   (385)   (3,204,000)   (320)   -          -          7,057,797    706    -     7,057,091         7,057,092 
Convertible Notes to Common Stock   -          -          -          -          6,177,229    618    -     6,176,611         6,177,229 
Stock Options to Common Stock   -          -          -          -          612,670    61    -     612,609         612,670 
Converting of Warrants to Common Stock   -          -          -          -          3,859,464    386    -     3,859,078         3,859,464 
Private OneMedNet to ONMD Public Shares   -          -          -          -          (2,257,326)   (226)   -     (2,257,100)        (2,257,326)
Issuance of PIPE Warrants   -          -          -          -          -          -     101,071         101,071 
Converting Data Knights Common Shares (A and B) to ONMD Public Shares   -          -          (585,275)   (59)   (4,253,517)   (425)   3,460,275    346    -     634,106         633,968 
Common stock redemption   -          -          -          -          -          (28,750,110)             (28,750,110)
Issuance Public Shares   -          -          -          -          111,957    11    -     111,946         111,957 
Retained earnings adjustment   -          -          -          -          -          -          11,632,743    11,632,743 
2023 net loss        -          -          -                                   (23,205,456)   (23,205,456)
Balances, December 31, 2023   0   $0    0   $0    0   $0    0   $0    23,572,232   $2,357   $0   $42,220,714   $(55,082,677)  $(12,859,606)

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-4
 

 

ONEMEDNET CORPORATION

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

   December 31, 2023   December 31, 2022 
   Year Ended 
   December 31, 2023   December 31, 2022 
Cash flow from Operating Activities          
Net Loss  $(23,205,456)  $(6,229,639)
           
Adjustments to reconcile net loss to net cash flows from operating activities:          
Depreciation and amortization   27,983    24,807 
Business combination cost   900,152    - 
Stock-based compensation expense   -    1,599,586 
Cash Held in Trust Account   29,029,416    88,291,558 
Prepaid Expenses   (64,594)     
Other current assets   -    (875,803)
Accounts payable and accrued Expenses   1,369,825    1,929,787 
Accounts receivable, net of allowance   (132,665)   72,767 
Deferred Revenue & Customer Deposits   70,314    (458,667)
Amount due to related party   (300)   11,500 
Exercise tax liability   113,353      
Extension loan   445,840    2,545,838 
Franchise tax payable   (69,966)   (94,043)
Income Tax Payable   (94,833)   214,850 
Working capital loan   (168,159)   207,081 
Net cash flows used in operating activities  $8,220,910   $87,239,622 
Cash used for Investing Activities          
Purchase of property and equipment  $(43,757)  $(58,137)
Cash flow from Financing Activities          
Class B Common Stock   -    137 
Proceeds (repayment) from issuance of convertible promissory note payable   (10,680,772)   5,543,162 
Proceeds from issuance of PIPE Convertible Notes and Warrants   1,549,820      
Proceed from related party loan   465,024    - 
Proceeds from Canada Emergency Business Loan Act   529    (2,754)
Common Stock Subject to Redemption   (28,750,109)   (88,549,890)
Deferred underwriting fee   (500,000)   - 
Warrant liability   (337,976)   (4,489,110)
Additional Paid-in Capital   18,189,350    2,825,823 
Class A Common Stock   (59)   - 
Class B Common Stock   (425)   - 
Retained Earnings adjustment   11,632,743    (3,359,594)
Net cash flows from financing activities   (8,431,875)   (88,032,226)
           
Net change in cash and cash equivalents   (254,722)   (850,741)
Cash and Cash Equivalents, Beginning   301,730    1,152,471 
Cash and Cash Equivalents, Ending   47,008    301,730 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-5
 

 

ONEMEDNET CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

1. Organization and Operations

 

OneMedNet Corporation (the “Company”) is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. The Company was incorporated in Delaware on September 20, 2006. The Company has been solely focused on creating solutions that simplify digital medical image management, exchange, and sharing. The Company has one wholly-owned subsidiary, OneMedNet Technologies (Canada) Inc., incorporated on October 16, 2015 under the provisions of the Business Corporations Act of British Columbia whose functional currency is the Canadian dollar. The Company’s headquarters location is Eden Prairie, Minnesota.

 

On November 7, 2023, as contemplated by the Company, Data Knights Merger Sub, Inc., a Delaware corporation (“Merger Sub”), and Data Knights, LLC, the Merger Sub’s sponsor merged with and into OneMedNet Corporation, with OneMedNet Corporation surviving the merger. The Business Combination is further described in Note 3, Business Combination.

 

Data Knights Acquisition Corp Merger

 

On November 7, 2023, we consummated a merger (the “Merger”) following the approval at the special meeting of the shareholders of Data Knights Acquisition Corp., a Delaware corporation held on October 17, 2023 (the “Special Meeting”), Data Knights Merger Sub, Inc., a Delaware corporation (“Merger Sub”) and a wholly-owned subsidiary of Data Knights Acquisition Corp., a Delaware corporation (“Data Knights”), consummated a merger (the “Merger”) with and into OneMedNet Solutions Corporation (formerly named OneMedNet Corporation), a Delaware corporation (“OneMedNet”) pursuant to an agreement and plan of merger, dated as of April 25, 2022 (the “Merger Agreement”), by and among Data Knights, Merger Sub, OneMedNet, Data Knights, LLC, a Delaware limited liability company (“Sponsor” or “Purchaser Representative”) in its capacity as the representative of the stockholders of Data Knights, and Paul Casey in his capacity as the representative of the stockholders of OneMedNet (“Seller Representative”). Accordingly, the Merger Agreement was adopted, and the Merger and other transactions contemplated thereby (collectively, the “Business Combination”) were approved and completed.

 

The Business Combination was accounted for as a as a reverse recapitalization with OneMedNet as the accounting acquirer under the accounting principles generally accepted in the United States of America (“U.S. GAAP”). Accordingly, the financial statements of the combined company represent a continuation of the financial statements of OneMedNet.

 

On June 28, 2023, the Company and Data Knights entered into a Securities Purchase Agreement (the “SPA”) with certain investors (collectively referred to herein as the “Purchasers”) for PIPE financing in the aggregate original principal amount of $1,595,744.70 and the purchase price of $1.5 million. Pursuant to the Securities Purchase Agreement, Data Knights will issue and sell to each of the Purchasers, a new series of senior secured convertible notes (the “PIPE Notes”), which are convertible into shares of Common Stock at the Purchasers election at a conversion price equal to the lower of (i) $10.00 per share, and (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) Trading Days immediately preceding the Conversion Date. The Purchasers’ $1.5 million investment in the PIPE Notes closed and funded contemporaneous to the Closing of the Business Combination.

 

Effective immediately prior to the Closing, OneMedNet, Inc. issued the PIPE Notes to the Purchasers under the private offering exemptions under Securities Act of 1933, as amended (the “Securities Act”).

 

Risks and Uncertainties

 

The Company is subject to risks common to companies in the markets it serves, including, but not limited to, global economic and financial market conditions, fluctuations in customer demand, acceptance of new products, development by its competitors of new technological innovations, dependence on key personnel, and protection of proprietary technology.

 

As previously reported on Form 8-K on February 9, 2024, the Company received written notice (the “Nasdaq Notice”), dated February 7, 2024, from the Nasdaq Stock Market (“Nasdaq”) indicating that for the preceding 30 consecutive business days, the market value of the Company’s listed securities (“MVLS”) did not maintain a minimum market value of $50,000,000 (the “Minimum MVLS Requirement”) as required by Nasdaq Listing Rule 5450(b)(2)(A). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has a compliance period of 180 calendar days, or until August 5, 2024, to regain compliance with the Minimum MVLS Requirement. Compliance may be achieved if the Company’s MVLS closes at $50,000,000 or more for a minimum of ten consecutive business days at any time during the 180-day compliance period, in which case Nasdaq will notify the Company of its compliance and the matter will be closed.

 

If the Company does not regain compliance with the Minimum MVLS Requirement by August 5, 2024, Nasdaq will provide written notification to the Company that its common stock is subject to delisting. At that time, the Company may appeal the relevant delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. However, there can be no assurance, if the Company does appeal the delisting determination by Nasdaq to the hearings panel, that such appeal would be successful. In such event, the Company may also seek to apply for a transfer to The Nasdaq Global Market if it meets the requirements for continued listing thereon. The Nasdaq Notice received have no immediate effect on the Company’s continued listing on the Nasdaq Global Market or the trading of Company’s common stock, subject to the Company’s compliance with the other continued listing requirements. The Company is presently evaluating potential actions to regain compliance with all applicable requirements for continued listing on the Nasdaq Global Market. There can be no assurance that the Company will be successful in maintaining the listing of its common stock on the Nasdaq Global Market.

 

F-6
 

 

2. Summary of Significant Accounting Policies

 

Basis of Presentation and Foreign Currency Translation

 

The consolidated financial statements have been prepared in U.S. dollars, in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. The consolidated financial statements include 100% of the accounts of wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

 

Business Combination

 

We account for business acquisitions under ASC Topic 805, Business Combinations (“ASC Topic 805”). The total purchase consideration for an acquisition is measured as the fair value of the assets given, equity instruments issued, and liabilities assumed at the acquisition date. Costs that are directly attributable to the acquisition are expensed as incurred. Identifiable assets (including intangible assets) and liabilities assumed (including contingent liabilities) are measured initially at their fair values at the acquisition date. We recognize goodwill if the fair value of the total purchase consideration is in excess of the net fair value of the identifiable assets acquired and the liabilities assumed. We recognize a bargain purchase gain within Other income (expense), net, in the consolidated statement of operations if the net fair value of the identifiable assets acquired and the liabilities assumed is in excess of the fair value of the total purchase consideration. We include the results of operations of the acquired business in the consolidated financial statements beginning on the acquisition date.

 

Use of Estimates

 

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the amounts disclosed in the related notes to the consolidated financial statements. Actual results and outcomes may differ materially from management’s estimates, judgments, and assumptions. Significant estimates, judgments, and assumptions used in these financial statements include, but are not limited to, those related to revenue, useful lives and realizability of long-lived assets, accounting for income taxes and related valuation allowances, and unit and stock-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts, and experience.

 

Operating Segments

 

The Company operates as one operating segment. Operating segments are defined as components of an enterprise for which separate financial information is regularly evaluated by the chief operating decision maker (“CODM”), which is the Company’s Chief Executive Officer, in deciding how to allocate resources and assess performance. The Company’s CODM evaluates the Company’s financial information and resources and assesses the performance of these resources on a consolidated basis. The Company is not organized by market and is managed and operated as one business. A single management team that reports to the chief executive officer comprehensively manages the entire business. Accordingly, the Company does not accumulate discrete financial information with respect to separate divisions and does not have separate operating or reportable segments. Since the Company operates in one operating segment, all required financial segment information can be found in the consolidated financial statements.

 

Cash and Cash Equivalents

 

Cash and cash equivalents consist of highly liquid, short-term investments with a maturity of three months or less when purchased. Cash equivalents consist of money market funds and are carried at cost, which approximates fair value. The balances, at times, may exceed FDIC Insured limits. The Company believes that, as of December 31, 2023, its risk relating to deposits exceeding federally insured limits was not significant.

 

Accounts Receivable

 

Accounts receivable are unsecured, recorded at net realizable value, and do not bear interest. Accounts receivable are considered past due if not paid within the terms established between the Company and the customer. Amounts are only written off after all attempts at collections have been exhausted. The Company determines the need for an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information. As of December 31, 2023 and 2022, the Company established allowances of $0 and $102,700 respectively. The net receivable balances outstanding are fully collectible.

 

The Company believes its credit policies are prudent and reflect normal industry terms and business risk. The Company generally does not require collateral from its customers and generally requires payment from 0 to 90 days from the invoice date. For the year ended December 31, 2023, there was 1 customer that accounted for 10% or more of total revenue, and there were 2 customers that accounted for 10% or more of total revenue for the years ended December 31, 2022 . The following table represents these customers’ aggregate percent of total revenue:

 Schedule Of Aggregate Percentage Revenue and Accounts Receivable

   December 31, 2023   December 31, 2022 
   Year Ended 
   December 31, 2023   December 31, 2022 
         
Customer 1   52%   31%
Customer 2   -    22%
Aggregate Percent of Total Revenue   52%   53%

 

F-7
 

 

As of December 31, 2023, three customers accounted for more than 10% of the Company’s accounts receivable balance, and two customers accounted for over 10% of the Company’s accounts receivable balance at December 31, 2022. The following table represents these customers’ aggregate percent of total accounts receivable:

 

   December 31, 2023   December 31, 2022 
   Year Ended 
   December 31, 2023   December 31, 2022 
Customer 1   -    40%
Customer 2   36%   - 
Customer 3   33%   - 
Customer 4   -    32%
Customer 5   27%   - 
Aggregate Percent of Total Accounts Receivable   96%   72%

 

Property and Equipment

 

Property and equipment are recorded at cost. The straight-line method is used for computing depreciation and amortization. Assets are depreciated over their estimated useful lives ranging from three to five years. Cost of maintenance and repairs are charged to expense when incurred.

 

Impairment of Long-Lived Assets

 

The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset may not be fully recoverable. An impairment loss would be recognized when the estimated future undiscounted net cash flows from the use of the asset are less than the carrying amount of that asset. There have been no losses during the years ended December 31, 2023 or December 31, 2022.

 

Fair Value of Financial Instruments

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value:

 

Level 1 — Valuations based on quoted prices for identical assets and liabilities in active markets.

Level 2 — Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.

Level 3 — Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.

 

We measure the fair value of money market funds and certain marketable equity securities based on quoted prices in active markets for identical assets or liabilities. Other marketable securities were valued either based on recent trades of securities in inactive markets or based on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. We did not hold significant amounts of marketable securities categorized as Level 3 assets as of the years ended December 31, 2022 and December 31, 2023.

 

The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, convertible notes payable and certain privately issued warrants. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable financial instruments approximate their fair value due to their short-term nature. The Company’s Private Warrants estimated fair values are provided by a third party pricing vendor and are reviewed by the Company’s management. The Private Warrants valuations are based on unobservable inputs reflecting the vendor’s assumptions, consistent with reasonably available assumptions made by other market participants and thus are classified as Level 3.

 

Revenue Recognition

 

Revenue is recognized in accordance with the five-step model set forth by Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (“Topic 606”), which involves identification of the contract, identification of performance obligations in the contract, determination of the transaction price, allocation of the transaction price to the previously identified performance obligations, and revenue recognition as the performance obligations are satisfied.

 

Revenue from all customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to a customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account under Topic 606. A contract’s transaction price is allocated to each distinct performance obligation in proportion to the standalone selling price for each and recognized as revenue when, or as, the performance obligation is satisfied.

 

F-8
 

 

Individual promised goods and services in a contract are considered a performance obligation and accounted for separately if the good or service is distinct. A good or service is considered distinct if the customer can benefit from the good or service on its own or with other resources that are readily available to the customer and the good or service is separately identifiable from other promises in the arrangement.

 

The transaction price for the products is the invoiced amount. Advanced billings from contracts are deferred and recognized as revenue when earned. Revenue is recognized only to the extent that it is probable that a significant reversal of revenue will not occur and when collection is considered probable The Company excludes from revenue taxes collected from a customer that are assessed by a governmental authority and imposed on and concurrent with a specific revenue-producing transaction. Deferred revenue consists of payments received in advance of performance under the contract. Such amounts are generally recognized as revenue over the contractual period. The Company receives payments from customers based upon contractual billing schedules. Accounts receivable is recorded when the right to consideration becomes unconditional. Payment terms on invoiced amounts typically range from zero to 90 days, with typical terms of 30 days.

 

The Company generates revenue from two streams: (1) iRWD (imaging Real World Data) which provides regulatory grade imaging and clinical data in the Pharmaceutical, Device Manufacturing, CRO’s and AI markets and (2) BEAM which is a Medical Imaging Exchange platform between Hospital/Healthcare Systems, Imaging Centers, Physicians and Patients. iRWD is sold on a fixed fee basis based on the number of data units and the cost per data unit committed to in the customer contract. Revenue is recognized when the data is delivered to the customer. Beam revenue is subscription-based revenue which is recognized ratably over the subscription period committed to by the customer. The Company invoices its Beam customers quarterly or annually in advance with the customer contracts automatically renewing unless the customer issues a cancellation notice.

 

Income Taxes

 

The Company is subject to U.S. federal, state and local income taxes. The Company accounts for income taxes in accordance with ASC Topic 740, Accounting for Income Taxes (“ASC Topic 740”), which requires the recognition of tax benefits or expenses on temporary differences between the financial reporting and tax bases of its assets and liabilities by applying the enacted tax rates in effect for the year in which the differences are expected to reverse. Such net tax effects on temporary differences are reflected on the Company’s consolidated balance sheets as deferred tax assets and liabilities.

 

ASC Topic 740 prescribes a two-step approach for the recognition and measurement of tax benefits associated with the positions taken or expected to be taken in a tax return that affects amounts reported in the financial statements. The Company has reviewed and will continue to review the conclusions reached regarding uncertain tax positions, which may be subject to review and adjustment at a later date based on ongoing analyses of tax laws, regulations and interpretations thereof. To the extent that the Company’s assessment of the conclusions reached regarding uncertain tax positions changes as a result of the evaluation of new information, such change in estimate will be recorded in the period in which such determination is made. The Company reports income tax-related interest and penalties relating to uncertain tax positions, if applicable, as a component of income tax expense

 

Deferred tax assets are reduced by a valuation allowance when the Company believes that it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. The Company provides deferred taxes at the enacted tax rate that is expected to apply when the temporary differences reverse. The Company has recorded a full valuation allowance against the net deferred tax asset due to the uncertainty of realizing the related benefits.

 

Patents and Trademarks

 

Costs associated with the submission of a patent application are expensed as incurred given the uncertainty of the patents resulting in probable future economic benefits to the Company and are included in research and development expenses on the consolidated statements of operations.

 

Research and Development

 

The Company account for its research and development cost in accordance with ASC Topic 730, Research and Development (“ASC Topic 730”). ASC Topic 730 requires that all R&D costs be recognized as an expense as incurred. However, some costs associated with R&D activities that have an alternative future use (e.g., materials, equipment, facilities) may be capitalizable. For the years ended December 31, 2023 and December 31, 2022 research and development expenditures were charged to operating expense as incurred..

 

Stock-based Compensation

 

The Company has a stock-based compensation plan, which is described in more detail in Note 8. The fair value of stock option and warrant grants are determined on the date of grant using the Black Scholes valuation model. Forfeitures of stock based awards are recorded as the actual forfeitures occur. Stock based compensation expense is recognized over the service period, net of estimated forfeitures, using the straight-line method. The Company converted all unvested stock based compensation awards to common shares in the year ended December 31, 2023.

 

F-9
 

 

General, and Administrative Expenses

 

General and administrative expenses include all costs that are not directly related to satisfaction of customer contracts. General, and administrative expenses include items for the Company’s selling and administrative functions, such as sales, finance, legal, human resources, and information technology support. These functions include costs for items such as salaries and benefits and other personnel-related costs, maintenance and supplies, professional fees for external legal, accounting, and other consulting services, intangible asset amortization, and depreciation expense.

 

Emerging Growth Company

 

The Company is an emerging growth company, as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has not elected to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company , can adopt the new or revised standard at the time private companies adopt the new or revised standard.

 

Accounting Pronouncements Not Yet Adopted

 

In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures (Topic 280). This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and included within each reported measure of a segment’s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is also permitted. This ASU will likely result in us including the additional required disclosures when adopted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2024.

 

In December 2023, the Financial Accounting Standards Board issued an Accounting Standards Update (“ASU”) amending existing income tax disclosure guidance, primarily requiring more detailed disclosure for income taxes paid and the effective tax rate reconciliation. The ASU is effective for annual reporting periods beginning after December 15, 2024, with early adoption permitted and can be applied on either a prospective or retroactive basis. We are currently evaluating the ASU to determine its impact on our income tax disclosures.

 

Recently adopted accounting pronouncements

 

In October 2021, the FASB issued ASU No. 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (ASC Topic 805). This ASU requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities (deferred revenue) from acquired contracts using the revenue recognition guidance in Topic 606. At the acquisition date, the acquirer applies the revenue model as if it had originated the acquired contracts. The ASU is effective for annual periods beginning after December 15, 2022, including interim periods within those fiscal years. We adopted this ASU prospectively on January 1, 2023. This ASU has not and is currently not expected to have a material impact on our consolidated financial statements.

 

3. Business Combination

 

The Business Combination was accounted for as a reverse recapitalization as OneMedNet Corporation was determined to be the accounting acquirer under Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 805, Business Combinations. This determination was primarily based on OneMedNet Corporation comprising the ongoing operations of the combined entity, OneMedNet Corporation’s senior management comprising of all the senior management of the combined company, and the prior shareholders of OneMedNet owning a majority of the voting power of the combined entity. Accordingly, for accounting purposes, the financial statements of the combined entity upon consummation of the Business Combination represented a continuation of the financial statements of OneMedNet Corporation with the merger being treated as the equivalent of OneMedNet issuing stock for the net assets of Data Knights Inc., accompanied by a recapitalization. Operations prior to the Business Combination are presented as those of OneMedNet Corporation in future reports of the combined entity.

 

4. Going Concern

 

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company does not have adequate liquidity to fund its operations through at least twelve months from the date these financial statements were available for issuance. The Company has an accumulated deficit 55,082,677 as of year-end December 31, 2023 and $43,509,964, as of year-end December 31, 2022 and has had negative cash flows from operating activities for the year ended December 31, 2023. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. To continue in existence and expand its operations, the Company will be required to, and management plans to, raise additional working capital through an equity or debt offering and ultimately attain profitable operations. If the Company is not able to raise additional working capital, it would have a material adverse effect on the operations of the Company and continuing research and development of its product. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to continue receiving working capital cash payments and generating cash flow from operations.

 

F-10
 

 

5. Property and Equipment

 

Property and equipment are summarized as of December 31:

 Schedule of Property And Equipment

   2023   2022 
Computers  $246,578   $259,207 
Furniture and equipment   35,708    3,785 
Total Property and Equipment   282,286    262,992 
Less: accumulated depreciation   (183,415)   (179,895)
Net Property and Equipment  $98,871   $83,097 

 

Depreciation and amortization expense was $27,983 and $24,807 for the years ended December 31, 2023 and 2022, respectively.

 

6. Income Taxes

 

The Company has generated both federal and state net operating losses (NOL) of approximately $21 million and $23 million, respectively, which if not used, will begin to expire in 2030. The Company believes that its ability to fully utilize the existing NOL carryforwards could be restricted on a portion of the NOL by changes in control that may have occurred or may occur in the future and by its ability to generate net income. The Company has not yet conducted a formal study of whether, or to what extent, past changes in control of the Company impairs its NOL carryforwards because such NOL carryforwards cannot be utilized until the Company achieves profitability.

 

Components of deferred income taxes are as follows as of December 31:

 

Schedule of Deferred Income Taxes

   2023   2022 
Deferred Tax Assets          
Net operating loss carry forward  $6,823,785    $6,973,587 
Stock Compensation   1,035,947    481,144 
Other   -    53,268 
Gross deferred tax assets   7,859,732    7,507,999 
Less valuation allowance   (7,859,732)   (7,507,999)
Net deferred tax assets   -    - 

 

The change in the valuation allowance was $351,734 and $1,384,220 for the years ended December 31, 2023 and 2022, respectively. The effective tax rate for the years ended December 31, 2023 and 2022 differs from the federal and state statutory rates due to the full valuation allowance. The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. The tax years from inception through December 31, 2023 remain subject to examination by all major taxing authorities due to the net operating loss carryovers. The Company is not currently under examination by any taxing jurisdiction. The Company did not incur any interest or penalties during the years ended December 31, 2023 or 2022.

 

As a result of the Business Combination, the Company was appointed as the sole managing member of Data Knights. The Company is subject to U.S. federal income taxes, in addition to state and local income taxes. The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the estimated future tax consequences attributable to temporary differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the temporary differences are expected to be settled or recovered. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future income, and tax planning strategies in making this assessment.

 

The Company has established a valuation allowance related deferred tax assets on deductible temporary differences, tax losses, and tax credit carryforwards. The valuation allowance as of December 31, 2023 was $168.3. The increase in the valuation allowance in fiscal year 2023 of $155.7 million primarily relates to the Company’s investment in Data Knights, and tax carryforward attributes.

 

F-11
 

 

As of December 31, 2023, the Company had a U.S. federal net operating loss carryforwards of $10.3 million and gross state net operating loss carryforwards of $8.9 million.

 

7. Convertible Promissory Notes held by Related Party

 

During 2023, the Company entered various Convertible Promissory Notes (“Note”) with related party investors totaling $2,300,000 (2022 - $4,700,000) and unrelated party investors of $1,875,000 (2022 - $440,000). The Notes issued are unsecured and bear an interest rate of six percent annually from the date of issuance until the outstanding principal is paid or converted. On November 11, 2022 the Convertible note agreement was amended and restated in order to (i) provide for the sale and issuance to Purchasers from the effective date of January 1, 2022 and after the date of this Agreement of up to an additional $5,000,000 aggregate principal amount of Notes and warrants to purchase shares of the Company’s capital stock, (ii) provide for the sale and issuance to Purchasers who purchased Notes under the Prior Agreement between the Effective Date and the date of this Agreement of warrants to purchase shares of the Company’s common stock at an exercise price of $1.00 per share; (iii) extend the maturity date of all outstanding Notes from December 31, 2022 to November 7, 2023.

 

The principal and unpaid accrued interest on each Note will convert: (i) automatically, upon the Company’s issuance of equity securities (the “Next Equity Financing”) in a single transaction, or series of related transactions, with aggregate gross proceeds to the Company of at least $5,000,000, into shares of the Company’s capital stock issued to investors in the Next Equity Financing, at a conversion price equal to the lesser of (A) a 20% discount to the lowest price per share of shares sold in the Next Equity Financing, or (B) $2.50 per share; (ii) at the noteholder’s option, in the event of a defined Corporate Transaction while such Note remains outstanding, into shares of the Company’s Series A-2 Preferred Stock at a conversion price equal to $2.50 per share; and (iii) at the noteholder’s option, on or after the Maturity Date while such Note remains outstanding, into shares of the Company’s Series A-2 Preferred Stock at a conversion price equal to $2.50 per share.

 

If a Corporate Transaction occurs before the repayment or conversion of the Notes, the Company will pay at the closing of the Corporate Transaction to each noteholder that elects not to convert its Notes in connection with such Corporate Transaction an amount equal to the outstanding principal amount of such noteholder’s Note plus a 20% premium. “Corporate Transaction” means (a) a sale by the Company of all or substantially all of its assets, (b) a merger of the Company with or into another entity (if after such merger the holders of a majority of the Company’s voting securities immediately prior to the transaction do not hold a majority of the voting securities of the successor entity) or (c) the transfer of more than 50% of the Company’s voting securities to a person or group.

 

During November 2019, the Company entered into a Convertible Promissory Note (“Note”) agreement with a related party investor. The total amount of the Note is $1,500,000. The Note is unsecured and bears interest at a rate of four percent annually from the date of issuance until the outstanding principal is paid or converted. The Note matures on January 1, 2025. The Note shall automatically convert into the next offering of preferred stock upon closing of such next equity financing. The number of shares of preferred stock to be issued upon conversion shall be equal to the number obtained by dividing the outstanding principal and unpaid accrued interest owed on the date of conversion, by the conversion price. The conversion price is 100 percent of the lowest price per share paid for the next equity preferred stock by other investors in the next equity financing. In the event that prior to the conversion or repayment of amounts owed, the Company completes a financing transaction in which the Company sells equity securities but such transaction does not qualify as next equity financing (i.e., an “alternative financing”), then the principal and unpaid accrued interest may (upon written election of the purchaser holding the Note) convert into the securities issued by the Company in the alternative financing. The number of alternative financing equity securities to be issued upon such conversion shall be equal to the number obtained by dividing the outstanding principal and unpaid accrued interest owed by an amount equal to 100 percent multiplied by the lowest price per share at which the alternative financing equity securities are sold and issued for cash in the alternative financing.

 

As of December 31, 2022 there was $9.9 million outstanding principal balance on the Notes and $690,771 in accrued interest, all included in long-term liabilities on the balance sheet. There were no payments of principal or interest during 2022. In connection with the $5,140,000 in convertible notes issued in 2022, 2,056,000 in warrants were issued.

 

In November 2023, the Business Combination between Data Knights and the Company triggered the Notes’ conversion to common stock. Approximately $15.4 million of the total outstanding Notes plus accrued interest were converted at $2.50 per share of common stock.

 

8. Canadian Emergency Business Loan Act (CEBA)

 

During December 2020, the Company applied for and received a $44,673 USD CEBA loan. The loan was provided by the Government of Canada to provide capital to organizations to see them through the current challenges and better position them to return to providing services and creating employment. The loan is unsecured. The loan was interest free through December 31, 2023. If the loan is paid back by January 18, 2024, $14,742 of the loan will be forgiven. If the loan is not paid back by January 18, 2023, the full $44,673 loan will be converted to loan repayable over three years with a 5% interest rate. The loan was paid back prior January 18, 2024. At December 31, 2023 the loans is classified as Canada Emergency Business Loan Act under Current Liabilities on the Consolidated Balance Sheet.

 

The Company accounted for the loan as debt in accordance with FASB Accounting Standards Codification 470 Debt and accrued interest in accordance with the interest method under FASB ASC 835-30.

 

F-12
 

 

9. Shareholders’ Equity

 

Series A-2 Preferred Stock

 

The Company’s previously issued and outstanding Series A-2 preferred stock included a $0.15 per share annual noncumulative dividend when and if declared by the board of directors. No dividends were declared in the years ended December 31, 2023 or December 31 2022. The Series A-2 preferred stock also includes a liquidation preference of 1.25 times the original issue price plus any declared but unpaid dividends upon the liquidation, dissolution, merger or sale of substantially all the assets of the Company and have a preference upon liquidation over Series A-1 preferred stock and common stock. Each share of Series A-2 preferred stock may be converted into equal shares of common stock at the option of the holder at any time. In addition, the Series A-2 preferred stock shares are automatically convertible into common shares upon the sale of shares of common stock to the public at the then applicable conversion price in a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $20 million in proceeds, net of underwriting discounts and commissions. Each share of Series A-2 preferred stock has voting rights equal to the number of shares of common stock then issuable upon conversion of such share of preferred stock. The Company is obligated to redeem shares of Series A-2 Preferred Stock in the occurrence of a Deemed Liquidation Event unless a majority of the holders of Series A-2 Preferred Stock and a majority of the Series A-1 Preferred Stock consent otherwise.

 

In November 2023, the Business Combination between Data Knights and the Company triggered the Series A-2 Preferred Stock and Series A-1 Preferred Stock convert 1-1 to commons stock.

 

Series A-1 Preferred Stock

 

The Company’s previously issued and outstanding Series A-1 preferred stock included a $0.15 per share annual noncumulative dividend when and if declared by the board of directors. No dividends were declared in the years ended December 31, 2023 or December 31 2022. The Series A-1 preferred stock also includes a liquidation preference of 1.25 times the original issue price plus any declared but unpaid dividends upon the liquidation, dissolution, merger or sale of substantially all the assets of the Company and have a preference upon liquidation over common stock. Each share of Series A-1 preferred stock may be converted into equal shares of common stock at the option of the holder at any time. In addition, the Series A-1 preferred stock shares are automatically convertible into common shares upon the sale of shares of common stock to the public at the then applicable conversion price in a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $20 million in proceeds, net of underwriting discounts and commissions. Each share of Series A-1 preferred stock has voting rights equal to the number of shares of common stock then issuable upon conversion of such share of preferred stock. The Company is obligated to redeem shares of Series A-1 Preferred Stock in the occurrence of a Deemed Liquidation Event unless a majority of the holders of Series A-1 Preferred Stock consent otherwise.

 

In November 2023, the Business Combination between Data Knights and the Company triggered the Series A-2 Preferred Stock and Series A-1 Preferred Stock convert 1-1 to commons stock.

 

Common Stock

 

In 2023, in connection with services performed by the Board of Directors common shares of 100,000 (100,000- 2022) were issued at $1.00 per share. These were expensed as general and administrative expenses in the Statement of Operations.

 

The table below summarizes the Common Stock activities during the year ended December 31, 2023. 

Schedule of Common Stock Activities 

   Common Stock 
Balances, December 31, 2022   4,550,166 
Preferred Stock to Common Stock   7,057,797 
Convertible Notes to Common Stock   6,177,229 
Stock Options to Common Stock   612,670 
Converting of Warrants to Common Stock   3,859,464 
Private OneMedNet to ONMD Public Shares   (2,257,326)
Converting Data Knights Common Stock (A and B) to ONMD Public Shares   3,460,275 
Issuance Public Shares   111,957 
Balances, December 31, 2023   23,572,232 

 

10. Stock Options

 

During 2020, the Company adopted a new equity incentive plan (the Plan), which provides for the granting of incentive and nonqualified stock options to employees, directors, and consultants. As of December 31, 2020, the Company has reserved 3,000,000 shares of common stock under the Plan. The Company believes that such awards better align the interests of its employees with those of its stockholders. Option awards are generally granted with an exercise price equal to the fair market value of the Company’s stock at the date of grant; those option awards generally vest with a range of one to four years of continuous service and have ten-year contractual terms. As there is no public data available for the share price valuation, the Company considers the Fair Market Value of $1 to be on the conservative side and similar to the exercise price. Certain option awards provide for accelerated vesting if there is a change in control, as defined in the Plan. The Plan also permits the granting of restricted stock and other stock-based awards. Unexercised options are cancelled upon termination of employment and become available under the Plan.

 

F-13
 

 

Information with respect to options outstanding is summarized as follows:

 

Schedule of Options Outstanding

   Options Outstanding   Weighted- Average Exercise Price   Aggregate Intrinsic Value 
Outstanding as of December 31, 2020   1,995,000   $1.00   $1,995,000 
Granted - under the Plan   25,000           
Exercised   -           
Cancelled   (1,072,816)          
Outstanding as of December 31, 2021   947,184   $1.00   $947,184 
Granted - under the Plan   577,000           
Exercised   (7,500)          
Cancelled   (485,684)          
Outstanding as of December 31, 2022   1,031,000   $1.00   $1,031,000 
Options exercisable as of December 31, 2022   567,581   $1.00   $567,581 

 

As of December 31, 2022 and 2021, there were 1,031,000 and 947,184 common stock options outstanding with a weighted average remaining contractual life of 7.11 years and 6.01 years, respectively.

 

As of December 31, 2022 and 2021, there were 567,581 and 723,431 common stock options exercisable at a weighted average remaining contractual life of 5.56 years and 5.27 years, respectively.

 

On November 7, 2023, the Company issued shares of common stock for 692,153 vested options less an exercise price of $1.00.

 

At the Special Meeting held on October 17, 2023, Data Knights shareholders considered and approved the OneMedNet Corporation 2022 Equity Incentive Plan (the “Plan”) and reserved an amount of shares of common stock equal to 10% of the number of shares of common stock of OneMedNet following the Business Combination for issuance thereunder. The Plan was approved by the OneMedNet pre-Closing board of directors on October 17, 2023. The Plan became effective immediately upon the Closing of the Business Combination.

 

Black Scholes Assumptions

 

The determination of the fair value of stock options using an option valuation model is affected by the Company’s stock price valuation, as well as assumptions regarding a number of complex and subjective variables. The volatility assumption is based on volatilities of similar companies over a period of time equal to the expected term of the stock options. The volatilities of similar companies are used in conjunction with the Company’s historical volatility because of the lack of sufficient relevant history for the Company’s common stock equal to the expected term. The expected term of the employee stock options represents the weighted average period for which the stock options are expected to remain outstanding. The expected term assumption is estimated based primarily on the options’ vesting terms and remaining contractual life and employees’ expected exercise and post- vesting employment termination behavior. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The dividend yield assumption is based on the expectation of no future dividend payouts by the Company.

 

The fair value of the Company’s previous stock options was estimated assuming no expected dividends and the following weighted average assumptions:

 

Schedule of Fair Value of Stock Options

   2022   2021 
Expected life in years   5.89    6.08 
Risk-free interest rate   0.55%   0.49%
Expected dividend yield   0.00%   0.00%
Expected volatility   32%   60%

 

The total expense recognized for share-based payments was $45,584 and $47,071 for the years ended December 31, 2022 and 2021, respectively. These costs are included in the statements of operations. As of December 31, 2022, there was $75,987 of unrecognized compensation costs related to stock option grants which will be recognized over the next four years.

 

During 2023, the Company issued common stock to employees and extinguished all outstanding stock options. The 612,720 shares outstanding were recorded as stock expense in the Consolidated Statement of Operations.

 

F-14
 

 

11. Stock Warrants

 

In 2021, there were 174,102 OneMedNet Corporation outstanding common stock warrants issued for service at a weighted average exercise price of $0.10. In 2022 for the exercise price of $1.00, the OneMedNet Corporation issued 145,746 warrants for 2021 service and 294,000 warrants for 2022 service, 2,056,000 in warrants were issued attached to convertible notes. The Company expensed $1,346,288 in 2022 in relation to the issuance of the Warrants. In 2023 for the exercise price of $1.00, the OneMedNet issued 1,670,000 in warrants attached to convertible notes. OneMedNet Corporation converted 4,165,746 warrants outstanding to common stock at an exercise price of $1.00 and converted 174,102 warrants outstanding to common stock at an exercise price of $0.10.

 

As of December 31, 2023 and December 31, 2022, the Company had 11,500,000 of publicly traded warrants. The warrants trade on the Nasdaq had closing price of $.0149 and $.0400 at December 31, 2023 and December 31, 2022 respectively.

 

As of December 31, 2023 and December 31, 2022, the Company had 681,019 and 585,275 of private warrants outstanding. These warrants are classified as liability on the Consolidated Balance Sheet. Changes in the warrant liabilities are recorded in the Statement of Operations. As of December 31, 2023 and December 31, 2022, the warrant liabilities were $0.6 million and $0.4 respectively.

 

12. Fair Value Measures

 

The fair value measurement accounting standards establish a framework for measuring fair value and expand disclosures about fair value measurements. The standard does not require any new fair value measurements; rather, it applies to other accounting pronouncements that require or permit fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. This pronouncement also establishes a three-level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

 

The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three levels are defined as follows:

 

Level 1—inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market

 

Level 2—inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model-derived valuations in which all significant inputs are observable for substantially the full term of the asset or liability

 

Level 3—inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability

 

The following table presents the Company’s financial assets measured and recorded at fair value on a recurring basis using the above input categories as of December 31, 2023 and December 31, 2022 (in thousands):

 

Schedule of Financial Assets 

   Year Ended 
   December 31, 2023   December 31, 2022 
   Level 1   Level 2   Level 3   Total   Level 1   Level 2   Level 3   Total 
Assets:                                
Investments held in Trust  $   $   $   $   $29,029,416   $   $   $29,029,416 
                                         
Total Assets  $   $   $   $   $29,029,416   $   $   $29,029,416 

 

13. Related Party Transactions

 

Loan Extensions

 

F-15
 

 

Data Knights closed its initial public offering in May 2021 and had 12 months to complete a business combination. Alternatively, the Data Knight could extend the period up to two times for an additional three months each time with an extension costing $1.2 million. Data Knights received a total of $300,000 from members of the Company’s Management and Directors. As of December 31, 2023 and December 31, 2022 the total extension loan including interest outstanding was $3.0 million and $2.5 million, respectively.

 

PIPE Convertible Notes and Warrants

 

In November 2023, the Company entered into a Securities Purchase Agreement (SPA) in which the Company was required to sell senior secured convertible notes and warrants to Directors of the Company. The SPA stipulates a collateral security agreement between the Company and the Directors for punctual payment and performance by the Company on its Obligations to the Directors. The Intellectual Property of the Company serves as the collateral for the Directors. The senior secured convertible notes and warrants were issued through a private issuance of a public entity (PIPE) transaction, which is a form of debt and equity offering under an exception in the securities law for qualifying private placements by issuers of publicly traded securities. The Company received a total of $1.5 million from the director in exchange for senior convertible notes of $1.6 million (plus accrued interest of $0.1 million) and 95,745 warrants to acquire common stock. The senior secured notes are convertible to the conversion rate of $10.00 per share, and 92.5% of the lowest VWAP for the ten (10) trading days immediately preceding the conversion Date, subject to the floor price of $1.14 (representing 20% of the closing price on the last trading day before the closing of the Business Combination), or the alternative conversion ratio the greater of the floor price and the lesser of 80% of the VWAP of the common stock as of the trading day and 80% of the price computed as the quotient of the sum of the VWAP of the Common Stock for each of the three Trading Days with the lowest VWAP of the Common Stock during the fifteen consecutive trading day period ending and including the trading day immediately preceding the delivery or deemed delivery of the applicable Conversion Notice, divided by three. All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification or similar transaction that proportionately decreases or increases the common stock.

 

The warrants are classified as equity and the total proceeds received from the Directors are allocated based on the relative fair values of the convertible notes and the warrants at the issued date. The portion allocable to warrants is accounted for as paid-in capital. The senior secured convertible notes are classified as long term debt in the Consolidated Balance Sheet. The estimate fair value of the senior secured convertible notes at December 31, 2023 was $1.2 million.

 

14. Commitments, Contingencies, and Concentrations Operating lease

 

The Company has a month-to-month lease for a suite at a cost of $575 per month. The Company incurred $7,695 and $7,694 of rent expense, including common tenant costs and cancellation costs, during the years ended December 31, 2023 and 2022, respectively.

 

15. Subsequent Events

 

The Company has evaluated subsequent events occurring through April 9, 2024, the date the financial statements were available for issuance, for events requiring recording or disclosure in the Company’s financial statements.

 

During 2024, through to the date of this report, the Company issued 256,944 and 20,834 shares of Common Stock to EF Hutton LLC and Kingwood Capital Partners, LLC, respectively, as consideration for $3.0 million owed by the Company for underwriting commission due at the closing of the Business Combination.

 

During 2024, through to the date of this report, the Company bought back 187,745 shares of Common Stock from a convertible note holder.

 

During 2024, through to the date of this report, the Company received $1,000,000 from a majority shareholder for the purchase of shares, and an additional $300,000 treated as a shareholder loan.

 

During 2024, through to the date of this report, the Company entered into a definitive securities purchase agreement with an institutional investor providing up to $4.54 million in funding through a private placement for the issuance of senior convertible notes.

 

As previously announced on Form 8-K, on March 28, 2024, OneMedNet Corporation (the “Company”) entered into a definitive securities purchase agreement (the “Securities Purchase Agreement”) with Helena Global Investment Opportunities 1 Ltd., an affiliate of Helena Partners Inc., a Cayman-Islands based advisor and investor providing for up to USD$4.54 million in funding through a private placement for the issuance of senior secured convertible notes (the “Notes”).

 

As previously announced on Form 8-K, on March 27, 2024, Paul J. Casey, Chief, Chief Executive Officer of the Company, notified the Company of his intention to retire as Chief Executive Officer of the Company effective March 29, 2024. Mr. Casey will continue to serve as a member of the Board of Directors (the “Board”) of the Company. In connection with Mr. Casey’s service on the Advisory Board of the Company, the Board approved a Stock Option Grant (the “Option Grant”) providing for the grant of 147,000 five-year options exercisable at $1.00 per share adviser to Mr. Casey. Also on March 27, 2024, Scott Holbrook, a member of the Board of the Company and a member of the Company’s Audit Committee, notified the Company of his intention to retire from the Company’s Board effective March 29, 2024.

 

Effective March 29, 2024, the Board (i) appointed Mr. Aaron Green, to serve as Chief Executive Officer of the Company to fill the vacancy created by the retirement of Paul Casey; (ii) appointed Mr. Aaron Green, to serve as a member of the Board to fill the vacancy created by the retirement of Scott Holbrook; and (iii) appointed Board member, Dr. Thomas Kosasa, to serve on the Company’s Audit Committee, also to fill the vacancy created by the retirement of Scott Holbrook.

 

F-16
 

 

PART II—INFORMATION NOT REQUIRED IN PROSPECTUS

 

Item 13. Other Expenses of Issuance and Distribution

 

The following table sets forth all expenses, other than the underwriting discounts and commissions, payable by the registrant in connection with the sale of the securities being registered. All the amounts shown are estimates except the SEC registration fee and the FINRA filing fee.

 

  Amount to be paid 
SEC registration fee  $[   ] 
Accounting fees and expenses  $* 
Legal fees and expenses  $* 
Printing and engraving expenses  $* 
Total  $* 

 

* These fees are calculated based on the securities offered and the number of issuances and accordingly cannot be determined at this time.

 

Item 14. Indemnification of Directors and Officers

 

Section 102 of the General Corporation Law of the State of Delaware (the “DGCL”) permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our Amended and Restated Certificate of Incorporation, as amended, provides that no director of the Company shall be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty.

 

Section 145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

 

II-1
 

 

Our Amended and Restated Certificate of Incorporation, as amended, and Amended and Restated Bylaws provide indemnification for our directors and officers to the fullest extent permitted by the DGCL. We will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of us) by reason of the fact that he or she is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an “Indemnitee”), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. Our Amended and Restated Certificate of Incorporation, as amended, and Amended and Restated Bylaws will provide that we will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us against all expenses (including attorneys’ fees) actually and reasonably incurred in connection therewith. Expenses must be advanced to an Indemnitee under certain circumstances.

 

We have entered into separate indemnification agreements with each of our directors and executive officers. Each indemnification agreement provide, among other things, for indemnification to the fullest extent permitted by law and our Amended and Restated Certificate of Incorporation, as amended, and Amended and Restated Bylaws against any and all expenses, judgments, fines, penalties and amounts paid in settlement of any claim. The indemnification agreements provide for the advancement or payment of all expenses to the indemnitee and for the reimbursement to us if it is found that such indemnitee is not entitled to such indemnification under applicable law and our Amended and Restated Certificate of Incorporation, as amended, and Amended and Restated Bylaws.

 

We also have a general liability insurance policy that covers certain liabilities of directors and officers of our corporation arising out of claims based on acts or omissions in their capacities as directors or officers.

 

Item 15. Recent Sales of Unregistered Securities

 

On June 28, 2023, the Company (formerly as Data Knights Acquisition Corp) and OneMedNet Solutions Corporation (formerly as OneMedNet Corporate) entered into a Securities Purchase Agreement (the “SPA”) with certain investors (collectively referred to herein as the “Purchasers”) for PIPE financing in the aggregate original principal amount of $1,595,744.70 and the purchase price of $1.5 million.

 

Effective immediately prior to the Closing on September 7, 2023, as provided under the SPA, the Company issued and sold to each of the Purchasers, a new series of senior secured convertible notes (the “Pre-Closing PIPE Notes”), which are convertible into shares of Common Stock at the Purchasers election at a conversion price equal to the lower of (i) $10.00 per share, and (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) Trading Days immediately preceding the Conversion Date. We deemed the offer, sale and issuance of such securities to be exempt from registration under the Securities Act in reliance on Section 4(2) of the Securities Act, including Regulation D and Rule 506 promulgated thereunder, relative to transactions by an issuer not involving a public offering.

 

On March 28, 2024, OneMedNet Corporation (the “Company”) entered into a definitive securities purchase agreement (the “Securities Purchase Agreement”) with Helena Global Investment Opportunities 1 Ltd. (the “Investor”), an affiliate of Helena Partners Inc., a Cayman-Islands based advisor and investor providing for up to USD$4.54 million in funding through a private placement for the issuance of senior secured convertible notes (the “Notes”). In connection with the issuance of the Notes, the Company will issue to the Investor common stock purchase warrants (the “Warrants”) across multiple tranches (the “Tranches”) consisting of an initial tranche (the “Initial Tranche”) of (i) an aggregate principal amount $2,000,000.00 and including an original issue discount (“OID”) of up to an aggregate of $300,000.00 plus Warrants to purchase a number of shares of Common Stock equal to the applicable Warrant Share Amounts (defined below). The second tranche (the “Second Tranche”) consists of an aggregate principal amount of Notes of up to $350,000.00 and including an OID of up to $52,500.00 and Warrants to purchase a number of shares of Common Stock equal to the applicable Warrant Share Amounts with respect to such Tranche. The Securities Purchase Agreement contemplates three subsequent Tranches each of which shall be in an aggregate principal amount of Notes of up to $1,000,000 each and each including an OID of 15.0% of the applicable principal amount, and Warrants to purchase a number of shares of Common Stock equal to the applicable Warrant Share Amounts with respect to such Tranches.

 

The purchase price of a Note and its accompanying Warrant shall be computed by subtracting the portion of the OID represented by that such Note from the portion of the principal amount represented by such Note (a “Purchase Price”). The Securities Purchase Agreement defines Warrant Share Amounts means in respect of any Warrant issued in a Closing the initial amount of shares of Common Stock (the “Warrant Shares”) for which such Warrant may be exercised and which shall be equal to the applicable principal amount of the Note issued to the Investor in such closing multiplied by 50% and divided by the 95% of lowest VWAP over the ten Trading Day period immediately preceding the applicable Closing Date.

 

In connection with the closings of each Tranche, a portion of the proceeds will be held in escrow (the “Escrow”) pursuant to an executed Escrow Agreement dated as of March 28, 2024 in accordance with the following: (i) $1,350,000.00 of the net proceeds of the Initial Tranche will be paid into the Escrow Account for distribution in accordance with the release of proceeds conditions (the “Release Conditions” discussed below), with the balance of the net proceeds paid to the Company less initial closing expenses relating to such Initial Tranche; (ii) 100% of the net proceeds of the Third Tranche shall be paid into the Escrow Account for distribution in accordance with the Release Conditions; and (iii) 75% of the net proceeds of the Third Tranche shall be paid into the Escrow Account for distribution in accordance with the Release Conditions with the balance of the net proceeds of the Third Tranche being paid to the Company less initial closing expenses relating to such Third Tranche.

 

Item 16. Exhibits and Financial Statement Schedules

 

EXHIBIT INDEX

 

Exhibit No.   Title of Document
2.1†   Agreement and Plan of Merger, dated April 25, 2022, by and among Data Knights, Merger Sub, Sponsor, OneMedNet, and Paul Casey (incorporated by reference to Exhibit 2.1 to the Company’s Form 8-K, filed with the SEC on April 25, 2022).
   
3.1*   Third Amended and Restated Certificate of Incorporation of OneMedNet Corporation.
   
3.2*   Amended and Restated Bylaws of OneMedNet Corporation.
   
4.1   Warrant Agreement, dated May 6, 2021, by and between Continental Stock Transfer & Trust Company and the Company (incorporated by reference to Exhibit 4.3 to the Company’s Form S-1/A, filed with the SEC on April 7, 2021).
   
4.2   Specimen Unit Certificate (incorporated by reference to Exhibit 4.1 to the Company’s Form S-1/A, filed with the SEC on April 7, 2021).
   
4.3   Specimen Class A Common Stock Certificate (incorporated by reference to Exhibit 4.2 to the Company’s Form S-1/A, filed with the SEC on April 7, 2021).

 

II-2
 

 

4.4   Specimen Warrant Certificate (incorporated by reference to Exhibit 4.3 to the Company’s Form S-1/A, filed with the SEC on April 7, 2021).
   
10.1+   Form of OneMedNet Corporation 2023 Equity Incentive Plan (incorporated by reference to Annex D to the proxy statement/prospectus which is part of the Registration Statement on Form S-4 declared effective by the SEC on September 22, 2023).
     
10.2*   Form of Registration Rights Agreement by certain OneMedNet equity holders (included as Exhibit G to Annex B to the proxy statement/prospectus).
   
10.3*   Lockup Agreement by certain OneMedNet equity holders (included as Exhibit C to Annex B to the proxy statement/ prospectus).
   
10.4   Sponsor Lock-up Agreement (as incorporated by reference to Exhibit B of Exhibit 2.1 to the Company’s Form 8-K, filed with the SEC on April 25, 2022).
   
10.5   Letter Agreement, dated May 6, 2021, by and between Data Knights, the initial security holders and the officers and directors of the Data Knights (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K, filed with the SEC on May 11, 2021)
   
10.6   Voting Agreement incorporated by reference to Form 8-K filed April 25, 2022 which is included as Appendix A to Exhibit 2.2.
   
10.7   Sponsor Support Agreement Voting Agreement. (incorporated by reference to Exhibit B to Annex B to the proxy statement/ prospectus filed by Data Knights Acquisition Corp.).
   
10.8*+   Employment Agreement between OneMedNet Corporation and Aaron Green, President.
   
10.9*+   Employment Agreement between OneMedNet Corporation and Lisa Embree, Chief Financial Officer.
   
10.10*   Securities Purchase Agreement dated June 28, 2023 with OneMedNet Corporation.
     
10.11   Securities Purchase Agreement entered into as of March 28, 2024, by and between OneMedNet Corporation and each investor identified on the signature pages thereto (incorporated by reference to Exhibit 10.1 on Form 8-K filed on April 2, 2024).
     
10.12   Registration Rights Agreement dated as of March 28, 2024, by and among OneMedNet Corporation and each of the investors to the Securities Purchase Agreement (incorporated by reference to Exhibit 10.2 on Form 8-K filed on April 2, 2024).
     
10.13   Subscription Escrow Agreement effective March 28, 2024, by and among OneMedNet Corporation, each investor identified on the signature pages thereto, and Rimon, P.C., as the Escrow Agent (incorporated by reference to Exhibit 10.3 on Form 8-K filed on April 2, 2024).
     
14.1*   Code of Ethics
   
21.1   Subsidiaries of the Registrant incorporated by reference to Exhibit 21.1 to the Company’s Form S-4, filed with the SEC on September 21, 2023).
   
23.1*   Consent of BF Borgers CPA PC.
     
24   Power of Attorney (included on signature page hereto).
     
107   Filing Fee Table

 

* Filed herewith
+ Indicates a management or compensatory plan.
Schedules to this exhibit have been omitted pursuant to Item 601(b)(2) of Registration S-K. The Registrant hereby agrees to furnish a copy of any omitted schedules to the SEC upon request.

 

II-3
 

 

Item 17. Undertakings

 

The undersigned registrant hereby undertakes:

 

  (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

 

  (i) To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;

 

  (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement.

 

  (iii)

To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; provided, however, that paragraphs (i), (ii) and (iii) do not apply if the registration statement is on Form S-1 and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement;

 

  (2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

  (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

 

  (4) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser: each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use; and

 

  (5) That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities: the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

 

  (i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

 

  (ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

 

  (iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

 

  (iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

 

  Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

 

II-4
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Registration Statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized on the 16th day of April 2024.

 

  ONEMEDNET CORPORATION
   
  By: /s/ Aaron Green
    Aaron Green
    Chief Executive Officer and Director

 

KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Carol Craig, his or her true and lawful attorney-in-fact and agent with full power of substitution and re-substitution, for him or her and in his or her name, place and stead, in any and all capacities to sign any or all amendments (including, without limitation, post-effective amendments) to this Registration Statement, any related Registration Statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and any or all pre- or post-effective amendments thereto, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that said attorney-in-fact and agent, or any substitute or substitutes for him, may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act of 1933, as amended, the following persons in the capacities and on the dates indicated have signed this Registration Statement below.

 

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-1 has been signed by the following persons in the capacities and on the dates indicated below.

 

Signature   Title   Date
         
/s/ Aaron Green   Chief Executive Officer (Principal Executive Officer) and Director   April 16, 2024
Aaron Green        
         
/s/ Lisa Embree   Chief Financial Officer   April 16, 2024
Lisa Embree   (Principal Financial and Accounting Officer)    
         
/s/ Dr. Jeffrey Yu   Chairman of the Board of Directors, Founder, Chief Medical Officer, Vice President   April 16, 2024
Dr. Jeffrey Yu        
         
/s/ Erkan Akyuz   Director   April 16, 2024
Erkan Akyuz        
         
/s/ Eric Casaburi   Director   April 16, 2024
Eric Casaburi        
         
/s/ Robert Golden   Director   April 16, 2024
Robert Golden        
         
/s/ Dr. Julianne Huh   Director   April 16, 2024
Dr. Julianne Huh        
         
/s/ Dr. Thomas Kosasa   Director   April 16, 2024
Dr. Thomas Kosasa        
         
/s/ Paul J. Casey   Director   April 16, 2024
Paul J. Casey        

 

II-5

 

EX-3.1 2 ex3-1.htm

 

Exhibit 3.1

 

THIRD AMENDED AND RESTATED

CERTIFICATE OF INCORPORATION

OF

ONEMEDNET CORPORATION

November 8, 2023

 

OneMedNet Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY AS FOLLOWS:

 

1. The name of the Corporation is “Data Knights Acquisition Corp” and hereby changes its name to “OneMedNet Corporation” The original certificate of incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on February 8, 2021, was amended and restated on March 8, 2021 by the First Amended and Restated Certificate, and was amended and restated on April 6, 2021 by the Second Amended and Restated Certificate, which Second Amended and Restated Certificate was further amended by the First Amendment to the Second Amended and Restated Certificate on November 11, 2022 and the Second Amendment to the Second Amended and Restated Certificate on August 11, 2023 (the “Certificate”).

 

2. This Third Amended and Restated Certificate of Incorporation (this “Third Amended and Restated Certificate”), which both restates and amends the provisions of the Certificate, was duly adopted in accordance with Sections 228, 242 and 245 of the General Corporation Law of the State of Delaware, as amended from time to time (the “DGCL”).

 

3. This Third Amended and Restated Certificate shall become effective on the date of filing with Secretary of State of Delaware.

 

4. The texts of the Certificate, as amended to the date hereof, is hereby restated and amended in their entirety to read as follows:

 

ARTICLE I

NAME

 

The name of the corporation is OneMedNet Corporation (the “Corporation”).

 

ARTICLE II

PURPOSE

 

The purpose of the Corporation is to engage in any lawful act or activity for which a corporation may be organized under the General Corporation Law of the State of Delaware (the “DGCL”).

 

ARTICLE III

REGISTERED OFFICE AND AGENT

 

The address of the Corporation’s registered office in the State of Delaware is 1209 Orange Street, Corporation Trust Center, City of Wilmington, County of New Castle, 19801. The name of its registered agent at that address is The Corporation Trust Company.

 

ARTICLE IV

CAPITAL STOCK

 

Section 4.1 The total number of shares of all classes of capital stock, each with a par value of $0.0001 per share, which the Corporation is authorized to issue is 101,000,000 shares, consisting of (a) 100,000,000 shares of common stock (the “Common Stock”), (b) 1,000,000 shares of preferred stock (the “Preferred Stock”).

 

 
 

 

Section 4.2 Shares of Preferred Stock may be issued from time to time in one or more classes or series. The Board of Directors of the Corporation (the “Board of Directors”) is hereby authorized to provide from time to time by resolution or resolutions for the creation and issuance, out of the authorized and unissued shares of Preferred Stock, of one or more classes or series of Preferred Stock by filing a certificate (a “Certificate of Designation”) pursuant to the DGCL, setting forth such resolution and, with respect to each such series, establishing the designation of such class or series and the number of shares to be included in such class or series and fixing the voting powers (full or limited, or no voting power), preferences and relative, participating, optional or other special rights, and the qualifications, limitations and restrictions thereof, of the shares of each such class or series. Without limiting the generality of the foregoing, the resolution or resolutions providing for the establishment of any class or series of Preferred Stock may, to the extent permitted by law, provide that such class or series shall be superior to, rank equally with or be junior to the Preferred Stock of any other class or series. The powers, preferences and relative, participating, optional and other special rights of each class or series of Preferred Stock, and the qualifications, limitations, or restrictions thereof, if any, may be different from those of any and all other classes or series at any time outstanding. Except as otherwise expressly provided in the resolution or resolutions providing for the establishment of any class or series of Preferred Stock, no vote of the holders of shares of Preferred Stock or Common Stock shall be a prerequisite to the issuance of any shares of any class or series of the Preferred Stock so authorized in accordance with this Third Amended and Restated Certificate. Unless otherwise provided in the Certificate of Designation establishing a class or series of Preferred Stock, the Board of Directors may, by resolution or resolutions, increase or decrease (but not below the number of shares of such class or series then outstanding) the number of shares of such class or series and, if the number of shares of such class or series shall be so decreased, the shares constituting such decrease shall resume the status that they had prior to the adoption of the resolution originally fixing the number of shares of such class or series.

 

Section 4.3 The Corporation has the authority to create and issue rights, warrants, and options entitling the holders thereof to purchase shares of any class or series of the Corporation’s capital stock or other securities of the Corporation, and such rights, warrants and options shall be evidenced by or in instrument(s) approved by the Board of Directors. The Board of Directors is empowered to set the exercise price, duration, times for exercise and other terms and conditions of such rights, warrants or options; provided, however, that the consideration to be received for any shares of capital stock subject thereto may not be less than the par value thereof.

 

Section 4.4

 

(a) Except as otherwise required by law or this Third Amended and Restated Certificate (or any Certificate of Designation made hereunder), the holders of Common Stock shall exclusively possess all voting power with respect to the Corporation. The holders of shares of Common Stock shall be entitled to one vote for each such share on each matter properly submitted to the stockholders on which the holders of the Common Stock are entitled to vote. The holders of shares of the Common Stock shall at all times vote together as one class on all matters submitted to a vote of the stockholders of the Corporation.

 

(b) Except as otherwise required by law or this Third Amended and Restated Certificate (or any Certificate of Designation made hereunder), at any annual or special meetings of the stockholders of the Corporation, the holders of the Common Stock shall have the exclusive right to vote for the election of directors and on all other matters properly submitted to a vote of the stockholders. Notwithstanding the foregoing, except as otherwise required by law or this Third Amended and Restated Certificate (or any Certificate of Designation made hereunder), the holders of the Common Stock shall not be entitled to vote on any amendment to this Third Amended and Restated Certificate (or any Certificate of Designation made hereunder) that relates solely to the terms of one or more outstanding class or series of the Preferred Stock if the holders of such affected class or series of Preferred Stock are entitled, either separately or together with the holders of one or more other such class or series, to vote thereon pursuant to this Third Amended and Restated Certificate (or any Certificate of Designation made hereunder) or the DGCL.

 

(c) Subject to applicable law and the rights, if any, of the holders of any outstanding class or series of the Preferred Stock, the holders of the shares of the Common Stock shall be entitled to receive such dividends and other distributions (payable in cash, property or capital stock of the Corporation) when, as and if declared thereon by the Board from time to time out of any assets or funds of the Corporation legally available therefor, and shall share equally on a per share basis in such dividends and distributions.

 

(d) Subject to applicable law and the rights, if any, of the holders of any outstanding class or series of the Preferred Stock, in the event of any voluntary or involuntary liquidation, dissolution or winding-up of the Corporation, after payment or provision for payment of the debts and other liabilities of the Corporation, the holders of the shares of the Common Stock shall be entitled to receive all the remaining assets of the Corporation available for distribution to its stockholders, ratably in proportion to the number of shares of the Common Stock held by them.

 

 
 

 

ARTICLE V

BOARD OF DIRECTORS

 

For the management of the business and for the conduct of the affairs of the Corporation it is further provided that:

 

Section 5.1

 

(a) The management of the business and the conduct of the affairs of the Corporation shall be vested in the Board of Directors. The number of directors of the Corporation shall be nine (9), which number may be increased or decreased by one or more resolutions adopted from time to time by the Board of Directors, subject to Sections 5.1(c) and 5.1(d). The Board of Directors shall be classified, with respect to the term for which the directors hold office, into three classes, one class serving for a term expiring at the annual meeting of stockholders to be held in 2023, the second class serving for a term expiring at the annual meeting of stockholders to be held in 2024, and the third class serving for a term expiring at the annual meeting of stockholders to be held in 2025. At each annual meeting of stockholders, directors elected to succeed those directors whose terms expire shall be elected for a term of office to expire at the third succeeding annual meeting of stockholders after their election. Notwithstanding the foregoing, the directors elected to each class shall hold office until their successors are duly elected and qualified or until their earlier resignation, death, or removal. If the number of directors is hereafter changed, any newly created directorships or decrease in directorships shall be so apportioned among the classes as to make all classes as nearly equal in number as is practicable, provided that no decrease in the number of directors constituting the entire Board shall shorten the term of any incumbent director. No reduction in the number of directors shall cause the removal of any director from office prior to the expiration of his or her term.

 

(b) Except as may otherwise be provided in the terms of any Preferred Stock issued by the Corporation, the Board of Directors or any individual director may be removed from office at any time but only by the affirmative vote of the holders of at least a majority of the voting power of all of the then outstanding shares of voting stock of the Corporation with the power to vote at an election of directors (the “Voting Stock”) and, in addition to and without limitation of the foregoing only for cause.

 

(c) Except as may otherwise be provided in the terms of any Preferred Stock issued by the Corporation and subject to Section 5.1(d) below, any vacancies on the Board of Directors resulting from death, resignation, disqualification, retirement, removal or other causes and any newly created directorships resulting from any increase in the number of directors shall, unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by the stockholders, and except as otherwise provided by law, be filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum, or by a sole remaining director, and shall not be filled by the stockholders. Any director appointed in accordance with the preceding sentence shall hold office for a term that shall coincide with the remaining term of the vacancy to which the director shall have been appointed and until such director’s successor shall have been elected and qualified or until his or her earlier death, resignation, disqualification, retirement, or removal.

 

(d) Effective as of the date of filing of this Third Amended and Restated Certificate, the Board of Directors of the Corporation shall consist of nine (9) members, constituted as follows:

 

(i) in the director class whose term expires at the annual meeting held in 2023, three (3) directors nominated by OneMedNet Technologies Corporation, f/k/a OneMedNet Corporation, a Delaware corporation (“OneMedNet Technologies”), one of whom shall qualify as an independent director under the rules of The Nasdaq Stock Market (an “Independent Director”);

 

(ii) in the director class whose term expires at the annual meeting held in 2024, (A) two (2) directors designated by OneMedNet Technologies, one (1) of whom shall be an Independent Director, and (B) one (1) director designated by Data Knights, LLC, a Delaware limited liability company and the Corporation’s sponsor (the “Sponsor”), who shall be an Independent Director; and

 

(iii) in the director class whose term expires at the annual meeting held in 2025, (A) two (2) directors designated by OneMedNet Technologies, one (1) of whom shall be an Independent Director, and (B) one (1) director designated by the Sponsor.

 

 
 

 

Section 5.2

 

(a) In furtherance and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to adopt, amend, alter, or repeal the Bylaws of the Corporation. In addition to any vote of the holders of any class or series of stock of the Corporation required by applicable law or by this Third Amended and Restated Certificate (including any Certificate of Designation in respect of one or more classes or series of Preferred Stock), the adoption, amendment or repeal of the Bylaws of the Corporation by the stockholders of the Corporation shall require the affirmative vote of the holders of at least sixty-six and two-thirds percent (66-2/3%) of the voting power of all the then-outstanding shares of the Voting Stock, voting together as a single class; provided that no Bylaws hereafter adopted by the stockholders of the Corporation shall invalidate any prior act of the Board of Directors that would have been valid if such Bylaws had not been adopted.

 

(b) The directors of the Corporation need not be elected by written ballot unless the Bylaws so provide.

 

ARTICLE VI

STOCKHOLDERS

 

Section 6.1 Subject to the special rights of the holders of one or more classes or series of Preferred Stock, any action required or permitted to be taken by the stockholders of the Corporation must be effected at a duly called annual or special meetings of the stockholders of the Corporation, and the taking of any action by written consent of the stockholders in lieu of a meeting of the stockholders is specifically denied.

 

Section 6.2 Subject to the special rights of the holders of one or more classes or series of Preferred Stock, special meetings of the stockholders of the Corporation may be called, for any purpose or purposes as is a proper matter for stockholder action under the DGCL, by (i) the Chairperson of the Board of Directors, (ii) the Chief Executive Officer, or (iii) the Board of Directors pursuant to a resolution adopted by a majority of the total number of authorized directors (whether or not there exist any vacancies in previously authorized directorships at the time any such resolution is presented to the Board of Directors for adoption). Such special meetings may not be called by stockholders or any other person or persons.

 

Section 6.3 Advance notice of stockholder nominations for the election of directors and of other business proposed to be brought by stockholders before any meeting of the stockholders of the Corporation shall be given in the manner provided in the Bylaws of the Corporation.

 

ARTICLE VII

LIABILITY AND INDEMNIFICATION; CORPORATE OPPORTUNITY

 

Section 7.1 To the fullest extent permitted by the DGCL, as the same exists or as may hereafter be amended, a director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. If the DGCL is amended after approval by the stockholders of this Article VII to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the DGCL as so amended, automatically and without further action, upon the date of such amendment.

 

Section 7.2 The Corporation, to the fullest extent permitted by law, shall indemnify and advance expenses to any person made or threatened to be made a party to an action, suit or proceeding, whether criminal, civil, administrative or investigative, by reason of the fact that he or she, or his or her testator or intestate, is or was a director or officer of the Corporation or any predecessor of the Corporation, or serves or served at any other enterprise as a director or officer at the request of the Corporation or any predecessor to the Corporation.

 

Section 7.3 The Corporation, to the fullest extent permitted by law, may indemnify and advance expenses to any person made or threatened to be made a party to an action, suit or proceeding, whether criminal, civil, administrative or investigative, by reason of the fact that he or she, or his or her testator or intestate, is or was an employee or agent of the Corporation or any predecessor of the Corporation, or serves or served at any other enterprise as an employee or agent at the request of the Corporation or any predecessor to the Corporation.

 

 
 

 

Section 7.4 Neither any amendment nor repeal of this Article VII, nor the adoption by amendment of this Third Amended and Restated Certificate of any provision inconsistent with this Article VII, shall eliminate or reduce the effect of this Article VII in respect of any matter occurring, or any action or proceeding accruing or arising (or that, but for this Article VII, would accrue or arise) prior to such amendment or repeal or adoption of an inconsistent provision.

 

ARTICLE VIII

BUSINESS COMBINATIONS

 

Section 8.1 The Corporation will be subject to Section 203 of the DGCL.

 

Section 8.2 Notwithstanding Section 8.1, the Corporation shall not engage in any business combination (as defined below), at any point in time at which the Corporation’s common stock is registered under Section 12(b) or 12(g) of the Exchange Act, with any interested stockholder (as defined below) for a period of three years following the time that such stockholder of the Corporation became an interested stockholder, unless:

 

(a) prior to such time, the Board approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder, or

 

(b) upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock (as defined below) of the Corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned by (i) persons who are directors and also officers of the Corporation or (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer, or

 

(c) at or subsequent to such time, the business combination is approved by the Board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 662∕3% of the outstanding voting stock of the Corporation which is not owned by the interested stockholder.

 

Section 8.3 For the purposes of this Article VIII:

 

(a) “affiliate” means a person that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, another person.

 

(b) “associate,” when used to indicate a relationship with any person, means: (i) any corporation, partnership, unincorporated association or other entity of which such person is a director, officer or partner or is, directly or indirectly, the owner of 20% or more of any class of voting stock; (ii) any trust or other estate in which such person has at least a 20% beneficial interest or as to which such person serves as trustee or in a similar fiduciary capacity; and (iii) any relative or spouse of such person, or any relative of such spouse, who has the same residence as such person.

 

(c) “business combination,” when used in reference to the Corporation and any interested stockholder, means:

 

(i) any merger or consolidation of the Corporation or any direct or indirect majority-owned subsidiary of the Corporation (A) with the interested stockholder, or (B) with any other corporation, partnership, unincorporated association or other entity if the merger or consolidation is caused by the interested stockholder and as a result of such merger or consolidation Article XI is not applicable to the surviving entity;

 

(ii) any sale, lease, exchange, mortgage, pledge, transfer or other disposition (in one transaction or a series of transactions), except proportionately as a stockholder of the Corporation, to or with the interested stockholder, whether as part of a dissolution or otherwise, of assets of the Corporation or of any direct or indirect majority-owned subsidiary of the Corporation which assets have an aggregate market value equal to 10% or more of either the aggregate market value of all the assets of the Corporation determined on a consolidated basis or the aggregate market value of all the outstanding stock of the Corporation;

 

(iii) any transaction which results in the issuance or transfer by the Corporation or by any direct or indirect majority-owned subsidiary of the Corporation of any stock of the Corporation or of such subsidiary to the interested stockholder, except: (A) pursuant to the exercise, exchange or conversion of securities exercisable for, exchangeable for or convertible into stock of the Corporation or any such subsidiary which securities were outstanding prior to the time that the interested stockholder became such; (B) pursuant to a merger under Section 251(g) of the DGCL; (C) pursuant to a dividend or distribution paid or made, or the exercise, exchange or conversion of securities exercisable for, exchangeable for or convertible into stock of the Corporation or any such subsidiary which security is distributed, pro rata to all holders of a class or series of stock of the Corporation subsequent to the time the interested stockholder became such; (D) pursuant to an exchange offer by the Corporation to purchase stock made on the same terms to all holders of said stock; or (E) any issuance or transfer of stock by the Corporation; provided, however, that in no case under items (C)-(E) of this subsection (iii) shall there be an increase in the interested stockholder’s proportionate share of the stock of any class or series of the Corporation or of the voting stock of the Corporation (except as a result of immaterial changes due to fractional share adjustments);

 

 
 

 

(iv) any transaction involving the Corporation or any direct or indirect majority-owned subsidiary of the Corporation which has the effect, directly or indirectly, of increasing the proportionate share of the stock of any class or series, or securities convertible into the stock of any class or series, of the Corporation or of any such subsidiary which is owned by the interested stockholder, except as a result of immaterial changes due to fractional share adjustments or as a result of any purchase or redemption of any shares of stock not caused, directly or indirectly, by the interested stockholder; or

 

(v) any receipt by the interested stockholder of the benefit, directly or indirectly (except proportionately as a stockholder of the Corporation), of any loans, advances, guarantees or pledges (other than those expressly permitted in subsections (i)-(iv) above) provided by or through the Corporation or any direct or indirect majority-owned subsidiary.

 

(d) “control,” including the terms “controlling,” “controlled by” and “under common control with,” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a person, whether through the ownership of voting stock, by contract, or otherwise. A person who is the owner of 20% or more of the outstanding voting stock of the Corporation, partnership, unincorporated association or other entity shall be presumed to have control of such entity, in the absence of proof by a preponderance of the evidence to the contrary. Notwithstanding the foregoing, a presumption of control shall not apply where such person holds voting stock, in good faith and not for the purpose of circumventing this Article VIII, as an agent, bank, broker, nominee, custodian or trustee for one or more owners who do not individually or as a group have control of such entity.

 

(e) “interested stockholder” means any person (other than the Corporation or any direct or indirect majority-owned subsidiary of the Corporation) that (i) is the owner of 15% or more of the outstanding voting stock of the Corporation, or (ii) is an affiliate or associate of the Corporation and was the owner of 15% or more of the outstanding voting stock of the Corporation at any time within the three year period immediately prior to the date on which it is sought to be determined whether such person is an interested stockholder, and the affiliates and associates of such person; provided, however, that the term “interested stockholder” shall not include (A) the Principal Stockholder or Principal Stockholder Transferees or any “group” (within the meaning of Rule 13d-5 of the Exchange Act) that includes any Principal Stockholder or Principal Stockholder Transferee or (B) any person whose ownership of shares in excess of the 15% limitation set forth herein is the result of any action taken solely by the Corporation; provided that such person specified in this clause (B) shall be an interested stockholder if thereafter such person acquires additional shares of voting stock of the Corporation, except as a result of further corporate action not caused, directly or indirectly, by such person. For the purpose of determining whether a person is an interested stockholder, the voting stock of the Corporation deemed to be outstanding shall include stock deemed to be owned by the person through application of the definition of “owner” below but shall not include any other unissued stock of the Corporation which may be issuable pursuant to any agreement, arrangement or understanding, or upon exercise of conversion rights, warrants or options, or otherwise.

 

(f) “owner,” including the terms “own” and “owned,” when used with respect to any stock, means a person that individually or with or through any of its affiliates or associates:

 

 
 

 

(i) beneficially owns such stock, directly or indirectly; or

 

(ii) has (A) the right to acquire such stock (whether such right is exercisable immediately or only after the passage of time) pursuant to any agreement, arrangement or understanding, or upon the exercise of conversion rights, exchange rights, warrants or options, or otherwise; provided, however, that a person shall not be deemed the owner of stock tendered pursuant to a tender or exchange offer made by such person or any of such person’s affiliates or associates until such tendered stock is accepted for purchase or exchange; or (B) the right to vote such stock pursuant to any agreement, arrangement or understanding; provided, however, that a person shall not be deemed the owner of any stock because of such person’s right to vote such stock if the agreement, arrangement or understanding to vote such stock arises solely from a revocable proxy or consent given in response to a proxy or consent solicitation made to ten or more persons; or

 

(iii) has any agreement, arrangement or understanding for the purpose of acquiring, holding, voting (except voting pursuant to a revocable proxy or consent as described in item (B) of subsection (ii) above), or disposing of such stock with any other person that beneficially owns, or whose affiliates or associates beneficially own, directly or indirectly, such stock.

 

(g) “person” means any individual, corporation, partnership, unincorporated association or other entity.

 

(h) “stock” means, with respect to any corporation, capital stock and, with respect to any other entity, any equity interest.

 

(i) “Principal Stockholder” means, collectively, (i) the Sponsor and (ii) any affiliate or successor of a person referenced in clauses (i) and (ii) of this definition.

 

(j) “Principal Stockholder Transferee” means any Person who acquires voting stock of the Corporation from the Principal Stockholder (other than in connection with a public offering) and who is designated in writing by the Principal Stockholder as a “Principal Stockholder Transferee.”

 

(k) “voting stock” means stock of any class or series entitled to vote generally in matters submitted for stockholders’ approval other than the election of directors.

 

ARTICLE IX

EXCLUSIVE FORUM

 

Section 9.1 Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for (a) any derivative action or proceeding brought on behalf of the Corporation, (b) any action asserting a claim of breach of fiduciary duty owed by any director, officer, employee, agent or stockholder of the Corporation to the Corporation or the Corporation’s stockholders, creditors or other constituents, (c) any action asserting a claim arising pursuant to any provision of the DGCL or this Third Amended and Restated Certificate or the Bylaws of the Corporation, or (d) any action asserting a claim governed by the internal affairs doctrine, in each case subject to said Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein; provided that suits brought to enforce any liability or duty created by the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or any other claim for which the federal courts have exclusive jurisdiction, shall be brought in the federal district court for the district of Delaware; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. To the fullest extent permitted by applicable law, any person or entity purchasing or otherwise acquiring or holding any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Article VIII. Notwithstanding any other provisions of law, this Third Amended and Restated Certificate or the Bylaws of the Corporation, and notwithstanding the fact that a lesser percentage may be specified by law, the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock of the Corporation entitled to vote thereon shall be required to amend or repeal, or to adopt any provision inconsistent with, this Article VIII. If any provision or provisions of this Article VIII shall be held to be invalid, illegal or unenforceable as applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Article VIII (including, without limitation, each portion of any sentence of this Article VIII containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby.

 

 
 

 

Section 9.2 If any action the subject matter of which is within the scope of Section 9.1 is filed in a court other than within the State of Delaware (a “Foreign Action”) in the name of any stockholder, such stockholder shall be deemed to have consented to (i) the personal jurisdiction of the state and federal courts of the State of Delaware in connection with any action brought in any such court to enforce Section 9.1 (an “FSC Enforcement Action”) and (ii) having service of process made upon such stockholder in any such FSC Enforcement Action by service upon such stockholder’s counsel in the Foreign Action as agent for such stockholder.

 

Section 9.3 If any provision or provisions of this Article VIII shall be held to be invalid, illegal or unenforceable as applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Article VIII (including, without limitation, each portion of any sentence of this Article VIII containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby. Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Article VIII.

 

ARTICLE X

AMENDMENTS

 

Notwithstanding any other provisions of this Third Amended and Restated Certificate or any provision of law which might otherwise permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any particular class or series of the Voting Stock required by law or by this Third Amended and Restated Certificate (including any Certificate of Designation in respect of one or more series of Preferred Stock), the affirmative vote of the holders of at least sixty-six and two-thirds percent (66-2/3%) of the voting power of all of the then-outstanding shares of the Voting Stock, voting together as a single class, shall be required to alter, amend or repeal Articles V, VI, VII, VIII, IX and this Article X.

 

*****

 

IN WITNESS WHEREOF, OneMedNet Corporation has caused this Amended and Restated Certificate to be duly executed and acknowledged in its name and on its behalf by an authorized officer as of the date first set forth above.

 

  ONEMEDNET CORPORATION
     
  By: /s/ Paul Casey  
  Name: Paul Casey
  Title: Chief Executive Officer

 

 

 

EX-3.2 3 ex3-2.htm

 

Exhibit 3.2

 

 

AMENDED AND RESTATED BYLAWS

OF

ONEMEDNET CORPORATION

(THE “CORPORATION”)

 

(Adopted November 8, 2023)

 

ARTICLE I

OFFICES

 

Section 1.1. Registered Office. The registered office of the Corporation within the State of Delaware shall be located at either (a) the principal place of business of the Corporation in the State of Delaware or (b) the office of the corporation or individual acting as the Corporation’s registered agent in Delaware.

 

Section 1.2. Additional Offices. The Corporation may, in addition to its registered office in the State of Delaware, have such other offices and places of business, both within and outside the State of Delaware, as the Board of Directors of the Corporation (the “Board”) may from time to time determine or as the business and affairs of the Corporation may require.

 

ARTICLE II

STOCKHOLDERS MEETINGS

 

Section 2.1. Annual Meetings. The annual meeting of stockholders shall be held at such place, either within or without the State of Delaware, and time and on such date as shall be determined by the Board and stated in the notice of the meeting, provided that the Board may in its sole discretion determine that the meeting shall not be held at any place, but may instead be held solely by means of remote communication pursuant to Section 9.5(a). At each annual meeting, the stockholders entitled to vote on such matters shall elect those directors of the Corporation to fill any term of a directorship that expires on the date of such annual meeting and may transact any other business as may properly be brought before the meeting.

 

Section 2.2. Special Meetings. Subject to the rights of the holders of any outstanding series of the preferred stock of the Corporation (“Preferred Stock”), and to the requirements of applicable law, special meetings of stockholders, for any purpose or purposes, may be called only by the Chairman of the Board, Chief Executive Officer, or the Board pursuant to a resolution adopted by a majority of the Board, and may not be called by any other person. Special meetings of stockholders shall be held at such place, either within or without the State of Delaware, and at such time and on such date as shall be determined by the Board and stated in the Corporation’s notice of the meeting, provided that the Board may in its sole discretion determine that the meeting shall not be held at any place, but may instead be held solely by means of remote communication pursuant to Section 9.5(a).

 

Section 2.3. Notices. Written notice of each stockholders meeting stating the place, if any, date, and time of the meeting, and the means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting and the record date for determining the stockholders entitled to vote at the meeting, if such date is different from the record date for determining stockholders entitled to notice of the meeting, shall be given in the manner permitted by Section 9.3 to each stockholder entitled to vote thereat as of the record date for determining the stockholders entitled to notice of the meeting, by the Corporation not less than 10 nor more than 60 days before the date of the meeting unless otherwise required by the General Corporation Law of the State of Delaware (the “DGCL”). If said notice is for a stockholders meeting other than an annual meeting, it shall in addition state the purpose or purposes for which the meeting is called, and the business transacted at such meeting shall be limited to the matters so stated in the Corporation’s notice of meeting (or any supplement thereto). Any meeting of stockholders as to which notice has been given may be postponed, and any meeting of stockholders as to which notice has been given may be cancelled, by the Board upon public announcement (as defined in Section 2.7(c)) given before the date previously scheduled for such meeting.

 

 

 

 

Section 2.4. Quorum. Except as otherwise provided by applicable law, the Corporation’s Certificate of Incorporation, as the same may be amended or restated from time to time (the “Certificate of Incorporation”) or these By Laws, the presence, in person or by proxy, at a stockholders meeting of the holders of shares of outstanding capital stock of the Corporation representing a majority of the voting power of all outstanding shares of capital stock of the Corporation entitled to vote at such meeting shall constitute a quorum for the transaction of business at such meeting, except that when specified business is to be voted on by a class or series of stock voting as a class, the holders of shares representing a majority of the voting power of the outstanding shares of such class or series shall constitute a quorum of such class or series for the transaction of such business. If a quorum shall not be present or represented by proxy at any meeting of the stockholders of the Corporation, the chairman of the meeting may adjourn the meeting from time to time in the manner provided in Section 2.6 until a quorum shall attend. The stockholders present at a duly convened meeting may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum. Shares of its own stock belonging to the Corporation or to another corporation, if a majority of the voting power of the shares entitled to vote in the election of directors of such other corporation is held, directly or indirectly, by the Corporation, shall neither be entitled to vote nor be counted for quorum purposes; provided, however, that the foregoing shall not limit the right of the Corporation or any such other corporation to vote shares held by it in a fiduciary capacity.

 

Section 2.5. Voting of Shares.

 

(a) Voting Lists. The Secretary of the Corporation (the “Secretary”) shall prepare, or shall cause the officer or agent who has charge of the stock ledger of the Corporation to prepare and make, at least 10 days before every meeting of stockholders, a complete list of the stockholders of record entitled to vote at such meeting; provided, however, that if the record date for determining the stockholders entitled to vote is less than 10 days before the meeting date, the list shall reflect the stockholders entitled to vote as of the tenth day before the meeting date, arranged in alphabetical order and showing the address and the number and class of shares registered in the name of each stockholder. Nothing contained in this Section 2.5(a) shall require the Corporation to include electronic mail addresses or other electronic contact information on such list. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours for a period of at least 10 days prior to the meeting: (i) on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (ii) during ordinary business hours, at the principal place of business of the Corporation. In the event that the Corporation determines to make the list available on an electronic network, the Corporation may take reasonable steps to ensure that such information is available only to stockholders of the Corporation. If the meeting is to be held at a place, then the list shall be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder who is present. If a meeting of stockholders is to be held solely by means of remote communication as permitted by Section 9.5(a), the list shall be open to the examination of any stockholder during the whole time of the meeting on a reasonably accessible electronic network, and the information required to access such list shall be provided with the notice of meeting. The stock ledger shall be the only evidence as to who are the stockholders entitled to examine the list required by this Section 2.5(a) or to vote in person or by proxy at any meeting of stockholders.

 

(b) Manner of Voting. At any stockholders meeting, every stockholder entitled to vote may vote in person or by proxy. If authorized by the Board, the voting by stockholders or proxy holders at any meeting conducted by remote communication may be effected by a ballot submitted by electronic transmission (as defined in Section 9.3), provided that any such electronic transmission must either set forth or be submitted with information from which the Corporation can determine that the electronic transmission was authorized by the stockholder or proxy holder. The Board, in its discretion, or the chairman of the meeting of stockholders, in such person’s discretion, may require that any votes cast at such meeting shall be cast by written ballot.

 

(c) Proxies. Each stockholder entitled to vote at a meeting of stockholders or to express consent or dissent to corporate action in writing without a meeting may authorize another person or persons to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period. Proxies need not be filed with the Secretary until the meeting is called to order, but shall be filed with the Secretary before being voted. Without limiting the manner in which a stockholder may authorize another person or persons to act for such stockholder as proxy, either of the following shall constitute a valid means by which a stockholder may grant such authority. No stockholder shall have cumulative voting rights.

 

 

 

 

(i) A stockholder may execute a writing authorizing another person or persons to act for such stockholder as proxy. Execution may be accomplished by the stockholder or such stockholder’s authorized officer, director, employee or agent signing such writing or causing such person’s signature to be affixed to such writing by any reasonable means, including, but not limited to, by facsimile signature.

 

(ii) A stockholder may authorize another person or persons to act for such stockholder as proxy by transmitting or authorizing the transmission of an electronic transmission to the person who will be the holder of the proxy or to a proxy solicitation firm, proxy support service organization or like agent duly authorized by the person who will be the holder of the proxy to receive such transmission, provided that any such electronic transmission must either set forth or be submitted with information from which it can be determined that the electronic transmission was authorized by the stockholder. Any copy, facsimile telecommunication or other reliable reproduction of the writing or transmission authorizing another person or persons to act as proxy for a stockholder may be substituted or used in lieu of the original writing or transmission for any and all purposes for which the original writing or transmission could be used; provided that such copy, facsimile telecommunication or other reproduction shall be a complete reproduction of the entire original writing or transmission.

 

(d) Required Vote. Subject to the rights of the holders of one or more series of Preferred Stock, voting separately by class or series, to elect directors pursuant to the terms of one or more series of Preferred Stock, at all meetings of stockholders at which a quorum is present, the election of directors shall be determined by a plurality of the votes cast by the stockholders present in person or represented by proxy at the meeting and entitled to vote thereon. All other matters presented to the stockholders at a meeting at which a quorum is present shall be determined by the vote of a majority of the votes cast by the stockholders present in person or represented by proxy at the meeting and entitled to vote thereon, unless the matter is one upon which, by applicable law, the Certificate of Incorporation, these By Laws or applicable stock exchange rules, a different vote is required, in which case such provision shall govern and control the decision of such matter.

 

(e) Inspectors of Election. The Board may, and shall if required by law, in advance of any meeting of stockholders, appoint one or more persons as inspectors of election, who may be employees of the Corporation or otherwise serve the Corporation in other capacities, to act at such meeting of stockholders or any adjournment thereof and to make a written report thereof. The Board may appoint one or more persons as alternate inspectors to replace any inspector who fails to act. If no inspectors of election or alternates are appointed by the Board, the chairman of the meeting shall appoint one or more inspectors to act at the meeting. Each inspector, before discharging his or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of his or her ability. The inspectors shall ascertain and report the number of outstanding shares and the voting power of each; determine the number of shares present in person or represented by proxy at the meeting and the validity of proxies and ballots; count all votes and ballots and report the results; determine and retain for a reasonable period a record of the disposition of any challenges made to any determination by the inspectors; and certify their determination of the number of shares represented at the meeting and their count of all votes and ballots. No person who is a candidate for an office at an election may serve as an inspector at such election. Each report of an inspector shall be in writing and signed by the inspector or by a majority of them if there is more than one inspector acting at such meeting. If there is more than one inspector, the report of a majority shall be the report of the inspectors.

 

Section 2.6. Adjournments. Any meeting of stockholders, annual or special, may be adjourned by the chairman of the meeting, from time to time, whether or not there is a quorum, to reconvene at the same or some other place. Notice need not be given of any such adjourned meeting if the date, time, and place, if any, thereof, and the means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting are announced at the meeting at which the adjournment is taken. At the adjourned meeting the stockholders, or the holders of any class or series of stock entitled to vote separately as a class, as the case may be, may transact any business that might have been transacted at the original meeting. If the adjournment is for more than 30 days, notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. If after the adjournment a new record date for stockholders entitled to vote is fixed for the adjourned meeting, the Board shall fix a new record date for notice of such adjourned meeting in accordance with Section 9.2, and shall give notice of the adjourned meeting to each stockholder of record entitled to vote at such adjourned meeting as of the record date fixed for notice of such adjourned meeting.

 

 

 

 

Section 2.7. Advance Notice for Business.

 

(a) Annual Meetings of Stockholders. No business may be transacted at an annual meeting of stockholders, other than business that is either (i) specified in the Corporation’s notice of meeting (or any supplement thereto) given by or at the direction of the Board, (ii) otherwise properly brought before the annual meeting by or at the direction of the Board or (iii) otherwise properly brought before the annual meeting by any stockholder of the Corporation (x) who is a stockholder of record entitled to vote at such annual meeting on the date of the giving of the notice provided for in this Section 2.7(a) and on the record date for the determination of stockholders entitled to vote at such annual meeting and (y) who complies with the notice procedures set forth in this Section 2.7(a). Notwithstanding anything in this Section 2.7(a) to the contrary, only persons nominated for election as a director to fill any term of a directorship that expires on the date of the annual meeting pursuant to Section 3.5 will be considered for election at such meeting.

 

(i) In addition to any other applicable requirements, for business (other than nominations) to be properly brought before an annual meeting by a stockholder, such stockholder must have given timely notice thereof in proper written form to the Secretary and such business must otherwise be a proper matter for stockholder action. Subject to Section 2.7(a)(iii), a stockholder’s notice to the Secretary with respect to such business, to be timely, must be received by the Secretary at the principal executive offices of the Corporation not later than the close of business on the 90th day nor earlier than the opening of business on the 120th day before the anniversary date of the immediately preceding annual meeting of stockholders; provided, however, that in the event that the annual meeting is more than 30 days before or more than 60 days after such anniversary date, notice by the stockholder to be timely must be so delivered not earlier than the close of business on the 120th day before the meeting and not later than the later of (x) the close of business on the 90th day before the meeting or (y) the close of business on the 10th day following the day on which public announcement of the date of the annual meeting is first made by the Corporation. The public announcement of an adjournment or postponement of an annual meeting shall not commence a new time period (or extend any time period) for the giving of a stockholder’s notice as described in this Section 2.7(a).

 

(ii) To be in proper written form, a stockholder’s notice to the Secretary with respect to any business (other than nominations) must set forth as to each such matter such stockholder proposes to bring before the annual meeting (A) a brief description of the business desired to be brought before the annual meeting, the text of the proposal or business (including the text of any resolutions proposed for consideration and in the event such business includes a proposal to amend these By Laws, the language of the proposed amendment) and the reasons for conducting such business at the annual meeting, (B) the name and record address of such stockholder and the name and address of the beneficial owner, if any, on whose behalf the proposal is made, (C) the class or series and number of shares of capital stock of the Corporation that are owned beneficially and of record by such stockholder and by the beneficial owner, if any, on whose behalf the proposal is made, (D) a description of all arrangements or understandings between such stockholder and the beneficial owner, if any, on whose behalf the proposal is made and any other person or persons (including their names) in connection with the proposal of such business by such stockholder, (E) any material interest of such stockholder and the beneficial owner, if any, on whose behalf the proposal is made in such business and (F) a representation that such stockholder (or a qualified representative of such stockholder) intends to appear in person or by proxy at the annual meeting to bring such business before the meeting.

 

(iii) The foregoing notice requirements of this Section 2.7(a) shall be deemed satisfied by a stockholder as to any proposal (other than nominations) if the stockholder has notified the Corporation of such stockholder’s intention to present such proposal at an annual meeting in compliance with Rule 14a-8 (or any successor thereof) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and such stockholder has complied with the requirements of such Rule for inclusion of such proposal in a proxy statement prepared by the Corporation to solicit proxies for such annual meeting. No business shall be conducted at the annual meeting of stockholders except business brought before the annual meeting in accordance with the procedures set forth in this Section 2.7(a), provided, however, that once business has been properly brought before the annual meeting in accordance with such procedures, nothing in this Section 2.7(a) shall be deemed to preclude discussion by any stockholder of any such business. If the Board or the chairman of the annual meeting determines that any stockholder proposal was not made in accordance with the provisions of this Section 2.7(a) or that the information provided in a stockholder’s notice does not satisfy the information requirements of this Section 2.7(a), such proposal shall not be presented for action at the annual meeting. Notwithstanding the foregoing provisions of this Section 2.7(a), if the stockholder (or a qualified representative of the stockholder) does not appear at the annual meeting of stockholders of the Corporation to present the proposed business, such proposed business shall not be transacted, notwithstanding that proxies in respect of such matter may have been received by the Corporation.

 

 

 

 

(iv) In addition to the provisions of this Section 2.7(a), a stockholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to the matters set forth herein. Nothing in this Section 2.7(a) shall be deemed to affect any rights of stockholders to request inclusion of proposals in the Corporation’s proxy statement pursuant to Rule 14a-8 under the Exchange Act.

 

(b) Special Meetings of Stockholders. Only such business shall be conducted at a special meeting of stockholders as shall have been brought before the meeting pursuant to the Corporation’s notice of meeting. Nominations of persons for election to the Board may be made at a special meeting of stockholders at which directors are to be elected pursuant to the Corporation’s notice of meeting only pursuant to Section 3.5.

 

(c) Public Announcement. For purposes of these By Laws, “public announcement” shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Sections 13, 14 or 15(d) of the Exchange Act (or any successor thereto).

 

Section 2.8. Conduct of Meetings. The chairman of each annual and special meeting of stockholders shall be the Chairman of the Board or, in the absence (or inability or refusal to act) of the Chairman of the Board, any Chief Executive Officer (if he or she shall be a director) or, in the absence (or inability or refusal to act of a Chief Executive Officer or if a Chief Executive Officer is not a director, the President (if he or she shall be a director) or, in the absence (or inability or refusal to act) of the President or if the President is not a director, such other person as shall be appointed by the Board. The date and time of the opening and the closing of the polls for each matter upon which the stockholders will vote at a meeting shall be announced at the meeting by the chairman of the meeting. The Board may adopt such rules and regulations for the conduct of the meeting of stockholders as it shall deem appropriate. Except to the extent inconsistent with these By Laws or such rules and regulations as adopted by the Board, the chairman of any meeting of stockholders shall have the right and authority to convene and to adjourn the meeting, to prescribe such rules, regulations and procedures and to do all such acts as, in the judgment of such chairman, are appropriate for the proper conduct of the meeting. Such rules, regulations or procedures, whether adopted by the Board or prescribed by the chairman of the meeting, may include, without limitation, the following: (a) the establishment of an agenda or order of business for the meeting; (b) rules and procedures for maintaining order at the meeting and the safety of those present; (c) limitations on attendance at or participation in the meeting to stockholders of record of the Corporation, their duly authorized and constituted proxies or such other persons as the chairman of the meeting shall determine; (d) restrictions on entry to the meeting after the time fixed for the commencement thereof; and (e) limitations on the time allotted to questions or comments by participants. Unless and to the extent determined by the Board or the chairman of the meeting, meetings of stockholders shall not be required to be held in accordance with the rules of parliamentary procedure. The secretary of each annual and special meeting of stockholders shall be the Secretary or, in the absence (or inability or refusal to act) of the Secretary, an Assistant Secretary so appointed to act by the chairman of the meeting. In the absence (or inability or refusal to act) of the Secretary and all Assistant Secretaries, the chairman of the meeting may appoint any person to act as secretary of the meeting.

 

Section 2.9. Consents in Lieu of Meeting. Unless otherwise provided by the Certificate of Incorporation, until the Corporation consummates an initial public offering (“Offering”), any action required to be taken at any annual or special meeting of stockholders, or any action which may be taken at any annual or special meeting of such stockholders, may be taken without a meeting, without prior notice and without a vote, if a consent in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock entitled to vote thereon having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted, and shall be delivered to the Corporation by delivery to its registered office in the State of Delaware, its principal place of business, or an officer or agent of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Delivery made to the Corporation’s registered office shall be by hand or by certified or registered mail, return receipt requested.

 

 

 

 

Every written consent shall bear the date of signature of each stockholder who signs the consent, and no written consent shall be effective to take the corporate action referred to therein unless, within 60 days of the earliest dated consent delivered in the manner required by this section and the DGCL to the Corporation, written consents signed by a sufficient number of holders entitled to vote to take action are delivered to the Corporation by delivery to its registered office in Delaware, its principal place of business or an officer or agent of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Delivery made to the Corporation’s registered office shall be by hand or by certified or registered mail, return receipt requested.

 

ARTICLE III

DIRECTORS

 

Section 3.1. Powers; Number. The business and affairs of the Corporation shall be managed by or under the direction of the Board, which may exercise all such powers of the Corporation and do all such lawful acts and things as are not by statute or by the Certificate of Incorporation or by these By Laws required to be exercised or done by the stockholders. Directors need not be stockholders or residents of the State of Delaware. Subject to the Certificate of Incorporation, the number of directors shall be fixed exclusively by resolution of the Board. Each director shall hold office until a successor is duly elected and qualified or until the director’s earlier death, resignation, disqualification, or removal.

 

Section 3.2. Newly Created Directorships and Vacancies. Any newly created directorships resulting from an increase in the authorized number of directors and any vacancies occurring in the Board of Directors, may be filled by the affirmative votes of a majority of the remaining members of the Board of Directors, although less than a quorum, or by a sole remaining director. A director so elected shall be elected to hold office until the earlier of the expiration of the term of office of the director whom he or she has replaced, a successor is duly elected and qualified, or the earlier of such director’s death, resignation, or removal.

 

Section 3.3. Resignations. Any director may resign at any time by notice given in writing or by electronic transmission to the Corporation. Such resignation shall take effect at the date of receipt of such notice by the Corporation or at such later effective date or upon the happening of an event or events as is therein specified.

 

Section 3.4. Removals. Except as prohibited by applicable law or the Certificate of Incorporation, the stockholders holding a majority of the shares then entitled to vote at an election of directors may remove any director from office with or without cause.

 

Section 3.5. Advance Notice for Nomination of Directors.

 

(a) Only persons who are nominated in accordance with the following procedures shall be eligible for election as directors of the Corporation, except as may be otherwise provided by the terms of one or more series of Preferred Stock with respect to the rights of holders of one or more series of Preferred Stock to elect directors. Nominations of persons for election to the Board at any annual meeting of stockholders, or at any special meeting of stockholders called for the purpose of electing directors as set forth in the Corporation’s notice of such special meeting, may be made (i) by or at the direction of the Board or (ii) by any stockholder of the Corporation (x) who is a stockholder of record entitled to vote in the election of directors on the date of the giving of the notice provided for in this Section 3.5 and on the record date for the determination of stockholders entitled to vote at such meeting and (y) who complies with the notice procedures set forth in this Section 3.5.

 

(b) In addition to any other applicable requirements, for a nomination to be made by a stockholder, such stockholder must have given timely notice thereof in proper written form to the Secretary. To be timely, a stockholder’s notice to the Secretary must be received by the Secretary at the principal executive offices of the Corporation (i) in the case of an annual meeting, not later than the close of business on the 90th day nor earlier than the opening of business on the 120th day before the anniversary date of the immediately preceding annual meeting of stockholders; provided, however, that in the event that the annual meeting is more than 30 days before or more than 60 days after such anniversary date, notice by the stockholder to be timely must be so received not earlier than the opening of business on the 120th day before the meeting and not later than the later of (x) the close of business on the 90th day before the meeting or (y) the close of business on the 10th day following the day on which public announcement of the date of the annual meeting was first made by the Corporation; and (ii) in the case of a special meeting of stockholders called for the purpose of electing directors, not later than the close of business on the 10th day following the day on which public announcement of the date of the special meeting is first made by the Corporation. In no event shall the public announcement of an adjournment or postponement of an annual meeting or special meeting commence a new time period (or extend any time period) for the giving of a stockholder’s notice as described in this Section 3.5.

 

 

 

 

(c) Notwithstanding anything in paragraph (b) to the contrary, in the event that the number of directors to be elected to the Board at an annual meeting is greater than the number of directors whose terms expire on the date of the annual meeting and there is no public announcement by the Corporation naming all of the nominees for the additional directors to be elected or specifying the size of the increased Board before the close of business on the 90th day prior to the anniversary date of the immediately preceding annual meeting of stockholders, a stockholder’s notice required by this Section 3.5 shall also be considered timely, but only with respect to nominees for the additional directorships created by such increase that are to be filled by election at such annual meeting, if it shall be received by the Secretary at the principal executive offices of the Corporation not later than the close of business on the 10th day following the date on which such public announcement was first made by the Corporation.

 

(d) To be in proper written form, a stockholder’s notice to the Secretary must set forth (i) as to each person whom the stockholder proposes to nominate for election as a director (A) the name, age, business address and residence address of the person, (B) the principal occupation or employment of the person, (C) the class or series and number of shares of capital stock of the Corporation that are owned beneficially or of record by the person and (D) any other information relating to the person that would be required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for election of directors pursuant to Section 14 of the Exchange Act and the rules and regulations promulgated thereunder; and (ii) as to the stockholder giving the notice (A) the name and record address of such stockholder as they appear on the Corporation’s books and the name and address of the beneficial owner, if any, on whose behalf the nomination is made, (B) the class or series and number of shares of capital stock of the Corporation that are owned beneficially and of record by such stockholder and the beneficial owner, if any, on whose behalf the nomination is made, (C) a description of all arrangements or understandings relating to the nomination to be made by such stockholder among such stockholder, the beneficial owner, if any, on whose behalf the nomination is made, each proposed nominee and any other person or persons (including their names), (D) a representation that such stockholder (or a qualified representative of such stockholder) intends to appear in person or by proxy at the meeting to nominate the persons named in its notice and (E) any other information relating to such stockholder and the beneficial owner, if any, on whose behalf the nomination is made that would be required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for election of directors pursuant to Section 14 of the Exchange Act and the rules and regulations promulgated thereunder. Such notice must be accompanied by a written consent of each proposed nominee to being named as a nominee and to serve as a director if elected.

 

(e) If the Board or the chairman of the meeting of stockholders determines that any nomination was not made in accordance with the provisions of this Section 3.5, or that the information provided in a stockholder’s notice does not satisfy the information requirements of this Section 3.5, then such nomination shall not be considered at the meeting in question. Notwithstanding the foregoing provisions of this Section 3.5, if the stockholder (or a qualified representative of the stockholder) does not appear at the meeting of stockholders of the Corporation to present the nomination, such nomination shall be disregarded, notwithstanding that proxies in respect of such nomination may have been received by the Corporation.

 

(f) In addition to the provisions of this Section 3.5, a stockholder shall also comply with all of the applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to the matters set forth herein. Nothing in this Section 3.5 shall be deemed to affect any rights of the holders of Preferred Stock to elect directors pursuant to the Certificate of Incorporation.

 

Section 3.6. Compensation. Unless otherwise restricted by the Certificate of Incorporation or these By Laws, the Board shall have the authority to fix the compensation of directors, including for service on a committee of the Board, and may be paid either a fixed sum for attendance at each meeting of the Board or other compensation as director. The directors may be reimbursed their expenses, if any, of attendance at each meeting of the Board. No such payment shall preclude any director from serving the Corporation in any other capacity and receiving compensation therefor. Members of committees of the Board may be allowed like compensation and reimbursement of expenses for service on the committee.

 

 

 

 

ARTICLE IV

BOARD MEETINGS

 

Section 4.1. Annual Meetings. The Board shall meet as soon as practicable after the adjournment of each annual stockholders meeting at the place of the annual stockholders meeting unless the Board shall fix another time and place and give notice thereof in the manner required herein for special meetings of the Board. No notice to the directors shall be necessary to legally convene this meeting, except as provided in this Section 4.1.

 

Section 4.2. Regular Meetings. Regularly scheduled, periodic meetings of the Board may be held without notice at such times, dates and places (within or without the State of Delaware) as shall from time to time be determined by the Board.

 

Section 4.3. Special Meetings. Special meetings of the Board (a) may be called by the Chairman of the Board or President and (b) shall be called by the Chairman of the Board, President or Secretary on the written request of at least a majority of directors then in office, or the sole director, as the case may be, and shall be held at such time, date and place (within or without the State of Delaware) as may be determined by the person calling the meeting or, if called upon the request of directors or the sole director, as specified in such written request. Notice of each special meeting of the Board shall be given, as provided in Section 9.3, to each director (i) at least 24 hours before the meeting if such notice is oral notice given personally or by telephone or written notice given by hand delivery or by means of a form of electronic transmission and delivery; (ii) at least two days before the meeting if such notice is sent by a nationally recognized overnight delivery service; and (iii) at least five days before the meeting if such notice is sent through the United States mail. If the Secretary shall fail or refuse to give such notice, then the notice may be given by the officer who called the meeting or the directors who requested the meeting. Any and all business that may be transacted at a regular meeting of the Board may be transacted at a special meeting. Except as may be otherwise expressly provided by applicable law, the Certificate of Incorporation, or these By Laws, neither the business to be transacted at, nor the purpose of, any special meeting need be specified in the notice or waiver of notice of such meeting. A special meeting may be held at any time without notice if all the directors are present or if those not present waive notice of the meeting in accordance with Section 9.4.

 

Section 4.4. Quorum; Required Vote. A majority of the Board shall constitute a quorum for the transaction of business at any meeting of the Board, and the act of a majority of the directors present at any meeting at which there is a quorum shall be the act of the Board, except as may be otherwise specifically provided by applicable law, the Certificate of Incorporation or these By Laws. If a quorum shall not be present at any meeting, a majority of the directors present may adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum is present.

 

Section 4.5. Consent In Lieu of Meeting. Unless otherwise restricted by the Certificate of Incorporation or these By Laws, any action required or permitted to be taken at any meeting of the Board or any committee thereof may be taken without a meeting if all members of the Board or committee, as the case may be, consent thereto in writing or by electronic transmission, and the writing or writings or electronic transmission or transmissions (or paper reproductions thereof) are filed with the minutes of proceedings of the Board or committee. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.

 

Section 4.6. Organization. The chairman of each meeting of the Board shall be the Chairman of the Board or, in the absence (or inability or refusal to act) of the Chairman of the Board, any Chief Executive Officer (if he or she shall be a director) or, in the absence (or inability or refusal to act) of a Chief Executive Officer or if a Chief Executive Officer is not a director, the President (if he or she shall be a director) or in the absence (or inability or refusal to act) of the President or if the President is not a director, a chairman elected from the directors present. The Secretary shall act as secretary of all meetings of the Board. In the absence (or inability or refusal to act) of the Secretary, an Assistant Secretary shall perform the duties of the Secretary at such meeting. In the absence (or inability or refusal to act) of the Secretary and all Assistant Secretaries, the chairman of the meeting may appoint any person to act as secretary of the meeting.

 

 

 

 

ARTICLE V

COMMITTEES OF DIRECTORS

 

Section 5.1. Establishment. The Board may by resolution of the Board designate one or more committees, each committee to consist of one or more of the directors of the Corporation. Each committee shall keep regular minutes of its meetings and report the same to the Board when required by the resolution designating such committee. The Board shall have the power at any time to fill vacancies in, to change the membership of, or to dissolve any such committee.

 

Section 5.2. Available Powers. Any committee established pursuant to Section 5.1 hereof, to the extent permitted by applicable law and by resolution of the Board, shall have and may exercise all of the powers and authority of the Board in the management of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers that may require it.

 

Section 5.3. Alternate Members. The Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of such committee. In the absence or disqualification of a member of the committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not he, she or they constitute a quorum, may unanimously appoint another member of the Board to act at the meeting in place of any such absent or disqualified member.

 

Section 5.4. Procedures. Unless the Board otherwise provides, the time, date, place, if any, and notice of meetings of a committee shall be determined by such committee. At meetings of a committee, a majority of the number of members of the committee (but not including any alternate member, unless such alternate member has replaced any absent or disqualified member at the time of, or in connection with, such meeting) shall constitute a quorum for the transaction of business. The act of a majority of the members present at any meeting at which a quorum is present shall be the act of the committee, except as otherwise specifically provided by applicable law, the Certificate of Incorporation, these By Laws or the Board. If a quorum is not present at a meeting of a committee, the members present may adjourn the meeting from time to time, without notice other than an announcement at the meeting, until a quorum is present. Unless the Board otherwise provides and except as provided in these By Laws, each committee designated by the Board may make, alter, amend and repeal rules for the conduct of its business. In the absence of such rules each committee shall conduct its business in the same manner as the Board is authorized to conduct its business pursuant to Article III and Article IV of these By Laws.

 

ARTICLE VI

OFFICERS

 

Section 6.1. Officers. The officers of the Corporation elected by the Board shall be one or more Chief Executive Officers, a Chief Financial Officer, a Secretary and such other officers (including without limitation, a Chairman of the Board, Presidents, Vice Presidents, Assistant Secretaries and a Treasurer) as the Board from time to time may determine. Officers elected by the Board shall each have such powers and duties as generally pertain to their respective offices, subject to the specific provisions of this Article VI. Such officers shall also have such powers and duties as from time to time may be conferred by the Board. Any Chief Executive Officer or President may also appoint such other officers (including without limitation one or more Vice Presidents and Controllers) as may be necessary or desirable for the conduct of the business of the Corporation. Such other officers shall have such powers and duties and shall hold their offices for such terms as may be provided in these By Laws or as may be prescribed by the Board or, if such officer has been appointed by any Chief Executive Officer or President, as may be prescribed by the appointing officer.

 

(a) Chairman of the Board. The Chairman of the Board shall preside when present at all meetings of the stockholders and the Board. The Chairman of the Board shall have general supervision and control of the acquisition activities of the Corporation subject to the ultimate authority of the Board, and shall be responsible for the execution of the policies of the Board with respect to such matters. In the absence (or inability or refusal to act) of the Chairman of the Board, any Chief Executive Officer (if he or she shall be a director) shall preside when present at all meetings of the stockholders and the Board. The powers and duties of the Chairman of the Board shall not include supervision or control of the preparation of the financial statements of the Corporation (other than through participation as a member of the Board). The position of Chairman of the Board and Chief Executive Officer may be held by the same person and may be held by more than one person.

 

 

 

 

(b) Chief Executive Officer. One or more Chief Executive Officers shall be the chief executive officer(s) of the Corporation, shall have general supervision of the affairs of the Corporation and general control of all of its business subject to the ultimate authority of the Board, and shall be responsible for the execution of the policies of the Board with respect to such matters, except to the extent any such powers and duties have been prescribed to the Chairman of the Board pursuant to Section 6.1(a) above. In the absence (or inability or refusal to act) of the Chairman of the Board, any Chief Executive Officer (if he or she shall be a director) shall preside when present at all meetings of the stockholders and the Board. The position of Chief Executive Officer and President may be held by the same person and may be held by more than one person.

 

(c) President. The President shall make recommendations to any Chief Executive Officer on all operational matters that would normally be reserved for the final executive responsibility of any Chief Executive Officer. In the absence (or inability or refusal to act) of the Chairman of the Board and a Chief Executive Officer, the President (if he or she shall be a director) shall preside when present at all meetings of the stockholders and the Board. The President shall also perform such duties and have such powers as shall be designated by the Board. The position of President and Chief Executive Officer may be held by the same person.

 

(d) Vice Presidents. In the absence (or inability or refusal to act) of the President, the Vice President (or in the event there be more than one Vice President, the Vice Presidents in the order designated by the Board) shall perform the duties and have the powers of the President. Any one or more of the Vice Presidents may be given an additional designation of rank or function.

 

(e) Secretary.

 

(i) The Secretary shall attend all meetings of the stockholders, the Board and (as required) committees of the Board and shall record the proceedings of such meetings in books to be kept for that purpose. The Secretary shall give, or cause to be given, notice of all meetings of the stockholders and special meetings of the Board and shall perform such other duties as may be prescribed by the Board, the Chairman of the Board, any Chief Executive Officer or President. The Secretary shall have custody of the corporate seal of the Corporation and the Secretary, or any Assistant Secretary, shall have authority to affix the same to any instrument requiring it, and when so affixed, it may be attested by his or her signature or by the signature of such Assistant Secretary. The Board may give general authority to any other officer to affix the seal of the Corporation and to attest the affixing thereof by his or her signature.

 

(ii) The Secretary shall keep, or cause to be kept, at the principal executive office of the Corporation or at the office of the Corporation’s transfer agent or registrar, if one has been appointed, a stock ledger, or duplicate stock ledger, showing the names of the stockholders and their addresses, the number and classes of shares held by each and, with respect to certificated shares, the number and date of certificates issued for the same and the number and date of certificates cancelled.

 

(f) Assistant Secretaries. The Assistant Secretary or, if there be more than one, the Assistant Secretaries in the order determined by the Board shall, in the absence (or inability or refusal to act) of the Secretary, perform the duties and have the powers of the Secretary.

 

(g) Chief Financial Officer. The Chief Financial Officer shall perform all duties commonly incident to that office (including, without limitation, the care and custody of the funds and securities of the Corporation, which from time to time may come into the Chief Financial Officer’s hands and the deposit of the funds of the Corporation in such banks or trust companies as the Board, any Chief Executive Officer or the President may authorize).

 

(h) Treasurer. The Treasurer shall, in the absence (or inability or refusal to act) of the Chief Financial Officer, perform the duties and exercise the powers of the Chief Financial Officer.

 

 

 

 

Section 6.2. Term of Office; Removal; Vacancies. The elected officers of the Corporation shall be appointed by the Board and shall hold office until their successors are duly elected and qualified by the Board or until their earlier death, resignation, retirement, disqualification, or removal from office. Any officer may be removed, with or without cause, at any time by the Board. Any officer appointed by any Chief Executive Officer or President may also be removed, with or without cause, by any Chief Executive Officer or President, as the case may be, unless the Board otherwise provides. Any vacancy occurring in any elected office of the Corporation may be filled by the Board. Any vacancy occurring in any office appointed by any Chief Executive Officer or President may be filled by any Chief Executive Officer, or President, as the case may be, unless the Board then determines that such office shall thereupon be elected by the Board, in which case the Board shall elect such officer.

 

Section 6.3. Other Officers. The Board may delegate the power to appoint such other officers and agents, and may also remove such officers and agents or delegate the power to remove same, as it shall from time to time deem necessary or desirable.

 

Section 6.4. Multiple Officeholders; Stockholder and Director Officers. Any number of offices may be held by the same person unless the Certificate of Incorporation or these By Laws otherwise provide. Officers need not be stockholders or residents of the State of Delaware.

 

ARTICLE VII

SHARES

 

Section 7.1. Certificated and Uncertificated Shares. The shares of the Corporation may be certificated or uncertificated, subject to the sole discretion of the Board and the requirements of the DGCL.

 

Section 7.2. Multiple Classes of Stock. If the Corporation shall be authorized to issue more than one class of stock or more than one series of any class, the Corporation shall (a) cause the powers, designations, preferences and relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights to be set forth in full or summarized on the face or back of any certificate that the Corporation issues to represent shares of such class or series of stock or (b) in the case of uncertificated shares, within a reasonable time after the issuance or transfer of such shares, send to the registered owner thereof a written notice containing the information required to be set forth on certificates as specified in clause (a) above; provided, however, that, except as otherwise provided by applicable law, in lieu of the foregoing requirements, there may be set forth on the face or back of such certificate or, in the case of uncertificated shares, on such written notice a statement that the Corporation will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences or rights.

 

Section 7.3. Signatures. Each certificate representing capital stock of the Corporation shall be signed by or in the name of the Corporation by (a) the Chairman of the Board, any Chief Executive Officer, the President or a Vice President and (b) the Treasurer, an Assistant Treasurer, the Secretary or an Assistant Secretary of the Corporation. Any or all the signatures on the certificate may be a facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, such certificate may be issued by the Corporation with the same effect as if such person were such officer, transfer agent or registrar on the date of issue.

 

Section 7.4. Consideration and Payment for Shares.

 

(a) Subject to applicable law and the Certificate of Incorporation, shares of stock may be issued for such consideration, having in the case of shares with par value a value not less than the par value thereof, and to such persons, as determined from time to time by the Board. The consideration may consist of any tangible or intangible property or any benefit to the Corporation including cash, promissory notes, services performed, contracts for services to be performed or other securities, or any combination thereof.

 

(b) Subject to applicable law and the Certificate of Incorporation, shares may not be issued until the full amount of the consideration has been paid, unless upon the face or back of each certificate issued to represent any partly paid shares of capital stock or upon the books and records of the Corporation in the case of partly paid uncertificated shares, there shall have been set forth the total amount of the consideration to be paid therefor and the amount paid thereon up to and including the time said certificate representing certificated shares or said uncertificated shares are issued.

 

 

 

 

Section 7.5. Lost, Destroyed or Wrongfully Taken Certificates.

 

(a) If an owner of a certificate representing shares claims that such certificate has been lost, destroyed or wrongfully taken, the Corporation shall issue a new certificate representing such shares or such shares in uncertificated form if the owner: (i) requests such a new certificate before the Corporation has notice that the certificate representing such shares has been acquired by a protected purchaser; (ii) if requested by the Corporation, delivers to the Corporation a bond sufficient to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, wrongful taking or destruction of such certificate or the issuance of such new certificate or uncertificated shares; and (iii) satisfies other reasonable requirements imposed by the Corporation.

 

(b) If a certificate representing shares has been lost, apparently destroyed or wrongfully taken, and the owner fails to notify the Corporation of that fact within a reasonable time after the owner has notice of such loss, apparent destruction or wrongful taking and the Corporation registers a transfer of such shares before receiving notification, the owner shall be precluded from asserting against the Corporation any claim for registering such transfer or a claim to a new certificate representing such shares or such shares in uncertificated form.

 

Section 7.6. Transfer of Stock.

 

(a) If a certificate representing shares of the Corporation is presented to the Corporation with an endorsement requesting the registration of transfer of such shares or an instruction is presented to the Corporation requesting the registration of transfer of uncertificated shares, the Corporation shall register the transfer as requested if:

 

(i) in the case of certificated shares, the certificate representing such shares has been surrendered;

 

(ii) (A) with respect to certificated shares, the endorsement is made by the person specified by the certificate as entitled to such shares; (B) with respect to uncertificated shares, an instruction is made by the registered owner of such uncertificated shares; or (C) with respect to certificated shares or uncertificated shares, the endorsement or instruction is made by any other appropriate person or by an agent who has actual authority to act on behalf of the appropriate person;

 

(iii) the Corporation has received a guarantee of signature of the person signing such endorsement or instruction or such other reasonable assurance that the endorsement or instruction is genuine and authorized as the Corporation may request;

 

(iv) the transfer does not violate any restriction on transfer imposed by the Corporation that is enforceable in accordance with Section 7.8(a); and

 

(v) such other conditions for such transfer as shall be provided for under applicable law have been satisfied.

 

(b) Whenever any transfer of shares shall be made for collateral security and not absolutely, the Corporation shall so record such fact in the entry of transfer if, when the certificate for such shares is presented to the Corporation for transfer or, if such shares are uncertificated, when the instruction for registration of transfer thereof is presented to the Corporation, both the transferor and transferee request the Corporation to do so.

 

Section 7.7. Registered Stockholders. Before due presentment for registration of transfer of a certificate representing shares of the Corporation or of an instruction requesting registration of transfer of uncertificated shares, the Corporation may treat the registered owner as the person exclusively entitled to inspect for any proper purpose the stock ledger and the other books and records of the Corporation, vote such shares, receive dividends or notifications with respect to such shares and otherwise exercise all the rights and powers of the owner of such shares, except that a person who is the beneficial owner of such shares (if held in a voting trust or by a nominee on behalf of such person) may, upon providing documentary evidence of beneficial ownership of such shares and satisfying such other conditions as are provided under applicable law, may also so inspect the books and records of the Corporation.

 

 

 

 

Section 7.8. Effect of the Corporation’s Restriction on Transfer.

 

(a) A written restriction on the transfer or registration of transfer of shares of the Corporation or on the amount of shares of the Corporation that may be owned by any person or group of persons, if permitted by the DGCL and noted conspicuously on the certificate representing such shares or, in the case of uncertificated shares, contained in a notice, offering circular or prospectus sent by the Corporation to the registered owner of such shares within a reasonable time prior to or after the issuance or transfer of such shares, may be enforced against the holder of such shares or any successor or transferee of the holder including an executor, administrator, trustee, guardian or other fiduciary entrusted with like responsibility for the person or estate of the holder.

 

(b) A restriction imposed by the Corporation on the transfer or the registration of shares of the Corporation or on the amount of shares of the Corporation that may be owned by any person or group of persons, even if otherwise lawful, is ineffective against a person without actual knowledge of such restriction unless: (i) the shares are certificated and such restriction is noted conspicuously on the certificate; or (ii) the shares are uncertificated and such restriction was contained in a notice, offering circular or prospectus sent by the Corporation to the registered owner of such shares within a reasonable time prior to or after the issuance or transfer of such shares.

 

Section 7.9. Regulations. The Board shall have power and authority to make such additional rules and regulations, subject to any applicable requirement of law, as the Board may deem necessary and appropriate with respect to the issue, transfer or registration of transfer of shares of stock or certificates representing shares. The Board may appoint one or more transfer agents or registrars and may require for the validity thereof that certificates representing shares bear the signature of any transfer agent or registrar so appointed.

 

ARTICLE VIII

INDEMNIFICATION

 

Section 8.1. Right to Indemnification. To the fullest extent permitted by applicable law, as the same exists or may hereafter be amended, the Corporation shall indemnify and hold harmless each person who was or is made a party or is threatened to be made a party to or is otherwise involved in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (hereinafter a “proceeding”), by reason of the fact that he or she is or was a director or officer of the Corporation or, while a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, other enterprise or nonprofit entity, including service with respect to an employee benefit plan (hereinafter an “Indemnitee”), whether the basis of such proceeding is alleged action in an official capacity as a director, officer, employee or agent, or in any other capacity while serving as a director, officer, employee or agent, against all liability and loss suffered and expenses (including, without limitation, attorneys’ fees, judgments, fines, ERISA excise taxes and penalties and amounts paid in settlement) reasonably incurred by such Indemnitee in connection with such proceeding; provided, however, that, except as provided in Section 8.3 with respect to proceedings to enforce rights to indemnification, the Corporation shall indemnify an Indemnitee in connection with a proceeding (or part thereof) initiated by such Indemnitee only if such proceeding (or part thereof) was authorized by the Board.

 

Section 8.2. Right to Advancement of Expenses. In addition to the right to indemnification conferred in Section 8.1, an Indemnitee shall also have the right to be paid by the Corporation to the fullest extent not prohibited by applicable law the expenses (including, without limitation, attorneys’ fees) incurred in defending or otherwise participating in any such proceeding in advance of its final disposition (hereinafter an “advancement of expenses”); provided, however, that, if the DGCL requires, an advancement of expenses incurred by an Indemnitee in his or her capacity as a director or officer of the Corporation (and not in any other capacity in which service was or is rendered by such Indemnitee, including, without limitation, service to an employee benefit plan) shall be made only upon the Corporation’s receipt of an undertaking (hereinafter an “undertaking”), by or on behalf of such Indemnitee, to repay all amounts so advanced if it shall ultimately be determined that such Indemnitee is not entitled to be indemnified under this Article VIII or otherwise.

 

 

 

 

Section 8.3. Right of Indemnitee to Bring Suit. If a claim under Section 8.1 or Section 8.2 is not paid in full by the Corporation within 60 days after a written claim therefor has been received by the Corporation, except in the case of a claim for an advancement of expenses, in which case the applicable period shall be 20 days, the Indemnitee may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim. If successful in whole or in part in any such suit, or in a suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Indemnitee shall also be entitled to be paid the expense of prosecuting or defending such suit. In (a) any suit brought by the Indemnitee to enforce a right to indemnification hereunder (but not in a suit brought by an Indemnitee to enforce a right to an advancement of expenses) it shall be a defense that, and (b) in any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall be entitled to recover such expenses upon a final judicial decision from which there is no further right to appeal (hereinafter a “final adjudication”) that, the Indemnitee has not met any applicable standard for indemnification set forth in the DGCL. Neither the failure of the Corporation (including its directors who are not parties to such action, a committee of such directors, independent legal counsel, or its stockholders) to have made a determination prior to the commencement of such suit that indemnification of the Indemnitee is proper in the circumstances because the Indemnitee has met the applicable standard of conduct set forth in the DGCL, nor an actual determination by the Corporation (including a determination by its directors who are not parties to such action, a committee of such directors, independent legal counsel, or its stockholders) that the Indemnitee has not met such applicable standard of conduct, shall create a presumption that the Indemnitee has not met the applicable standard of conduct or, in the case of such a suit brought by the Indemnitee, shall be a defense to such suit. In any suit brought by the Indemnitee to enforce a right to indemnification or to an advancement of expenses hereunder, or by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the burden of proving that the Indemnitee is not entitled to be indemnified, or to such advancement of expenses, under this Article VIII or otherwise shall be on the Corporation.

 

Section 8.4. Non-Exclusivity of Rights. The rights provided to any Indemnitee pursuant to this Article VIII shall not be exclusive of any other right, which such Indemnitee may have or hereafter acquire under applicable law, the Certificate of Incorporation, these By Laws, an agreement, a vote of stockholders or disinterested directors, or otherwise.

 

Section 8.5. Insurance. The Corporation may maintain insurance, at its expense, to protect itself and/or any director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise against any expense, liability or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the DGCL.

 

Section 8.6. Indemnification of Other Persons. This Article VIII shall not limit the right of the Corporation to the extent and in the manner authorized or permitted by law to indemnify and to advance expenses to persons other than Indemnitees. Without limiting the foregoing, the Corporation may, to the extent authorized from time to time by the Board, grant rights to indemnification and to the advancement of expenses to any employee or agent of the Corporation and to any other person who is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to an employee benefit plan, to the fullest extent of the provisions of this Article VIII with respect to the indemnification and advancement of expenses of Indemnitees under this Article VIII.

 

Section 8.7. Amendments. Any repeal or amendment of this Article VIII by the Board or the stockholders of the Corporation or by changes in applicable law, or the adoption of any other provision of these By Laws inconsistent with this Article VIII, will, to the extent permitted by applicable law, be prospective only (except to the extent such amendment or change in applicable law permits the Corporation to provide broader indemnification rights to Indemnitees on a retroactive basis than permitted prior thereto), and will not in any way diminish or adversely affect any right or protection existing hereunder in respect of any act or omission occurring prior to such repeal or amendment or adoption of such inconsistent provision; provided however, that amendments or repeals of this Article VIII shall require the affirmative vote of the stockholders holding at least 66.7% of the voting power of all outstanding shares of capital stock of the Corporation.

 

Section 8.8. Certain Definitions. For purposes of this Article VIII, (a) references to “other enterprise” shall include any employee benefit plan; (b) references to “fines” shall include any excise taxes assessed on a person with respect to an employee benefit plan; (c) references to “serving at the request of the Corporation” shall include any service that imposes duties on, or involves services by, a person with respect to any employee benefit plan, its participants, or beneficiaries; and (d) a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner “not opposed to the best interest of the Corporation” for purposes of Section 145 of the DGCL.

 

 

 

 

Section 8.9. Contract Rights. The rights provided to Indemnitees pursuant to this Article VIII shall be contract rights and such rights shall continue as to an Indemnitee who has ceased to be a director, officer, agent or employee and shall inure to the benefit of the Indemnitee’s heirs, executors and administrators.

 

Section 8.10. Severability. If any provision or provisions of this Article VIII shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Article VIII shall not in any way be affected or impaired thereby; and (b) to the fullest extent possible, the provisions of this Article VIII (including, without limitation, each such portion of this Article VIII containing any such provision held to be invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable.

 

ARTICLE IX

MISCELLANEOUS

 

Section 9.1. Place of Meetings. If the place of any meeting of stockholders, the Board or committee of the Board for which notice is required under these By Laws is not designated in the notice of such meeting, such meeting shall be held at the principal business office of the Corporation; provided, however, if the Board has, in its sole discretion, determined that a meeting shall not be held at any place, but instead shall be held by means of remote communication pursuant to Section 9.5 hereof, then such meeting shall not be held at any place.

 

Section 9.2. Fixing Record Dates.

 

(a) In order that the Corporation may determine the stockholders entitled to notice of any meeting of stockholders or any adjournment thereof, the Board may fix a record date, which shall not precede the date upon which the resolution fixing the record date is adopted by the Board, and which record date shall not be more than 60 nor less than 10 days before the date of such meeting. If the Board so fixes a date, such date shall also be the record date for determining the stockholders entitled to vote at such meeting unless the Board determines, at the time it fixes such record date, that a later date on or before the date of the meeting shall be the date for making such determination. If no record date is fixed by the Board, the record date for determining stockholders entitled to notice of and to vote at a meeting of stockholders shall be at the close of business on the business day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the business day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board may fix a new record date for the adjourned meeting, and in such case shall also fix as the record date for stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determination of stockholders entitled to vote in accordance with the foregoing provisions of this Section 9.2(a) at the adjourned meeting.

 

(b) In order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than 60 days prior to such action. If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board adopts the resolution relating thereto.

 

Section 9.3. Means of Giving Notice.

 

(a) Notice to Directors. Whenever under applicable law, the Certificate of Incorporation or these By Laws notice is required to be given to any director, such notice shall be given either (i) in writing and sent by mail, or by a nationally recognized delivery service, (ii) by means of facsimile telecommunication or other form of electronic transmission, or (iii) by oral notice given personally or by telephone. A notice to a director will be deemed given as follows: (i) if given by hand delivery, orally, or by telephone, when actually received by the director, (ii) if sent through the United States mail, when deposited in the United States mail, with postage and fees thereon prepaid, addressed to the director at the director’s address appearing on the records of the Corporation, (iii) if sent for next day delivery by a nationally recognized overnight delivery service, when deposited with such service, with fees thereon prepaid, addressed to the director at the director’s address appearing on the records of the Corporation, (iv) if sent by facsimile telecommunication, when sent to the facsimile transmission number for such director appearing on the records of the Corporation, (v) if sent by electronic mail, when sent to the electronic mail address for such director appearing on the records of the Corporation, or (vi) if sent by any other form of electronic transmission, when sent to the address, location or number (as applicable) for such director appearing on the records of the Corporation.

 

 

 

 

(b) Notice to Stockholders. Whenever under applicable law, the Certificate of Incorporation or these By Laws notice is required to be given to any stockholder, such notice may be given (i) in writing and sent either by hand delivery, through the United States mail, or by a nationally recognized overnight delivery service for next day delivery, or (ii) by means of a form of electronic transmission consented to by the stockholder, to the extent permitted by, and subject to the conditions set forth in Section 232 of the DGCL. A notice to a stockholder shall be deemed given as follows: (i) if given by hand delivery, when actually received by the stockholder, (ii) if sent through the United States mail, when deposited in the United States mail, with postage and fees thereon prepaid, addressed to the stockholder at the stockholder’s address appearing on the stock ledger of the Corporation, (iii) if sent for next day delivery by a nationally recognized overnight delivery service, when deposited with such service, with fees thereon prepaid, addressed to the stockholder at the stockholder’s address appearing on the stock ledger of the Corporation, and (iv) if given by a form of electronic transmission consented to by the stockholder to whom the notice is given and otherwise meeting the requirements set forth above, (A) if by facsimile transmission, when directed to a number at which the stockholder has consented to receive notice, (B) if by electronic mail, when directed to an electronic mail address at which the stockholder has consented to receive notice, (C) if by a posting on an electronic network together with separate notice to the stockholder of such specified posting, upon the later of (1) such posting and (2) the giving of such separate notice, and (D) if by any other form of electronic transmission, when directed to the stockholder. A stockholder may revoke such stockholder’s consent to receiving notice by means of electronic communication by giving written notice of such revocation to the Corporation. Any such consent shall be deemed revoked if (1) the Corporation is unable to deliver by electronic transmission two consecutive notices given by the Corporation in accordance with such consent and (2) such inability becomes known to the Secretary or an Assistant Secretary or to the Corporation’s transfer agent, or other person responsible for the giving of notice; provided, however, the inadvertent failure to treat such inability as a revocation shall not invalidate any meeting or other action.

 

(c) Electronic Transmission. “Electronic transmission” means any form of communication, not directly involving the physical transmission of paper, that creates a record that may be retained, retrieved and reviewed by a recipient thereof, and that may be directly reproduced in paper form by such a recipient through an automated process, including but not limited to transmission by telex, facsimile telecommunication, electronic mail, telegram and cablegram.

 

(d) Notice to Stockholders Sharing Same Address. Without limiting the manner by which notice otherwise may be given effectively by the Corporation to stockholders, any notice to stockholders given by the Corporation under any provision of the DGCL, the Certificate of Incorporation or these By Laws shall be effective if given by a single written notice to stockholders who share an address if consented to by the stockholders at that address to whom such notice is given. A stockholder may revoke such stockholder’s consent by delivering written notice of such revocation to the Corporation. Any stockholder who fails to object in writing to the Corporation within 60 days of having been given written notice by the Corporation of its intention to send such a single written notice shall be deemed to have consented to receiving such single written notice.

 

(e) Exceptions to Notice Requirements. Whenever notice is required to be given, under the DGCL, the Certificate of Incorporation or these By Laws, to any person with whom communication is unlawful, the giving of such notice to such person shall not be required and there shall be no duty to apply to any governmental authority or agency for a license or permit to give such notice to such person. Any action or meeting that shall be taken or held without notice to any such person with whom communication is unlawful shall have the same force and effect as if such notice had been duly given. In the event that the action taken by the Corporation is such as to require the filing of a certificate with the Secretary of State of Delaware, the certificate shall state, if such is the fact and if notice is required, that notice was given to all persons entitled to receive notice except such persons with whom communication is unlawful. Whenever notice is required to be given by the Corporation, under any provision of the DGCL, the Certificate of Incorporation or these By Laws, to any stockholder to whom (1) notice of two consecutive annual meetings of stockholders and all notices of stockholder meetings or of the taking of action by written consent of stockholders without a meeting to such stockholder during the period between such two consecutive annual meetings, or (2) all, and at least two payments (if sent by first-class mail) of dividends or interest on securities during a 12-month period, have been mailed addressed to such stockholder at such stockholder’s address as shown on the records of the Corporation and have been returned undeliverable, the giving of such notice to such stockholder shall not be required. Any action or meeting that shall be taken or held without notice to such stockholder shall have the same force and effect as if such notice had been duly given. If any such stockholder shall deliver to the Corporation a written notice setting forth such stockholder’s then current address, the requirement that notice be given to such stockholder shall be reinstated. In the event that the action taken by the Corporation is such as to require the filing of a certificate with the Secretary of State of Delaware, the certificate need not state that notice was not given to persons to whom notice was not required to be given pursuant to Section 230(b) of the DGCL. The exception in subsection (1) of the first sentence of this paragraph to the requirement that notice be given shall not be applicable to any notice returned as undeliverable if the notice was given by electronic transmission.

 

 

 

 

Section 9.4. Waiver of Notice. Whenever any notice is required to be given under applicable law, the Certificate of Incorporation, or these By Laws, a written waiver of such notice, signed by the person or persons entitled to said notice, or a waiver by electronic transmission by the person entitled to said notice, whether before or after the time stated therein, shall be deemed equivalent to such required notice. All such waivers shall be kept with the books of the Corporation. Attendance at a meeting shall constitute a waiver of notice of such meeting, except where a person attends for the express purpose of objecting to the transaction of any business on the ground that the meeting was not lawfully called or convened.

 

Section 9.5. Meeting Attendance via Remote Communication Equipment.

 

(a) Stockholder Meetings. If authorized by the Board in its sole discretion, and subject to such guidelines and procedures as the Board may adopt, stockholders entitled to vote at such meeting and proxy holders not physically present at a meeting of stockholders may, by means of remote communication:

 

(i) participate in a meeting of stockholders; and

 

(ii) be deemed present in person and vote at a meeting of stockholders, whether such meeting is to be held at a designated place or solely by means of remote communication, provided that (A) the Corporation shall implement reasonable measures to verify that each person deemed present and permitted to vote at the meeting by means of remote communication is a stockholder or proxy holder, (B) the Corporation shall implement reasonable measures to provide such stockholders and proxy holders a reasonable opportunity to participate in the meeting and, if entitled to vote, to vote on matters submitted to the applicable stockholders, including an opportunity to read or hear the proceedings of the meeting substantially concurrently with such proceedings, and (C) if any stockholder or proxy holder votes or takes other action at the meeting by means of remote communication, a record of such votes or other action shall be maintained by the Corporation.

 

(b) Board Meetings. Unless otherwise restricted by applicable law, the Certificate of Incorporation or these By Laws, members of the Board or any committee thereof may participate in a meeting of the Board or any committee thereof by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other. Such participation in a meeting shall constitute presence in person at the meeting, except where a person participates in the meeting for the express purpose of objecting to the transaction of any business on the ground that the meeting was not lawfully called or convened.

 

Section 9.6. Dividends. The Board may from time to time declare, and the Corporation may pay, dividends (payable in cash, property or shares of the Corporation’s capital stock) on the Corporation’s outstanding shares of capital stock, subject to applicable law and the Certificate of Incorporation.

 

Section 9.7. Reserves. The Board may set apart out of the funds of the Corporation available for dividends a reserve or reserves for any proper purpose and may abolish any such reserve.

 

Section 9.8. Contracts and Negotiable Instruments. Except as otherwise provided by applicable law, the Certificate of Incorporation or these By Laws, any contract, bond, deed, lease, mortgage or other instrument may be executed and delivered in the name and on behalf of the Corporation by such officer or officers or other employee or employees of the Corporation as the Board may from time to time authorize. Such authority may be general or confined to specific instances as the Board may determine. The Chairman of the Board, any Chief Executive Officer, the President, the Chief Financial Officer, the Treasurer or any Vice President may execute and deliver any contract, bond, deed, lease, mortgage or other instrument in the name and on behalf of the Corporation. Subject to any restrictions imposed by the Board, the Chairman of the Board , any Chief Executive Officer, President, the Chief Financial Officer, the Treasurer or any Vice President may delegate powers to execute and deliver any contract, bond, deed, lease, mortgage or other instrument in the name and on behalf of the Corporation to other officers or employees of the Corporation under such person’s supervision and authority, it being understood, however, that any such delegation of power shall not relieve such officer of responsibility with respect to the exercise of such delegated power.

 

 

 

 

Section 9.9. Fiscal Year. The fiscal year of the Corporation shall be fixed by the Board.

 

Section 9.10. Seal. The Board may adopt a corporate seal, which shall be in such form as the Board determines. The seal may be used by causing it or a facsimile thereof to be impressed, affixed or otherwise reproduced.

 

Section 9.11. Books and Records. The books and records of the Corporation may be kept within or outside the State of Delaware at such place or places as may from time to time be designated by the Board.

 

Section 9.12. Resignation. Any director, committee member or officer may resign by giving notice thereof in writing or by electronic transmission to the Chairman of the Board, any Chief Executive Officer, the President or the Secretary. The resignation shall take effect at the time it is delivered unless the resignation specifies a later effective date or an effective date determined upon the happening of an event or events. Unless otherwise specified therein, the acceptance of such resignation shall not be necessary to make it effective.

 

Section 9.13. Surety Bonds. Such officers, employees and agents of the Corporation (if any) as the Chairman of the Board, any Chief Executive Officer, President or the Board may direct, from time to time, shall be bonded for the faithful performance of their duties and for the restoration to the Corporation, in case of their death, resignation, retirement, disqualification or removal from office, of all books, papers, vouchers, money and other property of whatever kind in their possession or under their control belonging to the Corporation, in such amounts and by such surety companies as the Chairman of the Board, any Chief Executive Officer, President or the Board may determine. The premiums on such bonds shall be paid by the Corporation and the bonds so furnished shall be in the custody of the Secretary.

 

Section 9.14. Securities of Other Corporations. Powers of attorney, proxies, waivers of notice of meeting, consents in writing and other instruments relating to securities owned by the Corporation may be executed in the name of and on behalf of the Corporation by the Chairman of the Board, any Chief Executive Officer, President, any Vice President or any officers authorized by the Board. Any such officer, may, in the name of and on behalf of the Corporation, take all such action as any such officer may deem advisable to vote in person or by proxy at any meeting of security holders of any corporation in which the Corporation may own securities, or to consent in writing, in the name of the Corporation as such holder, to any action by such corporation, and at any such meeting or with respect to any such consent shall possess and may exercise any and all rights and power incident to the ownership of such securities and which, as the owner thereof, the Corporation might have exercised and possessed. The Board may from time to time confer like powers upon any other person or persons.

 

Section 9.15. Amendments. The Board shall have the power to adopt, amend, alter or repeal the By Laws. The affirmative vote of a majority of the Board shall be required to adopt, amend, alter or repeal the By Laws. The By Laws also may be adopted, amended, altered or repealed by the stockholders; provided, however, that in addition to any vote of the holders of any class or series of capital stock of the Corporation required by applicable law or the Certificate of Incorporation, the affirmative vote of the holders of at least a majority of the voting power (except as otherwise provided in Section 8.7) of all outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required for the stockholders to adopt, amend, alter or repeal the By Laws.

 

 

 

EX-10.2 4 ex10-2.htm

 

Exhibit 10.2

 

FORM OF REGISTRATION RIGHTS AGREEMENT

 

THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of November 7, 2023 (the “Effective Date”) by and among (i) Data Knights Acquisition Corp., a Delaware corporation (including its successors, the “Purchaser”), and (ii) and the undersigned parties listed on Exhibit A hereto (each such party, together with any person or entity who hereafter becomes a party to this Agreement pursuant to Section 6.2 of this Agreement, a “Holder” and collectively the “Holders”).

 

WHEREAS, on April 25, 2022, Purchaser, Data Knights Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Purchaser (“Merger Sub”), Data Knights, LLC, a Delaware limited liability company (the “Purchaser Representative”), Paul Casey (the “Seller Representative”), and (v) OneMedNet Corporation, a Delaware corporation (the “Company”), entered into that certain Agreement and Plan of Merger (as amended from time to time in accordance with the terms thereof, the “Merger Agreement”);

 

WHEREAS, pursuant to the Merger Agreement, subject to the terms and conditions thereof, upon the consummation of the transactions contemplated thereby (the “Closing”), among other matters, Merger Sub will merge with and into the Company, with the Company continuing as the surviving entity and a wholly-owned subsidiary of the Purchaser, and with the Holders, as stockholders of the Purchaser, receiving shares of the Purchaser’s Class A common stock (the “Merger Shares”), all upon the terms and subject to the conditions set forth in the Merger Agreement and in accordance with the provisions of applicable law;

 

WHEREAS, the Company is a party to that certain Investors’ Rights Agreement dated as of December 31, 2009, entered into with certain investors listed therein (the “Company Investors”) holding shares of Company capital stock to be exchanged into shares of Purchaser’s Class A common stock in the Merger (the “Prior Agreement”), and that certain Founders Registration Rights Agreement with the Founders with regard to the Founder Securities (each as such term is defined below) (together with the Prior Agreement, the “Existing Agreements”); and

 

WHEREAS, the parties desire to enter into this Agreement, and terminate the Existing Agreements, to provide the Holders and Founders with certain rights relating to the registration of the Merger Shares and Founder Securities.

 

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

1. DEFINITIONS. The following capitalized terms used herein have the following meanings:

 

Affiliate” means, with respect to any specified Person, any Person that, directly or indirectly through one or more entities, controls or is controlled by, or is under common control with, such specified Person. The term “control” (including the terms “controlled by” and “under common control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by Contract or otherwise.

 

Agreement” means this Agreement, as amended, restated, supplemented, or otherwise modified from time to time.

 

Business Combination” means the acquisition of direct or indirect ownership through a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar type of transaction, of one or more businesses or entities.

 

Commission” means the Securities and Exchange Commission, or any other Federal agency then administering the Securities Act or the Exchange Act.

 

 

 

 

Common Stock” means the Class A common stock, par value $0.000001 per share, of the Purchaser and the Class B common stock, par value $0.000001 per share of the Purchaser, along with any equity securities paid as dividends or distributions after the Closing with respect to such shares or into which such shares are exchanged or converted after the Closing.

 

Company” is defined in the preamble to this Agreement.

 

Demand Registration” is defined in Section 2.2.1.

 

Demanding Holder” is defined in Section 2.2.1.

 

Effectiveness Date means, with respect to the Initial Registration Statement, the 90th calendar day following the Filing Date (or in the event the Registration Statement receives a “full review” by the Commission, the 120th day following the Filing Date) and with respect to any additional Registration Statements which may be required pursuant to Sections 2.2 and 2.3, the 90th calendar day following the date on which an additional Registration Statement is required to be filed hereunder; provided, however, that in the event the Purchaser is notified by the Commission that one or more of the above Registration Statements will not be reviewed or is no longer subject to further review and comments, the Effectiveness Date as to such Registration Statement shall be the fifth Business Day following the date on which the Purchaser is so notified if such date precedes the dates otherwise required above; provided, further, that, if the Effectiveness Date falls on a Saturday, Sunday or any other day which shall be a legal holiday or a day on which the Commission is authorized or required by law or other government actions to close, the Effectiveness Date shall be the following Business Day.

 

Effectiveness Period” shall have the meaning set forth in Section 2.1.1

 

Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission promulgated thereunder, all as the same shall be in effect at the time.

 

Filing Date” means, with respect to the Initial Registration Statement required hereunder, the 30th calendar day following the date hereof and, with respect to any additional Registration Statements which may be required pursuant to Sections 2.2 and 2.3, the earliest practical date on which the Purchaser is permitted by Commission Guidance to file such additional Registration Statement related to the Registrable Securities; provided, however, that, if the Filing Date falls on a Saturday, Sunday or any other day which shall be a legal holiday or a day on which the Commission is authorized or required by law or other government actions to close, the Filing Date shall be the following Business Day.

 

Form S-3” is defined in Section 2.4.

 

Founder Registration Rights Agreement” means that certain Registration Rights Agreement, dated as of May 6, 2021, by and among Purchaser, Data Knights, LLC and certain directors of Purchaser.

 

Founder Securities” means all shares of Common Stock, and all securities convertible into or exercisable for shares of Common Stock, held by the Founders as of the Effective Date of this Agreement.

 

Founders” means Data Knights, LLC, Barry Anderson, Firdauz Edmin Bin Mokhtar, Syed Musheer Ahmed, Julianne Huh and Annie Damit Undikai, and any successors in interest thereto with respect to any Founder Securities.

 

Holder” is defined in the preamble to this Agreement.

 

Indemnified Party” is defined in Section 4.3.

 

Indemnifying Party” is defined in Section 4.3.

 

Initial Registration Statement” means the Registration Statement required to be filed pursuant to Section 2.1.

 

 

 

 

Holder Indemnified Party” is defined in Section 4.1.

 

Maximum Number of Shares” is defined in Section 2.2.4.

 

Merger Shares” means the shares of Common Stock of the Purchaser issued or issuable to the Holders pursuant to the terms of the Merger Agreement.

 

Notices” is defined in Section 6.3.

 

Piggy-Back Registration” is defined in Section 2.3.1.

 

Pro Rata” is defined in Section 2.2.4.

 

Purchaser” is defined in the preamble to this Agreement.

 

Register,” “Registered” and “Registration” mean a registration effected by preparing and filing a registration statement or similar document in compliance with the requirements of the Securities Act, and the applicable rules and regulations promulgated thereunder, and such registration statement becoming effective.

 

Registrable Securities” means (i) the Shares and any shares of Common Stock held by the Holders and Founders immediately following the closing of the Business Combination, and (ii) any warrants, shares of capital stock or other securities of the Purchaser acquired by a Holder or Founder after the Closing, or issued as a dividend or other distribution with respect to or in exchange for or in replacement of such Shares. As to any particular Registrable Securities, such securities shall cease to be Registrable Securities when: (a) a Registration Statement with respect to the sale of such securities shall have become effective under the Securities Act and such securities shall have been sold, transferred, disposed of or exchanged in accordance with such Registration Statement; (b) such securities shall have been otherwise transferred, new certificates for them not bearing a legend restricting further transfer shall have been delivered by the Purchaser and subsequent public distribution of them shall not require registration under the Securities Act; (c) such securities shall have ceased to be outstanding; or (d) the Registrable Securities are freely saleable under Rule 144 without volume limitations.

 

Registration Statement” means a registration statement filed by the Purchaser with the Commission in compliance with the Securities Act and the rules and regulations promulgated thereunder for a public offering and sale of equity securities, or securities or other obligations exercisable or exchangeable for, or convertible into, equity securities (other than a registration statement on Form S-4 or Form S-8, or their successors, or any registration statement covering only securities proposed to be issued in exchange for securities or assets of another entity).

 

Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations of the Commission promulgated thereunder, all as the same shall be in effect at the time.

 

Shares” means the Merger Shares and the Founder Securities.

 

Underwriter” means, solely for the purposes of this Agreement, a securities dealer who purchases any Registrable Securities as principal in an underwritten offering and not as part of such dealer’s market-making activities.

 

 

 

 

2.   REGISTRATION RIGHTS.

 

2.1           Shelf Registration.

 

2.1.1 On or prior to each Filing Date, the Purchaser shall prepare and file with the Commission a Registration Statement covering the resale of all or such maximum portion of the Registrable Securities as permitted by SEC Guidance (provided that, the Purchaser shall use diligent efforts to advocate with the Commission for the registration of all of the Registrable Securities in accordance with the SEC Guidance, including without limitation, the Manual of Publicly Available Telephone Interpretations D.29) that are not then registered on an effective Registration Statement for an offering to be made on a continuous basis pursuant to Rule 415. Each Registration Statement filed hereunder shall be on Form S-1 (except if the Purchaser is then eligible to register for resale the Registrable Securities on Form S-3, such registration shall be on Form S-3 in accordance herewith). Subject to the terms of this Agreement, the Purchaser shall use its commercially reasonable efforts to cause a Registration Statement to be declared effective under the Securities Act as promptly as practicable after the filing thereof, but in any event prior to the applicable Effectiveness Date, and shall use its commercially reasonable efforts to keep such Registration Statement continuously effective under the Securities Act until all Registrable Securities covered by such Registration Statement have been sold, or may be sold without volume or manner-of-sale restrictions pursuant to Rule 144, without the requirement for the Purchaser to be in compliance with the current public information requirement under Rule 144, as determined by the counsel to the Purchaser pursuant to a written opinion letter to such effect, addressed and acceptable to the Transfer Agent and the affected Holders (the “Effectiveness Period”). The Purchaser shall telephonically request effectiveness of a Registration Statement as of 5:00 p.m. New York City time on a Business Day. The Purchaser shall promptly notify the Holders by e-mail of the effectiveness of a Registration Statement on the same Business Day that the Purchaser telephonically confirms effectiveness with the Commission. The Purchaser shall, no later than the second Business Day after the effective date of such Registration Statement, file a final Prospectus with the Commission as required by Rule 424.

 

2.1.2 Notwithstanding any other provision of this Agreement, if any SEC Guidance sets forth a limitation on the number of Registrable Securities permitted to be registered on a particular Registration Statement (and notwithstanding that the Purchaser used diligent efforts to advocate with the Commission for the registration of all or a greater portion of Registrable Securities), the number of Registrable Securities to be registered shall be reduced on a on a pro rata basis based on the total number of Registrable Securities held by such Holders (such proportion is referred to herein as “Pro Rata”). In the event of a reduction hereunder, the Purchaser shall give the Holder and Founders, as applicable, at least five (5) Business Days prior written notice along with the calculations as to such Holder’s or Founder’s allotment. Promptly after such SEC Guidance is no longer applicable with respect to some or all of the remaining unregistered Registrable Securities, the Purchaser shall file an additional Registration Statement in accordance with this Section 2 to with respect to such shares.

 

2.1.3 Each Holder agrees to furnish to the Purchaser a completed Selling Securityholder Questionnaire within five (5) Business Days following the date of this Agreement. Each Holder further acknowledges and agrees that it shall not be entitled to be named as a selling security holder in the Registration Statement or use the Prospectus for offers and resales of Registrable Securities at any time unless such Holder has returned to the Purchaser a completed and signed Selling Securityholder Questionnaire. If a Holder of Registrable Securities returns a Selling Securityholder Questionnaire after the deadline specified in the previous sentence, the Purchaser shall use its commercially reasonable efforts to take such actions as are required to name such Holder as a selling security holder in the Registration Statement or any pre-effective or post-effective amendment thereto and to include (to the extent not theretofore included) in the Registration Statement the Registrable Securities identified in such late Selling Securityholder Questionnaire; provided that the Purchaser shall not be required to file an additional Registration Statement solely for such shares. Each Holder acknowledges and agrees that the information in the Selling Securityholder Questionnaire will be used by the Purchaser in the preparation of the Registration Statement and hereby consents to the inclusion of such information in the Registration Statement.

 

2.2 Demand Registration.

 

2.2.1 Request for Registration. At any time and from time to time on or after the date of this Agreement, the Holders of twenty-five percent (25%) of the Registrable Securities may make a written demand for registration under the Securities Act of all or part of their Registrable Securities, as the case may be (a “Demand Registration”). Any demand for a Demand Registration shall specify the number of shares of Registrable Securities proposed to be sold and the intended method(s) of distribution thereof. The Purchaser will within twenty (20) days of the Purchaser’s receipt of the Demand Registration notify all holders of Registrable Securities of the demand, and each holder of Registrable Securities who wishes to include all or a portion of such holder’s Registrable Securities in the Demand Registration (each such holder including shares of Registrable Securities in such registration, a “Demanding Holder”) shall so notify the Purchaser within ten (10) days after the receipt by the holder of the notice from the Purchaser. Upon any such request, the Demanding Holders shall be entitled to have their Registrable Securities included in the Demand Registration, subject to Section 2.1.4 and the provisos set forth in Section 3.1.1. The Purchaser shall not be obligated to effect no more than an aggregate of three (3) Demand Registrations under this Section 2.1.1 in respect of all Registrable Securities.

 

 

 

 

2.2.2 Effective Registration. A registration will not count as a Demand Registration until the Registration Statement filed with the Commission with respect to such Demand Registration has been declared effective and the Purchaser has complied with all of its obligations under this Agreement with respect thereto; provided, however, that if, after such Registration Statement has been declared effective, the offering of Registrable Securities pursuant to a Demand Registration is interfered with by any stop order or injunction of the Commission or any other governmental agency or court, the Registration Statement with respect to such Demand Registration will be deemed not to have been declared effective, unless and until, (i) such stop order or injunction is removed, rescinded or otherwise terminated, and (ii) a majority-in-interest of the Demanding Holders thereafter elect to continue the offering; provided, further, that the Purchaser shall not be obligated to file a second Registration Statement until a Registration Statement that has been filed is counted as a Demand Registration or is terminated.

 

2.2.3 Underwritten Offering. If a majority-in-interest of the Demanding Holders so elect and such holders so advise the Purchaser as part of their written demand for a Demand Registration, the offering of such Registrable Securities pursuant to such Demand Registration shall be in the form of an underwritten offering; provided that the total offering price is reasonably expected to exceed, in the aggregate, $50 million. In such event, the right of any holder to include its Registrable Securities in such registration shall be conditioned upon such holder’s participation in such underwriting and the inclusion of such holder’s Registrable Securities in the underwriting to the extent provided herein. All Demanding Holders proposing to distribute their Registrable Securities through such underwriting shall enter into an underwriting agreement in customary form with the Underwriter or Underwriters selected for such underwriting by a majority-in-interest of the holders initiating the Demand Registration.

 

2.2.4 Reduction of Offering. If the managing Underwriter or Underwriters for a Demand Registration that is to be an underwritten offering, in good faith, advises the Purchaser and the Demanding Holders in writing that the dollar amount or number of shares of Registrable Securities which the Demanding Holders desire to sell, taken together with all other shares of Common Stock or other securities which the Purchaser desires to sell and the shares of Common Stock, if any, as to which registration has been requested pursuant to written contractual piggy-back registration rights held by other shareholders of the Purchaser who desire to sell, exceeds the maximum dollar amount or maximum number of shares that can be sold in such offering without adversely affecting the proposed offering price, the timing, the distribution method, or the probability of success of such offering (such maximum dollar amount or maximum number of shares, as applicable, the “Maximum Number of Shares” ), then the Purchaser shall include in such registration: (i) first, the Registrable Securities as to which Demand Registration has been requested by the Demanding Holders (Pro Rata in accordance with the number of shares that each such Person has requested be included in such registration, regardless of the number of shares held by each such Person) that can be sold without exceeding the Maximum Number of Shares; (ii) second, to the extent that the Maximum Number of Shares has not been reached under the foregoing clause (i), the Registrable Securities of Holders exercising their rights to register their Registrable Securities that can be sold without exceeding the Maximum Number of Shares; and (iii) third, to the extent that the Maximum Number of Shares has not been reached under the foregoing clauses (i) and (ii), shares of Common Stock or other securities that the Purchaser desires to sell that can be sold without exceeding the Maximum Number of Shares.

 

2.2.5 Withdrawal. If, prior to filing of the applicable “red herring prospectus” or prospectus supplement used for marketing such registration, a majority-in-interest of the Demanding Holders disapprove of the terms of any underwriting or are not entitled to include all of their Registrable Securities in any offering, such majority-in-interest of the Demanding Holders may elect to withdraw from such offering by giving written notice to the Purchaser and the Underwriter or Underwriters of their request to withdraw prior to the effectiveness of the Registration Statement filed with the Commission with respect to such Demand Registration. If the majority-in-interest of the Demanding Holders withdraws from a proposed offering relating to a Demand Registration, then such registration shall not count as a Demand Registration provided for in Section 2.1.

 

 

 

 

2.3 Piggy-Back Registration.

 

2.3.1 Piggy-Back Rights. If at any time on or after the date of this Agreement the Purchaser proposes to file a Registration Statement under the Securities Act with respect to an offering of equity securities, or securities or other obligations exercisable or exchangeable for, or convertible into, equity securities, by the Purchaser for its own account or for shareholders of the Purchaser for their account (or by the Purchaser and by shareholders of the Purchaser including, without limitation, pursuant to Section 2.1), other than a Registration Statement (i) filed in connection with any employee stock option or other benefit plan, (ii) for an exchange offer or offering of securities solely to the Purchaser’s existing shareholders, (iii) for an offering of debt that is convertible into equity securities of the Purchaser or (iv) for a dividend reinvestment plan, then the Purchaser shall (x) give written notice of such proposed filing to the holders of Registrable Securities as soon as practicable but in no event less than twenty (20) days before the anticipated filing date, which notice shall describe the amount and type of securities to be included in such offering, the intended method(s) of distribution, and the name of the proposed managing Underwriter or Underwriters, if any, of the offering, and (y) offer to the holders of Registrable Securities in such notice the opportunity to register the sale of such number of shares of Registrable Securities as such holders may request in writing within ten (10) days following receipt of such notice (a “Piggy-Back Registration” ). The Purchaser shall, in good faith, cause such Registrable Securities to be included in such registration and shall use its best efforts to cause the managing Underwriter or Underwriters of a proposed underwritten offering to permit the Registrable Securities requested to be included in a Piggy-Back Registration on the same terms and conditions as any similar securities of the Purchaser and to permit the sale or other disposition of such Registrable Securities in accordance with the intended method(s) of distribution thereof. All holders of Registrable Securities proposing to distribute their securities through a Piggy-Back Registration that involves an Underwriter or Underwriters shall enter into an underwriting agreement in customary form with the Underwriter or Underwriters selected for such Piggy-Back Registration. Notwithstanding the provisions set forth in the immediately preceding sentences, the right to a Piggy-Back Registration set forth under this Section 2.2.1 with respect to the Registrable Securities shall terminate on the seventh anniversary of the Effective Date.

 

2.3.2 Reduction of Offering. If the managing Underwriter or Underwriters for a Piggy-Back Registration that is to be an underwritten offering advises the Purchaser and the holders of Registrable Securities in writing that the dollar amount or number of shares of Common Stock which the Purchaser desires to sell, taken together with the shares of Common Stock, if any, as to which registration has been demanded pursuant to written contractual arrangements with persons other than the holders of Registrable Securities hereunder, the Registrable Securities as to which registration has been requested under this Section 2.2, and the shares of Common Stock, if any, as to which registration has been requested pursuant to the terms hereof exceeds the Maximum Number of Shares, then the Purchaser shall include in any such registration:

 

a) If the registration is undertaken for the Purchaser’s account: (A) first, the shares of Common Stock or other securities that the Purchaser desires to sell that can be sold without exceeding the Maximum Number of Shares; and (B) second, to the extent that the Maximum Number of Shares has not been reached under the foregoing clause (A), the shares of Common Stock or other securities, if any, comprised of Registrable Securities as to which registration has been requested pursuant to the terms hereof, Pro Rata, that can be sold without exceeding the Maximum Number of Shares; and (C) third, to the extent that the Maximum Number of Shares has not been reached under the foregoing clauses (A) and (B), the shares of Common Stock or other securities for the account of other persons that the Purchaser is obligated to register pursuant to written contractual piggy-back registration rights with such persons and that can be sold without exceeding the Maximum Number of Shares;

 

b) If the registration is a “demand” registration undertaken at the demand of persons other than the holders of Registrable Securities, (A) first, the shares of Common Stock or other securities for the account of the demanding persons that can be sold without exceeding the Maximum Number of Shares; (B) second, to the extent that the Maximum Number of Shares has not been reached under the foregoing clause (A), the shares of Common Stock or other securities comprised of Registrable Securities, Pro Rata, as to which registration has been requested pursuant to the terms hereof, that can be sold without exceeding the Maximum Number of Shares; and (C) third, to the extent that the Maximum Number of Shares has not been reached under the foregoing clauses (A) and (B), the shares of Common Stock or other securities that the Purchaser desires to sell that can be sold without exceeding the Maximum Number of Shares; and (D) fourth, to the extent that the Maximum Number of Shares has not been reached under the foregoing clauses (A), (B) and (C), the shares of Common Stock or other securities for the account of other persons that the Purchaser is obligated to register pursuant to written contractual arrangements with such persons, that can be sold without exceeding the Maximum Number of Shares.

 

 

 

 

2.3.3 Withdrawal. Any holder of Registrable Securities may elect to withdraw such holder’s request for inclusion of Registrable Securities in any Piggy-Back Registration by giving written notice to the Purchaser of such request to withdraw prior to the effectiveness of the Registration Statement. The Purchaser (whether on its own determination or as the result of a withdrawal by persons making a demand pursuant to written contractual obligations) may withdraw a Registration Statement at any time prior to the effectiveness of such Registration Statement. Notwithstanding any such withdrawal, the Purchaser shall pay all expenses incurred by the holders of Registrable Securities in connection with such Piggy-Back Registration as provided in Section 3.3.

 

2.3.4 Unlimited Piggy-Back Registration Rights. For purposes of clarity, any Registration effected pursuant to Section 2.2 hereof shall not be counted as a Registration pursuant to a Demand Registration effected under Section 2.1 hereof. The Holders shall have unlimited Piggy-Back Registration Rights.

 

2.3.5 Registrations on Form S-3. The holders of Registrable Securities may at any time and from time to time, request in writing that the Purchaser register the resale of any or all of such Registrable Securities on Form S-3 or any similar short-form registration which may be available at such time (“Form S-3”); provided, however, that the Purchaser shall not be obligated to effect such request through an underwritten offering. Upon receipt of such written request, the Purchaser will promptly give written notice of the proposed registration to all other holders of Registrable Securities, and, as soon as practicable thereafter, effect the registration of all or such portion of such holder’s or holders’ Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities or other securities of the Purchaser, if any, of any other holder or holders joining in such request as are specified in a written request given within fifteen (15) days after receipt of such written notice from the Purchaser; provided, however, that the Purchaser shall not be obligated to effect any such registration pursuant to this Section 2.3: (i) if Form S-3 is not available for such offering; or (ii) if the holders of the Registrable Securities, together with the holders of any other securities of the Purchaser entitled to inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at any aggregate price to the public of less than $500,000. Registrations effected pursuant to this Section 2.3 shall not be counted as Demand Registrations effected pursuant to Section 2.1.

 

2.4 Block Trades; Other Coordinated Offerings.

 

2.4.1 Notwithstanding any other provision of this Section 2,4, at any time and from time to time when an effective Shelf Registration is on file with the Commission, if a Demanding Holder wishes to engage in (a) an underwritten registered offering (whether firm commitment or otherwise) not involving a “road show” or other substantial marketing efforts prior to pricing (commonly referred to as a “Block Trade”) or (b) an otherwise coordinated “at the market” or similar registered offering through a broker, sales agent or distribution agent, whether as agent or principal (an “Other Coordinated Offering”), in each case, with a total offering price reasonably expected to exceed, in the aggregate, either (x) $10 million or (y) all remaining Registrable Securities held by the Demanding Holder, then such Demanding Holder shall notify the Purchaser of the Block Trade or Other Coordinated Offering at least five (5) business days prior to the day such offering is expected to commence, and the Purchaser shall as expeditiously as possible use its commercially reasonable efforts to facilitate such Block Trade or Other Coordinated Offering; provided that the Demanding Holders representing a majority of the Registrable Securities wishing to engage in the Block Trade or Other Coordinated Offering shall use commercially reasonable efforts to work with the Purchaser and any Underwriters, brokers, sales agents or placement agents prior to making such request in order to facilitate preparation of the registration statement, prospectus and other offering documentation related to the Block Trade or Other Coordinated Offering.

 

2.4.2 The Purchaser may facilitate a Block Trade or Other Coordinated Offering if it determines that sufficient shares shall be traded by any Holder or Holders that would be more efficiently traded as a block trade.

 

2.4.3 Prior to the filing of the applicable “red herring” prospectus or prospectus supplement used in connection with a Block Trade or Other Coordinated Offering, a majority-in-interest of the Demanding Holders initiating such Block Trade or Other Coordinated Offering shall have the right to submit a notice to the Purchaser and the Underwriter(s) if any, of their intention to withdraw from such Block Trade or Other Coordinated Offering. Notwithstanding anything to the contrary in this Agreement, the Purchaser shall be responsible for the Registration Expenses incurred in connection with a block trade prior to its withdrawal under this Section 2.4.3.

 

 

 

 

2.4.4 Notwithstanding anything to the contrary in this Agreement, Section 2.3 shall not apply to a Block Trade or Other Coordinated Offering initiated by a Demanding Holder pursuant to this Section 2.4.

 

2.4.5 The Purchaser shall have the right to select the Underwriters, and brokers, sale agents or placement agents (if any) for such Block Trade or Other Coordinated Offering, in each case, which shall consist of one or more reputable nationally recognized investment bank.

 

2.4.6 A Holder in the aggregate may demand no more than two (2) Block Trades or Other Coordinated Offerings pursuant to this Section 2.4 in any twelve (12) month period.

 

3. REGISTRATION PROCEDURES.

 

3.1          Filings; Information. Whenever the Purchaser is required to effect the registration of any Registrable Securities pursuant to Section 2, the Purchaser shall use its best efforts to effect the registration and sale of such Registrable Securities in accordance with the intended method(s) of distribution thereof as expeditiously as practicable, and in connection with any such request:

 

3.1.1 Filing Registration Statement. The Purchaser shall use its best efforts to, as expeditiously as possible after receipt of a request for a Demand Registration pursuant to Section 2.1, prepare and file with the Commission a Registration Statement on any form for which the Purchaser then qualifies or which counsel for the Purchaser shall deem appropriate and which form shall be available for the sale of all Registrable Securities to be registered thereunder in accordance with the intended method(s) of distribution thereof, and shall use its best efforts to cause such Registration Statement to become effective and use its best efforts to keep it effective for the period required by Section 3.1.3; provided, however, that the Purchaser shall have the right to defer any Demand Registration for up to ninety (90) days, and any Piggy-Back Registration for such period as may be applicable to deferment of any demand registration to which such Piggy-Back Registration relates, in each case if the Purchaser shall furnish to the holders a certificate signed by Chief Executive Officer or Chairman of the Purchaser stating that, in the good faith judgment of the Board of Directors of the Purchaser, it would be materially detrimental to the Purchaser and its shareholders for such Registration Statement to be effected at such time; provided further, however, that the Purchaser shall not have the right to exercise the right set forth in this provision more than once in any 365-day period in respect of a Demand Registration hereunder.

 

3.1.2 Copies. The Purchaser shall, prior to filing a Registration Statement or prospectus, or any amendment or supplement thereto, furnish without charge to the holders of Registrable Securities included in such registration, and such holders’ legal counsel, copies of such Registration Statement as proposed to be filed, each amendment and supplement to such Registration Statement (in each case including all exhibits thereto and documents incorporated by reference therein), the prospectus included in such Registration Statement (including each preliminary prospectus), and such other documents as the holders of Registrable Securities included in such registration or legal counsel for any such holders may request in order to facilitate the disposition of the Registrable Securities owned by such holders.

 

3.1.3 Amendments and Supplements. The Purchaser shall prepare and file with the Commission such amendments, including post-effective amendments, and supplements to such Registration Statement and the prospectus used in connection therewith as may be necessary to keep such Registration Statement effective and in compliance with the provisions of the Securities Act until all Registrable Securities and other securities covered by such Registration Statement have been disposed of in accordance with the intended method(s) of distribution set forth in such Registration Statement or such securities have been withdrawn.

 

 

 

 

3.1.4 Notification. After the filing of a Registration Statement, the Purchaser shall promptly, and in no event more than two (2) business days after such filing, notify the holders of Registrable Securities included in such Registration Statement of such filing, and shall further notify such holders promptly and confirm such advice in writing in all events within two (2) business days of the occurrence of any of the following: (i) when such Registration Statement becomes effective; (ii) when any post-effective amendment to such Registration Statement becomes effective; (iii) the issuance or threatened issuance by the Commission of any stop order (and the Purchaser shall take all actions required to prevent the entry of such stop order or to remove it if entered); and (iv) any request by the Commission for any amendment or supplement to such Registration Statement or any prospectus relating thereto or for additional information or of the occurrence of an event requiring the preparation of a supplement or amendment to such prospectus so that, as thereafter delivered to the purchasers of the securities covered by such Registration Statement, such prospectus will not contain an untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading, and promptly make available to the holders of Registrable Securities included in such Registration Statement any such supplement or amendment; except that before filing with the Commission a Registration Statement or prospectus or any amendment or supplement thereto, including documents incorporated by reference, the Purchaser shall furnish to the holders of Registrable Securities included in such Registration Statement and to the legal counsel for any such holders, copies of all such documents proposed to be filed sufficiently in advance of filing to provide such holders and legal counsel with a reasonable opportunity to review such documents and comment thereon, and the Purchaser shall not file any Registration Statement or prospectus or amendment or supplement thereto, including documents incorporated by reference, to which such holders or their legal counsel shall object.

 

3.1.5 State Securities Laws Compliance. The Purchaser shall use its best efforts to (i) register or qualify the Registrable Securities covered by the Registration Statement under such securities or “blue sky” laws of such jurisdictions in the United States as the holders of Registrable Securities included in such Registration Statement (in light of their intended plan of distribution) may request and (ii) take such action necessary to cause such Registrable Securities covered by the Registration Statement to be registered with or approved by such other governmental authorities as may be necessary by virtue of the business and operations of the Purchaser and do any and all other acts and things that may be necessary or advisable to enable the holders of Registrable Securities included in such Registration Statement to consummate the disposition of such Registrable Securities in such jurisdictions; provided, however, that the Purchaser shall not be required to qualify generally to do business in any jurisdiction where it would not otherwise be required to qualify but for this paragraph or subject itself to taxation in any such jurisdiction.

 

3.1.6 Agreements for Disposition. The Purchaser shall enter into customary agreements (including, if applicable, an underwriting agreement in customary form) and take such other actions as are reasonably required in order to expedite or facilitate the disposition of such Registrable Securities. The representations, warranties and covenants of the Purchaser in any underwriting agreement which are made to or for the benefit of any Underwriters, to the extent applicable, shall also be made to and for the benefit of the holders of Registrable Securities included in such registration statement. No holder of Registrable Securities included in such registration statement shall be required to make any representations or warranties in the underwriting agreement except, if applicable, with respect to such holder’s organization, good standing, authority, title to Registrable Securities, lack of conflict of such sale with such holder’s material agreements and organizational documents, and with respect to written information relating to such holder that such holder has furnished in writing expressly for inclusion in such Registration Statement.

 

3.1.7 Cooperation. The principal executive officer of the Purchaser, the principal financial officer of the Purchaser, the principal accounting officer of the Purchaser and all other officers and members of the management of the Purchaser shall cooperate fully in any offering of Registrable Securities hereunder, which cooperation shall include, without limitation, the preparation of the Registration Statement with respect to such offering and all other offering materials and related documents, and participation in meetings with Underwriters, attorneys, accountants and potential Holders.

 

3.1.8 Records. The Purchaser shall make available for inspection by the holders of Registrable Securities included in such Registration Statement, any Underwriter participating in any disposition pursuant to such registration statement and any attorney, accountant or other professional retained by any holder of Registrable Securities included in such Registration Statement or any Underwriter, all financial and other records, pertinent corporate documents and properties of the Purchaser, as shall be necessary to enable them to exercise their due diligence responsibility, and cause the Purchaser’s officers, directors and employees to supply all information requested by any of them in connection with such Registration Statement.

 

 

 

 

3.1.9 Opinions and Comfort Letters. Upon request, the Purchaser shall furnish to each holder of Registrable Securities included in any Registration Statement a signed counterpart, addressed to such holder, of (i) any opinion of counsel to the Purchaser delivered to any Underwriter and (ii) any comfort letter from the Purchaser’s independent public accountants delivered to any Underwriter. In the event no legal opinion is delivered to any Underwriter, the Purchaser shall furnish to each holder of Registrable Securities included in such Registration Statement, at any time that such holder elects to use a prospectus, an opinion of counsel to the Purchaser to the effect that the Registration Statement containing such prospectus has been declared effective and that no stop order is in effect.

 

3.1.10          Earnings Statement. The Purchaser shall comply with all applicable rules and regulations of the Commission and the Securities Act, and make available to its shareholders, as soon as practicable, an earnings statement covering a period of twelve (12) months, which earnings statement shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 thereunder.

 

3.1.11          Listing. The Purchaser shall use its best efforts to cause all Registrable Securities included in any registration to be listed on such exchanges or otherwise designated for trading in the same manner as similar securities issued by the Purchaser are then listed or designated or, if no such similar securities are then listed or designated, in a manner satisfactory to the holders of a majority of the Registrable Securities included in such registration.

 

3.1.12          Road Show. If the registration involves the registration of Registrable Securities involving gross proceeds in excess of $50,000,000, the Purchaser shall use its reasonable efforts to make available senior executives of the Purchaser to participate in customary “road show” presentations that may be reasonably requested by the Underwriter in any underwritten offering.

 

3.2           Obligation to Suspend Distribution. Upon receipt of any notice from the Purchaser of the happening of any event of the kind described in Section 3.1.4(iv), or, in the case of a resale registration on Form S-3 pursuant to Section 2.3 hereof, upon any suspension by the Purchaser, pursuant to a written insider trading compliance program adopted by the Purchaser’s Board of Directors, of the ability of all “insiders” covered by such program to transact in the Purchaser’s securities because of the existence of material non-public information, each holder of Registrable Securities included in any registration shall immediately discontinue disposition of such Registrable Securities pursuant to the Registration Statement covering such Registrable Securities until such holder receives the supplemented or amended prospectus contemplated by Section 3.1.4(iv) or the restriction on the ability of “insiders” to transact in the Purchaser’s securities is removed, as applicable, and, if so directed by the Purchaser, each such holder will deliver to the Purchaser all copies, other than permanent file copies then in such holder’s possession, of the most recent prospectus covering such Registrable Securities at the time of receipt of such notice.

 

3.3 Registration Expenses. The Purchaser shall bear all costs and expenses incurred in connection with any Demand Registration pursuant to Section 2.2, any Piggy-Back Registration pursuant to Section 2.3, and any registration on Form S-3 effected pursuant to Section 2.4, and all expenses incurred in performing or complying with its other obligations under this Agreement, whether or not the Registration Statement becomes effective, including, without limitation: (i) all registration and filing fees; (ii) fees and expenses of compliance with securities or “blue sky” laws (including fees and disbursements of counsel in connection with blue sky qualifications of the Registrable Securities); (iii) printing expenses; (iv) the fees and expenses incurred in connection with the listing of the Registrable Securities as required by Section 3.1.11; (v) Financial Industry Regulatory Authority fees; (vi) fees and disbursements of counsel for the Purchaser and fees and expenses for independent certified public accountants retained by the Purchaser (including the expenses or costs associated with the delivery of any opinions or comfort letters requested pursuant to Section 3.1.9); and (viii) the reasonable fees and expenses of any special experts retained by the Purchaser in connection with such registration. The Purchaser shall have no obligation to pay (i) any underwriting discounts or selling commissions attributable to the Registrable Securities being sold by the holders thereof, which underwriting discounts or selling commissions shall be borne by such holders, or (ii) the fees and expenses of any legal counsel representing any Holders. Additionally, in an underwritten offering, all selling shareholders and the Purchaser shall bear the expenses of the Underwriter pro rata in proportion to the respective amount of shares each is selling in such offering.

 

 

 

 

3.4 Information. The holders of Registrable Securities shall provide such information as may reasonably be requested by the Purchaser, or the managing Underwriter, if any, in connection with the preparation of any Registration Statement, including amendments and supplements thereto, in order to effect the registration of any Registrable Securities under the Securities Act pursuant to Section 2 and in connection with the Purchaser’s obligation to comply with Federal and applicable state securities laws. In addition, the holders of Registrable Securities shall comply with all prospectus delivery requirements under the Securities Act and applicable SEC regulations.

 

3.5 Legend Removal Obligations. In connection with the written request of any Holder, the Purchaser shall remove any restrictive legend included on the certificates (or, in the case of book-entry shares, any other instrument or record) representing such Holder’s and/or its affiliates’ or permitted transferee’s ownership of Registrable Securities, and promptly issue a certificate (or evidence of the issuance of securities in book-entry form) without such restrictive legend or any other restrictive legend to the holder of the applicable shares of Registrable Securities upon which it is stamped, if (i) such Registrable Securities are registered for resale under the Securities Act and such Registration Statement for such Registrable Securities has not been suspended under the Securities Act, the Exchange Act or the rules and regulations of the Commission promulgated thereunder, (ii) such Registrable Securities are sold or transferred pursuant to Rule 144, or (iii) such Registrable Securities are eligible for sale pursuant to Section 4(a)(1) of the Securities Act or Rule 144 without volume or manner-of-sale restrictions. Following the earlier of (A) the effective date of a Registration Statement registering such Registrable Securities or (B) Rule 144 becoming available for the resale of such Registrable Securities without volume or manner-of-sale restrictions, the Purchaser upon the written request of the Holder or its permitted transferee, shall instruct the Purchaser’s transfer agent to remove the legend from such Registrable Securities (in whatever form) and shall cause the Purchaser’s counsel to issue any legend removal opinion required by the transfer agent. Any reasonable and documented fees (with respect to the transfer agent, the Purchaser’s counsel, or otherwise) associated with the removal of such legend shall be borne by the Purchaser. If a legend is no longer required pursuant to the foregoing, the Purchaser will, as soon as practicable following the delivery by any Holder or its permitted transferee to the Purchaser or the transfer agent (with notice to the Purchaser) of a legended certificate (if applicable) representing such Registrable Securities and, to the extent such sale is not pursuant to an effective registration statement, such other documentation as reasonably requested by the Purchaser, deliver or cause to be delivered to the holder of such Registrable Securities a certificate representing such Registrable Securities (or evidence of the issuance of such Registrable Securities in book-entry form) that is free from all restrictive legends; provided that, notwithstanding the foregoing, the Purchaser will not be required to deliver any opinion, authorization, certificate or direction to remove the restrictive legend pursuant to this Section 3.5 if (x) removal of the legend would result in or facilitate transfer of securities in violation of applicable law or (y) following receipt of instruction from the Purchaser, the transfer agent refuses to remove the legend.

 

4.   INDEMNIFICATION AND CONTRIBUTION.

 

4.1 Indemnification by the Purchaser. The Purchaser agrees to indemnify and hold harmless each Holder and each other holder of Registrable Securities, and each of their respective officers, employees, affiliates, directors, partners, members, attorneys and agents, and each person, if any, who controls an Holder and each other holder of Registrable Securities (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) (each, an “Holder Indemnified Party” ), from and against any expenses, losses, judgments, claims, damages or liabilities, whether joint or several, arising out of or based upon any untrue statement (or allegedly untrue statement) of a material fact contained in any Registration Statement under which the sale of such Registrable Securities was registered under the Securities Act, any preliminary prospectus, final prospectus or summary prospectus contained in the Registration Statement, or any amendment or supplement to such Registration Statement, or arising out of or based upon any omission (or alleged omission) to state a material fact required to be stated therein or necessary to make the statements therein not misleading, or any violation by the Purchaser of the Securities Act or any rule or regulation promulgated thereunder applicable to the Purchaser and relating to action or inaction required of the Purchaser in connection with any such registration; and the Purchaser shall promptly reimburse the Holder Indemnified Party for any legal and any other expenses reasonably incurred by such Holder Indemnified Party in connection with investigating and defending any such expense, loss, judgment, claim, damage, liability or action; provided, however, that the Purchaser will not be liable in any such case to the extent that any such expense, loss, claim, damage or liability arises out of or is based upon any untrue statement or allegedly untrue statement or omission or alleged omission made in such Registration Statement, preliminary prospectus, final prospectus, or summary prospectus, or any such amendment or supplement, in reliance upon and in conformity with information furnished to the Purchaser, in writing, by such selling Holder expressly for use therein. The Purchaser also shall indemnify any Underwriter of the Registrable Securities, their officers, affiliates, directors, partners, members and agents and each person who controls such Underwriter on substantially the same basis as that of the indemnification provided above in this Section 4.1.

 

 

 

 

4.2 Indemnification by Holders of Registrable Securities. Each selling Holder will, in the event that any registration is being effected under the Securities Act pursuant to this Agreement of any Registrable Securities held by such selling Holder, indemnify and hold harmless the Purchaser, each of its directors and officers and each Underwriter (if any), and each other selling Holder and each other person, if any, who controls another selling Holder or such Underwriter within the meaning of the Securities Act, against any losses, claims, judgments, damages or liabilities, whether joint or several, insofar as such losses, claims, judgments, damages or liabilities (or actions in respect thereof) arise out of or are based upon any untrue statement or allegedly untrue statement of a material fact contained in any Registration Statement under which the sale of such Registrable Securities was registered under the Securities Act, any preliminary prospectus, final prospectus or summary prospectus contained in the Registration Statement, or any amendment or supplement to the Registration Statement, or arise out of or are based upon any omission or the alleged omission to state a material fact required to be stated therein or necessary to make the statement therein not misleading, if the statement or omission was made in reliance upon and in conformity with information furnished in writing to the Purchaser by such selling Holder expressly for use therein, and shall reimburse the Purchaser, its directors and officers, and each other selling holder or controlling person for any legal or other expenses reasonably incurred by any of them in connection with investigation or defending any such loss, claim, damage, liability or action. Each selling Holder’s indemnification obligations hereunder shall be several and not joint and shall be limited to the amount of any net proceeds actually received by such selling Holder.

 

4.3 Conduct of Indemnification Proceedings. Promptly after receipt by any person of any notice of any loss, claim, damage or liability or any action in respect of which indemnity may be sought pursuant to Section 4.1 or 4.2, such person (the “Indemnified Party”) shall, if a claim in respect thereof is to be made against any other person for indemnification hereunder, notify such other person (the “Indemnifying Party” ) in writing of the loss, claim, judgment, damage, liability or action; provided, however, that the failure by the Indemnified Party to notify the Indemnifying Party shall not relieve the Indemnifying Party from any liability which the Indemnifying Party may have to such Indemnified Party hereunder, except and solely to the extent the Indemnifying Party is actually prejudiced by such failure. If the Indemnified Party is seeking indemnification with respect to any claim or action brought against the Indemnified Party, then the Indemnifying Party shall be entitled to participate in such claim or action, and, to the extent that it wishes, jointly with all other Indemnifying Parties, to assume control of the defense thereof with counsel satisfactory to the Indemnified Party. After notice from the Indemnifying Party to the Indemnified Party of its election to assume control of the defense of such claim or action, the Indemnifying Party shall not be liable to the Indemnified Party for any legal or other expenses subsequently incurred by the Indemnified Party in connection with the defense thereof other than reasonable costs of investigation; provided, however, that in any action in which both the Indemnified Party and the Indemnifying Party are named as defendants, the Indemnified Party shall have the right to employ separate counsel (but no more than one such separate counsel) to represent the Indemnified Party and its controlling persons who may be subject to liability arising out of any claim in respect of which indemnity may be sought by the Indemnified Party against the Indemnifying Party, with the fees and expenses of such counsel to be paid by such Indemnifying Party if, based upon the written opinion of counsel of such Indemnified Party, representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them. No Indemnifying Party shall, without the prior written consent of the Indemnified Party, consent to entry of judgment or effect any settlement of any claim or pending or threatened proceeding in respect of which the Indemnified Party is or could have been a party and indemnity could have been sought hereunder by such Indemnified Party, unless such judgment or settlement includes an unconditional release of such Indemnified Party from all liability arising out of such claim or proceeding.

 

4.4 Contribution.

 

4.4.1 If the indemnification provided for in the foregoing Sections 4.1, 4.2 and 4.3 is unavailable to any Indemnified Party in respect of any loss, claim, damage, liability or action referred to herein, then each such Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute to the amount paid or payable by such Indemnified Party as a result of such loss, claim, damage, liability or action in such proportion as is appropriate to reflect the relative fault of the Indemnified Parties and the Indemnifying Parties in connection with the actions or omissions which resulted in such loss, claim, damage, liability or action, as well as any other relevant equitable considerations. The relative fault of any Indemnified Party and any Indemnifying Party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by such Indemnified Party or such Indemnifying Party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.

 

 

 

 

4.4.2 The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 4.4 were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in the immediately preceding Section 4.4.1.

 

4.4.3 The amount paid or payable by an Indemnified Party as a result of any loss, claim, damage, liability or action referred to in the immediately preceding paragraph shall be deemed to include, subject to the limitations set forth above, any legal or other expenses incurred by such Indemnified Party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this Section 4.4, no holder of Registrable Securities shall be required to contribute any amount in excess of the dollar amount of the net proceeds (after payment of any underwriting fees, discounts, commissions or taxes) actually received by such holder from the sale of Registrable Securities which gave rise to such contribution obligation. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.

 

4.5 Survival. The indemnification provided for under this Agreement shall remain in full force and effect regardless of any investigation made by or on behalf of the Indemnified Party or any officer, director or controlling person of such Indemnified Party and shall survive the transfer of securities.

 

5.   RULE 144.

 

5.1 Rule 144. The Purchaser covenants that it shall file any reports required to be filed by it under the Securities Act and the Exchange Act and shall take such further action as the holders of Registrable Securities may reasonably request, all to the extent required from time to time to enable such holders to sell Registrable Securities without registration under the Securities Act within the limitation of the exemptions provided by Rule 144 under the Securities Act, as such Rules may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission.

 

6.   MISCELLANEOUS.

 

6.1 Other Registration Rights. The Purchaser represents and warrants that no person, other than the holders of the Registrable Securities, has any right to require the Purchaser to register any shares of the Purchaser’s capital stock for sale or to include shares of the Purchaser’s capital stock in any registration filed by the Purchaser for the sale of shares of capital stock for its own account or for the account of any other person. Further, the Purchaser represents and warrants that this Agreement supersedes any other registration rights agreement or agreement with similar terms and conditions and in the event of a conflict between any such agreement or agreements and this Agreement, the terms of this Agreement shall prevail.

 

6.2 Assignment; No Third Party Beneficiaries. This Agreement and the rights, duties and obligations of the Purchaser hereunder may not be assigned or delegated by the Purchaser in whole or in part. This Agreement and the rights, duties and obligations of the holders of Registrable Securities hereunder may be freely assigned or delegated by such holder of Registrable Securities in conjunction with and to the extent of any transfer of Registrable Securities by any such holder. This Agreement and the provisions hereof shall be binding upon and shall inure to the benefit of each of the parties, to the permitted assigns of the Holders or holder of Registrable Securities or of any assignee of the Holders or holder of Registrable Securities. This Agreement is not intended to confer any rights or benefits on any persons that are not party hereto other than as expressly set forth in Article 4 and this Section 6.2.

 

 

 

 

6.3 Notices. All notices, demands, requests, consents, approvals or other communications (collectively, “Notices” ) required or permitted to be given hereunder or which are given with respect to this Agreement shall be in writing and shall be personally served, delivered by reputable air courier service with charges prepaid, or transmitted by hand delivery, telegram, telex or facsimile, addressed as set forth below, or to such other address as such party shall have specified most recently by written notice. Notice shall be deemed given on the date of service or transmission if personally served or transmitted by telegram, telex or facsimile; provided, that if such service or transmission is not on a business day or is after normal business hours, then such notice shall be deemed given on the next business day. Notice otherwise sent as provided herein shall be deemed given on the next business day following timely delivery of such notice to a reputable air courier service with an order for next-day delivery.

 

To the Purchaser after the Closing:

 

OneMedNet Corporation

6385 Old Shady Oak Road

Suite 250

Eden Prairie, Minnesota 55344

Attn: Paul Casey

Telephone No.: (808) 228-5998

E-mail: paul.casey@onemednet.com

 

with a copy to:

 

Rimôn, P.C.

1990 K Street NW, Suite 420

Washington, D.C. 20006

Attn: Debbie Klis

Telephone: (202) 971-9494

E-mail: debbie.klis@rimonlaw.com

 

To a Holder, to the address set forth below such Holder’s name on Exhibit A hereto.

 

6.4 Severability. This Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect the validity or enforceability of this Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable term or provision, the parties hereto intend that there shall be added as a part of this Agreement a provision as similar in terms to such invalid or unenforceable provision as may be possible that is valid and enforceable.

 

6.5 Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original, and all of which taken together shall constitute one and the same instrument.

 

6.6 Entire Agreement. This Agreement (including all agreements entered into pursuant hereto and all certificates and instruments delivered pursuant hereto and thereto) constitute the entire agreement of the parties with respect to the subject matter hereof and supersede all prior and contemporaneous agreements, representations, understandings, negotiations and discussions between the parties, whether oral or written, including but not limited to the Existing Agreements.

 

6.7 Modifications and Amendments; Termination. No amendment, modification or termination of this Agreement shall be binding upon the Purchaser unless executed in writing by the Purchaser. No amendment, modification or termination of this Agreement shall be binding upon the holders of the Registrable Securities unless executed in writing by the holders of the majority Registrable Securities. This Agreement shall terminate with respect to any Holder on the date that such Holder no longer holds any Registrable Securities. The provisions of Article IV shall survive any termination.

 

6.8 Titles and Headings. Titles and headings of sections of this Agreement are for convenience only and shall not affect the construction of any provision of this Agreement.

 

6.9 Waivers and Extensions. Any party to this Agreement may waive any right, breach or default which such party has the right to waive, provided that such waiver will not be effective against the waiving party unless it is in writing, is signed by such party, and specifically refers to this Agreement. Waivers may be made in advance or after the right waived has arisen or the breach or default waived has occurred. Any waiver may be conditional. No waiver of any breach of any agreement or provision herein contained shall be deemed a waiver of any preceding or succeeding breach thereof nor of any other agreement or provision herein contained. No waiver or extension of time for performance of any obligations or acts shall be deemed a waiver or extension of the time for performance of any other obligations or acts.

 

6.10 Governing Law. This Agreement shall be governed by, interpreted under, and construed in accordance with the internal laws of the State of Delaware applicable to agreements made and to be performed within the State of Delaware, without giving effect to any choice-of-law provisions thereof that would compel the application of the substantive laws of any other jurisdiction.

 

6.11 Waiver of Trial by Jury. Each party hereby irrevocably and unconditionally waives the right to a trial by jury in any action, suit, counterclaim or other proceeding (whether based on contract, tort or otherwise) arising out of, connected with or relating to this Agreement, the transactions contemplated hereby, or the actions of the Holder in the negotiation, administration, performance or enforcement hereof.

 

6.12 Termination of Existing Agreements. The Existing Agreements are hereby terminated in their entirety.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

 

 

 

IN WITNESS WHEREOF, the parties have caused this Registration Rights Agreement to be executed and delivered by their duly authorized representatives as of the date first written above.

 

  PURCHASER:
   
  DATA KNIGHTS ACQUISITION CORP.
   
  By:                                          
  Name:  
  Title:      
   
  HOLDERS:
   
  [_______________________]

 

 

 

 

Exhibit A

 

Schedule of Holders

 

 

 

EX-10.3 5 ex10-3.htm

 

Exhibit 10.3

 

FORM OF LOCK-UP AGREEMENT

 

THIS LOCK-UP AGREEMENT (this “Agreement”) is made and entered into as of the Closing Date (as defined in the Merger Agreement, as defined below) by and between (i) Data Knights Acquisition Corp., a Delaware corporation (including any successor entity thereto, the “Purchaser”), and (ii) _______________ (the “Subject Party”). Any capitalized term used but not defined in this Agreement will have the meaning ascribed to such term in the Merger Agreement.

 

WHEREAS, on April 25, 2022, (i) the Purchaser, (ii) Data Knights Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Purchaser (“Merger Sub), (iii) Data Knights, LLC, a Delaware limited liability company (the “Purchaser Representative”), (iv) Paul Casey (the “Seller Representative”), and (v) OneMedNet Corporation, a Delaware corporation (the “Company”) entered into that certain Agreement and Plan of Merger (as amended from time to time in accordance with the terms thereof, the “Merger Agreement”), pursuant to which the parties thereto intend to effect the merger of Merger Sub with and into the Company, with the Company continuing as the surviving entity (the “Merger”), as a result of which all of the issued and outstanding capital stock of the Company immediately prior to the Effective Time shall be exchanged for the Stockholder Merger Consideration, all upon the terms and subject to the conditions set forth in this Agreement;

 

WHEREAS, pursuant to the Merger Agreement, and in view of the valuable consideration to be received by the Subject Party thereunder, the parties desire to enter into this Agreement, pursuant to which the Purchaser Common Stock received by the Subject Party in the Merger (all such securities, together with any securities paid as dividends or distributions with respect to such securities or into which such securities are exchanged or converted, the Restricted Securities) shall become subject to limitations on disposition as set forth herein.

 

NOW, THEREFORE, in consideration of the premises set forth above, which are incorporated into this Agreement as if fully set forth below, and intending to be legally bound hereby, the parties hereby agree as follows:

 

1. Lock-Up Provisions.

 

(a) The Subject Party hereby agrees not to, during the period commencing from the Closing and ending on the earliest of (x) six (6) months after the date of the Closing and (y) the date after the Closing on which the Purchaser consummates a liquidation, merger, capital stock exchange, reorganization, or other similar transaction with an unaffiliated third party that results in all of the Purchaser’s stockholders having the right to exchange their shares of the Purchaser Common Stock for cash, securities, or other property (the “Lock-Up Period”): (i) lend, offer, pledge, hypothecate, encumber, donate, assign, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Restricted Securities, (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Restricted Securities, or (iii) publicly disclose the intention to do any of the foregoing, whether any such transaction described in clauses (i), (ii), or (iii) above is to be settled by delivery of Restricted Securities or other securities, in cash or otherwise (any of the foregoing described in clauses (i), (ii), or (iii), a “Prohibited Transfer”).

 

(b) The foregoing shall not apply to the transfer of any or all of the Restricted Securities (I) to any Permitted Transferee or (II) pursuant to a court order or settlement agreement related to the distribution of assets in connection with the dissolution of marriage or civil union; provided, however, that in either of cases (I) or (II), it shall be a condition to such transfer that such transfer complies with the Securities Act of 1933, as amended, and other applicable law, and that the transferee executes and delivers to the Purchaser an agreement stating that the transferee is receiving and holding the Restricted Securities subject to the provisions of this Agreement applicable to the Subject Party, and there shall be no further transfer of such Restricted Securities except in accordance with this Agreement. As used in this Agreement, the term “Permitted Transferee” shall mean: (1) the members of the Subject Party’s immediate family (for purposes of this Agreement, “immediate family” shall mean with respect to any natural person, any of the following: such person’s spouse or domestic partner, the siblings of such person and his or her spouse or domestic partner, and the direct descendants and ascendants (including adopted and step children and parents) of such person and his or her spouses or domestic partners and siblings), (2) any trust for the direct or indirect benefit of the Subject Party or the immediate family of the Subject Party, (3) if the Subject Party is a trust, to the trustor or beneficiary of such trust or to the estate of a beneficiary of such trust, (4) in the case of an entity, officers, directors, general partners, limited partners, members, or stockholders of such entity that receive such transfer as a distribution, or related investment funds or vehicles controlled or managed by such persons or their respective affiliates, (5) to any affiliate of the Subject Party, and (6) any transferee whereby there is no change in beneficial ownership. The Subject Party further agrees to execute such agreements as may be reasonably requested by the Purchaser that are consistent with the foregoing or that are necessary to give further effect thereto.

 

 

 

 

(c) If any Prohibited Transfer is made or attempted contrary to the provisions of this Agreement, such purported Prohibited Transfer shall be null and void ab initio, and the Purchaser shall refuse to recognize any such purported transferee of the Restricted Securities as one of its equity holders for any purpose, and shall refuse to record any such purported transfer of the Restricted Securities in the books of the Company. In order to enforce this Section 1, the Purchaser may impose stop-transfer instructions with respect to the Restricted Securities of the Subject Party (and Permitted Transferees and assigns thereof) until the end of the Lock-Up Period.

 

(d) During the Lock-Up Period, each certificate evidencing any Restricted Securities shall be stamped or otherwise imprinted with a legend in substantially the following form, in addition to any other applicable legends:

 

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFER SET FORTH IN A LOCK-UP AGREEMENT, DATED AS OF [●], 2022, BY AND AMONG THE ISSUER OF SUCH SECURITIES (THE “ISSUER”) AND THE ISSUER’S SECURITY HOLDER NAMED THEREIN, AS AMENDED. A COPY OF SUCH LOCK-UP AGREEMENT WILL BE FURNISHED WITHOUT CHARGE BY THE ISSUER TO THE HOLDER HEREOF UPON WRITTEN REQUEST.”

 

(e) For the avoidance of any doubt, the Subject Party shall retain all of its rights as a stockholder of the Purchaser during the Lock-Up Period, including the right to vote any Restricted Securities.

 

(f) The foregoing notwithstanding, to the extent any Subject Party is granted a release or waiver from the restrictions contained in this Section 1 prior to the expiration of the Lock-Up Period, then all Subject Parties shall be automatically granted a release or waiver from the restrictions contained in this Section to the same extent, on substantially the same terms as and on a pro rata basis with, the Subject Party to which such release or waiver is granted.

 

2. Miscellaneous; No Third-Party Beneficiaries.

 

(a) Binding Effect; Assignment. This Agreement and all of the provisions herein shall be binding upon and inure to the benefit of the parties hereto and their respective permitted successors and assigns. This Agreement and all rights and obligations of a party are personal and may not be transferred or delegated at any time. Notwithstanding the foregoing, the Purchaser may freely assign any or all of its rights under this Agreement, in whole or in part, to any successor entity (whether by merger, consolidation, equity sale, asset sale, or otherwise) without obtaining the consent or approval of the Subject Party. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision herein be enforced by, any other person.

 

(b) Third Parties. Nothing contained in this Agreement or in any instrument or document executed by any party in connection with the transactions contemplated hereby shall create any rights in, or be deemed to have been executed for the benefit of, any person or entity that is not a party hereto or thereto or a successor or permitted assign of such a party.

 

2

 

 

(c) Governing Law; Jurisdiction. This Agreement and any dispute or controversy arising out of or relating to this Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to the conflict of law principles thereof. All Actions arising out of or relating to this Agreement shall be heard and determined exclusively in any state or federal court located in Wilmington, Delaware (or in any appellate courts thereof) (the “Specified Courts”). Each party hereto hereby (i) submits to the exclusive jurisdiction of any Specified Court for the purpose of any Action arising out of or relating to this Agreement brought by any party hereto and (ii) irrevocably waives, and agrees not to assert by way of motion, defense, or otherwise, in any such Action, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the Action is brought in an inconvenient forum, that the venue of the Action is improper, or that this Agreement or the transactions contemplated hereby may not be enforced in or by any Specified Court. Each party agrees that a final judgment in any Action shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law. Each party irrevocably consents to the service of the summons and complaint and any other process in any other action or proceeding relating to the transactions contemplated by this Agreement, on behalf of itself, or its property, by personal delivery of copies of such process to such party at the applicable address set forth in Section 2(f). Nothing in this Section shall affect the right of any party to serve legal process in any other manner permitted by applicable law.

 

(d) WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY ACTION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY HERETO (i) CERTIFIES THAT NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF ANY ACTION, SEEK TO ENFORCE THAT FOREGOING WAIVER AND (ii) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION.

 

(e) Interpretation. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in construing or interpreting this Agreement. In this Agreement, unless the context otherwise requires: (i) any pronoun used in this Agreement shall include the corresponding masculine, feminine, or neuter forms, and the singular form of nouns, pronouns, and verbs shall include the plural and vice versa; (ii) “including” (and with correlative meaning “include”) means including without limiting the generality of any description preceding or succeeding such term and shall be deemed in each case to be followed by the words “without limitation”; (iii) the words “herein,” “hereto,” and “hereby” and other words of similar import in this Agreement shall be deemed in each case to refer to this Agreement as a whole and not to any particular section or other subdivision of this Agreement; and (iv) the term “or” means “and/or”. The parties have participated jointly in the negotiation and drafting of this Agreement. Consequently, in the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provision of this Agreement.

 

(f) Notices. All notices, consents, waivers, and other communications hereunder shall be in writing and shall be deemed to have been duly given when delivered (i) in person, (ii) by facsimile or other electronic means, with affirmative confirmation of receipt, (iii) one Business Day after being sent, if sent by reputable, nationally recognized overnight courier service, or (iv) three (3) Business Days after being mailed, if sent by registered or certified mail, pre-paid and return receipt requested, in each case to the applicable party at the following addresses (or at such other address for a party as shall be specified by like notice):

 

3

 

 

If to the Purchaser before the Closing, to: with copies to (which shall not constitute notice):
   
Data Knights Acquisition Corp. Nelson Mullins Riley & Scarborough LLP
Unit G6, Frome Business Park, 101 Constitution Avenue, NW, Suite 900
Manor Road, Frome, BA11 4FN, Washington, D.C. 20001
United Kingdom

Attn: Andrew M. Tucker, Esq.

Tel: +44 203 833 4000 Facsimile No.: (202) 689-2860
Email: barry@dataknightsacuk.com Telephone No.: (202) 689-2987
  Email: andy.tucker@nelsonmullins.com
   
If to the Company (or to the Purchaser after the Closing), to: with copies to (which shall not constitute notice):
   
OneMedNet Corporation  
6385 Old Shady Oak Road Rimôn, P.C.
Suite 250 1990 K Street NW, Suite 420
Eden Prairie, Minnesota 55344 Washington, D.C. 20006
Attn: Paul Casey Attn: Debbie Klis; Debra Vernon
Telephone No.: (808) 228-5998 Telephone: (202) 971-9494; (650) 292-5910
E-mail: paul.casey@onemednet.com E-mail: debbie.klis@rimonlaw.com; debra.vernon@rimonlaw.com

 

If to the Subject Party, to: the address set forth below the Subject Party’s name on the signature page to this Agreement.

 

(g) Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Purchaser and the Subject Party. No failure or delay by a party in exercising any right hereunder shall operate as a waiver thereof. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision.

 

(h) Authorization on Behalf of the Purchaser. The parties acknowledge and agree that notwithstanding anything to the contrary contained in this Agreement, any and all determinations, actions, or other authorizations under this Agreement on behalf of the Purchaser, including enforcing the Purchaser’s rights and remedies under this Agreement, or providing any waivers with respect to the provisions hereof, shall solely be made, taken, and authorized by majority of the disinterested independent directors of the Purchaser’s board of directors. In the event that the Purchaser at any time does not have any disinterested directors, so long as the Subject Party has any remaining obligations under this Agreement, the Purchaser will promptly appoint one in connection with this Agreement. Without limiting the foregoing, in the event that an affiliate of a Subject Party serves as a director, officer, employee, or other authorized agent of the Purchaser or any of its current or future affiliates, neither the Subject Party nor its affiliate shall have authority, express or implied, to act or make any determination on behalf of the Purchaser or any of its current or future affiliates in connection with this Agreement or any dispute or Action with respect hereto.

 

(i) Severability. In case any provision in this Agreement shall be held invalid, illegal, or unenforceable in a jurisdiction, such provision shall be modified or deleted, as to the jurisdiction involved, only to the extent necessary to render the same valid, legal, and enforceable, and the validity, legality, and enforceability of the remaining provisions hereof shall not in any way be affected or impaired thereby nor shall the validity, legality, or enforceability of such provision be affected thereby in any other jurisdiction. Upon such determination that any term or other provision is invalid, illegal, or incapable of being enforced, the parties will substitute for any invalid, illegal, or unenforceable provision a suitable and equitable provision that carries out, so far as may be valid, legal, and enforceable, the intent and purpose of such invalid, illegal, or unenforceable provision.

 

(j) Specific Performance. Each party acknowledges that its obligations under this Agreement are unique, recognizes and affirms that, in the event of a breach of this Agreement, money damages will be inadequate and there will be no adequate remedy at law, and agrees that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. Accordingly, the adversely affected party or parties shall be entitled to an injunction or restraining order to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof, without the requirement to post any bond or other security, this being in addition to any other right or remedy available under this Agreement, at law or in equity.

 

4

 

 

(k) Entire Agreement. This Agreement constitutes the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled; provided, that, for the avoidance of doubt, the foregoing shall not affect the rights and obligations of the parties under the Merger Agreement or any Ancillary Document. Notwithstanding the foregoing, nothing in this Agreement shall limit any of the rights or remedies or any of the obligations of the parties hereto under any other agreement between a Subject Party and the Purchaser or any certificate or instrument delivered in connection with the Purchase, and nothing in any other agreement, certificate, or instrument shall limit any of the rights or remedies or any of the obligations under this Agreement.

 

(l) Further Assurances. From time to time, at another party’s request and without further consideration (but at the requesting party’s reasonable cost and expense), each party shall execute and deliver such additional documents and take all such further action as may be reasonably necessary to consummate the transactions contemplated by this Agreement.

 

(m) Counterparts; Facsimile. This Agreement may also be executed and delivered by facsimile signature or by email in portable document format in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

[Remainder of Page Intentionally Left Blank; Signature Pages Follow]

 

5

 

 

IN WITNESS WHEREOF, the parties have executed this Lock-Up Agreement as of the date first written above.

 

  The Purchaser:
     
  DATA KNIGHTS ACQUISITION CORP.
                  
  By:  
  Name:  
  Title:  

 

{Additional Signatures on the Following Pages}

 

The Subject Party:  
     
The Baba One Irrevocable Trust dated March 26, 2021  
     
By:    
Name: Bradley Overby  
Title: Trustee  

 

Number of Shares and Type of Purchaser Common Stock:  
     
Purchaser Common Stock:    

 

Address for Notice:  
     
Address:    
   
   
Attention:    
Email:    

 

with a copy (which will not constitute notice) to:  
   
   
   
   
Attn:    
Telephone No.:    
Email:    

 

6

 

 

The Subject Party:  
     
The Soph One Irrevocable Trust dated March 26, 2021  
     
By:    
Name: Bradley Overby  
Title: Trustee  

 

Number of Shares and Type of Purchaser Common Stock:  
     
Purchaser Common Stock:    

 

Address for Notice:  
     
Address:    
   
   
Attention:    
Email:    

 

with a copy (which will not constitute notice) to:  
     
   
   
   
Attn:    
Telephone No.:    
Email:    

 

The Subject Party:

 

Jeffrey Yu

     

 

Number of Shares and Type of Purchaser Common Stock:  
     
Purchaser Common Stock:    

 

Address for Notice:  
     
Address:    
   
   
Attention:    
Email:    

 

with a copy (which will not constitute notice) to:  
   
   
   
   
Attn:    
Telephone No.:    
Email:    

 

7

 

 

The Subject Party:  
     
The Revocable Trust of Jerry M. Hiatt dated March 17, 1997, as amended  
     
By:    
Name: Jerry M. Hiatt  
Title: Trustee  

 

Number of Shares and Type of Purchaser Common Stock:  
     
Purchaser Common Stock:    

 

Address for Notice:  
     
Address:    
   
   
Attention:    
Email:    

 

with a copy (which will not constitute notice) to:  
   
   
   
   
Attn:    
Telephone No.:    
Email:    

 

The Subject Party:

 

Paul Casey

   

 

Number of Shares and Type of Purchaser Common Stock:
     
Purchaser Common Stock:    

 

Address for Notice:  
     
Address:    
   
   
Attention:    
Email:    

 

with a copy (which will not constitute notice) to:  
   
   
   
   
Attn:    
Telephone No.:    
Email:    

 

8

 

 

The Subject Party:

 

Thomas Kosasa

   

 

Number of Shares and Type of Purchaser Common Stock:
     
Purchaser Common Stock:    

 

Address for Notice:  
     
Address:    
   
   
Attention:    
Email:    

 

with a copy (which will not constitute notice) to:  
   
   
   
   
Attn:    
Telephone No.:    
Email:    

 

The Subject Party:  
     
The Revocable Trust of Jerry M. Hiatt dated March 17, 1997,  
as amended, as Tenants in Common  
     
By:    
Name: Thomas Kosasa  
Title: Trustee  

 

By:    
Name: Jerry M. Hiatt  
Title: Trustee  

 

Number of Shares and Type of Purchaser Common Stock:
     
Purchaser Common Stock:    

 

Address for Notice:  
     
Address:    
   
   
Attention:    
Email:    

 

with a copy (which will not constitute notice) to:  
   
   
   
   
Attn:    
Telephone No.:    
Email:    

 

9

 

 

The Subject Party:

 

Erkan Akyuz

   

 

Number of Shares and Type of Purchaser Common Stock:
     
Purchaser Common Stock:    

 

Address for Notice:  
     
Address:    
   
   
Attention:    
Email:    

 

with a copy (which will not constitute notice) to:  
   
   
   
   
Attn:    
Telephone No.:    
Email:    

 

The Subject Party:

 

Lisa Embree

   

 

Number of Shares and Type of Purchaser Common Stock:
     
Purchaser Common Stock:    

 

Address for Notice:  
     
Address:    
   
   
Attention:    
Email:    

 

with a copy (which will not constitute notice) to:  
   
   
   
   
Attn:    
Telephone No.:    
Email:    

 

10

 

EX-10.8 6 ex10-8.htm

 

Exhibit 10.8

 

OneMedNet Corporation

 

April 18, 2023

Dear Aaron Green,

 

OneMedNet Corp. (the “Company”) is pleased to offer you employment on the following terms:

 

1. Position. Your title will be President and will have dual reporting to the CEO and the Chairman of the Board. This is a full-time, exempt position. While you render services to the Company, you will not engage in any other employment, consulting or other business activity (whether full-time or part-time) that would create a conflict of interest with the Company. By signing this letter agreement, you confirm to the Company that you have no contractual commitments or other legal obligations that would prohibit you from performing your duties for the Company.

 

2. Cash Compensation. The Company will pay you a starting salary at the rate of $350,000 USD per year, payable in accordance with the Company’s standard payroll schedule and subject to applicable deductions and withholdings. This salary will be subject to periodic review and adjustments at the Company’s discretion.

 

3. Annual Bonus. Beginning in fiscal year 2023, as pro-rated for the amount of the fiscal year that you are employed, you will also be eligible to receive an annual cash performance bonus of $175,000 USD upon the achievement of the perfo1mance goals set by the Company’s CEO and Board of Directors (the “Target Bonus”). The Target Bonus, or any portion thereof, will be paid as soon as practicable after the Company’s CEO and Board of Directors determines that the applicable performance goals have been achieved, provided that you must remain an employee of the Company through the date the Target Bonus is paid out in order to receive the Target Bonus.

 

4. Employee Benefits. As an employee of the Company, you will be eligible to receive certain employee benefits. Refer to benefit plan for further detail. You should note that the Company may modify job titles, salaries and benefits from time to time as it deems necessary.

 

5. Equity. Subject to the approval of the Company’s Board of Directors, you are eligible to receive 600,000 of the company’s outstanding shares at closing, as part of the Company’s Restricted Stock Unit Plan.

 

6. Proprietary Information and Inventions Agreement. Like all Company employees, you will be required, as a condition of your employment with the Company, to sign the Company’s standard Proprietary Information and Inventions Agreement, a copy of which is attached hereto as Exhibit A, requires, among other provisions, the assignment of patent rights to any invention made during your employment at the Company.

 

 

 

 

Aaron Green

Page 2

 

7. Employment Relationship. Employment with the Company is for no specific period of time. Your employment with the Company will be “at will,” meaning that either you or the Company may terminate your employment at any time and for any reason, with or without cause. Any contrary representations that may have been made to you are superseded by this letter agreement. This is the full and complete agreement between you and the Company on this term. Although your job duties, title, compensation and benefits, as well as the Company’s personnel policies and procedures, may change from time to time, the “at will” nature of your employment may only be changed in an express written agreement signed by you and a duly authorized officer of the Company (other than you).

 

8. Termination.

 

a. In the event that your employment with the Company is terminated by the Company without Cause (as defined below)), or is terminated by you for Good Reason (as defined below), after six months of employment, and you sign and do not revoke a standard release of claims with the Company in a form reasonably satisfactory to the Company’s Board of Directors (a “Release”), which Release becomes irrevocable no later than sixty (60) days (the “Release Deadline”) after the date of your termination of employment (the “Termination Date”) you will be entitled to the following severance payment (“Severance”):

 

i. If the Termination Date is after 6 months’ of employment, but before you have completed 12 months’ of employment, you will receive 3 months’ salary;

 

ii. If the Termination Date is after 12 months’ employment you will receive 6 months’ salary.

 

If the Release does not become effective and irrevocable by the Release Deadline, you will forfeit any right to Severance. In no event will Severance be paid or provided hereunder until the Release actually becomes effective and irrevocable.

 

The following terms referred to in this offer letter shall have the following meanings:

 

“Cause” shall mean: (i) your material failure to perform your stated duties, and your continued failure to cure such failure to the reasonable satisfaction of the Company within ten (10) days following written notice of such failure to you from the Company’s Board of Directors; (ii) your material violation of a written Company policy (including any insider trading policy) or any written agreement or covenant with the Company; (iii) your conviction of, or entry of a plea of guilty or nolo contendere to, a felony (other than motor vehicle offenses the effect of which do not materially impair your performance of your employment duties); (iv) a willful act by you that constitutes gross misconduct and which is injurious to the Company; (v) your commission of any act of fraud, embezzlement, dishonesty or any other willful misconduct that has caused or is reasonably expected to result in material injury to the Company; (vi) the unauthorized use or disclosure by you of any proprietary information or trade secrets of the Company or any other party to whom you owe an obligation of nondisclosure as a result of your relationship with the Company; or your willful failure to cooperate with an investigation by a governmental authority.

 

 

 

 

Aaron Green

Page 3

 

“Good Reason” shall mean your voluntary termination, within thirty (30) days following the expiration of any Company cure period (discussed below) following the occurrence of one or more of the following, without your consent: (i) a material reduction of your duties, authority, or responsibilities, relative to your title, duties, authority, or responsibilities as in effect immediately prior to such reduction; provided that your title, duties, authority and responsibilities will not be deemed to be materially reduced if you have reasonably comparable duties, authorities and responsibilities as an employee with respect to the Company’s business following a Change of Control, regardless of any change in title or whether you provide services to a subsidiary, affiliate, business unit, division or otherwise; (ii) a material reduction by the Company of your annual base salary, except to the extent the base salaries of all other senior executives of the Company are similarly reduced; (iii) a material change in the location of the performance of your work, required by the Company, of more than fifty (50) miles from your principal place of residence. You may not resign for Good Reason without first providing the Company with written notice within ninety (90) days of the initial existence of the condition that you believe constitutes Good Reason specifically identifying the acts or omissions constituting the grounds for Good Reason and a reasonable cure period of not less than thirty (30) days following the date of such notice.

 

9. Tax Matters.

 

a. Withholding. All forms of compensation referred to in this letter agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law.

 

b. Tax Advice. You are encouraged to obtain your own tax advice regarding your compensation from the Company. You agree that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or its Board of Directors related to tax liabilities arising from your compensation.

 

10. Interpretation, Amendment and Enforcement. This letter agreement and Exhibit A constitute the complete agreement between you and the Company, contain all of the terms of your employment with the Company and supersede any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. This letter agreement may not be amended or modified, except by an express written agreement signed by both you and a duly authorized officer of the Company. The terms of this letter agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this letter agreement or arising out of, related to, or in any way connected with, this letter agreement, your employment with the Company or any other relationship between you and the Company (the “Disputes”) will be governed by Delaware law, excluding laws relating to conflicts or choice of law. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in Delaware in connection with any Dispute or any claim related to any Dispute.

 

 

 

 

Aaron Green

Page 4

 

11. We also ask that, if you have not already done so, you disclose to the Company any and all agreements relating to your prior employment that may affect your eligibility to be employed by the Company or limit the manner in which you may be employed. It is the Company’s understanding that any such agreements will not prevent you from performing the duties of your position and you represent that such is the case. Moreover, you agree that, during the term of your employment with the Company, you will not engage in any other employment, occupation, consulting or other business activity directly related to the business in which the Company is now involved or becomes involved during the term of your employment, nor will you engage in any other activities that conflict with your obligations to the Company. Similarly, you agree not to bring any third-party confidential information to the Company, including that of your former employer, and that in performing your duties for the Company you will not in any way utilize any such information.

 

12. As a condition of your employment, you are also required to sign and comply with the Company’s standard Employee Non-Disclosure Agreement.

 

We hope that you will accept our offer to join the Company. You may indicate your agreement with these terms and accept this offer by signing and dating both the enclosed duplicate original of this letter agreement and the enclosed Proprietary Information and Inventions Agreement and returning them to me. This offer, if not accepted, will expire at the close of business on April 30, 2023. As required by law, your employment with the Company is contingent upon your providing legal proof of your identity and authorization to work in the United States. Your employment is also contingent upon successful background check and your starting work with the Company on May 23, 2023.

 

If you have any questions, please let me know.

 

Very truly yours,

 

/s/ Paul Casey    
Paul Casey    
Chief Executive Officer    

 

I have read and accept this employment offer:

 

/s/ Aaron Green    
Aaron Green    
Dated: May 7, 2023    

 

Attachment

 

Exhibit A: Proprietary Information and Inventions Agreement

 

 

 

 

Aaron Green

Page 6

 

Exhibit A

 

Proprietary Information and Inventions Agreement

 

 

 

 

Aaron Green

Page 7

 

PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT

 

The following confirms and memorializes an agreement that COMPANY NAME INC, Inc., a Delaware corporation (the “Company”) and I have had since the commencement of my employment (which term, for purposes of this agreement, shall be deemed to include any relationship of service to the Company that I may have had prior to actually becoming an employee) with the Company in any capacity and that is and has been a material part of the consideration for my employment by Company:

 

1. I have not entered into, and I agree I will not enter into, any agreement either written or oral in conflict with this Agreement or my employment with Company. I will not violate any agreement with or rights of any third party or, except as expressly authorized by Company in writing hereafter, use or disclose my own or any third party’s confidential information or intellectual property when acting within the scope of my employment or otherwise on behalf of Company. Further, I have not retained anything containing any confidential information of a prior employer or other third party, whether or not created by me.

 

2. Company shall own all right, title and interest (including patent rights, copyrights, trade secret rights, mask work rights, sui generis database 1ights and all other intellectual property rights of any sort throughout the world) relating to any and all inventions (whether or not patentable), works of authorship, mask works, designs, know-how, ideas and information made or conceived or reduced to practice, in whole or in part, by me during the term of my employment with Company to and only to the fullest extent allowed (which is attached as Appendix A) (collectively “Inventions”) and I will promptly disclose all Inventions to Company. Without disclosing any third party confidential information, I will also disclose anything I believe is excluded so that the Company can make an independent assessment. I hereby make all assignments necessary to accomplish the foregoing. I shall further assist Company, at Company’s expense, to further evidence, record and perfect such assignments, and to perfect, obtain, maintain, enforce, and defend any rights specified to be so owned or assigned. I hereby irrevocably designate and appoint Company as my agent and attorney-in-fact, coupled with an interest and with full power of substitution, to act for and in my behalf to execute and file any document and to do all other lawfully permitted acts to further the purposes of the foregoing with the same legal force and effect as if executed by me. If I wish to clarify that something created by me prior to my employment that relates to Company’s actual or proposed business is not within the scope of the foregoing assignment, I have listed it on Appendix B in a manner that does not violate any third party rights or disclose any confidential information. Without limiting Section 1 or Company’s other rights and remedies, if, when acting within the scope of my employment or otherwise on behalf of Company, I use or (except pursuant to this Section 2) disclose my own or any third party’s confidential information or intellectual property (or if any Invention cannot be fully made, used, reproduced, distributed and otherwise exploited without using or violating the foregoing), Company will have and I hereby grant Company a perpetual, i1Tevocable, worldwide, royalty-free, non-exclusive, sublicensable right and license to exploit and exercise all such confidential information and intellectual property rights.

 

 

 

 

Aaron Green

Page 8

 

3. To the extent allowed by law, paragraph 2 includes all rights of paternity, integrity, disclosure and withdrawal and any other rights that may be known as or referred to as “moral rights,” “artist’s rights,” “droit moral,” or the like (collectively “Moral Rights”). To the extent I retain any such Moral Rights under applicable law, I hereby ratify and consent to any action that may be taken with respect to such Moral Rights by or authorized by Company and agree not to assert any Moral Rights with respect thereto. I will confirm any such ratifications, consents and agreements from time to time as requested by the Company.

 

4. I agree that all Inventions and all other business, technical and financial information (including, without limitation, the identity of and information relating to customers or employees) I develop, learn or obtain during the term of my employment that relate to Company or the business or demonstrably anticipated business of Company or that are received by or for Company in confidence, constitute “Proprietary Information.” I will hold in confidence and not disclose or, except within the scope of my employment, use any Proprietary Information. However, I shall not be obligated under this paragraph with respect to information I can document is or becomes readily publicly available without restriction through no fault of mine. Upon termination of my employment, I will promptly return to Company all items containing or embodying Proprietary Information (including all copies), except that I may keep my personal copies of (i) my compensation records, (ii) materials distributed to shareholders generally and (iii) this Agreement. I also recognize and agree that I have no expectation of privacy with respect to Company’s telecommunications, networking or infom1ation processing systems (including, without limitation, stored computer files, embedded messages and voice messages) and that my activity and any files or messages on or using any of those systems may be monitored at any time without notice.

 

5. Until one year after the term of my employment, I will not encourage or solicit any employee or consultant of Company to leave Company for any reason (except for the bona fide firing of Company personnel within the scope of my employment).

 

6. I agree that during the term of my employment with Company (whether or not during business hours), I will not engage in any activity that is in any way competitive with the business or demonstrably anticipated business of Company, and I will not assist any other person or organization in competing or in preparing to compete with any business or demonstrably anticipated business of Company.

 

7. I agree that this Agreement is not an employment contract for any particular term and that I have the right to resign and the Company has the right to terminate my employment at will, at any time, for any or no reason, with or without cause. In addition, this Agreement does not purport to set forth all of the terms and conditions of my employment, and, as an employee of Company, I have obligations to Company which are not set forth in this Agreement. However, the terms of this Agreement govern over any inconsistent terms and can only be changed by a subsequent written agreement signed by the President of the Company.

 

8. I agree that my obligations under paragraphs 2, 3, 4 and 5 of this Agreement shall continue in effect after termination of my employment, regardless of the reason or reasons for termination, and whether such termination is voluntary or involuntary on my part, and that Company is entitled to communicate my obligations under this Agreement to any future employer or potential employer of mine. My obligations under paragraphs 2, 3 and 4 also shall be binding upon my heirs, executors, assigns, and administrators and shall insure to the benefit of Company, its subsidiaries, successors and assigns.

 

 

 

 

Aaron Green

Page 9

 

9. Any dispute in the meaning, effect or validity of this Agreement shall be resolved in accordance with the laws of the State of Delaware without regard to the conflict of laws provisions thereof. I further agree that if one or more provisions of this Agreement are held to be illegal or unenforceable under applicable law, such illegal or unenforceable portion(s) shall be limited or excluded from this Agreement to the minimum extent required so that this Agreement shall otherwise remain in full force and effect and enforceable in accordance with its te1ms. This Agreement is fully assignable and transferable by Company, but any purported assignment or transfer by me is void. I also understand that any breach of this Agreement will cause irreparable harm to Company for which damages would not be an adequate remedy, and, therefore, Company will be entitled to injunctive relief with respect thereto in addition to any other remedies and without any requirement to post bond.

 

10. I acknowledge receipt of the following notice under 18 U.S.C § 1833(b)(l): “An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.”

 

Remainder of Page Intentionally Left Blank

 

 

 

 

Aaron Green

Page 10

 

I HAVE READ THIS AGREEMENT CAREFULLY AND I UNDERSTAND AND ACCEPT THE OBLIGATIONS WHICH IT IMPOSES UPON ME WITHOUT RESERVATION. NO PROMISES OR REPRESENTATIONS HAVE BEEN MADE TO ME TO INDUCE ME TO SIGN THIS AGREEMENT. I SIGN THIS AGREEMENT VOLUNTARILY AND FREELY, IN DUPLICATE, WITH THE UNDERSTANDING THAT THE COMPANY WILL RETURN ONE COUNTERPART AND THE OTHER COUNTERPART WILL BE RETAINED BYME.

 

Employee

 

/s/ Aaron Green    
Signature    
May 7, 2023    
Aaron Green    

 

Accepted and Agreed to: OneMedNet Corp.    
       
By

/s/ Paul Casey

   
  Paul Casey    

 

 

 

 

Aaron Green

Page 11

 

APPENDIX A

 

Application of provision providing that employee shall assign or offer to assign rights in invention to employer.

 

(a) Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer’s equipment, supplies, facilities, or trade secret information except for those inventions that either:

 

1. Relate at the time of conception or reduction to practice of the invention to the employer’s business, or actual or demonstrably anticipated research or development of the employer; or

 

2. Result from any work performed by the employee for his employer.

 

(b) To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under subdivision (a), the provision is against the public policy of this state and is unenforceable.

 

 

 

 

Aaron Green

Page 12

 

APPENDIX B

 

PRIOR MATTER

 

 

EX-10.9 7 ex10-9.htm

 

Exhibit 10.9

 

OneMedNet Corporation

October 19, 2023

 

Dear Lisa Embree,

 

OneMedNet Corp. (the “Company”) is pleased to offer you employment on the following terms:

 

1. Position. Your title will be Chief Financial Officer, reporting to the CEO. This is a full-time, exempt position. While you render services to the Company, you will not engage in any other employment, consulting or other business activity (whether full-time or part-time) that would create a conflict of interest with the Company. By signing this letter agreement, you confirm to the Company that you have no contractual commitments or other legal obligations that would prohibit you from performing your duties for the Company.

 

2. Cash Compensation. The Company will pay you a starting salary at the rate of $225,000 USO per year, payable in accordance with the Company’s standard payroll schedule and subject to applicable deductions and withholdings. This salary will be subject to periodic review and adjustments at the Company’s discretion.

 

3. Annual Bonus. You will also be eligible to receive an annual cash performance bonus of 25% of your annual salary based on achievement of the performance goals set by the Company’s CEO. The Target Bonus, or any portion thereof, will be paid as soon as practicable after the Company’s CEO and Board of Directors determines that the applicable performance goals have been achieved, provided that you must remain an employee of the Company through the date the Target Bonus is paid out in order to receive the Target Bonus.

 

4. Employee Benefits. As an employee of the Company, you will be eligible to receive certain employee benefits. Refer to benefit plan for further detail. You should note that the Company may modify job titles, salaries and benefits from time to time as it deems necessary.

 

5. Equity. Subject to the approval of the Company’s Board of Directors, you are eligible to receive 260,000 of the company’s outstanding shares at closing, as part of the Company’s Restricted Stock Unit Plan.

 

6. Proprietary Information and Inventions Agreement. Like all Company employees, you will be required, as a condition of your employment with the Company, to sign the Company’s standard Proprietary Information and Inventions Agreement, a copy of which is attached hereto as Exhibit A, requires, among other provisions, the assignment of patent rights to any invention made during your employment at the Company.

 

 
 

 

Lisa Embree

Page 2

 

7. Employment Relationship. Employment with the Company is for no specific period of time. Your employment with the Company will be “at will,” meaning that either you or the Company may terminate your employment at any time and for any reason, with or without cause. Any contrary representations that may have been made to you are superseded by this letter agreement. This is the full and complete agreement between you and the Company on this term. Although your job duties, title, compensation and benefits, as well as the Company’s personnel policies and procedures, may change from time to time, the “at will” nature of your employment may only be changed in an express written agreement signed by you and a duly authorized officer of the Company (other than you).

 

8. Termination.

 

In the event that your employment with the Company is terminated by the Company without Cause (as defined below) or is terminated by you for Good Reason (as defined below). After the date of your termination of employment (the “Termination Date”) you will receive 6 months’ salary as a Severance Payment.

 

If the Release does not become effective and irrevocable by the Release Deadline, you will forfeit any right to Severance. In no event will Severance be paid or provided hereunder until the Release becomes effective and irrevocable.

 

The following terms referred to in this offer letter shall have the following meanings:

 

“Cause” shall mean: (i) your material failure to perform your stated duties, and your continued failure to cure such failure to the reasonable satisfaction of the Company within ten (10) days following written notice of such failure to you from the Company’s Board of Directors; (ii) your material violation of a written Company policy (including any insider trading policy) or any written agreement or covenant with the Company; (iii) your conviction of, or entry of a plea of guilty or nolo contendere to, a felony (other than motor vehicle offenses the effect of which do not materially impair your performance of your employment duties); (iv) a willful act by you that constitutes gross misconduct and which is injurious to the Company; (v) your commission of any act of fraud, embezzlement, dishonesty or any other willful misconduct that has caused or is reasonably expected to result in material injury to the Company; (vi) the unauthorized use or disclosure by you of any proprietary information or trade secrets of the Company or any other party to whom you owe an obligation of nondisclosure as a result of your relationship with the Company; or your willful failure to cooperate with an investigation by a governmental authority.

 

 
 

 

Lisa Embree

Page 3

 

“Good Reason” shall mean your voluntary termination, within thirty (30) days following the expiration of any Company cure period (discussed below) following the occurrence of one or more of the following, without your consent: (i) a material reduction of your duties, authority, or responsibilities, relative to your title, duties, authority, or responsibilities as in effect immediately prior to such reduction; provided that your title, duties, authority and responsibilities will not be deemed to be materially reduced if you have reasonably comparable duties, authorities and responsibilities as an employee with respect to the Company’s business following a Change of Control, regardless of any change in title or whether you provide services to a subsidiary, affiliate, business unit, division or otherwise; (ii) a material reduction by the Company of your annual base salary, except to the extent the base salaries of all other senior executives of the Company are similarly reduced; (iii) a material change in the location of the performance of your work, required by the Company, of more than fifty (50) miles from your principal place of residence. You may not resign for Good Reason without first providing the Company with written notice within ninety (90) days of the initial existence of the condition that you believe constitutes Good Reason specifically identifying the acts or omissions constituting the grounds for Good Reason and a reasonable cure period of not less than thirty (30) days following the date of such notice.

 

9. Tax Matters.

 

a. Withholding. All forms of compensation referred to in this letter agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law.

 

b. Tax Advice. You are encouraged to obtain your own tax advice regarding your compensation from the Company. You agree that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or its Board of Directors related to tax liabilities arising from your compensation.

 

10. Interpretation, Amendment and Enforcement. This letter agreement and Exhibit A constitute the complete agreement between you and the Company, contain all of the terms of your employment with the Company and supersede any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. This letter agreement may not be amended or modified, except by an express written agreement signed by both you and a duly authorized officer of the Company. The terms of this letter agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this letter agreement or arising out of, related to, or in any way connected with, this letter agreement, your employment with the Company or any 0th.er relationship between you and the Company (the “Disputes”) will be governed by Delaware law, excluding laws relating to conflicts or choice of law. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in Delaware in connection with any Dispute or any claim related to any Dispute.

 

 
 

 

Lisa Embree

Page 4

 

11. We also ask that, if you have not already done so, you disclose to the Company any and all agreements relating to your prior employment that may affect your eligibility to be employed by the Company or limit the manner in which you may be employed. It is the Company’s understanding that any such agreement will not prevent you from performing the duties of your position and you represent that such is the case. Moreover, you agree that, during the term of your employment with the Company, you will not engage in any other employment, occupation, consulting or other business activity directly related to the business in which the Company is now involved or becomes involved during the term of your employment, nor will you engage in any other activities that conflict with your obligations to the Company. Similarly, you agree not to bring any third-party confidential information to the Company, including that of your former employer, and that in performing your duties for the Company you will not in any way utilize any such information.

 

12. As a condition of your employment, you are also required to sign and comply with the Company’s standard Employee Non-Disclosure Agreement.

 

We hope that you will accept our offer to join the Company. You may indicate your agreement with these terms and accept this offer by signing and dating both the enclosed duplicate original of this letter agreement and the enclosed Proprietary Information and Inventions Agreement and returning them to me. This offer, if not accepted, will expire at the close of business on October 31, 2023. As required by law, your employment with the Company is contingent upon your providing legal proof of your identity and authorization to work in the United States.

 

If you have any questions, please let me know. Very truly

 

yours,

 

/s/ Paul Casey  
Paul Casey  
Chief Executive Officer  

 

I have read and accept this employment offer:

 

/s/ Lisa Embree  
Lisa Embree  

 

 
 

 

Lisa Embree

Page 5

 

PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT

 

The following confirms and memorializes an agreement that COMPANY NAME INC, Inc., a Delaware corporation (the “Company”) and I have had since the commencement of my employment (which term, for purposes of this agreement, shall be deemed to include any relationship of service to the Company that I may have had prior to actually becoming an employee) with the Company in any capacity and that is and has been a material part of the consideration for my employment by Company:

 

1. I have not entered into, and I agree I will not enter into, any agreement either written or oral in conflict with this Agreement or my employment with Company. I will not violate any agreement with or rights of any third party or, except as expressly authorized by Company in writing hereafter, use or disclose my own or any third party’s confidential information or intellectual property when acting within the scope of my employment or otherwise on behalf of Company. Further, I have not retained anything containing any confidential information of a prior employer or other third party, whether or not created by me.

 

2. Company shall own all right, title and interest (including patent rights, copyrights, trade secret rights, mask work rights, sui generis database rights and all other intellectual property rights of any sort throughout the world) relating to any and all inventions (whether or not patentable), works of authorship, mask works, designs, know-how, ideas and information made or conceived or reduced to practice, in whole or in part, by me during the term of my employment with Company to and only to the fullest extent allowed (which is attached as Appendix A) (collectively “Inventions”) and I will promptly disclose all Inventions to Company. Without disclosing any third party confidential information, I will also disclose anything I believe is excluded so that the Company can make an independent assessment. I hereby make all assignments necessary to accomplish the foregoing. I shall further assist Company, at Company’s expense, to further evidence, record and perfect such assignments, and to perfect, obtain, maintain, enforce, and defend any rights specified to be so owned or assigned. I hereby irrevocably designate and appoint Company as my agent and attorney-in-fact, coupled with an interest and with full power of substitution, to act for and in my behalf to execute and file any document and to do all other lawfully permitted acts to further the purposes of the foregoing with the same legal force and effect as if executed by me. If I wish to clarify that something created by me prior to my employment that relates to Company’s actual or proposed business is not within the scope of the foregoing assignment, I have listed it on Appendix B in a manner that does not violate any third party rights or disclose any confidential information. Without limiting Section 1 or Company’s other rights and remedies, if, when acting within the scope of my employment or otherwise on behalf of Company, I use or (except pursuant to this Section 2) disclose my own or any third party’s confidential information or intellectual property (or if any Invention cannot be fully made, used, reproduced, distributed and otherwise exploited without using or violating the foregoing), Company will have and I hereby grant Company a perpetual, irrevocable, worldwide, royalty-free, non-exclusive, sublicensable right and license to exploit and exercise all such confidential information and intellectual property rights.

 

 
 

 

Lisa Embree

Page 6

 

3. To the extent allowed by law, paragraph 2 includes all rights of paternity, integrity, disclosure and withdrawal and any other rights that may be known as or referred to as “moral rights,” “artist’s rights,” “droit moral,” or the like (collectively “Moral Rights”). To the extent I retain any such Moral Rights under applicable law, I hereby ratify and consent to any action that may be taken with respect to such Moral Rights by or authorized by Company and agree not to assert any Moral Rights with respect thereto. I will confirm any such ratifications, consents and agreements from time to time as requested by the Company.

 

4. I agree that all Inventions and all other business, technical and financial information (including, without limitation, the identity of and information relating to customers or employees) I develop, learn or obtain during the term of my employment that relate to Company or the business or demonstrably anticipated business of Company or that are received by or for Company in confidence, constitute “Proprietary Information.” I will hold in confidence and not disclose or, except within the scope of my employment, use any Proprietary Information. However, I shall not be obligated under this paragraph with respect to information I can document is or becomes readily publicly available without restriction through no fault of mine. Upon termination of my employment, I will promptly return to Company all items containing or embodying Proprietary Information (including all copies), except that I may keep my personal copies of (i) my compensation records, (ii) materials distributed to shareholders generally and (iii) this Agreement. I also recognize and agree that I have no expectation of privacy with respect to Company’s telecommunications, networking or information processing systems (including, without limitation, stored computer files, embedded messages and voice messages) and that my activity and any files or messages on or using any of those systems may be monitored at any time without notice.

 

5. Until one year after the term of my employment, I will not encourage or solicit any employee or consultant of Company to leave Company for any reason (except for the bona fide firing of Company personnel within the scope of my employment).

 

6. I agree that during the term of my employment with Company (whether or not during business hours), I will not engage in any activity that is in any way competitive with the business or demonstrably anticipated business of Company, and I will not assist any other person or organization in competing or in preparing to compete with any business or demonstrably anticipated business of Company.

 

7. I agree that this Agreement is not an employment contract for any particular term and that I have the right to resign a11d the Company has the right to terminate my employment at will, at any time, for any or no reason, with or without cause. In addition, this Agreement does not purport to set forth all of the terms and conditions of my employment, and, as an employee of Company, I have obligations to Company which are not set forth in this Agreement. However, the terms of this Agreement govern over any inconsistent terms and can only be changed by a subsequent written agreement signed by the President of the Company.

 

 
 

 

Lisa Embree

Page 7

 

8. I agree that my obligations under paragraphs 2, 3, 4 and 5 of this Agreement shall continue in effect after termination of my employment, regardless of the reason or reasons for termination, and whether such termination is voluntary or involuntary on my part, and that Company is entitled to communicate my obligations under this Agreement to any future employer or potential employer of mine. My obligations under paragraphs 2, 3 and 4 also shall be binding upon my heirs, executors, assigns, and administrators and shall insure to the benefit of Company, its subsidiaries, successors and assigns.

 

9. Any dispute in the meaning, effect or validity of this Agreement shall be resolved in accordance with the laws of the State of Delaware without regard to the conflict of laws provisions thereof. I further agree that if one or more provisions of this Agreement are held to be illegal or unenforceable under applicable law, such illegal or unenforceable portion(s) shall be limited or excluded from this Agreement to the minimum extent required so that this Agreement shall otherwise remain in full force and effect and enforceable in accordance with its terms. This Agreement is fully assignable and transferable by Company, but any purported assignment or transfer by me is void. I also understand that any breach of this Agreement will cause irreparable harm to Company for which damages would not be an adequate remedy, and, therefore, Company will be entitled to injunctive relief with respect thereto in addition to any other remedies and without any requirement to post bond.

 

10. I acknowledge receipt of the following notice under 18 U.S.C § 1833(b)(l): “An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.”

 

Remainder of Page Intentionally Left Blank

 

 
 

 

Lisa Embree

Page 8

 

I HAVE READ THIS AGREEMENT CAREFULLY AND I UNDERSTAND AND ACCEPT THE OBLIGATIONS WHICH IT IMPOSES UPON ME WITHOUT RESERVATION. NO PROMISES OR REPRESENTATIONS HAVE BEEN MADE TO ME TO INDUCE ME TO SIGN THIS AGREEMENT. I SIGN THIS AGREEMENT VOLUNTARILY AND FREELY, IN DUPLICATE, WITH THE UNDERSTANDING THAT THE COMPANY WILL RETURN ONE COUNTERPART AND THE OTHER COUNTERPART WILL BE RETAINED BY ME.

 

Employee

 

/s/ Lisa Embree  
Lisa Embree  

 

/s/ Paul Casey  
Paul Casey, CEO ONEMEDNET  

 

 
 

 

APPENDIX A

 

Application of provision providing that employee shall assign or offer to assign rights in invention to employer.

 

(a) Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer’s equipment, supplies, facilities, or trade secret information except for those inventions that either:

 

1. Relate at the time of conception or reduction to practice of the invention to the employer’s business, or actual or demonstrably anticipated research or development of the employer; or

 

2. Result from any work performed by the employee for his employer.

 

(b) To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under subdivision (a), the provision is against the public policy of this state and is unenforceable.

 

 

 

EX-10.10 8 ex10-10.htm

 

Exhibit 10.10

 

OneMedNet Corporation

 

March 28, 2022

 

Paul Casey

1010 Wilder Avenue

Apt. 1301

Honolulu, HI 96822

 

Dear Paul,

 

OneMedNet Corp. (the “Company”) is pleased to offer you employment on the following terms:

 

1. Position. Your title will be CEO and you will report to the Board of Directors. This is a full-time, exempt position. While you render services to the Company, you will not engage in any other employment, consulting or other business activity (whether full-time or part- time) that would create a conflict of interest with the Company. By signing this letter agreement, you confirm to the Company that you have no contractual commitments or other legal obligations that would prohibit you from performing your duties for the Company.

 

2. Cash Compensation. The Company will pay you a starting salary at the rate of $144,000 per year, payable in accordance with the Company’s standard payroll schedule and subject to applicable deductions and withholdings. This salary will be subject to periodic review and adjustments at the Company’s discretion.

 

3. Employee Benefits. As an employee of the Company, you will be eligible to receive certain employee benefits. Refer to benefit plan for further detail. You should note that the Company may modify job titles, salaries and benefits from time to time as it deems necessary.

 

4. Equity. You will be awarded 147,000 shares of stock upon the successful fundraising of an amount equal to or greater than $5,000,000. As part of the Company’s Restricted Stock Unit Plan, further equity will be rewarded subject to the approval of the Company’s Board of Directors.

 

5. Proprietary Information and Inventions Agreement. Like all Company employees, you will be required, as a condition of your employment with the Company, to sign the Company’s standard Proprietary Information and Inventions Agreement, a copy of which is attached hereto as Exhibit A, requires, among other provisions, the assignment of patent rights to any invention made during your employment at the Company.

 

6. Employment Relationship. Employment with the Company is for no specific period of time. Your employment with the Company will be “at will,” meaning that either you or the Company may terminate your employment at any time and for any reason, with or without cause. Any contrary representations that may have been made to you are superseded by this letter agreement. This is the full and complete agreement between you and the Company on this term. Although your job duties, title, compensation and benefits, as well as the Company’s personnel policies and procedures, may change from time to time, the “at will” nature of your employment may only be changed in an express written agreement signed by you and a duly authorized officer of the Company (other than you).

 

 

 

 

Paul Casey

Page 2

 

7. Termination.

 

a. In the event that your employment with the Company is terminated by the Company without Cause (as defined below)), or is terminated by you for Good Reason (as defined below), after six months of employment, and you sign and do not revoke a standard release of claims with the Company in a form reasonably satisfactory to the Company’s Board of Directors (a “Release”), which Release becomes irrevocable no later than sixty (60) days (the “Release Deadline”) after the date of your termination of employment (the “Termination Date”) you will be entitled to the following severance payment (“Severance”):

 

i. If the Termination Date is after 6 months’ of employment, but before you have completed 12 months’ of employment, you will receive 3 months’ salary;

 

ii. If the Termination Date is after 12 months’ employment you will receive 6 months’ salary.

 

If the Release does not become effective and irrevocable by the Release Deadline, you will forfeit any right to Severance. In no event will Severance be paid or provided hereunder until the Release actually becomes effective and irrevocable.

 

The following terms referred to in this offer letter shall have the following meanings:

 

Cause” shall mean: (i) your material failure to perform your stated duties, and your continued failure to cure such failure to the reasonable satisfaction of the Company within ten (10) days following written notice of such failure to you from the Company’s Board of Directors; (ii) your material violation of a written Company policy (including any insider trading policy) or any written agreement or covenant with the Company; (iii) your conviction of, or entry of a plea of guilty or nolo contendere to, a felony (other than motor vehicle offenses the effect of which do not materially impair your performance of your employment duties); (iv) a willful act by you that constitutes gross misconduct and which is injurious to the Company; (v) your commission of any act of fraud, embezzlement, dishonesty or any other willful misconduct that has caused or is reasonably expected to result in material injury to the Company; (vi) the unauthorized use or disclosure by you of any proprietary information or trade secrets of the Company or any other party to whom you owe an obligation of nondisclosure as a result of your relationship with the Company; or your willful failure to cooperate with an investigation by a governmental authority.

 

Good Reason” shall mean your voluntary termination, within thirty (30) days following the expiration of any Company cure period (discussed below) following the occurrence of one or more of the following, without your consent: (i) a material reduction of your duties, authority, or responsibilities, relative to your title, duties, authority, or responsibilities as in effect immediately prior to such reduction; provided that your title, duties, authority and responsibilities will not be deemed to be materially reduced if you have reasonably comparable duties, authorities and responsibilities as an employee with respect to the Company’s business following a Change of Control, regardless of any change in title or whether you provide services to a subsidiary, affiliate, business unit, division or otherwise; (ii) a material reduction by the Company of your annual base salary, except to the extent the base salaries of all other senior executives of the Company are similarly reduced; (iii) a material change in the location of the performance of your work, required by the Company, of more than fifty (50) miles from your principal place of residence. You may not resign for Good Reason without first providing the Company with written notice within ninety (90) days of the initial existence of the condition that you believe constitutes Good Reason specifically identifying the acts or omissions constituting the grounds for Good Reason and a reasonable cure period of not less than thirty (30) days following the date of such notice.

 

 

 

 

Paul Casey

Page 3

 

8. Tax Matters.

 

a. Withholding. All forms of compensation referred to in this letter agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law.

 

b. Tax Advice. You are encouraged to obtain your own tax advice regarding your compensation from the Company. You agree that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or its Board of Directors related to tax liabilities arising from your compensation.

 

9. Interpretation, Amendment and Enforcement. This letter agreement and Exhibit A constitute the complete agreement between you and the Company, contain all of the terms of your employment with the Company and supersede any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. This letter agreement may not be amended or modified, except by an express written agreement signed by both you and a duly authorized officer of the Company. The terms of this letter agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this letter agreement or arising out of, related to, or in any way connected with, this letter agreement, your employment with the Company or any other relationship between you and the Company (the “Disputes”) will be governed by Delaware law, excluding laws relating to conflicts or choice of law. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in Delaware in connection with any Dispute or any claim related to any Dispute.

 

10. For purposes of federal immigration law, you will be required to provide to the Company documentary evidence of your identity and eligibility for employment in the United States. Such documentation must be provided to us within three (3) business days of your date of hire, or our employment relationship with you may be terminated.

 

11. We also ask that, if you have not already done so, you disclose to the Company any and all agreements relating to your prior employment that may affect your eligibility to be employed by the Company or limit the manner in which you may be employed. It is the Company’s understanding that any such agreements will not prevent you from performing the duties of your position and you represent that such is the case. Moreover, you agree that, during the term of your employment with the Company, you will not engage in any other employment, occupation, consulting or other business activity directly related to the business in which the Company is now involved or becomes involved during the term of your employment, nor will you engage in any other activities that conflict with your obligations to the Company. Similarly, you agree not to bring any third-party confidential information to the Company, including that of your former employer, and that in performing your duties for the Company you will not in any way utilize any such information.

 

12. As a condition of your employment, you are also required to sign and comply with the Company’s standard Employee Non-Disclosure Agreement.

 

* * * * *

 

 

 

 

Paul Casey

Page 4

 

We hope that you will accept our offer to join the Company. You may indicate your agreement with these terms and accept this offer by signing and dating both the enclosed duplicate original of this letter agreement and the enclosed Proprietary Information and Inventions Agreement and returning them to me.

 

If you have any questions, please let me know.

 

Very truly yours,

 

/s/ Dr. Jeffrey Yu  
Dr. Jeffrey Yu Chairman of the Board  

 

I have read and accept this employment offer:

 

/s/ Paul Casey  
Paul Casey  

 

Dated: 02-Nov-2023  

 

Attachment

 

Exhibit A: Proprietary Information and Inventions Agreement

 

 

 

 

Paul Casey

Page 5

 

Exhibit A

 

Proprietary Information and Inventions Agreement

 

 

 

 

Paul Casey

Page 6

 

PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT

 

The following confirms and memorializes an agreement that COMPANY NAME INC, Inc., a Delaware corporation (the “Company”) and I have had since the commencement of my employment (which term, for purposes of this agreement, shall be deemed to include any relationship of service to the Company that I may have had prior to actually becoming an employee) with the Company in any capacity and that is and has been a material part of the consideration for my employment by Company:

 

1. I have not entered into, and I agree I will not enter into, any agreement either written or oral in conflict with this Agreement or my employment with Company. I will not violate any agreement with or rights of any third party or, except as expressly authorized by Company in writing hereafter, use or disclose my own or any third party’s confidential information or intellectual property when acting within the scope of my employment or otherwise on behalf of Company. Further, I have not retained anything containing any confidential information of a prior employer or other third party, whether or not created by me.

 

2. Company shall own all right, title and interest (including patent rights, copyrights, trade secret rights, mask work rights, sui generis database rights and all other intellectual property rights of any sort throughout the world) relating to any and all inventions (whether or not patentable), works of authorship, mask works, designs, know-how, ideas and information made or conceived or reduced to practice, in whole or in part, by me during the term of my employment with Company to and only to the fullest extent allowed (which is attached as Appendix A) (collectively “Inventions”) and I will promptly disclose all Inventions to Company. Without disclosing any third party confidential information, I will also disclose anything I believe is excluded so that the Company can make an independent assessment. I hereby make all assignments necessary to accomplish the foregoing. I shall further assist Company, at Company’s expense, to further evidence, record and perfect such assignments, and to perfect, obtain, maintain, enforce, and defend any rights specified to be so owned or assigned. I hereby irrevocably designate and appoint Company as my agent and attorney-in-fact, coupled with an interest and with full power of substitution, to act for and in my behalf to execute and file any document and to do all other lawfully permitted acts to further the purposes of the foregoing with the same legal force and effect as if executed by me. If I wish to clarify that something created by me prior to my employment that relates to Company’s actual or proposed business is not within the scope of the foregoing assignment, I have listed it on Appendix B in a manner that does not violate any third party rights or disclose any confidential information. Without limiting Section 1 or Company’s other rights and remedies, if, when acting within the scope of my employment or otherwise on behalf of Company, I use or (except pursuant to this Section 2) disclose my own or any third party’s confidential information or intellectual property (or if any Invention cannot be fully made, used, reproduced, distributed and otherwise exploited without using or violating the foregoing), Company will have and I hereby grant Company a perpetual, irrevocable, worldwide, royalty-free, non-exclusive, sublicensable right and license to exploit and exercise all such confidential information and intellectual property rights.

 

3. To the extent allowed by law, paragraph 2 includes all rights of paternity, integrity, disclosure and withdrawal and any other rights that may be known as or referred to as “moral rights,” “artist’s rights,” “droit moral,” or the like (collectively “Moral Rights”). To the extent I retain any such Moral Rights under applicable law, I hereby ratify and consent to any action that may be taken with respect to such Moral Rights by or authorized by Company and agree not to assert any Moral Rights with respect thereto. I will confirm any such ratifications, consents and agreements from time to time as requested by the Company.

 

 

 

 

Paul Casey

Page 7

 

4. I agree that all Inventions and all other business, technical and financial information (including, without limitation, the identity of and information relating to customers or employees) I develop, learn or obtain during the term of my employment that relate to Company or the business or demonstrably anticipated business of Company or that are received by or for Company in confidence, constitute “Proprietary Information.” I will hold in confidence and not disclose or, except within the scope of my employment, use any Proprietary Information. However, I shall not be obligated under this paragraph with respect to information I can document is or becomes readily publicly available without restriction through no fault of mine. Upon termination of my employment, I will promptly return to Company all items containing or embodying Proprietary Information (including all copies), except that I may keep my personal copies of (i) my compensation records, (ii) materials distributed to shareholders generally and (iii) this Agreement. I also recognize and agree that I have no expectation of privacy with respect to Company’s telecommunications, networking or information processing systems (including, without limitation, stored computer files, embedded messages and voice messages) and that my activity and any files or messages on or using any of those systems may be monitored at any time without notice.

 

5. Until one year after the term of my employment, I will not encourage or solicit any employee or consultant of Company to leave Company for any reason (except for the bona fide firing of Company personnel within the scope of my employment).

 

6. I agree that during the term of my employment with Company (whether or not during business hours), I will not engage in any activity that is in any way competitive with the business or demonstrably anticipated business of Company, and I will not assist any other person or organization in competing or in preparing to compete with any business or demonstrably anticipated business of Company.

 

7. I agree that this Agreement is not an employment contract for any particular term and that I have the right to resign and the Company has the right to terminate my employment at will, at any time, for any or no reason, with or without cause. In addition, this Agreement does not purport to set forth all of the terms and conditions of my employment, and, as an employee of Company, I have obligations to Company which are not set forth in this Agreement. However, the terms of this Agreement govern over any inconsistent terms and can only be changed by a subsequent written agreement signed by the President of the Company.

 

8. I agree that my obligations under paragraphs 2, 3, 4 and 5 of this Agreement shall continue in effect after termination of my employment, regardless of the reason or reasons for termination, and whether such termination is voluntary or involuntary on my part, and that Company is entitled to communicate my obligations under this Agreement to any future employer or potential employer of mine. My obligations under paragraphs 2, 3 and 4 also shall be binding upon my heirs, executors, assigns, and administrators and shall insure to the benefit of Company, its subsidiaries, successors and assigns.

 

 

 

 

Paul Casey

Page 8

 

9. Any dispute in the meaning, effect or validity of this Agreement shall be resolved in accordance with the laws of the State of Delaware without regard to the conflict of laws provisions thereof. I further agree that if one or more provisions of this Agreement are held to be illegal or unenforceable under applicable law, such illegal or unenforceable portion(s) shall be limited or excluded from this Agreement to the minimum extent required so that this Agreement shall otherwise remain in full force and effect and enforceable in accordance with its terms. This Agreement is fully assignable and transferable by Company, but any purported assignment or transfer by me is void. I also understand that any breach of this Agreement will cause irreparable harm to Company for which damages would not be an adequate remedy, and, therefore, Company will be entitled to injunctive relief with respect thereto in addition to any other remedies and without any requirement to post bond.

 

10. I acknowledge receipt of the following notice under 18 U.S.C § 1833(b)(1): “An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.”

 

Remainder of Page Intentionally Left Blank

 

 

 

 

Paul Casey

Page 9

 

I HAVE READ THIS AGREEMENT CAREFULLY AND I UNDERSTAND AND ACCEPT THE OBLIGATIONS WHICH IT IMPOSES UPON ME WITHOUT RESERVATION. NO PROMISES OR REPRESENTATIONS HAVE BEEN MADE TO ME TO INDUCE ME TO SIGN THIS AGREEMENT. I SIGN THIS AGREEMENT VOLUNTARILY AND FREELY, IN DUPLICATE, WITH THE UNDERSTANDING THAT THE COMPANY WILL RETURN ONE COUNTERPART AND THE OTHER COUNTERPART WILL BE RETAINED BY ME.

 

Employee

 

/s/ Paul Casey  
Signature  
   
/s/ Paul Casey  
Paul Casey  

 

Accepted and Agreed to:

 

OneMedNet Corp.

 

By /s/ Dr. Jeffrey Yu  

Dr. Jeffrey Yu  
Chairman of the Board  

 

 

 

 

Paul Casey

Page 10

 

APPENDIX A

 

Application of provision providing that employee shall assign or offer to assign rights in invention to employer.

 

(a) Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer’s equipment, supplies, facilities, or trade secret information except for those inventions that either:

 

1. Relate at the time of conception or reduction to practice of the invention to the employer’s business, or actual or demonstrably anticipated research or development of the employer; or

 

2. Result from any work performed by the employee for his employer.

 

(b) To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under subdivision (a), the provision is against the public policy of this state and is unenforceable.

 

 

 

 

Paul Casey

Page 11

 

APPENDIX B

 

PRIOR MATTER

 

 

EX-10.11 9 ex10-11.htm

 

Exhibit 10.11

 

SECURITIES PURCHASE AGREEMENT

 

This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of this 28th day of June 2023, is by and among Data Knights Acquisition Corp, a Delaware corporation with offices located at Unit G6, Frome Business Park, Manor Road, Frome, United Kingdom, BA11 4FN (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”).

 

RECITALS

 

A. The Company and each Buyer is executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”), and Rule 506(b) of Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission (the “SEC”) under the 1933 Act.

 

B. The Company has authorized a new series of senior secured convertible notes of the Company, in the aggregate original principal amount of $1,595,744.70, substantially in the form attached hereto as Exhibit A (the “Notes”), which Notes shall be convertible into shares of Common Stock (as defined below) (the shares of Common Stock issuable pursuant to the terms of the Notes, including, without limitation, upon conversion, as Pre-Delivery Shares (as defined in the Notes) or otherwise, collectively, the “Conversion Shares”), in accordance with the terms of the Notes. Each Buyer wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated in this Agreement, a Note in the aggregate original principal amount set forth opposite such Buyer’s name in column (2) on the Schedule of Buyers.

 

C. The Company has authorized a new series of Common Stock purchase warrants of the Company, substantially in the form attached hereto as Exhibit B (the “Warrants”), which Warrants shall be exercisable for up to 95,744.70 shares of Common Stock (as defined below) in the aggregate (the shares of Common Stock issuable pursuant to the terms of the Warrants, collectively, the “Warrant Shares”), in accordance with the terms of the Warrants. Each Buyer wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated in this Agreement, the number of Warrants set forth opposite such Buyer’s name in column (3) on the Schedule of Buyers.

 

D. At the Closing, the parties hereto shall execute and deliver a Registration Rights Agreement, in the form attached hereto as Exhibit C (the “Registration Rights Agreement”), pursuant to which the Company has agreed to provide certain registration rights with respect to the Registrable Securities (as defined in the Registration Rights Agreement), under the 1933 Act and the rules and regulations promulgated thereunder, and applicable state securities laws.

 

E. The Notes, the Warrants, the Warrant Shares and the Conversion Shares are collectively referred to herein as the “Securities.”

 

F. The Notes will be secured by a security interest in the existing intellectual property assets of the Company, as evidenced by a security agreement in the form attached hereto as Exhibit D (the “Security Agreement” and the other security documents and agreements entered into in connection with this Agreement, as each may be amended or modified from time to time, collectively, the “Security Documents”), executed by OneMedNet Solutions Corporation, a Delaware corporation and its subsidiary (the “OneMedNet”), which are prospective subsidiaries of the Company upon the closing of the Merger Agreement (as defined below).

 

 

 

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and each Buyer hereby agree as follows:

 

1. PURCHASE AND SALE OF NOTES AND WARRANTS.

 

(a) Purchase of Notes. Subject to the satisfaction (or waiver) of the conditions set forth in Sections 6 and 7 below, the Company shall issue and sell to each Buyer, and each Buyer severally, but not jointly, agrees to purchase from the Company on the applicable Closing Date (as defined below) a Note in the original principal amount as is set forth opposite such Buyer’s name in column (2) on the Schedule of Buyers.

 

(b) Purchase of Warrants. Subject to the satisfaction (or waiver) of the conditions set forth in Sections 6 and 7 below, the Company shall issue and sell to each Buyer, and each Buyer severally, but not jointly, agrees to purchase from the Company on the applicable Closing Date (as defined below) the number of Warrants as is set forth opposite such Buyer’s name in column (3) on the Schedule of Buyers.

 

(c) Closing. Following the execution of this Agreement, the closing and payment (the “Closing”) of the Purchase Price (as defined below) of the Notes and Warrants by the Buyers shall occur at the offices of Rimon P.C., 1990 K. Street, NW, Suite 420, Washington, DC 20006. The date and time of the Closing (the “Closing Date”) shall occur at 10:00 a.m., EST, on the closing date of the Merger Agreement (or such other date, time or place (including remotely) as is mutually agreed to by the Company and each Buyer). As used herein “Business Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed; provided, however, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to “stay at home”, “shelter-in-place”, “non-essential employee” or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are open for use by customers on such day.

 

(d) Purchase Price. The aggregate purchase price for the Notes and Warrants to be purchased by each Buyer (the “Purchase Price”) shall be the amount set forth opposite such Buyer’s name in column (4) on the Schedule of Buyers.

 

(e) Payment. On the Closing Date, (i) each Buyer shall pay its respective Purchase Price to the Company for the Notes and Warrants to be issued and sold to such Buyer at such Closing, by wire transfer of immediately available funds, and (ii) the Company shall deliver to each Buyer (1) a Note in the aggregate original principal amount as is set forth opposite such Buyer’s name in column (2) of the Schedule of Buyers, duly executed on behalf of the Company and registered in the name of such Buyer or its designee and (2) a Warrant in the amount as is set forth opposite such Buyer’s name in column (3) of the Schedule of Buyers, duly executed on behalf of the Company and registered in the name of such Buyer or its designee.

 

2. BUYER’S REPRESENTATIONS AND WARRANTIES.

 

Each Buyer, severally and not jointly, represents and warrants to the Company with respect to only itself that, as of the date hereof and as of the Closing Date:

 

(a) Organization; Authority. Such Buyer, if an entity and thus applicable, is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization with the requisite power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents to which it is a party and otherwise to carry out its obligations hereunder and thereunder.

 

2

 

 

(b) No Public Sale or Distribution. Such Buyer (i) is acquiring its Note and its Warrant, and (ii) upon conversion of its Note will acquire the Conversion Shares, and upon exercise of its Warrant will acquire the Warrant Shares, in each case, for its own account and not with a view towards, or for resale in connection with, the public sale or distribution thereof in violation of applicable securities laws, except pursuant to sales registered or exempted under the 1933 Act; provided, however, by making the representations herein, such Buyer does not agree, or make any representation or warranty, to hold any of the Securities for any minimum or other specific term and reserves the right to dispose of the Securities at any time in accordance with or pursuant to a registration statement or an exemption from registration under the 1933 Act. Such Buyer does not presently have any agreement or understanding, directly or indirectly, with any Person to distribute any of the Securities in violation of applicable securities laws. For purposes of this Agreement, “Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and any Governmental Entity or any department or agency thereof.

 

(c) Accredited Investor Status. Such Buyer is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D.

 

(d) Reliance on Exemptions. Such Buyer understands that the Securities are being offered and sold to it in reliance on specific exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying in part upon the truth and accuracy of, and such Buyer’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of such Buyer set forth herein in order to determine the availability of such exemptions and the eligibility of such Buyer to acquire the Securities.

 

(e) Information. Such Buyer and its advisors, if any, have been furnished with all materials relating to the business, finances and operations of the Company and its Subsidiaries and potential Subsidiaries and materials relating to the offer and sale of the Securities that have been requested by such Buyer and its Subsidiaries and potential Subsidiaries. Such Buyer and its advisors, if any, have been afforded the opportunity to ask questions of the Company and its Subsidiaries and potential Subsidiaries. Neither such inquiries nor any other due diligence investigations conducted by such Buyer or its advisors, if any, or its representatives shall modify, amend or affect such Buyer’s right to rely on the Company’s representations and warranties contained herein. Such Buyer understands that its investment in the Securities involves a high degree of risk. Such Buyer has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect to its acquisition of the Securities.

 

(f) No Governmental Review. Such Buyer understands that no United States federal or state agency or any other government or governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

 

3

 

 

(g) Transfer or Resale. Such Buyer understands that except as provided in the Registration Rights Agreement: (i) the Securities have not been and are not being registered under the 1933 Act or any state securities laws, and may not be offered for sale, sold, assigned or transferred unless (A) subsequently registered thereunder, (B) such Buyer shall have delivered to the Company (if requested by the Company) an opinion of counsel, in a form reasonably acceptable to the Company, to the effect that such Securities to be sold, assigned or transferred may be sold, assigned or transferred pursuant to an exemption from such registration, or (C) such Buyer provides the Company with reasonable assurance that such Securities can be sold, assigned or transferred pursuant to Rule 144 or Rule 144A promulgated under the 1933 Act (or a successor rule thereto) (collectively, “Rule 144”); (ii) any sale of the Securities made in reliance on Rule 144 may be made only in accordance with the terms of Rule 144, and further, if Rule 144 is not applicable, any resale of the Securities under circumstances in which the seller (or the Person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the 1933 Act) may require compliance with some other exemption under the 1933 Act or the rules and regulations of the SEC promulgated thereunder; and (iii) neither the Company nor any other Person is under any obligation to register the Securities under the 1933 Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder. Notwithstanding the foregoing, the Securities may be pledged in connection with a bona fide margin account or other loan or financing arrangement secured by the Securities and such pledge of Securities shall not be deemed to be a transfer, sale or assignment of the Securities hereunder, and no Buyer effecting a pledge of Securities shall be required to provide the Company with any notice thereof or otherwise make any delivery to the Company pursuant to this Agreement or any other Transaction Document (as defined in Section 3(b)), including, without limitation, this Section 2(g).

 

(h) Validity; Enforcement. This Agreement and the Registration Rights Agreement have been duly and validly authorized, executed and delivered on behalf of such Buyer and shall constitute the legal, valid and binding obligations of such Buyer enforceable against such Buyer in accordance with their respective terms, except as such enforceability may be limited by general principles of equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies.

 

(i) No Conflicts. The execution, delivery and performance by such Buyer of this Agreement and the Registration Rights Agreement and the consummation by such Buyer of the transactions contemplated hereby and thereby will not, where applicable, (i) result in a violation of the organizational documents of such Buyer, or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which such Buyer is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to such Buyer, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which could not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of such Buyer to perform its obligations hereunder.

 

3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

 

The Company represents and warrants to each of the Buyers that, as of the date hereof and as of the Closing Date:

 

(a) Organization and Qualification. The Company is an entity duly organized and validly existing and in good standing under the laws of the jurisdiction in which it is formed, and has the requisite power and authority to own its properties and to carry on its business as now being conducted and as presently proposed to be conducted. The Company is duly qualified as a foreign entity to do business and is in good standing in every jurisdiction in which its ownership of property or the nature of the business conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified or be in good standing would not reasonably be expected to have a Material Adverse Effect (as defined below). As used in this Agreement, “Material Adverse Effect” means any material adverse effect on (i) the business, properties, assets, liabilities, operations (including results thereof), condition (financial or otherwise) or prospects of the Company or any Subsidiary, individually or taken as a whole, (ii) the transactions contemplated hereby or in any of the other Transaction Documents or any other agreements or instruments to be entered into in connection herewith or therewith or (iii) the authority or ability of the Company or any of its Subsidiaries to perform any of their respective obligations under any of the Transaction Documents.

 

4

 

 

(b) Authorization; Enforcement; Validity. The Company has the requisite power and authority to enter into and perform its obligations under this Agreement and the other Transaction Documents and to issue the Securities in accordance with the terms hereof and thereof. Each Subsidiary has the requisite power and authority to enter into and perform its obligations under the Transaction Documents to which it is a party. The execution and delivery of this Agreement and the other Transaction Documents by the Company and its Subsidiaries, and the consummation by the Company and its Subsidiaries of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Notes and Warrants, respectively, and the reservation for the Conversion Shares issuable upon conversion of the Notes and the Warrant Shares issuable upon exercise of the Warrants, respectively) have been duly authorized by the Company’s board of directors and each of its Subsidiaries’ board of directors or other governing body, as applicable, and (other than the filing with the SEC of one or more Registration Statements in accordance with the requirements of the Registration Rights Agreement, a Form D with the SEC and any other filings as may be required by any state securities agencies) no further filing, consent or authorization is required by the Company, its Subsidiaries, their respective boards of directors or their stockholders or other governing body. This Agreement has been, and the other Transaction Documents to which it is a party will be prior to the Closing, duly executed and delivered by the Company, and each constitutes the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with its respective terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies and except as rights to indemnification and to contribution may be limited by federal or state securities law. Prior to the Closing, the Transaction Documents to which each Subsidiary is a party will be duly executed and delivered by each such Subsidiary, and shall constitute the legal, valid and binding obligations of each such Subsidiary, enforceable against each such Subsidiary in accordance with their respective terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies and except as rights to indemnification and to contribution may be limited by federal or state securities law. “Transaction Documents” means, collectively, this Agreement, the Notes, the Warrants, the Registration Rights Agreement, and the Guaranty, and each of the other agreements and instruments entered into or delivered by any of the parties hereto in connection with the transactions contemplated hereby and thereby, as may be amended from time to time.

 

(c) Issuance of Securities. The issuance of the Notes and Warrants are duly authorized and upon issuance in accordance with the terms of the Transaction Documents shall be validly issued, fully paid and non-assessable and free from all preemptive or similar rights, mortgages, defects, claims, liens, pledges, charges, taxes, rights of first refusal, encumbrances, security interests and other encumbrances (collectively “Liens”) with respect to the issuance thereof. As of the Closing, the Company shall have reserved from its duly authorized capital stock not less than 200% of the maximum number of Conversion Shares issuable upon conversion of the Notes (assuming for purposes hereof that (x) the Notes are convertible at the Alternate Conversion Price (as defined in the Notes) assuming an Alternate Conversion Date (as defined in the Note) as of the date hereof, (y) interest on the Notes shall accrue through the first anniversary of the Closing Date and will be converted in shares of Common Stock at a conversion price equal to the Alternate Conversion Price assuming an Alternate Conversion Date as of the date hereof and (z) any such conversion shall not take into account any limitations on the conversion of the Notes set forth in the Notes) and Warrant Shares issuable upon exercise of the Warrants (assuming for purposes hereof that any such exercise shall not take into account any limitations on the exercise of the Warrants set forth in the Warrants). Upon issuance or conversion in accordance with the Notes, the Conversion Shares, when issued, will be validly issued, fully paid and nonassessable and free from all preemptive or similar rights or Liens with respect to the issue thereof, with the holders being entitled to all rights accorded to a holder of Common Stock. Upon exercise in accordance with the Warrants, the Warrant Shares, when issued, will be validly issued, fully paid and nonassessable and free from all preemptive or similar rights or Liens with respect to the issue thereof, with the holders being entitled to all rights accorded to a holder of Common Stock. Subject to the accuracy of the representations and warranties of the Buyers in this Agreement, the offer and issuance by the Company of the Securities is exempt from registration under the 1933 Act.

 

5

 

 

(d) No Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and its Subsidiaries and the consummation by the Company and its Subsidiaries of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Notes and the Conversion Shares, the issuance of the Warrants and the Warrant Shares, and the reservation for issuance of the Conversion Shares and Warrant Shares, will not (i) result in a violation of the Certificate of Incorporation (as defined below) (including, without limitation, any certificate of designation contained therein), Bylaws (as defined below), certificate of formation, memorandum of association, articles of association, bylaws or other organizational documents of the Company or any of its Subsidiaries, or any capital stock or other securities of the Company or any of its Subsidiaries, (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) in any respect under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any of its Subsidiaries is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including, without limitation, foreign, federal and state securities laws and regulations and the rules and regulations of the Nasdaq Capital Market (the “Principal Market”) and including all applicable foreign, federal and state laws, rules and regulations) applicable to the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound or affected.

 

(e) Consents. Neither the Company nor any Subsidiary is required to obtain any consent from, authorization or order of, or make any filing or registration with (other than the filing with the SEC of one or more Registration Statements in accordance with the requirements of the Registration Rights Agreement, a Form D with the SEC and any other filings as may be required by any state securities agencies), any Governmental Entity (as defined below) or any regulatory or self-regulatory agency or any other Person in order for it to execute, deliver or perform any of its respective obligations under or contemplated by the Transaction Documents, in each case, in accordance with the terms hereof or thereof. All consents, authorizations, orders, filings and registrations which the Company or any Subsidiary is required to obtain pursuant to the preceding sentence have been or will be obtained or effected on or prior to the Closing Date, and neither the Company nor any of its Subsidiaries are aware of any facts or circumstances which might prevent the Company or any of its Subsidiaries from obtaining or effecting any of the registration, application or filings contemplated by the Transaction Documents. The Company is not in violation of the requirements of the Principal Market and has no knowledge of any facts or circumstances which could reasonably lead to delisting or suspension of the Common Stock in the foreseeable future.

 

(f) Acknowledgment Regarding Buyer’s Purchase of Securities. The Company acknowledges and agrees that each Buyer is acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby and that no Buyer is (i) an officer or director of the Company or any of its Subsidiaries, (ii) an “affiliate” (as defined in Rule 144) of the Company or any of its Subsidiaries or (iii) to its knowledge, a “beneficial owner” of more than 10% of the shares of Common Stock (as defined for purposes of Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the “1934 Act”)). The Company further acknowledges that no Buyer is acting as a financial advisor or fiduciary of the Company or any of its Subsidiaries (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated hereby and thereby, and any advice given by a Buyer or any of its representatives or agents in connection with the Transaction Documents and the transactions contemplated hereby and thereby is merely incidental to such Buyer’s purchase of the Securities. The Company further represents to each Buyer that the Company’s and each Subsidiary’s decision to enter into the Transaction Documents to which it is a party has been based solely on the independent evaluation by the Company, each Subsidiary and their respective representatives.

 

6

 

 

(g) No General Solicitation; Placement Agent’s Fees. Neither the Company, nor any of its Subsidiaries or affiliates, nor any Person acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with the offer or sale of the Securities. The Company shall be responsible for the payment of any placement agent’s fees, financial advisory fees, or brokers’ commissions (other than for Persons engaged by any Buyer or its investment advisor) relating to or arising out of the transactions contemplated hereby. The Company shall pay, and hold each Buyer harmless against, any liability, loss or expense (including, without limitation, attorney’s fees and out-of-pocket expenses) arising in connection with any such claim. The Company acknowledges that neither the Company nor any of its Subsidiaries has engaged any placement agent or other agent in connection with the offer or sale of the Securities.

 

(h) No Integrated Offering. None of the Company, its Subsidiaries or any of their affiliates, nor any Person acting on their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would require registration of the issuance of any of the Securities under the 1933 Act, whether through integration with prior offerings or otherwise, or cause this offering of the Securities to require approval of stockholders of the Company for purposes of the 1933 Act or under any applicable stockholder approval provisions, including, without limitation, under the rules and regulations of any exchange or automated quotation system on which any of the securities of the Company are listed or designated for quotation. None of the Company, its Subsidiaries, their affiliates nor any Person acting on their behalf will take any action or steps that would require registration of the issuance of any of the Securities under the 1933 Act or cause the offering of any of the Securities to be integrated with other offerings of securities of the Company.

 

(i) Dilutive Effect. The Company understands and acknowledges that the number of Conversion Shares and Warrant Shares will increase in certain circumstances. The Company further acknowledges that its obligation to issue the Conversion Shares pursuant to the terms of the Notes and its obligation to issue the Warrant Shares pursuant to the terms of the Warrants in accordance with this Agreement is, in each case, absolute and unconditional regardless of the dilutive effect that such issuance may have on the ownership interests of other stockholders of the Company.

 

(j) Application of Takeover Protections; Rights Agreement. The Company and its board of directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition, interested stockholder, business combination, poison pill (including, without limitation, any distribution under a rights agreement), stockholder rights plan or other similar anti-takeover provision under the Certificate of Incorporation, Bylaws or other organizational documents or the laws of the jurisdiction of its incorporation or otherwise which is or could become applicable to any Buyer as a result of the transactions contemplated by this Agreement, including, without limitation, the Company’s issuance of the Securities and any Buyer’s ownership of the Securities. The Company and its board of directors have taken all necessary action, if any, in order to render inapplicable any stockholder rights plan or similar arrangement relating to accumulations of beneficial ownership of shares of Common Stock or a change in control of the Company or any of its Subsidiaries.

 

7

 

 

(k) SEC Documents; Financial Statements. During the twelve (12) months prior to the date hereof, the Company has timely filed all reports, schedules, forms, proxy statements, statements and other documents pursuant to the reporting requirements of the 1934 Act (all of the foregoing filed prior to the date hereof and all exhibits and appendices included therein and financial statements, notes and schedules thereto and documents incorporated by reference therein being hereinafter referred to as the “SEC Documents”). The Company has delivered or has made available to the Buyers or their respective representatives true, correct and complete copies of each of the SEC Documents not available on the EDGAR system. As of their respective dates, the SEC Documents complied in all material respects with the requirements of the 1934 Act and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents, and none of the SEC Documents, at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. As of their respective dates, the financial statements of the Company included in the SEC Documents complied in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto as in effect as of the time of filing. Such financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”), consistently applied, during the periods involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto, or (ii) in the case of unaudited interim statements, to the extent they may exclude footnotes or may be condensed or summary statements) and fairly present in all material respects the financial position of the Company as of the dates thereof and the results of its operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments which will not be material, either individually or in the aggregate). No information provided by or on behalf of the Company to any of the Buyers which is not included in the SEC Documents contains any untrue statement of a material fact or omits to state any material fact necessary in order to make the statements therein not misleading, in the light of the circumstance under which they are or were made. The Company is not currently contemplating to amend or restate any of the financial statements (including, without limitation, any notes or any letter of the independent accountants of the Company with respect thereto) included in the SEC Documents (the “Financial Statements”), nor is the Company currently aware of facts or circumstances which would require the Company to amend or restate any of the Financial Statements, in each case, in order for any of the Financials Statements to be in compliance with GAAP and the rules and regulations of the SEC. The Company has not been informed by its independent accountants that they recommend that the Company amend or restate any of the Financial Statements or that there is any need for the Company to amend or restate any of the Financial Statements.

 

(l) Absence of Certain Changes. Since the date of the Company’s most recent audited financial statements contained in a Form 10-K, there has been no material adverse change and no material adverse development in the business, assets, liabilities, properties, operations (including results thereof), condition (financial or otherwise) or prospects of the Company or any of its Subsidiaries. Since the date of the Company’s most recent audited financial statements contained in a Form 10-K, neither the Company nor any of its Subsidiaries has (i) declared or paid any dividends, (ii) sold any assets, individually or in the aggregate, outside of the ordinary course of business or (iii) made any capital expenditures, individually or in the aggregate, outside of the ordinary course of business. Neither the Company nor any of its Subsidiaries has taken any steps to seek protection pursuant to any law or statute relating to bankruptcy, insolvency, reorganization, receivership, liquidation or winding up, nor does the Company or any Subsidiary have any knowledge or reason to believe that any of their respective creditors intend to initiate involuntary bankruptcy proceedings or any actual knowledge of any fact which would reasonably lead a creditor to do so. The Company and its Subsidiaries, individually and on a consolidated basis, are not as of the date hereof, and after giving effect to the transactions contemplated hereby to occur at the Closing, will not be Insolvent which means, (i) with respect to the Company and its Subsidiaries, on a consolidated basis, (A) the present fair saleable value of the Company’s and its Subsidiaries’ assets is less than the amount required to pay the Company’s and its Subsidiaries’ total Indebtedness (as defined below), (B) the Company and its Subsidiaries are unable to pay their debts and liabilities, subordinated, contingent or otherwise, as such debts and liabilities become absolute and matured or (C) the Company and its Subsidiaries intend to incur or believe that they will incur debts that would be beyond their ability to pay as such debts mature; and (ii) with respect to the Company and each Subsidiary, individually, (A) the present fair saleable value of the Company’s or such Subsidiary’s (as the case may be) assets is less than the amount required to pay its respective total Indebtedness, (B) the Company or such Subsidiary (as the case may be) is unable to pay its respective debts and liabilities, subordinated, contingent or otherwise, as such debts and liabilities become absolute and matured or (C) the Company or such Subsidiary (as the case may be) intends to incur or believes that it will incur debts that would be beyond its respective ability to pay as such debts mature.

 

8

 

 

(m) No Undisclosed Events, Liabilities, Developments or Circumstances. No event, liability, development or circumstance has occurred or exists, or is reasonably expected to exist or occur with respect to the Company, any of its Subsidiaries or any of their respective businesses, properties, liabilities, prospects, operations (including results thereof) or condition (financial or otherwise), that (i) would be required to be disclosed by the Company under applicable securities laws on a registration statement on Form S-1 filed with the SEC relating to an issuance and sale by the Company of its Common Stock and which has not been publicly announced, (ii) could have a material adverse effect on any Buyer’s investment hereunder or (iii) could have a Material Adverse Effect.

 

(n) Conduct of Business; Regulatory Permits. Neither the Company nor any of its Subsidiaries is in violation of any term of or in default under its Certificate of Incorporation, any certificate of designation, preferences or rights of any other outstanding series of preferred stock of the Company or any of its Subsidiaries or Bylaws or their organizational charter, certificate of formation, memorandum of association, articles of association, Certificate of Incorporation or certificate of incorporation or bylaws, respectively. Neither the Company nor any of its Subsidiaries is in violation of any judgment, decree or order or any statute, ordinance, rule or regulation applicable to the Company or any of its Subsidiaries, and neither the Company nor any of its Subsidiaries will conduct its business in violation of any of the foregoing, except in all cases for possible violations which could not, individually or in the aggregate, have a Material Adverse Effect. Without limiting the generality of the foregoing, the Company is not in violation of any of the rules, regulations or requirements of the Principal Market and has no knowledge of any facts or circumstances that could reasonably lead to delisting or suspension of the Common Stock by the Principal Market in the foreseeable future. As applicable, during the two years prior to the date hereof, (i) the Common Stock has been listed or designated for quotation on the Principal Market, (ii) trading in the Common Stock has not been suspended by the SEC or the Principal Market and (iii) the Company has received no communication, written or oral, from the SEC or the Principal Market regarding the suspension or delisting of the Common Stock from the Principal Market. The Company and each of its Subsidiaries possess all certificates, authorizations and permits issued by the appropriate regulatory authorities necessary to conduct their respective businesses, except where the failure to possess such certificates, authorizations or permits would not have, individually or in the aggregate, a Material Adverse Effect, and neither the Company nor any such Subsidiary has received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit. There is no agreement, commitment, judgment, injunction, order or decree binding upon the Company or any of its Subsidiaries or to which the Company or any of its Subsidiaries is a party which has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of the Company or any of its Subsidiaries, any acquisition of property by the Company or any of its Subsidiaries or the conduct of business by the Company or any of its Subsidiaries as currently conducted other than such effects, individually or in the aggregate, which have not had and would not reasonably be expected to have a Material Adverse Effect on the Company or any of its Subsidiaries.

 

(o) Foreign Corrupt Practices. Neither the Company, the Company’s subsidiary or any director, officer, agent, employee, nor any other person acting for or on behalf of the foregoing (individually and collectively, a “Company Affiliate”) have violated the U.S. Foreign Corrupt Practices Act (the “FCPA”) or any other applicable anti-bribery or anti-corruption laws, nor has any Company Affiliate offered, paid, promised to pay, or authorized the payment of any money, or offered, given, promised to give, or authorized the giving of anything of value, to any officer, employee or any other person acting in an official capacity for any Governmental Entity to any political party or official thereof or to any candidate for political office (individually and collectively, a “Government Official”) or to any person under circumstances where such Company Affiliate knew or was aware of a high probability that all or a portion of such money or thing of value would be offered, given or promised, directly or indirectly, to any Government Official, for the purpose of:

 

(i) (A) influencing any act or decision of such Government Official in his/her official capacity, (B) inducing such Government Official to do or omit to do any act in violation of his/her lawful duty, (C) securing any improper advantage, or (D) inducing such Government Official to influence or affect any act or decision of any Governmental Entity, or

 

9

 

 

(ii) assisting the Company or its Subsidiaries in obtaining or retaining business for or with, or directing business to, the Company or its Subsidiaries.

 

(p) Sarbanes-Oxley Act. The Company and each Subsidiary is in compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002, as amended, and any and all applicable rules and regulations promulgated by the SEC thereunder.

 

(q) Equity Capitalization.

 

(i) Definitions:

 

(A) “Common Stock” means (x) the Company’s shares of Class A common stock, $0.0001 par value per share, and (y) any capital stock into which such common stock shall have been changed or any share capital resulting from a reclassification of such common stock.

 

(B) “Preferred Stock” means (x) the Company’s blank check preferred stock, $0.0001 par value per share, the terms of which may be designated by the board of directors of the Company in a certificate of designations and (y) any capital stock into which such preferred stock shall have been changed or any share capital resulting from a reclassification of such preferred stock (other than a conversion of such preferred stock into Common Stock in accordance with the terms of such certificate of designations).

 

(ii) Authorized and Outstanding Capital Stock. As of the date hereof, the authorized capital stock of the Company consists of (A) 100,000,000 shares of Common Stock, of which, 3,316,819 shares of Class A Common Stock and 4,253,517 shares of Class B Common Stock are issued and outstanding and 1,908,080 shares are reserved for issuance pursuant to Convertible Securities exercisable or exchangeable for, or convertible into, shares of Common Stock and (B) 1,000,000 shares of Preferred Stock, none of which are issued and outstanding. “Convertible Securities” means any capital stock or other security of the Company or any of its Subsidiaries that is directly or indirectly convertible into, exercisable or exchangeable for, or which otherwise entitles the holder thereof to acquire, any capital stock or other security of the Company (including, without limitation, Common Stock) or any of its Subsidiaries.

 

(iii) Valid Issuance. All of such outstanding shares are duly authorized and have been, or upon issuance will be, validly issued and are fully paid and nonassessable.

 

10

 

 

(iv) Existing Securities; Obligations. Except as disclosed in the SEC Documents: (A) none of the Company’s or any Subsidiary’s shares, interests or capital stock is subject to preemptive rights or any other similar rights or Liens suffered or permitted by the Company or any Subsidiary; (B) there are no outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into, or exercisable or exchangeable for, any shares, interests or capital stock of the Company or any of its Subsidiaries, or contracts, commitments, understandings or arrangements by which the Company or any of its Subsidiaries is or may become bound to issue additional shares, interests or capital stock of the Company or any of its Subsidiaries or options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into, or exercisable or exchangeable for, any shares, interests or capital stock of the Company or any of its Subsidiaries; (C) there are no agreements or arrangements under which the Company or any of its Subsidiaries is obligated to register the sale of any of their securities under the 1933 Act (except pursuant to the Registration Rights Agreement); (D) there are no outstanding securities or instruments of the Company or any of its Subsidiaries which contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any of its Subsidiaries is or may become bound to redeem a security of the Company or any of its Subsidiaries; (E) there are no securities or instruments containing anti-dilution or similar provisions that will be triggered by the issuance of the Securities; and (F) neither the Company nor any Subsidiary has any stock appreciation rights or “phantom stock” plans or agreements or any similar plan or agreement.

 

(v) Organizational Documents. The Company has furnished to the Buyers true, correct and complete copies of the Company’s Certificate of Incorporation, as amended and as in effect on the date hereof (the “Certificate of Incorporation”), and the Company’s bylaws, as amended and as in effect on the date hereof (the “Bylaws”), and the terms of all Convertible Securities and the material rights of the holders thereof in respect thereto.

 

(r) Indebtedness and Other Contracts. Neither the Company nor any of its Subsidiaries, (i) is a party to any contract, agreement or instrument, the violation of which, or default under which, by the other party(ies) to such contract, agreement or instrument could reasonably be expected to result in a Material Adverse Effect, (ii) has any financing statements securing obligations in any amounts filed in connection with the Company or any of its Subsidiaries; (iii) is in violation of any term of, or in default under, any contract, agreement or instrument relating to any Indebtedness, except where such violations and defaults would not result, individually or in the aggregate, in a Material Adverse Effect, or (iv) is a party to any contract, agreement or instrument relating to any Indebtedness, the performance of which, in the judgment of the Company’s officers, has or is expected to have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries have any liabilities or obligations required to be disclosed in the SEC Documents which are not so disclosed in the SEC Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries’ respective businesses and which, individually or in the aggregate, do not or could not have a Material Adverse Effect. For purposes of this Agreement: (x) “Indebtedness” of any Person means, without duplication all indebtedness for borrowed money.

 

(s) Litigation. There is no action, suit, arbitration, proceeding, inquiry or investigation before or by the Principal Market, any court, public board, other Governmental Entity, self-regulatory organization or body pending or, to the knowledge of the Company, threatened against or affecting the Company or any of its Subsidiaries, the Common Stock or any of the Company’s or its Subsidiaries’ officers or directors, whether of a civil or criminal nature or otherwise, in their capacities as such. No director, officer or employee of the Company or any of its subsidiaries has willfully violated 18 U.S.C. §1519 or engaged in spoliation in reasonable anticipation of litigation. Without limitation of the foregoing, there has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the SEC involving the Company, any of its Subsidiaries or any current or former director or officer of the Company or any of its Subsidiaries. The SEC has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company under the 1933 Act or the 1934 Act. After reasonable inquiry of its employees, the Company is not aware of any fact which might result in or form the basis for any such action, suit, arbitration, investigation, inquiry or other proceeding. Neither the Company nor any of its Subsidiaries is subject to any order, writ, judgment, injunction, decree, determination or award of any Governmental Entity.

 

11

 

 

(t) Insurance. The Company and each of its Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company and its Subsidiaries are engaged. Neither the Company nor any such Subsidiary has been refused any insurance coverage sought or applied for, and neither the Company nor any such Subsidiary has any reason to believe that it will be unable to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not have a Material Adverse Effect.

 

(u) Employee Relations. Neither the Company nor any of its Subsidiaries is a party to any collective bargaining agreement or employs any member of a union. The Company and its Subsidiaries believe that their relations with their employees are good. No executive officer (as defined in Rule 501(f) promulgated under the 1933 Act) or other key employee of the Company or any of its Subsidiaries has notified the Company or any such Subsidiary that such officer intends to leave the Company or any such Subsidiary or otherwise terminate such officer’s employment with the Company or any such Subsidiary. No current (or former) executive officer or other key employee of the Company or any of its Subsidiaries is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement, non-competition agreement, or any other contract or agreement or any restrictive covenant, and the continued employment of each such executive officer or other key employee (as the case may be) does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all federal, state, local and foreign laws and regulations respecting labor, employment and employment practices and benefits, terms and conditions of employment and wages and hours, except where failure to be in compliance would not, either individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.

 

(v) Title.

 

(i) Real Property. Each of the Company and its Subsidiaries holds good title to all real property, leases in real property, facilities or other interests in real property owned or held by the Company or any of its Subsidiaries (the “Real Property”) owned by the Company or any of its Subsidiaries (as applicable). The Real Property is free and clear of all Liens and is not subject to any rights of way, building use restrictions, exceptions, variances, reservations, or limitations of any nature except for (a) Liens for current taxes not yet due and (b) zoning laws and other land use restrictions that do not impair the present or anticipated use of the property subject thereto. Any Real Property held under lease by the Company or any of its Subsidiaries are held by them under valid, subsisting and enforceable leases with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company or any of its Subsidiaries.

 

(ii) Fixtures and Equipment. Each of the Company and its Subsidiaries (as applicable) has good title to, or a valid leasehold interest in, the tangible personal property, equipment, improvements, fixtures, and other personal property and appurtenances that are used by the Company or its Subsidiary in connection with the conduct of its business (the “Fixtures and Equipment”). The Fixtures and Equipment are structurally sound, are in good operating condition and repair, are adequate for the uses to which they are being put, are not in need of maintenance or repairs except for ordinary, routine maintenance and repairs and are sufficient for the conduct of the Company’s and/or its Subsidiaries’ businesses (as applicable) in the manner as conducted prior to the Closing. Each of the Company and its Subsidiaries owns all of its Fixtures and Equipment free and clear of all Liens except for (a) liens for current taxes not yet due and (b) zoning laws and other land use restrictions that do not impair the present or anticipated use of the property subject thereto.

 

12

 

 

(w) Intellectual Property Rights. The Company and its Subsidiaries own or possess adequate rights or licenses to use all trademarks, trade names, service marks, service mark registrations, service names, original works of authorship, patents, patent rights, copyrights, inventions, licenses, approvals, governmental authorizations, trade secrets and other intellectual property rights and all applications and registrations therefor (“Intellectual Property Rights”) necessary to conduct their respective businesses as now conducted and presently proposed to be conducted. None of the Company’s Intellectual Property Rights have expired or terminated or have been abandoned or are expected to expire or terminate or are expected to be abandoned, within three years from the date of this Agreement. The Company does not have any knowledge of any infringement by the Company or its Subsidiaries of Intellectual Property Rights of others. There is no claim, action or proceeding being made or brought, or to the knowledge of the Company or any of its Subsidiaries, being threatened, against the Company or any of its Subsidiaries regarding its Intellectual Property Rights. Neither the Company nor any of its Subsidiaries is aware of any facts or circumstances which might give rise to any of the foregoing infringements or claims, actions or proceedings. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their Intellectual Property Rights.

 

(x) Environmental Laws. (i) The Company and its Subsidiaries (A) are in compliance with any and all Environmental Laws (as defined below), (B) have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (C) are in compliance with all terms and conditions of any such permit, license or approval where, in each of the foregoing clauses (A), (B) and (C), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect. The term “Environmental Laws” means all federal, state, local or foreign laws relating to pollution or protection of human health or the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata), including, without limitation, laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations issued, entered, promulgated or approved thereunder.

 

(i) No Hazardous Materials:

 

(A) have been disposed of or otherwise released from any Real Property of the Company or any of its Subsidiaries in violation of any Environmental Laws; or

 

(B) are present on, over, beneath, in or upon any Real Property or any portion thereof in quantities that would constitute a violation of any Environmental Laws. No prior use by the Company or any of its Subsidiaries of any Real Property has occurred that violates any Environmental Laws, which violation would have a material adverse effect on the business of the Company or any of its Subsidiaries.

 

(ii) Neither the Company nor any of its Subsidiaries knows of any other person who or entity which has stored, treated, recycled, disposed of or otherwise located on any Real Property any Hazardous Materials, including, without limitation, such substances as asbestos and polychlorinated biphenyls.

 

13

 

 

(iii) None of the Real Properties are on any federal or state “Superfund” list or Liability Information System (“CERCLIS”) list or any state environmental agency list of sites under consideration for CERCLIS, nor subject to any environmental related Liens.

 

(y) Subsidiary Rights. The Company or one of its Subsidiaries has the unrestricted right to vote, and (subject to limitations imposed by applicable law) to receive dividends and distributions on, all capital securities of its Subsidiaries as owned by the Company or such Subsidiary.

 

(z) Tax Status. The Company and each of its Subsidiaries (i) has timely made or filed all foreign, federal and state income and all other tax returns, reports and declarations required by any jurisdiction to which it is subject, and (ii) has timely paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations, except those being contested in good. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company and its Subsidiaries know of no basis for any such claim. The Company is not operated in such a manner as to qualify as a passive foreign investment company, as defined in Section 1297 of the Internal Revenue Code of 1986, as amended (the “Code”). The net operating loss carryforwards (“NOLs”) for United States federal income tax purposes of the consolidated group of which the Company is the common parent, if any, shall not be adversely effected by the transactions contemplated hereby. The transactions contemplated hereby do not constitute an “ownership change” within the meaning of Section 382 of the Code, thereby preserving the Company’s ability to utilize such NOLs.

 

(aa) Internal Accounting and Disclosure Controls. The Company and each of its Subsidiaries maintains internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the 1934 Act) that is effective to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, including that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset and liability accountability, (iii) access to assets or incurrence of liabilities is permitted only in accordance with management’s general or specific authorization and (iv) the recorded accountability for assets and liabilities is compared with the existing assets and liabilities at reasonable intervals and appropriate action is taken with respect to any difference. The Company maintains disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the 1934 Act) that are effective in ensuring that information required to be disclosed by the Company in the reports that it files or submits under the 1934 Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC, including, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the 1934 Act is accumulated and communicated to the Company’s management, including its principal executive officer or officers and its principal financial officer or officers, as appropriate, to allow timely decisions regarding required disclosure. Neither the Company nor any of its Subsidiaries has received any notice or correspondence from any accountant, Governmental Entity or other Person relating to any potential material weakness or significant deficiency in any part of the internal controls over financial reporting of the Company or any of its Subsidiaries.

 

(bb) Off Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company or any of its Subsidiaries and an unconsolidated or other off balance sheet entity that is required to be disclosed by the Company in its 1934 Act filings and is not so disclosed or that otherwise could be reasonably likely to have a Material Adverse Effect.

 

14

 

 

(cc) Investment Company Status. The Company is not, and upon consummation of the sale of the Securities will not be, an “investment company,” an affiliate of an “investment company,” a company controlled by an “investment company” or an “affiliated person” of, or “promoter” or “principal underwriter” for, an “investment company” as such terms are defined in the Investment Company Act of 1940, as amended.

 

(dd) Acknowledgement Regarding Buyers’ Trading Activity. It is understood and acknowledged by the Company that (i) following the public disclosure of the transactions contemplated by the Transaction Documents, in accordance with the terms thereof, none of the Buyers have been asked by the Company or any of its Subsidiaries to agree, nor has any Buyer agreed with the Company or any of its Subsidiaries, to desist from effecting any transactions in or with respect to (including, without limitation, purchasing or selling, long and/or short) any securities of the Company, or “derivative” securities based on securities issued by the Company or to hold any of the Securities for any specified term; (ii) any Buyer, and counterparties in “derivative” transactions to which any such Buyer is a party, directly or indirectly, presently may have a “short” position in the Common Stock which was established prior to such Buyer’s knowledge of the transactions contemplated by the Transaction Documents; (iii) each Buyer shall not be deemed to have any affiliation with or control over any arm’s length counterparty in any “derivative” transaction; and (iv) each Buyer may rely on the Company’s obligation to timely deliver shares of Common Stock upon conversion or exchange, as applicable, of the Securities as and when required pursuant to the Transaction Documents for purposes of effecting trading in the Common Stock of the Company. The Company further understands and acknowledges that following the public disclosure of the transactions contemplated by the Transaction Documents pursuant to the Press Release (as defined below) one or more Buyers may engage in hedging and/or trading activities (including, without limitation, the location and/or reservation of borrowable shares of Common Stock) at various times during the period that the Securities are outstanding, including, without limitation, during the periods that the value and/or number of the Conversion Shares and Warrant Shares deliverable with respect to the Securities are being determined and such hedging and/or trading activities (including, without limitation, the location and/or reservation of borrowable shares of Common Stock), if any, can reduce the value of the existing stockholders’ equity interest in the Company both at and after the time the hedging and/or trading activities are being conducted. The Company acknowledges that such aforementioned hedging and/or trading activities do not constitute a breach of this Agreement, the Notes, the Warrants, or any other Transaction Document or any of the documents executed in connection herewith or therewith.

 

(ee) Manipulation of Price. Neither the Company nor any of its Subsidiaries has, and, to the knowledge of the Company, no Person acting on their behalf has, directly or indirectly, (i) taken any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company or any of its Subsidiaries to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any of the Securities (other than the Placement Agent), (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company or any of its Subsidiaries or (iv) paid or agreed to pay any Person for research services with respect to any securities of the Company or any of its Subsidiaries.

 

(ff) U.S. Real Property Holding Corporation. Neither the Company nor any of its Subsidiaries is, or has ever been, and so long as any of the Securities are held by any of the Buyers, shall become, a U.S. real property holding corporation within the meaning of Section 897 of the Code, and the Company and each Subsidiary shall so certify upon any Buyer’s request.

 

(gg) Registration Eligibility. The Company is currently eligible to register the Registrable Securities (defined in the Registration Rights Agreement) for resale by the Buyers using Form S-1 promulgated under the 1933 Act.

 

15

 

 

(hh) Transfer Taxes. On the Closing Date, all stock transfer or other taxes (other than income or similar taxes) which are required to be paid in connection with the issuance, sale and transfer of the Securities to be sold to each Buyer hereunder will be, or will have been, fully paid or provided for by the Company, and all laws imposing such taxes will be or will have been complied with.

 

(ii) Bank Holding Company Act. Neither the Company nor any of its Subsidiaries is subject to the Bank Holding Company Act of 1956, as amended (the “BHCA”) and to regulation by the Board of Governors of the Federal Reserve System (the “Federal Reserve”). Neither the Company nor any of its Subsidiaries or affiliates owns or controls, directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%) or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.

 

(jj) Shell Company Status. The Company is not, and has never been, an issuer identified in, or subject to, Rule 144(i).

 

(kk) Illegal or Unauthorized Payments; Political Contributions. Neither the Company nor any of its Subsidiaries nor, to the best of the Company’s knowledge (after reasonable inquiry of its officers and directors), any of the officers, directors, employees, agents or other representatives of the Company or any of its Subsidiaries or any other business entity or enterprise with which the Company or any Subsidiary is or has been affiliated or associated, has, directly or indirectly, made or authorized any payment, contribution or gift of money, property, or services, whether or not in contravention of applicable law, (i) as a kickback or bribe to any Person or (ii) to any political organization, or the holder of or any aspirant to any elective or appointive public office except for personal political contributions not involving the direct or indirect use of funds of the Company or any of its Subsidiaries.

 

(ll) Money Laundering. The Company and its Subsidiaries are in compliance with, and have not previously violated, the USA Patriot Act of 2001 and all other applicable U.S. and non-U.S. anti-money laundering laws and regulations, including, without limitation, the laws, regulations and Executive Orders and sanctions programs administered by the U.S. Office of Foreign Assets Control, including, but not limited, to (i) Executive Order 13224 of September 23, 2001 entitled, “Blocking Property and Prohibiting Transactions With Persons Who Commit, Threaten to Commit, or Support Terrorism” (66 Fed. Reg. 49079 (2001)); and (ii) any regulations contained in 31 CFR, Subtitle B, Chapter V.

 

(mm) Management. During the past five year period, no current or former officer or director or, to the knowledge of the Company, no current ten percent (10%) or greater stockholder of the Company or any of its Subsidiaries has been the subject of:

 

(i) a petition under bankruptcy laws or any other insolvency or moratorium law or the appointment by a court of a receiver, fiscal agent or similar officer for such Person, or any partnership in which such person was a general partner at or within two years before the filing of such petition or such appointment, or any corporation or business association of which such person was an executive officer at or within two years before the time of the filing of such petition or such appointment;

 

(ii) a conviction in a criminal proceeding or a named subject of a pending criminal proceeding (excluding traffic violations that do not relate to driving while intoxicated or driving under the influence);

 

(iii) any order, judgment or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining any such person from, or otherwise limiting, the following activities:

 

16

 

 

(A) Acting as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, leverage transaction merchant, any other person regulated by the United States Commodity Futures Trading Commission or an associated person of any of the foregoing, or as an investment adviser, underwriter, broker or dealer in securities, or as an affiliated person, director or employee of any investment company, bank, savings and loan association or insurance company, or engaging in or continuing any conduct or practice in connection with such activity;

 

(B) Engaging in any particular type of business practice; or

 

(C) Engaging in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of securities laws or commodities laws;

 

(iv) any order, judgment or decree, not subsequently reversed, suspended or vacated, of any authority barring, suspending or otherwise limiting for more than sixty (60) days the right of any such person to engage in any activity described in the preceding sub paragraph, or to be associated with persons engaged in any such activity;

 

(v) a finding by a court of competent jurisdiction in a civil action or by the SEC or other authority to have violated any securities law, regulation or decree and the judgment in such civil action or finding by the SEC or any other authority has not been subsequently reversed, suspended or vacated; or

 

(vi) a finding by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated any federal commodities law, and the judgment in such civil action or finding has not been subsequently reversed, suspended or vacated.

 

(nn) Stock Option Plans. Each stock option granted by the Company was granted (i) in accordance with the terms of the applicable stock option plan of the Company and (ii) with an exercise price at least equal to the fair market value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the Company’s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no policy or practice of the Company to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or prospects.

 

(oo) No Disagreements with Accountants and Lawyers. There are no material disagreements of any kind presently existing, or reasonably anticipated by the Company to arise, between the Company and the accountants and lawyers formerly or presently employed by the Company and the Company is current with respect to any fees owed to its accountants and lawyers which could affect the Company’s ability to perform any of its obligations under any of the Transaction Documents. In addition, on or prior to the date hereof, the Company had discussions with its accountants about its financial statements previously filed with the SEC. Based on those discussions, the Company has no reason to believe that it will need to restate any such financial statements or any part thereof.

 

17

 

 

(pp) No Disqualification Events. With respect to Securities to be offered and sold hereunder in reliance on Rule 506(b) under the 1933 Act (“Regulation D Securities”), none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company participating in the offering contemplated hereby, any beneficial owner of 20% or more of the Company’s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the 1933 Act) connected with the Company in any capacity at the time of sale (each, an “Issuer Covered Person” and, together, “Issuer Covered Persons”) is subject to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the 1933 Act (a “Disqualification Event”), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished to the Buyers a copy of any disclosures provided thereunder.

 

(qq) Other Covered Persons. The Company is not aware of any Person (other than the Placement Agent) that has been or will be paid (directly or indirectly) remuneration for solicitation of Buyers or potential purchasers in connection with the sale of any Regulation D Securities.

 

(rr) No Additional Agreements. The Company does not have any agreement or understanding with any Buyer with respect to the transactions contemplated by the Transaction Documents other than as specified in the Transaction Documents.

 

(ss) Public Utility Holding Act. None of the Company nor any of its Subsidiaries is a “holding company,” or an “affiliate” of a “holding company,” as such terms are defined in the Public Utility Holding Act of 2005.

 

(tt) Federal Power Act. None of the Company nor any of its Subsidiaries is subject to regulation as a “public utility” under the Federal Power Act, as amended.

 

(uu) Ranking of Notes. No Indebtedness of the Company, at the Closing, will be senior to the Notes in right of payment, whether with respect to payment or redemptions, interest, damages, upon liquidation or dissolution or otherwise, unless waived by the Buyers.

 

(vv) Cybersecurity. The Company and its Subsidiaries’ information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, “IT Systems”) are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants that would reasonably be expected to have a Material Adverse Effect on the Company’s business. The Company and its Subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data, including “Personal Data,” used in connection with their businesses. “Personal Data” means (i) a natural person’s name, street address, telephone number, e-mail address, photograph, social security number or tax identification number, driver’s license number, passport number, credit card number, bank information, or customer or account number; (ii) any information which would qualify as “personally identifying information” under the Federal Trade Commission Act, as amended; (iii) “personal data” as defined by the European Union General Data Protection Regulation (“GDPR”) (EU 2016/679); (iv) any information which would qualify as “protected health information” under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, “HIPAA”); and (v) any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person’s health or sexual orientation. There have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person or such, nor any incidents under internal review or investigations relating to the same except in each case, where such would not, either individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. The Company and its Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification except in each case, where such would not, either individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.

 

18

 

 

(ww) Compliance with Data Privacy Laws. The Company and its Subsidiaries are, and at all prior times were, in compliance with all applicable state and federal data privacy and security laws and regulations, including without limitation HIPAA, and the Company and its Subsidiaries have taken commercially reasonable actions to prepare to comply with, and since May 25, 2018, have been and currently are in compliance with, the GDPR (EU 2016/679) (collectively, the “Privacy Laws”) except in each case, where such would not, either individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. To ensure compliance with the Privacy Laws, the Company and its Subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis of Personal Data (the “Policies”). The Company and its Subsidiaries have at all times made all disclosures to users or customers required by applicable laws and regulatory rules or requirements, and none of such disclosures made or contained in any Policy have, to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules or requirements in any material respect. The Company further certifies that neither it nor any Subsidiary: (i) has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law.

 

(xx) Disclosure. The Company confirms that neither it nor any other Person acting on its behalf has provided any of the Buyers or their agents or counsel with any information that constitutes or could reasonably be expected to constitute material, non-public information concerning the Company or any of its Subsidiaries, other than the existence of the transactions contemplated by this Agreement and the other Transaction Documents. The Company understands and confirms that each of the Buyers will rely on the foregoing representations in effecting transactions in securities of the Company. All disclosure provided to the Buyers regarding the Company and its Subsidiaries, their businesses and the transactions contemplated hereby, including the schedules to this Agreement, furnished by or on behalf of the Company or any of its Subsidiaries is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading.

 

4. COVENANTS.

 

(a) Best Efforts. Each Buyer shall use its best efforts to timely satisfy each of the covenants hereunder and conditions to be satisfied by it as provided in Section 6 of this Agreement. The Company shall use its best efforts to timely satisfy each of the covenants hereunder and conditions to be satisfied by it as provided in Section 7 of this Agreement.

 

19

 

 

(b) Form D and Blue Sky. The Company shall file a Form D with respect to the Securities as required under Regulation D and to provide a copy thereof to each Buyer promptly after such filing. The Company shall, on or before the Closing Date, take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to, qualify the Securities for sale to the Buyers at the Closing pursuant to this Agreement under applicable securities or “Blue Sky” laws of the states of the United States (or to obtain an exemption from such qualification), and shall provide evidence of any such action so taken to the Buyers on or prior to the Closing Date. Without limiting any other obligation of the Company under this Agreement, the Company shall timely make all filings and reports relating to the offer and sale of the Securities required under all applicable securities laws (including, without limitation, all applicable federal securities laws and all applicable “Blue Sky” laws), and the Company shall comply with all applicable foreign, federal, state and local laws, statutes, rules, regulations and the like relating to the offering and sale of the Securities to the Buyers.

 

(c) Reporting Status. Until the date on which the Buyers shall have sold all of the Registrable Securities (the “Reporting Period”), the Company shall timely file all reports required to be filed with the SEC pursuant to the 1934 Act, and the Company shall not terminate its status as an issuer required to file reports under the 1934 Act even if the 1934 Act or the rules and regulations thereunder would no longer require or otherwise permit such termination. From the time Form S-3 is available to the Company for the registration of the Registrable Securities, the Company shall take all actions necessary to maintain its eligibility to register the Registrable Securities for resale by the Buyers on Form S-3.

 

(d) Use of Proceeds. The Company will use the proceeds from the sale of the Securities for working capital, but not, directly or indirectly, for the redemption or repurchase of any securities of the Company or any of its Subsidiaries.

 

(e) Financial Information. The Company agrees to send the following to each Investor (as defined in the Registration Rights Agreement) during the Reporting Period (i) unless the following are filed with the SEC through EDGAR and are available to the public through the EDGAR system, within one (1) Business Day after the filing thereof with the SEC, a copy of its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, any interim reports or any consolidated balance sheets, income statements, stockholders’ equity statements and/or cash flow statements for any period other than annual, any Current Reports on Form 8-K and any registration statements (other than on Form S-8) or amendments filed pursuant to the 1933 Act, (ii) unless the following are either filed with the SEC through EDGAR or are otherwise widely disseminated via a recognized news release service (such as PR Newswire), on the same day as the release thereof, e-mail copies of all press releases issued by the Company or any of its Subsidiaries and (iii) unless the following are filed with the SEC through EDGAR, copies of any notices and other information made available or given to the stockholders of the Company generally, contemporaneously with the making available or giving thereof to the stockholders.

 

(f) Listing. The Company shall promptly secure the listing or designation for quotation (as the case may be) of all of the Registrable Securities upon each national securities exchange and automated quotation system, if any, upon which the Common Stock is then listed or designated for quotation (as the case may be) (subject to official notice of issuance) and shall maintain such listing or designation for quotation (as the case may be) of all Registrable Securities from time to time issuable under the terms of the Transaction Documents on such national securities exchange or automated quotation system. The Company shall maintain the Common Stock’s listing or authorization for quotation (as the case may be) on the Principal Market, The New York Stock Exchange, the Nasdaq American, the Nasdaq Global Market or the Nasdaq Global Select Market (each, an “Eligible Market”). Neither the Company nor any of its Subsidiaries shall take any action which could be reasonably expected to result in the delisting or suspension of the Common Stock on an Eligible Market. The Company shall pay all fees and expenses in connection with satisfying its obligations under this Section 4(f).

 

20

 

 

(g) Additional Registration Statements. Until the Applicable Date (as defined below) and at any time

 

(h) Dilutive Issuances. For so long as any Notes and Warrants remain outstanding, the Company shall not, in any manner, enter into or affect any Dilutive Issuance (as defined in the Notes) if the effect of such Dilutive Issuance is to cause the Company to be required to issue upon conversion of any Notes or exercise of any Warrants any shares of Common Stock in excess of that number of shares of Common Stock which the Company may issue upon conversion of the Notes or exercise of the Warrants without breaching the Company’s obligations under the rules or regulations of the Principal Market.

 

(i) Passive Foreign Investment Company. The Company shall conduct its business, and shall cause its Subsidiaries to conduct their respective businesses, in such a manner as will ensure that the Company will not be deemed to constitute a passive foreign investment company within the meaning of Section 1297 of the Code.

 

(j) Restriction on Redemption and Cash Dividends. So long as any Notes and Warrants are outstanding, the Company shall not, directly or indirectly, redeem, or declare or pay any cash dividend or distribution on, any securities of the Company without the prior express written consent of the Buyers.

 

(k) Corporate Existence. So long as any Buyer beneficially owns any Notes or Warrants, the Company shall not be party to any Fundamental Transaction (as defined in the Notes) unless the Company is in compliance with the applicable provisions governing Fundamental Transactions set forth in the Notes and Warrants.

 

(l) Stock Splits. Until the Notes and Warrants are no longer outstanding, the Company shall not effect any stock combination, reverse stock split or other similar transaction (or make any public announcement or disclosure with respect to any of the foregoing) without the prior written consent of a majority of the Buyers.

 

(m) Conversion Procedures. Each of the form of Conversion Notice and Exercise Notice (as defined in the Notes and Warrants, respectively) included in the Notes and Warrants set forth the totality of the procedures required of the Buyers in order to convert the Notes and exercise the Warrants. Except as provided in Section 5(d), no additional legal opinion, other information or instructions shall be required of the Buyers to convert their Notes or exercise their Warrants. The Company shall honor conversions of the Notes and exercises of the Warrants and shall deliver the Conversion Shares and Warrant Shares in accordance with the terms, conditions and time periods set forth in the Notes and Warrants.

 

(n) Regulation M. The Company will not take any action prohibited by Regulation M under the 1934 Act, in connection with the distribution of the Securities contemplated hereby.

 

(o) General Solicitation. None of the Company, any of its affiliates (as defined in Rule 501(b) under the 1933 Act) or any person acting on behalf of the Company or such affiliate will solicit any offer to buy or offer or sell the Securities by means of any form of general solicitation or general advertising within the meaning of Regulation D, including: (i) any advertisement, article, notice or other communication published in any newspaper, magazine or similar medium or broadcast over television or radio; and (ii) any seminar or meeting whose attendees have been invited by any general solicitation or general advertising.

 

21

 

 

(p) Integration. None of the Company, any of its affiliates (as defined in Rule 501(b) under the 1933 Act), or any person acting on behalf of the Company or such affiliate will sell, offer for sale, or solicit offers to buy or otherwise negotiate in respect of any security (as defined in the 1933 Act) which will be integrated with the sale of the Securities in a manner which would require the registration of the Securities under the 1933 Act or require stockholder approval under the rules and regulations of the Principal Market and the Company will take all action that is appropriate or necessary to assure that its offerings of other securities will not be integrated for purposes of the 1933 Act or the rules and regulations of the Principal Market, with the issuance of Securities contemplated hereby.

 

(q) Notice of Disqualification Events. The Company will notify the Buyers in writing, prior to the Closing Date of (i) any Disqualification Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, become a Disqualification Event relating to any Issuer Covered Person.

 

(r) Stockholder Approval. The Company shall either (x) if the Company shall have obtained the prior written consent of the requisite stockholders (the “Stockholder Consent”) to obtain the Stockholder Approval (as defined below), inform the stockholders of the Company of the receipt of the Stockholder Consent by preparing and filing with the SEC, as promptly as practicable after the date hereof.

 

(s) No Sales of Pre-Delivery Shares; Return of Pre-Delivery Shares. Each Buyer, severally, hereby covenants and agrees (i) not to sell any Pre-Delivery Shares issued to such Buyer until such time as such Pre-Delivery Shares shall become Delivery Shares (as defined in the Notes) and (ii) that if such Buyer holds any Pre-Delivery Shares after such date that no Notes are then held by such Buyer (whether following the conversion or redemption, as applicable, of all Notes then held by such Buyer, but after any applicable Delivery Share Applications (as defined in the Notes) related thereto), such remaining Pre-Delivery Shares shall be promptly returned by such Buyer to the Company for cancellation.

 

(t) Holding Period. For the purposes of Rule 144, the Company acknowledges that the holding period of the Pre-Delivery Shares may be tacked onto the holding period of the Notes and shall, consequently, be deemed to have been issued as of the Closing Date for purposes of Rule 144 and the Company agrees not to take a position contrary to this Section 4(dd).

 

(u) Closing Documents. On or prior to fourteen (14) calendar days after the Closing Date, the Company agrees to deliver, or cause to be delivered, to each Buyer and Rimon P.C., a complete closing set of the executed Transaction Documents, Securities and any other document required to be delivered to any party pursuant to Section 7 hereof or otherwise.

 

5. REGISTER; TRANSFER AGENT INSTRUCTIONS; LEGEND.

 

(a) Register. The Company shall maintain at its principal executive offices (or such other office or agency of the Company as it may designate by notice to each holder of Securities), a register for the Notes and Warrants in which the Company shall record the name and address of the Person in whose name the Notes and Warrants have been issued (including the name and address of each transferee), the principal amount of the Notes and Warrants held by such Person and the number of Conversion Shares issuable pursuant to the terms of the Notes and the number of Warrant Shares exercisable pursuant to the terms of the Warrants. The Company shall keep the register open and available at all times during business hours for inspection of any Buyer or its legal representatives.

 

22

 

 

(b) Transfer Agent Instructions. The Company shall issue irrevocable instructions to its transfer agent and any subsequent transfer agent (as applicable, the “Transfer Agent”) in a form acceptable to each of the Buyers (the “Irrevocable Transfer Agent Instructions”) to issue certificates or credit shares to the applicable balance accounts at The Depository Trust Company (“DTC”), registered in the name of each Buyer or its respective nominee(s), for the Conversion Shares and Warrant Shares in such amounts as specified from time to time by each Buyer to the Company upon conversion of the Notes and exercise of the Warrants. The Company represents and warrants that no instruction other than the Irrevocable Transfer Agent Instructions referred to in this Section 5(b), and stop transfer instructions to give effect to Section 2(g) hereof, will be given by the Company to its transfer agent with respect to the Securities, and that the Securities shall otherwise be freely transferable on the books and records of the Company, as applicable, to the extent provided in this Agreement and the other Transaction Documents. If a Buyer effects a sale, assignment or transfer of the Securities in accordance with Section 2(g), the Company shall permit the transfer and shall promptly instruct its transfer agent to issue one or more certificates or credit shares to the applicable balance accounts at DTC in such name and in such denominations as specified by such Buyer to effect such sale, transfer or assignment. In the event that such sale, assignment or transfer involves Conversion Shares or Warrant Shares sold, assigned or transferred pursuant to an effective registration statement or in compliance with Rule 144, the transfer agent shall issue such shares to such Buyer, assignee or transferee (as the case may be) without any restrictive legend in accordance with Section 5(d) below. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to a Buyer. Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations under this Section 5(b) will be inadequate and agrees, in the event of a breach or threatened breach by the Company of the provisions of this Section 5(b), that a Buyer shall be entitled, in addition to all other available remedies, to an order and/or injunction restraining any breach and requiring immediate issuance and transfer, without the necessity of showing economic loss and without any bond or other security being required. The Company shall cause its counsel to issue the legal opinion referred to in the Irrevocable Transfer Agent Instructions to the Company’s transfer agent on each Effective Date (as defined in the Registration Rights Agreement). Any fees (with respect to the transfer agent, counsel to the Company or otherwise) associated with the issuance of such opinion or the removal of any legends on any of the Securities shall be borne by the Company.

 

(c) Legends. Each Buyer understands that the Securities have been issued (or will be issued in the case of the Conversion Shares or Warrant Shares) pursuant to an exemption from registration or qualification under the 1933 Act and applicable state securities laws, and except as set forth below, the Securities shall bear any legend as required by the “blue sky” laws of any state and a restrictive legend in substantially the following form (and a stop-transfer order may be placed against transfer of such stock certificates):

 

[NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN][THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN] REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL TO THE HOLDER (IF REQUESTED BY THE COMPANY), IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

 

23

 

 

(d) Removal of Legends. Certificates evidencing Securities shall not be required to contain the legend set forth in Section 5(c) above or any other legend (i) while a registration statement (including a Registration Statement) covering the resale of such Securities is effective under the 1933 Act, (ii) following any sale of such Securities pursuant to Rule 144 (assuming the transferor is not an affiliate of the Company), (iii) if such Securities are eligible to be sold, assigned or transferred under Rule 144 (provided that a Buyer provides the Company with reasonable assurances that such Securities are eligible for sale, assignment or transfer under Rule 144 which shall not include an opinion of Buyer’s counsel), (iv) in connection with a sale, assignment or other transfer (other than under Rule 144), provided that such Buyer provides the Company with an opinion of counsel to such Buyer, in a generally acceptable form, to the effect that such sale, assignment or transfer of the Securities may be made without registration under the applicable requirements of the 1933 Act or (v) if such legend is not required under applicable requirements of the 1933 Act (including, without limitation, controlling judicial interpretations and pronouncements issued by the SEC). If a legend is not required pursuant to the foregoing, the Company shall no later than two (2) Trading Days (or such earlier date as required pursuant to the 1934 Act or other applicable law, rule or regulation for the settlement of a trade initiated on the date such Buyer delivers such legended certificate representing such Securities to the Company) following the delivery by a Buyer to the Company or the Transfer Agent (with notice to the Company) of a legended certificate representing such Securities (endorsed or with stock powers attached, signatures guaranteed, and otherwise in form necessary to affect the reissuance and/or transfer, if applicable), together with any other deliveries from such Buyer as may be required above in this Section 5(d), as directed by such Buyer, either: (A) provided that the Company’s Transfer Agent is participating in the DTC Fast Automated Securities Transfer Program (“FAST”) and such Securities are Conversion Shares or Warrant Shares, credit the aggregate number of shares of Common Stock to which such Buyer shall be entitled to such Buyer’s or its designee’s balance account with DTC through its Deposit/Withdrawal at Custodian system or (B) if the Company’s Transfer Agent is not participating in FAST, issue and deliver (via reputable overnight courier) to such Buyer, a certificate representing such Securities that is free from all restrictive and other legends, registered in the name of such Buyer or its designee (the date by which such credit is so required to be made to the balance account of such Buyer’s or such Buyer’s designee with DTC or such certificate is required to be delivered to such Buyer pursuant to the foregoing is referred to herein as the “Required Delivery Date”, and the date such shares of Common Stock are actually delivered without restrictive legend to such Buyer or such Buyer’s designee with DTC, as applicable, the “Share Delivery Date”). The Company shall be responsible for any Transfer Agent fees or DTC fees with respect to any issuance of Securities or the removal of any legends with respect to any Securities in accordance herewith.

 

6. CONDITIONS TO THE COMPANY’S OBLIGATION TO SELL.

 

(a) The obligation of the Company hereunder to issue and sell the Notes and Warrants to each Buyer at the Closing is subject to the satisfaction, at or before the Closing Date, of each of the following conditions, provided that these conditions are for the Company’s sole benefit and may be waived by the Company at any time in its sole discretion by providing each Buyer with prior written notice thereof:

 

(i) Such Buyer shall have executed each of the Transaction Documents to which it is a party and delivered the same to the Company.

 

(ii) Such Buyer and each other Buyer shall have delivered to the Company the Purchase Price for the Note and Warrant being purchased by such Buyer at the Closing by wire transfer of immediately available funds.

 

(iii) The representations and warranties of such Buyer shall be true and correct in all material respects as of the date when made and as of the Closing Date as though originally made at that time (except for representations and warranties that speak as of a specific date, which shall be true and correct as of such specific date), and such Buyer shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by such Buyer at or prior to the Closing Date.

 

24

 

 

7. CONDITIONS TO EACH BUYER’S OBLIGATION TO PURCHASE.

 

(a) The obligation of each Buyer hereunder to purchase its Note and Warrant at the Closing is subject to the satisfaction, at or before the Closing Date, of each of the following conditions, provided that these conditions are for each Buyer’s sole benefit and may be waived by such Buyer at any time in its sole discretion by providing the Company with prior written notice thereof:

 

(i) The Company shall have duly executed and delivered to such Buyer each of the Transaction Documents to which it is a party, and the Company shall have duly executed and delivered to such Buyer a Note in such original principal amount as is set forth across from such Buyer’s name in column (2) of the Schedule of Buyers as being purchased by such Buyer at the Closing pursuant to this Agreement.

 

(ii) The Company shall have duly executed and delivered to such Buyer each of the Transaction Documents to which it is a party, and the Company shall have duly executed and delivered to such Buyer a Warrant for such number of Warrant Shares as is set forth across from such Buyer’s name in column (3) of the Schedule of Buyers as being purchased by such Buyer at the Closing pursuant to this Agreement.

 

(iii) Such Buyer shall have received the opinion of Nelson Mullins, the Company’s counsel, dated as of the Closing Date, in the form acceptable to such Buyer.

 

(iv) The Company shall have delivered to such Buyer a certificate evidencing the formation and good standing of the Company in such entity’s jurisdiction of formation issued by the Secretary of State (or comparable office) of such jurisdiction of formation as of a date within ten (10) days of the Closing Date.

 

(v) The Company shall have delivered to such Buyer a certified copy of the Certificate of Incorporation as certified by the Delaware Secretary of State within ten (10) days of the Closing Date.

 

(vi) Each and every representation and warranty of the Company shall be true and correct as of the date when made and as of the Closing Date as though originally made at that time (except for representations and warranties that speak as of a specific date, which shall be true and correct as of such specific date) and the Company shall have performed, satisfied and complied in all respects with the covenants, agreements and conditions required to be performed, satisfied or complied with by the Company at or prior to the Closing Date. Such Buyer shall have received a certificate, duly executed by the Chief Executive Officer of the Company, dated as of the Closing Date, to the foregoing effect and as to such other matters as may be reasonably requested by such Buyer in the form acceptable to such Buyer.

 

(vii) The Company shall have delivered to such Buyer a letter from the Company’s Transfer Agent certifying the number of shares of Common Stock outstanding on the Closing Date immediately prior to the Closing.

 

(viii) The Common Stock (A) shall be designated for quotation or listed (as applicable) on the Principal Market and (B) shall not have been suspended, as of the Closing Date, by the SEC or the Principal Market from trading on the Principal Market nor shall suspension by the SEC or the Principal Market have been threatened, as of the Closing Date, either (I) in writing by the SEC or the Principal Market or (II) by falling below the minimum maintenance requirements of the Principal Market.

 

25

 

 

(ix) The Company shall have obtained all governmental, regulatory or third party consents and approvals, if any, necessary for the sale of the Securities, including without limitation, those required by the Principal Market, if any.

 

(x) No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or Governmental Entity of competent jurisdiction that prohibits the consummation of any of the transactions contemplated by the Transaction Documents.

 

(xi) Since the date of execution of this Agreement, no event or series of events shall have occurred that reasonably would have or result in a Material Adverse Effect.

 

(xii) Pursuant to an executed Merger Agreement (the “Merger Agreement”), the Company has consummated the merger of Data Knights Merger Sub, Inc., a Delaware corporation, a wholly-owned subsidiary of the Company, with and into OneMedNet Corporation, a Delaware corporation (“OneMedNet”), with OneMedNet continuing as the surviving corporation and wholly-owned subsidiary of the Company (the “Merger”)

 

8. TERMINATION.

 

In the event that the Closing shall not have occurred with respect to a Buyer by October 1, 2023, then such Buyer shall have the right to terminate its obligations under this Agreement with respect to itself at any time on or after the close of business on such date without liability of such Buyer to any other party; provided, however, (i) the right to terminate this Agreement under this Section 8 shall not be available to such Buyer if the failure of the transactions contemplated by this Agreement to have been consummated by such date is the result of such Buyer’s breach of this Agreement and (ii) the abandonment of the sale and purchase of the Notes and Warrants shall be applicable only to such Buyer providing such written notice, provided further that no such termination shall affect any obligation of the Company under this Agreement to reimburse such Buyer for the expenses described in Section 4(g) above. Nothing contained in this Section 8 shall be deemed to release any party from any liability for any breach by such party of the terms and provisions of this Agreement or the other Transaction Documents or to impair the right of any party to compel specific performance by any other party of its obligations under this Agreement or the other Transaction Documents.

 

9. MISCELLANEOUS.

 

(a) Governing Law; Jurisdiction; Jury Trial. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws of the State of Delaware, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Delaware or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of Delaware. The Company hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of Wilmington, Delaware, for the adjudication of any dispute hereunder or in connection herewith or under any of the other Transaction Documents or with any transaction contemplated hereby or thereby, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be deemed or operate to preclude any Buyer from bringing suit or taking other legal action against the Company in any other jurisdiction to collect on the Company’s obligations to such Buyer or to enforce a judgment or other court ruling in favor of such Buyer. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR UNDER ANY OTHER TRANSACTION DOCUMENT OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT, ANY OTHER TRANSACTION DOCUMENT OR ANY TRANSACTION CONTEMPLATED HEREBY OR THEREBY.

 

26

 

 

(b) Counterparts. This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party. In the event that any signature is delivered by facsimile transmission or by an e-mail which contains a portable document format (.pdf) file of an executed signature page, such signature page shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such signature page were an original thereof.

 

(c) Headings; Gender. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement. Unless the context clearly indicates otherwise, each pronoun herein shall be deemed to include the masculine, feminine, neuter, singular and plural forms thereof. The terms “including,” “includes,” “include” and words of like import shall be construed broadly as if followed by the words “without limitation.” The terms “herein,” “hereunder,” “hereof” and words of like import refer to this entire Agreement instead of just the provision in which they are found.

 

(d) Severability; Maximum Payment Amounts. If any provision of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity of the remaining provisions of this Agreement so long as this Agreement as so modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s). Notwithstanding anything to the contrary contained in this Agreement or any other Transaction Document (and without implication that the following is required or applicable), it is the intention of the parties that in no event shall amounts and value paid by the Company and/or any of its Subsidiaries (as the case may be), or payable to or received by any of the Buyers, under the Transaction Documents (including without limitation, any amounts that would be characterized as “interest” under applicable law) exceed amounts permitted under any applicable law. Accordingly, if any obligation to pay, payment made to any Buyer, or collection by any Buyer pursuant the Transaction Documents is finally judicially determined to be contrary to any such applicable law, such obligation to pay, payment or collection shall be deemed to have been made by mutual mistake of such Buyer, the Company and its Subsidiaries and such amount shall be deemed to have been adjusted with retroactive effect to the maximum amount or rate of interest, as the case may be, as would not be so prohibited by the applicable law. Such adjustment shall be effected, to the extent necessary, by reducing or refunding, at the option of such Buyer, the amount of interest or any other amounts which would constitute unlawful amounts required to be paid or actually paid to such Buyer under the Transaction Documents. For greater certainty, to the extent that any interest, charges, fees, expenses or other amounts required to be paid to or received by such Buyer under any of the Transaction Documents or related thereto are held to be within the meaning of “interest” or another applicable term to otherwise be violative of applicable law, such amounts shall be pro-rated over the period of time to which they relate.

 

27

 

 

(e) Entire Agreement; Amendments. This Agreement, the other Transaction Documents and the schedules and exhibits attached hereto and thereto and the instruments referenced herein and therein supersede all other prior oral or written agreements between the Buyers, the Company, its Subsidiaries, their affiliates and Persons acting on their behalf, including, without limitation, any transactions by any Buyer with respect to Common Stock or the Securities, and the other matters contained herein and therein, and this Agreement, the other Transaction Documents, the schedules and exhibits attached hereto and thereto and the instruments referenced herein and therein contain the entire understanding of the parties solely with respect to the matters covered herein and therein; provided, however, nothing contained in this Agreement or any other Transaction Document shall (or shall be deemed to) (i) have any effect on any agreements any Buyer has entered into with, or any instruments any Buyer has received from, the Company or any of its Subsidiaries prior to the date hereof with respect to any prior investment made by such Buyer in the Company or (ii) waive, alter, modify or amend in any respect any obligations of the Company or any of its Subsidiaries, or any rights of or benefits to any Buyer or any other Person, in any agreement entered into prior to the date hereof between or among the Company and/or any of its Subsidiaries and any Buyer, or any instruments any Buyer received from the Company and/or any of its Subsidiaries prior to the date hereof, and all such agreements and instruments shall continue in full force and effect. Except as specifically set forth herein or therein, neither the Company nor any Buyer makes any representation, warranty, covenant or undertaking with respect to such matters. No waiver shall be effective unless it is in writing and signed by an authorized representative of the waiving party. No consideration (other than reimbursement of reasonable legal fees) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of any of the Transaction Documents unless the same consideration also is offered to all of the parties to the Transaction Documents, all holders of the Notes and Warrants. Without limiting the foregoing, the Company confirms that, except as set forth in this Agreement, no Buyer has made any commitment or promise or has any other obligation to provide any financing to the Company, any Subsidiary or otherwise.

 

(f) Notices. Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered:(i) upon receipt, when delivered personally; (ii) upon receipt, when sent by electronic mail (provided that such sent email is kept on file (whether electronically or otherwise) by the sending party and the sending party does not receive an automatically generated message from the recipient’s email server that such e- mail could not be delivered to such recipient); or (iii) one (1) Business Day after deposit with an overnight courier service with next day delivery specified, in each case, properly addressed to the party to receive the same. The mailing addresses and e-mail addresses for such communications shall be:

 

If to the Company:

 

Data Knights Acquisition Corp

Unit G6, Frome Business Park

Manor Road Frome

United Kingdom, BA11 4FN Telephone:

011-44 203 833 4000 Attention: Barry

Anderson

Email: barryanderson8@gmail.com

 

28

 

 

With a copy (for informational purposes only) to:

 

Nelson Mullins Riley & Scarborough LLP 101

Constitution Avenue, NW, Suite 900

Washington, DC 20001

Telephone: (202) 689-2987 Attention:

Andy Tucker

Email: andy.tucker@nelsonmullins.com

 

If to OneMedNet Corporation:

 

OneMedNet Corporation

6385 Old Shady Oak Road, Suite 250

Eden Prairie, Minnesota 55344

Telephone: (808) 228-5998

Attention: Paul Casey

E-Mail: paul.casey@onemednet.com

 

With a copy (for informational purposes only) to:

 

Rimon PC

1990 K. Street, NW, Suite 420

Washington DC 20006

Telephone: 202-935-3390

Attention: Debbie A. Klis

E-Mail: debbie.klis@rimonlaw.com

 

If to a Buyer, to its mailing address and e-mail address set forth on the Schedule of Buyers, with copies to such Buyer’s representatives as set forth on the Schedule of Buyers, or to such other mailing address and/or e-mail address and/or to the attention of such other Person as the recipient party has specified by written notice given. Written confirmation of receipt (A) given by the recipient of such notice, consent, waiver or other communication, (B) mechanically or electronically generated by the sender’s e-mail containing the time, date and recipient’s e-mail or (C) provided by an overnight courier service shall be rebuttable evidence of personal service, receipt by e-mail or receipt from an overnight courier service in accordance with clause (i), (ii) or (iii) above, respectively.

 

(g) Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and assigns, including any purchasers of any of the Notes and Warrants. A Buyer may assign some or all of its rights hereunder in connection with any transfer of any of its Securities without the consent of the Company, in which event such assignee shall be deemed to be a Buyer hereunder with respect to such assigned rights.

 

(h) No Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, other than the Indemnitees referred to herein.

 

(i) Survival. The representations, warranties, agreements and covenants shall survive the Closings. Each Buyer shall be responsible only for its own representations, warranties, agreements and covenants hereunder.

 

29

 

 

(j) Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

(k) Indemnification. In consideration of each Buyer’s execution and delivery of the Transaction Documents and acquiring the Securities thereunder and in addition to all of the Company’s other obligations under the Transaction Documents, the Company shall defend, protect, indemnify and hold harmless each Buyer and each holder of any Securities and all of their stockholders, partners, members, officers, directors, employees and direct or indirect investors and any of the foregoing Persons’ agents or other representatives (including, without limitation, those retained in connection with the transactions contemplated by this Agreement) (collectively, the “Indemnitees”) from and against any and all actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages, and expenses in connection therewith (irrespective of whether any such Indemnitee is a party to the action for which indemnification hereunder is sought), and including reasonable attorneys’ fees and disbursements (the “Indemnified Liabilities”), incurred by any Indemnitee as a result of, or arising out of, or relating to (i) any misrepresentation or breach of any representation or warranty made by the Company or any Subsidiary in any of the Transaction Documents, (ii) any breach of any covenant, agreement or obligation of the Company or any Subsidiary contained in any of the Transaction Documents or (iii) any cause of action, suit, proceeding or claim brought or made against such Indemnitee by a third party (including for these purposes a derivative action brought on behalf of the Company or any Subsidiary) or which otherwise involves such Indemnitee that arises out of or results from (A) the execution, delivery, performance or enforcement of any of the Transaction Documents, (B) any transaction financed or to be financed in whole or in part, directly or indirectly, with the proceeds of the issuance of the Securities, (C) any disclosure properly made by such Buyer, or (D) the status of such Buyer or holder of the Securities either as an investor in the Company pursuant to the transactions contemplated by the Transaction Documents or as a party to this Agreement (including, without limitation, as a party in interest or otherwise in any action or proceeding for injunctive or other equitable relief). To the extent that the foregoing undertaking by the Company may be unenforceable for any reason, the Company shall make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under applicable law. Except as otherwise set forth herein, the mechanics and procedures with respect to the rights and obligations under this Section 9(k) shall be the same as those set forth in Section 6 of the Registration Rights Agreement.

 

(l) Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party. No specific representation or warranty shall limit the generality or applicability of a more general representation or warranty. Each and every reference to share prices, shares of Common Stock and any other numbers in this Agreement that relate to the Common Stock shall be automatically adjusted for any stock splits, stock dividends, stock combinations, recapitalizations or other similar transactions that occur with respect to the Common Stock after the date of this Agreement. Notwithstanding anything in this Agreement to the contrary, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty against, or a prohibition of, any actions with respect to the borrowing of, arrangement to borrow, identification of the availability of, and/or securing of, securities of the Company in order for such Buyer (or its broker or other financial representative) to effect short sales or similar transactions in the future.

 

(m) Remedies. Each Buyer and in the event of assignment by Buyer of its rights and obligations hereunder, each holder of Securities, shall have all rights and remedies set forth in the Transaction Documents and all rights and remedies which such holders have been granted at any time under any other agreement or contract and all of the rights which such holders have under any law. Any Person having any rights under any provision of this Agreement shall be entitled to enforce such rights specifically (without posting a bond or other security), to recover damages by reason of any breach of any provision of this Agreement and to exercise all other rights granted by law. Furthermore, the Company recognizes that in the event that it or any Subsidiary fails to perform, observe, or discharge any or all of its or such Subsidiary’s (as the case may be) obligations under the Transaction Documents, any remedy at law would inadequate relief to the Buyers. The Company therefore agrees that the Buyers shall be entitled to specific performance and/or temporary, preliminary and permanent injunctive or other equitable relief from any court of competent jurisdiction in any such case without the necessity of proving actual damages and without posting a bond or other security. The remedies provided in this Agreement and the other Transaction Documents shall be cumulative and in addition to all other remedies available under this Agreement and the other Transaction Documents, at law or in equity (including a decree of specific performance and/or other injunctive relief).

 

30

 

 

(n) Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) the Transaction Documents, whenever any Buyer exercises a right, election, demand or option under a Transaction Document and the Company or any Subsidiary does not timely perform its related obligations within the periods therein provided, then such Buyer may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company or such Subsidiary (as the case may be), any relevant notice, demand or election in whole or in part without prejudice to its future actions and rights.

 

(o) Independent Nature of Buyers’ Obligations and Rights. The obligations of each Buyer under the Transaction Documents are several and not joint with the obligations of any other Buyer, and no Buyer shall be responsible in any way for the performance of the obligations of any other Buyer under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken by any Buyer pursuant hereto or thereto, shall be deemed to constitute the Buyers as, and the Company acknowledges that the Buyers do not so constitute, a partnership, an association, a joint venture or any other kind of group or entity, or create a presumption that the Buyers are in any way acting in concert or as a group or entity, and the Company shall not assert any such claim with respect to such obligations or the transactions contemplated by the Transaction Documents or any matters, and the Company acknowledges that the Buyers are not acting in concert or as a group, and the Company shall not assert any such claim, with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Buyer acknowledges that no other Buyer has acted as agent for such Buyer in connection with such Buyer making its investment hereunder and that no other Buyer will be acting as agent of such Buyer in connection with monitoring such Buyer’s investment in the Securities or enforcing its rights under the Transaction Documents. The Company and each Buyer confirms that each Buyer has independently participated with the Company and its Subsidiaries in the negotiation of the transaction contemplated hereby with the advice of its own counsel and advisors. Each Buyer shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement or out of any other Transaction Documents, and it shall not be necessary for any other Buyer to be joined as an additional party in any proceeding for such purpose. The use of a single agreement to effectuate the purchase and sale of the Securities contemplated hereby was solely in the control of the Company, not the action or decision of any Buyer, and was done solely for the convenience of the Company and its Subsidiaries and not because it was required or requested to do so by any Buyer. It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction Document is between the Company, each Subsidiary and a Buyer, solely, and not between the Company, its Subsidiaries and the Buyers collectively and not between and among the Buyers.

 

[signature pages follow]

 

31

 

 

IN WITNESS WHEREOF, each Buyer and the Company have caused their respective signature page to this Agreement to be duly executed as of the date first written above.

 

  COMPANY:
     
   
  Name: Barry Anderson
  Title: Chief Executive Officer

 

32

 

 

IN WITNESS WHEREOF, each Buyer and the Company have caused their respective signature page to this Agreement to be duly executed as of the date first written above.

 

  BUYER:
     
  By: Thomas Kosasa
  Name: Thomas Kosasa

 

33

 

 

IN WITNESS WHEREOF, each Buyer and the Company have caused their respective signature page to this Agreement to be duly executed as of the date first written above.

 

  BUYER:
   
  By: Jeffrey N C Yu
 

Name:

Revocable Trust of Jeffrey N C Yu

  By: Dr. Jeffrey N C Yu
  Title: Trustee

 

34

 

 

IN WITNESS WHEREOF, each Buyer and the Company have caused their respective signature page to this Agreement to be duly executed as of the date first written above.

 

  BUYER:
     
  By: Aaron Green
  Name: Aaron Green

 

35

 

 

IN WITNESS WHEREOF, each Buyer and the Company have caused their respective signature page to this Agreement to be duly executed as of the date first written above.

 

  BUYER:
     
  By: Steve Kester
 

Name:

Iron Family Holdings LLC

  By: Steve Kester
  Title: Manager

 

36

 

 


Schedule of Buyers

Closing

 

1 – Name of Buyer   2 – Original Principal Amount of Notes  

3 –

Number of Warrant Shares

 

4 –

Purchase Price

  5 – Mailing Address and E-mail Address   6 – Legal Representative’s Mailing Address and E-mail Address
Thomas   $531,916.20   319,16.2   $500,000   c/o OneMedNet   Rimon PC
Kosasa               Corporation   1990 K. Street, NW, Suite
                6385 Old Shady Oak   420
                Rd., Ste. 250   Washington DC 20006
                Eden Prairie, MN   Tel: 202-935-3390
                55344   Attn: Debbie A. Klis
                Tel: (808) 228-5998   E-Mail:
                    debbie.klis@rimonlaw.com
                     
Dr. Jeffrey Yu   $531,916.20   31,916.2   $500,000   c/o OneMedNet   Rimon PC
by Revocable               Corporation   1990 K. Street, NW, Suite
Trust of               6385 Old Shady Oak   420
Jeffrey N C               Rd., Ste. 250   Washington DC 20006
Yu               Eden Prairie, MN   Tel: 202-935-3390
                55344   Attn: Debbie A. Klis
                Tel: (808) 228-5998   E-Mail:
                    debbie.klis@rimonlaw.com
                     
Aaron Green   $265,956.15   15,956.15   $250,000   c/o OneMedNet   Rimon PC
                Corporation   1990 K. Street, NW, Suite
                6385 Old Shady Oak   420
                Rd., Ste. 250   Washington DC 20006
                Eden Prairie, MN   Tel: 202-935-3390
                55344   Attn: Debbie A. Klis
                Tel: (808) 228-5998   E-Mail:
                    debbie.klis@rimonlaw.com
                     
Steve Kester   $265,956.15   15,956.15   $250,000   c/o OneMedNet   Rimon PC
by Iron               Corporation   1990 K. Street, NW, Suite
Family Holdings LLC              

6385 Old Shady Oak

Rd., Ste. 250

Eden Prairie, MN 55344

 

420

Washington DC 20006

Tel: 202-935-3390

Attn: Debbie A. Klis

                Tel: (808) 228-5998   E-Mail:
                    debbie.klis@rimonlaw.com
                     
TOTALS;   $1,595,744.70   95,744.70   $1,500,000        

 

 

 

 

Exhibit A

 

Note

 

(Attached)

 

 

 

 

Exhibit B

 

Warrant

 

(Attached)

 

 

 

 

Exhibit C Registration

 

Rights Agreement

 

(Attached)

 

 

 

 

Exhibit D

 

Security Agreement

 

(Attached)

 

 

EX-14.1 10 ex14-1.htm

 

Exhibit 14.1

 

 

ONEMEDNET CORPORATION

 

CODE OF ETHICS AND BUSINESS CONDUCT POLICY

 

(Adopted November 8, 2023)

 

I. INTRODUCTION

 

The Board of Directors (the “Board”) of OneMedNet Corporation (the “Company”) has adopted this code of ethics and business conduct policy (this “Code”), as amended from time to time by the Board, and which is applicable to all of the Company’s directors, officers and employees (to the extent that employees are hired in the future) to:

 

  promote honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships;
     
  promote the full, fair, accurate, timely and understandable disclosure in reports and documents that the Company files with, or submits to, the Securities and Exchange Commission (the “SEC”), as well as in other public communications made by or on behalf of the Company;
     
  promote compliance with applicable governmental laws, rules and regulations;
     
  deter wrongdoing; and
     
  require prompt internal reporting of breaches of, and accountability for adherence to, this Code.

 

In addition to following this Code in all aspects of business activities, the Company’s directors, officers and employees are expected to seek guidance in any situation where there is a question regarding compliance issues, whether with the letter or the spirit of the Company’s policies and applicable laws. Cooperation with this Code is essential to the continued success of the Company’s business and the cultivation and maintenance of its reputation as a good corporate citizen. Misconduct is never justified, even where sanctioned or ordered by an officer or other individual in a position of higher management. No individual, regardless of stature or position, can authorize actions that are illegal, or that jeopardize or violate Company standards. This Code sets forth general principles of conduct and ethics and is intended to work in conjunction with the policies and procedures that are covered in the Company’s specific policy statements.

 

Nothing in this Code prohibits the Company’s directors, officers or employees from reporting possible violations of federal law or regulation to any governmental agency or entity, including but not limited to the Department of Justice, the SEC, the Congress, and any agency Inspector General, or making other disclosures that are protected under the whistleblower provisions of U.S. federal law or regulation. No prior authorization from the Company is needed to make any such reports or disclosures and there is no duty to notify the Company that any such reports or disclosures have been made. The Company has a no-tolerance policy for retaliation against persons who raise good faith compliance, ethics or related issues.

 

This Code may be amended and modified by the Board. In this Code, references to the “Company” mean OneMedNet Corporation, Inc. and, in appropriate context, the Company’s subsidiaries, if any.

 

 

 

 

II. HONEST, ETHICAL AND FAIR CONDUCT

 

Each person owes a duty to the Company to act with integrity. Integrity requires, among other things, being honest, fair and candid. Deceit, dishonesty and subordination of principle are inconsistent with integrity. Service to the Company should never be subordinated to violations of laws or regulations, unscrupulous dealings or to personal gain and advantage.

 

Each person must:

 

  a. act with integrity, including being honest and candid while still maintaining the confidentiality of the Company’s information where required or when in the Company’s interests;
     
  b. observe all applicable governmental laws, rules and regulations;
     
  c. comply with the requirements of applicable accounting and auditing standards, as well as Company policies, in order to maintain a high standard of accuracy and completeness in the Company’s financial records and other business-related information and data;
     
  d. adhere to a high standard of business ethics and not seek competitive advantage through unlawful or unethical business practices;
     
  e. deal fairly with the Company’s customers, suppliers, competitors, employees and independent contractors;
     
  f. refrain from taking advantage of anyone through manipulation, concealment, abuse of privileged information, misrepresentation of material facts or any other unfair-dealing practice;
     
  g. protect the assets of the Company and ensure their proper use;
     
  h. until the earliest of (i) the Company’s liquidation, or (ii) such time that such person ceases to be an officer or director of the Company, in each case, to first present to the Company for the Company’s consideration, prior to presentation to any other entity, any business opportunity, but only if such opportunity is suitable for the Company, subject to the Company’s certificate of incorporation and bylaws in effect at such time and subject to any other fiduciary or contractual obligations such officer or director may have; and
     
  i. avoid actual or apparent conflicts between personal, private interests and the interests of the Company, wherever possible, including receiving improper personal benefits as a result of his or her position, except as may be allowed under guidelines or resolutions approved by the Board (or the appropriate committee of the Board) or as disclosed in the Company’s public filings with the SEC. Anything that would be a conflict for a person subject to this Code will also be a conflict for a member of his or her immediate family or any other close relative.

 

Examples of conflict of interest situations include, but are not limited to, the following:

 

  any significant ownership interest in any supplier or customer;
     
  any consulting or employment relationship with any supplier or customer;
     
  the receipt of any money, non-nominal gifts or excessive entertainment from any entity with which the Company has current or prospective business dealings;
     
  selling anything to the Company or buying anything from the Company, except on the same terms and conditions as a third party would buy or sell a comparable item in an arm’s-length transaction;
     
  any other financial transaction, arrangement or relationship (including any indebtedness or guarantee of indebtedness) involving the Company; and

 

2

 

 

  any other circumstance, event, relationship or situation in which the personal interest of a person subject to this Code interferes, or even appears to interfere, with the interests of the Company as a whole.

 

Any material transaction or relationship that reasonably could be expected to give rise to a conflict of interest shall be disclosed to the Board.

 

III. CONFIDENTIALITY

 

The Company’s directors, officers and employees must maintain and protect the confidentiality of information entrusted to them by the Company, or that otherwise comes into their possession, while carrying out their duties and responsibilities, except when disclosure is authorized by the Company or legally mandated.

 

Confidential information encompasses all non-public information (including, for example, “inside information” or information that third-parties have entrusted to the Company) that may be of use to competitors or may otherwise be harmful to the Company or its key stakeholders, if disclosed. Financial information is of special sensitivity and should under all circumstances be considered confidential, except where its disclosure is approved by the Company or when the information has been publicly disseminated.

 

IV. DISCLOSURE

 

The Company strives to ensure that the contents of and the disclosures in the reports and documents that the Company files with the SEC and other public communications shall be full, fair, accurate, timely and understandable in accordance with applicable disclosure standards, including standards of materiality, where appropriate. Each person must:

 

  not knowingly misrepresent, or cause others to misrepresent, facts about the Company to others, whether within or outside the Company, including to the Company’s independent registered public accountants, governmental regulators, self-regulating organizations and other governmental officials, as appropriate; and
     
  in relation to his or her area of responsibility, properly review and critically analyze proposed disclosure for accuracy and completeness.

 

In addition to the foregoing, the Chief Executive Officer and Chief Financial Officer of the Company and the Chief Executive Officer and the Chief Financial Officer of each subsidiary of the Company (or persons performing similar functions), if any, and each other person that typically is involved in the financial reporting of the Company must familiarize himself or herself with the disclosure requirements applicable to the Company as well as the business and financial operations of the Company.

 

Each person must promptly bring to the attention of the Board of Directors any information he or she may have concerning (a) significant deficiencies in the design or operation of internal and/or disclosure controls that could adversely affect the Company’s ability to record, process, summarize and report financial data or (b) any fraud that involves management or other employees who have a significant role in the Company’s financial reporting, disclosures or internal controls.

 

V. COMPLIANCE

 

It is the Company’s obligation and policy to comply with all applicable governmental laws, rules and regulations. All directors, officers and employees of the Company are expected to understand, respect and comply with all of the laws, regulations, policies and procedures that apply to them in their positions with the Company. Employees are responsible for talking to their supervisors to determine which laws, regulations and Company policies apply to their position and what training is necessary to understand and comply with them.

 

Directors, officers and employees are directed to specific policies and procedures available to persons they supervise.

 

3

 

 

VI. REPORTING AND ACCOUNTABILITY

 

The Board is responsible for applying this Code to specific situations in which questions are presented to it and has the authority to interpret this Code in any particular situation. Any person who becomes aware of any existing or potential breach of this Code is required to notify the Board promptly. Failure to do so is, in and of itself, a breach of this Code.

 

Specifically, each person must:

 

  Notify the Board promptly of any existing or potential violation of this Code.

 

  Not retaliate against any other person for reports of potential violations that are made in good faith.

 

The Company will follow the following procedures in investigating and enforcing this Code and in reporting on this Code:

 

  The Board will take all appropriate action to investigate any breaches reported to it.

 

  Upon determination by the Board that a breach has occurred, the Board (by majority decision) will take or authorize such disciplinary or preventive action as it deems appropriate, after consultation with the Company’s internal or external legal counsel, up to and including dismissal or, in the event of criminal or other serious violations of law, notification of the SEC or other appropriate law enforcement authorities.

 

No person following the above procedure shall, as a result of following such procedure, be subject by the Company or any officer or employee thereof to discharge, demotion suspension, threat, harassment or, in any manner, discrimination against such person in terms and conditions of employment.

 

VII. WAIVERS AND AMENDMENTS

 

Any waiver (defined below) or an implicit waiver (defined below) from a provision of this Code for the principal executive officer, principal financial officer, principal accounting officer or controller, and persons performing similar functions or any amendment (as defined below) to this Code is required to be disclosed in a Current Report on Form 8-K filed with the SEC. In lieu of filing a Current Report on Form 8-K to report any such waivers or amendments, the Company may provide such information on its website, in the event that it establishes one in the future, and if it keeps such information on the website for at least 12 months and discloses the website address as well as any intention to provide such disclosures in this manner in its most recently filed Annual Report on Form 10-K.

 

A “waiver” means the approval by the Board of a material departure from a provision of this Code. An “implicit waiver” means the Company’s failure to take action within a reasonable period of time regarding a material departure from a provision of this Code that has been made known to an executive officer of the Company. An “amendment” means any amendment to this Code other than minor technical, administrative or other non-substantive amendments hereto.

 

Any request for a waiver of any provision of this Code must be in writing and addressed to the Board. All persons should note that it is not the Company’s intention to grant or to permit waivers from the requirements of this Code. The Company expects full compliance with this Code.

 

VIII. INSIDER INFORMATION AND SECURITIES TRADING

 

The Company’s directors, officers or employees who have access to material, non-public information are not permitted to use that information for security trading purposes or for any purpose unrelated to the Company’s business. It is also against the law to trade or to “tip” others who might make an investment decision based on inside company information. For example, using non-public information to buy or sell the Company securities, options in the Company securities or the securities of any Company supplier, customer, competitor or potential target is prohibited. The consequences of insider trading violations can be severe. These rules also apply to the use of material, non-public information about other companies (including, for example, the Company’s customers, competitors, potential business partners and potential targets). In addition to directors, officers or employees, these rules apply to such person’s spouse, children, parents and siblings, as well as any other family members living in such person’s home.

 

4

 

 

IX. FINANCIAL STATEMENTS AND OTHER RECORDS

 

All of the Company’s books, records, accounts and financial statements must be maintained in reasonable detail, must appropriately reflect the Company’s transactions and must both conform to applicable legal requirements and to the Company’s system of internal controls. Unrecorded or “off the books” funds or assets should not be maintained unless permitted by applicable law or regulation.

 

Records should always be retained or destroyed according to the Company’s record retention policies. In accordance with those policies, in the event of litigation or governmental investigation, please consult the Board or the Company’s internal or external legal counsel.

 

Any and all reports received by the Company of questionable accounting, violations of internal accounting controls, or any other auditing or financial matters, or the reporting of fraudulent financial information or other questionable conduct that are submitted to an officer of the Company will be handled as follows:

 

  All reports received will be logged and include, among other things: (1) the date the report was received, (2) a description of the report, (3) the reporting party (if provided), and (4) the status and disposition of an investigation of the report.

 

  The Secretary of the Company will promptly submit to the Audit Committee of the Board (the “Audit Committee”) all reports received. The Audit Committee shall direct and oversee an investigation of all reports as it determines to be appropriate. The Audit Committee may also delegate the oversight and investigation of reports to the appropriate members of the Company’s management. The Audit Committee may request special treatment for any report and may re-assume the direction and oversight of an investigation of any report delegated to members of our management.

 

X. IMPROPER INFLUENCE ON CONDUCT OF AUDITS

 

No director or officer, or any other person acting under the direction thereof, shall directly or indirectly take any action to coerce, manipulate, mislead or fraudulently influence any public or certified public accountant engaged in the performance of an audit or review of the financial statements of the Company or take any action that such person knows or should know that if successful could result in rendering the Company’s financial statements materially misleading. Any person who believes such improper influence is being exerted should report such action to such person’s supervisor, or if that is impractical under the circumstances, to any of the Company’s directors.

 

Types of conduct that could constitute improper influence include, but are not limited to, directly or indirectly:

 

  Offering or paying bribes or other financial incentives, including future employment or contracts for non-audit services;
     
  Providing an auditor with an inaccurate or misleading legal analysis;
     
  Threatening to cancel or canceling existing non-audit or audit engagements if the auditor objects to the Company’s accounting;
     
  Seeking to have a partner removed from the audit engagement because the partner objects to the Company’s accounting;
     
  Blackmailing; and
     
  Making physical threats.

 

5

 

 

XI. ANTI-CORRUPTION LAWS

 

The Company complies with the anti-corruption laws of the countries in which it does business, including the U.S. Foreign Corrupt Practices Act of 1977 (“FCPA”). Directors, officers, employees and agents, such as third-party sales representatives, shall not take or cause to be taken any action that would reasonably result in the Company not complying with such anti-corruption laws, including the FCPA. If you are authorized to engage agents on the Company’s behalf, you are responsible for ensuring they are reputable and for obtaining a written agreement for them to uphold the Company’s standards in this area. The Company will comply with the Policy Statement Regarding Compliance and Ethics attached hereto as Schedule A.

 

XII. VIOLATIONS

 

The Board will investigate any reported violations and will oversee an appropriate response, including corrective action and preventative measures. Any director, officer or employee who violates this Code will face appropriate, case specific disciplinary action, which may include demotion or discharge. Such action is in addition to any civil or criminal liability which might be imposed by any court or regulatory agency.

 

XIII. OTHER POLICIES AND PROCEDURES

 

Any other policy or procedure set out by the Company in writing or made generally known to employees, officers or directors of the Company prior to the date hereof or hereafter are separate requirements and remain in full force and effect.

 

XIV. INQUIRIES

 

All inquiries and questions in relation to this Code or its applicability to particular people or situations should be addressed to the Board, or such other compliance officer as shall be designated from time to time by the Company.

 

6

 

 

Policy Statement Regarding Compliance & Ethics

 

I. INTRODUCTION

 

OneMedNet Corporation, Inc. (the “Company”) is committed to the highest ethical standards, and expects the same of its directors, officers and employees (to the extent that employees are hired in the future), Third Party (as defined below) representatives, and joint venture partners. Consistent with this commitment, all Company employees are expected to understand and comply with all applicable laws, rules, and regulations applicable to their job responsibilities at the Company.

 

This Policy Statement sets forth the Company’s general requirements and expectations relating to several key areas of business conduct and ethics. At the same time, this Policy Statement is not intended to be a comprehensive rulebook and cannot address every situation that a Company director, officer and employee (to the extent that employees are hired in the future) may face. If any Company director, officer or employee (to the extent that employees are hired in the future) feels uncomfortable about a situation or has any doubts about whether a situation or course of conduct is consistent with the Company’s ethical standards, such individuals are advised to seek help from the Company’s Chief Financial Officer.

 

II. COMPLIANCE WITH ALL LAWS INCLUDING BRIBERY AND OTHER CORRUPT PAYMENTS LAWS

 

The Company shall comply with all applicable laws, including applicable laws governing bribery, extortion, kickbacks, and the giving or receiving of gifts or hospitality to “Government Officials.”1 Consistent with this commitment, Company directors, officers or employees (to the extent that employees are hired in the future) are prohibited from offering, promising, giving, soliciting, accepting or authorizing another to offer, promise, give, solicit or accept anything of value, either directly or indirectly, for the purpose of corruptly influencing the decision of any person, or to otherwise obtain or retain business or a business advantage in connection with the Company. This includes all local, state and federal corruption laws, as well as international laws such as the Foreign Corrupt Practices Act, to the extent the Company is conducting business outside of the United States.

 

III. FACILITATION PAYMENTS

 

It is the Company’s policy not to make or authorize anyone to make any small, unofficial payment to secure or expedite the performance of a routine or necessary action by a Government Official (a “Facilitation Payment”)2 in connection with the Company.

 

IV. GIFTS & HOSPITALITY

 

The Company requires that all gifts and hospitality promised, offered or provided on behalf of the Company be reasonable, related to a legitimate business purpose, and lawful under applicable laws and regulations, including those relating to the nature and amount of gifts and hospitality that can be provided to Government Officials.

 

 

1 Government Official” means: (i) any person who is an officer, officeholder, full or part-time employee or representative of: (1) a national, state, regional, provincial, city, county or other local government; (2) independent agencies of any government; or (3) state-owned businesses or state-controlled businesses (e.g., a representative of a sovereign wealth fund or public pension fund, an affiliate of a state-owned company owning distressed assets); (ii) political party officials and candidates for political office; and (iii) any employees of quasi-public or non-governmental international organizations (sometimes called “NGOs”).

 

2 A “Facilitation Payment” may take the form of any kind of advantage, and is not limited to cash or cash equivalents.

 

7

 

 

No Company employee or Third Party may offer, promise, give, solicit, accept or authorize another to offer, promise, give, solicit or accept any gift or hospitality for the purpose of corruptly influencing the decision of any person, or to otherwise obtain or retain business or a business advantage on behalf of the Company.

 

All gifts and hospitality are required to be approved by appropriate Company personnel before being provided to any external party, and shall be documented fairly and accurately in the Company’s books and records.

 

V. POLITICAL AND CHARITABLE CONTRIBUTIONS

 

It is the policy of the Company that its funds or assets not be used to make a political or charitable contribution,3 unless prior approval has been given by the Company’s Chief Financial Officer. The Company shall not reimburse any Company employee or Third Party for their own personal political or charitable contributions. When Company employees participate in private political affairs, those employees should be careful to make it clear that their views and actions are their own, and not made on behalf of the Company.

 

Company employees are prohibited from making or authorizing any person to make a political or charitable contribution on behalf of the Company for the purpose of corruptly influencing the decision of any person, or to otherwise obtain or retain business or a business advantage.

 

VI. RELATIONSHIPS WITH THIRD PARTIES

 

The Company shall conduct reasonable commercial and risk-based due diligence on all third party vendors, suppliers, agents, representatives, and intermediaries (each a “Third Party” and collectively “Third Parties”) working on behalf of the Company.

 

All agreements with Third Parties relating to the Company shall be reduced to writing, accurately reflect the actual goods or services to be provided by the Third Party, and include appropriate anti-corruption compliance representations and warranties.

 

All payments to Third Parties made by or on behalf of the Company shall be made transparently, consistent with applicable written agreements, and reflected accurately in the Company’s books and records.

 

VII. DISCRIMINATION & HARASSMENT

 

Company employees shall not discriminate, harass, or authorize any discrimination or harassment on the basis of race, color, religion, sex, sexual orientation, gender identity or expression, age, disability, marital status, citizenship, genetic information, or any other characteristic protected by law.

 

The Company will not tolerate or authorize any unwelcome sexual advances, requests for sexual favors, or any other verbal or physical conduct of a sexual nature by any Company employee or Third Party in connection with the Company if and when: (i) submission to such conduct was made either explicitly or implicitly a term or condition of an individual’s employment; (ii) submission to or rejection of such conduct by an individual is used as the basis for employment decisions affecting such individual; or (iii) such conduct has the purpose or effect of unreasonably interfering with an individual’s work performance or creating an intimidating, hostile, or offensive working environment.

 

 

3 For purposes of this provision, the term “political contribution” refers to any contribution of something of value to an incumbent elected official, a candidate for elected office, a political party, a political committee, a political organization, a ballot measure committee, an inaugural committee, or a member of the transition team of a successful candidate. The term “charitable contribution” refers to any contribution of something of value to a charitable or philanthropic cause, including, but not limited to donations of cash or cash equivalents to registered charities.

 

8

 

 

VIII. MONEY LAUNDERING

 

It is the policy of the Company to prohibit and actively prevent money laundering and any activity that could conceivably facilitate money laundering, the funding of terrorism, or other criminal activity. Consistent with this policy, the local Company partner shall develop appropriate procedures to help ensure that the Company does not facilitate or engage in any money laundering activities.

 

IX. HEALTH, SAFETY, AND ENVIRONMENT

 

The Company is committed to conducting all business activities in a responsible manner, which helps ensure the health, safety, and security of people, preservation of the environment, quality of our business offerings, security, legal, quality, and regulatory requirements in all our business activities.

 

X. RECORDKEEPING

 

The Company shall make and maintain records that fairly and accurately reflect the business transactions of the Company.

 

XI. COOPERATION WITH AUDITS AND INSPECTIONS

 

The Company, including each Company employee and Third Party, shall cooperate fully with any and all requests made by its shareholders relating to the review and/or inspection of books and records relating to the Company.

 

XII. REPORTED CONCERNS

 

The Company encourages reporting of suspected violations of this policy statement, violations of law, and perceived incidents of discrimination or harassment. The Company will not tolerate actions by Company directors, officers or employees (to the extent that employees are hired in the future) or Third Parties to discourage or authorize discouragement of any kind against any individual who reports a perceived incident of discrimination or harassment in relation to the Company.

 

Retaliation of any kind against any individual who reports any perceived incident of discrimination or harassment, or who cooperates with any investigation relating to such reports in good faith is prohibited. Engaging in any form of retaliation may subject Company personnel to discipline, up to and including termination.

 

XIII. ACCOUNTABILITY

 

Failure to comply with the guidelines and requirements set forth in this Policy Statement is a serious matter. Violating applicable laws, regulations, or the policies set forth in this document, or otherwise engaging in illegal, improper, or unethical conduct may result in appropriate remedial action.

 

9

EX-23.1 11 ex23-1.htm

 

Exhibit 23.1

 

INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT

 

We hereby consent to the incorporation in this Form S-1 of our report dated December 31, 2023, relating to the financial statements of OneMedNet Corporation as of December 31, 2023 and 2022 and to all references to our firm included in this registration statement.

 

BF Borgers CPA PC

 

Certified Public Accountants

Lakewood, CO

April 16, 2024

 

 

 

EX-FILING FEES 12 ex107.htm

 

Exhibit 107

 

Calculation of Filing Fee Tables

 

FORM S-1

(Form Type)

 

ONEMEDNET CORPORATION

(Exact Name of Registrant as Specified in its Charter)

 

Table 1: Newly Registered Securities

 

Security Type   Title of each Class of Securities to be Registered  

Fee calculation

rule

    Amount
Registered(1)
    Proposed
Maximum
Offering
Price Per
Share
    Maximum
Aggregate
Offering
Price
    Fee Rate     Amount of
Registration
Fee(2)
 
Equity   Common Stock, $0.0001 par value, each underlying the warrants (Primary Offering)(2)     457 (g)     12,085,275     $ 11.50 (3)   $ 138,980,662.5       0.00014760     $ 20,513.55  
Equity   Common Stock, $0.0001 par value (Secondary Offering)(4)     457 (c)     19,683,367     $ 0.59 (5)   $ 11,613,186.53       0.00014760     $ 1,714.11  
Equity   Warrants to purchase Common Stock, $0.0001 par value (Secondary Offering)(6)     457 (i)     681,019       --       --       --       -- (7)
    Registration Fee Previously Paid     --       --       --       --               ---  
                  Total Offering Amounts               152,068,297.11             $ 22,227.66  
                  Total Fees Previously Paid                             $ --  
                  Net Fees Due                             $ 22,227.66  

 

(1)

Pursuant to Rule 416(a) promulgated under the U.S. Securities Act of 1933, as amended (the “Securities Act”), there are also being registered an indeterminable number of additional securities as may be issued to prevent dilution resulting from stock splits, stock dividends, or similar transactions.

   
(2)

Reflects up to 11,500,000 shares of Common Stock issuable upon the exercise of 11,500,000 warrants (the “Public Warrants”) originally issued in the initial public offering of Data Knights Acquisition Corp, a Delaware corporation (“DKAC”), and (ii) up to an aggregate of 585,275 shares of Common Stock issuable upon the exercise of 585,275 warrants (the “Private Warrants” and, together with the Public Warrants, the “Warrants”) that made up a part of the private units originally issued in a private placement in DKAC’s initial public offering.

   
(3)

Reflects the shares of Common Stock that may be issued upon exercise of the Warrants at an exercise price of $11.50 per share of Common Stock.

   
(4) Represents the resale of the selling shareholders named in this prospectus (including their permitted transferees, donees, pledgees and other successors-in-interest) (collectively, the “Selling Shareholders”) of up to an aggregate of 19,683,367 shares of Common Stock consisting of (i) 797,872 shares of Common Stock upon conversion of up to $1,595,744.70 of OneMedNet Senior Secured Convertible Notes (the “Pre-Closing PIPE Notes”) issued at the closing of the Business Combination (as defined below) subject to a floor price of $2.00 per share pursuant to the terms of the Securities Purchase Agreement dated June 28, 2023, by and among Data Knights Acquisition Corp, a Delaware corporation (“Data Knights”) and the named investors (the “Pre-Closing PIPE”), (ii) 95,744 shares underlying 95,744 warrants related to the Pre-Closing PIPE and the Warrant Agreements executed at the closing of the Business Combination, (iii) 7,312,817 shares of Common Stock upon conversion (the “Conversion Shares) of up to $4,547,500 of funding to the Company pursuant to the Securities Purchase Agreement and convertible promissory notes dated March 28, 2024 (the “PIPE Notes Financing”) with Helena Global Investment Opportunities 1 Ltd. (the “Notes Investor”), (iv) 3,656,408 shares underlying 3,656,408 warrants related to the PIPE Notes Financing with the Notes Investor, (v) 277,778 shares of Common Stock issued pursuant to the terms of the Satisfaction and Discharge Agreement at $10.88 per share dated as of June 28, 2023, by and among the Company, Data Knights, and EF Hutton LLC (“EF Hutton”), (vi) 1,315,840 shares of Common Stock issuable pursuant to the outstanding loans converted to equity for Data Knights to fund its extension payments prior to the Business Combination by certain of the Selling Securityholders named in this prospectus, (vii) 1,439,563 shares of Common Stock issued upon the closing of the Business Combination to ARC Group Limited, as consideration for its financial advisory services, (viii) 1,327,070 shares of Common Stock at $0.7535 (95% of VWAP 10-day average $0.7932) for $1,000,000 investment by Dr. Thomas Kosasa, and (ix) 3,609,859 shares of Common Stock issued to Data Knights LLC (the “Sponsor”) and its affiliates, including 2,875,000 shares of Common Stock originally issued as share of Class B Stock in connection with the initial public offering of DKAC for aggregate consideration of $25,000, or approximately $0.009 per share, and 585,275 shares of Common Stock originally issued to Sponsor as part of the Placement Units issued to the Sponsor in connection with DKAC’s initial public offering at $10.00 per unit, and which are subject to six month lock-up restrictions set forth herein; and (b) the selling warrant holders.
   
(5) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) under the Securities Act, as amended, based on the average of the high and low reported trading prices of the Registrant’s shares of Common Stock as reported on the Nasdaq Capital Market on April 11, 2024, such date being within five business days of the date that this Registration Statement was filed with the SEC.
   
(6) Represents the resale of the selling warrant holders named in this prospectus (including their permitted transferees, donees, pledgees and other successors-in-interest) of up to an aggregate of 585,275 Private Warrants.
   
(7) In accordance with Rule 457(i), the entire registration fee for the Private Warrants is allocated to the Common Shares underlying such warrants, and no separate fee is payable for the Private Warrants.

 

 

GRAPHIC 13 forms-1_001.jpg begin 644 forms-1_001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# H'!PD'!@H)" D+"PH,#QD0#PX. M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_ MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T] M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P 1" !? .H# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#V:BBFLV"% MR-QZ9H!NPZBH6E(D\N-2S8W9/W>O(SZ^U,-W'GY7,A +8C7.1G'Z57*R'4BB MS130W4$-P<9(ZTN9V_K "@!0 !V%1RVT4P^91NP0&'!&1C@UA*I"70[(4IP^U2)F1U)8X^4^V?6J$KO>!/)01V[ M;X)FDRDJ=AM/UK1N#,(&-N$,O\( *6O+OBUJ%[J&K:+X2LI3 FIN#,Z]2"VT ^W4 MGZ"N,[3J+CXE^$[:Y\B36[E6%DX2YFM!Y3$X^8%R.>W2NP^'GCE]>L)]'U@&'6[%2DB.,&4 M#C=]1W_.@#K=&\0Z7XABEDTF\2Z2%MCE 1M/IR*RKCXD>%+6XD@FUJ!)8F*. MI5N"#@CI7)_ G_D#ZS_U^_\ LM/O#6KW\5E8:M#-TW3+A(+V[2&5QN56 M!Y&<5RWA/4O >K:R$\.6UI]OA0RADM2A5> 2"0/[U9OQ(YUZW_Z]Q_Z$U=>" MP\<15]G)Z'+C*\J%+GB>E A@"""#T(JEJ&LV&EE!?7*0E\E0J7FLV.GPPS74XCCF^X<$[N,U4'BS1CTO5_P"^6_PK MG?&G_("T?_=_]E%4=.?PT+&(7L=P;G;^\*YQFG3P5-TE4=WJ]C&OCZL:SIQY M5HGK<[R+6+&:Q>\2<&WC.&?!P#_DU /$FDGI>I^1_P *S+J&RB\%7#:BBEU>\CM4E;8C.#@G\!7,ZKIS:!J$4 MEI*P5OF0GJ,=0?6N;^.$GVSPSH3]/-N,_3*UA7HQ@E.#NF;X+&SK3G1JQM./ MW'K2.LB*Z,&1@"K \$5G6WB+2[S6;C2;>\CDO[<;I8 #E1Q[8[C\Z\[^'?B: M\\,ZM_PAGB9MKK@V,['Y64\A<^A[?E2^$O\ DN_B;_KBW\XZYCT3M]5\<>'= M$OFLM2U2&WN4 +1LK$@'D=!51/B;X1=U5=;MRS' &U_\*\[\57>CV7QO>;Q$ ML;:>MNN\21EQG9QP/>NETS6/AEJ>IVUG86ED]U,X6)?L3#+=N2O% '4:EX\\ M-Z/?R66H:M#!A%5?\ A9_A#_H.6_\ WR_^%:6H>%=#U":6 MZO-*LY[AQ\TDD0+' QUKS3X.^'M)U:SUHZAIUMPM8[:TA2&",82-!A5'L*FH *S;RPC MD2\-]=O]CG5049MHC([ANW.*TJBN;:&\MI(+B,212##*>A%7"7*[D3BI*Q@7 M4J#5U\FZO(SIT&Z6(IN6>/'4>I]Z=HU^DT$#V\UQ>RW"';+*"B[0W*G' 89/ MUJQJ5PT!CT>Q$MO-+ 1;W&S?;R.H5PQ(!!P2..U>=?%3PYJ,USI MGB;18S/>:6X+0*N2RAMP('?!ZCT-=?H^J0WEC'/;^9]BCB.Z:5OG#+P0P^G. M:U8I5EC1T(974,&7D$?6N*I3<&TSKA-25TG3:!I-Q/YT^F M64DO)WO I)S[XJ\B)$@2-51%& JC %9EGE?BP_\ %]O#/_7$?S>K?Q,\&71N M$\5^&RT6JVGS2K&.95 ^]CN0.W<5Z')86DMVEU):P/<1C"2M&"Z_0]1UJQ0! MY3\!&+Z%JS-U-V"?^^:YGPEKOAS1?&'B9O$BQ,DMRPB\R#S.0[9['':O=;6Q MM;%76TMH8 YW,(HPNX^IQ55_#VCRNSR:38.['+,ULA)/J3B@#EM"\<^")M6A MM='\F.\N6$2>7:E"V>V<50^(AQXDM/\ KBO_ *$:[J'0=)MIEE@TNQBE0Y5T MMT5E/L0*GGL+2ZD#W%M#*X& SH"0*ZL'B%AZO.UGR)V.!\4^%KJ/6 M!-I<$KQ7?WEC'"-WSZ ]:A\7Z7'H]GI5I'C*QN7;^\W&37IE0SVEOAS5%'4*.Y)KG_C?$MMX?T&(' MB.ZVY^BUZND:1+MC147T48%0W=A:7ZHMY:P7 0Y42QAPI]1FL*U?VB48JR1M M@\#["4JLYO%>W@ # %0)8VL5V]U';0K@K MG/0/&_$NHZ5I?QS>YUP(;%;=0X>/>,F/CCZUTL/Q"^'5O,DL MXY4.5=+(@J M?8[:[FYT73+R8S76G6<\IZO+ K,?Q(J+_A&]$_Z ^G?^ R?X4 7V<26Y=3E6 M3(/MBO,/@8?]!U[_ *_1_(UZEM&W;@8QC%06MA:6"NMG:P6XNDJ.>"*Y@>&=% MDB<;65AD$5K2JHX MQ^M;L>HM#!<7]Y&%MH\"![=BZR1-C#;?49JEKVD7L.F6MOH<,+VL1(ELY "L MBGW/X_G59_L,7CFT@BN)[.XB@">3M_=2K@X4<\8_I7>U"M'F7F].B7DMK_-: MG(N:F[>F_=_G;Y,ZE+B-W"+*C.$#$9YP>AQZ5*#D GK7+076IQ6&H75S9VNH M7,3>4CV[#=+'GE3CT]*T;>YAAO=/M5T^Y0-;%HG.2L?&2C>AX[UR3P[5[:_= MVO\ UH=$:U]S7WCMR<9P.])(^Q20"S8)"CJ?I6;;:A=3VUL]OIKQ+YQCFCE. MUHU'\0]14BK%:SP#4;J.6Y:5_LS. K8/\(]>*S=)IV9?/=:%UV9(6=(V=L9V M C)]N:)8^P)(KK**Z5BZE[RL_5=M#%X>'33T9B_8]7 M?65F>Y7[!-!LF@SS&^.JGZ]Z6Q\.10V$5KJ$K7X@E\R%YA\R>G-;-%9NO.UE MIZ>12I1O=ZA1116)J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 &4444 ?_9 end GRAPHIC 14 forms-1_002.jpg begin 644 forms-1_002.jpg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end GRAPHIC 15 forms-1_003.jpg begin 644 forms-1_003.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# H'!PD'!@H)" D+"PH,#QD0#PX. M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_ MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T] M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P 1" "- F\# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#V:BBB@ HH MHH **** "BBB@ HJ&\G:ULYITADG>.-G6*/&Z0@9VC/NU6"^LV^]:$<8V_PD'/XD@\$4 >JT5%:W,=Y:0W,))BF02(64@X(R M.#R*EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I 0>A!^E8G MBG5Y+#1Y1ITW_$P=Q'"J1&9BW#$;!_L@FL+PI>MIVJFQ:.YM=/G,S1)<6DD> MZ9I7?[[#_GG@X_K0!W-%-1UD17C8,C#(93D$4Z@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH *R]3\0V6DW,=O<"X>:1#($AMWE.T'&3M!QR:U*YZ^LX M;_Q>MOK?\ @MG_ /B:/^$KL_\ GSU?_P % ML_\ \367_P )A)#\0H_#Z6Z?V:L8@-QSD7&PR!,YQC8/SK3M?&&F7<]E#$TV M^]N)K:+,>/GBSOSZ#@XH O:7K%MJZS_9A.K0.$D2:%HF4D!APP!Z$5?K%T?_ M )#^O_\ 7Q%_Z(2MJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***S M=>UVU\/:6U[=[V&X1Q11C<\TAX5%'
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forms-1_004.jpg begin 644 forms-1_004.jpg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�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forms-1_005.jpg begin 644 forms-1_005.jpg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forms-1_006.jpg begin 644 forms-1_006.jpg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

8>3Y4 MQEP0%QNR2,Y.#TP#0!V=&:Y1O#^I+/<"SE6W699 9I'\QU+="K ]?7..U6] M!T:\L+XS3MLC\@1F,."';/WL #\SSS0!ONZQHSNP55&23T I(I4FB62)@Z. MRLIR"/6N7;P[>F[G$:QB&<2B0SR>8?F!QM( /7L<@#I5*X\+ZK)IPMX5BB=+ M6.&$I+@(Z]6S@GD\_+CWH [..XAEDDCCD5GB.'4')4XS@T\UQ[^%]06ZNI8C M$JS7$<[A6'[X! I4Y&.HSSP:W="L+C3[%X[ER6:5G5=P(13T48 _*@#2HHHI M %VE>*20HR^:-D:= PY^;@=,#!)ZUU5<_)JFKK]KVVF9(W98 MX?(8C8& #[\X;C)P/I3 9=WFKOXAN[:Q\PQPK"8QL3R_F)W[B>>@[5')%XD^ MSVSJV;EMPE8K'^['F# '_ <^M07EYKUQ*?*BN!$FX))'&8_-&4()4\C^(5-' MK7B!HIF;3%#JI.S8V4.[''][YN:RXX_$(O#=2Q7+S"T\M@&C"!S("=@[C ZD9JZ]_J*7=NDJGS!?&!0J ME5GA*Y+XR>GK[5T8H XZ(>*!,MS<).S+'*BQQO& ?F&QCGC.W/Y5M^'WU5X; MC^UT*L)CY.=N3'@8SCOG-:]% ",,C!Z5Y]I&J#PEX@N-&O0D-J\DDRS;"2X. M-N,?C7H)K,UC0K;6HE$V^.:,[HIXCM>,^Q_I4R3W1K2G%)PELS /B"7Q5-9)% M[.[$]1YCCF\A^R762M_70XZ_\/:WXK\0:YJ=OKDUO:VID$;+DC:!RBX/ M3&:XCP;I-_K4LEG9:K+9)/*L4@7.U^I!(!YQBOI6RT^VTZS2UM(EB@08"@?S M]:Q_$>B>;8)-I<$4=W:RB>,(H7>1U'%*5U$J#IRJI;+^OU/G_P ;65YI7BLZ M;J6HR:@;18U$LQ.-I .,9X%='K_V23PA&Q6Q@CQ,8D5HI$)RNT(5PX/7'_CU M9_C*]CN_'T^J7$#1VLBH&,L6X*P7!!X/<>E5?[4T7^];?^ R_P#QJJ335T8R MBXMJ6YT/P:LHM0MO$=O. 4>WCZ]B"Q!KT3P]XSL8M$MHM1GD$\0*,PB9@<' M.0/2O-?A;>36G]M)9PM)/?A8K8*O!Y.3[ U[1H^A6VF:3;VC1I(T:?,Q7.6 MZDUF[N?NG3&T*-JBW>G3YD"^,]";_E_4?[R,/Z5(OBS0WX&IV^?=L5=.F63= M;6+_ +YJ-M#TY_O6D7_?-5[_ ',KT>S^]?Y#4\0Z2_W=2M#]90*F35+!_NWM MLWTE7_&JK^&=)?K91?E4#>#]&?K9I^ H]\/W7G^!KK=0-]V>(_1Q4@=6^ZP/ MT-<\W@;1CR+?:?8TQO NE_P^:OTOA M]9":/[ UU/N:]<'_ 'L'^E'-+L'LX?S_ (,ZFN?Q/\_TK M+FT/Q0=2CE35G*H,;C@#Z;>AJQI!D34)!.,_6H^1T7=[*8YM!669U-THD,2H55>0 V<\DG MG%;(=6=E5@67[P!Y'UK(N=-N!>RR6HQ$R1@@/@N Q++GJ.M6--M'M[N]E:$Q M1S,A12^X\#!^E..CV,ZGOQNY7-"BBBM#F':?(8-1"Y^63C'O5V2[M]-:=KF9 M(H0!)N[LS'^E*+ M7Q5/_K-0M8 ?^><(/\ZZ>BCD\P]L^D5]W^=SESX%'Z4SP3 M(MGH][;S-A[.XD$G'..N:ZDUS&JPRZ!K)UJUC:2TF 2]B49(]' ]N]3**BU) M&M.HZL73;WVZ:G&Z/XQLO(\42)9$E25@0*H/EL>A(Z\L6.?6JUQXNAC^&EN# M:C[1!.JQR"-/+;)^9U!XZ$C'O7<:5X3TIK'5Y=.G0QZR2QDBC4; <\#'UZ4^ MY\!V5WX8&B2S,T"SF:-VC4E/FW;16MSE::=F9U[X.M/&46BZG#J-_96\,:LL M,,FW: , +V4^I%@1X4HQ9^)! M_MI_Z-KVCX;W"6GPCCFD("HLQ.?J:IGX*V2PZ@AUBX O"&8^4ORX;=ZU:T;1 M%;3[?POIER]SIEI(7NKPKC>$!99$ *]"<^V#S@U-<:UJUF4<1KT:];4-, MBN'#AFR#OCV$X.,XR>/QJ_10 4444 %%%% !1110 4UJ=36H 2BBBD 4ZFTZ MF M%%% !1110 THI8,5&X=#CD4ZBD)H 6BH)[N"V&9YXHAZNX7^=5#X@TK./ M[2M/^_HI72*4)2V1I457@O;:Z&;>XBE'^PX;^53T]R6FMQ:*** "DI:* ,+6 M_!^D:]N-]:C>W5TX)^OK6"/A)H)2*.3S&BB)*KM0=>O.,FN[I*GD1JJTTK7, MW2/#^G:'$4T^V6+(P6ZL?QK2HI::5C.4G)WDPHHHIB"BBB@ HHHH **** "B MFYI'D2,9=U4>I.* '5R>IJ=/\0,3Q'<@,K?[0[?E6W<>(=)M?]=J-LI]!("? MTKF?$GBS1[JW2%!-<9/RRQ+C8W;&>M2YQ6[-H8>K/X8LZ:8B[M$F3DC@U2K* M\/ZZ<".9&5V'*.,;AZBMN1$D'F0G*GM3W,FG%V9#6=K<\D%I"T>:TL8I" PPP!'H1FDU_N)FN(!"SR!FWA".G(]?2JU MQK-TT-Q&AC606WG(ZC)'/IDUOA54850!Z 8H"*.BJ/H*GE?:3RT_N+_P!\BEIQ36[,ZDXR^%6"@G S M02 .:6"WDO6PN5B'5JHS)=,A,MRTY^XG SZU6N/$>G:?=R3WTQC5_DB(C)R! MUZ#US5R5Q.PT^Q.%7B60=%'<9]34E]H-C?VR07$(9%&!0[VT*AR\WO[>1-I^ MI6NJ6JW%G)YD1Z'&#^56QTKF)_!%LK^;I\\MG*.C1,5_E4>_Q1I/\46HPKV< M;7_,?X5/,UNC1TZV;^-7 M_/[S#'BNUQ\UGJ2G^Z;1\TA\17-QQ8:+?RD]&F41+^9-;A/%85]XPTNTNTLX MY6NKQVVI! -S$^F>E)W6[*ARR?N0O\_^&(FTC5=:/_$XNEMK4];6T)^;V9^O MY5N6=G!8VR06L2Q1)P%48%Y _P :M6>K M^)+G3(KW^RK39)&)!%YY$F",@=,9_&DFEJ5.,Y*S:2[71T]%C(V15J29C.E."NUI^'WEBB MDS2U1F%%%% !1110 4444 %%%% !1110 4UJ=36H 2BBBD 4ZFTZF M%%% ! M24M(>ASTH IZEJEMI-HUS>2[(QP!U+'T [FL=%UKQ !))*^E6+?=C09G<>Y_ MAJ#2H_\ A)=;FU6Y^:SM',5G&>A(ZN?>K?C;7I?#/A2]U.WC62:( 1ANF2<9 M-9J\]>ATRM0]U:RZ^1YK\0?$T'A'7/[,TO3K6YN%B5YKF^!F;)YP 3CI7%KX M^O5E\Q=+T3?Z_8A_C7HEO\)U\5VL6N:_KER][>QK-(8HU55!' &?05(?@/HP M7<=9O0I[D)C^56HQ70Q=69:3-JEFOWH)O]_B/P_JTKR1%4FAN(U* MR(3TX]Z]7TN\&I:5:7FW;Y\2R;C8]174(X=593E6&0:(M[/<5 M6"24H[/^K#Z*3-&>*LR%HJK/J-G; F>Z@CQ_?D K-E\8Z)%D?;TD([1*7_D* MER2ZEQI3E\*9N45S3>-[5O\ CUL;Z?T(BVC]341\3:QFB;?>:7^@%+G7 M0OV$^NGS1U.:3-"U%=6_E_P1)?&FBQ\)=-,?2*-F_I55_&R.<6FEWTWH64 M(/U-;D6DV4( CMHQCVJPL,:?=C4?046EW#GIK:/WO_*QS/\ ;^OW/_'MH\48 M/>60G^0HV>++KK;4F?2=#WS7#?+).A(6+\1U-*4K%4Z;J/3[^Q9M]2 M@NQ\KJS=P#R/PJ?*GH:S-$\"I;12MJ,ADGD8$2*QR/QJ\_AN[B.;747Q_=D& MZFFVM4*I&,9-1=T2Y'K2;U]:KMI^M0@DO:N@Y)((K)TO7KC5M0EL[5;;S8\X M)8X?'7%)R2T81IRDG**T6YN[QV!/T%.5)I/NIM'JU,73]:?[TUM$/]E2:G30 M)I/^/R_FD!ZJGRC]*H@C8V=JV;NX#R?\\DY)_ 5E>(;[7F@C?3+9X;?H4 RS M#W]/PKJ+32K.R'[F%0?[QY-6\4I*ZL73GR24K7]3GO">L07]@(<1Q7D7$L(! M!'OSU^M= *Y[6_"Z7DBWE@YMKZ/E)$X.:CTCQ.ZW(T[7$%M> X23HDOT]#4* M3CI(UE353WJ?W=O3NCIL48I,THK0YR&>RM[E2LT*.#ZBL"[\%6;R&:R=[2;L MT3%?Y5TU)2<4]RX5)0^%V.3V^*-(_P!7-'J$(_AE'S?]]"IH/&L,;;-5L[BR M?NQ7>GYC_"NFQ4,]G!UC+XX_=I_P/P&6FI6FH('L[F*9 M?]A@:L@USEYX+T^>3S;;?;3=0\1*G]*K_9?$VD\V]VE_$/X)QD_]]#FB\ENA M\E6#,;ASWKA[*REU/5/!5WH5V;;31&5:(%?W3(?WG7EBW0T1C; M5[DU*O-[L=(H[;PSXVTOQA_:EO*D CM)-I67E7CS@,=PQU'2I)_'-C:^.[;P MT F9(L^8"?E2[];&F^0U\5Y$S+E3CH2!QG-68G8^+/%^F^"]*MYHX[=UN+C MR]D?"_[;?*#R*DN=+B=UU+PU<1P7C()C"I^2=3R-R]L^M>7ND&B>!D7Q.XO6 MFU4F"/(.P(3O8%<_>[BNPT'3;YOBOM1ZS9EU0Q3Q'9/"W6-AU%:MU*&5B0""1UP>E "T4E+0 M 4UJ=36H 2BBBD 4ZFTZF M%%% !574RRZ7=E/OB%\?7!JU2, RD,,@C!H8T M[.Y@>"@H\)V&WNA+?7)S63\7/^2IW.@W)VJ6,UFQZ. MAZCZBK/CC09O$WA*]TVU=4GE ,9;H2#G!],U%-^[8VQ*_>M]'JOF/06OB#4KN/0HUOY9HW(6T+-^[;N2# MT^M>JVWQ;3PK:0Z+K>B7<5]8QK#((W4J<#@CZBE7XYZ&L[3+HMV)7 #2#9N8 M#H">M68">)-!O?#GP0N+#4KLW-RLB.QW%@F6'R@GL*ZSX9:.VB^"+.-[@SF? M_2 2,;0P!V]>U<1K?C>;XH::_AWP]I$XFF*O+)/(H6- ;M'\7 MZ#);S4?%\I@L1)9Z7GYICP\H]O05TFE:/:Z1;+#:QA0.IQR:N0PI!&L<2A54 M8 %/IQC;5[BJ57))M8Q&H\MP$X MZ5VA^Z:Y'PK_ ,C1K?\ O+6<]XG30;]G4]/U.OI:2EK0Y@HHHH 3%9NL:':Z MQ;-'<1@L>C8Y%:=)1:XU)Q=T<9;ZG?\ A29;75=]SI^<)<#EHQ[^HKKK>XBN MK=)K>19(G&593D$4ES:Q7<+13(&5N.17(SZ;J'A.X:YTG,]DQS):GI]1Z&L] M8>AT7C7WTE^#_P F=IFEK-T?6[36K;S;5_F7B2)N'0^A%:.:M-/5'/*+B[26 MHM%)2TQ"8HQ2T4 12VT4ZXEC5Q[BN.\6:'9Z:EKJEK J&"Y1I2O]W-=M5>[M M(KVTEMYUW12J58>U1./,K&M"JZ4U+H<[\0;^QM? FH3WT2SV\D815(R&9N%Z M<_B*X*QLCK6I^"K[2+UK.Q$91H X788SE]H)RV[OUKM(/+M;>3PSXE026%LR#(Y.>A(SP:HS/+'%OX=\#(->D&HM<:J3$A M;>(Q&?F((/4]Q^==CH6ESR?%:YU*'49&L9+-+B.'>/NN/E0KGA1VJQX-^'GV M30+BR\3!KMGN_.C1Y=P3:?E8$>O4BJESI$WASXD76NS7<\EK-%_HMJDN6ED( MQLV=E':DVEJRHQ'+@=(E[**27Q#+;ZB\%Q;K#%YA MCB]E=_,8>286)Z#/4\8[YJQ<>,_(TRSNQ;1L]S:2W M)C\W[NS''3OGK5BZ\23Z?(L%W;1_:;A%:T6-R1,Q."G(X(R#]*LP,G3[#7K2 MTMXA'/';QQVRRHA ?: V\*?7.W/Z5L:K:3WGA"]MK>.[:61"J+<,#(>?7/Y9 MJ&/Q5/-*!%8$JUPUL 20=PR,DD8QD=.N.:M $%W::Y;O/#I\EPUN8X&S(^YNI\P(3R#C']*:$UL)M)NC;M<9 M!&=ZIMZ?>W$$^X(K=T?5%U.&4_*)87\N1 &!4XSR& (/-:- 'GDVCZYJ%G+] MLAN&G^R2Q*Q8*Q_>AE&0>NT>M:7]G:E =2N[);M)I+J%H4+_ 'DPH;(SSQG. M:[&B@!!2T44 %-:G4UJ $HHHI %.IM,N;A+2TEN)<^7$A=L#)P!DTP)J*RH? M$%N[6GG0W%NEV/W+RJNUSC=C@G''/-/N=?TVUM)[E[R)HH%WR;&W$#IG H T MJ0U1CUBR>-Y#<1K&K!=S..21D=_0T^35]/B5"][;J'7U $.L:+;Z MQ;+'-N21#NBF3AHV]0:S(]7U'1?W.N6[SP+PM];H6!'^VHY!K7M]6L[G4)K* M&8//"BNP'3#="#WISZI8I<>0UW )BVS87&=WICU]JEQUNC6-6T>62NOZV/'? MB=X9A\0ZJ->TG5=-,3Q*DRS7"QD,. 1GVKSI?#\[2[/MFF#_ &C>QX_G7TK= MV/AO46E:XBT^1HP6D;Y05 ZDD>E4(_"O@Z99)8[>S98AEV$O"CU//2B\@M2? M5KY)_JCE/A;X=MO",%WJVK:GIY>X41QB&<.%4 M#>SJ51?=0>6-26ECX7L(UGMX]/C7=M#G!^;KCGO6I_:=CO\ +6Z@WXX4./3/ M\J5I/<:E3A\*N_/_ "_X)!HVAQ:1$Y#M/D/^'M6F!6;:^(=,N[& M&[2\B6&;.PN=I..O!IVI:[8:7 TES<)\JAMBD%B"<# _&J22V,Y2)VLI!'K=C-89.!-_ MK(C_ ,"'3\:?.EN'L)/X6GZ?Y;F_FEJ.*6.9%DB=71AE64Y!'UI^:HQ%HI,U M'/<16T+RS2+'&@RS,< 4 M=$29KF]9\4,ER=/T6,75^>&;JD7U/K[52N-4U# MQ3*UKH^^WL <271&&D]E]!6_HVAVNC6PCMXQN_B<]2:SNY;;'3R1I:SU?;_/ M_(SM&\+B"8WVIR&ZOGY9WYQ[#T%='C%&*6KC%1V,9SE-WD)2T44R I*** $/ M0UQ_A;/_ ENMCMD5V!/%+++2&LS-J$R6\@_U;@_,6[;0.<_2LVN76 M)T0G[2U.:OV[K_,Z4&BN+T+4O%$MGY2V"RQ@_NKJ\8QDK[KU-:HM?$\G+:EI MT6>R6S-C\2::G=;"G0Y'9R1OYHS6!Y'BB'E;S3+G'\+PM'^H)J,^)KO3CC7- M*FMH^]Q ?-B'UQR/Q%/F[B]BW\+3.CS1BH;2\M[VW6>UF2:)QPZ'(-351BU; M1E>]L+?4+9K>[A26)NJL*QET;5=)&-'OUF@'2VO,L![!QR*Z*DJ7%/4TA5E! M6Z=CCM&N/$^EW%Z-7LI;Z*:4R1&"16,0/\(R>GI5>74?%4GBZ*[M]+N!I*1> M6UL[A2Y/\77&0?TKN:*7*^Y7M(?R+\?\SFKJ'Q'K*K&&BT>(.&+QR>9*<=O3 M%7],\.VNGS-M]ZXG.YOP]!]*UL4"FH+=B=:37+'1>7]7$Q40LK83^> M+>$3=?,V#=^=3T51D51IEB"2+.VRP()\I>0>O:IGMX9'C9XHV:(YC+*"4/MZ M5)10!!]CM_/,_D1"8_\ +0(-WYU!;:1:6T4)!.YDF,OS&1O4Y^@J]10!' M#!%;IL@B2->NU% 'Z5)110 4444 %%%% !36IU-:@!****0!45];?;-/N+;= ML\Z-DW8SC(QFI:=3 R;?P]:VVGI!$BK,L'DB?;EE^7!(!SBLL^#"XD\V\7Y[ M)K/Y(VZ$@[N6/ITZ5U=(: .9'A4M?3\:HW-IKUU&\#1WV$B7BQQW]S*\HE/",ORD'.>?:@"[_ ,(6/L0M M6N\QQP20PL58LH88R>GM^M.B76 MO^$4F3,G]HJ[K&7(WE _'/3.SH?6LE[34X]5O;BR@U 13)!'YDS9<*"=V.=Q MZ]L'TH U(O"V+^&\EN5,RW"S-A3AMJE0/F8GOUIC>%)'O8IGO05BO/M8S&=Q MZ_*?FP!SU JA;6FL27MK->)>.EK>2^5EL$QF,;<\G(W9'.?>K&D#7%UFS:Z% MU]G>)_M(DY57XV]_KRH H =#X->WCC$5Z"R0&VRR, 8R21P&'//T/I4DOA!O ML-S96MVL<%R(_,\R'>P* ;3D<''0]*Z8=*6@!J#"@>@Q3J** "DI::: ,OQ M!K(TBU3RD\Z\G;R[>$?Q-_@*KZ1X?%O+]NU-Q=ZG)RTC#(C_ -E!V JI;K_: M7CVZDDY33H52,'H&;J:2Y\7SW&J3:=X?TXZA- <32-($C0^F>]9Q7,[LZ9OV M45".[5W_ )'48KCY_$FIZ[JL^F^&5BCCMSMGOIAE5/HH[U::^\7LI4Z+IV", M?\?9_P *Y3188M%BO?#OBE9+*.]<2QW".0K'TWCZ5J2PU==13'S6E["N)!Z @"KUQX1TV]TNRLFDN M_(M?FB9+@@GZGO537H=!TS48-7U*]EBGME"QQ+.?GQT^7O0,PM%UK[)#)J.F M0R16L+[=0TUCGR#_ 'T]O:O0;:XCNK=)X6#1R*&4CN#7&^"M,N+N\U;6KZW, M$>ID^7"PZH3G)%5M+U^?1K>ZT6U@>YO(;ET@!^ZJ9X)/H*Q;5-^3.N,7B(7^ MTOR[OT.OUC6[31;?S;I^6X2->7<^@%<]%INH>*[A;G5\P6"G,=HIZ^[>IJYI M'AE_M)U'69#=7K<_-]U/8#M72@ =!32&\FAT-K.*UC,C/>[EW@#/R@#D\5Y_X2^(ESJ' MBXQ6=I$+G46V_O<[!@>W/:LCQAK'BW1-RVU] MX+--N;N3Q MM+IXMY1$PFC4@DC(P7$?3;"N['U5LT6DMM04J<]) M*WFO\CU &EK!T+6+A[F72]554U" 9W#@3+_>']:W-6U%7EFN@H/V M>-1G9$#P#[ULW4T-S\0M]Y*B6VF6OF R-A59CUYK)\7Z_I][M:GAO7?#J6-KIFF:C"?)01I%(=CG\#@YJSG#QQK MESH6A"2RVBYGE6&-V&0A/\6*@'@@- &FUK5FOB,M<"Y.-W^YTQ[57\<:EH%] MIL^EW>H!;V-@\:0*9)$D'(X ING:UXH;P=<7UW81"Y2WW6^T,9';I\R8X]: M,;P^=1L[.]U&P(:XL;AH;RW08CN5'\8'9L>E>B:9J,&JZ?#>6K;HI5R/4>H/ MN*XWP7K>A:9I8MKO41'J-RYEN1=*8B9&ZCD8Q6CX0Q9ZQK>FQ$&WBF$T6#D M.,\5'PO3J=%_:TVWNOQ1UE%)15G.+124M !1110 44E+0 4444 %%%% !111 M0 4444 %%%% !36IU-:@!****0!3J;3J8"T444 %%%% !1110 4444 %%%% M!1110 4444 )29IU% '+6C#3O'UY%)PM_"LD9]2O!%8_@.>.P\0:[9W;K#<- M/N6.0[2PR>F>M=3XAT8ZM;1O _E7MNWF6\OHWH?8UDQ?V3XED6S\0:?%'JL( MPR2#:S>Z,.2*B+Y6XLZ:B]K%3CNEK\NIU7F)_?7\ZYSQKH4WB33(+2TEA1Q, M'9I#P!C]:=_P@'A[_GQ;_O\ O_C3)_A]H!A;;!+ <9\Q+AP5]^3BM#F(;;P) M8QPAM5OKR[GP 9&N&C [ \"L#0-+TY_B9<+I\*W%A;0_?8^8JOQW.>/PKF?!=NMRE_JKH,W=R[1DC^$<"FWU[+XJF.G:2S"P!Q=7?9 MA_<3U^M=+:VT5I;1P0($CC4*JCL!67Q2OT1U/]U3<7O+\$3"EI!2UH!6F:R?%%F]]X;OH8QES&64>I'-3*]G8 MTI).I'FVNCYVUK7=7L+_ %#28K^9+6>1/-C5L9.!W_'\:]PLOAEX3CL85.C0 MR,$&7D9BS''4G-?/WB20S>)KB7&-\BG]!7NWQ*;3E\(V?]JW][8P^:F)+1=S MD[3P>1Q1"W*K#K7]I+F[F)XO^'WB63Q@NL^%;B"W @2%/WFQHPJ[<<@Y&!4N MHZ=\3;[2+2SBDL[:6$8DN8[KYY^,?-D8J#X>OH;:9K_]G:SJUV@MOWS7*8:- M<'E.>M8G@F3PV?&&FBQ\0Z[3]:P_&+]2%[XBUVWN/-_>1019C0X' .>E=7\43&?A+#Y,CR1Y@VN_P!YAV)]Z .* M\$:[J>I:K=ZW?7DL\]K) "6/&UB5(QVZ"O? 0P!'0\U\Y_#8F9=0L8\F2[EM MU ]@Q)-?1BJ%4+_=&*SC\;L=%3^%"_G]W]7'T4E+6ASA2&EI* .!\3:-:R>/ M-,N-13?877R,I^Z9%SM#?G73:)JVGWUQ?6>GP&$V,ODR*(PHS[8[59UC28-9 MTZ2TN0=KO/;6TU;PEJEXMUJXL8KM]_VM[7SHY3[G/RFH^%^1TM M>VBK?$M+>1Z2+ZV-Z;07$7VD+O,.\;\>N.N*Y+Q!J_A+5[>ZL[N>%KA=R"46 M[LT3CH0P7L?>N7\22K>V;ZFGBBTN[ZSP8OLMJ(Y22< ;@'?" MT$4[!9-IFN'8_P 1Y))]OZ59S&1HOBO0=+TN!;[4HI+Q4"RW(MG7S#V))7^= M=DDBR1JZ'*L 01W%>=>)_$>C^(==T?34U&!M/27S[F3/RL1]U/J37H%W>6UA M;M-=S1P1*.6=L"@$F]$9.JZGI$NLIHNI6RS230-+F2,% HZY)Z5D?#G38[>W MO[R ,MM/,5MPW7RU/%4KK2'\;^)DU&V\ZWTR.'R6F8;3,,\A1UP?6N^MK:*T MMHX+= D4:A54= !4+WG?H=#_ '4'%[O\$97BR[GLO#\LMK(\\.(@RK]W.2 M3@?K42:M:SR00,L@>YW[$>,_-MZ^W>K.N,]*TU\2:0Z,L,4DBB$S, M$MR0$#$9/'JIJ:?7=)CV([*^521 L>X'?]W'N<$T 93>*+[[+>W7V:".*TCA MD:-B2S;P"1D' QG@UH:%?W5S=:L+N576"Y*QHJ894V@CZ]:GAU[3;F?R ^V1 MMP973&"@R5/N!S]*;:^(M/NKA5MEE>20*21$<@'[I/?% '/:=XEN5U^%K^X< M6EX[+;(,-NR<*''_ "S*^_7/KQ6]J>KS6FM6]C'):1++ \IDN">JD# P1ZUK MB&++,(TRW4[1S4,NG6T]XEU-"KS1H45FYPI.2,=.PH YN/Q7?2P7=PMG&J6U MM'.8SN+L6R/P'&([FUDE&RVNHH(TGEE@SM6,MAAU/S <^X!XKI=J@ MD[1D\$XI$BCC4JD:JIZ@# - ')2^+;@,MU':AK>6"6: ;F!9%=5#,/0Y)^E1 M3^)[VSUJZ3S(+N,+ B^3_JXRY.6//]?3I79^6@Q\J\# XZ"FK!$JE5B0*>H" MCF@#FK;Q'?W5_;6:06Z&6:2,RMD@A5#9 #<'G&,UU Z4U8D0*%10%^Z .GTI M] !1110 4444 %-:G4UJ $HHHI %.IM.I@+1110 4444 %%%% !1110 4444 M %%%% !1110 4F:#TKF=8GN$U6;9>1-&L0Q;/.]LRGGE6 P^??I0!TQYJCJ> MCV6KQA+R$,5^XXX9#['J*Y__ (2.\6UD?FU,-NDD45Y'F6Y)'(XQSD8X'>K* MZY=S7-TLTD%B82H2VF0EY04SD'([G''I2:3W'&3B[HF33-;T\8L=42YB'2.] M3)'MO'-86J:+XBUG40^J0I/8I]VSM[KRT)]6.,FI)/%NH0:4LZ)$'BM$F9'4 M_O&/89.3^&<=ZU]&O[F6TUFXD9F,5PYB5\D*-@( ]LU/);9FOMK_ !13_KRL M4;?0[R./RK7P_HMFG]Z0^:?T']:6V^']F]Y]KU(QRRG_ )9P1"&/\AR:;#KV ML/%&6>W!?33?'$#<,/X.O0_G21^*]1GQ(+>.(YBV0/UE# $D'.>YQ@'IS1R= MP]NU\"2]/\]SK(((K:)8H8UCC0855& *E&*XN_UR^DELR)UMW-^8WM%4AP@# M8+'T. ?3D8J.3Q;?P:4LT:QB2*S2=D=3F1CU R +>^1O[-O;K368Y MVP2LJ9^@(Q46<=MCH')[O1+S0]'MYIH-LAMF;@,. M.>.<&N"TEM4\(W^FZ^^GN(@V^W:92(Y>.Q^AKU+5O 'B-_$J:U$NG7)=0T2QLH=!TX30C$IN(HWB'&/W:Y^6CG1/L9=&OO1 MC^'/%7B'QI;SWFG^'/#\OEOLD,S$-G&?2F^.H_%VJ^&7L-4L=%L[^&>MV.D3Z?)?+:1SW"SO)!(ROD#&T;3TY]:[?1_"-EI;1RRO-> MW*#Y9KERY7Z ]*.9OX4"A".LW\E_GL92CJUJH)'U%=92U/*C7V\ M^NOJD<'_ ,*YGN;:UM[W5P8+4@Q+%;*I&.F3W_'-;UOX1T])EGO#-J%PO(DN MY-^/HO0?E6[11R('6GLM/33\A H X %+2T51D07=L+NW:)I'0'NA&?U! M%9D7A>SMV1X);B.9)&D$B, E&!29HS0 N!1M&S\M)<3?>D< A5&.>3_AFMR*WAADE>*-$>5MTC*,%S MC&3^ J-]/M)?.\RVB;SR#+E1\Y'0GZ4 8T7BTRW+VGV)ENQ.D"HSE5)92V<=]U:<^@6,L+QQPK!O96=HU7+$=, MY!S18:#I^G(1# K.2Y,C@%CN^]^>!Q0!FIXQ401S3V?E+/:_:HAYH)(R!M/' M!R1TS44_BRZ:X%M;V:QW"74$4@E9L%).XX!SQW%;QTJQ9$0V6*]"3[4 9EGXEEO)4MK:U\VX;S6(DD"*%1]O4#D MD^WUJYJ^I7=D-.^SQ1%KFY2&0.WW00I MI;.WGA2*6%&C0@JI'"D="/2@#"C\6,T=EM5[W MQC.MO(D=MY$_E1SQL^64HTBJ>H'//;(KHO[-LO+CC^R0[(MVQ=@PN[[V/KDU M$NAZ8N<6,&2NW)3/&00/ID"@"O;:\\NIK:7-K]E+LRQ^:Q#/CN.,'/7@DULU M3CTVSBN//CMHEE!)#!>A/4CTJUF@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@ M!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U%- >S1F@!U%-S1F@!U%-S1F@!U-:C-!.: $HHHI ?__9 end GRAPHIC 19 forms-1_007.jpg begin 644 forms-1_007.jpg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end GRAPHIC 20 forms-1_008.jpg begin 644 forms-1_008.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# H'!PD'!@H)" D+"PH,#QD0#PX. M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_ MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T] M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P 1" #- I8# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#V N2<"FG? MZBFI]]JDH ;^\]11^\]13JHZMJ@TBU^T-:7-RF<%;=0S#\"1G\* +G[SU%'[ MSU%9UGK]IJ=M;W&G;KJ&=]FY"!Y;8SA@2"#P:O?:K?S_ "//B\[IY>\;ORH M?^\]11^\]14#:E9([HUY;*Z,%93*H*D] 1G@FJ4_B?38K34+B*;[0-/!,Z0X M+#'7&<9Q0!J?O/44?O/456L-3M=2AC>VF1F>-9/+W#>H(R,@'BK,DBQ1M)(P M5%&6)["@ _>>HH_>>HJEH^M6>NZ<+VQD+1;F4AAAE(/(([5*FJ6$I01WUJQ< MD*%F4[B.H'- %C]YZBC]YZBHXKRVGB:6&XADC0D,Z2 A<=>HH_>>HJC=:W96JJ1-',6E6(K%*F5)Z9R1_C5J6\MH)1 M%+QV^:6 VG=R,$&@"_^\]11^\]167/XBM[77X-(G@G2>X4 MM#(VT1R8Z@'/7VQ3=/\ $UKJ%]J%FL4T-Q8#,R3;1QZC!.1[T :W[SU%'[SU M%5TU"#RHFN'6V>1=PCF=0V/SI\M]:6\OE374$0*=OK@GI[T 2_O/44 M?O/45G6WB"TNM988%N#)P8V0]"&!IH\163:Y;Z7&3)+<1-+')&59,+ MUR0<@_A0!I_O/44?O/45FZ_K]OX=LDN[R*9X6D6/,0!(8]."14\6IJ\K*\+Q MQJI+3%D**1C()!X/- %O]YZBC]YZBH8]0LY8TDCNX'CD.U&60$,?0'O4-GJ] MK>61NMZPQ"0QYDD3D@XZ@D<_7- %S]YZBC]YZBL[2M?M-7-\(0\?V*7RI6D* M[I]!0!+^\]11^\]1389XKA2T,L<@!P M2C X_*J!U^S_ +5GTZ,F2Z@ ,D895/(R-H8@M^% &C^\]11^\]14/VZ!((I9 MY!;^8,A9B$8?4&JMYKMM9:M8:?(LC27^[R70 IP,G)S0!H?O/44?O/457&J6 M!4,+VVVL_E@^:N"W]WKU]JB.MZ?]LN+1;J-KBV3?+&&&5'ISQF@"[^\]11^\ M]156VU2VN-/AO&=88I?N^:Z]?3()&?H:EDOK2(1-)=0(LO$9:0 /].>: )?W MGJ*/WGJ*B2^M9(3,EU T0.TNL@*Y],^M2HZR+NC97'JIR* #]YZBC]YZBLJS M\2VEWK(AHT<,[W!C\W> FT'!.>HH_>>HK,TSQ'8ZG9R7*N;>-)VMS]H(7+KU YYK0-S )A"9XA*>B M%QN_*@!_[SU%'[SU%5;75K&^N[BVM;F.6:W(655/W3Z5#<:]9V^K#32^;LQB M3865,J3C@L1D^PH T/WGJ*/WGJ*I-J\22VD4D4J273E51]JLN.Y!.>HH_>>HIB7,$DIB2:)I%ZH'!(_"I"0H)/0 MN"=OXXH T M_P!YZBC]YZBLF#Q3ITYMF5G$%U.UO!,5^61QGCU'0X)%:%[?6^GP"6Y?8I8( MH R78]% [DT 3?O/44?O/45E7'B**UUNTTJ2TN?M5VA>/&S;@=""OL <]CVH N?O/44?O/451LM8BU!(GMHWDBF!*R(RNH MXSR03@GWJE:^++>\34'ALKQAI[F.X 5201UP-W/X4 ;?[SU%'[SU%5]-U*UU M>PBO;"836\HRK#C\".QJKI7B*QU9)3&YA:.=KX%-C\3V>HH_>>HJI9ZO:WE@MYO6&)F*#S'3J#CJ"1^M3/?6D4<@"7]YZBC]YZBJ[ZC;"UDN(I!<11$^88"'*XZ\ ]O3K4UO<175O M'/;R++#(H9'4Y# ]Z '?O/44H+CN*6B@!5DS142?>;ZT4 $?WVJ2HX_OM4E M!5>[@FF: PRQIY<@<[D+;N",=1CK5BB@#(_X1FRC\0)K%KOM[CGSDC.$GXP" MR],C/6J+>"X61X/MDOV9[\:@1M_>;_[N_/3\,UTM% &-9^'4MO$6HZK))'-] MM" Q-%]S;TP<\_E54^$2+/7+6._(BU9VD.Z+)B+=<'/-='10!SVF^%?[.UJU MU 72L8+(6?EK#MW ?Q9SUK6O+2:[DB G$<"MN=%4[F(Z?-GC'TJW10!@Z;X: MDTC7KR_LKW;;WA#2VKQ[@7_OAL\'\*SH_ 02RM[?[3P3'/::W;RWK*FJS"<^5'M\IAT Y.1Q4MYX16]T"\T][B))KQ46:Y MCM\%@O0D;CD\>M='10!@ZOX775=+L[,31VYMI8Y6=(<[RG08S_C3[?PXUIK5 M[?0WFZ*]=99H)80^'7H5;/'Y&MNB@#F+KP:UW=+/)J."E^+V,+;J "!C:<'G MZ]:V-=TQM:T:ZT\3"$7*%&?9N(!]!DV\&&Q:PN+&_-O>VD8B:01; MDG0=F0G@^X(J8^$8FUF[OI9UFBO&1YH)8MP#KT*G/'XYQ7144 (+.*&61X)895EAGC^_&P/4?6H[CPO9SZS9:BK21R6T9C95/$ZGD!_7! MY]ZV:* ,#4O"J7]YJ5PMTT9U&V6VF#)OVJ.Z<\'\Q2MX5C_MK3+Y9PT>GVQM MDBECWEU(QDMGK^%;U% '.7?A".\U74KN2Z9(KZS%F8HDVF-1T(.>OX5);>%S M!JFEWS7@+Z?;&V55A"B1?4\\'Z5OT4 8OBGP\?$NF)9&Y%NBRK*6\O>25Z#J M*MVEA+:R (]M' 26DBA@V^8Q&,DY./RYJ_10!DZ/X?@T26Z-K(YAEE,L4##Y M+6%&,@Y-.?PH;GPW)H]Y?&1#"L*3Q0"-PJGY< M\G/3V%=#10!G:1I"Z6CL[127$BJLDR1;"X48&>3DU6U3PW#K!F%\+:X5S^[, ML&7@&/X6!!Z\UM44 <__ ,(FDS-+#9-9%K@>9N0_Q=1\U1P^#DM9]# M:"\?R](5E19$W&7=UR<\?E7244 I%8#J/]H!&@!(?^Z3GI^%:? M_".,FL:I?Q7F/[1A$3QM%D*0N 0<^_2MNB@#FM/\&KIT&CB.]+S:4)%C9H_D MO/4&HSX'B73M.LX[QBEE>&\)DCW>8Q.<8R %YKJ:* .;MO!L,5OJ$% MQ,D\=[=_:]OEE/+;_9(;(QV(YK8TJQ?3=.CMI+J6Z9,_O9?O')SCWQ[\UW78P!.63DG@TH\-NGBM=:2Z1=EO]F6 1=9XKF<7+0S1;BD@Z%6SQ^(.*Z&B@#)TO0_[+U74[M+DR)?RB9HF0#8V M,?>SR/PIVIZ'%JKN+Q;:Y@8 +#<0!Q&>Y5L@C-:E% '-?\(:J?V*([Z0KI4K M2IYJ[R^?X22V:6',D1?K\V<'\AGUK8T];U+%1J$D3W7.6C3:OMQG\\&K M5% &+9Z-J$.J->7>IPW <%64685MO9 VXX7\.:KV_@VU@BL;-2?]C.*S[+0; MN-[K^T=1CO([J,I-MM1&[Y&.6W'@#H!6Y10!S]KX2BMVTTFZ=O[,B>.T.P9& MX8W-V) ^E2Q^'#-J%I>ZG M@/7J>M6Z* ,*W\*VMMK,6I0"*VGC#9%K'Y2S9&/G .#CK4.G>%KC35U41:BN M=3E:1V\CF,D8.WYL=^]='10!0T/1K7P_I4-A9!_*BR=SG+,3R2:QO^$(B:QG ML9+UVMI[W[:^(P'W9SM!SP/?&:ZBB@#F;WP<;R]UNX^W!/[5@6!E\G/EA>A! MSR:EA\*O#J>EW@O5+:?:&U5/*X<$8W'YN/I70T4 %KJ:* ,&PT*;19=8 MN+9UN9=2E\T1;!&L;8QUR>/UJ[X?TG^PM"M=/\WS3"OS/C ))R<#TR:T:* " MBBB@"-/O-]:*$^\WUHH (_OM4E1Q_?:I* "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JE-K.F6\ MK13ZA:QR(<,CRJ"/J*NUXCXU'_%8ZE_UU'\A6U&FJCLSGQ-9T8J21Z]_PD&D M?]!2R_[_ *_XTZ/7-+ED6./4K-W8X55F4DGT'->!X'I6CX> _P"$DTSC_EZC M_P#0A6[PJ2O\T4'J:*XCTR-/O-]:*$^\WUHH (_OM4E1Q_?:I* M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI<'THP?2@!** M,$44 %%%% ',^-/$]SX9@M'M8893.S*PESQ@#I@UR?\ PM75/^?&R_\ '_\ M&M+XL?\ 'IIG_71_Y"O-:[Z%*$H)M'E8JO4A5<8O0[C_ (6KJG_/C9?^/_XU MZ#X?U&35]!M+Z9$22=-S*F<#DCC/TKP:O;O!7_(FZ9_UR/\ Z$:C$TXQBG%% MX*M.I-J3OH;E%%%<9Z05XCXU_P"1QU+_ *ZC^0KVZO$?&O\ R..I?]=1_(5U M83XV<&8?PUZF'6CX>_Y&33/^OJ/_ -"%9U:/A[_D9-,_Z^H__0A7=+X6>7#X MD>\GJ:*#U-%>.?1D:?>;ZT4)]YOK10 1_?:I*CC^^U24 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%RN5NO.A;:VR,$9]CFJC%RV1,YQ@KR=CIJ*Y# M_A9VA?W;W_OR/\:FL_B)HU]>PVL*W?F3.$7=$ ,GUYJO93[&:Q%)_:.IHHHK M,V"LWQ&2/#6ID$@BVDY'TK2K-\2?\BSJ?_7K)_Z#51^)$S^%GA0GFQ_KI/\ MOLTOGR_\]I/^^S48Z"BO7L?.79Z%\*9'>\U+>[-B-/O,3W->D5YK\)_^/S4_ M^N:?S->E5YN(_B,]O!_P4%%%%8'4>?\ Q8_X]-,_ZZ/_ "%>:UZ5\6/^/33/ M^NC_ ,A7FM>GAOX:/$QO\9A7MW@K_D3=,_ZY'_T(UXC7MW@K_D3=,_ZY'_T( MUGB_A1KE_P#$?H;E%%%_Y&33/^OJ/_ -"%9U:/A[_D9-,_Z^H__0A7=+X6 M>7#XD>\GJ:*#U-%>.?1D:?>;ZT4)]YOK10 1_?:I*CC^^U24 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%< MCX_\0ZAH$-BVG2I&9F8/N0-G &.M<7_PL;Q%_P _4/\ WX6MX8>4US(Y:F+I MTY._\+&\1?\ /U#_ -^%KT_PW>SZEX MII*\<^B"LWQ)_P BSJ?_ %ZR?^@UI5F^)/\ D6=3_P"O63_T&JC\2)G\+/!Q MT%% Z"BO7/G#T#X3_P#'YJ?_ %S3^9KTJO-?A/\ \?FI_P#7-/YFO2J\W$_Q M&>W@OX*"BBBL#J//_BQ_QZ:9_P!='_D*\UKTKXL?\>FF?]='_D*\UKT\-_#1 MXF-_C,*]N\%?\B;IG_7(_P#H1KQ&O;O!7_(FZ9_UR/\ Z$:SQ?PHUR_^(_0W M****X#U@KQ'QK_R..I?]=1_(5[=7B/C7_D<=2_ZZC^0KJPGQLX,P_AKU,.M' MP]_R,FF?]?4?_H0K.K1\/?\ (R:9_P!?4?\ Z$*[I?"SRX?$CWD]310>IHKQ MSZ,C3[S?6BA/O-]:* "/[[5)4RS3+"D;++O;[HVG//3B@"S#<17"DPR!P#@X M[&FI>VTDWE),C2N&*"4;$&,';SU-5K&32;*2#; MK5AYD7HM;&2QE)NR9Z!1116)TA5/6+R33 M]&O+N$*9((F=0PXR/6KE9GB;_D6-3_Z]G_E51U:)F[1;/._^%I:S_P ^]C_W MPW_Q5'_"TM9_Y]['_OAO_BJXP=!17I^QI]CP_K-7^8]<\#^*[WQ+->K>QP(( M%0KY2D9R3UR3Z5UU>;?";_CYU3_D_%C_CWTS_ 'W_ )"O-J]/#_PT>)C/XS"O;_!G_(G: M7_UQ_J:\0KV_P9_R)VE_]IB5I^&_\ D9=-_P"OE/YUF5I^ M&_\ D9=-_P"OE/YUW2^%GF4_C1[P>II*4]325XY]$%9OB3_D6=3_ .O63_T& MM*LWQ)_R+.I_]>LG_H-5'XD3/X6>#CH**!T%%>N?.'H'PG_X_-3_ .N:?S-> ME5YK\)_^/S4_^N:?S->E5YN)_B,]O!?P4%%%%8'4>?\ Q8_X]-,_ZZ/_ "%> M:UZ5\6/^/33/^NC_ ,A7FM>GAOX:/$QO\9A7MW@K_D3=,_ZY'_T(UXC7MW@K M_D3=,_ZY'_T(UGB_A1KE_P#$?H;E%%%_Y&33/^OJ/_ -"%9U:/A[_D9-,_ MZ^H__0A7=+X6>7#XD>\GJ:*#U-%>.?1D:?>;ZT4)]YOK10 1_?:I*CC^^U24 M %%%% !12X/H:,'T- "448([44 %%%% !17$?$?6=0TA=/\ [/NY+?S#)OV8 M^;&,?SKA_P#A,_$'_06N/T_PKHAAY3CS)G)5QD*2&0H90^TM_X[7?UX=XO_ .1NU3_KN:Z,/",Y-2.3&59TXIQ9 MTK?$V%P@;0+=A'P@,@.WZ?+5S3?B%%J^M6=O)HL*O-*L8E,@8KD]?NUYK6KX M6_Y&K2_^OE/YUU2H4TF['!#%UG))O\CW6BBBO-/:"LKQ3_R*VI_]>[_RK5K* M\4?\BMJ?_7N_\JJ'Q(BI\#]#PD 8Z4N!Z4#H**]<^=/0_A-_K=4_W8__ &:O M1Z\X^$W^MU3_ '8__9J]'KS<1_$9[>#_ (*_KJ%%%%8'4>>_%G_4Z7_O2?R6 MO-Z](^+/^ITO_>D_DM>;UZ>'_AH\3&?QG_70*]Q\'_\ (H:9_P!IHKQSZ(*S/$W_ "+&I_\ 7L_\JTZS/$W_ "+& MI_\ 7L_\JJ'Q(BI\#/"!T%% Z"BO7/G3T'X3?\?.J?[D?\S7I->;?";_ (^= M4_W(_P"9KTFO-Q'\1GMX/^"@HHHK ZCS[XL?\>^F?[[_ ,A7FU>D_%C_ (]] M,_WW_D*\VKT\/_#1XF,_C,*]O\&?\B=I?_7'^IKQ"O;_ 9_R)VE_P#7'^IK M/%_"C7+_ (WZ&W1117 >L%>(>,_^1QU/_KM_05[?7B'C/_D<=3_Z[?T%=6$^ M)G!F'\->IB5I^&_^1ETW_KY3^=9E:?AO_D9=-_Z^4_G7=+X6>93^-'O!ZFDI M3U-)7CGT05F^)/\ D6=3_P"O63_T&M*LWQ)_R+.I_P#7K)_Z#51^)$S^%G@X MZ"B@=!17KGSAZ!\)_P#C\U/_ *YI_,UZ57FOPG_X_-3_ .N:?S->E5YN)_B, M]O!?P4%%%%8'4>?_ !8_X]-,_P"NC_R%>:UZ5\6/^/33/^NC_P A7FM>GAOX M:/$QO\9A7MW@K_D3=,_ZY'_T(UXC7MW@K_D3=,_ZY'_T(UGB_A1KE_\ $?H; ME%%%IHH/ M4T5XY]&1I]YOK10GWF^M% !']]JDJ./[[5)0 5E>*69/"VILC%6%NQ!4X(XK M5K)\5_\ (IZI_P!>S_RJH?$B*GP/T/$_[0O/^?RY_P"_K?XT?VA>?\_ES_W] M;_&J]%>O9'SW,^YZ1\++B:=M3\Z:23 CQO9 MB/XC/;PG\%!1116)TGG?Q9^[I?UD_P#9:\YKT;XL_=TOZR?^RUYS7IX?^&CP M\9_&?]= /2OE>Y>$?^12TO_K@*SQ?PHVR_P"-^AL4 M445P'K!7AWB__D;M4_Z[FO<:\.\7_P#(W:I_UW-=6$^)G!F'P+U,:M7PM_R- M6E_]?*?SK*K5\+?\C5I?_7RG\Z[9_"SS*?QKU/=:***\@^B"LKQ1_P BMJ?_ M %[O_*M6LKQ1_P BMJ?_ %[O_*JA\2(J? _0\*'044#H**]<^=/0_A-_K=4_ MW8__ &:O1Z\X^$W^MU3_ '8__9J]'KS<1_$9[>#_ (*_KJ%%%%8'4>>_%G_4 MZ7_O2?R6O-Z](^+/^ITO_>D_DM>;UZ>'_AH\3&?QG_70*]Q\'_\ (H:9_P!< M!_,UX=7N/@__ )%#3/\ K@/YFL\7\*-IHKQSZ(*S/$W_ "+&I_\ 7L_\JTZS M/$W_ "+&I_\ 7L_\JJ'Q(BI\#/"!T%% Z"BO7/G3T'X3?\?.J?[D?\S7I->; M?";_ (^=4_W(_P"9KTFO-Q'\1GMX/^"@HHHK ZCS[XL?\>^F?[[_ ,A7FU>D M_%C_ (]],_WW_D*\VKT\/_#1XF,_C,*]O\&?\B=I?_7'^IKQ"O;_ 9_R)VE M_P#7'^IK/%_"C7+_ (WZ&W1117 >L%>(>,_^1QU/_KM_05[?7B'C/_D<=3_Z M[?T%=6$^)G!F'\->IB5I^&_^1ETW_KY3^=9E:?AO_D9=-_Z^4_G7=+X6>93^ M-'O!ZFDI3U-)7CGT05F^)/\ D6=3_P"O63_T&M*LWQ)_R+.I_P#7K)_Z#51^ M)$S^%G@XZ"B@=!17KGSAZ!\)_P#C\U/_ *YI_,UZ57FOPG_X_-3_ .N:?S-> ME5YN)_B,]O!?P4%%%%8'4>?_ !8_X]-,_P"NC_R%>:UZ5\6/^/33/^NC_P A M7FM>GAOX:/$QO\9A7MW@K_D3=,_ZY'_T(UXC7MW@K_D3=,_ZY'_T(UGB_A1K ME_\ $?H;E%%%IHH/4T5XY]&1I]YOK10GWF^M% !']]JDJ./[[5)0 5D^*_\ D4]4_P"O M9_Y5K5D^*_\ D4]4_P"O9_Y54/B1%3X'Z'A=%%%>N?.GHGPG^]JGTC_K7HU> M<_"?[VJ?2/\ K7HU>9B/XC/#_@K M^NH4445@=1Y[\6?]3I?^])_):\WKTCXL_P"ITO\ WI/Y+7F]>GA_X:/$QG\9 M_P!= KW'P?\ \BAIG_7 ?S->'5[CX/\ ^10TS_K@/YFL\7\*-IHKQSZ(*S/$ MW_(L:G_U[/\ RK3K,\3?\BQJ?_7L_P#*JA\2(J? SP@=!10.@HKUSYT]!^$W M_'SJG^Y'_,UZ37FWPF_X^=4_W(_YFO2:\W$?Q&>W@_X*"BBBL#J//OBQ_P > M^F?[[_R%>;5Z3\6/^/?3/]]_Y"O-J]/#_P -'B8S^,PKV_P9_P B=I?_ %Q_ MJ:\0KV_P9_R)VE_]II*4]325XY]$%9OB3_D6=3_Z]9/_ $&M*LWQ M)_R+.I_]>LG_ *#51^)$S^%G@XZ"B@=!17KGSAZ!\)_^/S4_^N:?S->E5YK\ M)_\ C\U/_KFG\S7I5>;B?XC/;P7\%!1116!U'G_Q8_X]-,_ZZ/\ R%>:UZ5\ M6/\ CTTS_KH_\A7FM>GAOX:/$QO\9A7MW@K_ )$W3/\ KD?_ $(UXC7MW@K_ M )$W3/\ KD?_ $(UGB_A1KE_\1^AN4445P'K!7B/C7_D<=2_ZZC^0KVZO$?& MO_(XZE_UU'\A75A/C9P9A_#7J8=:/A[_ )&33/\ KZC_ /0A6=6CX>_Y&33/ M^OJ/_P!"%=TOA9YIHH/4T5XY]&1I]YOK10GWF^M% !']]JDJ./[[5 M(0",'I0 5D^*_P#D4]4_Z]G_ )5J;%_NC\J;(D10B58]AX(<#!_.FG9W)DN: M+1\\;AZBEW#U%?0)L+%<;K6U&>F8UY_2E_L^R'_+G;?]^E_PKL^MKL>;_9S_ M )C@?A,06U3Z1_UKT:H8[>VA8K%%#&Q'(10"?RJ38O\ ='Y5RU)\\G([Z-/V M<%$=13=B_P!T?E1L7^Z/RJ#4\]^+) 72OK)_[+7G.X>HKZ$DM[:9@LT4,C#D M!U!/ZTP6%B6*BUM2PZ@1+D?I753Q"A%1L<%;!NK-SN?/I(QU%>Y^$/\ D4=+ M_P"N J^+"Q;.VUM3CKB-3C]*ECCA" 1+&$' " 8'Y5-:O[16L7A\*Z,F[W)* M*;L7^Z/RHV+_ '1^5X[%_NC\J@-G92EG-O;.< M_,VQ3^9K6C5]F[V.?$4/;12O8^?=P]16KX6(_P"$JTOG_EY3^=>V?8;';N^R MVNW^]Y:X_/%*MC9J0Z6MN,4N1^E=5/$6QPUL&ZLW.Y\^[AZBOHK3\,D?\)/IG(_X^4_G7MWV&PV[ MOLMKM_O>6N/SQ2K8V:X=+6V&.0PC7\\XK=XM-6LD.K+\3?\BOJ?_7L_P#*M+8O]T?E22)$4(E6/8>#O P?SIIV=Q25 MTT?.X(QU%+N'J*^@386*XW6MJ,],QKS^E!L+$$ VMJ">@,:Y/Z5V?6UV/,_L MY_S'G_PF(-SJG^Y'_,UZ34"06L#E8XX(V;J%55)J78O]T?E7-4GSRYCOH4_9 M04;CJ*;L7^Z/RHV+_='Y5F:G ?%@@6^F?[[_ ,A7FVX>HKZ$DM[:9@LT4+L. M0KJ"?P!I@L+$L5%K:EAU'E+D?I753Q')'EL<-?!NK-RN?/VX>HKV_P &?\B= MI?\ UQ_J:TA86+$A;6U)'4"-3C]*ECCA"!8EC"+P @&!^536K^T5K%8?"NC) MN]R2BF[%_NC\J-B_W1^5*/LEA&5;R+53U5MBC\C70\6FK6.6. ::?,6CU-)30J,,@* M1ZBC8O\ ='Y5Q'I#JS?$G_(LZG_UZR?^@UH;%_NC\J1TBV$2*FP\'=C!_.FG M9W%)731\[@C'44NX>HKZ!-C8J 3:VH!Z9C7G]*#86((!M;4$] 8UR?TKL^MK ML>9_9S_F//OA.0;S4^?^6:?S->E5#';6T+D10P1N1R$4 D?A4FQ?[H_*N:K/ MGES'?0I^R@HW'44W8O\ ='Y4;%_NC\JS-3@?BP0+33/^NC_R%>:[AZBOH26W MMIF"S10NPY"NH)_ &F"PL2Q46MKN'4>4N1^E=5+$6QPU\&ZLW*Y\^Y'J* M]O\ !/\ R)NF?]V[%_ MNC\J@-G9REG-O;.?XF**?S-:T:GLW>QSXBA[:*C>Q\^[AZBM#P\1_P ))IG( M_P"/J/\ ]"%>X_8;$KN^RVNW^]Y:X_/%*+*R3$@MK9<I)K1HH Q&T>X-]N3:B?:?/\S<"V.I'3 M=STQG%;=%% !1110!CR6$TVI;VLXD@682!XY!OSSM#';QR(JB&,Y&1G+' QWQ^%7Z* "BBB@"&[0R6DJ+$LQ92!&S;0WL M3VK(&DW,D;O)!$DK-&S1JP$;JISLP!^IS6[10!BMI]RB3/'9VS&68.D+O\D6 M%P6QC!)]*=)H_G:'+:F/$K%F4-)QN/?C@#VQQ6Q10 BC"@>@I:** "L_5()Y MC%]GMH)6&I'RCZ<_2MRB@#'-A-+J0D>SBCA2;S%:.0;V/] MYCC/_ 16Q110 4444 8\EA--J6][.)(%F$@>.0;W([L2,CZ"FV^E7$36P:*( M- SL\RO\TX(/!XSSD9SZ5M48H Q+?3)R7>:RMXV\HQI&DF(\''!P,G..I_*K M.FV,MK=W,K(L4[X M[]<=Z,'TH Q7T^Y43/%9VS&6572%W^2+"X+8Q@D^E))HUQ+I;VZN(PPIZ#UH *H:I!/,8?L]M!*PSEY2/D!]%/!/UK0P?2DP?2@##_ +(EC0!;:.5# M;^2J329,39)SG&.<]O2B?2[F39"UO%+&(T62<2 2R$#U(^4?3GZ5N'@9/ ]3 M1U&1T]: ,9M+N/[0>>)$5VG$AE9PPV\#&TC.<#'7WS6S03M&6X'J:&.U2S'" MCDD\ 4 %%!( !) ![T8Q0!CS6$TVHEVLXE@$HDWI(/,*\8'H .E;%% #(((K:%( M8(UCB0855' %/HHH *H:I!/-Y7V>V@F9299!-: MQ6Y,+1HL,N%4'U(&2?<_E5K3-/GMKN2>7:B-$L8C7;R0<[OE 'M6I10 4444 M 1W*E[:51&)"RD!"VT-[9[5BC2+F6*4O!##*P0;$<"-E5L[, 9Y]36]10!D# M3I=UQ(;6#9)(C+;[^$P,%AQC=^&.*BM](N+?R6>**>.-Y"('8;ZT4 $?WVJ2H MX_OM4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %9-4:X 5(UC4+(V3SEF)]3@=CQGUI!I%VR[9+P %0GR%A@%L MMCGJ0 !Z<]*UZ* ,F32+@SL\=UB(N6\G)VXP /7W)^M!TFZW0_Z7N$8499FY M&1VY)I@TFZN M]RS_ +F(QK&P\PL9.OY9]ZT** ,HZ9=-$0;D";G]\&; S?.S'W_A M'85HT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ? !1110 4444 %%%% !1110!&GWF^M%"?>;ZT4 ?_V0$! end GRAPHIC 21 forms-1_009.jpg begin 644 forms-1_009.jpg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end GRAPHIC 22 forms-1_010.jpg begin 644 forms-1_010.jpg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end GRAPHIC 23 forms-1_011.jpg begin 644 forms-1_011.jpg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end GRAPHIC 25 ex10-11_001.jpg begin 644 ex10-11_001.jpg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end GRAPHIC 26 ex14-1_001.jpg begin 644 ex14-1_001.jpg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ex23-1_001.jpg begin 644 ex23-1_001.jpg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onmd-20231231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Stockholders Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Stockholders Equity (Deficit) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Organization and Operations link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Business Combination link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Convertible Promissory Notes held by Related Party link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Canadian Emergency Business Loan Act (CEBA) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Shareholders’ Equity link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Stock Options link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Stock Warrants link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Fair Value Measures link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Commitments, Contingencies, and Concentrations Operating lease link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Shareholders’ Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Stock Options (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Fair Value Measures (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Organization and Operations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Schedule Of Aggregate Percentage Revenue and Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Schedule of Property And Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Schedule of Deferred Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Convertible Promissory Notes held by Related Party (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Canadian Emergency Business Loan Act (CEBA) (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Schedule of Common Stock Activities (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Shareholders’ Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Schedule of Options Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Schedule of Fair Value of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Stock Options (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Stock Warrants (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Schedule of Financial Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Commitments, Contingencies, and Concentrations Operating lease (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 29 onmd-20231231_cal.xml XBRL CALCULATION FILE EX-101.DEF 30 onmd-20231231_def.xml XBRL DEFINITION FILE EX-101.LAB 31 onmd-20231231_lab.xml XBRL LABEL FILE Entity Addresses, Address Type [Axis] Business Contact [Member] Related Party, Type [Axis] Related Party [Member] Class of Stock [Axis] Series A-2 Preferred Stock [Member] Series A-1 Preferred Stock [Member] Common Class A [Member] Common Class A One [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Business Acquisition [Axis] Data Knights Acquisition Corp [Member] Common Class B [Member] Commitment [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Securities Purchase Agreement [Member] Concentration Risk Benchmark [Axis] Revenue from Contract with Customer Benchmark [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Customer [Axis] One Customer [Member] Two Customers [Member] Accounts Receivable [Member] Three Customers [Member] Customer One [Member] Customer Two [Member] Customers [Member] Customer Three [Member] Customer Four [Member] Customer Five [Member] Long-Lived Tangible Asset [Axis] Computer Equipment [Member] Furniture and Fixtures [Member] Income Tax Authority [Axis] Domestic Tax Authority [Member] State and Local Jurisdiction [Member] Nonrelated Party [Member] Debt Instrument [Axis] Convertible Promissory Notes [Member] CEBA Loan [Member] Title of Individual [Axis] Board Of Directors [Member] Board of Directors Chairman [Member] Employees Directors and Consultants [Member] Plan Name [Axis] New Equity Incentive Plan [Member] Statistical Measurement [Axis] Maximum [Member] Award Type [Axis] Share-Based Payment Arrangement, Option [Member] Measurement Input Type [Axis] Measurement Input, Expected Term [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Expected Dividend Rate [Member] Measurement Input, Price Volatility [Member] 2021 Service [Member] 2022 Service [Member] Convertiable Notes [Member] Class of Warrant or Right [Axis] Warrant One [Member] Publicly Traded Warrants [Member] Private Warrants [Member] Warrant [Member] Measurement Frequency [Axis] Fair Value, Recurring [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Asset Class [Axis] Investments Held in Trust [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Management and Directors [Member] Senior Convertible Notes [Member] Scenario [Axis] Forecast [Member] Legal Entity [Axis] EF Hutton [Member] Kingwood Capital Partners LLC [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Majority Shareholder [Member] Entity Addresses [Table] Entity Addresses [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Contact Personnel Name Statement [Table] Statement [Line Items] Current Assets Cash and cash equivalents Investments held in Trust Accounts receivable, net of allowance Prepaid expenses and other assets Receivable from SPAC Total current assets Property and Equipment, Net Total assets Current Liabilities Accounts payable & accrued expenses Loan Amount due to related parties Excise tax Loan Extensions Deferred revenues Loan Payable Convertible promissory notes Canada Emergency Business Loan Act Income tax payable Franchise tax payable Pipe Notes, net of discount including interest Deferred underwriter fee payable Total current liabilities Long Term Liabilities Convertible promissory note Canada Emergency Business Loan Act Accrued interest Loan, related party of OMN Warrant liabilities Deferred underwriter fee payable Working capital Loan Extension loans Total liabilities Stockholders’ Equity (Deficit) Preferred value Common stock value Commitments and contingencies Additional paid in capital Accumulated deficit Total stockholders’ equity (deficit) Total liabilities and stockholders’ equity (deficit) Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Authorized Preferred Stock, Shares Outstanding Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common Stock, Shares, Outstanding Income Statement [Abstract] Revenue Cost of Revenue Gross Margin Operating Expenses General and administrative Operations Sales & Marketing Research and development Total Operating Expenses Operating loss Other Expense (income) Impairment Income tax provision Interest expense Other expense Change in FV of Warrants Stock Expense Unrealized gain or loss Other Expense (income) Net loss Loss per share of Common Stock:(1) Earnings Per Share, Diluted Weighted-average shares of Common Stock outstanding: Weighted Average Number of Shares Outstanding, Diluted Beginning balance Beginning balance, shares Issuance of common shares in exchange for services Issuance of common shares in exchange for services, share Issuance Public Shares Issuance public shares, share Issuance of Data Knights Acquisition Corp. Class B Common Stock Issuance of common class B stock, shares Common stock redemption Stock-based compensation expense Net loss Preferred Stock to Common Stock Preferred stock to common stock, shares Convertible Notes to Common Stock Convertible notes to common stock, shares Stock Options to Common Stock Stock issued during period shares options to common stock Converting of Warrants to Common Stock Converting of warrants to common stock, shares Private OneMedNet to ONMD Public Shares Stock issued during period shares other Issuance of PIPE Warrants Converting Data Knights Common Shares (A and B) to ONMD Public Shares Converting Data Knights Common Shares (A and B) to ONMD Public Shares, shares Retained earnings adjustment Ending Balance Ending balance, shares Statement of Stockholders' Equity [Abstract] Share Price Statement of Cash Flows [Abstract] Cash flow from Operating Activities Net Loss Adjustments to reconcile net loss to net cash flows from operating activities: Depreciation and amortization Business combination cost Stock-based compensation expense Cash Held in Trust Account Prepaid Expenses Other current assets Accounts payable and accrued Expenses Accounts receivable, net of allowance Deferred Revenue & Customer Deposits Amount due to related party Exercise tax liability Extension loan Franchise tax payable Income Tax Payable Working capital loan Net cash flows used in operating activities Cash used for Investing Activities Purchase of property and equipment Cash flow from Financing Activities Class B Common Stock Proceeds (repayment) from issuance of convertible promissory note payable Proceeds from issuance of PIPE Convertible Notes and Warrants Proceed from related party loan Proceeds from Canada Emergency Business Loan Act Common Stock Subject to Redemption Deferred underwriting fee Warrant liability Additional Paid-in Capital Class A Common Stock Class B Common Stock Retained Earnings adjustment Net cash flows from financing activities Net change in cash and cash equivalents Cash and Cash Equivalents, Beginning Cash and Cash Equivalents, Ending Accounting Policies [Abstract] Organization and Operations Summary of Significant Accounting Policies Business Combination and Asset Acquisition [Abstract] Business Combination Organization, Consolidation and Presentation of Financial Statements [Abstract] Going Concern Property, Plant and Equipment [Abstract] Property and Equipment Income Tax Disclosure [Abstract] Income Taxes Debt Disclosure [Abstract] Convertible Promissory Notes held by Related Party Canadian Emergency Business Loan Act (CEBA) Equity [Abstract] Shareholders’ Equity Share-Based Payment Arrangement [Abstract] Stock Options Stock Warrants Stock Warrants Fair Value Disclosures [Abstract] Fair Value Measures Related Party Transactions [Abstract] Related Party Transactions Commitments and Contingencies Disclosure [Abstract] Commitments, Contingencies, and Concentrations Operating lease Subsequent Events [Abstract] Subsequent Events Basis of Presentation and Foreign Currency Translation Business Combination Use of Estimates Operating Segments Cash and Cash Equivalents Accounts Receivable Property and Equipment Impairment of Long-Lived Assets Fair Value of Financial Instruments Revenue Recognition Income Taxes Patents and Trademarks Research and Development Stock-based Compensation General, and Administrative Expenses Emerging Growth Company Accounting Pronouncements Not Yet Adopted Recently adopted accounting pronouncements Schedule Of Aggregate Percentage Revenue and Accounts Receivable Schedule of Property And Equipment Schedule of Deferred Income Taxes Schedule of Common Stock Activities Schedule of Options Outstanding Schedule of Fair Value of Stock Options Schedule of Financial Assets Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Debt Instrument, Issued, Principal Payments to Acquire Businesses, Gross Debt Instrument, Description Investments Schedule of Product Information [Table] Product Information [Line Items] Aggregate Percent of Revenue and Accounts Receivable Accounts Receivable, Allowance for Credit Loss, Current Concentration Risk, Percentage Impairment of Long-Lived Assets to be Disposed of Retained Earnings (Accumulated Deficit) Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Total Property and Equipment Less: accumulated depreciation Net Property and Equipment Depreciation, Depletion and Amortization, Nonproduction Deferred Tax Assets Net operating loss carry forward Stock Compensation Other Gross deferred tax assets Less valuation allowance Net deferred tax assets Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Line Items] Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Deferred Tax Assets, Valuation Allowance Operating Loss Carryforwards Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Convertible Notes Payable Debt Instrument, Face Amount Class of Warrant or Right, Exercise Price of Warrants or Rights Proceeds from Issuance or Sale of Equity [custom:EquityFinancingDescription] Preferred Stock, Convertible, Conversion Price Accrued Liabilities Class of Warrant or Right, Number of Securities Called by Warrants or Rights Debt Instrument, Convertible, Conversion Price Proceeds from Issuance of Unsecured Debt Debt Instrument, Decrease, Forgiveness Debt Conversion, Original Debt, Amount Debt Instrument, Term Debt Instrument, Interest Rate, Stated Percentage Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Preferred Stock to Common Stock Convertible Notes to Common Stock Stock Options to Common Stock Converting of Warrants to Common Stock Private OneMedNet to ONMD Public Shares Converting Data Knights Common Stock (A and B) to ONMD Public Shares Issuance Public Shares Schedule of Stock by Class [Table] Class of Stock [Line Items] Shares Issued, Price Per Share Dividends, Preferred Stock Proceeds from Issuance of Preferred Stock and Preference Stock Preferred Stock, Convertible, Terms Stock Issued During Period, Shares, Issued for Services Options outstanding, ending balance Weighted average exercise price, begining balance Aggregate Intrinsic value, begining balance Options, Granted - under the Plan Options, Granted - under the Plan Options, cancelled Weighted average exercise price, ending balance Aggregate Intrinsic value, ending balance Options, Granted - under the Plan Options outstanding, ending balance Options exercisable Weighted average exercise price, exercisable Aggregate Intrinsic value, exercisable Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] [custom:EquitySecuritiesFvNiMeasurementTerm] Equity Securities, FV-NI, Measurement Input Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Stock Issued During Period, Shares, New Issues Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Description Share-Based Payment Arrangement, Expense Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Proceeds from Issuance of Warrants Class of Warrant or Right, Outstanding Other Liabilities Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Assets measured and recorded fair value Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] [custom:ExtensionLoan-0] Proceeds from Convertible Debt Stock Issued During Period, Shares, Acquisitions Senior Notes, Current Operating Lease, Cost Operating Leases, Rent Expense, Net Subsequent Event [Table] Subsequent Event [Line Items] Business Combination, Consideration Transferred Stock Repurchased During Period, Shares Related Party Transaction, Amounts of Transaction Proceeds from Related Party Debt Proceeds from Issuance of Private Placement Securities Purchase Agreement [Member] Data Knights Acquisition Corp [Member] Operating Segments [Policy Text Block] Customer One [Member] Customer Two [Member] Customer Three [Member] Customer Four [Member] Customer Five [Member] Deferred underwriter fee payable noncurrent. Deferred underwriter fee payable current. Working capital loan. Loan extensions current. Patents And Trademarks [Policy Text Block] Emerging Growth Company [Policy Text Block] Accounting Pronouncements Not Yet Adopted [Policy Text Block] Series A Two Preferred Stock [Member] Series A One Preferred Stock [Member] Increase decrease franchise tax payable. Proceeds from issuance of common stock one. Proceeds from issuance of common stock two. Common Class A One [Member] Procceds from retained earnings adjustment. Proceeds from business loan. Proceeds from deferred under writing fee. Proceeds from common stock subject to redemption. Business combination cost. Cash held in trust account. Unrealized gain loss. Increase decrease in extension loan. Increase decrease in working capital loan. Increase decrease in exercise tax liability. Class B common stock. Stock issued during period value issuance of pipe warrants. Customers [Member] Stock issued during period value stock options to common stock. Stock issued during period value converting of warrants to common stock. Stock issued during period value converting data knights common shares. Stock issued during period shares stock options to common stock. Stock issued during period shares converting of warrants to common stock. Stock Issued During Period shares converting data knights common shares. Equity financing description. CEBA Loan [Member] Board Of Directors [Member] Employees Directors and Consultants [Member] New Equity Incentive Plan [Member] Equity securities FvNi measurement term. Stock warrants disclosure text block. Twenty Twenty One Service [Member] Twenty Twenty Two Service [Member] Convertiable Notes [Member] Extension loan. Warrant One [Member] Publicly Traded Warrants [Member] Private Warrants [Member] Senior Convertible Notes [Member] Management and Directors [Member] EF Hutton [Member] Kingwood Capital Partners LLC [Member] Convertible Promissory Notes [Member] Warrant liability non current. Stock issued during period shares convertible notes to common stock. One Customer [Member] Two Customers [Member] Three Customers [Member] Stock issued during period shares issuance of pipe warrants. Proceeds from warrant liability. Investments Held In Trust [Member] Accrued interest related party. Stock issued during period value common stock redemption. Common stock subject to possible redemption value. Stock issued during period value convertible notes to common stock. Retained earnings adjustment. Commitment [Member] Assets, Current Assets Liabilities, Current Unsecured Debt DeferredUnderwriterFeePayableNonCurrent Liabilities Equity, Attributable to Parent Liabilities and Equity Operating Expenses [Default Label] Operating Income (Loss) UnrealizedGainLoss Nonoperating Income (Expense) Shares, Outstanding Share-Based Payment Arrangement, Noncash Expense Increase (Decrease) in Prepaid Expense Increase (Decrease) in Other Current Assets Increase (Decrease) in Accounts Receivable IncreaseDecreaseFranchiseTaxPayable Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment ProceedsFromWarrantLiability ClassBCommonStock Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations StockWarrantsDisclosureTextBlock Business Combinations Policy [Policy Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Deferred Tax Assets, Gross Deferred Tax Assets, Net of Valuation Allowance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value EX-101.PRE 32 onmd-20231231_pre.xml XBRL PRESENTATION FILE EXCEL 83 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

6\AXS\3R]EY/S*%F:'11?+%3*S> MK=YFMZZ^USZ:M=7B5Q+ MUL,_ %FUOBA1<<7U%FXB6<3)W>KZ.474KC3DK1$.D??Z2VL(#%"H_!:_:@.O M!P+5*BM&1.N!Z*XGBE6#YH]\-!,?\8+=!0*A:2E9L!AQ8>G12YOV,$@>.;!= MZ[C3NGY $QMF',##1A2635L7L:7DD7M>2KP0QMQUZT*+]?X!"EQ#*?=O9-I6 MIC2E4!_C)L;OH*ZE%DC@*X]F3OF=;,MZ-*X#,"IT$(^^S=5WE:=&&?$KD0C=\"C#)&^$095;NV,XO4,AL]EB7]=P:BTI)[@BD M/YN0 B/1M'NBADXW@DL"]<(^+@F"2\+BD$Z"RP(Q4IW$Q!!T2UEO=;9AE5GL M/XO<8;T8L$X:VT*7HO!MRJ/EOT\YZS5O\\G[X\.\_&L2\+SAZJO2B) M"'17?&9[LD<.[YS,4P^LN@!,0^G01B(FFOD,-1#!EX42ZZ:) NK*/_H\P^F0 MR/[VZ7HUA!UJESA9Y!P!7*"4W*//5)56!M#0OR&%^=.CK5&9L4MHUW] U9[: MQCK*-6]2N#U;S!9GXL1K;H4U%_AE/C"BUD9#/)\RCFE*D!S108Z#K7ZPH%M_ MT_>RVT,O>SX5G6WRT-.RAY*91!95A+*P1QMQ9_&8#-#3C%<'VJQ@;\+(DY3> MW?"8/V&EU5R6T@;4D5LZ#G0EX4OK$-QU[ %PA#^VW6W:[HZW(R=R2^TWY5[[ ML=OZ#7F2^^PCYV?'L%3K>Q]OS"92385F%(ZDWP-[NMZO4TP"%V+^,CDS4I0N$ M:C ;4.3"1^EK4 &DST;U%.1D%+2S\WPFXMV5+A!\@6H,U:/^Y7%$I=HP5!"N M!]VF*72Z>MR':RJ!V*S06HW.2T,-//1$PI+6NH(/I73M4GT&>CJIDMNG@VK#-=5U]:#3P):M5$_H%H7 MLC$P;);]?ZWQ3RI91T&'B$B-S/3GA3HX:Q0+<",MGP+NZ)Z7^")?3$7U]2!# MW];_FD,\H.E^>SE^43X=(M.+]$U?'-=NXA[,#^6&@W7TP1\WSB8T[W0!L._ M,J[^!U!+ P04 " !.E)!8A(7^+[8" !8!@ &0 'AL+W=OI*RVR/!8IF6;]_B153.AD/HU[MW8^-9670N.M M!5QN@=)L9\D@V6_I9< M#2X7HY ?$[X)W+J#&(*3E3$/8?$IGR7]( @E<8E2!B"2\:O!3%K* M4'@8[]$_1._D9<4<+HW\+G)?S)*+!')*$#B_EWELZ%53GYTNCE/#49>^ZL#3:"[U!S072DND\;'$ZM"STT,'G$D.H M-R"1>C%-/6D(2"EO^!8U7_8"WR"#&V(I'+S7.>9_ J0DOG60[1TLLI.(U\A[ M,!QT(>MGPQ-XP[8CPX@W_'M']AUX;@I<"\>E<95%^'&U:T--,CI. M$CZU2UIU_$P)? M"@P0)=,[*!B]#E#A[IQY<$9>I(Q6H@+RF%J KBVI%LO;7-@)0D'6)UI481Y7< M]>#894@/OG:%=A-GFB/*2OOZPV]WV[%Y54^+Y_1ZYMXPNQ'4>(EK*NWWSL<) MV'J.U0MORC@[5L;3)(IA0:,?;4B@\[4Q?K\(!.V?R?PW4$L#!!0 ( $Z4 MD%BOP,OU0@8 "H0 9 >&PO=V]R:W-H965TH!HJ"*C.W3$@@EZK)!<)"2(K [L/6/FCL]EB+;1E)GLG\_9Z6 M+YD)0S84#V1LN=5]=/IT2^)PJ#7*JB=WSHQZ[-\:&N7*8*NC;"5GDNS>J$ M,KT\ZHUZ[X,_%2WMVK/@EKL+Q6[]*BWWQ,Q);+*W&>]O*!F/;OL+]*9]7_%LK8=O^Z) MJ+).Y\UD(,A54?_*VX:'M0G[PY],&#<3QAYW'&-'_Q2 M_6R 4P4GY<89?%68YXYOJIFE[Q453IPO\-<>#AS<\L=!U+@XJ5V,?^)B-!:7 MNG"I%>=%3/&F@P'P=*#&+:B3\8,>SRCJBYU1*,;#\YX?SN/7:3X M>SJSSD 2_VQ;;^UMLMT;E\D;6\J(CGJH TMF0;WC9T]&KX8'#V"==%@G#WE_ M7$(>=C':[0<_+OE+2L&ISDM9K$0JK:"%S"KI*$9!=K94V^HHJHQ1Q5RXU.AJ MGHII:50F7ON43$(,DX@QV3\DJI!%I&0FK,-8[ETLR9"0"ZDR.REMW,P!\'_$W.9FSMT!E!QVA_+]R;[/Z,K<3H7$A> M[H*,4Y!%4&BX3W6&A?PF#JB'0&D,[D;A<#CD?T$3,9?_:M"T$AY8'XE &KPCKEJ@:S L_80$Q0&KU0OK*J MDK$\%9/^[J33%PHL@9;6RUT*U/L"<(,R0Z?S05K"VC+FE5@J%(;74BHXI2C$ M*8 :6BA=V6P%;(6N,"<.$(^W4['_\D,H\'(IL1HQWF\[RU5!EQ1_PG'D5!LP M5!?%'JPU@O'HX,4&:<$OD+;N\^;.\KJUG+:6721/\P5.%(44[S(] M \?O/WU7)":T*[R88B8\N[H=>1DFB,M7DOIG>]@0XB-@*S6*5R^+E>YM! M?-:?-*"Q>*$L^&4]MMD4=]GT3E4=/&.+^D$]/5M"0]8E' M6E)^.=-[;::O<7(2?_2QIHJ3Y$>>W0.)S> 7R(E17T\&:Y(<,2R4* M6-?K!T9<6E "%LJZ@2(,.<5;D7VD:T%)4K?G%G&SZ_7%I6G00@E9QBRA]:+9 M(@'^&%#WA)SRV9W7$RU-S+WE#"@BY,]N",]_[@2VB:0/<7"0HCG!>OEU&+J- MD$,K3F.]3TYKS:SJR/=Y"SI,0I:L)%99TY^O2A_FG9'WJF/]0X=U4X9L/?<3 M$7 TV:O;+TA\N2(),KP''#INR43*^B,!MBCTZC[L2M#E.VDM>+R!T6ZA4%AF M]38%W43:.7&ALYG!L3_WA@&F]\Z2J<5&K_?O)1S1(]7FVC4YC>> M;9YK2/9I*X_-#5(0;:GRDY#$E847SV$)& MZ HK$37[7'/PJ!?Q)\[7KLW, .(_'LSU#OQ2>I_K$!VWB#WQ. 6,#1^VZ M#A>*,Z#ZDFI<:,4';:65:[CT]@/F#R*0+,,M6(/_Q]J)M+_MBC!8N[_E9.;^ MELKGPJIP]56N&^TNPM/Z_G=G7M^BH9HY3@$BHP13A_V]W9XP]_/" ;K_'CC^#U!+ P04 " !.E)!8C@0W9.8= M #/70 &0 'AL+W=OW1_:UQY\OP9/7M7/W]6=6WA2ONNUDVWW9KZ M[H4MJIL?3^8G_L%[M]ZT^.#^\V<[L[97MOVX>U?#7_<#E-QM;=FXJM2U7?UX MWFQY,G)SJW*],5[?OJYA76I5NYS)2M MOLBRJBM;5Z[UNZIPF;.-/O7_NO?L?@M+(X#[F2SS@I=9'%EFOM!OJK+=-/I5 MF=N\#^ ^X!P07WC$7RQ&(;ZTV52?SR=Z,5N@V%XJ$U/FYW)[(\GH"Z-K:_MR?-__&W^:/;#"+8/ K8/QJ _ M?V$:UR#3WB'LLC4LXF6N059!$DM]V=6U+;,[_:$V95/0"T.[&%UG>!>TN/JK MB^L/&ZNRJFR NKEI;:Y7KC1EYDRA&X!A0=?;1F_,M=5+:TL-"^Y,#>^Y4G^< M7DUU7A6%J9L)/C# KCJ'SRTH3+NAOX5]N]H!U%T!#%S;TM:F*.[P=[MK"9AJ M-U9_+!W^=84+$R$OMK8&V=>G__C;D\5B]L//%Q?OZ)_S'^Y-$7=:8KLSY1TN M\N6- !)%EUO=RJ<=/H2%\.]+!J209@X>WVPJ1+*Z*0%:TRT;ESM3@PCRRE^_ MV'PV^\XODB[*"YP-+7!1%,J5K:UE=V#D"J1K0QQMD8&&+&C*&ULX,$:&"9K@ M!Z]-]8A\/PSR_7![KLXVX%6( MA@[@$P"%2)@R75Z#OF^M:3K4"-,0AU?&U?K:%)T-/&\:"QQ?@Z"TC2=S2?$V\*9I2L .O(:GF\10K(",: 8"H&$G9#-! ,PT^60A$ ML@K0YP6,:*_T'S"_]X"E!JY4VVM/A6.W9L@3F1PVWT[%*P/X*D@ M2JQ%]-VW[D6/[&607 ?@U1C%B1RI40:+ *$;04O0#\93D JF8(@&0[98+>W: ME24*8U4>$:01"_DH6,A'HQ;R8T.[?M6T;HL^;,@ZCD(8MHX 5J5@R6NS)V:Y MA1^_QAWA2Y@SH/TA!XW^%$A.5 5+9DJ(^4EZP&9LS6!%,8F<9HHBWP"<>R>>Y:[*B M:MBO\0(%[;.LD!ILX+X^?Q4M=1>W"<(T%E=,0 W8[@,9-/I^W'A;3>!; M();R1 +R!#H#]%57P,O7$DI TEBX/YDEE' 45;D^P]_SP+(DC$,7*.:H-;A52I^SS&69LN<;0!A@N=B *-^X(5-]5.= - M>0#80]['9"DPH2-YWX CLBS5KLZZ+1"(%@0+E'G"HDA!0 7/1]7[<5#OQZ/J M_98M$M#ARC+_AA1\%,:P@@? R@,F%9>(5"PA&5XP7]9;1L"CX=>G^NW^(Z8C MI,*N9!^/Y(:/O3J"W<;X$N)R%#-@Z\W&91OXFHQ*(GD0AW*=01QD;=<=1/S M%\L,1WM\QV9XX^PJP2ZWF:-* =J2.L1?EV]?OO%AUT36=4T:@P-O-[EK$)??BXKTEV#\-_UJ#ET]-O35;#B'9;'M[*MRTGO: /-&>!*FV M&RP"7=OB3F UE,%A(%'W5J24$!>]FZ0TA;S1\J; NG3;#BT(V?G:IL*G4T*3 MRP+*[I4@&Q0-Q&U2\ M"4J=]Z")UU'R>P]_\ *0J(&R=67^U9'+J.%Z$@S7DU'#=6F:#8D&_>,58 MR M?LQ^C8(:ME\(5@W!U^&7#'^QR2\4!S9DRS=@U$&0"@<_0QK4;( W9V"4[RARV'MZOH04WEY;3NDFI+\K_=)F=KL$Q?.%M0F5)\!P?V;7B_(( MZI"#3#?X"Z]&[MKF4FIQO"J'"4 C0RJBFAB?C K:]T'0OA\5M M?WG@/2 /! M0<&&1&P4R+"(><@J0M;A61V?(>LZ"",SW.Z$4JTZ9S9B]N/C'7B3^,9Q0EZ1 MP5A:@^$-2!X(W32 UWO@?08#4'<&Y"B'7,>M%$+8&9?[Y(VR31!B"A;A8]=L MT'+;]@:+-:F9\?$NEY9M#4M+Y(O+527P[P9$OK48Z8/O7@%8,CR0YUL('!L6 MTD*JZHU*:D*W&P-040]20_JYGY!W^KN>SQ>3Q;.8]"3FQJ?H@Z7'" MZU!S@QP!HTO:'W($Z $L\02'5Z>]<"UH,6H:TT+O?/F:HMNZPY1;(H<50@'Y M@RVCO\N!2/6=2 Z^$9)=I&>?C;&4ZIV>$E]$V&$: S IAR%B[Z8H5'Y?@;9\5W#3ZA84%Y7$ 9(SOP3B @^O4/-L=A%"*Q2T5PA5RW9 MG'G 0:I6+%4B??.9_D[!_[=5S;$250YZ2:* PO\LDOW\56#TAD>\V$BDJ,UZ#6$R1AT0,&3PIMI'X*F^RD!(NP)C M6GT1WG_'[T- !2:44<5M#]A5=4#H ](OU+^1+]3=48F9,]S M/MO/'P$?S^*3=-U[;,-C]!QI.(-1 M*4L<]D.Q+G*&J^JM;3<5)8542T))QY2MDY0UNN_E+I M0-X$"2)-X9J\KV+E_5I2C6T!C#C93Z!F@_=88=Y()I9[%11R&XRP2E8BC7'V]Q26E3*Y_PXK7;U3QXNT/LG<4 MXC![XS)J:)E>S, UKF:H_!;[*+M4&H-@3+@J%_>$)+/(,=25EA*CI%H6PHE> MV4Q!X.&H>D*NE*(X2("HK,*S&H2B71-O\-&$D09(+F- M(UO@2 '?)]V!3V*P7%8*D04ZY9!B2C [%"%$PPNT'7 #8U*ZB%*Z&)72GS"Y M_)?OI/P4:@.O8^=P4%)'H0Y+*BZEQI?2] XW=L"T)(5%*G+5+A/123EM29"I M5(/9BI<>(!HE2EAHPE8VUMQ-Z S^D9R5?-YQ61%>^<2#<=;:YPZU" MX@(F4TI>K@332D6S6/]F$UP5U1I#?C+#V%%AV,ER3_5OH*.%FLO_%_+_<^Q] M^]YXI'?P MCK>F/\F.DBAI%S@!E8Q=4YF3$R+!GN'YQV3J687$(^Z7Y)DV5_ M[5C*9]P.< EFJ5$(+^A@5R8"+BHAU0CO^QB5F _%/N7$2Q %'%R8-TU5 C#8 MU[4!391I@M#9W(*NPR94E=B,/0M."7XGL6 !'X-:]?1DW+7&L<+YZ!S@T6&"+89? M00"2@<@KK$B9&FS_QQWZN62\Z:/OKH%9F#\XFWT_"7D3VCHP$25-4$I-_3+D MQQX$3T<]FCTZ:-.5UU5!I2V9&;8/@/)R%J- M4U#HT% DF0K*I,7ED:4,&J@M]H2=-":)*WNAVLA*O4*VENXDA>M 1,R#_$@? M#^X%24.T_&K!X!PR%%&4/B^GB0:D,J!S;%\EI4Z8Z.+T3T5Q&U5T38%M/8Q. M94A5RMX$EL4@L,DT02B08Q/0?AE! Y)P*RX1,2-GN$ MWVLX'!43]\I;O?*+0LW[L<0OMD2<=DG^?F:Y)5PY$%F"!Q]S6+"$A:&-R MM@\+B8$^_0;C>C8[[ =")UR%,48\R.!Z;F1(K(9607HGNT[GVCC(HR6%^&%Z MC!QEXD+5H=CYTN.F$@(;( 7 =,ETX[(V@M2<9&Z,60VPH(X-4E# M!AG$JH09V:785E)]>0@+I T)>TNC2;)K#YM'A022#[C-?BN@MGYP0H*C-584 M2F0+%D([2*FP[\L3#]M=)6$,A8<5%XA\+&)BSTEP.&/.46 3N3N%(%I8X7&5 ML(;"3VF'-#&51=UD#JL]E\;F+/5D4WW5H15)6GEIRV6(Z[[.%F#@M!K/0O4; M/X(0!=J,(HM9\#!)ERZ%)5*I&VD^-,-=3A$TJC2&*DU-HU<@ZI"NC/W*'Z\0[^M'65])TF$A?QJQ[82I_S MS_V^&U,7^_)U$NU0"P!B?VNVS5-].K^GW?M/+_4IQ.=4L7QO ?"GJH9$#@_K MW)-(1^)T/^_45C4L@.FJ]A^2X $U"3/,#'TH\VYC0"@RVU'J/ $9(^/TQI0= M=DRIM#31E^_?QL :J]FO0[:+?YXN[ND7KR[>Q/DHH]]8&HG3KP6#5[=]'/_F;\0%R(N5(Y%4W@_C"A%O7VCPX2(BI[ M40I8=C*]X4[T QK_P>SJ&TXY,4Q%,/LT):;^+I-A=#))AE\F/$S% MARNJC$H!<8"U;U9#_>!@SG4@60O'2-3C![-)FIKAU^GN!TZ>P"?[N57HPO.$ M7[8TLY#.F<0J",^]>>M%4$W#Y3/2 M5:E"[1WI0&^\VQ5WOBQ@L3QG^?LP'V=Y_AOVKL)$ )YDH+V1GB;8^0,H63*@ M7#=67"96_!$V@^QO\@",E"RB%=HKD*B]X4INW]+A3*JWA6 ,5QPFP!1YK0+C M,)U$]5^2 H%[X72=JDJ8-_A@L9GY MCGM5:&.L/*>$@7AAP;F4.AG';X*W#3/Y;E\FTEG#5!DV')AP\8GB00P1^2P/ MU<@4_^H#%HC\> BSQNR)3.K:T.PG6"!?!$0TP[Z\Y&,W:6E3!1;(E-3DOW<\ M J@ID*6I%JKLQY)P5:XK%FI3W(D\XTJ%N:%3!N3!_8 H3W@!#UMY1C,EU8H: M!?O!].!8 $6I@8W]W:NOWGUHRAD4(SZ3X ':V$N )V#'TZ$HL&BH)>+[4?6D MVL@<6L8VL8](Q$4%=:3O^W46QP6Z_3"3)X*C*3SSP_Y^3(XH"L8(P@Q'T5(< M2 S[5GMI9O 86M.&4V.' M>TT*Y2IPFOMIO''O+;S$>%LW'E[$PZCS\=.H$*6&%L\'#,PQ>AX.-+[A0*I M5WWH?.!2#1EK,%Y;"*I$8PWDCF1$1,Y'3UWRR5 IDO4(2;HK^V0#P87LT-D"W"SV-/D$5@LL%<\:=*++HX>,=P[I#?. MUGB";CY^A.Y]BM3+B-0@8[_A+)V'K_;@]Z+)]-BQ8]H/4XJ2FK'84#\^GV'U M?7A30X'A>0@,IZKW. T0T1."YK[_A]GN?GA):#1[TQ5H5D)\]=@(/:PAE 4VQDA85E;8&M;FG9D;ZHSU1^9X7D,J8:OT8RQY M0NZ1 .B1QDO&7OTU5 .D^LQ1%IW.1GR2'G!<:\+;DP[$X=A>WUM+8YV'V<$Y MX&$8F_=VVD-4MDTUNNT6'C0@Z+'0/3:E/2[I\:#1?/RDT<]0>VD4.;':X M33(3K\2M#$K]-YPZ\FNID;6TO*0XE>B]$]R+_MKJ8&V'M;F0.NZG'+Y#-;"+%<0,$E=36&^PYU3005A* M\2# +B 5 30VW=:4L>'"=$L/J+4VVY0XM70'H'88])(X-LDB 5^F$SM(Q#Q9 MF^XPX:,+(;T-]<'O5\LP-O"(K/E-N6MF(E41LM!@.:[DKJ[%J;GG M@]*K.-!TD9&UFW]_?LZIW)8MS"F^)^%-__50^() &FVY"ZUM^.+7;KN#$+-N M]=NNCA>Y7.&C;A>66\SFB]X2O[Y]<94"GP:\Y[/%Z?(>%OX%>?\JGFW%TU-J MF!#.M[&6%G\+ASS9NE("AH$2)N=THO2:&KJQKI(6H$NK^=Q51/140$]0W\I1#M-*'MXB;10@HX5TJ$')>5YGQ!\K2I)U.%]HB5 "2G1#4D:U(C1-/25J:)_(2.>9;L"AH]$6%5J79;,XG8'&6MUO"4YKJW9?KWNF\B<]) MANV.GA"S3(Y[.Q2'@*^22@F>KQW0I"]^/VK&%_%HR&+\:$AZ-UT-V3>F[BP: M$![K?X-7N4!,]N_5DVOTON&T2%Q0C2^H7Y?JGQ"=4GH43N E8]V#4V0O*I0% MGY#^=''U(DR1B71<7'V$I:8$\FSV&!N)J'5>(2I(<\.I>KG'0KWDJULHS#[E M5';Q9$:W;8'8(<1NETO/=O](OK_WI:OW=&_ICRS2B99D!9H"3N<'/T.@NI+TN-10X"TS"1K[^'L6ZJ$@E: M(<[#4,?1@#P>1$BH!*ET%0L "6'\Z)MK9=S6UUG#[4YAZBB9?5,RRD:77E!0 M25$.I("AZ$RW:OA7.G^;16@C^$'YK]D'54BH:)Y;!51')@ M/32XMU5HE8K)PU*(O^Z)#TN':L'\H3]^&#H!;NL_4\*P%9 7@'$1XDN@'DQ9 M[Q*2(X;-QI^#(*-)#8&VKN*18]DBGR<(B,M1P5BZ'^[3O"*!-7Y=FHH# =EA M8MW*:6^1'*I(9]KF]S/;D07G:B68J?!!H9N[:+!-!ZZB7?! M>&BD2DV\N\M+L=S)P]XX6.IM[S@N9JBB;KT*SP.H&==2K-43L>=>SPAN!@_(?B>SJ?X MS=L\C4!W/><[Z-V_#KCZ(G 4^+=96XF\ST7>P3S)P1B"'_4.)SOQ MDA;_[+>DQT^9SK'!<'7:NS,S==_!)_F;,6NZP0%O-@P'#9,[/:FW&VX_C$WQ M9. U(AJ>);UX=9KOC>S=DWE"?SE@G(>)E<2A:6ZOKXAM.H8\?-'D)#Z%'7(D M''PB ^=Y?4.W+3I.VJK:K>5*UN3S/*T2_;LY*J# KP9PJ>]T&PO=V]R:W-H965TW.226#AVL-UV M_'O.3I-VK"T2$B^-?;[[[KL[W[FCM=(_3(EHX;X2THR#TMKZ*@Q-6F+%S)FJ M4=))KG3%+&UU$9I:(\N\427".(K.PXIQ&4Q&7C;3DY%:6L$ESC28954Q_>L: MA5J/@W[0"FYY45HG"">CFA4X1_NIGFG:A1U*QBN4ABL)&O-Q,.U?70^(+SVPY#BX#R#!G2V%OU?H=;N(9.KQ4">-_8=WHG@\#2)?&JFIC M3 PJ+ILON]_D819OF:6349:K4$[;4)S"Q^JMR9R7+JB MS*VF4TYV=C)OB@$JASDO),]YRJ2%:9JJI;1<%C!3@J<<#3R_8PN!YL4HM.38 MF8?IQLEUXR0^X*0?PPP@0$N..=MS2OHZ/(K[&] R2_@G$49P< MP4NZ-"0>+SF MR_>;].%L9JNS?=]$3=X@_UXKI6N3,U2' ?4*P;U"H/)LR?] M\^C5$;:#CNW@&/ID3JV9+07"QQRF1:&Q8!9AACI%::F5X!97*)<(3&9M*0T) M4^0K5\-]\1SUN#\>:'GT_I%'C\J(U0)UKRTE_"F)>U^1Z>;>=.KP2!TZ]1O? M,R3IPS"&IW0 3[?"&$XA)G'O$5W7 7?*,M&1]N;#A'ZFID>GC[R?@"TUXJ9- M41N:,3Y&S(#&)51*(ZDP"?V(7!*$+1%N5%4S^>O9D\NX?_&JLS$TXMJ\T)P1 M3*9XXA-GU^J@"[5RD?X;.C#[.']G<$IM/Z_.YA\+5?Z[\*0RBAV5/SJF.IUM) DGR4#(@JR3>M1I"?.%UCER6 M/;<:7CI?%P=OV5^:8FN^;U*$.Z.>.!;^03/@49JIWTF[-W/:/!5;]>;!_&ULA53?;YLP$'[/7V&Q:FHE5, D ;($*>D/==(Z16VW/4Q[<."2 MH!I,;=.T__W.)F&IE&0O<&?NOOO.QW?CC9#/:@V@R5O)*S5QUEK7(\]3V1I* MIBY%#15^60I9,HVN7'FJEL!RFU1RC_K^T"M943GIV)[-93H6C>9%!7-)5%.6 M3+[/@(O-Q F34PG"R&>C?,UGSB^(00<,FT0&+Y>X0HX-T!(XV6+Z70E3>*^ MO4._M;UC+PNFX$KP7T6NUQ,G=D@.2]9P_2 V=[#M9V#P,L&5?9)-&]O'BEFC MM"BWR>B71=6^V=OV'O828O]( MTF4,N[+6197C/-TK$4&R)--*(9P[9JLY%< M49FA/&J)7PO,T^ELRLG-2U/4>..:G#^Q!0=U,?8T%C&A7K8%G+6 M] A@0,F]J/1:D9LJA_PC@(?L.HIT1W%&3R)>0W9)PL EU*?A";RP:SFT>.%_ M6G;)G#/L]6/GOZ<+I27^+'\.]=XB]P\C&P&-5,TRF#BH$ 7R%9ST\Z=@Z'\Y MP;O?\>Z?0D\?49!YPX&()>G&-MTG?XCQ2K>-K K=2+#7#-TUAP,W\F,2NE$\Z#T)S3@Y\BO2 MF+HT'A(ZI&Z2T-XW4&J$:LZ:LN%,0XXB1.Y9P:S,SX,X=/O!@%R@&25NG*#9 M^X[K[0C^&4EB-XX"-##33R)R:%;>GL1*D"N[2!3)1%/I5FW=:;>KIJU$_X6W MB^Z>R551*<)AB:G^931PB&R71^MH45O!+H1&^5MSC?L6I G [TLA],XQ!;H- MGOX%4$L#!!0 ( $Z4D%A1 S!HV@( "H& 9 >&PO=V]R:W-H965T M> MI](<*Z8N18V<3E9"5DS34JX]54MDF0VJ2B_P_9Y7L8([DY'=NY63D=CHLN!X M*T%MJHK)YQF68CMVNLY^XZY8Y]IL>)-1S=:X0/V]OI6T\EJ4K*B0JT)PD+@: M.]/NHW^TVDG+DBF\$N7/(M/YV.D[D.&*;4I])[:?<:]K=PT% WW\E(-@%!)9WD\BRG#/-)B,IMB"--Z$9 MPTJUT42NX*8H"RWIM* X/;GFJ:@0[MD3*CB[9\L2U?G(TP1M'+QT!S-K8()7 M8+H!W BN(;9OP ><6J)!7MBL^ DXAS32PB[+@1^$)[ "UNAH<4+_RL4 MYH5*2Z$V$N'7=*FTI%?C]S'-#6)T'-&TRU#5+,6Q0_V@4#ZB,WGWIMOSWY_@ M&[5\HU/HDP6U7[8I$<0*YKA"*3&#PVH=(WP2\CCA*U'5@B/7JD.9LGVFHLFD M[7O!Z*:8@I4HJ8>5,2VI%*LE2BK2$/9L.Z^Q[9@RFEH&G?;<%Q*$;]/J=3]+@MU))(TDR-"!Q^_' 3<* MK-A/W,%@T/F"Y/S(RDV#SLP=,)XBG+UXGYO%+@#.K9IC\!?T._9J> ?]6Z%< MVRE%-R V7#>MW.ZV@W#:]/^+>S-%;YA<%UQ!B2L*]2^3V '93*9FH45MI\%2 M:)HMULQIF*,T#G2^$D+O%R9!^WF8_ 502P,$% @ 3I206/S\>W8> P M#@< !D !X;"]W;W)K&UL?55=;]LZ#'W/KR \ M8&@!H[;EV&Z[)$#2[F+#T#98]O$PW ?%9F*AMI1)7W\EV?&2+F2(VV0CZK$E'#K[KB:NR56F]N@T#E)=9478D-JOF[DTNZ!G*5B-7#'!0>)J[$VCV]G0XAW@&\.MVEN#S60IQ+/=?"S& M7F@%886YM@S4O%[P#JO*$AD9/SM.KP]I'??7._9_7.XFER55>">J[ZS0Y=B[ M]J# %6TJ_5EL/V"73V+Y M<""= W&ZVT!.Y3W5=#*28@O2H@V;7;A4G;<1Q[@MRD)+\Y49/SU9E%1B*:H" MI7K[YII$V3MX_[-A^A4NOM!EA>IR%&@3R,*#O".=M:3D!&E$X$%P72IXSPLL M#@D"H["7278R9^0LXSWF5Q!'/I"0Q&?XXC[MV/'%)_BZ%'],ETI+H_+_8B,P]),D]*,T MW:'V+'/3SRBE4='R:W$8+_/#)/.SF\R$XR\H-;-)/PIM,_T#F_I1EOF$W+2: MX&EC9\@17$3\- M[1O-'3)K?J924Z[_AL7^=W/C#=&C$LA>J$9XX/F#Q:*:O MP3X]/MS#O%E6+ ?7F HNB$^,ZIBD<+D?Q38[?.)VYJC#&!=3H+R V>4)QMC$ M#WV2)8./2C7N'QX"HBCR;Y+L3!UB(+&?9$9:3/I"_#;!L?,?[,VH&N7:36(% MN6BX;L=5;^V'_;2=<;_A[4WQ0.6:F6)4N#*NX566>"#;Z=MNM-BXB;<4VLQ/ MMRS-A872 LSWE3!%[S8V0'\%3OX'4$L#!!0 ( $Z4D%@D5^*\QP, /X( M 9 >&PO=V]R:W-H965T,MB=5 M(A'V LLE!21(V],\5(V2GO;AZ#R8W8&ULFM3VT XO[YC[P52$927M3V>^>:; M\8R]XYU43SI#-/!=.QD]VHZEAN3K7@@:\R8P7^=+QF M*WQ$\\_Z7M'*;U!27J#07 I0N)QXL_!F'EM]I_"#XTX?S<%&LI#RR2[NTHD7 M6$*88V(L J-AB[>8YQ:(:/RJ,+W&I34\GM?HGUWL%,N":;R5^4^>FFSB#3U( M<,()C+7[@N[4K?7]2#9:".+RI@8%%R4(WNN\G!D, Q>,8@J M@\CQ+ATYEA^98=.QDCM05IO0[,2%ZJR)'!?V4!Z-HEU.=F;Z:&3R!-_6-D4: M+K^S18[Z:NP;PK8:?E+AS$N18OH2P"=2#;.H9C:/SB)^ MQ*0#W; -41!US^!UFTB[#J_[6J094W@]IQ-,X9[MJ; ,S)1B8H5N_N]LH8VB M*OGO5/0E=N\TMNV<&[UF"4X\:@V-:HO>]/V[L!]\.,.\US#OG4.?/E(GIIL< M02Z;D_JV,=HPD7*Q.D7W+.!ING>B;'&";^VXR:CE])IZ!XP$67F5!Z_ ==7) M_'_**-.PE#FUN+Z!FF_K--_6"1G\=.V#Z37,MJCH.H!/SZ@2KA'N%4\09JN5 MPA4S"'?"*$ZW0@(_6+[!UC$,T2"G5#I8+%#5Y1- V!Z-XG80!/ 7A)URJ$6M MOZD(R#5#P1\$+@?MF&ROCGGTAG&[3[AO81%1V '-_\A$)6I.!DN' M]C)X%2CN$Y=A>("I!6^'N&K:4%W-: M-MFWLE@SL7__;AB%@P\:J"FV7&ZHP)VWNOIWE K4AE.3N(JG\K>9%I+R93N% MA"G?\A1%JH&.P6&776'U=E6) RLKO.402NR737,FY);+O:TGJHK*:&(^AW@F'K@>NGZZ5"NVF0VMF L@T4=.(8+FCHC>#B %-SASW'/*5M M.M6+:CAH;65.=T3.S1ZZ$>WW:??4B?M';U*!:N5>7@V)W A3/D^-M'G<9^6; M=E O_PR^,K6BAH<&ULM57;3MM $'WW5XQ,A4!"^))P:4@L)5!4I"(A M2*FJJ@\;>QRO6.^ZN^L$_KY[2=RTA/#4AV0O,W/FS'AF=K@4\DE5B!J>:\;5 M**RT;@91I/(*:Z*.18/<2$HA:Z+-45MA=1-FS('!]0?VWNI#E%'4I!:^2* M"@X2RU$X3@:3OM5W"H\4EVIC#S:2F1!/]G!3C,+8$D*&N;8(Q"P+O$3&+)"A M\6N%&78NK>'F?HU^[6(WLY6'#X#Q^PR!=&:2.MW?D6%X13;*A%$N0 M5MN@V8T+U5D;S:T(E/!+6(MPB4:U$!0=3,F.H#H>1-AZL M7I2OT"8>+7T#+4GA5G!=*?C$"RS^!H@,M8Y?NN8W27W MZW7Q]AQ>[_UXKZC*F? A_QC/E):F1'YN"]I#]K=#VK89J(;D. I-7RB4"PRS M_;WD-+[80;C?$>[O0L\>3!L6+4,0)5Q33GA."8.Q4JC5-JX[T;9SG588E(*9 M_J1\#MI^?'!2KA7H"N%2U WA+_M[YVER=J&@['@0QP-J7SH%$%Z85LV%+.Q! M0VG3O7#IMBUH9:V4UHUI):J@5<%W)-+7:? :_Q5V\ 47R" !OZ:K MM0=3H0WF3FG@/0Z"&[Y I6N7V I9 8;O5)HNAP_@LIM>O+M+/Q[%YM=/3M]5 M"#PW[_W_N(!M)1YMS*,:Y=Q-706Y:+GVHZF[[0;[V,^S/^K^5;@EKC$5*Z&7MO;3'SBB\38"7\TR-D";]%\R6>*1GZ%$O,,A>92@,*[H7?1 M/ANW VO@5OS)<:6WGL%2F4OYW0ZF\= +;$288F0L!*.?)8XQ32T2Q7&_!O4J MG]9P^WF#_M&1)S)SIG$LT[]X;)*AU_<@QCM6I.:37/V*:T)=BQ?)5+O_L%JO M#3R("FUDMC:F"#(NRE_V8RW$?S$(UP;A$X/>Z3,&G;5!QQ$M(W.T)LRPT4#) M%2B[FM#L@]/&61,;+NPVWAI%;SG9F=&-6C#!_V:EIB*&FQR5&VEH3- PGFJX M9LK.+?$(?H9;C K%#4<-LT)%"6D(%PN%2)MKX.L59G-4WVCAE]L)- Z/!KZA M.*TW/UK'-"YC"I^)J0U74IA$PP<18[QK[Q._BF2X(7D9U@+^5H@6A/TFA$'8 MV1=/O?FU7+:@$^PSWPFG4VG><7B=9_#HR*5L+DM)X8*T%8M2/;L!V^,;DZ " MDS !NT9?_R!,F!K,]+<]A"[+ ([W!V!+PYG.681#CW)?HUJB-WK_KMT+SO>I M\T9@.UH=5UH=UZ&/)C@W,!7:J,(JTH0)ZDCQW)[0?<1KT5Y*O#ZTSPD>:!1< M4E6T.8$Q"&DH+9A"B*18HC)\GB(825NXF2KK'S,(\@X.:Q3J5@IUZQ6BM(?? MA2U7&BZB^X)K[K)Y+%5>Y>,^K6IQ7ZK5&X'M2-"K).C]WPG5>TNMW@AL1ZN3 M2JN3ER745.L"XR;,%!<1SUFZCWZ)V7>8MC-8CMK=T^[)\7'K9. OM[G5>G\E MMW[%K5_+;<8>+"=M,\YE B7B9:%IE=:HF_"+DEKOHU?"=G?H!?;O";E:]Z\D M=UJ1.WW32EB/1I]N73!A#M;%J?:K3KZVB\R*IREP>VQK;@]/Y)S=RJE =E_6Q8A/?O^F$8G,^FLP]P;:?=1/O\J FK MA).GIU66"XI!)S3MO(QEEE$1O#4R^@[,/(D*'OM(*A+;I3E7/,(#O"]8NBG< MU.I2T2#,!C^"PW;0"@*@+JETUG0:-#B].@U;W9\V"E@C;6 I4]HN6+EVDM@R M\D/M,1C%8BX6I3N@=MP9&130: ='\+E\?3!A#QIXEF',Z9.1/M!ZC-!9VO7C MQ[AIA["UK]C4GH-7GMEV\-A>!K7G;$H!:N.R^;5NWDI#7^K8^=JMKJK7+@.W7]<7EYTKIA:<&J64[PCTZ!U0EQ4>72T/-O'M,Z+Z%RBZ@]W>23O=Z8!U4-[C1/U!+ P04 " !.E)!84YUY M0'L$ #X'@ &0 'AL+W=OD[2W0CR]UL6BZ,GW! M[+[8NG#.< X/!P?B>,?XNX@!)/F!9( M=!RMX _G[>L[5G=N@1$D&N4A83C@L)\Z#=S^CHR*@'/%' M CMQ<$V*4A:,O1>:B(, KW\B@-8!]#B@>R+ KP/\LM!J9F593X$,IF/.=H07 MHQ5:<5%R4T:K:I*\6,8WR=7;1,7)Z9O21;1)@7Q!^52 MO2;BG7QZ@6P!_*^Q*]6TB^1N6$_QL9HB/3%%CY(7ELM8D)_S""(3P%7U-D73 M?=&/U(KX!.$=\;T?".U0OV5"L\O#J64Z?K,&?HG7/8&WIWC)6590IW@+I=*! MC#6CCY"'L=IHFDCRKW[[,0X%^L@A(FC6H$ O@5G^NTW7K_S4QLY M2& &5=V&JFZ)[I^@:LY9M%'D/.=5!ROD]>E7-8@\2\A$:_%=S.*1P(SB>TWQ M/:M._K<_"5N>VY]MA%191F66HLUOIYV[GA+R]K#0MD&^UPPR"N@W!?2_L-!_ MVS&KT*WYKUUK)#"#JD%#U0!=Z /,XI' C.*'3?'#KR)T:Y;V&D@;%\.6O4!I M^UX8-36.ONQ>$-:-8$U^K1:0P R>O(YV*!WTK5!#(M6/A682<O*^R'>HT M9QI_^RB_7>T>U450>Q$MWO$6*V-/<_7*(J&9I&CCY_GXTD8UO^XK]_@Z(BM3NWFO#-V[C+UVPV-/.&IPP\%3[,GK&EUW:U6,. M=E-C3W3MVF*AF;1HITL:^72K_9'NF^Z-^N,-",UG19H\.\>6/ZNVPT$P"M+>C M]@][:/(?M7UU'!QW_QM\7&OW=P_.$)5J5^71JB#E5*N3M>9I1E#$ $O M!JCW2\;D_J9(T!QV3_\#4$L#!!0 ( $Z4D%@,FM,QX , #,3 9 M>&PO=V]R:W-H965T^+^,4=/9G&?#+S M>(09QLI $/VUPPEFF4'2?OQ=@7JU3:-X^GQ _[4@K\DLB<0)S_ZBB4H'WHT' M":[(-E-SOO\-*T(=@Q?S3!:?L*]D P_BK50\KY2U!SEEY3?Y6@7B1"'LOJ 0 M50K1B*QH0I&,4QWS)%V1IF/*,Q10GOIJ@(S21\)$(0$_WW\ $^ M+:;P[L?W?5]I;PRF'U>6QZ7EZ 7+802/G*E4PB\LP:0)X&L:-9?HP&4<61&G M&%]#*[R"*(A:9QR:O%X]LKC3JD/;*O!:+^#-!$^VL8)[5E:;R=K/#UH([A7F M\LNYD)6([?.(IJ3OY(;$./!TS4H4._2&/_T0=H.?S]%U!-8@WZ[)MVWHPRJ! M),PQ1KHCRPRO8)3I6X.P&$%'!"8"$ZK@@4MY!9.M$,C4N9B4ACJ%(7,K[89! MW]^=$OU>(@RB7G 4:U#HU!0Z5@KW^890H:\L9:KC@;/UAP>=] F,I$3-3'%8 M(DRIW'"I=_GJG/-6$Y<>:,<2B0;%;DVQ:Z4XQQVRK3X.P7.8Z&H4^EK5-Y!* M]8&8NP<%C)'%J;XCGN#S(^9+%%_@W^-;K12CT2O2>TYE0^QWG>RUZ&'_7)BL M;EX:)D=@C8CVZHCVG!=]SR5Y1V -\CW_6B!_['DM*JT58O7STB1Q!-8(:1@<6X[ >8U4D([X MNT)K!N"DYPH=UXD=\&+ZH;7LFJRB(ZOHTI_\_[0B[.Y<'!-':,W@'7O%T'VS M&#KM%EVA-0-P[!=#>\/XAIJP EY,OWU!31Q;R-#>0SJJB50@OK8JG':[8_-1*@8:QQARG'2(Q%KRB1DN-*0P75/YZ4H)S3E0O%- M,>1889*P M4P( $ % 9 >&PO=V]R:W-H965T$ ]NVZ/'35"/JH=@$9/)>,J]G9:5S.,5;J#DJ@K40$W.[F0)=$FE 56E022 M.5#)<.#[$UP2RKTDL6F&AB;^@=$FM:[+1-X"2J M2 $;T _52IH(]RP9+8$K*CB2D,?>?#A;A+;>%7RET*BC-;)*MD(\VN!C%GN^ M;0@8I-HR$//9PP(8LT2FC9\=I]=.5E+HDD22=$@::L-FUVXV3BT44.Y_14%V@A M> J2H\$2-*%,H<]$2F('?('>HH?-$@U>7T18FP,M#*<=^6U+'IPA7T)ZA<+A M)0K\(#P!7[P<'CR'8R.SUQKT6@/'%Y[A^R(+PNEO8OUS:34KP6A&6COQ#*TD M*."Z38@$H)0QN3!.-=K=#W^59I:=SWX]0\V@9&IQNP-W*F*I)"[%7V M++D'+WGS:CCQWYV:SG\B>S:KL)]5^"_V9&V-P"%#[XGDQB(*#>9I6I345_8]HZ/_&W? MED]$%I0KQ" W4/]J:CAD>U_;0(O*67XKM+E ;KDS3QQ(6V#V&ULM59=;YLP%/TK%INF3FK+5_C*$J0V6;5*[10UZ_8P[<$A M-PDJ8&J;I/WWLX%02 EJ)?J2V'#/\3G7U^:.=H0^L T 1T]QE+"QLN$\':HJ M"S808W9.4DC$FQ6A,>9B2MN-UP^4/U1BM_:KW+PPL\ ,)B3Z$R[Y9JRX"EK""F<1OR.['U :LB1?0"*6_Z)= M$6M9"@HRQDE<@H6".$R*?_Q4)J(&T =' $8),-X*,$N F1LME.6VIIAC?T3) M#E$9+=CD(,]-CA9NPD1NXYQ3\384..[/15TLLP@06:$9%=5!^3.Z2);H^V,6 MIF*_.#J9 L=AQ+ZB,W0_GZ*3SU]'*A=K2P8U*->Y+-8QCJPSA> $%O?< W#M4?JMFZI)ZUGM@JU*L-4I^*>XA=^>6^N5 M",]U'?U ZNLHU]0\IUVH70FU.X5.2)QF'&C]"-Q"O #:6OZ=9.\M_Y[(&KZ= MRK?S@;> TV<:>B)KI,&MTN#V>@NXKVK0&-B6XQZ4:DN8Y1G:D5KU*K%>I]BK MC"8ASRCD.J_")SEFG?7:2?C>C>J)K.%=UUZ^UMH'5FQ)WE,F^F)KIJ+6N.B] M5FU)5_\JF9:C'59M6YCC'GX)U%K')=O=6TS78<)0!"L!T\X=@:=%!UE,.$GS M)FQ!N&CI\N%&=-U 98!XOR*$[R>RKZOZ>/\_4$L#!!0 ( $Z4D%@0\0:^ M;0( -$% 9 >&PO=V]R:W-H965T+*0JJ(&3;4,=:V M%@Y4\3".HK.PHDP$V<#MS50VD(WA3,!,$=U4%54O8^!R/0SZP6;CCBU+8S?" M;%#3)=R#>:AG"JVP8RE8!4(S*8B"Q3 8]2\GJ?5W#M\8K/76FMA*YE(^6N-K M,0PBFQ!PR(UEH/A;P00XMT28QE/+&70A+7![O6&_=K5C+7.J82+Y=U:8:".K%HP95$SX/WUN==@"]-\" MQ"T@?@U(WP D+2!QA?K,7%E3:F@V4')-E/5&-KMPVC@T5L.$O<5[H_"4(#T&!DBP_S M-LK81XG?B-*/R8T4IM3D2A10[!*$F'*7=[S)>QP?9)Q"?D*2?H_$49SL26CR M[_#X0#I))V/B^)*_R-@C,TY1OUTU?XSFVBA\L3_W2>>9T_W,MHLO=4US& ;8 MIAK4"H+LP[O^6?1Y7]G_B6Q'A+03(3W$CJ(B:08N#;U448U1)9=BO M]NQ6BEK)HG&MO$\3'^C4!;*#:)7%YY\N\*)7V\7N\4HOHO/.RU<1;G5'!6KI MAH8FN6R$\0^NV^WFTLBUXZO], M,+)V/3B7!CO:+4NY:\**&2!:^(@,7$NG#/IXF.;P)^%%#+O3;13NXXO]>= MJWQB.5H0,,B49J#XVL(4&--$*.-7QVGU4VK@?GO'_J'QCE[NJ(0I9S^+7*TF M5F*1'!9TP]0-KS]!YR?4?!EGLGF2NHT- XMD&ZEXV8%105E4[9L^=.NP!W"/ M ;P.X+T4X'< OS':*FMLS:BBZ5CPF@@=C6RZT:Q-@T8W1:5W<:X$?BT0I](Y M'HM\PX#P!9G! H2 G%Q5&2^!?*"1X#=14Y";S+6/8,.J[8)M&B>?'23BVM_N^#'&CV ^3 MN(][(CGH)0>#DN>*9_=DRDN\KR35*6\2V7)$>Y.[CA^.@OB9R,.X(''=(#!K M#'N-X:#&;VH%PB1K$&;>:V(Z,^&![-#WHL2L.NI51X.J/PJ]__DN!12F #V: M M&! CP!N+_>LP4VQ(5./!J-S%KC7FL\J/4SH-0M91O:7OH,JPZM,C!)C0\D MG)JUF@*'Q":]V.2/6?;"91TD^HL#\N\\K5-[KX+HZOV%BF512<)@@THOFZ*RAU76**:Y@I_(D#H /R^X%SM.KI.];\EZ6]02P,$% @ M3I206,[=863G P 4A( !D !X;"]W;W)K&UL MQ5C1FY&:.Z,AV;NCH^'K)0IS>&.(U%F&>&/ MUY"RSH]=>#^ M]1/Z>T->D5D0 5.6_DD3N1XY?0P&X]T* OPWPGP=T7P@(M@&!(5IE9FC-B"3C(6<; MQ/5JA:8OC#8F6K&AN?XWSB57=ZF*D^.;/&89H#_( PCT9@:2T%2@CX1SHO6] M0&_1Y_D,O?GQ8NA*M9^.Q A6ZM0M>&/OY"TI(83TY2]50@>0P=-(,E< Z)KBPT$0)D!ZE:4T\: ;K. MJJN+#IIDK,QEDT#5KJ'953^-[L=!B*.@.W3O]ZD?+\-!O^O[7KWN@%58LPJM MK(X)B YJH-J4>87#*/"?I1X>I1Z%7C08#)I3[]6I]^RIJPQ @JB6(#J?,Z,V56@)[$"% M?JU"_W]Q9O^HOG$81I[^>U;AUOQ>R7Y0LQ^MR.>6MYMH1WRW^M>\/E\OL5N2XF6T Z5\'=* M^*=7NTV>#IJ7B[]5-XTD0^\>"LJ-+QJ%\H_LX&.OR0WV)%\KPJX?P]9&QUH. MC<2"8Y][C3:W;_Q:8KL6"]M[K+DD$A#)$T4L)BGZM>14)+1Z%;*ZW8I[35 48UD*PP9P +)B7+S.4:2 )<+U#WEXS) MIX'>H#Y&&O\#4$L#!!0 ( $Z4D%AJS)FV; < !E" 9 >&PO=V]R M:W-H965TRR2U3/GT MGHNO[GSF)A3 MN>'\JSGXN#@;>*9'+&>I,@BJ_]RQ.G\P- ME6S.\[^RA5J=#8X'9,&6=).KS_S^5]:&C!K M F95L>IWMRI-2!4]/Q7\G@C36M/,@ZJ^5;2N2%8:*5XKH5_-=)PZG_/RC@F5 MW>2,7 E>9%)R\4 NN6*2K%B^(#B"O0J9HEDMR286@1DFO MR5ORQW5(7KU\?3I4NE>&/4R;'GRH>Q \TX-+?G=$?/\-";P@Z B?N\-#EAZ1 M41T^Z@@/#\@^\IX-CP[/WM7Y^/!POR,\.;CS_HD=/M0ZV(HAV(HAJ'BC9WC7 M*R[4V]^9*$C(;A3Y\DDW(!\5*^3?786M:>-NFAE$W\DU3=G90(^2DHD[-CC_ MY2=_ZKWO*C,2%B)A$1(6(V$)"&:)9;05R\A%MT:.>KBXH@]4'W4IQ8GJJQ0D M+$3"HAHVJ6!F$7!W/O''GOYW.KS;%0$R:0*"62(8;T4P=HL@IU(2OB1_F;F@ M5(0+4BUGWI#H.Q-I)LVTDJ5LIXW<-I)=4G$F["N5\5Y!?+L4(3)=]'_3Q76+ MXYT6WM&3-@FH2U9!)]N"3IP%O4A3L=%3_:>,WF1YIC+6620GI&^1D+ 0"8LF M>_6FV^M,?_3A?;HH;)LQKURS=B$H99$[SG%5+Q,,^ MV\[L?66#A(5(6%3#ICNR";S)='\:V&_GS\:^%SP9#T!]LQ0QVRIB=O LOW=] M\.4W9D31N39T8ON6&@D+D; ("8N1L 0$LU1SO%7-,?1"XA@I%B0L1,(B)"Q& MPA(0S!++R58L)\XAIE+(QU(JL2E8J:>:6&ZT7Y3F58/M,KMG%#>HK B@MA-(B*"V&TA(4S9;+ MCG7I0V>9!H<2#9(60FD1E!9#:0F*9HNFM3A]IRG6S[9RLWHK)M@;TH-1QY > M0M-WW,F,\ZYI)H&D3%,VN<^M.^FY[LGLN(?\EYFL2\I^RND8E%^FW32:S MZENQ.1=K]Z0#=3&AM!!*BZ"T&$I+4#1;5ZWAZ8^QDP[4SX320B@M@M)B*"U! MT6S1M*:J[W95^TTZ4'.UH5DF4] YZ>R;G?YDW-$R@G8PAM(2%,TN=.N?^FX# M=>]:=J?RCP?5+H[J2Y'.ZD,]4B@M;&B[WUX$1Y.GZD"FC*&T!$6SU=%ZJ;[; M3'UV3?+#+JL[86^U0'U6*"V"TF(H+4'1;%FU9JN/=5M]J-T*I8506@2EQ5!: M@J+9HFE-5]_MNO9;DD ]5R@MA-(B*"V&TA)_WQ+V)_8"S=[VU1JO@=MX[6O! M-SAKHXO7L52CJA>L*6,+299ZY4H^2KFAI5&&(-RWA/7F79:T)5%5KJU=)* MHYCXY:?CP)^]ER]X=2IO'N'LCIDQ+"6M;\2X M7V7Z$R(WZ:I:@Q'!S-TC>B3=**EHN:CZE)7Z!)M3T$R38,Z+-2T?'O.3:R8R M)E]>->=BW0W&]_[P\;U)J& MTF(H+4'1[ ];:TT'3A?S']H+NETM(](E(Y<)X>Y6[_L H!8WE!9!:3&4EJ!H MMOA:BSN80$V( .IR0VDAE!9!:3&4EJ!HMFA:NSQPV^5/1ID?L,N# RSIN;L7 MO=4!W2L,I<506H*BV>IH[?+ ;9=?\E(H]GD"=<"@M@M)B*"U!T6S% MM$YX@'7" Z@3#J6%4%H$I<506H*BV:)IG? Z(2[6;T5T^'H'L\F^U_.0]-& M'6G'7;_F1Q-^H^+67#KG;*GQWM%,GYVH?X>@/E!\7=T& M?\.5XD7U<,6HOHHW#?3K2ZYKWQR8.^NWOP9Q_C]02P,$% @ 3I206-=K M]A\> P B0D !D !X;"]W;W)K&ULK59M;],P M$/XKIX#0)G5-FKZ-T4;JRQ"5-JA6!A\F/KC)M8V6V,5VVNW?!+ MXI=['M]S9_O&Z*EQARE1=K)'3S$+(E&GJRJ6K MUA)99$%IXOJ>UW%3%G,GZ-FQJ0QZ(M-)S'$J065IRN3C$!.Q[3L-9S]P$R]7 MV@RX06_-ECA#?;N>2NJY!4L4I\A5+#A(7/2=0>-B=&[LK<&7&+?JH U&R5R( M>].91'W',PYA@J$V#(Q^&QQADA@B_;W53EKF3.%()%_C M2*_ZSKD#$2Y8EN@;L?V .SUMPQ>*1-DO;'>VG@-AIK1(=V#R((UY_F%%N0QIK83,/&QJ))3AR.#B%DS%J%B<*/C(IF0G_ M*9R!F6;XW7#GQ3#WPG_&BP9<"ZY7"BYYA%$)?O0"WJ\@ M<"DD15S\?5R&?B7C&,,Z-!LU\#W?@]O9&$Y>GY8Y]L\T3]QK%FEK6M[F,[RS ME9#Z[#/*%,8XUW!W108PT9BJTO#G;*UR-G-37*@U"['OT%6@4&[0"=Z\:G2\ M=V62_Q/9$^&M0GBKBCV82A$B1@H64J0P42IC/$00"[CE"L-,8F0C4A:$G+EM MFU"7;M2G:OD/59;YX5-\$1;M]#6/2YOYF262:FD.59*M4]->$0F5<6N/"_4 MG1^G;L(UDG\:;IBFK3G3](M@BC*D::K]9Q-VK>^U?SMX+1KGW[D&U MLT7+/ (4A&;[Y(6O&"W>&0-;7MV?YODCY9K1H>(*$EP0U*MW:5_(O/#G'2W6 MMG;.A:9*;)LK>BNA- 8TOQ!"[SMF@>+U%?P 4$L#!!0 ( $Z4D%C2-,0Z M9P, (<) 9 >&PO=V]R:W-H965TA]^QLGV2P<@>,- MB1W/W[\9/#,>':1ZT1F (;^*7.BQDQFS>W!=G610,'TO=R#PRT:J@ADSXSNO$5[[- MC)UPX]&.;6$%YJ_=4N'(;5527H#07 JB8#-V)O[#U*?6H%KQ-X>#/GHGUI6U ME"]V\)B.'<\200Z)L1(,'WN809Y;)>3XV8@Z[9[6\/C]5?V/RGET9LTTS&3^ MC:(G-=_9)#L]9S2%)J(XO&& D*+NHG^]4$ MXLB ^A<,:&-0!<*M-ZHHY\RP>*3D@2B[&M7L2^5J98UP7-A_9644?N5H9^(5 M_LUIF0.1&S*318&!6AF9O)")#110GHJX**K MK;_TU=\IO:HXA^2>]/SWA'JT1W3&%.@KLKTVC+U*MG=!=I(D95'FS$!*GDT& MR@8*TR2SYWG/CWW_S0^WC%DW[K2?^:>CR%+1>"BRT>]IR)!-YW1JD&K:7"2LKF_S[N M!X'GA^'(W7I,%DN($E/&,)_2BB=-C-$K4LT566.A;/.UO-;N*(.CAH&'G= M&(,68W!32/"$8+I_8THQ86[B&9SQ] ;!L!_VNX&&+=#P?TX+WV/BD6(CQJ!?Y7X4>O2YOL-#/X9@^_[P^!"KOGT M#8%>1< B?V/A:82.$6@OP!SKT?] N$>]L0"UK6X FB2R%*9ND^UL>\N8U+WU M;7E]15DPA;51DQPV:.K=1UAT5-WUZX&1NZK3KJ7!OEV]9GA3 F47X/>-Q!+2 M#.P&[=TK_A=02P,$% @ 3I206.BMO>_[ P *Q( !D !X;"]W;W)K M&ULM5C;;MLX$'W?KQBH1=$"3B3*\26I;2"V6VR MS:Y1;W8?BGV@I;%-1!)=DK;;OU^24N3+*JSC5?(0\S:'Y1)1 MP?BBYPBNIA-1&Z MYY]V[)S8ATC(%=\1?#K=QK@Z$RX_S1=.[BOA<8CS#!2!D( MJG\V.,(D,4C:CV\%J%?N:0SWVT_HGRUY369&)8YX\C>+U;+O=3V(<4[7B?K" MM[]B0:AE\"*>2/L?ML7:P(-H+15/"V/M0A$'&-T"4W2@# (FQ4.C4XW#QWN-,MH-RU>\QF\44*E!#Z'J>+1(WS] M3<_#G<)4_E,5K1SLJAK,"/Q&KFB$?4\K6*+8H#=X]X:T@X]53&L".^!]5?*^ MT'^,QWENP/1].R;M3I\X[=?*N">R =[?DW74GJZ5[)^5::VV\%BQ;P$3KD,<-L(FL MOQ'%K*Y C$0W.J\KM9]OU-[/Q<#\E0F9L_WIL@,>UR6/Z_\CNFN'3G*WG/!G M/@02[+[IP0EO1JAZ,[KDYT9]:1[6A788@[VZAM0IP0*M+NXUH1UR#W?]MS:>V*)^*L4705P2/$6,)<\-2R MHYDFII]QU?<_'T.S8OK,AWU8;+BOY/#X#>-VZES2N\J)G%+E5)8Q3BW75+,4 M,7B-"HCL2B#2JE7+M19%=:$=0\N= M$[1<:W'D[QV[4Q0+>QLA]7%BG:G\B%J.EC<>M_:ZI M6#!]-$EPKB&#RXZF)_*;B;RC^,H>[F=<*9[:YA*I/LV;!7I^SKEZZI@-RONA MP;]02P,$% @ 3I206 /7>8N\ P T@X !D !X;"]W;W)K&ULK5??CYLX$/Y7+.YT:J7=!4. 9"]!2G:O=WVH&G75]J&Z M!P/?10(@T7-&],480(9$7>L@%P]63.>$:FV/#9%P8%$E5)&3=NR/#,C:6X$T^ILR8,I*R5- M,8!M]8+E, M!/HKCR Z!C 5XY:VO:.]L <1'R&\0PZ^0;9EVSV$'JY7QP-TG#:*3H7GG(MB M0CC<+E0Z16A)?J@TEVC..]6>?XZ\$=A2&41N&T1!ZL$L@MD^@&P1U(JT()7D(??[7H%X% MJJ^=33 9^7@\FIJ;0\^Z8G@R<2W+:N6.2+LM:7>0]->JTM6+(QO@ZN9"\ P\ M3 6@@J/SZA,<=)K[;H3MHM[]@T4"M3EJ')MP1/"OF8OKVG;[]^QC>81XG0D_/#IG\^Z?&^4>/!!OC2%M6@ M>I=?1U=P\'7L6RN^KK.$W#M[W7?SBQGO)MVXW[7\Y@P1^UD'S8#K(@,?5T"10R,I3D?*$'MFKJV,/4T]X'PM47AT 4U@K2NO.5B[P>H.J-9$4U@ZR8 M5!--M4S4T E<"ZCG:\;D;J,-M&-L\#]02P,$% @ 3I206.'_K=*/ P MX0\ !D !X;"]W;W)K&ULQ5?;;MLX$/V5@198 M=('4NMB6DZQMH+D8&V#3#>)N^A#T@9'&-A%)5$C*3OZ^)*7(DB-KZU:+O%@B MQ3DS,QD6K)E[9( M.9+0&,61[3F.;\>$)M9T;/9N^'3,,AG1!&\XB"R."7\YPXAM)I9KO6[]N HGEJ,CP@@#J2&(>JSQ'*-((ZDXG@I0J_2I#:OOK^@SD[Q*YH$(/&?1 M5QK*U<0ZMB#$!<;8#KTPI-OQANC+7*AB;Z M&N>2JZ]4V(M@_9>@S[S6A$O,.A!WST"S_&\ MAH#.?]S<;0FG7W+8-WB#/7C72$3&48E;PE629O((+I]3I5,,X0OR&.ZO,7Y M_JV)NU9H7<2G(B4!3BQ5I0+Y&JWI[[^YOO-G4]X=@=58&)0L# QZ?P\+%?6\ M(40 24+SD9CB_8+!*J%/&0JX_UOAP)7$6#3R,^B2GX[ :OP,2WZ&K2JYSZOY M]/(IH_)ECD'&J:0H9NO/M$*8%DPC$>WH0WA!P@6X#L1YL7D.A.1%--'0#N47 M4-Y) T M=;],W3^T0&ZI>(091W7UB43%MH1;(K&U5%J='"J%CL!J?(Q*/D;O M42JC+OGI"*S&SW')SW&K7O(2@6V-','L[N/GJZ.W=#7QD(.[CD'7?&IP4IZJ17Y21G[RTW\%%W1-0U27^Y]";_5QZ$5V!%:CPW6V[87S M'E(OO'9$45=H=8XJ+9C[?\J]0/>K0M[1>NN1>M3>-FKO4*G?D M4VH3>3O\P5?8$5J=C&T'Z/;?1>:==H==H=4YVO:';FM[]GT1JKAXOD\F2\D2\U(]L"D:@G-ZTK-X,CU ?5]P9A\76@'Y50__0Y0 M2P,$% @ 3I206&#\^ "I!@ 5S0 !D !X;"]W;W)K&ULS9M=;Z,X%(;O]U=8V0_-2)T&DQ"2;ANI+1];:=N)ICLS%Z.] M<(F3H &'^-7Q^: 3U>,?Q4+2B5ZB*-$ MG'464BY/NET1+&A,Q#%;TD1=F3$>$ZF*?-X52T[)-#.*HZYI&(-N3,*D,S[- MSDWX^)2E,@H3.N%(I'%,^.,%C=CJK(,[3R<^A/.%U">ZX],EF=-;*C\N)UR5 MNB5E&L8T$2%+$*>SL\XY/O%-4QMD-3Z%="76CI'NRAUC7W7A:GK6,;1'-**! MU BB?N[I)8TB35)^?"N@G;)-;;A^_$3WLLZKSMP102]9]#FH5!;\/ M'88] N#_J9!?X>!51A8FR[M,A@4!H-]#>S"P,X&*[^[V= X M1)+Q*6$G7:D:U&;=H(!?YG!S!QR;Z)HE;> M_N9&@[G?;G[#[H^1T7CK:D/1*Y73RWB]7/:+W>A#QFI\]7A$_1E]\5$EU)&HL_&_ISD;??;VY?Q^@3L20! M/>NH("PHOZ>=\2\_XH'Q:Y,P(&$.),R%A'F0,!\(5I-7OY17OXW^H.$.3ELD,'TXN)^C(T>-@P5!N[7I;1= M;]2W\;!?K^8UX$8C:POG _6A-OY6.?[6ZXS_YVQUHFJ?WU.N5EOH ]5+-G5- MM9-(KA9'*8G0'Y3'32)I]?I0D4#"G/;[::-'2KA &,5Z2D8C-"6/HBD>M7,& M!:>WR]Z#[)0/!*M)<%!*GVHD"!A3OO]M(KP,LC# ME$ FWAFH]B/UGDCVSH@%V3\?"%93X[!4X_"[J?$3%5I^:MI4PES20!D,EFK$H8BL]KVO;BU2HYH307;L+D[QG,\91*$1*DH#J6IRFR;0QXEZV^WZH M2D%I+BC- Z7Y4+2ZJ->RL'AO49=BK?1\E,7&1#0&N7;TH5$.E.84M/4 T+>L MS82$VU3--NS-IP90WWPH6GW(S6K(S9<-^0U+[O/)L39G'JG0(*2Z*M4"5ZK' M@H#-D_ OJBJ@K0^^;8V&]J9&(!OU0&D^%*TNI2H3 MCULSL<]+*5<.^G)-]4ATS-89FT MU'/A#5WE-9HR-A?M#1PL(VO[,1F;MKGQ/L0!;=4%I7F@-!^*5A=(E7C'[9EW M-UY&[)&J1R4CNE*/2(G^< %- M(O+,C >:; >E.: T%Y3F@=)\*%I=:57Z'MNO/>.!IN)!:0XHS06E>: T'XI6 MEUF5E\?/).9?/N.!YM)!:0XHS06E>7@[!=XSLK^-CQV@FJTKI$JIXSURZJ*0 MR%&>TM82R>71J C0[#8HS0&EN: T#[BU<57I:)-_,HK(A,T80U*D(WSE_C$R_>X5)A\R\TU MX?,P$2BB,X4TCFVU.N#Y+I:\(-DRVT1QQZ1D<7:XH&1*N:Z@KL\8DT\%W4"Y MEVC\#U!+ P04 " !.E)!8AYIN ZT% !*+ &0 'AL+W=O;E!T>*OF&WESC'*NS+E_$=^\G%VV7'SB%C" M(I5#4/VW86.6)#F2CN.?"K13^\P-=X\?T#\4G=>=F5+)QCSY%L_4\K+3[Z 9 MF]-UHK[P[1^LZE WQXMX(HM?M"W;]@8=%*VEXFEEK"-(XZS\IS\K(G8,_4#?J! T4Q*]"IFB<2+1;7XE?R2OT5OT]2Y$KWY]/724 M]IC;.5&%?EVBDT?0,4$W/%-+B=YG,S8S 1P=:ATO>8CWFE@10Q9=( ^_0<0E MI"6@\?/-O1;S\/GFV-(;KV;?*_"\Q]A?4L'>7NMQ.T-CGNIDEK1(AZO\>2R8 M3C"%IO=HM]V$WA>7K[94S-#W3QH2?50LE7^W/9_2O]_N/R\J[^2*1NRRHZN& M9&+#.J/??L&!^WL;MY!@(1"8P;M?\^[;T$?CA$J)^/QAX",N4%'RWJ#;=3IE M(K]WQZ*UB%7,)!K3)-'4ZR=19\J#A6QCO?0>%-[SRKL9$;<;N*X[=#:[A%JC M/);00Z>XYV.7U#X-JKHU5=U3J7K_DXDHE@Q-1!RQG39/L%,Z[.X&NL?+DRW" MLD5_IX5[@=M[&M0]#:P]G0@>,3:3:"YXBCY*N::9V:VVS@2'H7I^0/K]O2Y9 M?1_[J(' #)IZ-4T]^X#@::HK5/GB^'[#\G1I+3U6F&-+#R18" 1FT->OZ>N? MN>3W(7F'! N!P S>!S7O@[.6?*OW8UD?/%7*2SZ!?!I\8K>9.;K_]YO![O%8 M%BNTQUX2)8=0+DT2=Z;?V$KB W>?=4K;BJD=YFAF(-%"*#230M)02,Y<4:L MH,B'1 NAT$SR&P&#K?/T%RD"H)JE0K/-):$5=;Z:<4\ MFBI(M! *S>2SD3TX.'?]A!0_8U"T$ K-)+\14_@)-?4"];/TV#.F/:Z_IT?; M6V%_L)_L+R&6<*.6L%44_)?BV#^<1..NZQY^A;&'@F5@QN9@^TZ1P^6 M#57LF5415+6 HH50:.9GYD;=$/?,59& BAU0M! *S22_447$KHI.S_H*>#?K MN_TNZ77WT01X\C4'4"A6;2UZ@3 MTZE];K0)>6*UA&<;)I3N<\+0+5?,_OZUHQT]>D!5"12:R62C2LBY50D! M526@:"$4FDE^HTK(R:H$Y&-YY?[I!=*6ACCHM>7]2\@4TL@48I(?S@(%_. VPAWDTJ:"ZR-G9?)DRL2@VL4H4 M\76FRGV8]=5ZH^Q5L3W4:9J7NVQOJ%C$F40)FVM3]Z*GI^"BW+A:GBB^*K9R M3KE2/"T.EXS.F,@;Z/MSKB5'=9([J+&PO=V]R:W-H965T49N*: 4I$9=L#9GZ9L%X M2J1J\J4KUAQ(G!>EB8L];^2FA&9..,WO/?-PRC8RH1D\0L-W, M\9W#C1>Z7$E]PPVG:[*$5Y"?U\])(#8 MW3C&01)0GZ( 1(@=[=@20T$>_1 M[^CSZQUZ]^O[J2O5J+K6C8H1;O8CX#=&N(/H$@7^!<(>#AK*;W^^'-?+7<6U M)(Q+PCC'"][ NR>4HR\DV<#%@2;)8O1(R9PF5%(0Z F(V'"(D=IF+Q!M.*?9 M,N_UB66\O'%#!!7HZZ,: #U(2,7?3>+L9S-HGHTVZ;58DPAFCG*A +X%)_SM M%W_D_=$DE26PFG!!*5Q@0@\+L=*#.%H/)0;CL6HLM*I;K6J3!D;@YFFC)OI[ MG&&.HW^?MB&>>'@R\(=3=]M ;5!2&QBI'>^):L&_/D$Z!]ZXJD:\MJMJ":Q& M?5A2'YZ5'88VA;,$5A-N5 HW.I4=C, M[+#'&?W?#J-F.XQ+:N,>=D#_H8=L M"T*JA[D2X",D,:(9^I.KAY71,\9!VRZ]);":/E>E/E=GY9DKF\)9 JL)-RF% MFYS*,T;@%IZ9M/2,[U5!RNOGFN,.#]EZ(\4%>H0M),@W^L8\;MOUMX565^DH M;OIGY9UB.K;$LX16%Z^*KKXQX/7QCQFYA8$*H!8.J@*F;TZ85AS4^?%DGESK MG6()K2YE%6C]P7G9S&H@MH56%Z^*Q+XQ./:R68=(VFRS85N;5<'5-R?7'C;# M9@=U"+:&36 )K:Y2E8']\7DYR&H\MH56%Z\*R+XQ1O9R4(> VNR@_D!U]E7* M]O2MG8?&[< MQV =(FZSP4Z1E7&5E;$Y*UMQ6>=GG7ERK7?3*B\K&@UKMM"JXM7 MQ75L/K/N8\4.6;G9BOV!]NS=H_>Y^F7Z$^%+F@F4P$(A>Y=CM5'Y_OWTOB'9 M.G_%.V=2LC2_7 &)@>L.ZOL%8_+0T&^-R_\2"'\ 4$L#!!0 ( $Z4D%C@ MAU%]@@< %@Z 9 >&PO=V]R:W-H965T]%8'^>A>(Y(\3TDK]9)O&[-E5I<=CHRG-.8R#9? MT$1?F7(1$Z4/Q:PC%X*226H41QWL./U.3%C2&EVEY\9B=,67*F()'0LDEW%, MQ--[&O'U=QEX/6.0WO$WHVM9^HU,51XY_VX.[B;7+<<\$8UHJ R"Z#\K>DNCR)#T<_S( MH:UMF<:P_'M#_SVMO*[,(Y'TED=?V43-KUL7+32A4[*,U">^_H/F%4H?,.21 M3/]'Z_Q>IX7"I50\SHWU$\0LR?Z2G[DC7F* ;I!6O9/5/76<3Q0970F^1L+9^@M^O+@H]/79U<= MI4LWC$Z8EW2;E80/E.2B>YZHN41!,J&3&GO_&7ML 71TM;=UQYNZO\=6XI_+ MI(WPQ3G"#O;J*F0W_\A7;>0Y!\U]N[E/0VWN'C0/7FZ.+<[PMB^"E_*\IB\" M^O9!WXKN%(WE/S7/^3[C=NNYIJ.[E L2TNN6[LDD%2O:&KUYY?:==W4NAX3Y MD+ "%8)3G<;G*Z-/KKER8H*Q1XCBCYR1:4.TQ/11W7QL**:Q@,2YD/"@@S6 M2V'F<[@:]=RNH_]==58UKNYM7=VSNGHL>$CI1**IX#$J.]ZGCZK.WU9>4W]# MPOS>GHO<7G=X@0L79:X$*K3B[_[6WWVKOV_"4"QUO_.!D4<6,<6HK'.R%=+4 MR9 P'Q(69+!^*6+]H3,8N/7O]&#KXX'5QP\T85QD/<IE M2)@_V'.,BYU*:\\<"%1HQ,!0MKY8*]@,8QQ?OM:*\)09880-&J M 2ADLVL5?B_\Z*-_T5>317EF'& OJW$L0,4T*"V HE6C5NAIMWNDT8 +*J]! M:3XH+8"B54-4Z'#7+L0?% ^_HSLIC3KT=1M+9FA,!>.3<_0PU]\ +65NPA]+ M)EF:KZP-%J@VSVEE$3+L#;J]W>X-LM BE:-0J'.7;L\?W'WEFO,_4R5M;\# ME?6@-!^4%D#1JF$L$@#NX%C]'6A. )3F@]("*%HU1$7RP+5G#WY! 8&F#7): M9>36KU5 H#D!*%K5ZT56P+7JVIV&8>VK0/, H#0?E!9 T:J3J@-#^GE3V4>7+/E?LI MRSN;+0 MXMBNQ>L[\W1P^JN9>7N)C3T.JLA!:0$4K1J[0I'C8RER#*K(06D^*"V HE5# M5"AR;%?D+YRJM5,:QV-?=+MUHU+04@,H6M73A>K&=M5]L".[)PF99;T622;( M9X*&B@N[RK87UC@@H"H;E!9 T:IA*U0V/I;*QJ J&Y3F@]("*%HU1(7*QG:5 MW6BT!:JO06E^3ML?;>T.MHXAKW$AK[%=7ILUJ>BOQ*S6E>5L+;KE8@$T0@/5 MY: T'Y060-&JZT,+7>X=2Y=[H+HY..5"35AQI#23@W,_,&MV$(>8X(2NA:WR4,7%_? MF?@O3?>?9(L 3@WAS:L+C)UWX[MQD.4ATA/NN[-SM)XS7=+N4@&6Z&>0Z>R1 M*>66Q[%^?[.I)J)VG@H5VQGT<*N\OF!A)M-/Z(\EB3:K#R*^IL(P3]D9>NTZ M;<=!"WTF+>P\]<$ITY>&N-W[;>,!8R056O%(QPNMTUT-NK9$EZ.'>4@),C'3 M7FEQ:*K]88STAPN=NLZ9:8+F\HE/GB1B<4PG3#?0Z$G?3T.:6IK[2XL =(1H MN[9-@6950&D!%*W:IHK\C/?,"HN7?L)>GDJVE]BX/P1-XX#2 BA:-7:E/0U' MV]0 NZL!=EL#[+Z&8^1]O"+OXUF3%LU2R796XZAT:];\=>N2"W5WUBX_AGK MJC.+#(UGS]#\_]5@]@(:>SBC7913O>W=]1*@1090M"P"G=+.NIB*6;JE4>JA MP#)1V2:[[=GMMLF;=+-@I[@]VW-Y3\2,)1)%=*I-G?9 /ZC(MC%F!XHOTGUZ MCUQIA9K^G%,RH<+^8$I8+N9=/0?4$L#!!0 ( $Z4D%CWF6H] MD@( +<& 9 >&PO=V]R:W-H965T^K[,2*JJ/90T"=Y925=3@5!6^KA70 MW#55W ^#8.17E DO3=S:M4H3N3*<";A61*^JBJH?$^!R,_8&WG9ASHK2V 4_ M36I:P V8V_I:X/N>(M^X;2CE@75,)7\"\M-.?;> M>"2')5UQ,Y>;]]#J<00SR;7[)9NV-O!(MM)&5FTS,JB8:/[I?>O#3L-@]$Q# MV#:$3QN&SS1$;4/DA#;,G*P9-31-E-P09:L1S0Z<-ZX;U3!AG^*-4;C+L,^D M4UE5S.!C,?J(3*4P3!0@,@8XI2*W2QEN*FI-U^13#78H"L(!S2,',S"4<4VN MJ+(;:S@DK\GMS8P M*2!?SQ8:7<_,MSX7FT.&_8?8BW^J:YK!V,.;K4&MP4M?O1B,@G=]#OPGL$=^ M##L_AOO0TX?WZ:-]G^PKJ$V?X@8F=C VF=9I?!(G_GI7R-ZC_E%(W F)_T8( MWIXY/F1R?H]Q:W5=0:^L^!=9)Z.W3W7U%@V[HH:OOY,!%:C"1:,FF5P)TUR7 M;K5+WS,7.D_6)YC*38@^P#21?DE5P3 $."P1,C@^04JJB:6 M&Y;X90%E"W!_*:793NP!W;&ULK9K;;N,V$(9?A7"+8A=( M8TL^)K4-)":##9HLC*3;7A2]H*5QK$82O21M[P)]^%*'2&:L,'%V"?DHUH!:/(MB5,U::VT7I^WVRI80<+5J5A#:CY9"IEP;3;E0UNM M)? P#TKBMM_I#-H)C]+6=)SOF\OI6&QT'*4PET1MDH3+[Y<0B]VDY;6>=MQ% M#RN=[6A/QVO^ />@OZSGTFRU*TH8)9"J2*1$PG+2NO#.F3_( O(C_HQ@I_;> MD^Q4%D(\9AO7X:35R68$,00Z0W#S;PLSB..,9.;QM82VJC&SP/WW3_2K_.3- MR2RX@IF(_XI"O9JT1BT2PI)O8GTG=I^@/*%^Q@M$K/)7LBN.[9^U2+!16B1E ML)E!$J7%?_ZM3,1>@-=[(< O _SG 8,7 KIE0/>M(_3*@-Y; _IE0'[J[>+< M\\11KOET+,6.R.QH0\O>Y-G/HTV^HC3[HMQK:3Z-3)R>WF\6"KYN(-6$;$G]X0OR.WVN:D#N<0G!*NMZ+X?3MX=V& MB3^=2! "A(DLI$G(',=<0DCF7 M^CNAL-!-LCB)Q\J"":,%K)_#LK:SG?8&_?RGL]U/^#O&)(Y<]ZM<]YVYOE]Q M"60NHP":TNH,/C:MF#"*"6/] XV\2AXKK8,JK0-W6@_*RBTD"Y"-)<6).C;) MF#"*"6-(,$N/8:7'$+?,#S$UP8113!A#@EF:C"I-1D>4^6NE-CP-@(AE5HZV MIN:3>6S&-E?5C17?"3]6H=%AD>[W.N;/KM(4IC48'MX25/"194&D4E<:P M:+8R>Q;0<_Z6["O4/R1/%<]M_ FY2,0F,X6FJ.WM;U3+.<;1:A6TP?X53:?3 M4-!0AV58-%L(OQ;"=PIQ)20$7+FOMMR,HQ.-2:.H-(9%L]6HG;6';*T]5&^- M2J.H-(9%LY6I_;7G-MB7&V7V*$5F(EE$*2]JU4RD*C*M/M\LRM42I'Q^SZG4 M"M5P>XGNO>&\M@D=R!^N-#%9?9133<6S^-8_ M3SNJ#<>BV6FOC;CG])2'/=H8CDO!99A=(]'(?*B%-)5IQ2.9\-3=RE%=.BJ- MHM(8%LT6K7;JW@BYE:.ZP':;4G]YW.\K6[YV5T\WWE\ED;JJU&I3$LFIWVK<$ MY$.^Z%"1('MN4:PIJ_96"QLO\N5\S_;/O'-6+$^L,<5JR5LN'Z)4D1B6!MDY M'9HOD2P6(!8;6JSS%78+82[MDOSM"G@(,CO ?+X40C]M9 -4RT"G_P-02P,$ M% @ 3I206-["]9\B P #A( T !X;"]S='EL97,N>&ULW5AM3]LP M$/XKD1D32!-I&PC-:"MME9 F;1,2?-@WY#9.:\FQ,\=E+;]^/CM-7_ AQH>M M+%6)?8_ON<=W%QQU4)N58+=SQDRT+(6LAV1N3/4QCNOIG)6T/E,5DQ8IE"ZI ML5,]B^M*,YK7X%2*N-?II'%)N22C@5R4UZ6IHZE:2#,DYZTI\K;JQRMF0W)^\_[E0YNI=Y.]''XZ..O>G5_OV$P>O$"TK..O5!FAV+T MZ8'EIR:('*H9D3 6?: Y> M!2VY6'ES#PQ3)92.C*VL#=0%2_WHX:Z?0=$;GI)+I5UL'\'_G33+]X#U# 1R M(5J!/>(-HT%%C6%:7MN)6^R,3Z"H&=^M*JMPINFJV[L@&P=WLT$F2N=,MV&Z M9&T:#00K0([FLSGIGT=;U3Q!V4^+^QVI)M#C[$;S0J^=/-ET0K MV+LX.ZTJL?HD^$R6S&_^Q0%' [KVB^9*\T<;#5IE:@U,D^B!:<.GVY9?FE9W M;&G6[;0L<,V]-ZCY[^9YQB335&R+MKU_R%E^M>+F"/D7FMV_E7W%09')Y>%K M;([-0Q>9O@61;Z#<27:0&N/F:-PZ?W=.W]8:P5O.D'R'MR6Q"1I-%EP8+IO9 MG.3:76$$\_%8& $,BX,IP'R\%Q;G M?]I/']V/QS!M_2#21WWZJ(_W"B%C]\'BA'TR>X5WFF5)DJ981L?CH((QEK61:N-A8' M/+ J8+T#\<-QH*?"/DD"5<6T84\PCF09AD OAGLT39'LI/ )UP=[2I(DR\(( M8&$%28(A\#3B"*8 -&!(DKAS<.\\BM?G5+SY!6CT&U!+ P04 " !.E)!8 MEXJ[', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S M9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X M 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7) MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 M ( $Z4D%BW>RRE9 0 +P@ / >&PO=V]R:V)O;VLN>&ULQ9K;;MLX M$$!_A?!3%EBLK4O2-J@+N''2#=#&1AVDCP4MT381B71)RJGS]3N4XW24NH-] MF?C)$74[&E%SAF3>/UAW/[?V7ORL*^.'O54(Z_-^WQ:NC[>L$$505L#C;'A3JL'_VM_ MW!0;[?5<5SILA[WV[TKU1*V-KO6C*H>]04_XE7WXUSK]:$V0U:QPMJJ&O62W MXTZYH(O?FF<1\E;.?=L2Y/RK!)!A[VP %UQHYT-[1'M]"8P;!0?OMII@KW05 ME!O+H#XYVZRU6<;+P%/TT6.T<=C_[H)X[OY/&.UBH0LUMD53*Q-V<72JBH#& MK_3:]X21M1KV+NQ&N?@\<(/KZE^"@K M:0HEVA!Z!)@2@.G1 ,7)5"+(C(#,7A%R%B'B"5[8A9BL.Z\Z)R#SHT'.@BT0 MY"D!>7I$R.\I@CPC(,^.!GDA_0I!OB$@W_!"3MQ2&OW8[A#2E&U/W!V& -\2 M@&]Y 6=-74NW;5^M7AH-ITD3Q*@H;&."1I#O",AWO) ?&Z^-\EY-D^61 8@$%&=!THTB?,0H'B /I9V+9=[O)'H]?Q!$Q'R21AMLFU M*6RMQ*W\J?!7D%#N2/CEL8G%#MQ50/1J[;V%S^(&BBPO5@IC4O9(N/4AC2RU M-.*R5FZI3+$5SQ_'9XM%G%#^2)@%,EM)IU:V*I7SW]L.&+:8C=)&PNR-J-E[ MR,,ODW!":2)A]L0.ZIMT#K)OAXIR0\(LARNIG;B35:/$%R5]X[K?*V6$A%D) M7V,CB'\J8YJ[A;!Y6;Q\I2DEAI19#."J6H>V)OD[^B& )^"#U0HV(2UC3$H5 M*;,J9LWXN&VS?^D0SN>4/GI. MZ1B3LDUV)-L\A15C4K;)N(K:V.,25DH9[;0 MGV=KY:5:@,C* M&[B%A_9"5L74B?BSF_3/3^.DW:*IJ@MHFYC/5I;[Q??]/PY\^ ]02P,$% M @ 3I206(YA./J] 0 >AT !H !X;"]?[0YI6ZYS;MQ#2?!WW=>HW;3R;^M5##H8C$)W/Z-ZG]S/[,U.;?S/Q&:YW,SC1S/_WL=#_F-P M^&FZ;5K'F*O>K.Y6,4^K<-S=;J=PN4C_/+GJ?2ZF5?>YD"J4#E((TO)!!D%6 M/L@AR,L'#2%H6#YH!$&C\D$O$/12/N@5@E[+!XTA:%P^2 8HXX @Z0%K JT% MN18"KP7!%@*Q!$6 KD%Z18"NP7Q%@*]%?56 KT5 M]58"O?7A9YM ;T6]E4!O1;V50&]%O95 ;T6]E4!O1;V50&]%O95 ;T6]E4!O M0[V-0&]#O8U ;T.]C4!O>]@L(=#;4&\CT-M0;R/0VU!O(]#;4&\CT-M0;R/0 MVU!O(]#;46\GT-M1;R?0VU%O)]#;46\GT-L?-KL)]';4VPGT=M3;"?1VU-L) M]';4VPGT=M3;GZEWRJ==3+>>ZQJ/;IY)=3Z_&V^?ORRO-Q'GX07G $>M[[]0 M2P,$% @ 3I206)PKTP^] 0 =QT !, !;0V]N=&5N=%]4>7!E&ULS=G);L(P% 707T'9(F(\E X"-FVW+8O^@)L\2$026[:A\/=UPB"UHJB( M2KV;1(GM=U]LZ6PR?MM:\KU-735^DA0AV ?&?%90K7UJ+#5Q9&Y\B:]]:9I)XJCR2>]Q-['-FB3: MVJK,=(CC;-WDWU(&^X0TKNSF^**TOA\G).QD0COR<\!^W>N:G"MSZLVT"R^Z MCK/8IF(^;"ORZ?D2)WHT\WF946ZR51V7I-XZTKDOB$)=I;NB_?/)(>XP[:[\ MZORNS+G .'/FC/7QQ!Q='G&UL4$L! A0#% @ 3I206 _J7,7O *P( !$ M ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ M3I206)E&PO=V]R:W-H965T&UL4$L! A0#% @ M3I206+\"^ YU" +B\ !@ ("!/0T 'AL+W=O&PO=V]R M:W-H965T&UL4$L! A0#% @ 3I206/\_"T3""@ 26( M !@ ("!Z1\ 'AL+W=O$J !X M;"]W;W)KH' M !^(0 & @($E+0 >&PO=V]R:W-H965T&UL4$L! A0#% @ 3I206,7WN+E^"P (QX !@ ("! M134 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 3I206.B( K[M @ B 8 !D M ("!EF8 'AL+W=O&PO M=V]R:W-H965TUQ !X;"]W;W)K&UL4$L! A0#% @ 3I206%6Q5/[M P Y @ !D ("! M*GL 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ 3I206%Y@2*_L P $@H !D ("!I(\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 3I206(2%_B^V M @ 6 8 !D ("!)Z 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 3I206!\ &PO=V]R M:W-H965T&UL M4$L! A0#% @ 3I206/S\>W8> P #@< !D ("!Z] M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M3I206&0F.?A0! S0T !D ("!6ML 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 3I206-YADK!3 @ M0 4 !D ("!JN@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 3I206,H^=.W- @ H@@ !D M ("!&_$ 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ 3I206-=K]A\> P B0D !D ("!X/\ 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 3I20 M6 /7>8N\ P T@X !D ("!!0L! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 3I206(>:;@.M!0 2BP M !D ("!GAD! 'AL+W=O&PO=V]R:W-H965THC 0!X;"]W;W)K&UL4$L! A0#% @ 3I206/>9:CV2 @ MP8 !D M ("!HRL! 'AL+W=OZ6+7X% 2*@ &0 @(%L+@$ >&PO=V]R:W-H965T MPO6?(@, X2 - M " 2$T 0!X;"]S='EL97,N>&UL4$L! A0#% @ 3I206)>* MNQS $P( L ( !;C@\ 0!X;"]?7!E&UL4$L%!@ Y #D A@\ ,M 0 $! end XML 84 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 85 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 87 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 164 245 1 true 63 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://onemednet.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://onemednet.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://onemednet.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations Sheet http://onemednet.com/role/StatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Stockholders Equity (Deficit) Sheet http://onemednet.com/role/StatementsOfStockholdersEquityDeficit Consolidated Statements of Stockholders Equity (Deficit) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Stockholders Equity (Deficit) (Parenthetical) Sheet http://onemednet.com/role/StatementsOfStockholdersEquityDeficitParenthetical Consolidated Statements of Stockholders Equity (Deficit) (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - Consolidated Statements of Cash Flows Sheet http://onemednet.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 00000008 - Disclosure - Organization and Operations Sheet http://onemednet.com/role/OrganizationAndOperations Organization and Operations Notes 8 false false R9.htm 00000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://onemednet.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Business Combination Sheet http://onemednet.com/role/BusinessCombination Business Combination Notes 10 false false R11.htm 00000011 - Disclosure - Going Concern Sheet http://onemednet.com/role/GoingConcern Going Concern Notes 11 false false R12.htm 00000012 - Disclosure - Property and Equipment Sheet http://onemednet.com/role/PropertyAndEquipment Property and Equipment Notes 12 false false R13.htm 00000013 - Disclosure - Income Taxes Sheet http://onemednet.com/role/IncomeTaxes Income Taxes Notes 13 false false R14.htm 00000014 - Disclosure - Convertible Promissory Notes held by Related Party Notes http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedParty Convertible Promissory Notes held by Related Party Notes 14 false false R15.htm 00000015 - Disclosure - Canadian Emergency Business Loan Act (CEBA) Sheet http://onemednet.com/role/CanadianEmergencyBusinessLoanActCeba Canadian Emergency Business Loan Act (CEBA) Notes 15 false false R16.htm 00000016 - Disclosure - Shareholders??? Equity Sheet http://onemednet.com/role/ShareholdersEquity Shareholders??? Equity Notes 16 false false R17.htm 00000017 - Disclosure - Stock Options Sheet http://onemednet.com/role/StockOptions Stock Options Notes 17 false false R18.htm 00000018 - Disclosure - Stock Warrants Sheet http://onemednet.com/role/StockWarrants Stock Warrants Notes 18 false false R19.htm 00000019 - Disclosure - Fair Value Measures Sheet http://onemednet.com/role/FairValueMeasures Fair Value Measures Notes 19 false false R20.htm 00000020 - Disclosure - Related Party Transactions Sheet http://onemednet.com/role/RelatedPartyTransactions Related Party Transactions Notes 20 false false R21.htm 00000021 - Disclosure - Commitments, Contingencies, and Concentrations Operating lease Sheet http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLease Commitments, Contingencies, and Concentrations Operating lease Notes 21 false false R22.htm 00000022 - Disclosure - Subsequent Events Sheet http://onemednet.com/role/SubsequentEvents Subsequent Events Notes 22 false false R23.htm 00000023 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://onemednet.com/role/SummaryOfSignificantAccountingPolicies 23 false false R24.htm 00000024 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://onemednet.com/role/SummaryOfSignificantAccountingPolicies 24 false false R25.htm 00000025 - Disclosure - Property and Equipment (Tables) Sheet http://onemednet.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://onemednet.com/role/PropertyAndEquipment 25 false false R26.htm 00000026 - Disclosure - Income Taxes (Tables) Sheet http://onemednet.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://onemednet.com/role/IncomeTaxes 26 false false R27.htm 00000027 - Disclosure - Shareholders??? Equity (Tables) Sheet http://onemednet.com/role/ShareholdersEquityTables Shareholders??? Equity (Tables) Tables http://onemednet.com/role/ShareholdersEquity 27 false false R28.htm 00000028 - Disclosure - Stock Options (Tables) Sheet http://onemednet.com/role/StockOptionsTables Stock Options (Tables) Tables http://onemednet.com/role/StockOptions 28 false false R29.htm 00000029 - Disclosure - Fair Value Measures (Tables) Sheet http://onemednet.com/role/FairValueMeasuresTables Fair Value Measures (Tables) Tables http://onemednet.com/role/FairValueMeasures 29 false false R30.htm 00000030 - Disclosure - Organization and Operations (Details Narrative) Sheet http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative Organization and Operations (Details Narrative) Details http://onemednet.com/role/OrganizationAndOperations 30 false false R31.htm 00000031 - Disclosure - Schedule Of Aggregate Percentage Revenue and Accounts Receivable (Details) Sheet http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails Schedule Of Aggregate Percentage Revenue and Accounts Receivable (Details) Details 31 false false R32.htm 00000032 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesTables 32 false false R33.htm 00000033 - Disclosure - Going Concern (Details Narrative) Sheet http://onemednet.com/role/GoingConcernDetailsNarrative Going Concern (Details Narrative) Details http://onemednet.com/role/GoingConcern 33 false false R34.htm 00000034 - Disclosure - Schedule of Property And Equipment (Details) Sheet http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails Schedule of Property And Equipment (Details) Details 34 false false R35.htm 00000035 - Disclosure - Property and Equipment (Details Narrative) Sheet http://onemednet.com/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://onemednet.com/role/PropertyAndEquipmentTables 35 false false R36.htm 00000036 - Disclosure - Schedule of Deferred Income Taxes (Details) Sheet http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails Schedule of Deferred Income Taxes (Details) Details 36 false false R37.htm 00000037 - Disclosure - Income Taxes (Details Narrative) Sheet http://onemednet.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://onemednet.com/role/IncomeTaxesTables 37 false false R38.htm 00000038 - Disclosure - Convertible Promissory Notes held by Related Party (Details Narrative) Notes http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative Convertible Promissory Notes held by Related Party (Details Narrative) Details http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedParty 38 false false R39.htm 00000039 - Disclosure - Canadian Emergency Business Loan Act (CEBA) (Details Narrative) Sheet http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative Canadian Emergency Business Loan Act (CEBA) (Details Narrative) Details http://onemednet.com/role/CanadianEmergencyBusinessLoanActCeba 39 false false R40.htm 00000040 - Disclosure - Schedule of Common Stock Activities (Details) Sheet http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails Schedule of Common Stock Activities (Details) Details 40 false false R41.htm 00000041 - Disclosure - Shareholders??? Equity (Details Narrative) Sheet http://onemednet.com/role/ShareholdersEquityDetailsNarrative Shareholders??? Equity (Details Narrative) Details http://onemednet.com/role/ShareholdersEquityTables 41 false false R42.htm 00000042 - Disclosure - Schedule of Options Outstanding (Details) Sheet http://onemednet.com/role/ScheduleOfOptionsOutstandingDetails Schedule of Options Outstanding (Details) Details 42 false false R43.htm 00000043 - Disclosure - Schedule of Fair Value of Stock Options (Details) Sheet http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails Schedule of Fair Value of Stock Options (Details) Details 43 false false R44.htm 00000044 - Disclosure - Stock Options (Details Narrative) Sheet http://onemednet.com/role/StockOptionsDetailsNarrative Stock Options (Details Narrative) Details http://onemednet.com/role/StockOptionsTables 44 false false R45.htm 00000045 - Disclosure - Stock Warrants (Details Narrative) Sheet http://onemednet.com/role/StockWarrantsDetailsNarrative Stock Warrants (Details Narrative) Details http://onemednet.com/role/StockWarrants 45 false false R46.htm 00000046 - Disclosure - Schedule of Financial Assets (Details) Sheet http://onemednet.com/role/ScheduleOfFinancialAssetsDetails Schedule of Financial Assets (Details) Details 46 false false R47.htm 00000047 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://onemednet.com/role/RelatedPartyTransactions 47 false false R48.htm 00000048 - Disclosure - Commitments, Contingencies, and Concentrations Operating lease (Details Narrative) Sheet http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLeaseDetailsNarrative Commitments, Contingencies, and Concentrations Operating lease (Details Narrative) Details http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLease 48 false false R49.htm 00000049 - Disclosure - Subsequent Events (Details Narrative) Sheet http://onemednet.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://onemednet.com/role/SubsequentEvents 49 false false All Reports Book All Reports forms-1a.htm onmd-20231231.xsd onmd-20231231_cal.xml onmd-20231231_def.xml onmd-20231231_lab.xml onmd-20231231_pre.xml forms-1_001.jpg forms-1_002.jpg forms-1_003.jpg forms-1_004.jpg forms-1_005.jpg forms-1_006.jpg forms-1_007.jpg forms-1_008.jpg forms-1_009.jpg forms-1_010.jpg forms-1_011.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 89 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "forms-1a.htm": { "nsprefix": "ONMD", "nsuri": "http://onemednet.com/20231231", "dts": { "inline": { "local": [ "forms-1a.htm" ] }, "schema": { "local": [ "onmd-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "onmd-20231231_cal.xml" ] }, "definitionLink": { "local": [ "onmd-20231231_def.xml" ] }, "labelLink": { "local": [ "onmd-20231231_lab.xml" ] }, "presentationLink": { "local": [ "onmd-20231231_pre.xml" ] } }, "keyStandard": 206, "keyCustom": 39, "axisStandard": 24, "axisCustom": 0, "memberStandard": 31, "memberCustom": 31, "hidden": { "total": 80, "http://fasb.org/us-gaap/2023": 61, "http://onemednet.com/20231231": 16, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 164, "entityCount": 1, "segmentCount": 63, "elementCount": 454, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 526, "http://xbrl.sec.gov/dei/2023": 26 }, "report": { "R1": { "role": "http://onemednet.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:AmendmentDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:AmendmentDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R2": { "role": "http://onemednet.com/role/BalanceSheets", "longName": "00000002 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R3": { "role": "http://onemednet.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R4": { "role": "http://onemednet.com/role/StatementsOfOperations", "longName": "00000004 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R5": { "role": "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit", "longName": "00000005 - Statement - Consolidated Statements of Stockholders Equity (Deficit)", "shortName": "Consolidated Statements of Stockholders Equity (Deficit)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesATwoPreferredStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R6": { "role": "http://onemednet.com/role/StatementsOfStockholdersEquityDeficitParenthetical", "longName": "00000006 - Statement - Consolidated Statements of Stockholders Equity (Deficit) (Parenthetical)", "shortName": "Consolidated Statements of Stockholders Equity (Deficit) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:SharePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true }, "uniqueAnchor": null }, "R7": { "role": "http://onemednet.com/role/StatementsOfCashFlows", "longName": "00000007 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "unique": true } }, "R8": { "role": "http://onemednet.com/role/OrganizationAndOperations", "longName": "00000008 - Disclosure - Organization and Operations", "shortName": "Organization and Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R9": { "role": "http://onemednet.com/role/SummaryOfSignificantAccountingPolicies", "longName": "00000009 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R10": { "role": "http://onemednet.com/role/BusinessCombination", "longName": "00000010 - Disclosure - Business Combination", "shortName": "Business Combination", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R11": { "role": "http://onemednet.com/role/GoingConcern", "longName": "00000011 - Disclosure - Going Concern", "shortName": "Going Concern", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R12": { "role": "http://onemednet.com/role/PropertyAndEquipment", "longName": "00000012 - Disclosure - Property and Equipment", "shortName": "Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R13": { "role": "http://onemednet.com/role/IncomeTaxes", "longName": "00000013 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R14": { "role": "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedParty", "longName": "00000014 - Disclosure - Convertible Promissory Notes held by Related Party", "shortName": "Convertible Promissory Notes held by Related Party", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R15": { "role": "http://onemednet.com/role/CanadianEmergencyBusinessLoanActCeba", "longName": "00000015 - Disclosure - Canadian Emergency Business Loan Act (CEBA)", "shortName": "Canadian Emergency Business Loan Act (CEBA)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R16": { "role": "http://onemednet.com/role/ShareholdersEquity", "longName": "00000016 - Disclosure - Shareholders\u2019 Equity", "shortName": "Shareholders\u2019 Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R17": { "role": "http://onemednet.com/role/StockOptions", "longName": "00000017 - Disclosure - Stock Options", "shortName": "Stock Options", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R18": { "role": "http://onemednet.com/role/StockWarrants", "longName": "00000018 - Disclosure - Stock Warrants", "shortName": "Stock Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "ONMD:StockWarrantsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "ONMD:StockWarrantsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R19": { "role": "http://onemednet.com/role/FairValueMeasures", "longName": "00000019 - Disclosure - Fair Value Measures", "shortName": "Fair Value Measures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R20": { "role": "http://onemednet.com/role/RelatedPartyTransactions", "longName": "00000020 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R21": { "role": "http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLease", "longName": "00000021 - Disclosure - Commitments, Contingencies, and Concentrations Operating lease", "shortName": "Commitments, Contingencies, and Concentrations Operating lease", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R22": { "role": "http://onemednet.com/role/SubsequentEvents", "longName": "00000022 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R23": { "role": "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "00000023 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R24": { "role": "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesTables", "longName": "00000024 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R25": { "role": "http://onemednet.com/role/PropertyAndEquipmentTables", "longName": "00000025 - Disclosure - Property and Equipment (Tables)", "shortName": "Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R26": { "role": "http://onemednet.com/role/IncomeTaxesTables", "longName": "00000026 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R27": { "role": "http://onemednet.com/role/ShareholdersEquityTables", "longName": "00000027 - Disclosure - Shareholders\u2019 Equity (Tables)", "shortName": "Shareholders\u2019 Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R28": { "role": "http://onemednet.com/role/StockOptionsTables", "longName": "00000028 - Disclosure - Stock Options (Tables)", "shortName": "Stock Options (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R29": { "role": "http://onemednet.com/role/FairValueMeasuresTables", "longName": "00000029 - Disclosure - Fair Value Measures (Tables)", "shortName": "Fair Value Measures (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R30": { "role": "http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative", "longName": "00000030 - Disclosure - Organization and Operations (Details Narrative)", "shortName": "Organization and Operations (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "From2023-11-012023-11-30_custom_SecuritiesPurchaseAgreementMember", "name": "us-gaap:DebtInstrumentDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-06-282023-06-28_custom_SecuritiesPurchaseAgreementMember_custom_DataKnightsAcquisitionCorpMember", "name": "us-gaap:DebtInstrumentIssuedPrincipal", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "span", "span", "p", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "unique": true } }, "R31": { "role": "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails", "longName": "00000031 - Disclosure - Schedule Of Aggregate Percentage Revenue and Accounts Receivable (Details)", "shortName": "Schedule Of Aggregate Percentage Revenue and Accounts Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "From2023-01-012023-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R32": { "role": "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "00000032 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "p", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "p", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R33": { "role": "http://onemednet.com/role/GoingConcernDetailsNarrative", "longName": "00000033 - Disclosure - Going Concern (Details Narrative)", "shortName": "Going Concern (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true }, "uniqueAnchor": null }, "R34": { "role": "http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails", "longName": "00000034 - Disclosure - Schedule of Property And Equipment (Details)", "shortName": "Schedule of Property And Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R35": { "role": "http://onemednet.com/role/PropertyAndEquipmentDetailsNarrative", "longName": "00000035 - Disclosure - Property and Equipment (Details Narrative)", "shortName": "Property and Equipment (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R36": { "role": "http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails", "longName": "00000036 - Disclosure - Schedule of Deferred Income Taxes (Details)", "shortName": "Schedule of Deferred Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R37": { "role": "http://onemednet.com/role/IncomeTaxesDetailsNarrative", "longName": "00000037 - Disclosure - Income Taxes (Details Narrative)", "shortName": "Income Taxes (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R38": { "role": "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative", "longName": "00000038 - Disclosure - Convertible Promissory Notes held by Related Party (Details Narrative)", "shortName": "Convertible Promissory Notes held by Related Party (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:ConvertibleNotesPayable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_custom_ConvertiblePromissoryNotesMember", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "span", "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "unique": true } }, "R39": { "role": "http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative", "longName": "00000039 - Disclosure - Canadian Emergency Business Loan Act (CEBA) (Details Narrative)", "shortName": "Canadian Emergency Business Loan Act (CEBA) (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "From2020-12-012020-12-31_custom_CEBALoanMember", "name": "us-gaap:ProceedsFromIssuanceOfUnsecuredDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2020-12-012020-12-31_custom_CEBALoanMember", "name": "us-gaap:ProceedsFromIssuanceOfUnsecuredDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R40": { "role": "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails", "longName": "00000040 - Disclosure - Schedule of Common Stock Activities (Details)", "shortName": "Schedule of Common Stock Activities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R41": { "role": "http://onemednet.com/role/ShareholdersEquityDetailsNarrative", "longName": "00000041 - Disclosure - Shareholders\u2019 Equity (Details Narrative)", "shortName": "Shareholders\u2019 Equity (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ConvertiblePreferredStockTermsOfConversion", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ConvertiblePreferredStockTermsOfConversion", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R42": { "role": "http://onemednet.com/role/ScheduleOfOptionsOutstandingDetails", "longName": "00000042 - Disclosure - Schedule of Options Outstanding (Details)", "shortName": "Schedule of Options Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "AsOf2021-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2020-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "unique": true } }, "R43": { "role": "http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails", "longName": "00000043 - Disclosure - Schedule of Fair Value of Stock Options (Details)", "shortName": "Schedule of Fair Value of Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "From2022-01-012022-12-31_us-gaap_MeasurementInputExpectedTermMember", "name": "ONMD:EquitySecuritiesFvNiMeasurementTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31_us-gaap_MeasurementInputExpectedTermMember", "name": "ONMD:EquitySecuritiesFvNiMeasurementTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R44": { "role": "http://onemednet.com/role/StockOptionsDetailsNarrative", "longName": "00000044 - Disclosure - Stock Options (Details Narrative)", "shortName": "Stock Options (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "unique": true } }, "R45": { "role": "http://onemednet.com/role/StockWarrantsDetailsNarrative", "longName": "00000045 - Disclosure - Stock Warrants (Details Narrative)", "shortName": "Stock Warrants (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:ProceedsFromIssuanceOfWarrants", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "p", "ONMD:StockWarrantsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "unique": true } }, "R46": { "role": "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails", "longName": "00000046 - Disclosure - Schedule of Financial Assets (Details)", "shortName": "Schedule of Financial Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:AssetsHeldInTrustCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember", "name": "us-gaap:AssetsHeldInTrustCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "unique": true } }, "R47": { "role": "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative", "longName": "00000047 - Disclosure - Related Party Transactions (Details Narrative)", "shortName": "Related Party Transactions (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:ConvertibleNotesPayable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:SeniorNotesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "unique": true } }, "R48": { "role": "http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLeaseDetailsNarrative", "longName": "00000048 - Disclosure - Commitments, Contingencies, and Concentrations Operating lease (Details Narrative)", "shortName": "Commitments, Contingencies, and Concentrations Operating lease (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true, "unique": true } }, "R49": { "role": "http://onemednet.com/role/SubsequentEventsDetailsNarrative", "longName": "00000049 - Disclosure - Subsequent Events (Details Narrative)", "shortName": "Subsequent Events (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ProceedsFromRelatedPartyDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-12-31_us-gaap_SubsequentEventMember", "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "span", "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "forms-1a.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "ONMD_AccountingPronouncementsNotYetAdoptedPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://onemednet.com/20231231", "localname": "AccountingPronouncementsNotYetAdoptedPolicyTextBlock", "presentation": [ "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Accounting Pronouncements Not Yet Adopted", "documentation": "Accounting Pronouncements Not Yet Adopted [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable & accrued expenses", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r25" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": [ "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails", "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r558" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts receivable, net of allowance", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r226", "r227" ] }, "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Franchise tax payable", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r27", "r67", "r564" ] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Income tax payable", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": [ "r91", "r133" ] }, "ONMD_AccruedInterestRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://onemednet.com/20231231", "localname": "AccruedInterestRelatedParty", "crdr": "credit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued interest", "documentation": "Accrued interest related party." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative", "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities." } } }, "auth_ref": [ "r83" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r51", "r158", "r448" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r169", "r170", "r396", "r397", "r398", "r399", "r400", "r401" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r169", "r170", "r396", "r397", "r398", "r399", "r400", "r401" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r94", "r585", "r693" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r343", "r344", "r345", "r471", "r632", "r633", "r634", "r674", "r695" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AddressTypeDomain", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r65", "r66", "r310" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": [ "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of PIPE Warrants", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": [ "r14", "r52", "r124" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://onemednet.com/role/StockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r339", "r346" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r164", "r230", "r235" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r612" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative", "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r372" ] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetImpairmentCharges", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Impairment", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r8", "r49" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r131", "r159", "r179", "r209", "r217", "r221", "r232", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r373", "r375", "r395", "r441", "r507", "r585", "r597", "r641", "r642", "r679" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r154", "r165", "r179", "r232", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r373", "r375", "r395", "r585", "r641", "r642", "r679" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsHeldInTrustCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsHeldInTrustCurrent", "crdr": "debit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets", "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Investments held in Trust", "verboseLabel": "Assets measured and recorded fair value", "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate within one year of the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited." } } }, "auth_ref": [ "r626" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r612" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://onemednet.com/role/StockOptionsDetailsNarrative", "http://onemednet.com/role/StockWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338" ] }, "srt_BoardOfDirectorsChairmanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "BoardOfDirectorsChairmanMember", "presentation": [ "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails", "http://onemednet.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Board of Directors Chairman [Member]" } } }, "auth_ref": [ "r637" ] }, "ONMD_BoardOfDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "BoardOfDirectorsMember", "presentation": [ "http://onemednet.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Board Of Directors [Member]", "documentation": "Board Of Directors [Member]" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative", "http://onemednet.com/role/IncomeTaxesDetailsNarrative", "http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative", "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative", "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r369", "r580", "r581" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative", "http://onemednet.com/role/IncomeTaxesDetailsNarrative", "http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative", "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative", "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r72", "r73", "r369", "r580", "r581" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://onemednet.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r2", "r3", "r12" ] }, "ONMD_BusinessCombinationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://onemednet.com/20231231", "localname": "BusinessCombinationCost", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Business combination cost", "documentation": "Business combination cost." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://onemednet.com/role/BusinessCombination" ], "lang": { "en-us": { "role": { "label": "Business Combination", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r127", "r370" ] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Business Combination", "label": "Business Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r71" ] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "BusinessContactMember", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r611", "r612" ] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Foreign Currency Translation", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r88", "r110", "r112" ] }, "ONMD_CEBALoanMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "CEBALoanMember", "presentation": [ "http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "CEBA Loan [Member]", "documentation": "CEBA Loan [Member]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r37", "r156", "r563" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r38" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and Cash Equivalents, Beginning", "periodEndLabel": "Cash and Cash Equivalents, Ending", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r37", "r107", "r175" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net change in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r4", "r107" ] }, "ONMD_CashHeldInTrustAccount": { "xbrltype": "monetaryItemType", "nsuri": "http://onemednet.com/20231231", "localname": "CashHeldInTrustAccount", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Held in Trust Account", "documentation": "Cash held in trust account." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ONMD_ClassBCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://onemednet.com/20231231", "localname": "ClassBCommonStock", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Class B Common Stock", "documentation": "Class B common stock.", "label": "ClassBCommonStock" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://onemednet.com/role/BalanceSheets", "http://onemednet.com/role/BalanceSheetsParenthetical", "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative", "http://onemednet.com/role/ShareholdersEquityDetailsNarrative", "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r151", "r160", "r161", "r162", "r179", "r199", "r200", "r202", "r204", "r207", "r208", "r232", "r242", "r244", "r245", "r246", "r249", "r250", "r278", "r279", "r283", "r286", "r293", "r395", "r462", "r463", "r464", "r465", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r494", "r516", "r539", "r552", "r553", "r554", "r555", "r556", "r618", "r627", "r636" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://onemednet.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r160", "r161", "r162", "r207", "r278", "r279", "r281", "r283", "r286", "r291", "r293", "r462", "r463", "r464", "r465", "r575", "r618", "r627" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://onemednet.com/role/StockWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r60" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://onemednet.com/role/StockWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative", "http://onemednet.com/role/StockWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r294" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative", "http://onemednet.com/role/StockWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r294" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://onemednet.com/role/StockWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r372" ] }, "ONMD_CommitmentMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "CommitmentMember", "presentation": [ "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Commitment [Member]", "documentation": "Commitment [Member]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r32", "r85", "r442", "r493" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLease" ], "lang": { "en-us": { "role": { "label": "Commitments, Contingencies, and Concentrations Operating lease", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r118", "r236", "r237", "r559", "r640" ] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassAMember", "presentation": [ "http://onemednet.com/role/BalanceSheets", "http://onemednet.com/role/BalanceSheetsParenthetical", "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Common Class A [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": [ "r695" ] }, "ONMD_CommonClassAOneMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "CommonClassAOneMember", "presentation": [ "http://onemednet.com/role/BalanceSheets", "http://onemednet.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Class A One [Member]", "documentation": "Common Class A One [Member]" } } }, "auth_ref": [] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassBMember", "presentation": [ "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Common Class B [Member]", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": [ "r695" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails", "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit", "http://onemednet.com/role/StockWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r587", "r588", "r589", "r591", "r592", "r593", "r594", "r632", "r633", "r674", "r691", "r695" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://onemednet.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r93" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://onemednet.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r93", "r494" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://onemednet.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r14", "r93", "r494", "r513", "r695", "r696" ] }, "ONMD_CommonStockSubjectToPossibleRedemptionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://onemednet.com/20231231", "localname": "CommonStockSubjectToPossibleRedemptionValue", "crdr": "debit", "presentation": [ "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Common stock redemption", "documentation": "Common stock subject to possible redemption value." } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock value", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r93", "r444", "r585" ] }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationRelatedCostsPolicyTextBlock", "presentation": [ "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Stock-based Compensation", "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense." } } }, "auth_ref": [ "r63" ] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": [ "http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails", "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r42", "r44", "r76", "r77", "r225", "r558" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails", "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r42", "r44", "r76", "r77", "r225", "r459", "r558" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails", "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r42", "r44", "r76", "r77", "r225", "r558", "r622" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails", "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Aggregate Percent of Revenue and Accounts Receivable", "verboseLabel": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r42", "r44", "r76", "r77", "r225" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails", "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r42", "r44", "r76", "r77", "r225", "r558" ] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ContactPersonnelName", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "ONMD_ConvertiableNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "ConvertiableNotesMember", "presentation": [ "http://onemednet.com/role/StockWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertiable Notes [Member]", "documentation": "Convertiable Notes [Member]" } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtCurrent", "crdr": "credit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Convertible promissory notes", "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r90" ] }, "us-gaap_ConvertibleDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtNoncurrent", "crdr": "credit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Convertible promissory note", "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock." } } }, "auth_ref": [ "r30" ] }, "us-gaap_ConvertibleNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayable", "crdr": "credit", "presentation": [ "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative", "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": [ "r20", "r134", "r688" ] }, "us-gaap_ConvertiblePreferredStockTermsOfConversion": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertiblePreferredStockTermsOfConversion", "presentation": [ "http://onemednet.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Convertible, Terms", "documentation": "Description of conversion terms for preferred stock." } } }, "auth_ref": [ "r21", "r56", "r59", "r92", "r122", "r123" ] }, "ONMD_ConvertiblePromissoryNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "ConvertiblePromissoryNotesMember", "presentation": [ "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Promissory Notes [Member]", "documentation": "Convertible Promissory Notes [Member]" } } }, "auth_ref": [] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r101", "r179", "r232", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r395", "r641" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails", "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r43", "r225" ] }, "ONMD_CustomerFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "CustomerFiveMember", "presentation": [ "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Customer Five [Member]", "documentation": "Customer Five [Member]" } } }, "auth_ref": [] }, "ONMD_CustomerFourMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "CustomerFourMember", "presentation": [ "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Customer Four [Member]", "documentation": "Customer Four [Member]" } } }, "auth_ref": [] }, "ONMD_CustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "CustomerOneMember", "presentation": [ "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Customer One [Member]", "documentation": "Customer One [Member]" } } }, "auth_ref": [] }, "ONMD_CustomerThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "CustomerThreeMember", "presentation": [ "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Customer Three [Member]", "documentation": "Customer Three [Member]" } } }, "auth_ref": [] }, "ONMD_CustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "CustomerTwoMember", "presentation": [ "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Customer Two [Member]", "documentation": "Customer Two [Member]" } } }, "auth_ref": [] }, "ONMD_CustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "CustomersMember", "presentation": [ "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Customers [Member]", "documentation": "Customers [Member]" } } }, "auth_ref": [] }, "ONMD_DataKnightsAcquisitionCorpMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "DataKnightsAcquisitionCorpMember", "presentation": [ "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative", "http://onemednet.com/role/IncomeTaxesDetailsNarrative", "http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative", "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative", "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Data Knights Acquisition Corp [Member]", "documentation": "Data Knights Acquisition Corp [Member]" } } }, "auth_ref": [] }, "us-gaap_DebtConversionOriginalDebtAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionOriginalDebtAmount1", "crdr": "credit", "presentation": [ "http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Conversion, Original Debt, Amount", "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r39", "r40" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://onemednet.com/role/CanadianEmergencyBusinessLoanActCeba" ], "lang": { "en-us": { "role": { "label": "Canadian Emergency Business Loan Act (CEBA)", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r119", "r177", "r251", "r257", "r258", "r259", "r260", "r261", "r262", "r267", "r274", "r275", "r276" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative", "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative", "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative", "http://onemednet.com/role/StockWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r20", "r90", "r91", "r132", "r134", "r183", "r252", "r253", "r254", "r255", "r256", "r258", "r263", "r264", "r265", "r266", "r268", "r269", "r270", "r271", "r272", "r273", "r404", "r570", "r571", "r572", "r573", "r574", "r628" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative", "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Conversion Price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r120", "r254" ] }, "us-gaap_DebtInstrumentDecreaseForgiveness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentDecreaseForgiveness", "crdr": "debit", "presentation": [ "http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Decrease, Forgiveness", "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument." } } }, "auth_ref": [ "r628" ] }, "us-gaap_DebtInstrumentDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentDescription", "presentation": [ "http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative", "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Description", "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total." } } }, "auth_ref": [ "r20", "r56", "r86", "r90", "r132", "r134" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r78", "r80", "r252", "r404", "r571", "r572" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r29", "r253" ] }, "us-gaap_DebtInstrumentIssuedPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentIssuedPrincipal", "crdr": "credit", "presentation": [ "http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Issued, Principal", "documentation": "Amount of principal of debt issued." } } }, "auth_ref": [ "r462" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative", "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative", "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative", "http://onemednet.com/role/StockWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r30", "r183", "r252", "r253", "r254", "r255", "r256", "r258", "r263", "r264", "r265", "r266", "r268", "r269", "r270", "r271", "r272", "r273", "r404", "r570", "r571", "r572", "r573", "r574", "r628" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueCurrent", "crdr": "credit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred revenues", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r623" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Gross deferred tax assets", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r357" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net deferred tax assets", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r672" ] }, "us-gaap_DeferredTaxAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNetAbstract", "presentation": [ "http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Net operating loss carry forward", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r70", "r673" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "crdr": "debit", "presentation": [ "http://onemednet.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r70", "r673" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Stock Compensation", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r70", "r673" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://onemednet.com/role/IncomeTaxesDetailsNarrative", "http://onemednet.com/role/ScheduleOfDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r358" ] }, "ONMD_DeferredUnderwriterFeePayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://onemednet.com/20231231", "localname": "DeferredUnderwriterFeePayableCurrent", "crdr": "credit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred underwriter fee payable", "documentation": "Deferred underwriter fee payable current." } } }, "auth_ref": [] }, "ONMD_DeferredUnderwriterFeePayableNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://onemednet.com/20231231", "localname": "DeferredUnderwriterFeePayableNonCurrent", "crdr": "credit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred underwriter fee payable", "documentation": "Deferred underwriter fee payable noncurrent.", "label": "DeferredUnderwriterFeePayableNonCurrent" } } }, "auth_ref": [] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortization", "crdr": "debit", "presentation": [ "http://onemednet.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r8", "r50" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r8", "r213" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://onemednet.com/role/StockOptions" ], "lang": { "en-us": { "role": { "label": "Stock Options", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r308", "r312", "r340", "r341", "r342", "r583" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "ONMD_DisclosureStockWarrantsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://onemednet.com/20231231", "localname": "DisclosureStockWarrantsAbstract", "lang": { "en-us": { "role": { "label": "Stock Warrants" } } }, "auth_ref": [] }, "us-gaap_DividendsPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPreferredStock", "crdr": "debit", "presentation": [ "http://onemednet.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dividends, Preferred Stock", "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)." } } }, "auth_ref": [ "r6", "r124" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r611" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r609", "r611", "r612" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r610" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r598" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r611" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r611" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r613" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r601" ] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticCountryMember", "presentation": [ "http://onemednet.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Domestic Tax Authority [Member]", "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile." } } }, "auth_ref": [] }, "ONMD_EFHuttonMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "EFHuttonMember", "presentation": [ "http://onemednet.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "EF Hutton [Member]", "documentation": "EF Hutton [Member]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://onemednet.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Loss per share of Common Stock:(1)" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://onemednet.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r173", "r189", "r190", "r191", "r192", "r193", "r199", "r202", "r203", "r204", "r205", "r385", "r386", "r437", "r451", "r566" ] }, "ONMD_EmergingGrowthCompanyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://onemednet.com/20231231", "localname": "EmergingGrowthCompanyPolicyTextBlock", "presentation": [ "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Emerging Growth Company", "documentation": "Emerging Growth Company [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://onemednet.com/role/StockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r671" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://onemednet.com/role/StockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "ONMD_EmployeesDirectorsAndConsultantsMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "EmployeesDirectorsAndConsultantsMember", "presentation": [ "http://onemednet.com/role/StockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Employees Directors and Consultants [Member]", "documentation": "Employees Directors and Consultants [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityAddressesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesLineItems", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityAddressesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesTable", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses [Table]", "documentation": "Container of address information for the entity" } } }, "auth_ref": [ "r600" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r604" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r600" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://onemednet.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r600" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r617" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r600" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r614" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r612" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r600" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r600" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r600" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r600" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r615" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative", "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails", "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit", "http://onemednet.com/role/StockWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r14", "r152", "r169", "r170", "r171", "r184", "r185", "r186", "r188", "r194", "r196", "r206", "r233", "r234", "r295", "r343", "r344", "r345", "r362", "r363", "r377", "r378", "r379", "r380", "r381", "r382", "r384", "r396", "r397", "r398", "r399", "r400", "r401", "r406", "r454", "r455", "r456", "r471", "r539" ] }, "ONMD_EquityFinancingDescription": { "xbrltype": "stringItemType", "nsuri": "http://onemednet.com/20231231", "localname": "EquityFinancingDescription", "presentation": [ "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "[custom:EquityFinancingDescription]", "documentation": "Equity financing description." } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesFvNiMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiMeasurementInput", "presentation": [ "http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Equity Securities, FV-NI, Measurement Input", "documentation": "Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r392" ] }, "ONMD_EquitySecuritiesFvNiMeasurementTerm": { "xbrltype": "durationItemType", "nsuri": "http://onemednet.com/20231231", "localname": "EquitySecuritiesFvNiMeasurementTerm", "presentation": [ "http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "[custom:EquitySecuritiesFvNiMeasurementTerm]", "documentation": "Equity securities FvNi measurement term." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "ONMD_ExtensionLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://onemednet.com/20231231", "localname": "ExtensionLoan", "crdr": "credit", "presentation": [ "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "[custom:ExtensionLoan-0]", "documentation": "Extension loan." } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Change in FV of Warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r1", "r8" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r388", "r389", "r393" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r388", "r389", "r393" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r15" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://onemednet.com/role/StockOptionsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value of Stock Options", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r15" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://onemednet.com/role/FairValueMeasuresTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Financial Assets", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r74", "r129" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [ "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Class of asset." } } }, "auth_ref": [ "r16" ] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByAssetClassAxis", "presentation": [ "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r74", "r75" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r265", "r299", "r300", "r301", "r302", "r303", "r304", "r389", "r418", "r419", "r420", "r571", "r572", "r577", "r578", "r579" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r388", "r389", "r391", "r392", "r394" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://onemednet.com/role/FairValueMeasures" ], "lang": { "en-us": { "role": { "label": "Fair Value Measures", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r387" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r265", "r299", "r304", "r389", "r418", "r577", "r578", "r579" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r265", "r299", "r304", "r389", "r419", "r571", "r572", "r577", "r578", "r579" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r265", "r299", "r300", "r301", "r302", "r303", "r304", "r389", "r420", "r571", "r572", "r577", "r578", "r579" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r265", "r299", "r300", "r301", "r302", "r303", "r304", "r418", "r419", "r420", "r571", "r572", "r577", "r578", "r579" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r387", "r394" ] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r10", "r19" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r102", "r518" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://onemednet.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Gross Margin", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r100", "r179", "r209", "r216", "r220", "r222", "r232", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r395", "r568", "r641" ] }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "crdr": "debit", "presentation": [ "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Impairment of Long-Lived Assets to be Disposed of", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale." } } }, "auth_ref": [ "r8", "r115" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Impairment of Long-Lived Assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r117" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://onemednet.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://onemednet.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://onemednet.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r180", "r349", "r353", "r354", "r360", "r364", "r366", "r367", "r368", "r467" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income tax provision", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r142", "r150", "r195", "r196", "r214", "r352", "r365", "r452" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r168", "r350", "r351", "r354", "r355", "r359", "r361", "r461" ] }, "ONMD_IncreaseDecreaseFranchiseTaxPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://onemednet.com/20231231", "localname": "IncreaseDecreaseFranchiseTaxPayable", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Franchise tax payable", "documentation": "Increase decrease franchise tax payable.", "label": "IncreaseDecreaseFranchiseTaxPayable" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued Expenses", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable, net of allowance", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income Tax Payable", "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Deferred Revenue & Customer Deposits", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r423", "r625" ] }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDueToRelatedParties", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amount due to related party", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence." } } }, "auth_ref": [ "r7" ] }, "ONMD_IncreaseDecreaseInExerciseTaxLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://onemednet.com/20231231", "localname": "IncreaseDecreaseInExerciseTaxLiability", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Exercise tax liability", "documentation": "Increase decrease in exercise tax liability." } } }, "auth_ref": [] }, "ONMD_IncreaseDecreaseInExtensionLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://onemednet.com/20231231", "localname": "IncreaseDecreaseInExtensionLoan", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Extension loan", "documentation": "Increase decrease in extension loan." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other current assets", "label": "Increase (Decrease) in Other Current Assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": [ "r625" ] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid Expenses", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r7" ] }, "ONMD_IncreaseDecreaseInWorkingCapitalLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://onemednet.com/20231231", "localname": "IncreaseDecreaseInWorkingCapitalLoan", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Working capital loan", "documentation": "Increase decrease in working capital loan." } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r79", "r137", "r172", "r212", "r403", "r524", "r595", "r694" ] }, "us-gaap_Investments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Investments", "crdr": "debit", "presentation": [ "http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Investments", "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments." } } }, "auth_ref": [ "r440" ] }, "ONMD_InvestmentsHeldInTrustMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "InvestmentsHeldInTrustMember", "presentation": [ "http://onemednet.com/role/ScheduleOfFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Investments Held in Trust [Member]", "documentation": "Investments Held In Trust [Member]" } } }, "auth_ref": [] }, "ONMD_KingwoodCapitalPartnersLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "KingwoodCapitalPartnersLLCMember", "presentation": [ "http://onemednet.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Kingwood Capital Partners LLC [Member]", "documentation": "Kingwood Capital Partners LLC [Member]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://onemednet.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r26", "r179", "r232", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r374", "r375", "r376", "r395", "r492", "r567", "r597", "r641", "r679", "r680" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity (deficit)", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r98", "r135", "r446", "r585", "r629", "r638", "r676" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r28", "r155", "r179", "r232", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r374", "r375", "r376", "r395", "r585", "r641", "r679", "r680" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current Liabilities" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long Term Liabilities" } } }, "auth_ref": [] }, "ONMD_LoanExtensionsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://onemednet.com/20231231", "localname": "LoanExtensionsCurrent", "crdr": "credit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Loan Extensions", "documentation": "Loan extensions current." } } }, "auth_ref": [] }, "us-gaap_LoansPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansPayable", "crdr": "credit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Loan Payable", "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer)." } } }, "auth_ref": [ "r20", "r134", "r688" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtTextBlock", "presentation": [ "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedParty" ], "lang": { "en-us": { "role": { "label": "Convertible Promissory Notes held by Related Party", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": [ "r119" ] }, "us-gaap_LongTermLoansPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermLoansPayable", "crdr": "credit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Extension loans", "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": [ "r30" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails", "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": [ "r225", "r576", "r644", "r689", "r690" ] }, "us-gaap_MajorityShareholderMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MajorityShareholderMember", "presentation": [ "http://onemednet.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Majority Shareholder [Member]", "documentation": "Owner that controls more than 50 percent of the voting interest in the entity through direct or indirect ownership." } } }, "auth_ref": [] }, "ONMD_ManagementAndDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "ManagementAndDirectorsMember", "presentation": [ "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Management and Directors [Member]", "documentation": "Management and Directors [Member]" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://onemednet.com/role/StockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r238", "r239", "r240", "r241", "r306", "r422", "r453", "r483", "r484", "r547", "r548", "r549", "r550", "r551", "r560", "r561", "r569", "r575", "r582", "r586", "r643", "r681", "r682", "r683", "r684", "r685", "r686" ] }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": [ "http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Dividend Rate [Member]", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": [ "r675" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r675" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r675" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r675" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r390" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://onemednet.com/role/ScheduleOfFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails", "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "auth_ref": [ "r225", "r576", "r644", "r689", "r690" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r174" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flow from Financing Activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash used for Investing Activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash flows used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r107", "r108", "r109" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flow from Operating Activities" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://onemednet.com/role/StatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows", "http://onemednet.com/role/StatementsOfOperations", "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Net loss", "verboseLabel": "Net Loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r99", "r109", "r136", "r153", "r166", "r167", "r171", "r179", "r187", "r189", "r190", "r191", "r192", "r195", "r196", "r201", "r209", "r216", "r220", "r222", "r232", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r386", "r395", "r450", "r515", "r537", "r538", "r568", "r595", "r641" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recently adopted accounting pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ONMD_NewEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "NewEquityIncentivePlanMember", "presentation": [ "http://onemednet.com/role/StockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "New Equity Incentive Plan [Member]", "documentation": "New Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://onemednet.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Other Expense (income)", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r104" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://onemednet.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other Expense (income)" } } }, "auth_ref": [] }, "us-gaap_NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonrelatedPartyMember", "presentation": [ "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Nonrelated Party [Member]", "documentation": "Party not related to reporting entity." } } }, "auth_ref": [ "r630", "r631" ] }, "ONMD_OneCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "OneCustomerMember", "presentation": [ "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "One Customer [Member]", "documentation": "One Customer [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total Operating Expenses", "label": "Operating Expenses [Default Label]", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://onemednet.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Expenses" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://onemednet.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r209", "r216", "r220", "r222", "r568" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLeaseDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r405", "r584" ] }, "us-gaap_OperatingLeasesRentExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasesRentExpenseNet", "crdr": "debit", "presentation": [ "http://onemednet.com/role/CommitmentsContingenciesAndConcentrationsOperatingLeaseDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating Leases, Rent Expense, Net", "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income." } } }, "auth_ref": [ "r141" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://onemednet.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r69" ] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsLineItems", "presentation": [ "http://onemednet.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsTable", "presentation": [ "http://onemednet.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Table]", "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization." } } }, "auth_ref": [ "r68" ] }, "ONMD_OperatingSegmentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://onemednet.com/20231231", "localname": "OperatingSegmentsPolicyTextBlock", "presentation": [ "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Operating Segments", "documentation": "Operating Segments [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [ "http://onemednet.com/role/OrganizationAndOperations" ], "lang": { "en-us": { "role": { "label": "Organization and Operations", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": [ "r110", "r111", "r112", "r128" ] }, "us-gaap_OtherGeneralExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherGeneralExpense", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operations", "documentation": "Amount of general expenses not normally included in Other Operating Costs and Expenses." } } }, "auth_ref": [ "r103" ] }, "us-gaap_OtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilities", "crdr": "credit", "presentation": [ "http://onemednet.com/role/StockWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Other Liabilities", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": [ "r84", "r439", "r487", "r488", "r597", "r692" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Loan, related party of OMN", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r31" ] }, "us-gaap_OtherNonoperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingExpense", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other expense", "documentation": "Amount of expense related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r105" ] }, "us-gaap_OtherNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNotesPayableCurrent", "crdr": "credit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Pipe Notes, net of discount including interest", "documentation": "Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r27" ] }, "us-gaap_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherReceivables", "crdr": "debit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Receivable from SPAC", "documentation": "Amount due from parties in nontrade transactions, classified as other." } } }, "auth_ref": [ "r163", "r502" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r611" ] }, "us-gaap_OtherShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherShortTermBorrowings", "crdr": "credit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Loan Amount due to related parties", "documentation": "Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r22", "r491" ] }, "ONMD_PatentsAndTrademarksPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://onemednet.com/20231231", "localname": "PatentsAndTrademarksPolicyTextBlock", "presentation": [ "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Patents and Trademarks", "documentation": "Patents And Trademarks [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r35", "r371" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r106" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://onemednet.com/role/StockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://onemednet.com/role/StockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r605" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r606" ] }, "us-gaap_PreferredStockConvertibleConversionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockConvertibleConversionPrice", "presentation": [ "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Convertible, Conversion Price", "documentation": "Per share conversion price of preferred stock." } } }, "auth_ref": [ "r280" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": [ "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r587", "r588", "r591", "r592", "r593", "r594", "r691", "r695" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://onemednet.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r92", "r278" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://onemednet.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r92", "r494" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://onemednet.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r92", "r494", "r513", "r695", "r696" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred value", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r92", "r443", "r585" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r624" ] }, "ONMD_PrivateWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "PrivateWarrantsMember", "presentation": [ "http://onemednet.com/role/StockWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Private Warrants [Member]", "documentation": "Private Warrants [Member]" } } }, "auth_ref": [] }, "ONMD_ProccedsFromRetainedEarningsAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://onemednet.com/20231231", "localname": "ProccedsFromRetainedEarningsAdjustment", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Retained Earnings adjustment", "documentation": "Procceds from retained earnings adjustment." } } }, "auth_ref": [] }, "ONMD_ProceedsFromBusinessLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://onemednet.com/20231231", "localname": "ProceedsFromBusinessLoan", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Canada Emergency Business Loan Act", "documentation": "Proceeds from business loan." } } }, "auth_ref": [] }, "ONMD_ProceedsFromCommonStockSubjectToRedemption": { "xbrltype": "monetaryItemType", "nsuri": "http://onemednet.com/20231231", "localname": "ProceedsFromCommonStockSubjectToRedemption", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Common Stock Subject to Redemption", "documentation": "Proceeds from common stock subject to redemption." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromContributedCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromContributedCapital", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital", "documentation": "The cash inflow associated with the amount received by a corporation from a shareholder during the period." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative", "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of PIPE Convertible Notes and Warrants", "verboseLabel": "Proceeds from Convertible Debt", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r36" ] }, "ONMD_ProceedsFromDeferredUnderwritingFee": { "xbrltype": "monetaryItemType", "nsuri": "http://onemednet.com/20231231", "localname": "ProceedsFromDeferredUnderwritingFee", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Deferred underwriting fee", "documentation": "Proceeds from deferred under writing fee." } } }, "auth_ref": [] }, "ONMD_ProceedsFromIssuanceOfCommonStockOne": { "xbrltype": "monetaryItemType", "nsuri": "http://onemednet.com/20231231", "localname": "ProceedsFromIssuanceOfCommonStockOne", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Class B Common Stock", "documentation": "Proceeds from issuance of common stock one." } } }, "auth_ref": [] }, "ONMD_ProceedsFromIssuanceOfCommonStockTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://onemednet.com/20231231", "localname": "ProceedsFromIssuanceOfCommonStockTwo", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Class A Common Stock", "documentation": "Proceeds from issuance of common stock two." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "crdr": "debit", "presentation": [ "http://onemednet.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Preferred Stock and Preference Stock", "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": [ "http://onemednet.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Private Placement", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ProceedsFromIssuanceOfUnsecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfUnsecuredDebt", "crdr": "debit", "presentation": [ "http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Unsecured Debt", "documentation": "The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt." } } }, "auth_ref": [ "r36" ] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": [ "http://onemednet.com/role/StockWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [ "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r5", "r462" ] }, "us-gaap_ProceedsFromRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRelatedPartyDebt", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows", "http://onemednet.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceed from related party loan", "verboseLabel": "Proceeds from Related Party Debt", "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates." } } }, "auth_ref": [ "r36" ] }, "us-gaap_ProceedsFromRepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRepaymentsOfNotesPayable", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds (repayment) from issuance of convertible promissory note payable", "documentation": "Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation." } } }, "auth_ref": [] }, "ONMD_ProceedsFromWarrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://onemednet.com/20231231", "localname": "ProceedsFromWarrantLiability", "crdr": "credit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Warrant liability", "documentation": "Proceeds from warrant liability.", "label": "ProceedsFromWarrantLiability" } } }, "auth_ref": [] }, "us-gaap_ProductInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductInformationLineItems", "presentation": [ "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails", "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r9" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://onemednet.com/role/PropertyAndEquipment" ], "lang": { "en-us": { "role": { "label": "Property and Equipment", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r114", "r145", "r148", "r149" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Total Property and Equipment", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r116", "r157", "r449" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://onemednet.com/role/BalanceSheets", "http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property and Equipment, Net", "totalLabel": "Net Property and Equipment", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r9", "r438", "r449", "r585" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Property and Equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r9", "r145", "r148", "r447" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://onemednet.com/role/PropertyAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Property And Equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r9" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r116" ] }, "ONMD_PubliclyTradedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "PubliclyTradedWarrantsMember", "presentation": [ "http://onemednet.com/role/StockWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Publicly Traded Warrants [Member]", "documentation": "Publicly Traded Warrants [Member]" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://onemednet.com/role/StockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r238", "r239", "r240", "r241", "r298", "r306", "r335", "r336", "r337", "r421", "r422", "r453", "r483", "r484", "r547", "r548", "r549", "r550", "r551", "r560", "r561", "r569", "r575", "r582", "r586", "r589", "r639", "r643", "r682", "r683", "r684", "r685", "r686" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://onemednet.com/role/StockOptionsDetailsNarrative" ], "auth_ref": [ "r238", "r239", "r240", "r241", "r298", "r306", "r335", "r336", "r337", "r421", "r422", "r453", "r483", "r484", "r547", "r548", "r549", "r550", "r551", "r560", "r561", "r569", "r575", "r582", "r586", "r589", "r639", "r643", "r682", "r683", "r684", "r685", "r686" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://onemednet.com/role/BalanceSheets", "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative", "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative", "http://onemednet.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r305", "r410", "r411", "r486", "r487", "r488", "r489", "r490", "r512", "r514", "r546" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://onemednet.com/role/BalanceSheets", "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative", "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r181", "r182", "r410", "r411", "r412", "r413", "r486", "r487", "r488", "r489", "r490", "r512", "r514", "r546" ] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://onemednet.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r82", "r410" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r519", "r520", "r523" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://onemednet.com/role/BalanceSheets", "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative", "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative", "http://onemednet.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r305", "r410", "r411", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r486", "r487", "r488", "r489", "r490", "r512", "r514", "r546", "r678" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://onemednet.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r407", "r408", "r409", "r411", "r414", "r468", "r469", "r470", "r521", "r522", "r523", "r543", "r545" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r87", "r348", "r687" ] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r347" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets", "http://onemednet.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "negatedLabel": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r95", "r124", "r445", "r457", "r458", "r466", "r495", "r585" ] }, "ONMD_RetainedEarningsAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://onemednet.com/20231231", "localname": "RetainedEarningsAdjustment", "crdr": "credit", "presentation": [ "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Retained earnings adjustment", "documentation": "Retained earnings adjustment." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r152", "r184", "r185", "r186", "r188", "r194", "r196", "r233", "r234", "r343", "r344", "r345", "r362", "r363", "r377", "r379", "r380", "r382", "r384", "r454", "r456", "r471", "r695" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://onemednet.com/role/StatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r210", "r211", "r215", "r218", "r219", "r223", "r224", "r225", "r296", "r297", "r424" ] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerMember", "presentation": [ "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails", "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer Benchmark [Member]", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r225", "r621" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r517", "r562", "r565" ] }, "us-gaap_SalesAndExciseTaxPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesAndExciseTaxPayableCurrent", "crdr": "credit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Excise tax", "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r23" ] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioForecastMember", "presentation": [ "http://onemednet.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]" } } }, "auth_ref": [ "r307", "r635" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://onemednet.com/role/SubsequentEventsDetailsNarrative" ], "auth_ref": [ "r197", "r307", "r619", "r635" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r372" ] }, "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "presentation": [ "http://onemednet.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Common Stock Activities", "documentation": "Tabular disclosure of the change in common stock outstanding." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://onemednet.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Income Taxes", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r126" ] }, "us-gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfProductInformationTable", "presentation": [ "http://onemednet.com/role/ScheduleOfAggregatePercentageRevenueAndAccountsReceivableDetails", "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Product Information [Table]", "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://onemednet.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r81", "r82", "r519", "r520", "r523" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://onemednet.com/role/StockOptionsDetailsNarrative", "http://onemednet.com/role/StockWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r309", "r311", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://onemednet.com/role/StockOptionsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Options Outstanding", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r17", "r18", "r64" ] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShortTermDebtTable", "presentation": [ "http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative", "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Short-Term Debt [Table]", "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation." } } }, "auth_ref": [ "r24" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://onemednet.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r53", "r54", "r55", "r56", "r57", "r58", "r59", "r122", "r123", "r124", "r160", "r161", "r162", "r207", "r278", "r279", "r281", "r283", "r286", "r291", "r293", "r462", "r463", "r464", "r465", "r575", "r618", "r627" ] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": [ "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Aggregate Percentage Revenue and Accounts Receivable", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r41", "r42", "r44", "r45", "r76", "r130" ] }, "ONMD_SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "SecuritiesPurchaseAgreementMember", "presentation": [ "http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative", "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Securities Purchase Agreement [Member]", "documentation": "Securities Purchase Agreement [Member]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r599" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r603" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r602" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r607" ] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Sales & Marketing", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "presentation": [ "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "General, and Administrative Expenses", "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption." } } }, "auth_ref": [ "r11" ] }, "ONMD_SeniorConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "SeniorConvertibleNotesMember", "presentation": [ "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Senior Convertible Notes [Member]", "documentation": "Senior Convertible Notes [Member]" } } }, "auth_ref": [] }, "us-gaap_SeniorNotesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotesCurrent", "crdr": "credit", "presentation": [ "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Senior Notes, Current", "documentation": "Carrying value as of the balance sheet date of the portion of long-term notes having the highest claim on the assets of the issuer in case of bankruptcy or liquidation, due within one year or the normal operating cycle, if longer. Senior note holders are paid off in full before any payments are made to debt holders having a lesser priority of repayment." } } }, "auth_ref": [ "r27", "r585" ] }, "ONMD_SeriesAOnePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "SeriesAOnePreferredStockMember", "presentation": [ "http://onemednet.com/role/BalanceSheets", "http://onemednet.com/role/BalanceSheetsParenthetical", "http://onemednet.com/role/ShareholdersEquityDetailsNarrative", "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Series A-1 Preferred Stock [Member]", "documentation": "Series A One Preferred Stock [Member]" } } }, "auth_ref": [] }, "ONMD_SeriesATwoPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "SeriesATwoPreferredStockMember", "presentation": [ "http://onemednet.com/role/BalanceSheets", "http://onemednet.com/role/BalanceSheetsParenthetical", "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative", "http://onemednet.com/role/ShareholdersEquityDetailsNarrative", "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Series A-2 Preferred Stock [Member]", "documentation": "Series A Two Preferred Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://onemednet.com/role/StockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r583" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription", "presentation": [ "http://onemednet.com/role/StockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description", "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance." } } }, "auth_ref": [ "r60", "r62" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://onemednet.com/role/StockOptionsDetailsNarrative", "http://onemednet.com/role/StockWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r309", "r311", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://onemednet.com/role/ScheduleOfOptionsOutstandingDetails", "http://onemednet.com/role/StockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "periodEndLabel": "Options exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r318" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://onemednet.com/role/ScheduleOfOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted average exercise price, exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r318" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://onemednet.com/role/ScheduleOfOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Options, cancelled", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r651" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://onemednet.com/role/ScheduleOfOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Options, Granted - under the Plan", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r320" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://onemednet.com/role/ScheduleOfOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Aggregate Intrinsic value, begining balance", "periodEndLabel": "Aggregate Intrinsic value, ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r61" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://onemednet.com/role/ScheduleOfOptionsOutstandingDetails", "http://onemednet.com/role/StockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "periodStartLabel": "Options outstanding, ending balance", "periodEndLabel": "Options outstanding, ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r316", "r317" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://onemednet.com/role/ScheduleOfOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise price, begining balance", "periodEndLabel": "Weighted average exercise price, ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r316", "r317" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://onemednet.com/role/StockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r332" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://onemednet.com/role/StockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r332" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://onemednet.com/role/StockOptionsDetailsNarrative", "http://onemednet.com/role/StockWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://onemednet.com/role/ShareholdersEquityDetailsNarrative", "http://onemednet.com/role/StatementsOfStockholdersEquityDeficitParenthetical", "http://onemednet.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://onemednet.com/role/ScheduleOfOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Aggregate Intrinsic value, exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r61" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://onemednet.com/role/StockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r61" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://onemednet.com/role/StockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r125" ] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://onemednet.com/role/ShareholdersEquityDetailsNarrative", "http://onemednet.com/role/StockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails", "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance, shares", "periodEndLabel": "Ending balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtLineItems", "presentation": [ "http://onemednet.com/role/CanadianEmergencyBusinessLoanActCebaDetailsNarrative", "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://onemednet.com/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r110", "r176" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r608" ] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://onemednet.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "State and Local Jurisdiction [Member]", "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://onemednet.com/role/BalanceSheets", "http://onemednet.com/role/BalanceSheetsParenthetical", "http://onemednet.com/role/ConvertiblePromissoryNotesHeldByRelatedPartyDetailsNarrative", "http://onemednet.com/role/ShareholdersEquityDetailsNarrative", "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r151", "r160", "r161", "r162", "r179", "r199", "r200", "r202", "r204", "r207", "r208", "r232", "r242", "r244", "r245", "r246", "r249", "r250", "r278", "r279", "r283", "r286", "r293", "r395", "r462", "r463", "r464", "r465", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r494", "r516", "r539", "r552", "r553", "r554", "r555", "r556", "r618", "r627", "r636" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative", "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails", "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit", "http://onemednet.com/role/StockWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r14", "r34", "r152", "r169", "r170", "r171", "r184", "r185", "r186", "r188", "r194", "r196", "r206", "r233", "r234", "r295", "r343", "r344", "r345", "r362", "r363", "r377", "r378", "r379", "r380", "r381", "r382", "r384", "r396", "r397", "r398", "r399", "r400", "r401", "r406", "r454", "r455", "r456", "r471", "r539" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://onemednet.com/role/BalanceSheets", "http://onemednet.com/role/BalanceSheetsParenthetical", "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r184", "r185", "r186", "r206", "r424", "r460", "r482", "r485", "r486", "r487", "r488", "r489", "r490", "r494", "r497", "r498", "r499", "r500", "r501", "r503", "r504", "r505", "r506", "r508", "r509", "r510", "r511", "r512", "r514", "r517", "r518", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r539", "r590" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://onemednet.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r197", "r307", "r619", "r620", "r635" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://onemednet.com/role/BalanceSheets", "http://onemednet.com/role/BalanceSheetsParenthetical", "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r184", "r185", "r186", "r206", "r424", "r460", "r482", "r485", "r486", "r487", "r488", "r489", "r490", "r494", "r497", "r498", "r499", "r500", "r501", "r503", "r504", "r505", "r506", "r508", "r509", "r510", "r511", "r512", "r514", "r517", "r518", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r539", "r590" ] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative", "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of common class B stock, shares", "verboseLabel": "Stock Issued During Period, Shares, Acquisitions", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": [ "r92", "r93", "r124" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails", "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Preferred stock to common stock, shares", "verboseLabel": "Preferred Stock to Common Stock", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r14", "r33", "r56", "r124", "r268" ] }, "ONMD_StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://onemednet.com/20231231", "localname": "StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock", "presentation": [ "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails", "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Convertible notes to common stock, shares", "verboseLabel": "Convertible Notes to Common Stock", "documentation": "Stock issued during period shares convertible notes to common stock." } } }, "auth_ref": [] }, "ONMD_StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://onemednet.com/20231231", "localname": "StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares", "presentation": [ "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails", "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Converting Data Knights Common Shares (A and B) to ONMD Public Shares, shares", "verboseLabel": "Converting Data Knights Common Stock (A and B) to ONMD Public Shares", "documentation": "Stock Issued During Period shares converting data knights common shares." } } }, "auth_ref": [] }, "ONMD_StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://onemednet.com/20231231", "localname": "StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock", "presentation": [ "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails", "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Converting of warrants to common stock, shares", "verboseLabel": "Converting of Warrants to Common Stock", "documentation": "Stock issued during period shares converting of warrants to common stock." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://onemednet.com/role/ShareholdersEquityDetailsNarrative", "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of common shares in exchange for services, share", "verboseLabel": "Stock Issued During Period, Shares, Issued for Services", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails", "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit", "http://onemednet.com/role/StockOptionsDetailsNarrative", "http://onemednet.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance public shares, share", "verboseLabel": "Issuance Public Shares", "terseLabel": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r14", "r92", "r93", "r124", "r462", "r539", "r553" ] }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": [ "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails", "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock issued during period shares other", "verboseLabel": "Private OneMedNet to ONMD Public Shares", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://onemednet.com/role/ScheduleOfOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Options, Granted - under the Plan", "negatedLabel": "Options, Granted - under the Plan", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r14", "r92", "r93", "r124", "r321" ] }, "ONMD_StockIssuedDuringPeriodSharesStockOptionsToCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://onemednet.com/20231231", "localname": "StockIssuedDuringPeriodSharesStockOptionsToCommonStock", "presentation": [ "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails", "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock issued during period shares options to common stock", "verboseLabel": "Stock Options to Common Stock", "documentation": "Stock issued during period shares stock options to common stock." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": [ "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of Data Knights Acquisition Corp. Class B Common Stock", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": [ "r14", "r34", "r124" ] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Preferred Stock to Common Stock", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r14", "r34", "r124" ] }, "ONMD_StockIssuedDuringPeriodValueConvertibleNotesToCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://onemednet.com/20231231", "localname": "StockIssuedDuringPeriodValueConvertibleNotesToCommonStock", "crdr": "credit", "presentation": [ "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Convertible Notes to Common Stock", "documentation": "Stock issued during period value convertible notes to common stock." } } }, "auth_ref": [] }, "ONMD_StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares": { "xbrltype": "monetaryItemType", "nsuri": "http://onemednet.com/20231231", "localname": "StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares", "crdr": "credit", "presentation": [ "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Converting Data Knights Common Shares (A and B) to ONMD Public Shares", "documentation": "Stock issued during period value converting data knights common shares." } } }, "auth_ref": [] }, "ONMD_StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://onemednet.com/20231231", "localname": "StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock", "crdr": "credit", "presentation": [ "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Converting of Warrants to Common Stock", "documentation": "Stock issued during period value converting of warrants to common stock." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of common shares in exchange for services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance Public Shares", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r14", "r92", "r93", "r124", "r471", "r539", "r553", "r596" ] }, "us-gaap_StockIssuedDuringPeriodValueOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueOther", "crdr": "credit", "presentation": [ "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Private OneMedNet to ONMD Public Shares", "documentation": "Value of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "ONMD_StockIssuedDuringPeriodValueStockOptionsToCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://onemednet.com/20231231", "localname": "StockIssuedDuringPeriodValueStockOptionsToCommonStock", "crdr": "credit", "presentation": [ "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Options to Common Stock", "documentation": "Stock issued during period value stock options to common stock." } } }, "auth_ref": [] }, "us-gaap_StockOptionPlanExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockOptionPlanExpense", "crdr": "debit", "calculation": { "http://onemednet.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Stock Expense", "documentation": "Amount of noncash expense for option under share-based payment arrangement." } } }, "auth_ref": [ "r8" ] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://onemednet.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r14", "r92", "r93", "r124", "r465", "r539", "r555" ] }, "ONMD_StockWarrantsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://onemednet.com/20231231", "localname": "StockWarrantsDisclosureTextBlock", "presentation": [ "http://onemednet.com/role/StockWarrants" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock Warrants", "documentation": "Stock warrants disclosure text block.", "label": "StockWarrantsDisclosureTextBlock" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets", "http://onemednet.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity (deficit)", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r93", "r96", "r97", "r113", "r496", "r513", "r540", "r541", "r585", "r597", "r629", "r638", "r676", "r695" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity (Deficit)" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://onemednet.com/role/ShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r121", "r178", "r277", "r279", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r292", "r295", "r383", "r542", "r544", "r557" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://onemednet.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r402", "r416" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://onemednet.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r402", "r416" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://onemednet.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r402", "r416" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://onemednet.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r402", "r416" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://onemednet.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r402", "r416" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://onemednet.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r415", "r417" ] }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": [ "http://onemednet.com/role/GoingConcern" ], "lang": { "en-us": { "role": { "label": "Going Concern", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": [ "r89" ] }, "ONMD_ThreeCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "ThreeCustomersMember", "presentation": [ "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Three Customers [Member]", "documentation": "Three Customers [Member]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative", "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails", "http://onemednet.com/role/ShareholdersEquityDetailsNarrative", "http://onemednet.com/role/StockOptionsDetailsNarrative", "http://onemednet.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r637", "r677" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative", "http://onemednet.com/role/ScheduleOfCommonStockActivitiesDetails", "http://onemednet.com/role/ShareholdersEquityDetailsNarrative", "http://onemednet.com/role/StockOptionsDetailsNarrative", "http://onemednet.com/role/SubsequentEventsDetailsNarrative" ], "auth_ref": [] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r138", "r139", "r140", "r228", "r229", "r231" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ONMD_TwentyTwentyOneServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "TwentyTwentyOneServiceMember", "presentation": [ "http://onemednet.com/role/StockWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2021 Service [Member]", "documentation": "Twenty Twenty One Service [Member]" } } }, "auth_ref": [] }, "ONMD_TwentyTwentyTwoServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "TwentyTwentyTwoServiceMember", "presentation": [ "http://onemednet.com/role/StockWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2022 Service [Member]", "documentation": "Twenty Twenty Two Service [Member]" } } }, "auth_ref": [] }, "ONMD_TwoCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "TwoCustomersMember", "presentation": [ "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Two Customers [Member]", "documentation": "Two Customers [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://onemednet.com/role/OrganizationAndOperationsDetailsNarrative", "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r372" ] }, "ONMD_UnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://onemednet.com/20231231", "localname": "UnrealizedGainLoss", "crdr": "credit", "calculation": { "http://onemednet.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://onemednet.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized gain or loss", "documentation": "Unrealized gain loss.", "label": "UnrealizedGainLoss" } } }, "auth_ref": [] }, "us-gaap_UnsecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnsecuredDebt", "crdr": "credit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Canada Emergency Business Loan Act", "label": "Unsecured Debt", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer)." } } }, "auth_ref": [ "r20", "r134", "r688" ] }, "us-gaap_UnsecuredDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnsecuredDebtCurrent", "crdr": "credit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Canada Emergency Business Loan Act", "documentation": "Carrying value as of the balance sheet date of the portion of long-term, uncollateralized debt obligations due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r90", "r132" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://onemednet.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r46", "r47", "r48", "r143", "r144", "r146", "r147" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://onemednet.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r356" ] }, "ONMD_WarrantLiabilityNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://onemednet.com/20231231", "localname": "WarrantLiabilityNonCurrent", "crdr": "credit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Warrant liabilities", "documentation": "Warrant liability non current." } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://onemednet.com/role/RelatedPartyTransactionsDetailsNarrative", "http://onemednet.com/role/StockWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r587", "r588", "r591", "r592", "r593", "r594" ] }, "ONMD_WarrantOneMember": { "xbrltype": "domainItemType", "nsuri": "http://onemednet.com/20231231", "localname": "WarrantOneMember", "presentation": [ "http://onemednet.com/role/StockWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant One [Member]", "documentation": "Warrant One [Member]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://onemednet.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r198", "r204" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "presentation": [ "http://onemednet.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted-average shares of Common Stock outstanding:" } } }, "auth_ref": [] }, "ONMD_WorkingCapitalLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://onemednet.com/20231231", "localname": "WorkingCapitalLoan", "crdr": "credit", "calculation": { "http://onemednet.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://onemednet.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Working capital Loan", "documentation": "Working capital loan." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://onemednet.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r616" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(b),(f(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "720", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483384/720-30-45-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)-(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-40/tableOfContent" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//250/tableOfContent" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-15" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(h))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r563": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r565": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r566": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r567": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r568": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r569": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r570": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r571": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r572": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r573": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r574": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r575": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r576": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r577": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r580": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r581": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r582": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r583": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r585": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r586": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r587": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r589": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r594": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r595": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r596": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r597": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r598": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r599": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r600": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r601": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r602": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r604": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r605": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r606": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r607": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r608": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r609": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r610": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r611": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r612": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r613": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r615": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r616": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r617": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r618": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r619": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r620": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 90 0001493152-24-014918-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-014918-xbrl.zip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Ź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�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�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end XML 93 forms-1a_htm.xml IDEA: XBRL DOCUMENT 0001849380 2023-01-01 2023-12-31 0001849380 dei:BusinessContactMember 2023-01-01 2023-12-31 0001849380 2023-12-31 0001849380 2022-12-31 0001849380 us-gaap:RelatedPartyMember 2023-12-31 0001849380 us-gaap:RelatedPartyMember 2022-12-31 0001849380 ONMD:SeriesATwoPreferredStockMember 2023-12-31 0001849380 ONMD:SeriesATwoPreferredStockMember 2022-12-31 0001849380 ONMD:SeriesAOnePreferredStockMember 2023-12-31 0001849380 ONMD:SeriesAOnePreferredStockMember 2022-12-31 0001849380 us-gaap:CommonClassAMember 2023-12-31 0001849380 us-gaap:CommonClassAMember 2022-12-31 0001849380 ONMD:CommonClassAOneMember 2023-12-31 0001849380 ONMD:CommonClassAOneMember 2022-12-31 0001849380 2022-01-01 2022-12-31 0001849380 ONMD:SeriesATwoPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001849380 ONMD:SeriesAOnePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001849380 ONMD:DataKnightsAcquisitionCorpMember us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-12-31 0001849380 ONMD:DataKnightsAcquisitionCorpMember us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-12-31 0001849380 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-12-31 0001849380 ONMD:CommitmentMember 2021-12-31 0001849380 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001849380 us-gaap:RetainedEarningsMember 2021-12-31 0001849380 2021-12-31 0001849380 ONMD:SeriesATwoPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001849380 ONMD:SeriesAOnePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001849380 ONMD:DataKnightsAcquisitionCorpMember us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-12-31 0001849380 ONMD:DataKnightsAcquisitionCorpMember us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-12-31 0001849380 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-12-31 0001849380 ONMD:CommitmentMember 2022-12-31 0001849380 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001849380 us-gaap:RetainedEarningsMember 2022-12-31 0001849380 ONMD:SeriesATwoPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001849380 ONMD:SeriesAOnePreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001849380 ONMD:DataKnightsAcquisitionCorpMember us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001849380 ONMD:DataKnightsAcquisitionCorpMember us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001849380 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001849380 ONMD:CommitmentMember 2022-01-01 2022-12-31 0001849380 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001849380 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001849380 ONMD:SeriesATwoPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001849380 ONMD:SeriesAOnePreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001849380 ONMD:DataKnightsAcquisitionCorpMember us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001849380 ONMD:DataKnightsAcquisitionCorpMember us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001849380 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001849380 ONMD:CommitmentMember 2023-01-01 2023-12-31 0001849380 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001849380 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001849380 ONMD:SeriesATwoPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001849380 ONMD:SeriesAOnePreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001849380 ONMD:DataKnightsAcquisitionCorpMember us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-12-31 0001849380 ONMD:DataKnightsAcquisitionCorpMember us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-12-31 0001849380 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-12-31 0001849380 ONMD:CommitmentMember 2023-12-31 0001849380 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001849380 us-gaap:RetainedEarningsMember 2023-12-31 0001849380 ONMD:DataKnightsAcquisitionCorpMember ONMD:SecuritiesPurchaseAgreementMember 2023-06-28 2023-06-28 0001849380 ONMD:DataKnightsAcquisitionCorpMember ONMD:SecuritiesPurchaseAgreementMember 2023-06-28 0001849380 ONMD:OneCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001849380 ONMD:TwoCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001849380 ONMD:ThreeCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001849380 ONMD:TwoCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001849380 ONMD:CustomerOneMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001849380 ONMD:CustomerOneMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001849380 ONMD:CustomerTwoMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001849380 ONMD:CustomerTwoMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001849380 ONMD:CustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001849380 ONMD:CustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001849380 ONMD:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001849380 ONMD:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001849380 ONMD:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001849380 ONMD:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001849380 ONMD:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001849380 ONMD:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001849380 ONMD:CustomerFourMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001849380 ONMD:CustomerFourMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001849380 ONMD:CustomerFiveMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001849380 ONMD:CustomerFiveMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001849380 ONMD:CustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001849380 ONMD:CustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001849380 us-gaap:ComputerEquipmentMember 2023-12-31 0001849380 us-gaap:ComputerEquipmentMember 2022-12-31 0001849380 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001849380 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001849380 us-gaap:DomesticCountryMember 2023-12-31 0001849380 us-gaap:StateAndLocalJurisdictionMember 2023-12-31 0001849380 ONMD:DataKnightsAcquisitionCorpMember 2023-12-31 0001849380 ONMD:DataKnightsAcquisitionCorpMember 2023-01-01 2023-12-31 0001849380 us-gaap:NonrelatedPartyMember 2023-12-31 0001849380 us-gaap:NonrelatedPartyMember 2022-12-31 0001849380 ONMD:ConvertiblePromissoryNotesMember us-gaap:RelatedPartyMember 2022-11-11 0001849380 ONMD:ConvertiblePromissoryNotesMember us-gaap:RelatedPartyMember 2022-11-10 2022-11-11 0001849380 ONMD:ConvertiblePromissoryNotesMember us-gaap:RelatedPartyMember ONMD:SeriesATwoPreferredStockMember 2022-11-11 0001849380 ONMD:ConvertiblePromissoryNotesMember us-gaap:RelatedPartyMember 2019-11-30 0001849380 ONMD:ConvertiblePromissoryNotesMember 2022-12-31 0001849380 ONMD:DataKnightsAcquisitionCorpMember us-gaap:RelatedPartyMember 2023-11-30 0001849380 ONMD:CEBALoanMember 2020-12-01 2020-12-31 0001849380 ONMD:CEBALoanMember 2020-01-01 2020-12-31 0001849380 ONMD:CEBALoanMember 2020-12-31 0001849380 ONMD:SeriesATwoPreferredStockMember 2023-01-01 2023-12-31 0001849380 ONMD:SeriesAOnePreferredStockMember 2023-01-01 2023-12-31 0001849380 ONMD:BoardOfDirectorsMember 2023-01-01 2023-12-31 0001849380 ONMD:BoardOfDirectorsMember 2022-01-01 2022-12-31 0001849380 ONMD:BoardOfDirectorsMember 2023-12-31 0001849380 srt:BoardOfDirectorsChairmanMember us-gaap:CommonStockMember 2022-12-31 0001849380 srt:BoardOfDirectorsChairmanMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001849380 srt:BoardOfDirectorsChairmanMember us-gaap:CommonStockMember 2023-12-31 0001849380 ONMD:EmployeesDirectorsAndConsultantsMember ONMD:NewEquityIncentivePlanMember 2020-01-01 2020-12-31 0001849380 srt:MaximumMember ONMD:EmployeesDirectorsAndConsultantsMember ONMD:NewEquityIncentivePlanMember 2020-01-01 2020-12-31 0001849380 ONMD:EmployeesDirectorsAndConsultantsMember ONMD:NewEquityIncentivePlanMember 2020-12-31 0001849380 2021-01-01 2021-12-31 0001849380 2023-11-07 0001849380 2023-10-17 2023-10-17 0001849380 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001849380 2020-12-31 0001849380 us-gaap:MeasurementInputExpectedTermMember 2022-01-01 2022-12-31 0001849380 us-gaap:MeasurementInputExpectedTermMember 2021-01-01 2021-12-31 0001849380 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001849380 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001849380 us-gaap:MeasurementInputExpectedDividendRateMember 2022-12-31 0001849380 us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001849380 us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001849380 us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001849380 ONMD:TwentyTwentyOneServiceMember 2022-12-31 0001849380 ONMD:TwentyTwentyTwoServiceMember 2022-12-31 0001849380 ONMD:ConvertiableNotesMember 2022-12-31 0001849380 ONMD:ConvertiableNotesMember 2023-12-31 0001849380 ONMD:WarrantOneMember 2023-12-31 0001849380 us-gaap:CommonStockMember 2023-12-31 0001849380 ONMD:PubliclyTradedWarrantsMember 2022-12-31 0001849380 ONMD:PubliclyTradedWarrantsMember 2023-12-31 0001849380 ONMD:PrivateWarrantsMember 2023-12-31 0001849380 ONMD:PrivateWarrantsMember 2022-12-31 0001849380 us-gaap:WarrantMember 2023-12-31 0001849380 us-gaap:WarrantMember 2022-12-31 0001849380 ONMD:InvestmentsHeldInTrustMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001849380 ONMD:InvestmentsHeldInTrustMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001849380 ONMD:InvestmentsHeldInTrustMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001849380 ONMD:InvestmentsHeldInTrustMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001849380 ONMD:InvestmentsHeldInTrustMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001849380 ONMD:InvestmentsHeldInTrustMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001849380 ONMD:InvestmentsHeldInTrustMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001849380 ONMD:InvestmentsHeldInTrustMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001849380 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001849380 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001849380 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001849380 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001849380 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001849380 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001849380 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001849380 ONMD:DataKnightsAcquisitionCorpMember us-gaap:RelatedPartyMember 2023-12-31 0001849380 ONMD:ManagementAndDirectorsMember us-gaap:RelatedPartyMember 2023-12-31 0001849380 ONMD:SecuritiesPurchaseAgreementMember 2023-11-01 2023-11-30 0001849380 ONMD:SeniorConvertibleNotesMember ONMD:SecuritiesPurchaseAgreementMember 2023-11-01 2023-11-30 0001849380 us-gaap:RelatedPartyMember ONMD:SecuritiesPurchaseAgreementMember 2023-11-30 0001849380 us-gaap:WarrantMember ONMD:SecuritiesPurchaseAgreementMember 2023-11-01 2023-11-30 0001849380 ONMD:SecuritiesPurchaseAgreementMember 2023-11-30 0001849380 srt:ScenarioForecastMember ONMD:EFHuttonMember 2024-01-01 2024-12-31 0001849380 srt:ScenarioForecastMember ONMD:KingwoodCapitalPartnersLLCMember 2024-01-01 2024-12-31 0001849380 srt:ScenarioForecastMember 2024-01-01 2024-12-31 0001849380 us-gaap:MajorityShareholderMember us-gaap:SubsequentEventMember 2024-01-01 2024-12-31 0001849380 us-gaap:SubsequentEventMember 2024-01-01 2024-12-31 0001849380 srt:ScenarioForecastMember srt:BoardOfDirectorsChairmanMember 2024-03-26 2024-03-27 0001849380 srt:ScenarioForecastMember srt:BoardOfDirectorsChairmanMember 2024-03-27 iso4217:USD shares iso4217:USD shares pure ONMD:Integer true 0001849380 S-1/A Amendment No. 1 ONEMEDNET CORPORATION DE 86-2049355 6385 Old Shady Oak Road Suite 250 Eden Prairie MN 55344 800 918-7189 Debbie A. Klis, Esq. 1990 K. Street NW, Suite 420 Washington DC 20006 (202) 935-3390 Non-accelerated Filer true true false 47008 301730 29029415 151640 18975 165538 100945 900152 364186 30351217 98871 83097 463057 30434314 4184398 2814570 11200 11500 113353 2991679 253997 183683 38921 8490000 44673 120017 214850 69966 1549820 3525000 12833058 11784569 1500000 44144 690772 465023 24582 362558 4025000 207081 2545839 13322663 21159963 0.0001 4200000 0 3853797 385 0.0001 4400000 0 3204000 320 320 0.0001 30000000 23572232 4550166 2357 455 0.0001 4200000 0 3853797 59 0.0001 4200000 0 3853797 425 425 28750110 42220714 24032561 -55082677 -43509964 -12859606 9274351 463057 30434314 1021651 1152738 1149551 1513428 -127900 -360690 5273503 8755620 226257 398760 1114977 957690 1631613 952701 8246350 11064771 -8374250 -11425461 10504327 214850 749213 403307 52256 46820 -46822 -4489110 3572232 1371689 -14831206 5195822 -23205456 -6229639 -0.98 23572232 3853797 385 3204000 320 585275 59 2875000 288 4342666 434 28750110 19607173 -33920734 14438035 200000 20 199980 200000 1.00 7500 1 7499 7500 1378517 137 2825823 2825960 -3359591 -3359591 1392086 1392086 -6229639 -6229639 3853797 385 3204000 320 585275 59 4253517 425 4550166 455 28750110 24032561 -43509964 9274351 3853797 385 3204000 320 585275 59 4253517 425 4550166 455 28750110 24032561 -43509964 9274351 1892741 1892741 -3853797 -385 -3204000 -320 7057797 706 7057091 7057092 6177229 618 6176611 6177229 612670 61 612609 612670 3859464 386 3859078 3859464 -2257326 -226 -2257100 -2257326 101071 101071 -585275 -59 -4253517 -425 3460275 346 634106 633968 -28750110 -28750110 111957 11 111946 111957 11632743 11632743 -23205456 -23205456 -23205456 -23205456 0 0 0 0 0 0 0 0 23572232 2357 0 42220714 -55082677 -12859606 0 0 0 0 0 0 0 0 23572232 2357 0 42220714 -55082677 -12859606 -23205456 -6229639 27983 24807 900152 1599586 29029416 88291558 64594 875803 1369825 1929787 132665 -72767 70314 -458667 -300 11500 113353 445840 2545838 -69966 -94043 -94833 214850 -168159 207081 8220910 87239622 43757 58137 137 -10680772 5543162 1549820 465024 529 -2754 -28750109 -88549890 -500000 337976 4489110 18189350 2825823 -59 -425 11632743 -3359594 -8431875 -88032226 -254722 -850741 301730 1152471 47008 301730 <p id="xdx_809_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zV9YseO4iab1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_82A_zfz7jzRiBva7">Organization and Operations</span></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet Corporation (the “Company”) is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. The Company was incorporated in Delaware on September 20, 2006. The Company has been solely focused on creating solutions that simplify digital medical image management, exchange, and sharing. The Company has one wholly-owned subsidiary, OneMedNet Technologies (Canada) Inc., incorporated on October 16, 2015 under the provisions of the Business Corporations Act of British Columbia whose functional currency is the Canadian dollar. The Company’s headquarters location is Eden Prairie, Minnesota.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 7, 2023, as contemplated by the Company, Data Knights Merger Sub, Inc., a Delaware corporation (“Merger Sub”), and Data Knights, LLC, the Merger Sub’s sponsor merged with and into OneMedNet Corporation, with OneMedNet Corporation surviving the merger. The Business Combination is further described in Note 3, <span style="background-color: white"><i>Business Combination.</i></span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Data Knights Acquisition Corp Merger</i></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On November 7, 2023, we consummated a merger (the “Merger”) </span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">following the approval at the special meeting of the shareholders of Data Knights Acquisition Corp., a Delaware corporation held on October 17, 2023 (the “Special Meeting”), Data Knights Merger Sub, Inc., a Delaware corporation (“Merger Sub”) and a wholly-owned subsidiary of Data Knights Acquisition Corp., a Delaware corporation (“Data Knights”), consummated a merger (the “Merger”) with and into OneMedNet Solutions Corporation (formerly named OneMedNet Corporation), a Delaware corporation (“OneMedNet”) pursuant to an agreement and plan of merger, dated as of April 25, 2022 (the “Merger Agreement”), by and among Data Knights, Merger Sub, OneMedNet, Data Knights, LLC, a Delaware limited liability company (“Sponsor” or “Purchaser Representative”) in its capacity as the representative of the stockholders of Data Knights, and Paul Casey in his capacity as the representative of the stockholders of OneMedNet (“Seller Representative”). Accordingly, the Merger Agreement was adopted, and the Merger and other transactions contemplated thereby (collectively, the “Business Combination”) were approved and completed.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Business Combination was accounted for as a </span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as a reverse recapitalization with OneMedNet as the accounting acquirer <span style="background-color: white">under the accounting principles generally accepted in the United States of America (“U.S. GAAP”). Accordingly, the financial statements of the combined company represent a continuation of the financial statements of OneMedNet.</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On June 28, 2023, the Company and Data Knights entered into a Securities Purchase Agreement (the “SPA”) with certain investors (collectively referred to herein as the “Purchasers”) for PIPE financing in the aggregate original principal amount of $<span id="xdx_902_eus-gaap--DebtInstrumentIssuedPrincipal_pp2d_c20230628__20230628__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zd35VsLoAFv9">1,595,744.70 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">and the purchase price of $<span id="xdx_904_eus-gaap--PaymentsToAcquireBusinessesGross_pn5n6_c20230628__20230628__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zLfq0MnZLOhi">1.5 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">million. <span id="xdx_90A_eus-gaap--DebtInstrumentDescription_c20230628__20230628__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zcrEXy9YpNK3">Pursuant to the Securities Purchase Agreement, Data Knights will issue and sell to each of the Purchasers, a new series of senior secured convertible notes (the “PIPE Notes”), which are convertible into shares of Common Stock at the Purchasers election at a conversion price equal to the lower of (i) $10.00 per share, and (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) Trading Days immediately preceding the Conversion Date.</span></span></span> <span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Purchasers’ $<span id="xdx_904_eus-gaap--Investments_iI_pn5n6_c20230628__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_z2iQWtEALUT4">1.5 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">million investment in the PIPE Notes closed and funded contemporaneous to the Closing of the Business Combination.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Effective immediately prior to the Closing, OneMedNet, Inc. issued the PIPE Notes to the Purchasers under the private offering exemptions under Securities Act of 1933, as amended (the “Securities Act”).</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks and Uncertainties</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to risks common to companies in the markets it serves, including, but not limited to, global economic and financial market conditions, fluctuations in customer demand, acceptance of new products, development by its competitors of new technological innovations, dependence on key personnel, and protection of proprietary technology.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As previously reported on Form 8-K on February 9, 2024, the Company received written notice (the “Nasdaq Notice”), dated February 7, 2024, from the Nasdaq Stock Market (“Nasdaq”) indicating that for the preceding 30 consecutive business days, the market value of the Company’s listed securities (“MVLS”) did not maintain a minimum market value of $50,000,000 (the “Minimum MVLS Requirement”) as required by Nasdaq Listing Rule 5450(b)(2)(A). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has a compliance period of 180 calendar days, or until August 5, 2024, to regain compliance with the Minimum MVLS Requirement. Compliance may be achieved if the Company’s MVLS closes at $50,000,000 or more for a minimum of ten consecutive business days at any time during the 180-day compliance period, in which case Nasdaq will notify the Company of its compliance and the matter will be closed.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt; background-color: white"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Company does not regain compliance with the Minimum MVLS Requirement by August 5, 2024, Nasdaq will provide written notification to the Company that its common stock is subject to delisting. At that time, the Company may appeal the relevant delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. However, there can be no assurance, if the Company does appeal the delisting determination by Nasdaq to the hearings panel, that such appeal would be successful. In such event, the Company may also seek to apply for a transfer to The Nasdaq Global Market if it meets the requirements for continued listing thereon. The Nasdaq Notice received have no immediate effect on the Company’s continued listing on the Nasdaq Global Market or the trading of Company’s common stock, subject to the Company’s compliance with the other continued listing requirements. The Company is presently evaluating potential actions to regain compliance with all applicable requirements for continued listing on the Nasdaq Global Market. There can be no assurance that the Company will be successful in maintaining the listing of its common stock on the Nasdaq Global Market.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></span></p> 1595744.70 1500000 Pursuant to the Securities Purchase Agreement, Data Knights will issue and sell to each of the Purchasers, a new series of senior secured convertible notes (the “PIPE Notes”), which are convertible into shares of Common Stock at the Purchasers election at a conversion price equal to the lower of (i) $10.00 per share, and (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) Trading Days immediately preceding the Conversion Date. 1500000 <p id="xdx_802_eus-gaap--SignificantAccountingPoliciesTextBlock_zGbBSfC6KOC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. <span id="xdx_820_zKg7KUIVwbK9">Summary of Significant Accounting Policies</span></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></span></p> <p id="xdx_842_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zvzejhltBzmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_86A_zHiorFzUGPkd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis of Presentation and Foreign Currency Translation</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt; background-color: white"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements have been prepared in U.S. dollars, in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. The consolidated financial statements include 100% of the accounts of wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></span></p> <p id="xdx_840_eus-gaap--BusinessCombinationsPolicy_zndaSaMzFgIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_868_z9lk6RJzb8ma" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business Combination</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We account for business acquisitions under ASC Topic 805, Business Combinations (“ASC Topic 805”). The total purchase consideration for an acquisition is measured as the fair value of the assets given, equity instruments issued, and liabilities assumed at the acquisition date. Costs that are directly attributable to the acquisition are expensed as incurred. Identifiable assets (including intangible assets) and liabilities assumed (including contingent liabilities) are measured initially at their fair values at the acquisition date. We recognize goodwill if the fair value of the total purchase consideration is in excess of the net fair value of the identifiable assets acquired and the liabilities assumed. We recognize a bargain purchase gain within Other income (expense), net, in the consolidated statement of operations if the net fair value of the identifiable assets acquired and the liabilities assumed is in excess of the fair value of the total purchase consideration. We include the results of operations of the acquired business in the consolidated financial statements beginning on the acquisition date.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_843_eus-gaap--UseOfEstimates_zjt1UdiaaVH7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_869_zIt7XWTLer6d" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the amounts disclosed in the related notes to the consolidated financial statements. Actual results and outcomes may differ materially from management’s estimates, judgments, and assumptions. Significant estimates, judgments, and assumptions used in these financial statements include, but are not limited to, those related to revenue, useful lives and realizability of long-lived assets, accounting for income taxes and related valuation allowances, and unit and stock-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts, and experience.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_843_ecustom--OperatingSegmentsPolicyTextBlock_zACDXJyzWbLk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_862_zQstZ0yF89o" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating Segments</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company operates as one operating segment. Operating segments are defined as components of an enterprise for which separate financial information is regularly evaluated by the chief operating decision maker (“CODM”), which is the Company’s Chief Executive Officer, in deciding how to allocate resources and assess performance. The Company’s CODM evaluates the Company’s financial information and resources and assesses the performance of these resources on a consolidated basis. The Company is not organized by market and is managed and operated as one business. A single management team that reports to the chief executive officer comprehensively manages the entire business. Accordingly, the Company does not accumulate discrete financial information with respect to separate divisions and does not have separate operating or reportable segments. Since the Company operates in one operating segment, all required financial segment information can be found in the consolidated financial statements.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_84C_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zMlRvLLBGcYl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_867_zKdmKLGHFwQ8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash and Cash Equivalents</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents consist of highly liquid, short-term investments with a maturity of three months or less when purchased. Cash equivalents consist of money market funds and are carried at cost, which approximates fair value. The balances, at times, may exceed FDIC Insured limits. The Company believes that, as of December 31, 2023, its risk relating to deposits exceeding federally insured limits was not significant.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_84D_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zHSkOZjoaDAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_863_zDnAqV8hKKmb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounts Receivable</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable are unsecured, recorded at net realizable value, and do not bear interest. Accounts receivable are considered past due if not paid within the terms established between the Company and the customer. Amounts are only written off after all attempts at collections have been exhausted. The Company determines the need for an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information. As of December 31, 2023 and 2022, the Company established allowances of $<span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20231231_zsgeggHAEi86">0</span></span></span> <span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20221231_zELlL3nc7kY7">102,700</span></span></span> <span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">respectively. The net receivable balances outstanding are fully collectible.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes its credit policies are prudent and reflect normal industry terms and business risk. The Company generally does not require collateral from its customers and generally requires payment from 0 to 90 days from the invoice date. For the year ended December 31, 2023, there was 1 customer that accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zYlEzIbkEdmk">10</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% or more of total revenue, and there were 2 customers that accounted for <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zWk6srTqOOyb">10</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% or more of total revenue for the years ended December 31, 2022 . The following table represents these customers’ aggregate percent of total revenue:</span></span></p> <p id="xdx_899_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zQi7JmXQvsj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zGLv6h4dCOii">Schedule Of Aggregate Percentage Revenue and Accounts Receivable</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" id="xdx_49D_20230101__20231231_zUGdB37NKUn6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">December 31, 2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" id="xdx_492_20220101__20221231_zcYb7a6l5vo2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Year Ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">December 31, 2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_403_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zEHO2Q3PAb9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%"><span style="-sec-ix-redline: true">Customer 1</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="-sec-ix-redline: true">52</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="-sec-ix-redline: true">31</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr> <tr id="xdx_405_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zZGLElbzyVq4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Customer 2</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0725">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">22</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr> <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_z5Y4MjatHXV" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Aggregate Percent of Total Revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">52</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">53</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, three customers accounted for more than <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeCustomersMember_zaeCBpShTQP9">10</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of the Company’s accounts receivable balance, and two customers accounted for over <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_z1pBVCbDsh6b">10</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of the Company’s accounts receivable balance at December 31, 2022. The following table represents these customers’ aggregate percent of total accounts receivable:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" id="xdx_49D_20230101__20231231_zFefwqYRVOU8" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">December 31, 2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" id="xdx_49E_20220101__20221231_z2cFFNbI99Sb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Year Ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">December 31, 2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zUQw8G4cVKZe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="-sec-ix-redline: true">Customer 1</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0733">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-redline: true">40</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr> <tr id="xdx_400_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zbivTlCYEB3g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true">Customer 2</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">36</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0737">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_400_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zUf1RqDmH0z5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true">Customer 3</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">33</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0740">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFourMember_zMcJm0AG6jMd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true">Customer 4</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0742">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">32</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr> <tr id="xdx_404_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFiveMember_zXVSrVaFghWj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Customer 5</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">27</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0746">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_404_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_zdgdbAAO0zIb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Aggregate Percent of Total Accounts Receivable</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">96</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">72</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr> <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_zg1FiXjCH2xe" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Aggregate Percent of Revenue and Accounts Receivable</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">96</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">72</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr> </table> <p id="xdx_8A5_zHDNCw2Iq6Qc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zoEI6ToaNBQc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_868_z4IcW1vRIm1b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Property and Equipment</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are recorded at cost. The straight-line method is used for computing depreciation and amortization. Assets are depreciated over their estimated useful lives ranging from three to five years. Cost of maintenance and repairs are charged to expense when incurred.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zqQEFN1kkqcg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_862_zNNfTwY6IbVa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment of Long-Lived Assets</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset may not be fully recoverable. An impairment loss would be recognized when the estimated future undiscounted net cash flows from the use of the asset are less than the carrying amount of that asset. There have been <span id="xdx_90A_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_do_c20220101__20221231_zU0HgIgIqy09">no </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">losses during the years ended December 31, 2023 or December 31, 2022.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_845_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zDiDCTuKvzr" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_865_zS2oqDkolOjj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair Value of Financial Instruments</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 1</b> — Valuations based on quoted prices for identical assets and liabilities in active markets.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 2</b> — Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 3</b> — Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We measure the fair value of money market funds and certain marketable equity securities based on quoted prices in active markets for identical assets or liabilities. Other marketable securities were valued either based on recent trades of securities in inactive markets or based on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. We did not hold significant amounts of marketable securities categorized as Level 3 assets as of the years ended December 31, 2022 and December 31, 2023.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, convertible notes payable and certain privately issued warrants. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable financial instruments approximate their fair value due to their short-term nature. The Company’s Private Warrants estimated fair values are provided by a third party pricing vendor and are reviewed by the Company’s management. The Private Warrants valuations are based on unobservable inputs reflecting the vendor’s assumptions, consistent with reasonably available assumptions made by other market participants and thus are classified as Level 3.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_z8kXah7HUIp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_860_zetssCGQ3aL3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue Recognition</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue is recognized in accordance with the five-step model set forth by Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (“Topic 606”), which involves identification of the contract, identification of performance obligations in the contract, determination of the transaction price, allocation of the transaction price to the previously identified performance obligations, and revenue recognition as the performance obligations are satisfied.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue from all customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to a customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account under Topic 606. A contract’s transaction price is allocated to each distinct performance obligation in proportion to the standalone selling price for each and recognized as revenue when, or as, the performance obligation is satisfied.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual promised goods and services in a contract are considered a performance obligation and accounted for separately if the good or service is distinct. A good or service is considered distinct if the customer can benefit from the good or service on its own or with other resources that are readily available to the customer and the good or service is separately identifiable from other promises in the arrangement.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The transaction price for the products is the invoiced amount. Advanced billings from contracts are deferred and recognized as revenue when earned. Revenue is recognized only to the extent that it is probable that a significant reversal of revenue will not occur and when collection is considered probable The Company excludes from revenue taxes collected from a customer that are assessed by a governmental authority and imposed on and concurrent with a specific revenue-producing transaction. Deferred revenue consists of payments received in advance of performance under the contract. Such amounts are generally recognized as revenue over the contractual period. The Company receives payments from customers based upon contractual billing schedules. Accounts receivable is recorded when the right to consideration becomes unconditional. Payment terms on invoiced amounts typically range from zero to 90 days, with typical terms of 30 days.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company generates revenue from two streams: (1) iRWD (imaging Real World Data) which provides regulatory grade imaging and clinical data in the Pharmaceutical, Device Manufacturing, CRO’s and AI markets and (2) BEAM which is a Medical Imaging Exchange platform between Hospital/Healthcare Systems, Imaging Centers, Physicians and Patients. iRWD is sold on a fixed fee basis based on the number of data units and the cost per data unit committed to in the customer contract. Revenue is recognized when the data is delivered to the customer. Beam revenue is subscription-based revenue which is recognized ratably over the subscription period committed to by the customer. The Company invoices its Beam customers quarterly or annually in advance with the customer contracts automatically renewing unless the customer issues a cancellation notice.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></span></p> <p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zJ6mvQ9t6Vg8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_86A_zWc184B7YKG7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income Taxes</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to U.S. federal, state and local income taxes. The Company accounts for income taxes in accordance with ASC Topic 740, Accounting for Income Taxes (“ASC Topic 740”), which requires the recognition of tax benefits or expenses on temporary differences between the financial reporting and tax bases of its assets and liabilities by applying the enacted tax rates in effect for the year in which the differences are expected to reverse. Such net tax effects on temporary differences are reflected on the Company’s consolidated balance sheets as deferred tax assets and liabilities.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC Topic 740 prescribes a two-step approach for the recognition and measurement of tax benefits associated with the positions taken or expected to be taken in a tax return that affects amounts reported in the financial statements. The Company has reviewed and will continue to review the conclusions reached regarding uncertain tax positions, which may be subject to review and adjustment at a later date based on ongoing analyses of tax laws, regulations and interpretations thereof. To the extent that the Company’s assessment of the conclusions reached regarding uncertain tax positions changes as a result of the evaluation of new information, such change in estimate will be recorded in the period in which such determination is made. The Company reports income tax-related interest and penalties relating to uncertain tax positions, if applicable, as a component of income tax expense</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets are reduced by a valuation allowance when the Company believes that it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. The Company provides deferred taxes at the enacted tax rate that is expected to apply when the temporary differences reverse. The Company has recorded a full valuation allowance against the net deferred tax asset due to the uncertainty of realizing the related benefits.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></span></p> <p id="xdx_843_ecustom--PatentsAndTrademarksPolicyTextBlock_zllmj1Dmzjha" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_866_zbuYUjfdq4qd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patents and Trademarks</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs associated with the submission of a patent application are expensed as incurred given the uncertainty of the patents resulting in probable future economic benefits to the Company and are included in research and development expenses on the consolidated statements of operations.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 30pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zqccu0sxztVd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_86F_zoLfadaIiS4e" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research and Development</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 30pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company account for its research and development cost in accordance with ASC Topic 730, Research and Development (“ASC Topic 730”). ASC Topic 730 requires that all R&amp;D costs be recognized as an expense as incurred. However, some costs associated with R&amp;D activities that have an alternative future use (e.g., materials, equipment, facilities) may be capitalizable. For the years ended December 31, 2023 and December 31, 2022 research and development expenditures were charged to operating expense as incurred..</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 30pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_845_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zY1upFaeMacf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_869_z2L8cRNHHXpg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-based Compensation</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has a stock-based compensation plan, which is described in more detail in Note 8. The fair value of stock option and warrant grants are determined on the date of grant using the Black Scholes valuation model. Forfeitures of stock based awards are recorded as the actual forfeitures occur. Stock based compensation expense is recognized over the service period, net of estimated forfeitures, using the straight-line method. The Company converted all unvested stock based compensation awards to common shares in the year ended December 31, 2023.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></span></p> <p id="xdx_846_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zob83QmMzd2g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_862_zp3OEq1qEjda" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General, and Administrative Expenses</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative expenses include all costs that are not directly related to satisfaction of customer contracts. General, and administrative expenses include items for the Company’s selling and administrative functions, such as sales, finance, legal, human resources, and information technology support. These functions include costs for items such as salaries and benefits and other personnel-related costs, maintenance and supplies, professional fees for external legal, accounting, and other consulting services, intangible asset amortization, and depreciation expense.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_84B_ecustom--EmergingGrowthCompanyPolicyTextBlock_zSv3ZJ534jDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_861_zPmGBlQam70g" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Emerging Growth Company</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is an emerging growth company, as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has not elected to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company , can adopt the new or revised standard at the time private companies adopt the new or revised standard.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_845_ecustom--AccountingPronouncementsNotYetAdoptedPolicyTextBlock_zkriRDHeinT3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_86B_zXnyAgn1N81h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounting Pronouncements Not Yet Adopted</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures (Topic 280). This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and included within each reported measure of a segment’s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is also permitted. This ASU will likely result in us including the additional required disclosures when adopted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2024.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the Financial Accounting Standards Board issued an Accounting Standards Update (“ASU”) amending existing income tax disclosure guidance, primarily requiring more detailed disclosure for income taxes paid and the effective tax rate reconciliation. The ASU is effective for annual reporting periods beginning after December 15, 2024, with early adoption permitted and can be applied on either a prospective or retroactive basis. We are currently evaluating the ASU to determine its impact on our income tax disclosures.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></span></p> <p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zMFQj8yXoSH2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_86F_zcTBCyVWS00i" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently adopted accounting pronouncements</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2021, the FASB issued ASU No. 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (ASC Topic 805). This ASU requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities (deferred revenue) from acquired contracts using the revenue recognition guidance in Topic 606. At the acquisition date, the acquirer applies the revenue model as if it had originated the acquired contracts. The ASU is effective for annual periods beginning after December 15, 2022, including interim periods within those fiscal years. We adopted this ASU prospectively on January 1, 2023. This ASU has not and is currently not expected to have a material impact on our consolidated financial statements.</span></span></p> <p id="xdx_85B_zXwne0u5Kej2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_842_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zvzejhltBzmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_86A_zHiorFzUGPkd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis of Presentation and Foreign Currency Translation</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt; background-color: white"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements have been prepared in U.S. dollars, in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. The consolidated financial statements include 100% of the accounts of wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></span></p> <p id="xdx_840_eus-gaap--BusinessCombinationsPolicy_zndaSaMzFgIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_868_z9lk6RJzb8ma" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business Combination</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We account for business acquisitions under ASC Topic 805, Business Combinations (“ASC Topic 805”). The total purchase consideration for an acquisition is measured as the fair value of the assets given, equity instruments issued, and liabilities assumed at the acquisition date. Costs that are directly attributable to the acquisition are expensed as incurred. Identifiable assets (including intangible assets) and liabilities assumed (including contingent liabilities) are measured initially at their fair values at the acquisition date. We recognize goodwill if the fair value of the total purchase consideration is in excess of the net fair value of the identifiable assets acquired and the liabilities assumed. We recognize a bargain purchase gain within Other income (expense), net, in the consolidated statement of operations if the net fair value of the identifiable assets acquired and the liabilities assumed is in excess of the fair value of the total purchase consideration. We include the results of operations of the acquired business in the consolidated financial statements beginning on the acquisition date.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_843_eus-gaap--UseOfEstimates_zjt1UdiaaVH7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_869_zIt7XWTLer6d" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the amounts disclosed in the related notes to the consolidated financial statements. Actual results and outcomes may differ materially from management’s estimates, judgments, and assumptions. Significant estimates, judgments, and assumptions used in these financial statements include, but are not limited to, those related to revenue, useful lives and realizability of long-lived assets, accounting for income taxes and related valuation allowances, and unit and stock-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts, and experience.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_843_ecustom--OperatingSegmentsPolicyTextBlock_zACDXJyzWbLk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_862_zQstZ0yF89o" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating Segments</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company operates as one operating segment. Operating segments are defined as components of an enterprise for which separate financial information is regularly evaluated by the chief operating decision maker (“CODM”), which is the Company’s Chief Executive Officer, in deciding how to allocate resources and assess performance. The Company’s CODM evaluates the Company’s financial information and resources and assesses the performance of these resources on a consolidated basis. The Company is not organized by market and is managed and operated as one business. A single management team that reports to the chief executive officer comprehensively manages the entire business. Accordingly, the Company does not accumulate discrete financial information with respect to separate divisions and does not have separate operating or reportable segments. Since the Company operates in one operating segment, all required financial segment information can be found in the consolidated financial statements.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_84C_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zMlRvLLBGcYl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_867_zKdmKLGHFwQ8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash and Cash Equivalents</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents consist of highly liquid, short-term investments with a maturity of three months or less when purchased. Cash equivalents consist of money market funds and are carried at cost, which approximates fair value. The balances, at times, may exceed FDIC Insured limits. The Company believes that, as of December 31, 2023, its risk relating to deposits exceeding federally insured limits was not significant.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_84D_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zHSkOZjoaDAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_863_zDnAqV8hKKmb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounts Receivable</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable are unsecured, recorded at net realizable value, and do not bear interest. Accounts receivable are considered past due if not paid within the terms established between the Company and the customer. Amounts are only written off after all attempts at collections have been exhausted. The Company determines the need for an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information. As of December 31, 2023 and 2022, the Company established allowances of $<span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20231231_zsgeggHAEi86">0</span></span></span> <span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20221231_zELlL3nc7kY7">102,700</span></span></span> <span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">respectively. The net receivable balances outstanding are fully collectible.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes its credit policies are prudent and reflect normal industry terms and business risk. The Company generally does not require collateral from its customers and generally requires payment from 0 to 90 days from the invoice date. For the year ended December 31, 2023, there was 1 customer that accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zYlEzIbkEdmk">10</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% or more of total revenue, and there were 2 customers that accounted for <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zWk6srTqOOyb">10</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% or more of total revenue for the years ended December 31, 2022 . The following table represents these customers’ aggregate percent of total revenue:</span></span></p> <p id="xdx_899_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zQi7JmXQvsj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zGLv6h4dCOii">Schedule Of Aggregate Percentage Revenue and Accounts Receivable</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" id="xdx_49D_20230101__20231231_zUGdB37NKUn6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">December 31, 2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" id="xdx_492_20220101__20221231_zcYb7a6l5vo2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Year Ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">December 31, 2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_403_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zEHO2Q3PAb9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%"><span style="-sec-ix-redline: true">Customer 1</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="-sec-ix-redline: true">52</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="-sec-ix-redline: true">31</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr> <tr id="xdx_405_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zZGLElbzyVq4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Customer 2</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0725">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">22</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr> <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_z5Y4MjatHXV" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Aggregate Percent of Total Revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">52</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">53</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, three customers accounted for more than <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeCustomersMember_zaeCBpShTQP9">10</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of the Company’s accounts receivable balance, and two customers accounted for over <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_z1pBVCbDsh6b">10</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of the Company’s accounts receivable balance at December 31, 2022. The following table represents these customers’ aggregate percent of total accounts receivable:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" id="xdx_49D_20230101__20231231_zFefwqYRVOU8" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">December 31, 2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" id="xdx_49E_20220101__20221231_z2cFFNbI99Sb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Year Ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">December 31, 2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zUQw8G4cVKZe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="-sec-ix-redline: true">Customer 1</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0733">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-redline: true">40</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr> <tr id="xdx_400_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zbivTlCYEB3g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true">Customer 2</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">36</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0737">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_400_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zUf1RqDmH0z5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true">Customer 3</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">33</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0740">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFourMember_zMcJm0AG6jMd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true">Customer 4</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0742">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">32</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr> <tr id="xdx_404_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFiveMember_zXVSrVaFghWj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Customer 5</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">27</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0746">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_404_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_zdgdbAAO0zIb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Aggregate Percent of Total Accounts Receivable</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">96</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">72</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr> <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_zg1FiXjCH2xe" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Aggregate Percent of Revenue and Accounts Receivable</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">96</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">72</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr> </table> <p id="xdx_8A5_zHDNCw2Iq6Qc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> 0 102700 0.10 0.10 <p id="xdx_899_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zQi7JmXQvsj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zGLv6h4dCOii">Schedule Of Aggregate Percentage Revenue and Accounts Receivable</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" id="xdx_49D_20230101__20231231_zUGdB37NKUn6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">December 31, 2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" id="xdx_492_20220101__20221231_zcYb7a6l5vo2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Year Ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">December 31, 2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_403_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zEHO2Q3PAb9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%"><span style="-sec-ix-redline: true">Customer 1</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="-sec-ix-redline: true">52</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="-sec-ix-redline: true">31</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr> <tr id="xdx_405_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zZGLElbzyVq4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Customer 2</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0725">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">22</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr> <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_z5Y4MjatHXV" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Aggregate Percent of Total Revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">52</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">53</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, three customers accounted for more than <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeCustomersMember_zaeCBpShTQP9">10</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of the Company’s accounts receivable balance, and two customers accounted for over <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_z1pBVCbDsh6b">10</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of the Company’s accounts receivable balance at December 31, 2022. The following table represents these customers’ aggregate percent of total accounts receivable:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" id="xdx_49D_20230101__20231231_zFefwqYRVOU8" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">December 31, 2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" id="xdx_49E_20220101__20221231_z2cFFNbI99Sb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Year Ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">December 31, 2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zUQw8G4cVKZe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="-sec-ix-redline: true">Customer 1</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0733">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-redline: true">40</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr> <tr id="xdx_400_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zbivTlCYEB3g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true">Customer 2</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">36</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0737">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_400_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zUf1RqDmH0z5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true">Customer 3</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">33</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0740">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFourMember_zMcJm0AG6jMd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true">Customer 4</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0742">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">32</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr> <tr id="xdx_404_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFiveMember_zXVSrVaFghWj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Customer 5</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">27</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0746">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_404_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_zdgdbAAO0zIb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Aggregate Percent of Total Accounts Receivable</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">96</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">72</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr> <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_zg1FiXjCH2xe" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Aggregate Percent of Revenue and Accounts Receivable</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">96</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">72</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr> </table> 0.52 0.31 0.22 0.52 0.53 0.10 0.10 0.40 0.36 0.33 0.32 0.27 0.96 0.72 0.96 0.72 <p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zoEI6ToaNBQc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_868_z4IcW1vRIm1b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Property and Equipment</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are recorded at cost. The straight-line method is used for computing depreciation and amortization. Assets are depreciated over their estimated useful lives ranging from three to five years. Cost of maintenance and repairs are charged to expense when incurred.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zqQEFN1kkqcg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_862_zNNfTwY6IbVa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment of Long-Lived Assets</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset may not be fully recoverable. An impairment loss would be recognized when the estimated future undiscounted net cash flows from the use of the asset are less than the carrying amount of that asset. There have been <span id="xdx_90A_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_do_c20220101__20221231_zU0HgIgIqy09">no </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">losses during the years ended December 31, 2023 or December 31, 2022.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> 0 <p id="xdx_845_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zDiDCTuKvzr" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_865_zS2oqDkolOjj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair Value of Financial Instruments</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 1</b> — Valuations based on quoted prices for identical assets and liabilities in active markets.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 2</b> — Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 3</b> — Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 12.95pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We measure the fair value of money market funds and certain marketable equity securities based on quoted prices in active markets for identical assets or liabilities. Other marketable securities were valued either based on recent trades of securities in inactive markets or based on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. We did not hold significant amounts of marketable securities categorized as Level 3 assets as of the years ended December 31, 2022 and December 31, 2023.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, convertible notes payable and certain privately issued warrants. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable financial instruments approximate their fair value due to their short-term nature. The Company’s Private Warrants estimated fair values are provided by a third party pricing vendor and are reviewed by the Company’s management. The Private Warrants valuations are based on unobservable inputs reflecting the vendor’s assumptions, consistent with reasonably available assumptions made by other market participants and thus are classified as Level 3.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_z8kXah7HUIp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_860_zetssCGQ3aL3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue Recognition</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue is recognized in accordance with the five-step model set forth by Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (“Topic 606”), which involves identification of the contract, identification of performance obligations in the contract, determination of the transaction price, allocation of the transaction price to the previously identified performance obligations, and revenue recognition as the performance obligations are satisfied.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue from all customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to a customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account under Topic 606. A contract’s transaction price is allocated to each distinct performance obligation in proportion to the standalone selling price for each and recognized as revenue when, or as, the performance obligation is satisfied.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual promised goods and services in a contract are considered a performance obligation and accounted for separately if the good or service is distinct. A good or service is considered distinct if the customer can benefit from the good or service on its own or with other resources that are readily available to the customer and the good or service is separately identifiable from other promises in the arrangement.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The transaction price for the products is the invoiced amount. Advanced billings from contracts are deferred and recognized as revenue when earned. Revenue is recognized only to the extent that it is probable that a significant reversal of revenue will not occur and when collection is considered probable The Company excludes from revenue taxes collected from a customer that are assessed by a governmental authority and imposed on and concurrent with a specific revenue-producing transaction. Deferred revenue consists of payments received in advance of performance under the contract. Such amounts are generally recognized as revenue over the contractual period. The Company receives payments from customers based upon contractual billing schedules. Accounts receivable is recorded when the right to consideration becomes unconditional. Payment terms on invoiced amounts typically range from zero to 90 days, with typical terms of 30 days.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 12.95pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company generates revenue from two streams: (1) iRWD (imaging Real World Data) which provides regulatory grade imaging and clinical data in the Pharmaceutical, Device Manufacturing, CRO’s and AI markets and (2) BEAM which is a Medical Imaging Exchange platform between Hospital/Healthcare Systems, Imaging Centers, Physicians and Patients. iRWD is sold on a fixed fee basis based on the number of data units and the cost per data unit committed to in the customer contract. Revenue is recognized when the data is delivered to the customer. Beam revenue is subscription-based revenue which is recognized ratably over the subscription period committed to by the customer. The Company invoices its Beam customers quarterly or annually in advance with the customer contracts automatically renewing unless the customer issues a cancellation notice.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></span></p> <p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zJ6mvQ9t6Vg8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_86A_zWc184B7YKG7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income Taxes</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to U.S. federal, state and local income taxes. The Company accounts for income taxes in accordance with ASC Topic 740, Accounting for Income Taxes (“ASC Topic 740”), which requires the recognition of tax benefits or expenses on temporary differences between the financial reporting and tax bases of its assets and liabilities by applying the enacted tax rates in effect for the year in which the differences are expected to reverse. Such net tax effects on temporary differences are reflected on the Company’s consolidated balance sheets as deferred tax assets and liabilities.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC Topic 740 prescribes a two-step approach for the recognition and measurement of tax benefits associated with the positions taken or expected to be taken in a tax return that affects amounts reported in the financial statements. The Company has reviewed and will continue to review the conclusions reached regarding uncertain tax positions, which may be subject to review and adjustment at a later date based on ongoing analyses of tax laws, regulations and interpretations thereof. To the extent that the Company’s assessment of the conclusions reached regarding uncertain tax positions changes as a result of the evaluation of new information, such change in estimate will be recorded in the period in which such determination is made. The Company reports income tax-related interest and penalties relating to uncertain tax positions, if applicable, as a component of income tax expense</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets are reduced by a valuation allowance when the Company believes that it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. The Company provides deferred taxes at the enacted tax rate that is expected to apply when the temporary differences reverse. The Company has recorded a full valuation allowance against the net deferred tax asset due to the uncertainty of realizing the related benefits.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></span></p> <p id="xdx_843_ecustom--PatentsAndTrademarksPolicyTextBlock_zllmj1Dmzjha" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_866_zbuYUjfdq4qd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patents and Trademarks</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs associated with the submission of a patent application are expensed as incurred given the uncertainty of the patents resulting in probable future economic benefits to the Company and are included in research and development expenses on the consolidated statements of operations.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 30pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zqccu0sxztVd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_86F_zoLfadaIiS4e" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research and Development</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 30pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company account for its research and development cost in accordance with ASC Topic 730, Research and Development (“ASC Topic 730”). ASC Topic 730 requires that all R&amp;D costs be recognized as an expense as incurred. However, some costs associated with R&amp;D activities that have an alternative future use (e.g., materials, equipment, facilities) may be capitalizable. For the years ended December 31, 2023 and December 31, 2022 research and development expenditures were charged to operating expense as incurred..</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 30pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_845_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zY1upFaeMacf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_869_z2L8cRNHHXpg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-based Compensation</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has a stock-based compensation plan, which is described in more detail in Note 8. The fair value of stock option and warrant grants are determined on the date of grant using the Black Scholes valuation model. Forfeitures of stock based awards are recorded as the actual forfeitures occur. Stock based compensation expense is recognized over the service period, net of estimated forfeitures, using the straight-line method. The Company converted all unvested stock based compensation awards to common shares in the year ended December 31, 2023.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></span></p> <p id="xdx_846_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zob83QmMzd2g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_862_zp3OEq1qEjda" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General, and Administrative Expenses</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative expenses include all costs that are not directly related to satisfaction of customer contracts. General, and administrative expenses include items for the Company’s selling and administrative functions, such as sales, finance, legal, human resources, and information technology support. These functions include costs for items such as salaries and benefits and other personnel-related costs, maintenance and supplies, professional fees for external legal, accounting, and other consulting services, intangible asset amortization, and depreciation expense.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_84B_ecustom--EmergingGrowthCompanyPolicyTextBlock_zSv3ZJ534jDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_861_zPmGBlQam70g" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Emerging Growth Company</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is an emerging growth company, as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has not elected to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company , can adopt the new or revised standard at the time private companies adopt the new or revised standard.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_845_ecustom--AccountingPronouncementsNotYetAdoptedPolicyTextBlock_zkriRDHeinT3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_86B_zXnyAgn1N81h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounting Pronouncements Not Yet Adopted</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures (Topic 280). This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and included within each reported measure of a segment’s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is also permitted. This ASU will likely result in us including the additional required disclosures when adopted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2024.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the Financial Accounting Standards Board issued an Accounting Standards Update (“ASU”) amending existing income tax disclosure guidance, primarily requiring more detailed disclosure for income taxes paid and the effective tax rate reconciliation. The ASU is effective for annual reporting periods beginning after December 15, 2024, with early adoption permitted and can be applied on either a prospective or retroactive basis. We are currently evaluating the ASU to determine its impact on our income tax disclosures.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></span></p> <p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zMFQj8yXoSH2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_86F_zcTBCyVWS00i" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently adopted accounting pronouncements</i></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2021, the FASB issued ASU No. 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (ASC Topic 805). This ASU requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities (deferred revenue) from acquired contracts using the revenue recognition guidance in Topic 606. At the acquisition date, the acquirer applies the revenue model as if it had originated the acquired contracts. The ASU is effective for annual periods beginning after December 15, 2022, including interim periods within those fiscal years. We adopted this ASU prospectively on January 1, 2023. This ASU has not and is currently not expected to have a material impact on our consolidated financial statements.</span></span></p> <p id="xdx_80D_eus-gaap--BusinessCombinationDisclosureTextBlock_z4vKWwQH9wHb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3. <span id="xdx_82B_zeoEFUOzArqf">Business Combination</span></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Business Combination was accounted for as a reverse recapitalization as OneMedNet Corporation was determined to be the accounting acquirer under Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 805, Business Combinations. This determination was primarily based on OneMedNet Corporation comprising the ongoing operations of the combined entity, OneMedNet Corporation’s senior management comprising of all the senior management of the combined company, and the prior shareholders of OneMedNet owning a majority of the voting power of the combined entity. Accordingly, for accounting purposes, the financial statements of the combined entity upon consummation of the Business Combination represented a continuation of the financial statements of OneMedNet Corporation with the merger being treated as the equivalent of OneMedNet issuing stock for the net assets of Data Knights Inc., accompanied by a recapitalization. Operations prior to the Business Combination are presented as those of OneMedNet Corporation in future reports of the combined entity.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_80C_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z9GQMeGj2eO9" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. <span id="xdx_820_zNMLide1oM86">Going Concern</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company does not have adequate liquidity to fund its operations through at least twelve months from the date these financial statements were available for issuance. The Company has an accumulated deficit <span id="xdx_900_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20231231_zLT6O9l1Mpdd">55,082,677</span></span></span> <span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as of year-end December 31, 2023 and $<span id="xdx_90A_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20221231_zFrRkvZ0DDf6">43,509,964</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, as of year-end December 31, 2022 and has had negative cash flows from operating activities for the year ended December 31, 2023. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. To continue in existence and expand its operations, the Company will be required to, and management plans to, raise additional working capital through an equity or debt offering and ultimately attain profitable operations. If the Company is not able to raise additional working capital, it would have a material adverse effect on the operations of the Company and continuing research and development of its product. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to continue receiving working capital cash payments and generating cash flow from operations.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></span></p> -55082677 -43509964 <p id="xdx_80B_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z2S0u7LSVuZ2" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5. <span id="xdx_822_zswcSU5RuXy">Property and Equipment</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are summarized as of December 31:</span></span></p> <p id="xdx_89A_eus-gaap--PropertyPlantAndEquipmentTextBlock_zAazqlokgi91" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_z8Gw2Lkw6J59">Schedule of Property And Equipment </span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.75in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" id="xdx_493_20231231_zxbghYXtYgG" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" id="xdx_498_20221231_zt0fc4NDUIdi" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_ziE4TvzcdXC8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="-sec-ix-redline: true">Computers</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-redline: true">246,578</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-redline: true">259,207</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zo9jdq1Pm0n1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Furniture and equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">35,708</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">3,785</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzSdJ_zRVEXvJRbLte" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Total Property and Equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">282,286</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">262,992</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_408_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzSdJ_zESw8MyMt588" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Less: accumulated depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">(183,415</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">(179,895</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzSdJ_zkzCLNMdEYJ2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">Net Property and Equipment</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">98,871</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">83,097</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> </table> <p id="xdx_8A2_z2Z5jWJEfOhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation and amortization expense was $<span id="xdx_905_eus-gaap--DepreciationAndAmortization_c20230101__20231231_z4c8S5We6ZWd">27,983</span></span></span> <span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_901_eus-gaap--DepreciationAndAmortization_c20220101__20221231_zRDHKmXJDHP7">24,807 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the years ended December 31, 2023 and 2022, respectively.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_89A_eus-gaap--PropertyPlantAndEquipmentTextBlock_zAazqlokgi91" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_z8Gw2Lkw6J59">Schedule of Property And Equipment </span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.75in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" id="xdx_493_20231231_zxbghYXtYgG" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" id="xdx_498_20221231_zt0fc4NDUIdi" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_ziE4TvzcdXC8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="-sec-ix-redline: true">Computers</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-redline: true">246,578</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-redline: true">259,207</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zo9jdq1Pm0n1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Furniture and equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">35,708</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">3,785</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzSdJ_zRVEXvJRbLte" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Total Property and Equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">282,286</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">262,992</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_408_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzSdJ_zESw8MyMt588" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Less: accumulated depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">(183,415</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">(179,895</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzSdJ_zkzCLNMdEYJ2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">Net Property and Equipment</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">98,871</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">83,097</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> </table> 246578 259207 35708 3785 282286 262992 183415 179895 98871 83097 27983 24807 <p id="xdx_80C_eus-gaap--IncomeTaxDisclosureTextBlock_zQGKlG3kSa4g" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6. <span id="xdx_828_zYHZpHPvRJn6">Income Taxes</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has generated both federal and state net operating losses (NOL) of approximately $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_pn6n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zrJBbv8G4Dve">21 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_905_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_pn6n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z5CpxqCHQ7id">23 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, respectively, which if not used, will begin to expire in 2030. The Company believes that its ability to fully utilize the existing NOL carryforwards could be restricted on a portion of the NOL by changes in control that may have occurred or may occur in the future and by its ability to generate net income. The Company has not yet conducted a formal study of whether, or to what extent, past changes in control of the Company impairs its NOL carryforwards because such NOL carryforwards cannot be utilized until the Company achieves profitability.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zOTyCca4QW1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Components of deferred income taxes are as follows as of December 31:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_8B6_zo03RUu2UEKe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of Deferred Income Taxes</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" id="xdx_490_20231231_zuzdypJa1VJe" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" id="xdx_492_20221231_zvNXwFlUwyx6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsNetAbstract_iB_z1AfkgxFsRQc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Deferred Tax Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzqvH_z5F5Wc4Dlonj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="-sec-ix-redline: true">Net operating loss carry forward</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,823,785 </span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-redline: true">6,973,587</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzqvH_znQ6MjBxc6q2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="-sec-ix-redline: true">Stock Compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">1,035,947</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">481,144</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzqvH_zYoSYWKgPhFb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Other</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0821">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">53,268</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzqvH_maDTANzhf6_zP6nBXkfV5Hc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Gross deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,859,732</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">7,507,999</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzhf6_zvM5foPdYXh1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Less valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">(7,859,732</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">(7,507,999</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzhf6_zpjeP5OEWge3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Net deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0830">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0831">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> </table> <p id="xdx_8A1_z2sdkuOVvkC" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The change in the valuation allowance was $<span id="xdx_901_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20230101__20231231_z0SoQZV1P5eh">351,734 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_907_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20220101__20221231_zDJsXDusfHxb">1,384,220 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the years ended December 31, 2023 and 2022, respectively. The effective tax rate for the years ended December 31, 2023 and 2022 differs from the federal and state statutory rates due to the full valuation allowance. The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. The tax years from inception through December 31, 2023 remain subject to examination by all major taxing authorities due to the net operating loss carryovers. The Company is not currently under examination by any taxing jurisdiction. The Company did not incur any interest or penalties during the years ended December 31, 2023 or 2022.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of the Business Combination, the Company was appointed as the sole managing member of Data Knights. The Company is subject to U.S. federal income taxes, in addition to state and local income taxes. The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the estimated future tax consequences attributable to temporary differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the temporary differences are expected to be settled or recovered. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future income, and tax planning strategies in making this assessment.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has established a valuation allowance related deferred tax assets on deductible temporary differences, tax losses, and tax credit carryforwards. The valuation allowance as of December 31, 2023 was $<span id="xdx_90C_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pn5n6_c20231231__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zc9I8GCxiNOl">168.3</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The increase in the valuation allowance in fiscal year 2023 of $<span id="xdx_90C_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zAXOyzAGvkna">155.7 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million primarily relates to the Company’s investment in Data Knights, and tax carryforward attributes.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, the Company had a U.S. federal net operating loss carryforwards of $<span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_z3uZn3tL8Luk">10.3 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and gross state net operating loss carryforwards of $<span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zW99MiPyTjFe">8.9 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> 21000000 23000000 <p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zOTyCca4QW1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Components of deferred income taxes are as follows as of December 31:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_8B6_zo03RUu2UEKe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of Deferred Income Taxes</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" id="xdx_490_20231231_zuzdypJa1VJe" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" id="xdx_492_20221231_zvNXwFlUwyx6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsNetAbstract_iB_z1AfkgxFsRQc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Deferred Tax Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzqvH_z5F5Wc4Dlonj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="-sec-ix-redline: true">Net operating loss carry forward</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,823,785 </span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-redline: true">6,973,587</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzqvH_znQ6MjBxc6q2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="-sec-ix-redline: true">Stock Compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">1,035,947</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">481,144</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzqvH_zYoSYWKgPhFb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Other</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0821">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">53,268</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzqvH_maDTANzhf6_zP6nBXkfV5Hc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Gross deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,859,732</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">7,507,999</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzhf6_zvM5foPdYXh1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Less valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">(7,859,732</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">(7,507,999</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzhf6_zpjeP5OEWge3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Net deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0830">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0831">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> </table> 6823785 6973587 1035947 481144 53268 7859732 7507999 7859732 7507999 351734 1384220 168300000 155700000 10300000 8900000 <p id="xdx_804_eus-gaap--LongTermDebtTextBlock_zs77GuAQ061c" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7. <span id="xdx_822_zC14DSedB2je">Convertible Promissory Notes held by Related Party</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2023, the Company entered various Convertible Promissory Notes (“Note”) with related party investors totaling $<span id="xdx_90E_eus-gaap--ConvertibleNotesPayable_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zJ0A9yJtOCIj">2,300,000 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2022 - $<span id="xdx_909_eus-gaap--ConvertibleNotesPayable_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zvGkZMJNdQSf">4,700,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">) and unrelated party investors of $<span id="xdx_90B_eus-gaap--ConvertibleNotesPayable_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_ze08HTFx5wN">1,875,000 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2022 - $<span id="xdx_909_eus-gaap--ConvertibleNotesPayable_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zO5hNPsSKwdd">440,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">). The Notes issued are unsecured and bear an interest rate of six percent annually from the date of issuance until the outstanding principal is paid or converted. On November 11, 2022 the Convertible note agreement was amended and restated in order to (i) provide for the sale and issuance to Purchasers from the effective date of January 1, 2022 and after the date of this Agreement of up to an additional $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20221111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_ze3YghPcbhM5">5,000,000 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">aggregate principal amount of Notes and warrants to purchase shares of the Company’s capital stock, (ii) provide for the sale and issuance to Purchasers who purchased Notes under the Prior Agreement between the Effective Date and the date of this Agreement of warrants to purchase shares of the Company’s common stock at an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221111__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z0g21z8lG49c">1.00 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share; (iii) extend the maturity date of all outstanding Notes from December 31, 2022 to November 7, 2023.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The principal and unpaid accrued interest on each Note will convert: (i) automatically, upon the Company’s issuance of equity securities (the “Next Equity Financing”) in a single transaction, or series of related transactions, with aggregate gross proceeds to the Company of at least $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20221110__20221111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zAHMpalxTCIi">5,000,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, into shares of the Company’s capital stock issued to investors in the Next Equity Financing, at a conversion price equal to the lesser of (A) <span id="xdx_906_ecustom--EquityFinancingDescription_c20221110__20221111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zP3bi3FMTxA8">a 20% discount to the lowest price per share of shares sold in the Next Equity Financing, or (B) $2.50 per share; (ii) at the noteholder’s option, in the event of a defined Corporate Transaction while such Note remains outstanding, into shares of the Company’s Series A-2 Preferred Stock at a conversion price equal to $</span></span></span><span style="-sec-ix-redline: true"><span id="xdx_907_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20221111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zzxoqgGTU0af" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.50 </span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share; and (iii) at the noteholder’s option, on or after the Maturity Date while such Note remains outstanding, into shares of the Company’s Series A-2 Preferred Stock at a conversion price equal to $</span></span><span style="-sec-ix-redline: true"><span id="xdx_901_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20221111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zwlO38ap7fT2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.50 </span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a Corporate Transaction occurs before the repayment or conversion of the Notes, the Company will pay at the closing of the Corporate Transaction to each noteholder that elects not to convert its Notes in connection with such Corporate Transaction an amount equal to the outstanding principal amount of such noteholder’s Note plus a 20% premium. “Corporate Transaction” means (a) a sale by the Company of all or substantially all of its assets, (b) a merger of the Company with or into another entity (if after such merger the holders of a majority of the Company’s voting securities immediately prior to the transaction do not hold a majority of the voting securities of the successor entity) or (c) the transfer of more than 50% of the Company’s voting securities to a person or group.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During November 2019, the Company entered into a Convertible Promissory Note (“Note”) agreement with a related party investor. The total amount of the Note is $<span id="xdx_90B_eus-gaap--ConvertibleNotesPayable_iI_c20191130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zv56oApNNbeh">1,500,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Note is unsecured and bears interest at a rate of four percent annually from the date of issuance until the outstanding principal is paid or converted. The Note matures on January 1, 2025. The Note shall automatically convert into the next offering of preferred stock upon closing of such next equity financing. The number of shares of preferred stock to be issued upon conversion shall be equal to the number obtained by dividing the outstanding principal and unpaid accrued interest owed on the date of conversion, by the conversion price. The conversion price is 100 percent of the lowest price per share paid for the next equity preferred stock by other investors in the next equity financing. In the event that prior to the conversion or repayment of amounts owed, the Company completes a financing transaction in which the Company sells equity securities but such transaction does not qualify as next equity financing (i.e., an “alternative financing”), then the principal and unpaid accrued interest may (upon written election of the purchaser holding the Note) convert into the securities issued by the Company in the alternative financing. The number of alternative financing equity securities to be issued upon such conversion shall be equal to the number obtained by dividing the outstanding principal and unpaid accrued interest owed by an amount equal to 100 percent multiplied by the lowest price per share at which the alternative financing equity securities are sold and issued for cash in the alternative financing.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 there was $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20221231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zzQfngxlNZv">9.9 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million outstanding principal balance on the Notes and $<span id="xdx_90D_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20221231_zdNy3XL0rF12">690,771</span></span></span> <span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in accrued interest, all included in long-term liabilities on the balance sheet. There were no payments of principal or interest during 2022. In connection with the $<span id="xdx_909_eus-gaap--ConvertibleNotesPayable_iI_c20221231_zHeJIptueIbd">5,140,000 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in convertible notes issued in 2022, <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231_ztjzjo3Remni">2,056,000 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in warrants were issued.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the Business Combination between Data Knights and the Company triggered the Notes’ conversion to common stock. Approximately $<span id="xdx_90F_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20231130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_zWFSXJD2XsXd">15.4 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of the total outstanding Notes plus accrued interest were converted at $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember_z22nSokD3835">2.50 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share of common stock.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 29.95pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> 2300000 4700000 1875000 440000 5000000 1.00 5000000 a 20% discount to the lowest price per share of shares sold in the Next Equity Financing, or (B) $2.50 per share; (ii) at the noteholder’s option, in the event of a defined Corporate Transaction while such Note remains outstanding, into shares of the Company’s Series A-2 Preferred Stock at a conversion price equal to $ 2.50 2.50 1500000 9900000 690771 5140000 2056000 15400000 2.50 <p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_zoh1A7v8pgNb" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8. <span id="xdx_823_z8QgZaljwfyc">Canadian Emergency Business Loan Act (CEBA)</span></span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During December 2020, the Company applied for and received a $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfUnsecuredDebt_c20201201__20201231__us-gaap--DebtInstrumentAxis__custom--CEBALoanMember_z9FBa1FDxqQ1">44,673 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD CEBA loan. The loan was provided by the Government of Canada to provide capital to organizations to see them through the current challenges and better position them to return to providing services and creating employment. The loan is unsecured. The loan was interest free through December 31, 2023. If the loan is paid back by January 18, 2024, $<span id="xdx_90B_eus-gaap--DebtInstrumentDecreaseForgiveness_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--CEBALoanMember_zHgzJPz57Uf1">14,742 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of the loan will be forgiven. If the loan is not paid back by January 18, 2023, the full $<span id="xdx_90F_eus-gaap--DebtConversionOriginalDebtAmount1_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--CEBALoanMember_zezZ4lDkBQNf">44,673 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loan will be converted to loan repayable over <span id="xdx_90A_eus-gaap--DebtInstrumentTerm_dc_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--CEBALoanMember_z527KNug8vY8">three years</span></span></span> <span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with a <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20201231__us-gaap--DebtInstrumentAxis__custom--CEBALoanMember_z3pHMKrhHD42">5% </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interest rate. The loan was paid back prior January 18, 2024. At December 31, 2023 the loans is classified as Canada Emergency Business Loan Act under Current Liabilities on the Consolidated Balance Sheet.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounted for the loan as debt in accordance with FASB Accounting Standards Codification 470 Debt and accrued interest in accordance with the interest method under FASB ASC 835-30.</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></span></p> 44673 14742 44673 P3Y 0.05 <p id="xdx_802_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zwIUK3ZPhU96" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9. <span id="xdx_82C_zMJnazzhoipg">Shareholders’ Equity</span></span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series A-2 Preferred Stock</b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s previously issued and outstanding Series A-2 preferred stock included a $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_zq4f8awROcvj">0.15 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share annual noncumulative dividend when and if declared by the board of directors. <span id="xdx_90A_eus-gaap--DividendsPreferredStock_do_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_zfb2qGerALUh">No </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">dividends were declared in the years ended December 31, 2023 or December 31 2022. The Series A-2 preferred stock also includes a liquidation preference of 1.25 times the original issue price plus any declared but unpaid dividends upon the liquidation, dissolution, merger or sale of substantially all the assets of the Company and have a preference upon liquidation over Series A-1 preferred stock and common stock. Each share of Series A-2 preferred stock may be converted into equal shares of common stock at the option of the holder at any time. In addition, the Series A-2 preferred stock shares are automatically convertible into common shares upon the sale of shares of common stock to the public at the then applicable conversion price in a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn5n6_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_z2VdHHmRJnT">20 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million in proceeds, net of underwriting discounts and commissions. Each share of Series A-2 preferred stock has voting rights equal to the number of shares of common stock then issuable upon conversion of such share of preferred stock. The Company is obligated to redeem shares of Series A-2 Preferred Stock in the occurrence of a Deemed Liquidation Event unless a majority of the holders of Series A-2 Preferred Stock and a majority of the Series A-1 Preferred Stock consent otherwise.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the Business Combination between Data Knights and the Company triggered the <span id="xdx_90A_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20230101__20231231_zq6xgWTwPSXg">Series A-2 Preferred Stock and Series A-1 Preferred Stock convert 1-1 to commons stock</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series A-1 Preferred Stock</b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s previously issued and outstanding Series A-1 preferred stock included a $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zPFWdKqH8CR2">0.15 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share annual noncumulative dividend when and if declared by the board of directors. <span id="xdx_905_eus-gaap--DividendsPreferredStock_do_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zcOAGK1oCteb">No </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">dividends were declared in the years ended December 31, 2023 or December 31 2022. The Series A-1 preferred stock also includes a liquidation preference of 1.25 times the original issue price plus any declared but unpaid dividends upon the liquidation, dissolution, merger or sale of substantially all the assets of the Company and have a preference upon liquidation over common stock. Each share of Series A-1 preferred stock may be converted into equal shares of common stock at the option of the holder at any time. In addition, the Series A-1 preferred stock shares are automatically convertible into common shares upon the sale of shares of common stock to the public at the then applicable conversion price in a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn5n6_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_ziTTDyaYppZj">20 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million in proceeds, net of underwriting discounts and commissions. Each share of Series A-1 preferred stock has voting rights equal to the number of shares of common stock then issuable upon conversion of such share of preferred stock. The Company is obligated to redeem shares of Series A-1 Preferred Stock in the occurrence of a Deemed Liquidation Event unless a majority of the holders of Series A-1 Preferred Stock consent otherwise.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the Business Combination between Data Knights and the Company triggered the <span id="xdx_90A_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20230101__20231231_zPmigUwb7mv3">Series A-2 Preferred Stock and Series A-1 Preferred Stock convert 1-1 to commons stock</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock</b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2023, in connection with services performed by the Board of Directors common shares of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zUbEE9Udi2H9">100,000 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220101__20221231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zvCTDm0x78h6">100,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">- 2022) were issued at $<span id="xdx_902_eus-gaap--SharePrice_iI_c20231231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zoQnKnHOJV64">1.00 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. These were expensed as general and administrative expenses in the Statement of Operations.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_893_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_z57uq3swwTu3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font: normal 10pt Times New Roman, Times, Serif">The table below summarizes the Common Stock activities during the year ended December 31, 2023. </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_8B9_z64bu48q1ymf" style="font: normal 10pt Times New Roman, Times, Serif">Schedule of Common Stock Activities</span></span><span style="-sec-ix-redline: true"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 1in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" id="xdx_49E_20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_z2msICVrt1Qb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">Common Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_40A_eus-gaap--SharesOutstanding_iS_zLHH8ANuCOvi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; width: 80%"><span style="-sec-ix-redline: true">Balances, December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-redline: true">4,550,166</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_407_eus-gaap--SharesOutstanding_iS_zW2yvdRyeAgd" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true">Balance</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">4,550,166</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_z2wlaGxg9Xb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Preferred Stock to Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">7,057,797</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_40C_ecustom--StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock_zJwjfDx64uRl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Convertible Notes to Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">6,177,229</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodSharesStockOptionsToCommonStock_z3uhYW1PO4Ql" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Stock Options to Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">612,670</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_404_ecustom--StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock_z3UmWOkuvHcd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Converting of Warrants to Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">3,859,464</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodSharesOther_zuvjfYqYrP3e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Private OneMedNet to ONMD Public Shares</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">(2,257,326</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr> <tr id="xdx_407_ecustom--StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares_zO0iuFy9if3i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Converting Data Knights Common Stock (A and B) to ONMD Public Shares</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">3,460,275</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_z2eiIknVjv5e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Issuance Public Shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">111,957</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_408_eus-gaap--SharesOutstanding_iE_zyOXDTAsVnxi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true">Balances, December 31, 2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">23,572,232</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_400_eus-gaap--SharesOutstanding_iE_zOLEX9Io8sth" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true">Balance</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">23,572,232</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> </table> <p id="xdx_8A0_z6jRMRei6Rl1" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> 0.15 20000000 Series A-2 Preferred Stock and Series A-1 Preferred Stock convert 1-1 to commons stock 0.15 20000000 Series A-2 Preferred Stock and Series A-1 Preferred Stock convert 1-1 to commons stock 100000 100000 1.00 <p id="xdx_893_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_z57uq3swwTu3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font: normal 10pt Times New Roman, Times, Serif">The table below summarizes the Common Stock activities during the year ended December 31, 2023. </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_8B9_z64bu48q1ymf" style="font: normal 10pt Times New Roman, Times, Serif">Schedule of Common Stock Activities</span></span><span style="-sec-ix-redline: true"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 1in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" id="xdx_49E_20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_z2msICVrt1Qb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">Common Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_40A_eus-gaap--SharesOutstanding_iS_zLHH8ANuCOvi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; width: 80%"><span style="-sec-ix-redline: true">Balances, December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-redline: true">4,550,166</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_407_eus-gaap--SharesOutstanding_iS_zW2yvdRyeAgd" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true">Balance</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">4,550,166</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_z2wlaGxg9Xb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Preferred Stock to Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">7,057,797</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_40C_ecustom--StockIssuedDuringPeriodSharesConvertibleNotesToCommonStock_zJwjfDx64uRl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Convertible Notes to Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">6,177,229</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodSharesStockOptionsToCommonStock_z3uhYW1PO4Ql" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Stock Options to Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">612,670</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_404_ecustom--StockIssuedDuringPeriodSharesConvertingOfWarrantsToCommonStock_z3UmWOkuvHcd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Converting of Warrants to Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">3,859,464</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodSharesOther_zuvjfYqYrP3e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Private OneMedNet to ONMD Public Shares</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">(2,257,326</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr> <tr id="xdx_407_ecustom--StockIssuedDuringPeriodSharesConvertingDataKnightsCommonShares_zO0iuFy9if3i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Converting Data Knights Common Stock (A and B) to ONMD Public Shares</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">3,460,275</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_z2eiIknVjv5e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Issuance Public Shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">111,957</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_408_eus-gaap--SharesOutstanding_iE_zyOXDTAsVnxi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true">Balances, December 31, 2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">23,572,232</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr id="xdx_400_eus-gaap--SharesOutstanding_iE_zOLEX9Io8sth" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true">Balance</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true">23,572,232</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> </table> 4550166 4550166 7057797 6177229 612670 3859464 -2257326 3460275 111957 23572232 23572232 <p id="xdx_806_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zAjaUuhHpcC9" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10. <span id="xdx_828_zssYNJtF6ti3">Stock Options</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2020, the Company adopted a new equity incentive plan (the Plan), which provides for the granting of incentive and nonqualified stock options to employees, directors, and consultants. As of December 31, 2020, the Company has reserved <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200101__20201231__srt--TitleOfIndividualAxis__custom--EmployeesDirectorsAndConsultantsMember__us-gaap--PlanNameAxis__custom--NewEquityIncentivePlanMember_zOPY3Epoom39">3,000,000 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock under the Plan. The Company believes that such awards better align the interests of its employees with those of its stockholders. Option awards are generally granted with an exercise price equal to the fair market value of the Company’s stock at the date of grant; those option awards generally vest with a range of one </span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20200101__20201231__srt--TitleOfIndividualAxis__custom--EmployeesDirectorsAndConsultantsMember__us-gaap--PlanNameAxis__custom--NewEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zana3dh21Z82">four years</span></span></span> <span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of continuous service and have ten-year contractual terms. As there is no public data available for the share price valuation, the Company considers the Fair Market Value of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20201231__srt--TitleOfIndividualAxis__custom--EmployeesDirectorsAndConsultantsMember__us-gaap--PlanNameAxis__custom--NewEquityIncentivePlanMember_zuowjumEyy9k">1 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to be on the conservative side and similar to the exercise price. Certain option awards provide for accelerated vesting if there is a change in control, as defined in the Plan. The Plan also permits the granting of restricted stock and other stock-based awards. Unexercised options are cancelled upon termination of employment and become available under the Plan.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zOOwKvbrQpb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information with respect to options outstanding is summarized as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_8B8_zQRZFYMZHvh1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of Options Outstanding</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Options Outstanding</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Weighted- Average Exercise Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Aggregate Intrinsic Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 52%"><span style="-sec-ix-redline: true">Outstanding as of December 31, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zadM3myKcRSg" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Options outstanding, begining balance"><span style="-sec-ix-redline: true">1,995,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zP106pErband" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price, begining balance"><span style="-sec-ix-redline: true">1.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20210101__20211231_z121yn1pvKH9" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Aggregate Intrinsic value, begining balance"><span style="-sec-ix-redline: true">1,995,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Granted - under the Plan</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zXHo6mISQpKb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Granted - under the Plan"><span style="-sec-ix-redline: true">25,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231_zyywVTg5nGIa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Granted - under the Plan"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0917">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210101__20211231_zSn9l0NAWEk4" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, cancelled"><span style="-sec-ix-redline: true">(1,072,816</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true">Outstanding as of December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zaCQmCo4rgci" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options outstanding, ending balance"><span style="-sec-ix-redline: true">947,184</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_zXDcIpQgUsAi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, ending balance"><span style="-sec-ix-redline: true">1.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20210101__20211231_zhXfMFmK7TH1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic value, ending balance"><span style="-sec-ix-redline: true">947,184</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Granted - under the Plan</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_z3d4RVyP48Li" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Granted - under the Plan"><span style="-sec-ix-redline: true">577,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220101__20221231_z3Cg4GHDeiCb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Granted - under the Plan"><span style="-sec-ix-redline: true">(7,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220101__20221231_z6qJl1wVmuyk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, cancelled"><span style="-sec-ix-redline: true">(485,684</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true">Outstanding as of December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zS1IVj8CRw3j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options outstanding, ending balance"><span style="-sec-ix-redline: true">1,031,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zX1i6YPg8JM9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, ending balance"><span style="-sec-ix-redline: true">1.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20220101__20221231_zM05DsMkmdHa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic value, ending balance"><span style="-sec-ix-redline: true">1,031,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Options exercisable as of December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_ztwl4L855yl8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options exercisable"><span style="-sec-ix-redline: true">567,581</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231_zYrTENj4cnQg" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercisable"><span style="-sec-ix-redline: true">1.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20220101__20221231_zj3Qf8Lulmh7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic value, exercisable"><span style="-sec-ix-redline: true">567,581</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> </table> <p id="xdx_8A8_z8EfnFrKpN6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and 2021, there were <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231_zCusyY0Eadkf">1,031,000 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231_z60y0LjYvs75">947,184 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">common stock options outstanding with a weighted average remaining contractual life of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zTZjpFpO9Ie2">7.11 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years and <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zCiL8vS0y486">6.01 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years, respectively.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and 2021, there were <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20221231_zQD82gnRuEM2">567,581 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20211231_zX6RDBNpqYZi">723,431 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">common stock options exercisable at a weighted average remaining contractual life of <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zCQqssRftxz1">5.56 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years and <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_zoakaW2uUSNa">5.27 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years, respectively.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 7, 2023, the Company issued shares of common stock for <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20231107_zC2U5iJKuiKl">692,153 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vested options less an exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_c20231107_zIYsl5WuH4K1">1.00</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">At the Special Meeting </span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">held on October 17, 2023<span style="background-color: white">, Data Knights shareholders considered and approved the OneMedNet Corporation 2022 Equity Incentive Plan (the “Plan”) and reserved an amount of shares of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_pid_c20231017__20231017_zIGkitfX4Hnb">common stock equal to 10% of the number of shares of common stock of OneMedNet following the Business Combination for issuance thereunder</span></span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">. The Plan was approved by the OneMedNet pre-Closing board of directors on October 17, 2023. The Plan became effective immediately upon the Closing of the Business Combination.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Black Scholes Assumptions</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The determination of the fair value of stock options using an option valuation model is affected by the Company’s stock price valuation, as well as assumptions regarding a number of complex and subjective variables. The volatility assumption is based on volatilities of similar companies over a period of time equal to the expected term of the stock options. The volatilities of similar companies are used in conjunction with the Company’s historical volatility because of the lack of sufficient relevant history for the Company’s common stock equal to the expected term. The expected term of the employee stock options represents the weighted average period for which the stock options are expected to remain outstanding. The expected term assumption is estimated based primarily on the options’ vesting terms and remaining contractual life and employees’ expected exercise and post- vesting employment termination behavior. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The dividend yield assumption is based on the expectation of no future dividend payouts by the Company.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_898_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zay0AEYnB9Ej" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the Company’s previous stock options was estimated assuming no expected dividends and the following weighted average assumptions:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span id="xdx_8B6_zJo0ngyYGTwc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of Fair Value of Stock Options</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="-sec-ix-redline: true">Expected life in years</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-redline: true"><span id="xdx_901_ecustom--EquitySecuritiesFvNiMeasurementTerm_dtY_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zoolrrCQTN9h">5.89</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-redline: true"><span id="xdx_905_ecustom--EquitySecuritiesFvNiMeasurementTerm_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zyneyj3ZuwJ">6.08</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Risk-free interest rate</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span id="xdx_907_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z9y58LCpnxXh">0.55</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span id="xdx_90C_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zWq5I7FYdBS2">0.49</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Expected dividend yield</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span id="xdx_900_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z69uRpV0a13b">0.00</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span id="xdx_90A_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z4ohD9teCjj4">0.00</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Expected volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span id="xdx_90D_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zY9O0q7FP8Pk">32</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span id="xdx_902_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zSQ9xugXtAYb">60</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr> </table> <p id="xdx_8AF_zPAh7czH2RHd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total expense recognized for share-based payments was $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231_zs5NCE7xjYwb">45,584 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231_zh4A4jq44eFh">47,071 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the years ended December 31, 2022 and 2021, respectively. These costs are included in the statements of operations. As of December 31, 2022, there was $<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20221231_z0GkDmV9WgF7">75,987 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of unrecognized compensation costs related to stock option grants which will be recognized over the next four years.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2023, the Company issued common stock to employees and extinguished all outstanding stock options. The <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyhahePb5iy">612,720 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares outstanding were recorded as stock expense in the Consolidated Statement of Operations.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></span></p> 3000000 P4Y 1 <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zOOwKvbrQpb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information with respect to options outstanding is summarized as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_8B8_zQRZFYMZHvh1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of Options Outstanding</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Options Outstanding</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Weighted- Average Exercise Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Aggregate Intrinsic Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 52%"><span style="-sec-ix-redline: true">Outstanding as of December 31, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zadM3myKcRSg" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Options outstanding, begining balance"><span style="-sec-ix-redline: true">1,995,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zP106pErband" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price, begining balance"><span style="-sec-ix-redline: true">1.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20210101__20211231_z121yn1pvKH9" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Aggregate Intrinsic value, begining balance"><span style="-sec-ix-redline: true">1,995,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Granted - under the Plan</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zXHo6mISQpKb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Granted - under the Plan"><span style="-sec-ix-redline: true">25,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231_zyywVTg5nGIa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Granted - under the Plan"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0917">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210101__20211231_zSn9l0NAWEk4" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, cancelled"><span style="-sec-ix-redline: true">(1,072,816</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true">Outstanding as of December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zaCQmCo4rgci" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options outstanding, ending balance"><span style="-sec-ix-redline: true">947,184</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_zXDcIpQgUsAi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, ending balance"><span style="-sec-ix-redline: true">1.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20210101__20211231_zhXfMFmK7TH1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic value, ending balance"><span style="-sec-ix-redline: true">947,184</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Granted - under the Plan</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_z3d4RVyP48Li" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Granted - under the Plan"><span style="-sec-ix-redline: true">577,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220101__20221231_z3Cg4GHDeiCb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Granted - under the Plan"><span style="-sec-ix-redline: true">(7,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220101__20221231_z6qJl1wVmuyk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, cancelled"><span style="-sec-ix-redline: true">(485,684</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true">Outstanding as of December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zS1IVj8CRw3j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options outstanding, ending balance"><span style="-sec-ix-redline: true">1,031,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zX1i6YPg8JM9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, ending balance"><span style="-sec-ix-redline: true">1.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20220101__20221231_zM05DsMkmdHa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic value, ending balance"><span style="-sec-ix-redline: true">1,031,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Options exercisable as of December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_ztwl4L855yl8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options exercisable"><span style="-sec-ix-redline: true">567,581</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231_zYrTENj4cnQg" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercisable"><span style="-sec-ix-redline: true">1.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20220101__20221231_zj3Qf8Lulmh7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic value, exercisable"><span style="-sec-ix-redline: true">567,581</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> </table> 1995000 1.00 1995000 25000 1072816 947184 1.00 947184 577000 7500 485684 1031000 1.00 1031000 567581 1.00 567581 1031000 947184 P7Y1M9D P6Y3D 567581 723431 P5Y6M21D P5Y3M7D 692153 1.00 common stock equal to 10% of the number of shares of common stock of OneMedNet following the Business Combination for issuance thereunder <p id="xdx_898_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zay0AEYnB9Ej" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the Company’s previous stock options was estimated assuming no expected dividends and the following weighted average assumptions:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span id="xdx_8B6_zJo0ngyYGTwc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of Fair Value of Stock Options</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="-sec-ix-redline: true">Expected life in years</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-redline: true"><span id="xdx_901_ecustom--EquitySecuritiesFvNiMeasurementTerm_dtY_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zoolrrCQTN9h">5.89</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-redline: true"><span id="xdx_905_ecustom--EquitySecuritiesFvNiMeasurementTerm_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zyneyj3ZuwJ">6.08</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Risk-free interest rate</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span id="xdx_907_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z9y58LCpnxXh">0.55</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span id="xdx_90C_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zWq5I7FYdBS2">0.49</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Expected dividend yield</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span id="xdx_900_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z69uRpV0a13b">0.00</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span id="xdx_90A_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z4ohD9teCjj4">0.00</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Expected volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span id="xdx_90D_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zY9O0q7FP8Pk">32</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"><span id="xdx_902_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zSQ9xugXtAYb">60</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr> </table> P5Y10M20D P6Y29D 0.55 0.49 0.00 0.00 32 60 45584 47071 75987 612720 <p id="xdx_806_ecustom--StockWarrantsDisclosureTextBlock_z8PGkPv4zKwa" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11. <span id="xdx_82B_zW0uKdrIgtgh">Stock Warrants</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2021, there were <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211231_zVMpckQCE4Bf">174,102 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OneMedNet Corporation outstanding common stock warrants issued for service at a weighted average exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231_zc6DmaF0LKM7">0.10</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. In 2022 for the exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231_zgf5jJhyAZkb">1.00</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, the OneMedNet Corporation issued <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--AwardTypeAxis__custom--TwentyTwentyOneServiceMember_zx0H5C9JD5ok">145,746 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants for 2021 service and <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--AwardTypeAxis__custom--TwentyTwentyTwoServiceMember_zF9lMoCrpHyc">294,000 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants for 2022 service, <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ConvertiableNotesMember_zo7PsnZa1bXl">2,056,000 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in warrants were issued attached to convertible notes. The Company expensed $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfWarrants_c20220101__20221231_ziimEIM50841">1,346,288</span></span></span> <span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in 2022 in relation to the issuance of the Warrants. In 2023 for the exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231_zwObMnOHBCT1">1.00</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, the OneMedNet issued <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ConvertiableNotesMember_zbfmaPMF2PY9">1,670,000 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in warrants attached to convertible notes. OneMedNet Corporation converted <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zYX8MxovCp9d">4,165,746 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants outstanding to common stock at an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zDVAXmd1vmK9">1.00 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and converted <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zy008UtCDFD9">174,102 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants outstanding to common stock at an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGTMTgjKR4f3">0.10</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and December 31, 2022, the Company had <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--PubliclyTradedWarrantsMember_zlBN1dUU6NMh">11,500,000 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of publicly traded warrants. The warrants trade on the Nasdaq had closing price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PubliclyTradedWarrantsMember_zYDKyHofnc49">.0149 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--PubliclyTradedWarrantsMember_z3715RMmux9c">.0400 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at December 31, 2023 and December 31, 2022 respectively.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and December 31, 2022, the Company had <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsMember_zGRZgpppUqL1">681,019 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsMember_zoyczQ9iZHv2">585,275 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of private warrants outstanding. These warrants are classified as liability on the Consolidated Balance Sheet. Changes in the warrant liabilities are recorded in the Statement of Operations. As of December 31, 2023 and December 31, 2022, the warrant liabilities were $<span id="xdx_907_eus-gaap--OtherLiabilities_iI_pn5n6_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_ztu26qdbHEN6">0.6 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_906_eus-gaap--OtherLiabilities_iI_pn5n6_c20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z5jxlvTWlcW8">0.4 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">respectively.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> 174102 0.10 1.00 145746 294000 2056000 1346288 1.00 1670000 4165746 1.00 174102 0.10 11500000 0.0149 0.0400 681019 585275 600000 400000 <p id="xdx_803_eus-gaap--FairValueDisclosuresTextBlock_zR5YrFIBCSuh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12. <span id="xdx_829_zGhU1cTHD9La">Fair Value Measures</span></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value measurement accounting standards establish a framework for measuring fair value and expand disclosures about fair value measurements. The standard does not require any new fair value measurements; rather, it applies to other accounting pronouncements that require or permit fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. This pronouncement also establishes a three-level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three levels are defined as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1—inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2—inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model-derived valuations in which all significant inputs are observable for substantially the full term of the asset or liability</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3—inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_89F_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zF46BGIp4EFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the Company’s financial assets measured and recorded at fair value on a recurring basis using the above input categories as of December 31, 2023 and December 31, 2022 (in thousands):</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_8BF_zdP5BhYaW47c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of Financial Assets</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="30" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Year Ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true"><b>December 31, 2023</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true"><b>December 31, 2022</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Level 1</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Level 2</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Level 3</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Level 1</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Level 2</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Level 3</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Assets:</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: left"><span style="-sec-ix-redline: true">Investments held in Trust</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_985_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zEQFhQkyIfN" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0996">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98D_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zLZI52abmujj" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0998">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98C_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zoUYLwzbPZ09" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1000">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_983_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zXBMFEw6Jxej" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1002">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98D_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zvIGgDiejqOl" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"><span style="-sec-ix-redline: true">29,029,416</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_980_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zcCKPwhX93uc" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1006">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98F_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zvXhmGsmuOr7" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1008">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_981_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zrAoAx5qHUz5" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"><span style="-sec-ix-redline: true">29,029,416</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Total Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_987_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zmIvjjLwQdvj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1012">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98A_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zVtsygBqkh22" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1014">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98F_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUnskt8YvWJ7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1016">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98B_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zYdjoewzQqGk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1018">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98A_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJDtEWqItAIb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"><span style="-sec-ix-redline: true">29,029,416</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98A_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWmgRXu5v5Aj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1022">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98C_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zMRKEoTtJrC9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1024">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_986_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ziDpKsUYsNjf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"><span style="-sec-ix-redline: true">29,029,416</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p id="xdx_89F_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zF46BGIp4EFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the Company’s financial assets measured and recorded at fair value on a recurring basis using the above input categories as of December 31, 2023 and December 31, 2022 (in thousands):</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_8BF_zdP5BhYaW47c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of Financial Assets</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="30" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Year Ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true"><b>December 31, 2023</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true"><b>December 31, 2022</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Level 1</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Level 2</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Level 3</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Level 1</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Level 2</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Level 3</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline: true">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true">Assets:</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: left"><span style="-sec-ix-redline: true">Investments held in Trust</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_985_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zEQFhQkyIfN" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0996">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98D_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zLZI52abmujj" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0998">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98C_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zoUYLwzbPZ09" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1000">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_983_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zXBMFEw6Jxej" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1002">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98D_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zvIGgDiejqOl" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"><span style="-sec-ix-redline: true">29,029,416</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_980_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zcCKPwhX93uc" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1006">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98F_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zvXhmGsmuOr7" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1008">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_981_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--InvestmentsHeldInTrustMember_zrAoAx5qHUz5" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right" title="Investments held in Trust"><span style="-sec-ix-redline: true">29,029,416</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-sec-ix-redline: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">Total Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_987_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zmIvjjLwQdvj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1012">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98A_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zVtsygBqkh22" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1014">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98F_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUnskt8YvWJ7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1016">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98B_eus-gaap--AssetsHeldInTrustCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zYdjoewzQqGk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1018">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98A_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJDtEWqItAIb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"><span style="-sec-ix-redline: true">29,029,416</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98A_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWmgRXu5v5Aj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1022">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98C_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zMRKEoTtJrC9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1024">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline: true"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_986_eus-gaap--AssetsHeldInTrustCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ziDpKsUYsNjf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets measured and recorded fair value"><span style="-sec-ix-redline: true">29,029,416</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-redline: true"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> 29029416 29029416 29029416 29029416 <p id="xdx_805_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zVfbIOnskmzk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13. <span id="xdx_829_z8h35XY0FX7d">Related Party Transactions</span></b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Loan Extensions</i></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data Knights closed its initial public offering in May 2021 and had 12 months to complete a business combination. Alternatively, the Data Knight could extend the period up to two times for an additional three months each time with an extension costing $<span id="xdx_908_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20231231__us-gaap--BusinessAcquisitionAxis__custom--DataKnightsAcquisitionCorpMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z0CG6fi9Tq7i">1.2 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. Data Knights received a total of $<span id="xdx_90D_ecustom--ExtensionLoan_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--ManagementAndDirectorsMember_zA1fifUXV765">300,000 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from members of the Company’s Management and Directors. As of December 31, 2023 and December 31, 2022 the total extension loan including interest outstanding was $<span id="xdx_905_ecustom--ExtensionLoan_iI_pn5n6_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zO7QOwXdAHNg">3.0 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_90C_ecustom--ExtensionLoan_iI_pn5n6_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zn10KaDPlSY">2.5 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, respectively.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>PIPE Convertible Notes and Warrants</i></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the Company entered into a Securities Purchase Agreement (SPA) in which the Company was required to sell senior secured convertible notes and warrants to Directors of the Company. The SPA stipulates a collateral security agreement between the Company and the Directors for punctual payment and performance by the Company on its Obligations to the Directors. The Intellectual Property of the Company serves as the collateral for the Directors. The senior secured convertible notes and warrants were issued through a private issuance of a public entity (PIPE) transaction, which is a form of debt and equity offering under an exception in the securities law for qualifying private placements by issuers of publicly traded securities. The Company received a total of $<span id="xdx_909_eus-gaap--ProceedsFromConvertibleDebt_pn5n6_c20231101__20231130__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zHfl035q52V8">1.5 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million from the director in exchange for senior convertible notes of $<span id="xdx_901_eus-gaap--ProceedsFromConvertibleDebt_pn5n6_c20231101__20231130__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleNotesMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zBMVzI03gT53">1.6 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million (plus accrued interest of $<span id="xdx_902_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn5n6_c20231130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zWkuosgJLyol">0.1 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million) and <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20231101__20231130__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3r0Tli7e5mb">95,745 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants to acquire common stock. <span id="xdx_909_eus-gaap--DebtInstrumentDescription_c20231101__20231130__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z4uH06NxL485">The senior secured notes are convertible to the conversion rate of $</span></span></span><span style="-sec-ix-redline: true"><span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20231130__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zo5virPJQB77" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.00 </span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, and 92.5% of the lowest VWAP for the ten (10) trading days immediately preceding the conversion Date, subject to the floor price of $1.14 (representing 20% of the closing price on the last trading day before the closing of the Business Combination), or the alternative conversion ratio the greater of the floor price and the lesser of 80% of the VWAP of the common stock as of the trading day and 80% of the price computed as the quotient of the sum of the VWAP of the Common Stock for each of the three Trading Days with the lowest VWAP of the Common Stock during the fifteen consecutive trading day period ending and including the trading day immediately preceding the delivery or deemed delivery of the applicable Conversion Notice, divided by three</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification or similar transaction that proportionately decreases or increases the common stock.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The warrants are classified as equity and the total proceeds received from the Directors are allocated based on the relative fair values of the convertible notes and the warrants at the issued date. The portion allocable to warrants is accounted for as paid-in capital. The senior secured convertible notes are classified as long term debt in the Consolidated Balance Sheet. The estimate fair value of the senior secured convertible notes at December 31, 2023 was $<span id="xdx_90A_eus-gaap--SeniorNotesCurrent_iI_pn5n6_c20231231_z2qCGfNbO6v4">1.2 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> 1200000 300000 3000000.0 2500000 1500000 1600000 100000 95745 The senior secured notes are convertible to the conversion rate of $ 10.00 1200000 <p id="xdx_808_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zwxSvY1JlXvj" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14. <span id="xdx_826_zgUaC2z4h9U3">Commitments, Contingencies, and Concentrations Operating lease</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has a month-to-month lease for a suite at a cost of $<span id="xdx_905_eus-gaap--OperatingLeaseCost_c20230101__20231231_zPWRhci46SQk">575 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per month. The Company incurred $<span id="xdx_908_eus-gaap--OperatingLeasesRentExpenseNet_c20230101__20231231_zin38NTu1i35">7,695 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_909_eus-gaap--OperatingLeasesRentExpenseNet_c20220101__20221231_zCwDNKWtXxr1">7,694 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of rent expense, including common tenant costs and cancellation costs, during the years ended December 31, 2023 and 2022, respectively.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> 575 7695 7694 <p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_zJvyAX1Zop84" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15. <span id="xdx_82C_zUZBTByM5AI1">Subsequent Events</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has evaluated subsequent events occurring through April 9, 2024, the date the financial statements were available for issuance, for events requiring recording or disclosure in the Company’s financial statements.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2024, through to the date of this report, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember__dei--LegalEntityAxis__custom--EFHuttonMember_zaAfsIKOPiMl">256,944 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember__dei--LegalEntityAxis__custom--KingwoodCapitalPartnersLLCMember_zuM3Moi0ltog">20,834 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock to EF Hutton LLC and Kingwood Capital Partners, LLC, respectively, as consideration for $<span id="xdx_903_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zuOa4HNu8XSg">3.0 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million owed by the Company for underwriting commission due at the closing of the Business Combination.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2024, through to the date of this report, the Company bought back <span id="xdx_907_eus-gaap--StockRepurchasedDuringPeriodShares_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zotKVRYt0Kbh">187,745 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock from a convertible note holder.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2024, through to the date of this report, the Company received $<span id="xdx_902_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20240101__20241231__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--MajorityShareholderMember_z3LcYbfqQwm3">1,000,000 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from a majority shareholder for the purchase of shares, and an additional $<span id="xdx_90A_eus-gaap--ProceedsFromRelatedPartyDebt_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zz1aR5stuiD7">300,000 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">treated as a shareholder loan.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2024, through to the date of this report, the Company entered into a definitive securities purchase agreement with an institutional investor providing up to $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn4n6_c20240101__20241231__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z10C4pdnNwd9">4.54 </span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million in funding through a private placement for the issuance of senior convertible notes.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true">As previously announced on Form 8-K, on March 28, 2024, OneMedNet Corporation (the “Company”) <span style="background-color: white">entered into a definitive securities purchase agreement (the “Securities Purchase Agreement”) with Helena Global Investment Opportunities 1 Ltd., an affiliate of Helena Partners Inc., a Cayman-Islands based advisor and investor providing for up to USD$</span>4.54 million <span style="background-color: white">in funding through a private placement for the issuance of senior secured convertible notes (the “Notes”).</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true">As previously announced on Form 8-K, on March 27, 2024, Paul J. Casey, Chief, Chief Executive Officer of the Company, notified the Company of his intention to retire as Chief Executive Officer of the Company effective March 29, 2024. Mr. Casey will continue to serve as a member of the Board of Directors (the “Board”) of the Company. In connection with Mr. Casey’s service on the Advisory Board of the Company, the Board approved a Stock Option Grant (the “Option Grant”) providing for the grant of <span id="xdx_901_eus-gaap--StockRepurchasedDuringPeriodShares_c20240326__20240327__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zuUqsqqUT0Ph">147,000 </span></span><span style="-sec-ix-redline: true">five-year options exercisable at $<span id="xdx_90A_eus-gaap--SharePrice_iI_c20240327__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zm1HBlB7Oone">1.00 </span></span><span style="-sec-ix-redline: true">per share adviser to Mr. Casey. Also on March 27, 2024, Scott Holbrook, a member of the Board of the Company and a member of the Company’s Audit Committee, notified the Company of his intention to retire from the Company’s Board effective March 29, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-sec-ix-redline: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true">Effective March 29, 2024, the Board (i) appointed Mr. Aaron Green, to serve as Chief Executive Officer of the Company to fill the vacancy created by the retirement of Paul Casey; (ii) appointed Mr. Aaron Green, to serve as a member of the Board to fill the vacancy created by the retirement of Scott Holbrook; and (iii) appointed Board member, Dr. Thomas Kosasa, to serve on the Company’s Audit Committee, also to fill the vacancy created by the retirement of Scott Holbrook.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> 256944 20834 3000000.0 187745 1000000 300000 4540000 147000 1.00 Loss per share information has not been presented for periods prior to the Business Combination (as defined in Note 3, Business Combination), as it resulted in values that would not be meaningful to the users of these consolidated financial statements. Refer to Note 3, Business Combination for further information. This has been indicated on these statements of operations as “N/M”. XML 94 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover
12 Months Ended
Dec. 31, 2023
Entity Addresses [Line Items]  
Document Type S-1/A
Amendment Flag true
Amendment Description Amendment No. 1
Entity Registrant Name ONEMEDNET CORPORATION
Entity Central Index Key 0001849380
Entity Tax Identification Number 86-2049355
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 6385 Old Shady Oak Road
Entity Address, Address Line Two Suite 250
Entity Address, City or Town Eden Prairie
Entity Address, State or Province MN
Entity Address, Postal Zip Code 55344
City Area Code 800
Local Phone Number 918-7189
Entity Filer Category Non-accelerated Filer
Entity Small Business true
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Business Contact [Member]  
Entity Addresses [Line Items]  
Entity Address, Address Line One 1990 K. Street
Entity Address, Address Line Two NW, Suite 420
Entity Address, Address Line Three Washington
Entity Address, State or Province DC
Entity Address, Postal Zip Code 20006
City Area Code (202)
Local Phone Number 935-3390
Contact Personnel Name Debbie A. Klis, Esq.
XML 95 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Current Assets    
Cash and cash equivalents $ 47,008 $ 301,730
Investments held in Trust 29,029,415
Accounts receivable, net of allowance 151,640 18,975
Prepaid expenses and other assets 165,538 100,945
Receivable from SPAC   900,152
Total current assets 364,186 30,351,217
Property and Equipment, Net 98,871 83,097
Total assets 463,057 30,434,314
Current Liabilities    
Accounts payable & accrued expenses 4,184,398 2,814,570
Loan Amount due to related parties 11,200 11,500
Excise tax 113,353
Loan Extensions 2,991,679
Deferred revenues 253,997 183,683
Loan Payable 38,921
Convertible promissory notes 8,490,000
Canada Emergency Business Loan Act 44,673
Income tax payable 120,017 214,850
Franchise tax payable 69,966
Pipe Notes, net of discount including interest 1,549,820
Deferred underwriter fee payable 3,525,000
Total current liabilities 12,833,058 11,784,569
Long Term Liabilities    
Convertible promissory note   1,500,000
Canada Emergency Business Loan Act   44,144
Accrued interest   690,772
Warrant liabilities 24,582 362,558
Deferred underwriter fee payable 4,025,000
Working capital Loan 207,081
Extension loans 2,545,839
Total liabilities 13,322,663 21,159,963
Stockholders’ Equity (Deficit)    
Common stock value 2,357 455
Commitments and contingencies 28,750,110
Additional paid in capital 42,220,714 24,032,561
Accumulated deficit (55,082,677) (43,509,964)
Total stockholders’ equity (deficit) (12,859,606) 9,274,351
Total liabilities and stockholders’ equity (deficit) 463,057 30,434,314
Series A-2 Preferred Stock [Member]    
Stockholders’ Equity (Deficit)    
Preferred value 385
Series A-1 Preferred Stock [Member]    
Stockholders’ Equity (Deficit)    
Preferred value 320
Common Class A [Member]    
Stockholders’ Equity (Deficit)    
Common stock value 59
Common Class A One [Member]    
Stockholders’ Equity (Deficit)    
Common stock value 425
Related Party [Member]    
Long Term Liabilities    
Loan, related party of OMN $ 465,023
XML 96 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2023
Dec. 31, 2022
Common Stock, Par or Stated Value Per Share   $ 0.0001
Common Stock, Shares Authorized   30,000,000
Common Stock, Shares, Outstanding 23,572,232 4,550,166
Series A-2 Preferred Stock [Member]    
Preferred Stock, Par or Stated Value Per Share   $ 0.0001
Preferred Stock, Shares Authorized   4,200,000
Preferred Stock, Shares Outstanding 0 3,853,797
Series A-1 Preferred Stock [Member]    
Preferred Stock, Par or Stated Value Per Share   $ 0.0001
Preferred Stock, Shares Authorized   4,400,000
Preferred Stock, Shares Outstanding 0 3,204,000
Common Class A [Member]    
Common Stock, Par or Stated Value Per Share   $ 0.0001
Common Stock, Shares Authorized   4,200,000
Common Stock, Shares, Outstanding 0 3,853,797
Common Class A One [Member]    
Common Stock, Par or Stated Value Per Share   $ 0.0001
Common Stock, Shares Authorized   4,200,000
Common Stock, Shares, Outstanding 0 3,853,797
XML 97 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]    
Revenue $ 1,021,651 $ 1,152,738
Cost of Revenue 1,149,551 1,513,428
Gross Margin (127,900) (360,690)
Operating Expenses    
General and administrative 5,273,503 8,755,620
Operations 226,257 398,760
Sales & Marketing 1,114,977 957,690
Research and development 1,631,613 952,701
Total Operating Expenses 8,246,350 11,064,771
Operating loss (8,374,250) (11,425,461)
Other Expense (income)    
Impairment 10,504,327  
Income tax provision 214,850
Interest expense 749,213 403,307
Other expense 52,256 46,820
Change in FV of Warrants (46,822) (4,489,110)
Stock Expense 3,572,232  
Unrealized gain or loss (1,371,689)
Other Expense (income) 14,831,206 (5,195,822)
Net loss $ (23,205,456) $ (6,229,639)
Loss per share of Common Stock:(1)    
Earnings Per Share, Diluted [1] $ (0.98)  
Weighted-average shares of Common Stock outstanding:    
Weighted Average Number of Shares Outstanding, Diluted 23,572,232  
[1] Loss per share information has not been presented for periods prior to the Business Combination (as defined in Note 3, Business Combination), as it resulted in values that would not be meaningful to the users of these consolidated financial statements. Refer to Note 3, Business Combination for further information. This has been indicated on these statements of operations as “N/M”.
XML 98 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Stockholders Equity (Deficit) - USD ($)
Preferred Stock [Member]
Series A-2 Preferred Stock [Member]
Preferred Stock [Member]
Series A-1 Preferred Stock [Member]
Common Stock [Member]
Common Class A [Member]
Data Knights Acquisition Corp [Member]
Common Stock [Member]
Common Class A [Member]
Common Stock [Member]
Common Class B [Member]
Data Knights Acquisition Corp [Member]
Commitment [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance at Dec. 31, 2021 $ 385 $ 320 $ 59 $ 434 $ 288 $ 28,750,110 $ 19,607,173 $ (33,920,734) $ 14,438,035
Beginning balance, shares at Dec. 31, 2021 3,853,797 3,204,000 585,275 4,342,666 2,875,000        
Issuance of common shares in exchange for services       $ 20   199,980   200,000
Issuance of common shares in exchange for services, share       200,000          
Issuance Public Shares       $ 1   7,499   7,500
Issuance public shares, share       7,500          
Issuance of Data Knights Acquisition Corp. Class B Common Stock         $ 137 2,825,823   2,825,960
Issuance of common class B stock, shares         1,378,517        
Common stock redemption             (3,359,591) (3,359,591)
Stock-based compensation expense           1,392,086   1,392,086
Net loss     (6,229,639) (6,229,639)
Ending Balance at Dec. 31, 2022 $ 385 $ 320 $ 59 $ 455 $ 425 28,750,110 24,032,561 (43,509,964) 9,274,351
Ending balance, shares at Dec. 31, 2022 3,853,797 3,204,000 585,275 4,550,166 4,253,517        
Issuance Public Shares       $ 11   111,946   111,957
Issuance public shares, share       111,957          
Common stock redemption           (28,750,110)     (28,750,110)
Stock-based compensation expense             1,892,741   1,892,741
Net loss         (23,205,456) (23,205,456)
Preferred Stock to Common Stock $ (385) $ (320)   $ 706   7,057,091   7,057,092
Preferred stock to common stock, shares (3,853,797) (3,204,000)   7,057,797          
Convertible Notes to Common Stock       $ 618   6,176,611   6,177,229
Convertible notes to common stock, shares       6,177,229          
Stock Options to Common Stock       $ 61   612,609   612,670
Stock issued during period shares options to common stock       612,670          
Converting of Warrants to Common Stock       $ 386   3,859,078   3,859,464
Converting of warrants to common stock, shares       3,859,464          
Private OneMedNet to ONMD Public Shares       $ (226)   (2,257,100)   (2,257,326)
Stock issued during period shares other       (2,257,326)          
Issuance of PIPE Warrants           101,071   101,071
Converting Data Knights Common Shares (A and B) to ONMD Public Shares     $ (59) $ 346 $ (425) 634,106   633,968
Converting Data Knights Common Shares (A and B) to ONMD Public Shares, shares     (585,275) 3,460,275 (4,253,517)        
Retained earnings adjustment             11,632,743 11,632,743
Ending Balance at Dec. 31, 2023 $ 0 $ 0 $ 0 $ 2,357 $ 0 $ 0 $ 42,220,714 $ (55,082,677) $ (12,859,606)
Ending balance, shares at Dec. 31, 2023 0 0 0 23,572,232 0        
XML 99 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Stockholders Equity (Deficit) (Parenthetical)
Dec. 31, 2022
$ / shares
Statement of Stockholders' Equity [Abstract]  
Share Price $ 1.00
XML 100 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash flow from Operating Activities    
Net Loss $ (23,205,456) $ (6,229,639)
Adjustments to reconcile net loss to net cash flows from operating activities:    
Depreciation and amortization 27,983 24,807
Business combination cost 900,152
Stock-based compensation expense 1,599,586
Cash Held in Trust Account 29,029,416 88,291,558
Prepaid Expenses (64,594)  
Other current assets (875,803)
Accounts payable and accrued Expenses 1,369,825 1,929,787
Accounts receivable, net of allowance (132,665) 72,767
Deferred Revenue & Customer Deposits 70,314 (458,667)
Amount due to related party (300) 11,500
Exercise tax liability 113,353  
Extension loan 445,840 2,545,838
Franchise tax payable (69,966) (94,043)
Income Tax Payable (94,833) 214,850
Working capital loan (168,159) 207,081
Net cash flows used in operating activities 8,220,910 87,239,622
Cash used for Investing Activities    
Purchase of property and equipment (43,757) (58,137)
Cash flow from Financing Activities    
Class B Common Stock 137
Proceeds (repayment) from issuance of convertible promissory note payable (10,680,772) 5,543,162
Proceeds from issuance of PIPE Convertible Notes and Warrants 1,549,820  
Proceed from related party loan 465,024
Proceeds from Canada Emergency Business Loan Act 529 (2,754)
Common Stock Subject to Redemption (28,750,109) (88,549,890)
Deferred underwriting fee (500,000)
Warrant liability (337,976) (4,489,110)
Additional Paid-in Capital 18,189,350 2,825,823
Class A Common Stock (59)
Class B Common Stock (425)
Retained Earnings adjustment 11,632,743 (3,359,594)
Net cash flows from financing activities (8,431,875) (88,032,226)
Net change in cash and cash equivalents (254,722) (850,741)
Cash and Cash Equivalents, Beginning 301,730 1,152,471
Cash and Cash Equivalents, Ending $ 47,008 $ 301,730
XML 101 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Organization and Operations
12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Organization and Operations

1. Organization and Operations

 

OneMedNet Corporation (the “Company”) is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. The Company was incorporated in Delaware on September 20, 2006. The Company has been solely focused on creating solutions that simplify digital medical image management, exchange, and sharing. The Company has one wholly-owned subsidiary, OneMedNet Technologies (Canada) Inc., incorporated on October 16, 2015 under the provisions of the Business Corporations Act of British Columbia whose functional currency is the Canadian dollar. The Company’s headquarters location is Eden Prairie, Minnesota.

 

On November 7, 2023, as contemplated by the Company, Data Knights Merger Sub, Inc., a Delaware corporation (“Merger Sub”), and Data Knights, LLC, the Merger Sub’s sponsor merged with and into OneMedNet Corporation, with OneMedNet Corporation surviving the merger. The Business Combination is further described in Note 3, Business Combination.

 

Data Knights Acquisition Corp Merger

 

On November 7, 2023, we consummated a merger (the “Merger”) following the approval at the special meeting of the shareholders of Data Knights Acquisition Corp., a Delaware corporation held on October 17, 2023 (the “Special Meeting”), Data Knights Merger Sub, Inc., a Delaware corporation (“Merger Sub”) and a wholly-owned subsidiary of Data Knights Acquisition Corp., a Delaware corporation (“Data Knights”), consummated a merger (the “Merger”) with and into OneMedNet Solutions Corporation (formerly named OneMedNet Corporation), a Delaware corporation (“OneMedNet”) pursuant to an agreement and plan of merger, dated as of April 25, 2022 (the “Merger Agreement”), by and among Data Knights, Merger Sub, OneMedNet, Data Knights, LLC, a Delaware limited liability company (“Sponsor” or “Purchaser Representative”) in its capacity as the representative of the stockholders of Data Knights, and Paul Casey in his capacity as the representative of the stockholders of OneMedNet (“Seller Representative”). Accordingly, the Merger Agreement was adopted, and the Merger and other transactions contemplated thereby (collectively, the “Business Combination”) were approved and completed.

 

The Business Combination was accounted for as a as a reverse recapitalization with OneMedNet as the accounting acquirer under the accounting principles generally accepted in the United States of America (“U.S. GAAP”). Accordingly, the financial statements of the combined company represent a continuation of the financial statements of OneMedNet.

 

On June 28, 2023, the Company and Data Knights entered into a Securities Purchase Agreement (the “SPA”) with certain investors (collectively referred to herein as the “Purchasers”) for PIPE financing in the aggregate original principal amount of $1,595,744.70 and the purchase price of $1.5 million. Pursuant to the Securities Purchase Agreement, Data Knights will issue and sell to each of the Purchasers, a new series of senior secured convertible notes (the “PIPE Notes”), which are convertible into shares of Common Stock at the Purchasers election at a conversion price equal to the lower of (i) $10.00 per share, and (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) Trading Days immediately preceding the Conversion Date. The Purchasers’ $1.5 million investment in the PIPE Notes closed and funded contemporaneous to the Closing of the Business Combination.

 

Effective immediately prior to the Closing, OneMedNet, Inc. issued the PIPE Notes to the Purchasers under the private offering exemptions under Securities Act of 1933, as amended (the “Securities Act”).

 

Risks and Uncertainties

 

The Company is subject to risks common to companies in the markets it serves, including, but not limited to, global economic and financial market conditions, fluctuations in customer demand, acceptance of new products, development by its competitors of new technological innovations, dependence on key personnel, and protection of proprietary technology.

 

As previously reported on Form 8-K on February 9, 2024, the Company received written notice (the “Nasdaq Notice”), dated February 7, 2024, from the Nasdaq Stock Market (“Nasdaq”) indicating that for the preceding 30 consecutive business days, the market value of the Company’s listed securities (“MVLS”) did not maintain a minimum market value of $50,000,000 (the “Minimum MVLS Requirement”) as required by Nasdaq Listing Rule 5450(b)(2)(A). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has a compliance period of 180 calendar days, or until August 5, 2024, to regain compliance with the Minimum MVLS Requirement. Compliance may be achieved if the Company’s MVLS closes at $50,000,000 or more for a minimum of ten consecutive business days at any time during the 180-day compliance period, in which case Nasdaq will notify the Company of its compliance and the matter will be closed.

 

If the Company does not regain compliance with the Minimum MVLS Requirement by August 5, 2024, Nasdaq will provide written notification to the Company that its common stock is subject to delisting. At that time, the Company may appeal the relevant delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. However, there can be no assurance, if the Company does appeal the delisting determination by Nasdaq to the hearings panel, that such appeal would be successful. In such event, the Company may also seek to apply for a transfer to The Nasdaq Global Market if it meets the requirements for continued listing thereon. The Nasdaq Notice received have no immediate effect on the Company’s continued listing on the Nasdaq Global Market or the trading of Company’s common stock, subject to the Company’s compliance with the other continued listing requirements. The Company is presently evaluating potential actions to regain compliance with all applicable requirements for continued listing on the Nasdaq Global Market. There can be no assurance that the Company will be successful in maintaining the listing of its common stock on the Nasdaq Global Market.

 

 

XML 102 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies
12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

 

Basis of Presentation and Foreign Currency Translation

 

The consolidated financial statements have been prepared in U.S. dollars, in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. The consolidated financial statements include 100% of the accounts of wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

 

Business Combination

 

We account for business acquisitions under ASC Topic 805, Business Combinations (“ASC Topic 805”). The total purchase consideration for an acquisition is measured as the fair value of the assets given, equity instruments issued, and liabilities assumed at the acquisition date. Costs that are directly attributable to the acquisition are expensed as incurred. Identifiable assets (including intangible assets) and liabilities assumed (including contingent liabilities) are measured initially at their fair values at the acquisition date. We recognize goodwill if the fair value of the total purchase consideration is in excess of the net fair value of the identifiable assets acquired and the liabilities assumed. We recognize a bargain purchase gain within Other income (expense), net, in the consolidated statement of operations if the net fair value of the identifiable assets acquired and the liabilities assumed is in excess of the fair value of the total purchase consideration. We include the results of operations of the acquired business in the consolidated financial statements beginning on the acquisition date.

 

Use of Estimates

 

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the amounts disclosed in the related notes to the consolidated financial statements. Actual results and outcomes may differ materially from management’s estimates, judgments, and assumptions. Significant estimates, judgments, and assumptions used in these financial statements include, but are not limited to, those related to revenue, useful lives and realizability of long-lived assets, accounting for income taxes and related valuation allowances, and unit and stock-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts, and experience.

 

Operating Segments

 

The Company operates as one operating segment. Operating segments are defined as components of an enterprise for which separate financial information is regularly evaluated by the chief operating decision maker (“CODM”), which is the Company’s Chief Executive Officer, in deciding how to allocate resources and assess performance. The Company’s CODM evaluates the Company’s financial information and resources and assesses the performance of these resources on a consolidated basis. The Company is not organized by market and is managed and operated as one business. A single management team that reports to the chief executive officer comprehensively manages the entire business. Accordingly, the Company does not accumulate discrete financial information with respect to separate divisions and does not have separate operating or reportable segments. Since the Company operates in one operating segment, all required financial segment information can be found in the consolidated financial statements.

 

Cash and Cash Equivalents

 

Cash and cash equivalents consist of highly liquid, short-term investments with a maturity of three months or less when purchased. Cash equivalents consist of money market funds and are carried at cost, which approximates fair value. The balances, at times, may exceed FDIC Insured limits. The Company believes that, as of December 31, 2023, its risk relating to deposits exceeding federally insured limits was not significant.

 

Accounts Receivable

 

Accounts receivable are unsecured, recorded at net realizable value, and do not bear interest. Accounts receivable are considered past due if not paid within the terms established between the Company and the customer. Amounts are only written off after all attempts at collections have been exhausted. The Company determines the need for an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information. As of December 31, 2023 and 2022, the Company established allowances of $0 and $102,700 respectively. The net receivable balances outstanding are fully collectible.

 

The Company believes its credit policies are prudent and reflect normal industry terms and business risk. The Company generally does not require collateral from its customers and generally requires payment from 0 to 90 days from the invoice date. For the year ended December 31, 2023, there was 1 customer that accounted for 10% or more of total revenue, and there were 2 customers that accounted for 10% or more of total revenue for the years ended December 31, 2022 . The following table represents these customers’ aggregate percent of total revenue:

 Schedule Of Aggregate Percentage Revenue and Accounts Receivable

   December 31, 2023   December 31, 2022 
   Year Ended 
   December 31, 2023   December 31, 2022 
         
Customer 1   52%   31%
Customer 2   -    22%
Aggregate Percent of Total Revenue   52%   53%

 

 

As of December 31, 2023, three customers accounted for more than 10% of the Company’s accounts receivable balance, and two customers accounted for over 10% of the Company’s accounts receivable balance at December 31, 2022. The following table represents these customers’ aggregate percent of total accounts receivable:

 

   December 31, 2023   December 31, 2022 
   Year Ended 
   December 31, 2023   December 31, 2022 
Customer 1   -    40%
Customer 2   36%   - 
Customer 3   33%   - 
Customer 4   -    32%
Customer 5   27%   - 
Aggregate Percent of Total Accounts Receivable   96%   72%

 

Property and Equipment

 

Property and equipment are recorded at cost. The straight-line method is used for computing depreciation and amortization. Assets are depreciated over their estimated useful lives ranging from three to five years. Cost of maintenance and repairs are charged to expense when incurred.

 

Impairment of Long-Lived Assets

 

The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset may not be fully recoverable. An impairment loss would be recognized when the estimated future undiscounted net cash flows from the use of the asset are less than the carrying amount of that asset. There have been no losses during the years ended December 31, 2023 or December 31, 2022.

 

Fair Value of Financial Instruments

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value:

 

Level 1 — Valuations based on quoted prices for identical assets and liabilities in active markets.

Level 2 — Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.

Level 3 — Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.

 

We measure the fair value of money market funds and certain marketable equity securities based on quoted prices in active markets for identical assets or liabilities. Other marketable securities were valued either based on recent trades of securities in inactive markets or based on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. We did not hold significant amounts of marketable securities categorized as Level 3 assets as of the years ended December 31, 2022 and December 31, 2023.

 

The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, convertible notes payable and certain privately issued warrants. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable financial instruments approximate their fair value due to their short-term nature. The Company’s Private Warrants estimated fair values are provided by a third party pricing vendor and are reviewed by the Company’s management. The Private Warrants valuations are based on unobservable inputs reflecting the vendor’s assumptions, consistent with reasonably available assumptions made by other market participants and thus are classified as Level 3.

 

Revenue Recognition

 

Revenue is recognized in accordance with the five-step model set forth by Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (“Topic 606”), which involves identification of the contract, identification of performance obligations in the contract, determination of the transaction price, allocation of the transaction price to the previously identified performance obligations, and revenue recognition as the performance obligations are satisfied.

 

Revenue from all customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to a customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account under Topic 606. A contract’s transaction price is allocated to each distinct performance obligation in proportion to the standalone selling price for each and recognized as revenue when, or as, the performance obligation is satisfied.

 

 

Individual promised goods and services in a contract are considered a performance obligation and accounted for separately if the good or service is distinct. A good or service is considered distinct if the customer can benefit from the good or service on its own or with other resources that are readily available to the customer and the good or service is separately identifiable from other promises in the arrangement.

 

The transaction price for the products is the invoiced amount. Advanced billings from contracts are deferred and recognized as revenue when earned. Revenue is recognized only to the extent that it is probable that a significant reversal of revenue will not occur and when collection is considered probable The Company excludes from revenue taxes collected from a customer that are assessed by a governmental authority and imposed on and concurrent with a specific revenue-producing transaction. Deferred revenue consists of payments received in advance of performance under the contract. Such amounts are generally recognized as revenue over the contractual period. The Company receives payments from customers based upon contractual billing schedules. Accounts receivable is recorded when the right to consideration becomes unconditional. Payment terms on invoiced amounts typically range from zero to 90 days, with typical terms of 30 days.

 

The Company generates revenue from two streams: (1) iRWD (imaging Real World Data) which provides regulatory grade imaging and clinical data in the Pharmaceutical, Device Manufacturing, CRO’s and AI markets and (2) BEAM which is a Medical Imaging Exchange platform between Hospital/Healthcare Systems, Imaging Centers, Physicians and Patients. iRWD is sold on a fixed fee basis based on the number of data units and the cost per data unit committed to in the customer contract. Revenue is recognized when the data is delivered to the customer. Beam revenue is subscription-based revenue which is recognized ratably over the subscription period committed to by the customer. The Company invoices its Beam customers quarterly or annually in advance with the customer contracts automatically renewing unless the customer issues a cancellation notice.

 

Income Taxes

 

The Company is subject to U.S. federal, state and local income taxes. The Company accounts for income taxes in accordance with ASC Topic 740, Accounting for Income Taxes (“ASC Topic 740”), which requires the recognition of tax benefits or expenses on temporary differences between the financial reporting and tax bases of its assets and liabilities by applying the enacted tax rates in effect for the year in which the differences are expected to reverse. Such net tax effects on temporary differences are reflected on the Company’s consolidated balance sheets as deferred tax assets and liabilities.

 

ASC Topic 740 prescribes a two-step approach for the recognition and measurement of tax benefits associated with the positions taken or expected to be taken in a tax return that affects amounts reported in the financial statements. The Company has reviewed and will continue to review the conclusions reached regarding uncertain tax positions, which may be subject to review and adjustment at a later date based on ongoing analyses of tax laws, regulations and interpretations thereof. To the extent that the Company’s assessment of the conclusions reached regarding uncertain tax positions changes as a result of the evaluation of new information, such change in estimate will be recorded in the period in which such determination is made. The Company reports income tax-related interest and penalties relating to uncertain tax positions, if applicable, as a component of income tax expense

 

Deferred tax assets are reduced by a valuation allowance when the Company believes that it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. The Company provides deferred taxes at the enacted tax rate that is expected to apply when the temporary differences reverse. The Company has recorded a full valuation allowance against the net deferred tax asset due to the uncertainty of realizing the related benefits.

 

Patents and Trademarks

 

Costs associated with the submission of a patent application are expensed as incurred given the uncertainty of the patents resulting in probable future economic benefits to the Company and are included in research and development expenses on the consolidated statements of operations.

 

Research and Development

 

The Company account for its research and development cost in accordance with ASC Topic 730, Research and Development (“ASC Topic 730”). ASC Topic 730 requires that all R&D costs be recognized as an expense as incurred. However, some costs associated with R&D activities that have an alternative future use (e.g., materials, equipment, facilities) may be capitalizable. For the years ended December 31, 2023 and December 31, 2022 research and development expenditures were charged to operating expense as incurred..

 

Stock-based Compensation

 

The Company has a stock-based compensation plan, which is described in more detail in Note 8. The fair value of stock option and warrant grants are determined on the date of grant using the Black Scholes valuation model. Forfeitures of stock based awards are recorded as the actual forfeitures occur. Stock based compensation expense is recognized over the service period, net of estimated forfeitures, using the straight-line method. The Company converted all unvested stock based compensation awards to common shares in the year ended December 31, 2023.

 

 

General, and Administrative Expenses

 

General and administrative expenses include all costs that are not directly related to satisfaction of customer contracts. General, and administrative expenses include items for the Company’s selling and administrative functions, such as sales, finance, legal, human resources, and information technology support. These functions include costs for items such as salaries and benefits and other personnel-related costs, maintenance and supplies, professional fees for external legal, accounting, and other consulting services, intangible asset amortization, and depreciation expense.

 

Emerging Growth Company

 

The Company is an emerging growth company, as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has not elected to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company , can adopt the new or revised standard at the time private companies adopt the new or revised standard.

 

Accounting Pronouncements Not Yet Adopted

 

In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures (Topic 280). This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and included within each reported measure of a segment’s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is also permitted. This ASU will likely result in us including the additional required disclosures when adopted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2024.

 

In December 2023, the Financial Accounting Standards Board issued an Accounting Standards Update (“ASU”) amending existing income tax disclosure guidance, primarily requiring more detailed disclosure for income taxes paid and the effective tax rate reconciliation. The ASU is effective for annual reporting periods beginning after December 15, 2024, with early adoption permitted and can be applied on either a prospective or retroactive basis. We are currently evaluating the ASU to determine its impact on our income tax disclosures.

 

Recently adopted accounting pronouncements

 

In October 2021, the FASB issued ASU No. 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (ASC Topic 805). This ASU requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities (deferred revenue) from acquired contracts using the revenue recognition guidance in Topic 606. At the acquisition date, the acquirer applies the revenue model as if it had originated the acquired contracts. The ASU is effective for annual periods beginning after December 15, 2022, including interim periods within those fiscal years. We adopted this ASU prospectively on January 1, 2023. This ASU has not and is currently not expected to have a material impact on our consolidated financial statements.

 

XML 103 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Business Combination
12 Months Ended
Dec. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Business Combination

3. Business Combination

 

The Business Combination was accounted for as a reverse recapitalization as OneMedNet Corporation was determined to be the accounting acquirer under Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 805, Business Combinations. This determination was primarily based on OneMedNet Corporation comprising the ongoing operations of the combined entity, OneMedNet Corporation’s senior management comprising of all the senior management of the combined company, and the prior shareholders of OneMedNet owning a majority of the voting power of the combined entity. Accordingly, for accounting purposes, the financial statements of the combined entity upon consummation of the Business Combination represented a continuation of the financial statements of OneMedNet Corporation with the merger being treated as the equivalent of OneMedNet issuing stock for the net assets of Data Knights Inc., accompanied by a recapitalization. Operations prior to the Business Combination are presented as those of OneMedNet Corporation in future reports of the combined entity.

 

XML 104 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Going Concern
12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Going Concern

4. Going Concern

 

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company does not have adequate liquidity to fund its operations through at least twelve months from the date these financial statements were available for issuance. The Company has an accumulated deficit 55,082,677 as of year-end December 31, 2023 and $43,509,964, as of year-end December 31, 2022 and has had negative cash flows from operating activities for the year ended December 31, 2023. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. To continue in existence and expand its operations, the Company will be required to, and management plans to, raise additional working capital through an equity or debt offering and ultimately attain profitable operations. If the Company is not able to raise additional working capital, it would have a material adverse effect on the operations of the Company and continuing research and development of its product. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to continue receiving working capital cash payments and generating cash flow from operations.

 

 

XML 105 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Property and Equipment
12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
Property and Equipment

5. Property and Equipment

 

Property and equipment are summarized as of December 31:

 Schedule of Property And Equipment

   2023   2022 
Computers  $246,578   $259,207 
Furniture and equipment   35,708    3,785 
Total Property and Equipment   282,286    262,992 
Less: accumulated depreciation   (183,415)   (179,895)
Net Property and Equipment  $98,871   $83,097 

 

Depreciation and amortization expense was $27,983 and $24,807 for the years ended December 31, 2023 and 2022, respectively.

 

XML 106 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes
12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Income Taxes

6. Income Taxes

 

The Company has generated both federal and state net operating losses (NOL) of approximately $21 million and $23 million, respectively, which if not used, will begin to expire in 2030. The Company believes that its ability to fully utilize the existing NOL carryforwards could be restricted on a portion of the NOL by changes in control that may have occurred or may occur in the future and by its ability to generate net income. The Company has not yet conducted a formal study of whether, or to what extent, past changes in control of the Company impairs its NOL carryforwards because such NOL carryforwards cannot be utilized until the Company achieves profitability.

 

Components of deferred income taxes are as follows as of December 31:

 

Schedule of Deferred Income Taxes

   2023   2022 
Deferred Tax Assets          
Net operating loss carry forward  $6,823,785    $6,973,587 
Stock Compensation   1,035,947    481,144 
Other   -    53,268 
Gross deferred tax assets   7,859,732    7,507,999 
Less valuation allowance   (7,859,732)   (7,507,999)
Net deferred tax assets   -    - 

 

The change in the valuation allowance was $351,734 and $1,384,220 for the years ended December 31, 2023 and 2022, respectively. The effective tax rate for the years ended December 31, 2023 and 2022 differs from the federal and state statutory rates due to the full valuation allowance. The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. The tax years from inception through December 31, 2023 remain subject to examination by all major taxing authorities due to the net operating loss carryovers. The Company is not currently under examination by any taxing jurisdiction. The Company did not incur any interest or penalties during the years ended December 31, 2023 or 2022.

 

As a result of the Business Combination, the Company was appointed as the sole managing member of Data Knights. The Company is subject to U.S. federal income taxes, in addition to state and local income taxes. The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the estimated future tax consequences attributable to temporary differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the temporary differences are expected to be settled or recovered. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future income, and tax planning strategies in making this assessment.

 

The Company has established a valuation allowance related deferred tax assets on deductible temporary differences, tax losses, and tax credit carryforwards. The valuation allowance as of December 31, 2023 was $168.3. The increase in the valuation allowance in fiscal year 2023 of $155.7 million primarily relates to the Company’s investment in Data Knights, and tax carryforward attributes.

 

 

As of December 31, 2023, the Company had a U.S. federal net operating loss carryforwards of $10.3 million and gross state net operating loss carryforwards of $8.9 million.

 

XML 107 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Convertible Promissory Notes held by Related Party
12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
Convertible Promissory Notes held by Related Party

7. Convertible Promissory Notes held by Related Party

 

During 2023, the Company entered various Convertible Promissory Notes (“Note”) with related party investors totaling $2,300,000 (2022 - $4,700,000) and unrelated party investors of $1,875,000 (2022 - $440,000). The Notes issued are unsecured and bear an interest rate of six percent annually from the date of issuance until the outstanding principal is paid or converted. On November 11, 2022 the Convertible note agreement was amended and restated in order to (i) provide for the sale and issuance to Purchasers from the effective date of January 1, 2022 and after the date of this Agreement of up to an additional $5,000,000 aggregate principal amount of Notes and warrants to purchase shares of the Company’s capital stock, (ii) provide for the sale and issuance to Purchasers who purchased Notes under the Prior Agreement between the Effective Date and the date of this Agreement of warrants to purchase shares of the Company’s common stock at an exercise price of $1.00 per share; (iii) extend the maturity date of all outstanding Notes from December 31, 2022 to November 7, 2023.

 

The principal and unpaid accrued interest on each Note will convert: (i) automatically, upon the Company’s issuance of equity securities (the “Next Equity Financing”) in a single transaction, or series of related transactions, with aggregate gross proceeds to the Company of at least $5,000,000, into shares of the Company’s capital stock issued to investors in the Next Equity Financing, at a conversion price equal to the lesser of (A) a 20% discount to the lowest price per share of shares sold in the Next Equity Financing, or (B) $2.50 per share; (ii) at the noteholder’s option, in the event of a defined Corporate Transaction while such Note remains outstanding, into shares of the Company’s Series A-2 Preferred Stock at a conversion price equal to $2.50 per share; and (iii) at the noteholder’s option, on or after the Maturity Date while such Note remains outstanding, into shares of the Company’s Series A-2 Preferred Stock at a conversion price equal to $2.50 per share.

 

If a Corporate Transaction occurs before the repayment or conversion of the Notes, the Company will pay at the closing of the Corporate Transaction to each noteholder that elects not to convert its Notes in connection with such Corporate Transaction an amount equal to the outstanding principal amount of such noteholder’s Note plus a 20% premium. “Corporate Transaction” means (a) a sale by the Company of all or substantially all of its assets, (b) a merger of the Company with or into another entity (if after such merger the holders of a majority of the Company’s voting securities immediately prior to the transaction do not hold a majority of the voting securities of the successor entity) or (c) the transfer of more than 50% of the Company’s voting securities to a person or group.

 

During November 2019, the Company entered into a Convertible Promissory Note (“Note”) agreement with a related party investor. The total amount of the Note is $1,500,000. The Note is unsecured and bears interest at a rate of four percent annually from the date of issuance until the outstanding principal is paid or converted. The Note matures on January 1, 2025. The Note shall automatically convert into the next offering of preferred stock upon closing of such next equity financing. The number of shares of preferred stock to be issued upon conversion shall be equal to the number obtained by dividing the outstanding principal and unpaid accrued interest owed on the date of conversion, by the conversion price. The conversion price is 100 percent of the lowest price per share paid for the next equity preferred stock by other investors in the next equity financing. In the event that prior to the conversion or repayment of amounts owed, the Company completes a financing transaction in which the Company sells equity securities but such transaction does not qualify as next equity financing (i.e., an “alternative financing”), then the principal and unpaid accrued interest may (upon written election of the purchaser holding the Note) convert into the securities issued by the Company in the alternative financing. The number of alternative financing equity securities to be issued upon such conversion shall be equal to the number obtained by dividing the outstanding principal and unpaid accrued interest owed by an amount equal to 100 percent multiplied by the lowest price per share at which the alternative financing equity securities are sold and issued for cash in the alternative financing.

 

As of December 31, 2022 there was $9.9 million outstanding principal balance on the Notes and $690,771 in accrued interest, all included in long-term liabilities on the balance sheet. There were no payments of principal or interest during 2022. In connection with the $5,140,000 in convertible notes issued in 2022, 2,056,000 in warrants were issued.

 

In November 2023, the Business Combination between Data Knights and the Company triggered the Notes’ conversion to common stock. Approximately $15.4 million of the total outstanding Notes plus accrued interest were converted at $2.50 per share of common stock.

 

XML 108 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Canadian Emergency Business Loan Act (CEBA)
12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
Canadian Emergency Business Loan Act (CEBA)

8. Canadian Emergency Business Loan Act (CEBA)

 

During December 2020, the Company applied for and received a $44,673 USD CEBA loan. The loan was provided by the Government of Canada to provide capital to organizations to see them through the current challenges and better position them to return to providing services and creating employment. The loan is unsecured. The loan was interest free through December 31, 2023. If the loan is paid back by January 18, 2024, $14,742 of the loan will be forgiven. If the loan is not paid back by January 18, 2023, the full $44,673 loan will be converted to loan repayable over three years with a 5% interest rate. The loan was paid back prior January 18, 2024. At December 31, 2023 the loans is classified as Canada Emergency Business Loan Act under Current Liabilities on the Consolidated Balance Sheet.

 

The Company accounted for the loan as debt in accordance with FASB Accounting Standards Codification 470 Debt and accrued interest in accordance with the interest method under FASB ASC 835-30.

 

 

XML 109 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Shareholders’ Equity
12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Shareholders’ Equity

9. Shareholders’ Equity

 

Series A-2 Preferred Stock

 

The Company’s previously issued and outstanding Series A-2 preferred stock included a $0.15 per share annual noncumulative dividend when and if declared by the board of directors. No dividends were declared in the years ended December 31, 2023 or December 31 2022. The Series A-2 preferred stock also includes a liquidation preference of 1.25 times the original issue price plus any declared but unpaid dividends upon the liquidation, dissolution, merger or sale of substantially all the assets of the Company and have a preference upon liquidation over Series A-1 preferred stock and common stock. Each share of Series A-2 preferred stock may be converted into equal shares of common stock at the option of the holder at any time. In addition, the Series A-2 preferred stock shares are automatically convertible into common shares upon the sale of shares of common stock to the public at the then applicable conversion price in a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $20 million in proceeds, net of underwriting discounts and commissions. Each share of Series A-2 preferred stock has voting rights equal to the number of shares of common stock then issuable upon conversion of such share of preferred stock. The Company is obligated to redeem shares of Series A-2 Preferred Stock in the occurrence of a Deemed Liquidation Event unless a majority of the holders of Series A-2 Preferred Stock and a majority of the Series A-1 Preferred Stock consent otherwise.

 

In November 2023, the Business Combination between Data Knights and the Company triggered the Series A-2 Preferred Stock and Series A-1 Preferred Stock convert 1-1 to commons stock.

 

Series A-1 Preferred Stock

 

The Company’s previously issued and outstanding Series A-1 preferred stock included a $0.15 per share annual noncumulative dividend when and if declared by the board of directors. No dividends were declared in the years ended December 31, 2023 or December 31 2022. The Series A-1 preferred stock also includes a liquidation preference of 1.25 times the original issue price plus any declared but unpaid dividends upon the liquidation, dissolution, merger or sale of substantially all the assets of the Company and have a preference upon liquidation over common stock. Each share of Series A-1 preferred stock may be converted into equal shares of common stock at the option of the holder at any time. In addition, the Series A-1 preferred stock shares are automatically convertible into common shares upon the sale of shares of common stock to the public at the then applicable conversion price in a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $20 million in proceeds, net of underwriting discounts and commissions. Each share of Series A-1 preferred stock has voting rights equal to the number of shares of common stock then issuable upon conversion of such share of preferred stock. The Company is obligated to redeem shares of Series A-1 Preferred Stock in the occurrence of a Deemed Liquidation Event unless a majority of the holders of Series A-1 Preferred Stock consent otherwise.

 

In November 2023, the Business Combination between Data Knights and the Company triggered the Series A-2 Preferred Stock and Series A-1 Preferred Stock convert 1-1 to commons stock.

 

Common Stock

 

In 2023, in connection with services performed by the Board of Directors common shares of 100,000 (100,000- 2022) were issued at $1.00 per share. These were expensed as general and administrative expenses in the Statement of Operations.

 

The table below summarizes the Common Stock activities during the year ended December 31, 2023. 

Schedule of Common Stock Activities 

   Common Stock 
Balances, December 31, 2022   4,550,166 
Preferred Stock to Common Stock   7,057,797 
Convertible Notes to Common Stock   6,177,229 
Stock Options to Common Stock   612,670 
Converting of Warrants to Common Stock   3,859,464 
Private OneMedNet to ONMD Public Shares   (2,257,326)
Converting Data Knights Common Stock (A and B) to ONMD Public Shares   3,460,275 
Issuance Public Shares   111,957 
Balances, December 31, 2023   23,572,232 

 

XML 110 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock Options
12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Stock Options

10. Stock Options

 

During 2020, the Company adopted a new equity incentive plan (the Plan), which provides for the granting of incentive and nonqualified stock options to employees, directors, and consultants. As of December 31, 2020, the Company has reserved 3,000,000 shares of common stock under the Plan. The Company believes that such awards better align the interests of its employees with those of its stockholders. Option awards are generally granted with an exercise price equal to the fair market value of the Company’s stock at the date of grant; those option awards generally vest with a range of one to four years of continuous service and have ten-year contractual terms. As there is no public data available for the share price valuation, the Company considers the Fair Market Value of $1 to be on the conservative side and similar to the exercise price. Certain option awards provide for accelerated vesting if there is a change in control, as defined in the Plan. The Plan also permits the granting of restricted stock and other stock-based awards. Unexercised options are cancelled upon termination of employment and become available under the Plan.

 

 

Information with respect to options outstanding is summarized as follows:

 

Schedule of Options Outstanding

   Options Outstanding   Weighted- Average Exercise Price   Aggregate Intrinsic Value 
Outstanding as of December 31, 2020   1,995,000   $1.00   $1,995,000 
Granted - under the Plan   25,000           
Exercised   -           
Cancelled   (1,072,816)          
Outstanding as of December 31, 2021   947,184   $1.00   $947,184 
Granted - under the Plan   577,000           
Exercised   (7,500)          
Cancelled   (485,684)          
Outstanding as of December 31, 2022   1,031,000   $1.00   $1,031,000 
Options exercisable as of December 31, 2022   567,581   $1.00   $567,581 

 

As of December 31, 2022 and 2021, there were 1,031,000 and 947,184 common stock options outstanding with a weighted average remaining contractual life of 7.11 years and 6.01 years, respectively.

 

As of December 31, 2022 and 2021, there were 567,581 and 723,431 common stock options exercisable at a weighted average remaining contractual life of 5.56 years and 5.27 years, respectively.

 

On November 7, 2023, the Company issued shares of common stock for 692,153 vested options less an exercise price of $1.00.

 

At the Special Meeting held on October 17, 2023, Data Knights shareholders considered and approved the OneMedNet Corporation 2022 Equity Incentive Plan (the “Plan”) and reserved an amount of shares of common stock equal to 10% of the number of shares of common stock of OneMedNet following the Business Combination for issuance thereunder. The Plan was approved by the OneMedNet pre-Closing board of directors on October 17, 2023. The Plan became effective immediately upon the Closing of the Business Combination.

 

Black Scholes Assumptions

 

The determination of the fair value of stock options using an option valuation model is affected by the Company’s stock price valuation, as well as assumptions regarding a number of complex and subjective variables. The volatility assumption is based on volatilities of similar companies over a period of time equal to the expected term of the stock options. The volatilities of similar companies are used in conjunction with the Company’s historical volatility because of the lack of sufficient relevant history for the Company’s common stock equal to the expected term. The expected term of the employee stock options represents the weighted average period for which the stock options are expected to remain outstanding. The expected term assumption is estimated based primarily on the options’ vesting terms and remaining contractual life and employees’ expected exercise and post- vesting employment termination behavior. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The dividend yield assumption is based on the expectation of no future dividend payouts by the Company.

 

The fair value of the Company’s previous stock options was estimated assuming no expected dividends and the following weighted average assumptions:

 

Schedule of Fair Value of Stock Options

   2022   2021 
Expected life in years   5.89    6.08 
Risk-free interest rate   0.55%   0.49%
Expected dividend yield   0.00%   0.00%
Expected volatility   32%   60%

 

The total expense recognized for share-based payments was $45,584 and $47,071 for the years ended December 31, 2022 and 2021, respectively. These costs are included in the statements of operations. As of December 31, 2022, there was $75,987 of unrecognized compensation costs related to stock option grants which will be recognized over the next four years.

 

During 2023, the Company issued common stock to employees and extinguished all outstanding stock options. The 612,720 shares outstanding were recorded as stock expense in the Consolidated Statement of Operations.

 

 

XML 111 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock Warrants
12 Months Ended
Dec. 31, 2023
Stock Warrants  
Stock Warrants

11. Stock Warrants

 

In 2021, there were 174,102 OneMedNet Corporation outstanding common stock warrants issued for service at a weighted average exercise price of $0.10. In 2022 for the exercise price of $1.00, the OneMedNet Corporation issued 145,746 warrants for 2021 service and 294,000 warrants for 2022 service, 2,056,000 in warrants were issued attached to convertible notes. The Company expensed $1,346,288 in 2022 in relation to the issuance of the Warrants. In 2023 for the exercise price of $1.00, the OneMedNet issued 1,670,000 in warrants attached to convertible notes. OneMedNet Corporation converted 4,165,746 warrants outstanding to common stock at an exercise price of $1.00 and converted 174,102 warrants outstanding to common stock at an exercise price of $0.10.

 

As of December 31, 2023 and December 31, 2022, the Company had 11,500,000 of publicly traded warrants. The warrants trade on the Nasdaq had closing price of $.0149 and $.0400 at December 31, 2023 and December 31, 2022 respectively.

 

As of December 31, 2023 and December 31, 2022, the Company had 681,019 and 585,275 of private warrants outstanding. These warrants are classified as liability on the Consolidated Balance Sheet. Changes in the warrant liabilities are recorded in the Statement of Operations. As of December 31, 2023 and December 31, 2022, the warrant liabilities were $0.6 million and $0.4 respectively.

 

XML 112 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measures
12 Months Ended
Dec. 31, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measures

12. Fair Value Measures

 

The fair value measurement accounting standards establish a framework for measuring fair value and expand disclosures about fair value measurements. The standard does not require any new fair value measurements; rather, it applies to other accounting pronouncements that require or permit fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. This pronouncement also establishes a three-level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

 

The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three levels are defined as follows:

 

Level 1—inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market

 

Level 2—inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model-derived valuations in which all significant inputs are observable for substantially the full term of the asset or liability

 

Level 3—inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability

 

The following table presents the Company’s financial assets measured and recorded at fair value on a recurring basis using the above input categories as of December 31, 2023 and December 31, 2022 (in thousands):

 

Schedule of Financial Assets 

   Year Ended 
   December 31, 2023   December 31, 2022 
   Level 1   Level 2   Level 3   Total   Level 1   Level 2   Level 3   Total 
Assets:                                
Investments held in Trust  $   $   $   $   $29,029,416   $   $   $29,029,416 
                                         
Total Assets  $   $   $   $   $29,029,416   $   $   $29,029,416 

 

XML 113 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Related Party Transactions
12 Months Ended
Dec. 31, 2023
Related Party Transactions [Abstract]  
Related Party Transactions

13. Related Party Transactions

 

Loan Extensions

 

 

Data Knights closed its initial public offering in May 2021 and had 12 months to complete a business combination. Alternatively, the Data Knight could extend the period up to two times for an additional three months each time with an extension costing $1.2 million. Data Knights received a total of $300,000 from members of the Company’s Management and Directors. As of December 31, 2023 and December 31, 2022 the total extension loan including interest outstanding was $3.0 million and $2.5 million, respectively.

 

PIPE Convertible Notes and Warrants

 

In November 2023, the Company entered into a Securities Purchase Agreement (SPA) in which the Company was required to sell senior secured convertible notes and warrants to Directors of the Company. The SPA stipulates a collateral security agreement between the Company and the Directors for punctual payment and performance by the Company on its Obligations to the Directors. The Intellectual Property of the Company serves as the collateral for the Directors. The senior secured convertible notes and warrants were issued through a private issuance of a public entity (PIPE) transaction, which is a form of debt and equity offering under an exception in the securities law for qualifying private placements by issuers of publicly traded securities. The Company received a total of $1.5 million from the director in exchange for senior convertible notes of $1.6 million (plus accrued interest of $0.1 million) and 95,745 warrants to acquire common stock. The senior secured notes are convertible to the conversion rate of $10.00 per share, and 92.5% of the lowest VWAP for the ten (10) trading days immediately preceding the conversion Date, subject to the floor price of $1.14 (representing 20% of the closing price on the last trading day before the closing of the Business Combination), or the alternative conversion ratio the greater of the floor price and the lesser of 80% of the VWAP of the common stock as of the trading day and 80% of the price computed as the quotient of the sum of the VWAP of the Common Stock for each of the three Trading Days with the lowest VWAP of the Common Stock during the fifteen consecutive trading day period ending and including the trading day immediately preceding the delivery or deemed delivery of the applicable Conversion Notice, divided by three. All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification or similar transaction that proportionately decreases or increases the common stock.

 

The warrants are classified as equity and the total proceeds received from the Directors are allocated based on the relative fair values of the convertible notes and the warrants at the issued date. The portion allocable to warrants is accounted for as paid-in capital. The senior secured convertible notes are classified as long term debt in the Consolidated Balance Sheet. The estimate fair value of the senior secured convertible notes at December 31, 2023 was $1.2 million.

 

XML 114 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments, Contingencies, and Concentrations Operating lease
12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments, Contingencies, and Concentrations Operating lease

14. Commitments, Contingencies, and Concentrations Operating lease

 

The Company has a month-to-month lease for a suite at a cost of $575 per month. The Company incurred $7,695 and $7,694 of rent expense, including common tenant costs and cancellation costs, during the years ended December 31, 2023 and 2022, respectively.

 

XML 115 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Subsequent Events
12 Months Ended
Dec. 31, 2023
Subsequent Events [Abstract]  
Subsequent Events

15. Subsequent Events

 

The Company has evaluated subsequent events occurring through April 9, 2024, the date the financial statements were available for issuance, for events requiring recording or disclosure in the Company’s financial statements.

 

During 2024, through to the date of this report, the Company issued 256,944 and 20,834 shares of Common Stock to EF Hutton LLC and Kingwood Capital Partners, LLC, respectively, as consideration for $3.0 million owed by the Company for underwriting commission due at the closing of the Business Combination.

 

During 2024, through to the date of this report, the Company bought back 187,745 shares of Common Stock from a convertible note holder.

 

During 2024, through to the date of this report, the Company received $1,000,000 from a majority shareholder for the purchase of shares, and an additional $300,000 treated as a shareholder loan.

 

During 2024, through to the date of this report, the Company entered into a definitive securities purchase agreement with an institutional investor providing up to $4.54 million in funding through a private placement for the issuance of senior convertible notes.

 

As previously announced on Form 8-K, on March 28, 2024, OneMedNet Corporation (the “Company”) entered into a definitive securities purchase agreement (the “Securities Purchase Agreement”) with Helena Global Investment Opportunities 1 Ltd., an affiliate of Helena Partners Inc., a Cayman-Islands based advisor and investor providing for up to USD$4.54 million in funding through a private placement for the issuance of senior secured convertible notes (the “Notes”).

 

As previously announced on Form 8-K, on March 27, 2024, Paul J. Casey, Chief, Chief Executive Officer of the Company, notified the Company of his intention to retire as Chief Executive Officer of the Company effective March 29, 2024. Mr. Casey will continue to serve as a member of the Board of Directors (the “Board”) of the Company. In connection with Mr. Casey’s service on the Advisory Board of the Company, the Board approved a Stock Option Grant (the “Option Grant”) providing for the grant of 147,000 five-year options exercisable at $1.00 per share adviser to Mr. Casey. Also on March 27, 2024, Scott Holbrook, a member of the Board of the Company and a member of the Company’s Audit Committee, notified the Company of his intention to retire from the Company’s Board effective March 29, 2024.

 

Effective March 29, 2024, the Board (i) appointed Mr. Aaron Green, to serve as Chief Executive Officer of the Company to fill the vacancy created by the retirement of Paul Casey; (ii) appointed Mr. Aaron Green, to serve as a member of the Board to fill the vacancy created by the retirement of Scott Holbrook; and (iii) appointed Board member, Dr. Thomas Kosasa, to serve on the Company’s Audit Committee, also to fill the vacancy created by the retirement of Scott Holbrook.

XML 116 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Basis of Presentation and Foreign Currency Translation

Basis of Presentation and Foreign Currency Translation

 

The consolidated financial statements have been prepared in U.S. dollars, in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. The consolidated financial statements include 100% of the accounts of wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

 

Business Combination

Business Combination

 

We account for business acquisitions under ASC Topic 805, Business Combinations (“ASC Topic 805”). The total purchase consideration for an acquisition is measured as the fair value of the assets given, equity instruments issued, and liabilities assumed at the acquisition date. Costs that are directly attributable to the acquisition are expensed as incurred. Identifiable assets (including intangible assets) and liabilities assumed (including contingent liabilities) are measured initially at their fair values at the acquisition date. We recognize goodwill if the fair value of the total purchase consideration is in excess of the net fair value of the identifiable assets acquired and the liabilities assumed. We recognize a bargain purchase gain within Other income (expense), net, in the consolidated statement of operations if the net fair value of the identifiable assets acquired and the liabilities assumed is in excess of the fair value of the total purchase consideration. We include the results of operations of the acquired business in the consolidated financial statements beginning on the acquisition date.

 

Use of Estimates

Use of Estimates

 

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the amounts disclosed in the related notes to the consolidated financial statements. Actual results and outcomes may differ materially from management’s estimates, judgments, and assumptions. Significant estimates, judgments, and assumptions used in these financial statements include, but are not limited to, those related to revenue, useful lives and realizability of long-lived assets, accounting for income taxes and related valuation allowances, and unit and stock-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts, and experience.

 

Operating Segments

Operating Segments

 

The Company operates as one operating segment. Operating segments are defined as components of an enterprise for which separate financial information is regularly evaluated by the chief operating decision maker (“CODM”), which is the Company’s Chief Executive Officer, in deciding how to allocate resources and assess performance. The Company’s CODM evaluates the Company’s financial information and resources and assesses the performance of these resources on a consolidated basis. The Company is not organized by market and is managed and operated as one business. A single management team that reports to the chief executive officer comprehensively manages the entire business. Accordingly, the Company does not accumulate discrete financial information with respect to separate divisions and does not have separate operating or reportable segments. Since the Company operates in one operating segment, all required financial segment information can be found in the consolidated financial statements.

 

Cash and Cash Equivalents

Cash and Cash Equivalents

 

Cash and cash equivalents consist of highly liquid, short-term investments with a maturity of three months or less when purchased. Cash equivalents consist of money market funds and are carried at cost, which approximates fair value. The balances, at times, may exceed FDIC Insured limits. The Company believes that, as of December 31, 2023, its risk relating to deposits exceeding federally insured limits was not significant.

 

Accounts Receivable

Accounts Receivable

 

Accounts receivable are unsecured, recorded at net realizable value, and do not bear interest. Accounts receivable are considered past due if not paid within the terms established between the Company and the customer. Amounts are only written off after all attempts at collections have been exhausted. The Company determines the need for an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information. As of December 31, 2023 and 2022, the Company established allowances of $0 and $102,700 respectively. The net receivable balances outstanding are fully collectible.

 

The Company believes its credit policies are prudent and reflect normal industry terms and business risk. The Company generally does not require collateral from its customers and generally requires payment from 0 to 90 days from the invoice date. For the year ended December 31, 2023, there was 1 customer that accounted for 10% or more of total revenue, and there were 2 customers that accounted for 10% or more of total revenue for the years ended December 31, 2022 . The following table represents these customers’ aggregate percent of total revenue:

 Schedule Of Aggregate Percentage Revenue and Accounts Receivable

   December 31, 2023   December 31, 2022 
   Year Ended 
   December 31, 2023   December 31, 2022 
         
Customer 1   52%   31%
Customer 2   -    22%
Aggregate Percent of Total Revenue   52%   53%

 

 

As of December 31, 2023, three customers accounted for more than 10% of the Company’s accounts receivable balance, and two customers accounted for over 10% of the Company’s accounts receivable balance at December 31, 2022. The following table represents these customers’ aggregate percent of total accounts receivable:

 

   December 31, 2023   December 31, 2022 
   Year Ended 
   December 31, 2023   December 31, 2022 
Customer 1   -    40%
Customer 2   36%   - 
Customer 3   33%   - 
Customer 4   -    32%
Customer 5   27%   - 
Aggregate Percent of Total Accounts Receivable   96%   72%

 

Property and Equipment

Property and Equipment

 

Property and equipment are recorded at cost. The straight-line method is used for computing depreciation and amortization. Assets are depreciated over their estimated useful lives ranging from three to five years. Cost of maintenance and repairs are charged to expense when incurred.

 

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

 

The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset may not be fully recoverable. An impairment loss would be recognized when the estimated future undiscounted net cash flows from the use of the asset are less than the carrying amount of that asset. There have been no losses during the years ended December 31, 2023 or December 31, 2022.

 

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value:

 

Level 1 — Valuations based on quoted prices for identical assets and liabilities in active markets.

Level 2 — Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.

Level 3 — Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.

 

We measure the fair value of money market funds and certain marketable equity securities based on quoted prices in active markets for identical assets or liabilities. Other marketable securities were valued either based on recent trades of securities in inactive markets or based on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. We did not hold significant amounts of marketable securities categorized as Level 3 assets as of the years ended December 31, 2022 and December 31, 2023.

 

The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, convertible notes payable and certain privately issued warrants. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable financial instruments approximate their fair value due to their short-term nature. The Company’s Private Warrants estimated fair values are provided by a third party pricing vendor and are reviewed by the Company’s management. The Private Warrants valuations are based on unobservable inputs reflecting the vendor’s assumptions, consistent with reasonably available assumptions made by other market participants and thus are classified as Level 3.

 

Revenue Recognition

Revenue Recognition

 

Revenue is recognized in accordance with the five-step model set forth by Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (“Topic 606”), which involves identification of the contract, identification of performance obligations in the contract, determination of the transaction price, allocation of the transaction price to the previously identified performance obligations, and revenue recognition as the performance obligations are satisfied.

 

Revenue from all customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to a customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account under Topic 606. A contract’s transaction price is allocated to each distinct performance obligation in proportion to the standalone selling price for each and recognized as revenue when, or as, the performance obligation is satisfied.

 

 

Individual promised goods and services in a contract are considered a performance obligation and accounted for separately if the good or service is distinct. A good or service is considered distinct if the customer can benefit from the good or service on its own or with other resources that are readily available to the customer and the good or service is separately identifiable from other promises in the arrangement.

 

The transaction price for the products is the invoiced amount. Advanced billings from contracts are deferred and recognized as revenue when earned. Revenue is recognized only to the extent that it is probable that a significant reversal of revenue will not occur and when collection is considered probable The Company excludes from revenue taxes collected from a customer that are assessed by a governmental authority and imposed on and concurrent with a specific revenue-producing transaction. Deferred revenue consists of payments received in advance of performance under the contract. Such amounts are generally recognized as revenue over the contractual period. The Company receives payments from customers based upon contractual billing schedules. Accounts receivable is recorded when the right to consideration becomes unconditional. Payment terms on invoiced amounts typically range from zero to 90 days, with typical terms of 30 days.

 

The Company generates revenue from two streams: (1) iRWD (imaging Real World Data) which provides regulatory grade imaging and clinical data in the Pharmaceutical, Device Manufacturing, CRO’s and AI markets and (2) BEAM which is a Medical Imaging Exchange platform between Hospital/Healthcare Systems, Imaging Centers, Physicians and Patients. iRWD is sold on a fixed fee basis based on the number of data units and the cost per data unit committed to in the customer contract. Revenue is recognized when the data is delivered to the customer. Beam revenue is subscription-based revenue which is recognized ratably over the subscription period committed to by the customer. The Company invoices its Beam customers quarterly or annually in advance with the customer contracts automatically renewing unless the customer issues a cancellation notice.

 

Income Taxes

Income Taxes

 

The Company is subject to U.S. federal, state and local income taxes. The Company accounts for income taxes in accordance with ASC Topic 740, Accounting for Income Taxes (“ASC Topic 740”), which requires the recognition of tax benefits or expenses on temporary differences between the financial reporting and tax bases of its assets and liabilities by applying the enacted tax rates in effect for the year in which the differences are expected to reverse. Such net tax effects on temporary differences are reflected on the Company’s consolidated balance sheets as deferred tax assets and liabilities.

 

ASC Topic 740 prescribes a two-step approach for the recognition and measurement of tax benefits associated with the positions taken or expected to be taken in a tax return that affects amounts reported in the financial statements. The Company has reviewed and will continue to review the conclusions reached regarding uncertain tax positions, which may be subject to review and adjustment at a later date based on ongoing analyses of tax laws, regulations and interpretations thereof. To the extent that the Company’s assessment of the conclusions reached regarding uncertain tax positions changes as a result of the evaluation of new information, such change in estimate will be recorded in the period in which such determination is made. The Company reports income tax-related interest and penalties relating to uncertain tax positions, if applicable, as a component of income tax expense

 

Deferred tax assets are reduced by a valuation allowance when the Company believes that it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. The Company provides deferred taxes at the enacted tax rate that is expected to apply when the temporary differences reverse. The Company has recorded a full valuation allowance against the net deferred tax asset due to the uncertainty of realizing the related benefits.

 

Patents and Trademarks

Patents and Trademarks

 

Costs associated with the submission of a patent application are expensed as incurred given the uncertainty of the patents resulting in probable future economic benefits to the Company and are included in research and development expenses on the consolidated statements of operations.

 

Research and Development

Research and Development

 

The Company account for its research and development cost in accordance with ASC Topic 730, Research and Development (“ASC Topic 730”). ASC Topic 730 requires that all R&D costs be recognized as an expense as incurred. However, some costs associated with R&D activities that have an alternative future use (e.g., materials, equipment, facilities) may be capitalizable. For the years ended December 31, 2023 and December 31, 2022 research and development expenditures were charged to operating expense as incurred..

 

Stock-based Compensation

Stock-based Compensation

 

The Company has a stock-based compensation plan, which is described in more detail in Note 8. The fair value of stock option and warrant grants are determined on the date of grant using the Black Scholes valuation model. Forfeitures of stock based awards are recorded as the actual forfeitures occur. Stock based compensation expense is recognized over the service period, net of estimated forfeitures, using the straight-line method. The Company converted all unvested stock based compensation awards to common shares in the year ended December 31, 2023.

 

 

General, and Administrative Expenses

General, and Administrative Expenses

 

General and administrative expenses include all costs that are not directly related to satisfaction of customer contracts. General, and administrative expenses include items for the Company’s selling and administrative functions, such as sales, finance, legal, human resources, and information technology support. These functions include costs for items such as salaries and benefits and other personnel-related costs, maintenance and supplies, professional fees for external legal, accounting, and other consulting services, intangible asset amortization, and depreciation expense.

 

Emerging Growth Company

Emerging Growth Company

 

The Company is an emerging growth company, as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has not elected to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company , can adopt the new or revised standard at the time private companies adopt the new or revised standard.

 

Accounting Pronouncements Not Yet Adopted

Accounting Pronouncements Not Yet Adopted

 

In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures (Topic 280). This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and included within each reported measure of a segment’s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is also permitted. This ASU will likely result in us including the additional required disclosures when adopted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2024.

 

In December 2023, the Financial Accounting Standards Board issued an Accounting Standards Update (“ASU”) amending existing income tax disclosure guidance, primarily requiring more detailed disclosure for income taxes paid and the effective tax rate reconciliation. The ASU is effective for annual reporting periods beginning after December 15, 2024, with early adoption permitted and can be applied on either a prospective or retroactive basis. We are currently evaluating the ASU to determine its impact on our income tax disclosures.

 

Recently adopted accounting pronouncements

Recently adopted accounting pronouncements

 

In October 2021, the FASB issued ASU No. 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (ASC Topic 805). This ASU requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities (deferred revenue) from acquired contracts using the revenue recognition guidance in Topic 606. At the acquisition date, the acquirer applies the revenue model as if it had originated the acquired contracts. The ASU is effective for annual periods beginning after December 15, 2022, including interim periods within those fiscal years. We adopted this ASU prospectively on January 1, 2023. This ASU has not and is currently not expected to have a material impact on our consolidated financial statements.

XML 117 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Schedule Of Aggregate Percentage Revenue and Accounts Receivable

 Schedule Of Aggregate Percentage Revenue and Accounts Receivable

   December 31, 2023   December 31, 2022 
   Year Ended 
   December 31, 2023   December 31, 2022 
         
Customer 1   52%   31%
Customer 2   -    22%
Aggregate Percent of Total Revenue   52%   53%

 

 

As of December 31, 2023, three customers accounted for more than 10% of the Company’s accounts receivable balance, and two customers accounted for over 10% of the Company’s accounts receivable balance at December 31, 2022. The following table represents these customers’ aggregate percent of total accounts receivable:

 

   December 31, 2023   December 31, 2022 
   Year Ended 
   December 31, 2023   December 31, 2022 
Customer 1   -    40%
Customer 2   36%   - 
Customer 3   33%   - 
Customer 4   -    32%
Customer 5   27%   - 
Aggregate Percent of Total Accounts Receivable   96%   72%
XML 118 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Property and Equipment (Tables)
12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
Schedule of Property And Equipment

 Schedule of Property And Equipment

   2023   2022 
Computers  $246,578   $259,207 
Furniture and equipment   35,708    3,785 
Total Property and Equipment   282,286    262,992 
Less: accumulated depreciation   (183,415)   (179,895)
Net Property and Equipment  $98,871   $83,097 
XML 119 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Schedule of Deferred Income Taxes

Components of deferred income taxes are as follows as of December 31:

 

Schedule of Deferred Income Taxes

   2023   2022 
Deferred Tax Assets          
Net operating loss carry forward  $6,823,785    $6,973,587 
Stock Compensation   1,035,947    481,144 
Other   -    53,268 
Gross deferred tax assets   7,859,732    7,507,999 
Less valuation allowance   (7,859,732)   (7,507,999)
Net deferred tax assets   -    - 
XML 120 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Shareholders’ Equity (Tables)
12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Schedule of Common Stock Activities

The table below summarizes the Common Stock activities during the year ended December 31, 2023. 

Schedule of Common Stock Activities 

   Common Stock 
Balances, December 31, 2022   4,550,166 
Preferred Stock to Common Stock   7,057,797 
Convertible Notes to Common Stock   6,177,229 
Stock Options to Common Stock   612,670 
Converting of Warrants to Common Stock   3,859,464 
Private OneMedNet to ONMD Public Shares   (2,257,326)
Converting Data Knights Common Stock (A and B) to ONMD Public Shares   3,460,275 
Issuance Public Shares   111,957 
Balances, December 31, 2023   23,572,232 
XML 121 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock Options (Tables)
12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Options Outstanding

Information with respect to options outstanding is summarized as follows:

 

Schedule of Options Outstanding

   Options Outstanding   Weighted- Average Exercise Price   Aggregate Intrinsic Value 
Outstanding as of December 31, 2020   1,995,000   $1.00   $1,995,000 
Granted - under the Plan   25,000           
Exercised   -           
Cancelled   (1,072,816)          
Outstanding as of December 31, 2021   947,184   $1.00   $947,184 
Granted - under the Plan   577,000           
Exercised   (7,500)          
Cancelled   (485,684)          
Outstanding as of December 31, 2022   1,031,000   $1.00   $1,031,000 
Options exercisable as of December 31, 2022   567,581   $1.00   $567,581 
Schedule of Fair Value of Stock Options

The fair value of the Company’s previous stock options was estimated assuming no expected dividends and the following weighted average assumptions:

 

Schedule of Fair Value of Stock Options

   2022   2021 
Expected life in years   5.89    6.08 
Risk-free interest rate   0.55%   0.49%
Expected dividend yield   0.00%   0.00%
Expected volatility   32%   60%
XML 122 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measures (Tables)
12 Months Ended
Dec. 31, 2023
Fair Value Disclosures [Abstract]  
Schedule of Financial Assets

The following table presents the Company’s financial assets measured and recorded at fair value on a recurring basis using the above input categories as of December 31, 2023 and December 31, 2022 (in thousands):

 

Schedule of Financial Assets 

   Year Ended 
   December 31, 2023   December 31, 2022 
   Level 1   Level 2   Level 3   Total   Level 1   Level 2   Level 3   Total 
Assets:                                
Investments held in Trust  $   $   $   $   $29,029,416   $   $   $29,029,416 
                                         
Total Assets  $   $   $   $   $29,029,416   $   $   $29,029,416 

 

XML 123 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Organization and Operations (Details Narrative) - Securities Purchase Agreement [Member] - USD ($)
1 Months Ended
Jun. 28, 2023
Nov. 30, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Debt Instrument, Description   The senior secured notes are convertible to the conversion rate of $
Data Knights Acquisition Corp [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Debt Instrument, Issued, Principal $ 1,595,744.70  
Payments to Acquire Businesses, Gross $ 1,500,000  
Debt Instrument, Description Pursuant to the Securities Purchase Agreement, Data Knights will issue and sell to each of the Purchasers, a new series of senior secured convertible notes (the “PIPE Notes”), which are convertible into shares of Common Stock at the Purchasers election at a conversion price equal to the lower of (i) $10.00 per share, and (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) Trading Days immediately preceding the Conversion Date.  
Investments $ 1,500,000  
XML 124 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule Of Aggregate Percentage Revenue and Accounts Receivable (Details) - Customer Concentration Risk [Member]
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenue from Contract with Customer Benchmark [Member] | Customer One [Member]    
Product Information [Line Items]    
Aggregate Percent of Revenue and Accounts Receivable 52.00% 31.00%
Revenue from Contract with Customer Benchmark [Member] | Customer Two [Member]    
Product Information [Line Items]    
Aggregate Percent of Revenue and Accounts Receivable 22.00%
Revenue from Contract with Customer Benchmark [Member] | Customers [Member]    
Product Information [Line Items]    
Aggregate Percent of Revenue and Accounts Receivable 52.00% 53.00%
Accounts Receivable [Member] | Customer One [Member]    
Product Information [Line Items]    
Aggregate Percent of Revenue and Accounts Receivable 40.00%
Accounts Receivable [Member] | Customer Two [Member]    
Product Information [Line Items]    
Aggregate Percent of Revenue and Accounts Receivable 36.00%
Accounts Receivable [Member] | Customers [Member]    
Product Information [Line Items]    
Aggregate Percent of Revenue and Accounts Receivable 96.00% 72.00%
Accounts Receivable [Member] | Customer Three [Member]    
Product Information [Line Items]    
Aggregate Percent of Revenue and Accounts Receivable 33.00%
Accounts Receivable [Member] | Customer Four [Member]    
Product Information [Line Items]    
Aggregate Percent of Revenue and Accounts Receivable 32.00%
Accounts Receivable [Member] | Customer Five [Member]    
Product Information [Line Items]    
Aggregate Percent of Revenue and Accounts Receivable 27.00%
XML 125 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Product Information [Line Items]    
Accounts Receivable, Allowance for Credit Loss, Current $ 0 $ 102,700
Impairment of Long-Lived Assets to be Disposed of   $ 0
Revenue from Contract with Customer Benchmark [Member] | Customer Concentration Risk [Member] | One Customer [Member]    
Product Information [Line Items]    
Concentration Risk, Percentage 10.00%  
Revenue from Contract with Customer Benchmark [Member] | Customer Concentration Risk [Member] | Two Customers [Member]    
Product Information [Line Items]    
Concentration Risk, Percentage   10.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Two Customers [Member]    
Product Information [Line Items]    
Concentration Risk, Percentage   10.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Three Customers [Member]    
Product Information [Line Items]    
Concentration Risk, Percentage 10.00%  
XML 126 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Going Concern (Details Narrative) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Retained Earnings (Accumulated Deficit) $ 55,082,677 $ 43,509,964
XML 127 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Property And Equipment (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Total Property and Equipment $ 282,286 $ 262,992
Less: accumulated depreciation (183,415) (179,895)
Net Property and Equipment 98,871 83,097
Computer Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Total Property and Equipment 246,578 259,207
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Total Property and Equipment $ 35,708 $ 3,785
XML 128 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Property and Equipment (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Abstract]    
Depreciation, Depletion and Amortization, Nonproduction $ 27,983 $ 24,807
XML 129 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Deferred Income Taxes (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Deferred Tax Assets    
Net operating loss carry forward $ 6,823,785 $ 6,973,587
Stock Compensation 1,035,947 481,144
Other 53,268
Gross deferred tax assets 7,859,732 7,507,999
Less valuation allowance (7,859,732) (7,507,999)
Net deferred tax assets
XML 130 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Operating Loss Carryforwards [Line Items]    
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount $ 351,734 $ 1,384,220
Deferred Tax Assets, Valuation Allowance 7,859,732 $ 7,507,999
Data Knights Acquisition Corp [Member]    
Operating Loss Carryforwards [Line Items]    
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 155,700,000  
Deferred Tax Assets, Valuation Allowance 168,300,000  
Domestic Tax Authority [Member]    
Operating Loss Carryforwards [Line Items]    
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration 21,000,000  
Operating Loss Carryforwards 10,300,000  
State and Local Jurisdiction [Member]    
Operating Loss Carryforwards [Line Items]    
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration 23,000,000  
Operating Loss Carryforwards $ 8,900,000  
XML 131 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Convertible Promissory Notes held by Related Party (Details Narrative) - USD ($)
Nov. 11, 2022
Dec. 31, 2023
Nov. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Nov. 30, 2019
Short-Term Debt [Line Items]            
Convertible Notes Payable       $ 5,140,000    
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 1.00   $ 1.00 $ 0.10  
Accrued Liabilities       $ 690,771    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights       2,056,000 174,102  
Convertible Promissory Notes [Member]            
Short-Term Debt [Line Items]            
Debt Instrument, Face Amount       $ 9,900,000    
Related Party [Member]            
Short-Term Debt [Line Items]            
Convertible Notes Payable   $ 2,300,000   4,700,000    
Related Party [Member] | Data Knights Acquisition Corp [Member]            
Short-Term Debt [Line Items]            
Convertible Notes Payable   1,200,000 $ 15,400,000      
Debt Instrument, Convertible, Conversion Price     $ 2.50      
Related Party [Member] | Convertible Promissory Notes [Member]            
Short-Term Debt [Line Items]            
Convertible Notes Payable           $ 1,500,000
Debt Instrument, Face Amount $ 5,000,000          
Class of Warrant or Right, Exercise Price of Warrants or Rights $ 1.00          
Proceeds from Issuance or Sale of Equity $ 5,000,000          
[custom:EquityFinancingDescription] a 20% discount to the lowest price per share of shares sold in the Next Equity Financing, or (B) $2.50 per share; (ii) at the noteholder’s option, in the event of a defined Corporate Transaction while such Note remains outstanding, into shares of the Company’s Series A-2 Preferred Stock at a conversion price equal to $          
Related Party [Member] | Convertible Promissory Notes [Member] | Series A-2 Preferred Stock [Member]            
Short-Term Debt [Line Items]            
Preferred Stock, Convertible, Conversion Price $ 2.50          
Nonrelated Party [Member]            
Short-Term Debt [Line Items]            
Convertible Notes Payable   $ 1,875,000   $ 440,000    
XML 132 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Canadian Emergency Business Loan Act (CEBA) (Details Narrative) - CEBA Loan [Member]
1 Months Ended 12 Months Ended
Dec. 31, 2020
USD ($)
Dec. 31, 2020
USD ($)
Short-Term Debt [Line Items]    
Proceeds from Issuance of Unsecured Debt $ 44,673  
Debt Instrument, Decrease, Forgiveness   $ 14,742
Debt Conversion, Original Debt, Amount   $ 44,673
Debt Instrument, Term   3 years
Debt Instrument, Interest Rate, Stated Percentage 5.00% 5.00%
XML 133 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Common Stock Activities (Details) - Common Stock [Member] - Board of Directors Chairman [Member]
12 Months Ended
Dec. 31, 2023
shares
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Beginning balance, shares 4,550,166
Preferred Stock to Common Stock 7,057,797
Convertible Notes to Common Stock 6,177,229
Stock Options to Common Stock 612,670
Converting of Warrants to Common Stock 3,859,464
Private OneMedNet to ONMD Public Shares (2,257,326)
Converting Data Knights Common Stock (A and B) to ONMD Public Shares 3,460,275
Issuance Public Shares 111,957
Ending balance, shares 23,572,232
XML 134 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Shareholders’ Equity (Details Narrative) - USD ($)
$ / shares in Units, $ in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Class of Stock [Line Items]    
Preferred Stock, Convertible, Terms Series A-2 Preferred Stock and Series A-1 Preferred Stock convert 1-1 to commons stock  
Share Price   $ 1.00
Board Of Directors [Member]    
Class of Stock [Line Items]    
Stock Issued During Period, Shares, Issued for Services 100,000 100,000
Share Price $ 1.00  
Series A-2 Preferred Stock [Member]    
Class of Stock [Line Items]    
Shares Issued, Price Per Share $ 0.15  
Proceeds from Issuance of Preferred Stock and Preference Stock $ 20.0  
Series A-1 Preferred Stock [Member]    
Class of Stock [Line Items]    
Shares Issued, Price Per Share $ 0.15  
Proceeds from Issuance of Preferred Stock and Preference Stock $ 20.0  
XML 135 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Options Outstanding (Details) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]    
Options outstanding, ending balance 947,184 1,995,000
Weighted average exercise price, begining balance $ 1.00 $ 1.00
Aggregate Intrinsic value, begining balance $ 947,184 $ 1,995,000
Options, Granted - under the Plan 577,000 25,000
Options, Granted - under the Plan 7,500
Options, cancelled (485,684) (1,072,816)
Weighted average exercise price, ending balance $ 1.00 $ 1.00
Aggregate Intrinsic value, ending balance $ 1,031,000 $ 947,184
Options, Granted - under the Plan (7,500)
Options outstanding, ending balance 1,031,000 947,184
Options exercisable 567,581 723,431
Weighted average exercise price, exercisable $ 1.00  
Aggregate Intrinsic value, exercisable $ 567,581  
XML 136 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Fair Value of Stock Options (Details)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Measurement Input, Expected Term [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
[custom:EquitySecuritiesFvNiMeasurementTerm] 5 years 10 months 20 days 6 years 29 days
Measurement Input, Risk Free Interest Rate [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Equity Securities, FV-NI, Measurement Input 0.55 0.49
Measurement Input, Expected Dividend Rate [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Equity Securities, FV-NI, Measurement Input 0.00 0.00
Measurement Input, Price Volatility [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Equity Securities, FV-NI, Measurement Input 32 60
XML 137 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock Options (Details Narrative) - USD ($)
12 Months Ended
Oct. 17, 2023
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Nov. 07, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number     1,031,000 947,184 1,995,000  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term     7 years 1 month 9 days 6 years 3 days    
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number     567,581 723,431    
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term     5 years 6 months 21 days 5 years 3 months 7 days    
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number           692,153
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price           $ 1.00
Share-Based Compensation Arrangement by Share-Based Payment Award, Description common stock equal to 10% of the number of shares of common stock of OneMedNet following the Business Combination for issuance thereunder          
Share-Based Payment Arrangement, Expense     $ 45,584 $ 47,071    
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount     $ 75,987      
Share-Based Payment Arrangement, Option [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Stock Issued During Period, Shares, New Issues   612,720        
Employees Directors and Consultants [Member] | New Equity Incentive Plan [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Stock Issued During Period, Shares, New Issues         3,000,000  
Shares Issued, Price Per Share         $ 1  
Employees Directors and Consultants [Member] | New Equity Incentive Plan [Member] | Maximum [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period         4 years  
XML 138 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock Warrants (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 2,056,000   174,102
Class of Warrant or Right, Exercise Price of Warrants or Rights $ 1.00 $ 1.00 $ 0.10
Proceeds from Issuance of Warrants $ 1,346,288    
Common Stock [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights   174,102  
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 0.10  
Warrant One [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 1.00  
Class of Warrant or Right, Outstanding   4,165,746  
Publicly Traded Warrants [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.0400 $ 0.0149  
Class of Warrant or Right, Outstanding 11,500,000    
Private Warrants [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Class of Warrant or Right, Outstanding 585,275 681,019  
Warrant [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Other Liabilities $ 400,000 $ 600,000  
Convertiable Notes [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 2,056,000 1,670,000  
2021 Service [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 145,746    
2022 Service [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 294,000    
XML 139 R46.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Financial Assets (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured and recorded fair value $ 29,029,415
Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured and recorded fair value 29,029,416
Fair Value, Recurring [Member] | Investments Held in Trust [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured and recorded fair value 29,029,416
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured and recorded fair value 29,029,416
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Investments Held in Trust [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured and recorded fair value 29,029,416
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured and recorded fair value
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Investments Held in Trust [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured and recorded fair value
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured and recorded fair value  
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Investments Held in Trust [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured and recorded fair value
XML 140 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Related Party Transactions (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Jun. 28, 2023
Nov. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Related Party Transaction [Line Items]        
Convertible Notes Payable       $ 5,140,000
Proceeds from Convertible Debt     $ 1,549,820  
Accrued Liabilities       690,771
Senior Notes, Current     1,200,000  
Securities Purchase Agreement [Member]        
Related Party Transaction [Line Items]        
Proceeds from Convertible Debt   $ 1,500,000    
Debt Instrument, Description   The senior secured notes are convertible to the conversion rate of $    
Debt Instrument, Convertible, Conversion Price   $ 10.00    
Securities Purchase Agreement [Member] | Warrant [Member]        
Related Party Transaction [Line Items]        
Stock Issued During Period, Shares, Acquisitions   95,745    
Securities Purchase Agreement [Member] | Senior Convertible Notes [Member]        
Related Party Transaction [Line Items]        
Proceeds from Convertible Debt   $ 1,600,000    
Related Party [Member]        
Related Party Transaction [Line Items]        
Convertible Notes Payable     2,300,000 4,700,000
[custom:ExtensionLoan-0]     3,000,000.0 $ 2,500,000
Related Party [Member] | Securities Purchase Agreement [Member]        
Related Party Transaction [Line Items]        
Accrued Liabilities   100,000    
Related Party [Member] | Management and Directors [Member]        
Related Party Transaction [Line Items]        
[custom:ExtensionLoan-0]     300,000  
Data Knights Acquisition Corp [Member] | Securities Purchase Agreement [Member]        
Related Party Transaction [Line Items]        
Debt Instrument, Description Pursuant to the Securities Purchase Agreement, Data Knights will issue and sell to each of the Purchasers, a new series of senior secured convertible notes (the “PIPE Notes”), which are convertible into shares of Common Stock at the Purchasers election at a conversion price equal to the lower of (i) $10.00 per share, and (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) Trading Days immediately preceding the Conversion Date.      
Data Knights Acquisition Corp [Member] | Related Party [Member]        
Related Party Transaction [Line Items]        
Convertible Notes Payable   $ 15,400,000 $ 1,200,000  
Debt Instrument, Convertible, Conversion Price   $ 2.50    
XML 141 R48.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments, Contingencies, and Concentrations Operating lease (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]    
Operating Lease, Cost $ 575  
Operating Leases, Rent Expense, Net $ 7,695 $ 7,694
XML 142 R49.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Subsequent Events (Details Narrative) - USD ($)
12 Months Ended
Mar. 27, 2024
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Subsequent Event [Line Items]        
Proceeds from Related Party Debt     $ 465,024
Share Price       $ 1.00
Subsequent Event [Member]        
Subsequent Event [Line Items]        
Proceeds from Issuance of Private Placement   $ 4,540,000    
Subsequent Event [Member] | Majority Shareholder [Member]        
Subsequent Event [Line Items]        
Related Party Transaction, Amounts of Transaction   1,000,000    
Forecast [Member]        
Subsequent Event [Line Items]        
Business Combination, Consideration Transferred   $ 3,000,000.0    
Stock Repurchased During Period, Shares   187,745    
Proceeds from Related Party Debt   $ 300,000    
Forecast [Member] | Board of Directors Chairman [Member]        
Subsequent Event [Line Items]        
Stock Repurchased During Period, Shares 147,000      
Share Price $ 1.00      
Forecast [Member] | EF Hutton [Member]        
Subsequent Event [Line Items]        
Stock Issued During Period, Shares, New Issues   256,944    
Forecast [Member] | Kingwood Capital Partners LLC [Member]        
Subsequent Event [Line Items]        
Stock Issued During Period, Shares, New Issues   20,834    

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